Clustering O 0 0.00031465929350815713
of O 0 1.3331105947145261e-05
missense O 0 0.0027112795505672693
mutations O 0 0.000960751436650753
in O 0 3.185436435160227e-05
the O 0 0.0009660945506766438
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 1.0
gene O 0 0.0002570846409071237
in O 0 8.926967893785331e-07
a O 0 3.599589717850904e-06
sporadic B-Disease 0 0.0004214232030790299
T I-Disease 1 0.981860876083374
- I-Disease 1 0.8444538712501526
cell I-Disease 1 0.8608711361885071
leukaemia I-Disease 1 0.9962707757949829
. O 0 2.2724085283698514e-05

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999992847442627
telangiectasia I-Disease 1 1.0
( O 0 0.33852607011795044
A B-Disease 1 0.9999955892562866
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
) O 0 2.334036935280892e-06
is O 0 1.2092849033251696e-07
a O 0 1.3825690530211432e-06
recessive B-Disease 0 0.000955157564021647
multi I-Disease 0 0.01925661414861679
- I-Disease 1 0.997381865978241
system I-Disease 0 0.14432625472545624
disorder I-Disease 0 0.07684796303510666
caused O 0 7.51241213947651e-06
by O 0 5.724845095755882e-07
mutations O 0 4.065725988766644e-06
in O 0 1.0616579260158687e-07
the O 0 2.8485095526775694e-07
ATM O 0 0.00016031390987336636
gene O 0 4.343786713434383e-06
at O 0 2.2492372409033123e-06
11q22 O 0 1.1544857443368528e-05
- O 0 0.0006753357592970133
q23 O 0 4.646819070330821e-05
( O 0 6.990599104028661e-07
ref O 0 2.6802028514794074e-05
. O 0 2.5467699060754967e-07
3 O 0 2.2458850708062528e-06
) O 0 1.2901742820758955e-06
. O 0 4.71013163405587e-06

The O 0 2.522691102058161e-05
risk O 0 6.161663623061031e-05
of O 0 3.581137889341335e-06
cancer B-Disease 0 0.018598252907395363
, O 0 3.3519959288241807e-06
especially O 0 1.1910244666069048e-06
lymphoid B-Disease 0 0.00013892885181121528
neoplasias I-Disease 0 0.0027560400776565075
, O 0 3.193547172486433e-06
is O 0 2.716654421419662e-07
substantially O 0 2.956017397082178e-06
elevated O 0 1.6608459191047587e-05
in O 0 1.0682349056878593e-05
A B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.00042830477468669415
and O 0 9.996517746913014e-07
has O 0 2.1155922240723157e-06
long O 0 2.4255382413684856e-06
been O 0 2.4800567643978866e-06
associated O 0 2.7751405013987096e-06
with O 0 3.754761200980283e-05
chromosomal O 1 0.9999998807907104
instability O 1 0.9999271631240845
. O 0 0.00015393902140203863

By O 0 3.9996084524318576e-05
analysing O 0 0.0009143592324107885
tumour B-Disease 1 0.9999983310699463
DNA O 0 0.005010864231735468
from O 0 1.335620072495658e-05
patients O 0 1.2585863260028418e-05
with O 0 3.4088452594005503e-07
sporadic B-Disease 0 9.505757043370977e-05
T I-Disease 1 0.9110739827156067
- I-Disease 0 0.24859412014484406
cell I-Disease 0 0.37967365980148315
prolymphocytic I-Disease 1 0.6796323657035828
leukaemia I-Disease 1 0.9994117021560669
( O 0 1.6036325177992694e-05
T B-Disease 0 0.23735913634300232
- I-Disease 0 0.004314581397920847
PLL I-Disease 0 0.00014680232561659068
) O 0 2.862891790300637e-07
, O 0 5.570055705561572e-08
a O 0 2.600559696475102e-07
rare O 0 1.4913734958099667e-06
clonal B-Disease 0 2.8826256311731413e-05
malignancy I-Disease 0 0.0014829583233222365
with O 0 4.5508230073210143e-07
similarities O 0 1.673371002652857e-06
to O 0 2.9093737907714967e-07
a O 0 4.808094672625884e-06
mature B-Disease 0 6.197911716299132e-05
T I-Disease 0 0.07727290689945221
- I-Disease 0 0.009679166600108147
cell I-Disease 0 0.1280951201915741
leukaemia I-Disease 1 0.8267228603363037
seen O 0 2.9053331672912464e-05
in O 0 4.85600048705237e-06
A B-Disease 1 0.9999070167541504
- I-Disease 1 0.9999734163284302
T I-Disease 1 0.9999998807907104
, O 0 3.4660129131225403e-06
we O 0 5.9376230154839504e-08
demonstrate O 0 5.25008800877913e-08
a O 0 6.91589434609341e-08
high O 0 4.053570137330098e-07
frequency O 0 8.457414537588193e-07
of O 0 1.6617333642443555e-07
ATM O 0 0.0017857881030067801
mutations O 0 5.634157787426375e-05
in O 0 2.893410510296235e-06
T B-Disease 0 0.16535599529743195
- I-Disease 0 0.008422642014920712
PLL I-Disease 0 0.0019023934146389365
. O 0 2.0915609638905153e-05

In O 0 1.912080369947944e-05
marked O 0 8.32227487990167e-06
contrast O 0 1.9853844150929945e-06
to O 0 1.422443460796785e-07
the O 0 1.5728761582067818e-07
ATM O 0 0.00025905275833792984
mutation O 0 8.851385246089194e-06
pattern O 0 1.5655712559237145e-05
in O 0 6.077877515053842e-06
A B-Disease 1 0.9999667406082153
- I-Disease 1 0.9999958276748657
T I-Disease 1 1.0
, O 0 1.7050870155799203e-06
the O 0 3.943219795132791e-08
most O 0 2.981657942768834e-08
frequent O 0 2.8792186412829324e-07
nucleotide O 0 2.5572503545845393e-06
changes O 0 1.779513212341044e-07
in O 0 1.836266960708599e-07
this O 0 5.61720071345917e-07
leukaemia B-Disease 0 0.14144115149974823
were O 0 1.4002509487909265e-05
missense O 0 0.0007229459006339312
mutations O 0 0.00019761227304115891
. O 0 1.1842439562315121e-05

These O 0 2.397732259851182e-06
clustered O 0 8.286154297820758e-06
in O 0 9.738424751049024e-07
the O 0 2.7276928449282423e-07
region O 0 1.615033738744387e-06
corresponding O 0 1.9539727702522214e-07
to O 0 9.4485983481718e-08
the O 0 9.789689414674285e-08
kinase O 0 8.048821655393112e-06
domain O 0 1.3118708466208773e-06
, O 0 2.748242309280613e-07
which O 0 1.2708441943232174e-07
is O 0 5.5755510430799404e-08
highly O 0 1.0858045840222985e-07
conserved O 0 2.0948257883901533e-07
in O 0 3.009047020441358e-07
ATM O 0 8.356206672033295e-05
- O 0 7.172232290031388e-05
related O 0 7.111900686140871e-07
proteins O 0 1.7411711894510518e-07
in O 0 2.3707646334969468e-07
mouse O 0 7.534496944572311e-06
, O 0 8.058515845732472e-07
yeast O 0 2.1549440134549513e-05
and O 0 3.963938070228323e-06
Drosophila O 0 1.714097015792504e-05
. O 0 9.330599823442753e-06

The O 0 1.071632777893683e-05
resulting O 0 5.252128630672814e-06
amino O 0 2.059541429844103e-06
- O 0 5.6177414080593735e-05
acid O 0 6.380635568348225e-06
substitutions O 0 5.504248292709235e-07
are O 0 3.592602837443337e-08
predicted O 0 1.3834355740982573e-06
to O 0 9.917620502619684e-08
interfere O 0 2.6075326786667574e-07
with O 0 2.2666611698696215e-07
ATP O 0 0.007703421637415886
binding O 0 1.1519035069795791e-05
or O 0 1.3541570069719455e-06
substrate O 0 5.655178756569512e-05
recognition O 0 9.732355465530418e-06
. O 0 9.689977559901308e-06

Two O 0 4.621232619683724e-06
of O 0 9.021262030728394e-07
seventeen O 0 1.0300156645826064e-05
mutated O 0 7.644003198947757e-05
T B-Disease 0 0.0013992144959047437
- I-Disease 0 0.00011214584083063528
PLL I-Disease 0 0.00010707537148846313
samples O 0 6.850892987131374e-06
had O 0 1.5623721765223308e-06
a O 0 8.651760481370729e-07
previously O 0 4.114603507332504e-05
reported O 0 0.0003441342560108751
A B-Disease 1 0.9970521926879883
- I-Disease 1 0.9999079704284668
T I-Disease 1 0.9999988079071045
allele O 0 0.00036202670889906585
. O 0 1.3208027667133138e-05

In O 0 3.626688339863904e-05
contrast O 0 2.5163573809550144e-05
, O 0 2.322129830645281e-06
no O 0 5.472300017572707e-07
mutations O 0 2.0774568838533014e-06
were O 0 4.513961471275252e-07
detected O 0 2.542295533203287e-06
in O 0 8.401946161029628e-08
the O 0 8.11661919897233e-08
p53 O 0 3.378680730747874e-07
gene O 0 1.3849709148416878e-06
, O 0 3.5155949262843933e-07
suggesting O 0 1.046300894813612e-06
that O 0 3.8533306678800727e-07
this O 0 3.248949724365957e-06
tumour B-Disease 1 0.9999995231628418
suppressor O 0 0.0073671466670930386
is O 0 2.47741400016821e-06
not O 0 1.82885855792847e-07
frequently O 0 4.0049729932434275e-07
altered O 0 1.0586451026028953e-05
in O 0 1.0134406238648808e-06
this O 0 3.397457703613327e-06
leukaemia B-Disease 1 0.6952151656150818
. O 0 1.717808481771499e-05

Occasional O 0 0.0004248645273037255
missense O 0 0.0034902337938547134
mutations O 0 0.0009686221601441503
in O 0 2.5219196686521173e-06
ATM O 0 0.0002618999860715121
were O 0 8.227711077779531e-06
also O 0 2.085955884467694e-06
found O 0 2.5759504751476925e-06
in O 0 7.891986570029985e-06
tumour B-Disease 1 0.9999995231628418
DNA O 0 0.006699282675981522
from O 0 1.7145902120319079e-06
patients O 0 8.219297455980268e-07
with O 0 7.998147566468106e-08
B B-Disease 0 4.790895036421716e-05
- I-Disease 0 0.002456506248563528
cell I-Disease 0 0.04823480173945427
non I-Disease 0 0.00044432864524424076
- I-Disease 1 0.996951699256897
Hodgkins I-Disease 1 0.9999991655349731
lymphomas I-Disease 1 0.9955164790153503
( O 0 3.1069685064721853e-06
B B-Disease 0 3.840395584120415e-05
- I-Disease 0 0.00045924572623334825
NHL I-Disease 0 1.65640412888024e-05
) O 0 1.1814251621444782e-07
and O 0 9.619512297831534e-08
a O 0 8.148042525135679e-07
B B-Disease 0 4.270570570952259e-05
- I-Disease 0 9.629505075281486e-05
NHL I-Disease 0 1.474471628171159e-05
cell O 0 6.717450014548376e-05
line O 0 4.7137942601693794e-05
. O 0 9.90245916909771e-06

The O 0 1.295066158490954e-05
evidence O 0 1.557507516736223e-06
of O 0 5.932200508595997e-08
a O 0 5.808402647744515e-07
significant O 0 5.250503818388097e-07
proportion O 0 1.3499882243195316e-06
of O 0 5.043282271799399e-07
loss O 0 4.2019553802674636e-05
- O 0 2.123873491655104e-05
of O 0 5.746352371716057e-07
- O 0 0.00019939555204473436
function O 0 1.2699346143563162e-06
mutations O 0 3.034156634384999e-06
and O 0 2.7824387416330865e-07
a O 0 5.504080604623596e-07
complete O 0 4.68174312118208e-06
absence O 0 3.1181454573925294e-07
of O 0 2.8162220999661258e-08
the O 0 9.029338343680138e-08
normal O 0 1.7571618116107857e-07
copy O 0 8.809412292976049e-07
of O 0 3.0504565984301735e-08
ATM O 0 3.0094255635049194e-05
in O 0 1.2830707873945357e-07
the O 0 9.820022484063884e-08
majority O 0 4.415969385718199e-07
of O 0 7.799319519108394e-07
mutated O 0 0.0007284132880158722
tumours B-Disease 1 0.9999978542327881
establishes O 0 3.2770170946605504e-05
somatic O 0 4.18697927671019e-05
inactivation O 0 0.00022445425565820187
of O 0 1.4760254885004542e-07
this O 0 1.6941608294018806e-07
gene O 0 9.409765766577038e-07
in O 0 1.9902553560768865e-07
the O 0 6.643469419032044e-07
pathogenesis O 0 7.489263225579634e-05
of O 0 4.849017045671644e-07
sporadic B-Disease 0 0.0001533265458419919
T I-Disease 1 0.6527799963951111
- I-Disease 0 0.0025749464984983206
PLL I-Disease 0 0.0001475179597036913
and O 0 2.3457430415874114e-06
suggests O 0 5.276319257063733e-07
that O 0 4.645025342142617e-08
ATM O 0 1.3095434951537754e-05
acts O 0 9.055862051354779e-07
as O 0 8.780659186413686e-07
a O 0 0.00011120680574094877
tumour B-Disease 1 0.9999994039535522
suppressor O 0 0.16656243801116943
. O 0 3.917403955711052e-05

As O 0 2.9873166567995213e-05
constitutional O 0 9.40569952945225e-06
DNA O 0 6.832754297647625e-05
was O 0 2.3245705961016938e-05
not O 0 1.993195866134556e-07
available O 0 1.0453459253767505e-07
, O 0 8.494859571328561e-08
a O 0 1.5390991165986634e-06
putative O 0 0.0005771187134087086
hereditary O 1 0.8756605386734009
predisposition O 0 0.003949691075831652
to O 0 6.460970325861126e-05
T B-Disease 1 0.9290446639060974
- I-Disease 0 0.010134677402675152
PLL I-Disease 0 0.00029167637694627047
will O 0 1.0024651828643982e-06
require O 0 1.1596045368378327e-07
further O 0 2.8512437211247743e-07
investigation O 0 2.164552142858156e-06
. O 0 5.943434757682553e-07
. O 0 2.4651774310768815e-06

Myotonic B-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.9999997615814209
protein O 0 0.014341248199343681
kinase O 0 0.009347249753773212
is O 0 5.546622105612187e-06
involved O 0 3.4506135193623777e-07
in O 0 1.047959159450329e-07
the O 0 6.525432638682105e-08
modulation O 0 6.504704970211606e-07
of O 0 5.0348237579100896e-08
the O 0 3.45238078125476e-07
Ca2 O 0 1.767067806213163e-05
+ O 0 5.4914242355152965e-05
homeostasis O 0 8.864924893714488e-05
in O 0 3.0612566206400516e-06
skeletal O 0 0.005060290917754173
muscle O 0 0.0003455844707787037
cells O 0 0.0001669944467721507
. O 0 1.1165806427015923e-05

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9992989301681519
DM B-Disease 1 1.0
) O 0 0.00014768516120966524
, O 0 7.807147994753905e-07
the O 0 1.659348356497503e-07
most O 0 8.445075536656077e-07
prevalent O 0 0.0001281722215935588
muscular B-Disease 1 0.9388396143913269
disorder I-Disease 0 0.3333212435245514
in O 0 7.931847903819289e-06
adults O 0 1.3073723494017031e-05
, O 0 1.6069679986685514e-06
is O 0 2.3185607460618485e-06
caused O 0 5.993609192955773e-06
by O 0 1.1756429785236833e-06
( O 0 7.968012027959048e-07
CTG O 0 6.124849460320547e-05
) O 0 3.82211510441266e-07
n O 0 9.364196557726245e-06
- O 0 1.144479483627947e-05
repeat O 0 3.4754991702357074e-06
expansion O 0 1.8692011849452683e-07
in O 0 4.035698708548807e-08
a O 0 1.0589540266892072e-07
gene O 0 1.3062724235624046e-07
encoding O 0 1.0267100947203289e-07
a O 0 4.798172881237406e-07
protein O 0 6.107894478191156e-06
kinase O 0 0.0002869594027288258
( O 0 1.5890636859694496e-05
DM B-Disease 1 0.9999970197677612
protein O 0 2.082830724248197e-05
kinase O 0 3.6648976674769074e-05
; O 0 1.212639176628727e-06
DMPK O 0 7.168935553636402e-05
) O 0 1.6531173230305285e-07
and O 0 9.608124429405507e-08
involves O 0 1.3480465099746652e-07
changes O 0 1.6358909249447606e-07
in O 0 3.359159563842695e-07
cytoarchitecture O 0 0.0001315064582740888
and O 0 9.832317118707579e-06
ion O 0 0.0003662208328023553
homeostasis O 0 0.0005238588200882077
. O 0 1.3762029993813485e-05

To O 0 1.1685255230986513e-05
obtain O 0 6.881904937472427e-06
clues O 0 1.685544521023985e-05
to O 0 4.81189260881365e-07
the O 0 2.6319068524571776e-07
normal O 0 1.0927850553343887e-06
biological O 0 9.022010658554791e-07
role O 0 3.237559553781466e-07
of O 0 1.0668401984048614e-07
DMPK O 0 0.00010684222070267424
in O 0 1.1702368283295073e-06
cellular O 0 4.579071173793636e-05
ion O 0 4.195696601527743e-05
homeostasis O 0 5.538419645745307e-05
, O 0 5.463164711727586e-07
we O 0 3.3483932071476374e-08
have O 0 1.7960916309789354e-08
compared O 0 1.654268544371007e-07
the O 0 1.0186676746570811e-07
resting O 0 1.0134937838301994e-05
[ O 0 1.2056639207003172e-06
Ca2 O 0 1.5939576769596897e-06
+ O 0 6.792628482799046e-06
] O 0 6.490874397968582e-07
i O 0 2.0902699304770067e-07
, O 0 1.4378095158917858e-08
the O 0 1.1936102772835966e-08
amplitude O 0 6.612926739535396e-08
and O 0 2.219735506514553e-07
shape O 0 1.4593651940231211e-06
of O 0 3.0463931466329086e-07
depolarization O 0 2.155727088393178e-05
- O 0 0.0024776053614914417
induced O 0 0.0001212070492329076
Ca2 O 0 5.268703716865275e-06
+ O 0 9.037769814312924e-06
transients O 0 1.1126031495223287e-05
, O 0 1.0232341907112641e-07
and O 0 3.526261949104992e-08
the O 0 2.5969503880673983e-08
content O 0 1.1001785082953575e-07
of O 0 3.759267741543226e-08
ATP O 0 0.00017681525787338614
- O 0 2.5232489861082286e-05
driven O 0 5.030484317103401e-06
ion O 0 4.025304406241048e-06
pumps O 0 2.1493385702342493e-06
in O 0 1.8208757524007524e-07
cultured O 0 2.306534042872954e-05
skeletal O 0 0.00028526977985166013
muscle O 0 1.4798853953834623e-05
cells O 0 1.3732994830206735e-06
of O 0 4.1205893808182736e-08
wild O 0 2.8046169973094948e-06
- O 0 8.357601473107934e-05
type O 0 5.0088847274309956e-06
and O 0 2.2343124328472186e-06
DMPK O 0 0.00024544133339077234
[ O 0 2.4347293674509274e-06
- O 0 4.983685357728973e-05
/ O 0 0.00014490660396404564
- O 0 0.00011372976587153971
] O 0 1.4230068700271659e-05
knockout O 0 0.0004198765382170677
mice O 0 0.00044354156125336885
. O 0 1.0173305781790987e-05

In O 0 4.967344648321159e-05
vitro O 0 0.0008396463235840201
- O 0 0.0014362041838467121
differentiated O 0 0.000168231941643171
DMPK O 0 0.0010021098423749208
[ O 0 1.1694821296259761e-05
- O 0 0.000259283056948334
/ O 0 9.515133569948375e-05
- O 0 3.120890323771164e-05
] O 0 1.2900906085633324e-06
myotubes O 0 3.306050530227367e-06
exhibit O 0 4.831397859561548e-07
a O 0 4.124848658193514e-07
higher O 0 1.5755498452563188e-06
resting O 0 1.246744068339467e-05
[ O 0 1.600258883627248e-06
Ca2 O 0 4.036964583065128e-06
+ O 0 7.066717898851493e-06
] O 0 1.1126180652354378e-06
i O 0 2.8026735776620626e-07
than O 0 2.8329068868515606e-08
do O 0 4.2468528249628434e-08
wild O 0 1.6692638382664882e-07
- O 0 1.715989492367953e-05
type O 0 4.527526471065357e-06
myotubes O 0 2.600775405880995e-05
because O 0 7.529789769478157e-08
of O 0 1.3533324683123737e-08
an O 0 4.2424323964951327e-07
altered O 0 2.4101667804643512e-05
open O 0 7.735844519629609e-06
probability O 0 2.064570594484394e-07
of O 0 5.93978661811434e-08
voltage O 0 3.05377398035489e-05
- O 0 0.0003653527528513223
dependent O 0 1.5697361959610134e-05
l O 0 3.424862734391354e-05
- O 0 1.2450000212993473e-05
type O 0 1.5036639524623752e-06
Ca2 O 0 2.7922767458221642e-06
+ O 0 4.416956471686717e-06
and O 0 7.387023970295559e-07
Na O 0 2.1416048184619285e-05
+ O 0 7.081363492034143e-06
channels O 0 4.422267011250369e-06
. O 0 3.778969585255254e-06

The O 0 9.73225360212382e-06
mutant O 0 4.1194911318598315e-05
myotubes O 0 9.73577843979001e-05
exhibit O 0 3.0759824767301325e-06
smaller O 0 5.871055464012898e-07
and O 0 3.961886534398218e-07
slower O 0 3.45205944540794e-06
Ca2 O 0 2.736760279731243e-06
+ O 0 2.8966380796191515e-06
responses O 0 1.613560698388028e-07
upon O 0 7.03386717759713e-08
triggering O 0 1.3959451052869554e-06
by O 0 2.0479920692650921e-07
acetylcholine O 0 9.643473458709195e-05
or O 0 2.0096863408980425e-06
high O 0 3.961707989219576e-06
external O 0 1.3643232705362607e-05
K O 0 3.19367645715829e-05
+ O 0 2.9173441362218e-05
. O 0 5.481939751916798e-06

In O 0 1.9663228158606216e-05
addition O 0 2.015133077293285e-06
, O 0 9.338835980088334e-07
we O 0 1.7008629527026642e-07
observed O 0 2.3176907859578932e-07
that O 0 4.927835561829852e-08
these O 0 2.7929633716894386e-08
Ca2 O 0 2.2596991584578063e-06
+ O 0 2.4073528038570657e-05
transients O 0 5.052199776400812e-05
partially O 0 4.032495417050086e-05
result O 0 6.272168207033246e-07
from O 0 2.8701409249265453e-08
an O 0 4.053117308444598e-08
influx O 0 6.126032303654938e-08
of O 0 2.192376591381162e-08
extracellular O 0 2.629232653816871e-07
Ca2 O 0 1.7173640571854776e-06
+ O 0 1.2715390766970813e-06
through O 0 7.656993261662137e-08
the O 0 2.6179631618106214e-07
l O 0 5.8826961321756244e-05
- O 0 4.176172660663724e-05
type O 0 4.682002327172086e-06
Ca2 O 0 7.056413778627757e-06
+ O 0 1.0273923180648126e-05
channel O 0 2.9456128686433658e-05
. O 0 4.838203949475428e-06

Neither O 0 5.9118381614098325e-05
the O 0 1.8589381625133683e-06
content O 0 1.0376883210483356e-06
nor O 0 4.310827534936834e-07
the O 0 3.4420345684793574e-08
activity O 0 6.435437427398938e-08
of O 0 5.1949434975995246e-08
Na O 0 3.826128158834763e-05
+ O 0 1.611306652193889e-05
/ O 0 3.7004747355240397e-06
K O 0 1.932720579134184e-06
+ O 0 2.145693088095868e-06
ATPase O 0 1.1037122021662071e-05
and O 0 1.0043485190180945e-06
sarcoplasmic O 0 4.048153277835809e-05
reticulum O 0 4.112692840863019e-05
Ca2 O 0 1.2658580999413971e-05
+ O 0 2.2397620341507718e-05
- O 0 3.746342190424912e-05
ATPase O 0 6.0721198678947985e-05
are O 0 1.2308132113503234e-07
affected O 0 2.0121819943597075e-07
by O 0 2.282866375935555e-07
DMPK O 0 0.0005940219270996749
absence O 0 1.0442501661600545e-05
. O 0 5.415542091213865e-06

In O 0 3.990415279986337e-05
conclusion O 0 4.333839115133742e-06
, O 0 3.995473889517598e-07
our O 0 1.982898822916468e-07
data O 0 8.133686719702382e-07
suggest O 0 4.091222933766403e-07
that O 0 1.155881435010997e-07
DMPK O 0 7.004589133430272e-05
is O 0 3.845929086310207e-07
involved O 0 1.0159551067090433e-07
in O 0 2.4383095365010377e-07
modulating O 0 2.693811666176771e-06
the O 0 2.7580094297263713e-07
initial O 0 6.777472663088702e-07
events O 0 4.383894491866158e-08
of O 0 4.866255309821099e-08
excitation O 0 4.75613160233479e-06
- O 0 0.00035990661126561463
contraction O 0 6.558711174875498e-05
coupling O 0 3.3458445614087395e-06
in O 0 3.224874490115326e-06
skeletal O 0 0.008099042810499668
muscle O 0 0.00012161550694145262
. O 0 3.095050487900153e-06
. O 0 5.136731033417163e-06

Constitutional O 0 0.0005588369676843286
RB1 O 0 0.09870880842208862
- O 0 0.02989349327981472
gene O 0 0.00011801324581028894
mutations O 0 0.00010414119606139138
in O 0 2.416010602246388e-06
patients O 0 1.0997271601809189e-05
with O 0 1.6528761079825927e-06
isolated O 0 0.000981741352006793
unilateral B-Disease 0 0.01501283049583435
retinoblastoma I-Disease 0 0.4097394347190857
. O 0 8.195174450520426e-05

In O 0 2.4148555894498713e-05
most O 0 2.472316054991097e-06
patients O 0 6.870245670143049e-06
with O 0 5.608764581666037e-07
isolated O 0 9.214621968567371e-05
unilateral B-Disease 0 0.0006393324583768845
retinoblastoma I-Disease 0 0.1619260609149933
, O 0 3.669576835818589e-05
tumor B-Disease 0 0.00014633245882578194
development O 0 6.887656809340115e-07
is O 0 3.845261744572781e-07
initiated O 0 7.363306622210075e-07
by O 0 1.6486099241319607e-07
somatic O 0 7.211416232166812e-06
inactivation O 0 0.0001019348856061697
of O 0 5.255878932075575e-08
both O 0 1.969587231087644e-07
alleles O 0 5.337863058230141e-07
of O 0 1.6303465599776246e-07
the O 0 5.092403171147453e-06
RB1 O 0 0.01272521074861288
gene O 0 4.899023406323977e-05
. O 0 6.083885182306403e-06

However O 0 3.080443639191799e-05
, O 0 2.785717754250072e-07
some O 0 1.9035967468994386e-08
of O 0 2.288219036472583e-08
these O 0 8.846373589221912e-08
patients O 0 1.920412387335091e-06
can O 0 3.1743581985210767e-07
transmit O 0 6.482582830358297e-05
retinoblastoma B-Disease 0 0.0033057762775570154
predisposition O 0 0.00013522300287149847
to O 0 2.461005578879849e-06
their O 0 1.0482051948201843e-05
offspring O 0 0.00028200855012983084
. O 0 1.50898104038788e-05

To O 0 2.163844146707561e-05
determine O 0 4.07573725169641e-06
the O 0 3.069841056912992e-07
frequency O 0 3.3144542612717487e-06
and O 0 8.499330306221964e-07
nature O 0 3.602491176479816e-07
of O 0 2.081074654824988e-07
constitutional O 0 2.063827650999883e-06
RB1 O 0 0.0030137640424072742
- O 0 0.005281278397887945
gene O 0 1.864553996711038e-05
mutations O 0 8.26635914563667e-06
in O 0 5.575146246883378e-07
patients O 0 1.8974924387293868e-06
with O 0 2.598519017737999e-07
isolated O 0 3.6847854062216356e-05
unilateral B-Disease 0 0.00037606473779305816
retinoblastoma I-Disease 0 0.004168832674622536
, O 0 1.852923674050544e-06
we O 0 8.094186654261648e-08
analyzed O 0 5.88062675888068e-07
DNA O 0 3.984268005297054e-06
from O 0 3.6583253404387506e-07
peripheral O 0 5.141161091160029e-05
blood O 0 3.54423355020117e-05
and O 0 6.780506282666465e-06
from O 0 1.0169309462071396e-05
tumor B-Disease 0 0.055084336549043655
tissue O 0 0.0022123008966445923
. O 0 1.821784462663345e-05

The O 0 1.003027591650607e-05
analysis O 0 1.0783415746118408e-05
of O 0 3.555258672349737e-06
tumors B-Disease 1 0.9999957084655762
from O 0 5.495706773217535e-06
54 O 0 2.940628291980829e-05
( O 0 4.870675525125989e-07
71 O 0 3.3940189041459234e-06
% O 0 2.501329561255261e-07
) O 0 5.111487411113558e-08
of O 0 5.191278873439842e-08
76 O 0 1.2443400009942707e-05
informative O 0 1.5031311704660766e-05
patients O 0 3.953710984205827e-05
showed O 0 4.043863373226486e-05
loss O 0 2.034839053521864e-05
of O 0 1.0890978501265636e-06
constitutional O 0 3.7197845813352615e-05
heterozygosity O 0 0.05126769095659256
( O 0 0.00012474230607040226
LOH O 1 0.9999889135360718
) O 0 2.9702146093768533e-06
at O 0 2.698285470614792e-06
intragenic O 0 0.00035506451968103647
loci O 0 4.193252607365139e-05
. O 0 1.1261905456194654e-05

Three O 0 1.179147875518538e-05
of O 0 2.057091478491202e-06
13 O 0 3.8112189940875396e-05
uninformative O 0 0.021719301119446754
patients O 0 0.0006475077825598419
had O 0 2.749349550867919e-05
constitutional O 0 7.491628366551595e-06
deletions O 0 0.00015790156612638384
. O 0 2.5817524146987125e-05

For O 0 8.826298653730191e-06
39 O 0 1.885314668470528e-05
randomly O 0 1.3293451047502458e-05
selected O 0 3.1315783417085186e-05
tumors B-Disease 1 0.9999903440475464
, O 0 6.974576535867527e-06
SSCP O 0 0.00047629245091229677
, O 0 1.908907051983988e-06
hetero O 0 4.658256875700317e-05
- O 0 5.587511623161845e-05
duplex O 0 0.0019844453781843185
analysis O 0 2.656736342032673e-06
, O 0 1.1852090153752215e-07
sequencing O 0 5.759750933975738e-07
, O 0 1.535732963020564e-07
and O 0 1.7071032232252037e-07
Southern O 0 1.2863927167927613e-06
blot O 0 0.0001465220848331228
analysis O 0 6.008793889122899e-07
were O 0 9.578865700632377e-08
used O 0 3.328529771806643e-07
to O 0 9.95305526885204e-07
identify O 0 1.934945430548396e-05
mutations O 0 9.143006172962487e-05
. O 0 9.809174116526265e-06

Mutations O 0 0.002128103980794549
were O 0 2.3801872885087505e-05
detected O 0 2.5968893169192597e-05
in O 0 1.0249975730403094e-06
21 O 0 9.11980532691814e-06
( O 0 3.9281090380427486e-07
91 O 0 1.267396214643668e-06
% O 0 2.72455736194388e-07
) O 0 1.1064896909829258e-07
of O 0 5.137810603628168e-07
23 O 0 0.006736749317497015
tumors B-Disease 1 0.9999996423721313
with O 0 0.0003966517688240856
LOH O 1 0.9999971389770508
. O 0 0.00011344404629198834

In O 0 4.208764948998578e-05
6 O 0 3.660412767203525e-05
( O 0 5.959929580967582e-07
38 O 0 1.1234047860853025e-06
% O 0 2.513970969175716e-07
) O 0 1.0430376562453603e-07
of O 0 2.0122895705299015e-07
16 O 0 0.0011146952165290713
tumors B-Disease 1 0.9999997615814209
without O 0 4.300473665352911e-05
LOH O 1 0.9999573230743408
, O 0 1.987661789826234e-06
one O 0 3.8399775803554803e-07
mutation O 0 1.6749197584431386e-06
was O 0 1.3129837498127017e-05
detected O 0 4.822771188628394e-06
, O 0 1.3474708282501524e-07
and O 0 3.0085072921792744e-07
in O 0 3.4466012266420876e-07
9 O 0 1.3479141671268735e-05
( O 0 1.1190501680857778e-07
56 O 0 7.261645578182652e-07
% O 0 9.98218325776179e-08
) O 0 3.7205769132242494e-08
of O 0 1.048205007236902e-07
the O 0 7.304132304852828e-05
tumors B-Disease 1 0.9999998807907104
without O 0 6.935060810064897e-05
LOH O 1 0.9999912977218628
, O 0 1.8699015527090523e-06
both O 0 4.891506364401721e-07
mutations O 0 1.1423171599744819e-05
were O 0 1.933970679601771e-06
found O 0 7.662086318305228e-06
. O 0 9.181327186524868e-06

Thus O 0 3.465001282165758e-05
, O 0 7.085343440849101e-07
a O 0 1.5207186265797645e-07
total O 0 1.325423113485158e-07
of O 0 3.961795158602399e-08
45 O 0 1.1729754305633833e-06
mutations O 0 3.374215793883195e-06
were O 0 9.001402077046805e-07
identified O 0 1.3912449503550306e-05
in O 0 1.8937929780804552e-05
tumors B-Disease 1 0.9999972581863403
of O 0 1.9066856111749075e-06
36 O 0 0.00011460156383691356
patients O 0 3.745034700841643e-05
. O 0 5.238852281763684e-06

Thirty O 0 8.685422653798014e-05
- O 0 7.5714269769378e-05
nine O 0 1.8240962162963115e-06
of O 0 9.659630251235285e-08
the O 0 4.103046080672357e-07
mutations O 0 4.0231439015769865e-06
- O 0 5.253671588434372e-06
including O 0 1.8871737950121314e-07
34 O 0 5.044344675297907e-07
small O 0 2.9574567861345713e-07
mutations O 0 2.7414569103711983e-06
, O 0 9.056019933950665e-08
2 O 0 6.439735216190456e-07
large O 0 1.0456006975800847e-06
structural O 0 0.00024996025604195893
alterations O 0 7.249645568663254e-05
, O 0 2.8132105853728717e-06
and O 0 2.424959802738158e-06
hypermethylation O 0 6.369294715113938e-05
in O 0 4.449918378668372e-06
3 O 0 0.04552154988050461
tumors O 1 0.9999998807907104
- O 0 0.011184267699718475
were O 0 2.684399987629149e-06
not O 0 2.3156250961164915e-07
detected O 0 9.146031629825302e-07
in O 0 3.08163805584627e-08
the O 0 1.3730543457768363e-07
corresponding O 0 1.931976157720783e-06
peripheral O 0 9.921686432790011e-05
blood O 0 0.00013764256436843425
DNA O 0 0.0005601462326012552
. O 0 1.5640849596820772e-05

In O 0 4.904665911453776e-05
6 O 0 7.886028470238671e-05
( O 0 1.398642211825063e-06
17 O 0 1.6314055528710014e-06
% O 0 2.0100569031455962e-07
) O 0 3.781597612828591e-08
of O 0 1.2698284201917431e-08
the O 0 3.3258041298722674e-07
36 O 0 1.7533198843011633e-05
patients O 0 1.5468392575712642e-06
, O 0 5.5315709346359654e-08
a O 0 8.115657124108111e-07
mutation O 0 8.04940555099165e-06
was O 0 2.220053102064412e-05
detected O 0 1.0350650882173795e-05
in O 0 4.3390065229687025e-07
constitutional O 0 2.5701368144837033e-07
DNA O 0 1.8499436919228174e-05
, O 0 9.407477818967891e-07
and O 0 4.3842791797032987e-07
1 O 0 9.295447966906067e-07
of O 0 4.348542503862518e-08
these O 0 9.480676510520425e-08
mutations O 0 2.893584451157949e-06
is O 0 4.2217115492348967e-07
known O 0 9.475186857343942e-07
to O 0 4.1352112134518393e-07
be O 0 2.853792580026493e-07
associated O 0 6.411644335457822e-07
with O 0 1.280772721656831e-06
reduced O 0 0.0001022234937408939
expressivity O 0 0.002003306522965431
. O 0 4.1324594349134713e-05

The O 0 6.222886895557167e-06
presence O 0 1.0607536751194857e-06
of O 0 1.816974446455788e-07
a O 0 1.1027284472220344e-06
constitutional O 0 2.101897052853019e-06
mutation O 0 1.0708094123401679e-05
was O 0 2.051788214885164e-05
not O 0 2.4336654291801096e-07
associated O 0 9.759188657199047e-08
with O 0 7.545777691575495e-08
an O 0 1.4832064607617212e-06
early O 0 1.3574214790423866e-05
age O 0 1.2927471289003734e-06
at O 0 5.19517925567925e-06
treatment O 0 2.2889033061801456e-05
. O 0 5.2092791520408355e-06

In O 0 2.720177326409612e-05
1 O 0 5.4929641919443384e-05
patient O 0 2.626585410325788e-05
, O 0 5.060973649051448e-07
somatic O 0 1.1986785466433503e-05
mosaicism O 0 0.0004033929144497961
was O 0 6.164184742374346e-05
demonstrated O 0 1.863757574938063e-06
by O 0 1.1782903186485782e-07
molecular O 0 3.857363481074572e-06
analysis O 0 6.584255061170552e-07
of O 0 1.3246105368125427e-07
DNA O 0 4.329971125116572e-05
and O 0 2.371470827711164e-06
RNA O 0 1.4125555026112124e-05
from O 0 1.6522991472811555e-06
peripheral O 0 0.00026047907886095345
blood O 0 0.00014515260409098119
. O 0 1.6058364053606056e-05

In O 0 4.8703757784096524e-05
2 O 0 0.0001565317070344463
patients O 0 1.2792414054274559e-05
without O 0 1.5533244379639655e-07
a O 0 1.367066602142586e-06
detectable O 0 3.0507813789881766e-05
mutation O 0 1.3481224414135795e-05
in O 0 1.7227264379471308e-06
peripheral O 0 0.0004064950335305184
blood O 0 0.0002928175963461399
, O 0 7.189579719124595e-06
mosaicism O 0 0.00012495611736085266
was O 0 2.978833617817145e-05
suggested O 0 2.0246800431777956e-06
because O 0 5.116208257049948e-08
1 O 0 4.3637311364363995e-07
of O 0 7.223724907134965e-08
the O 0 3.4643310300452868e-06
patients O 0 2.0521874830592424e-05
showed O 0 4.796165740117431e-05
multifocal O 1 0.982894778251648
tumors B-Disease 1 1.0
and O 0 4.013165380456485e-06
the O 0 1.847528352527661e-07
other O 0 7.770011478669403e-08
later O 0 2.013037374126725e-06
developed O 0 2.885680942199542e-06
bilateral B-Disease 0 1.3862797459296416e-05
retinoblastoma I-Disease 0 0.005869234912097454
. O 0 4.946498665958643e-05

In O 0 2.1473968445206992e-05
conclusion O 0 4.690941295848461e-06
, O 0 8.083739544417767e-07
our O 0 3.760405036246084e-07
results O 0 1.235576746694278e-06
emphasize O 0 6.227852509255172e-07
that O 0 1.201550645646421e-07
the O 0 1.3871239445961692e-07
manifestation O 0 3.4252179830218665e-06
and O 0 1.3475417972586001e-06
transmissibility O 0 8.393164534936659e-06
of O 0 2.843621302872634e-07
retinoblastoma B-Disease 0 9.638719348004088e-05
depend O 0 2.043656195382937e-06
on O 0 4.099039870197885e-06
the O 0 2.8124196660428424e-07
nature O 0 4.1506123693579866e-07
of O 0 3.843618756604883e-08
the O 0 2.525324873658974e-07
first O 0 3.89974093195633e-06
mutation O 0 5.34320122369536e-07
, O 0 5.375543565833141e-08
its O 0 1.623796919147935e-07
time O 0 3.500877312490047e-07
in O 0 1.281536015085294e-07
development O 0 1.4677016224595718e-07
, O 0 2.5093601152548217e-07
and O 0 1.4811850235219026e-07
the O 0 5.2038291897815725e-08
number O 0 7.812125346617904e-08
and O 0 1.7638691929278139e-07
types O 0 9.945295431634804e-08
of O 0 3.7257393614709144e-08
cells O 0 3.847693733405322e-06
that O 0 7.569105946458876e-07
are O 0 1.1998514537481242e-07
affected O 0 3.839545286155044e-07
. O 0 4.7079305431907414e-07
. O 0 3.702635012814426e-06

Hereditary B-Disease 1 0.9999949932098389
deficiency I-Disease 1 0.9997076392173767
of I-Disease 0 2.105359726556344e-06
the I-Disease 0 1.945413941939478e-06
fifth I-Disease 0 2.9419046768452972e-05
component I-Disease 0 1.949646730281529e-06
of I-Disease 0 7.895909703847792e-08
complement I-Disease 0 1.4707338777952828e-06
in O 0 1.7823815596784698e-06
man O 0 0.00019337995036039501
. O 0 1.574948510096874e-05

I O 0 0.0017381253419443965
. O 0 0.00013323873281478882

Clinical O 0 0.010769138112664223
, O 0 3.253237082390115e-05
immunochemical O 0 0.00046849550562910736
, O 0 7.350828582275426e-06
and O 0 3.5045959521085024e-06
family O 0 1.3672981367562898e-05
studies O 0 7.803071639500558e-06
. O 0 6.452247816923773e-06

The O 0 1.2342422451183666e-05
first O 0 1.4622735761804506e-05
recognized O 0 2.4204175588238286e-06
human O 0 1.524328126834007e-06
kindred O 0 0.0017546896124258637
with O 0 0.0007925119716674089
hereditary B-Disease 1 0.9999985694885254
deficiency I-Disease 1 0.9489244818687439
of I-Disease 0 3.7589921930702985e-07
the I-Disease 0 2.0754332581418566e-06
fifth I-Disease 0 9.9352233519312e-05
component I-Disease 0 3.569623004295863e-06
of I-Disease 0 1.6782664147285686e-07
complement I-Disease 0 4.583167083183071e-06
( O 0 2.039888386207167e-06
C5 O 0 0.0008673592819832265
) O 0 6.683147830699454e-07
is O 0 9.429609804101347e-07
described O 0 3.432252196944319e-05
. O 0 9.689699254522566e-06

The O 0 2.1751888198195957e-05
proband O 0 0.00017798205954022706
, O 0 8.503173489771143e-07
a O 0 3.1634181141271256e-07
20 O 0 8.772079809205025e-07
- O 0 2.749208033492323e-05
year O 0 2.954185447379132e-06
- O 0 2.467146623530425e-05
old O 0 1.5426643585669808e-05
black O 0 2.983866215799935e-05
female O 0 4.227227691444568e-05
with O 0 0.013925203122198582
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999998807907104
erythematosus I-Disease 1 0.9999998807907104
since O 0 0.0001741643063724041
age O 0 8.6472182374564e-06
11 O 0 4.396816621010657e-06
, O 0 1.5715340850874782e-06
lacked O 0 1.8037229892797768e-05
serum O 0 5.118833723827265e-05
hemolytic O 0 0.0004954792675562203
complement O 0 1.8040625491266837e-06
activity O 0 9.816855026656413e-07
, O 0 3.461311735009076e-07
even O 0 8.324873306264635e-07
during O 0 7.272336006280966e-06
remission O 0 0.00013155459600966424
. O 0 8.820476068649441e-06

C5 O 0 0.023970767855644226
was O 0 0.00045367502025328577
undetectable O 0 4.0574763261247426e-05
in O 0 1.6731412415538216e-06
her O 0 1.051691833708901e-05
serum O 0 6.791216492274543e-06
by O 0 1.456367328955821e-07
both O 0 3.9157217202046013e-07
immunodiffusion O 0 0.00040221985545940697
and O 0 5.412420796346851e-05
hemolytic O 0 0.2069186568260193
assays O 0 0.0003758528910111636
. O 0 3.829946581390686e-05

Other O 0 3.208622047168319e-06
complement O 0 3.253181830586982e-06
components O 0 3.943132469430566e-06
were O 0 8.175908874363813e-07
normal O 0 7.091805969139386e-07
during O 0 1.9508611330820713e-06
remission O 0 3.775889126700349e-05
of O 0 3.029325171155506e-06
lupus O 1 0.9363356828689575
, O 0 2.725633066802402e-06
but O 0 4.6608579395979177e-07
C1 O 0 6.422178557841107e-05
, O 0 1.0550483011684264e-06
C4 O 0 0.000801408605184406
, O 0 1.9778967725869734e-06
C2 O 0 3.6622881452785805e-05
, O 0 3.587447281461209e-07
and O 0 3.198303204499098e-07
C3 O 0 0.000791042170021683
levels O 0 4.072971023560967e-06
fell O 0 0.0001671966165304184
during O 0 7.02509714756161e-06
exacerbations O 0 0.0031201387755572796
. O 0 1.4256541362556163e-05

A O 0 5.813582174596377e-05
younger O 0 3.7463847547769547e-05
half O 0 6.590791144844843e-06
- O 0 0.0004110792651772499
sister O 0 0.0011448038276284933
, O 0 2.715561095101293e-06
who O 0 3.793528321693884e-06
had O 0 1.1922190424229484e-05
no O 0 6.178006515256129e-06
underlying O 0 0.005743579473346472
disease O 0 0.008321955800056458
, O 0 2.7317537387716584e-06
was O 0 2.387391396041494e-05
also O 0 3.4717559174168855e-06
found O 0 1.5893053841864457e-06
to O 0 6.78506523854594e-07
lack O 0 2.3807024263078347e-06
immunochemically O 0 0.0004446068196557462
detectable O 0 9.702829993329942e-05
C5 O 0 0.0007214221404865384
. O 0 1.4812253539275844e-05

By O 0 9.947224316420034e-05
hemolytic O 1 0.7631714344024658
assay O 0 0.03794426470994949
, O 0 0.0001264110323973
she O 0 2.5111674403888173e-05
exhibited O 0 4.843780516239349e-06
1 O 0 2.8213619316375116e-06
- O 0 5.4046278819441795e-05
2 O 0 6.032931196386926e-06
% O 0 8.036759879814781e-08
of O 0 1.268780103202971e-08
the O 0 1.844241666049129e-07
normal O 0 1.152371851276257e-06
serum O 0 2.798824425553903e-06
C5 O 0 3.963095514336601e-05
level O 0 3.520610789564671e-07
and O 0 1.0698845898104992e-07
normal O 0 1.6818603398860432e-07
concentrations O 0 4.7174319206533255e-07
of O 0 2.2130851817792063e-08
other O 0 4.3093887569511935e-08
complement O 0 1.0442533948662458e-06
components O 0 1.176283785753185e-05
. O 0 5.256387794361217e-06

C5 O 0 0.004820965696126223
levels O 0 1.3368103282118682e-05
of O 0 2.913572245688556e-07
other O 0 9.125829336653624e-08
family O 0 4.884183226749883e-07
members O 0 7.837601856408583e-08
were O 0 1.5338153502852947e-07
either O 0 4.2005389389032644e-08
normal O 0 1.4673209136617515e-07
or O 0 1.4000032422245567e-07
approximately O 0 1.1675185618287287e-07
half O 0 6.49406899810856e-07
- O 0 3.250725058023818e-05
normal O 0 2.3006621177046327e-06
, O 0 3.2986704923132493e-07
consistent O 0 7.299158824025653e-07
with O 0 9.914931524690473e-07
autosomal O 0 0.0011464395793154836
codominant O 0 0.00041244132444262505
inheritance O 0 1.0792940884130076e-05
of O 0 3.6196271935295954e-07
the O 0 4.402934791869484e-06
gene O 0 0.00018926266056951135
determining O 0 0.0035186398308724165
C5 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
. O 0 5.410191079135984e-05

Normal O 0 0.0032020374201238155
hemolytic O 1 0.9935262203216553
titers O 0 0.004089242313057184
were O 0 2.6934343622997403e-05
restored O 0 1.722808701742906e-05
to O 0 1.3478887694873265e-06
both O 0 2.756739149845089e-06
homozygous O 0 0.0004960678634233773
C5 B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999990463256836
deficient I-Disease 1 0.9999998807907104
( O 0 0.00013890978880226612
C5D B-Disease 1 0.9999988079071045
) O 0 4.6996906348795164e-06
sera O 0 8.636044185550418e-06
by O 0 3.5989192070928766e-08
addition O 0 7.400873869300995e-08
of O 0 7.302216431526176e-08
highly O 0 2.8942383778485237e-06
purified O 0 5.5178181355586275e-05
human O 0 7.1108479460235685e-06
C5 O 0 0.0011505408911034465
. O 0 1.9005270587513223e-05

In O 0 1.8415334125165828e-05
specific O 0 5.112441158416914e-06
C5 O 0 0.000855655234772712
titrations O 0 0.000719045230653137
, O 0 8.73320095706731e-06
however O 0 7.94971981576964e-07
, O 0 2.959448579531454e-07
it O 0 2.0218982399455854e-07
was O 0 4.891030130238505e-06
noted O 0 8.013903993742133e-07
that O 0 7.554014302968426e-08
when O 0 1.5640551964679617e-07
limited O 0 1.2535684845715878e-07
amounts O 0 5.883241271931183e-08
of O 0 5.067223085575279e-08
C5 O 0 0.0001029081322485581
were O 0 1.2989769402338425e-06
assayed O 0 1.1378519957361277e-06
in O 0 5.6218322441736746e-08
the O 0 3.2804990723889205e-08
presence O 0 5.832938398953047e-08
of O 0 4.75382755382725e-08
low O 0 4.73026648251107e-06
dilutions O 0 3.345132790855132e-05
of O 0 3.6763267985406856e-07
either O 0 5.7073962125286926e-06
C5D B-Disease 1 0.9999982118606567
serum O 0 7.049721170915291e-05
, O 0 2.1511131365059555e-07
curving O 0 1.3823397466694587e-06
rather O 0 1.156440490035493e-07
than O 0 4.766884487139578e-08
linear O 0 1.0065558626592974e-06
dose O 0 1.21662278615986e-05
- O 0 2.198076617787592e-05
response O 0 3.767537464227644e-07
plots O 0 1.7947324977285462e-06
were O 0 1.4187802435117192e-06
consistently O 0 4.118832293897867e-06
obtained O 0 1.3013328725719475e-06
, O 0 1.5242149231653457e-07
suggesting O 0 5.183156304156e-07
some O 0 6.825263909604473e-08
inhibitory O 0 4.7209464355546515e-06
effect O 0 4.450626875041053e-06
. O 0 4.4610337681660894e-06

Further O 0 2.6799472834682092e-05
studies O 0 5.143799626239343e-06
suggested O 0 2.0779600617970573e-06
that O 0 1.8388990952189488e-07
low O 0 4.563445145322476e-06
dilutions O 0 0.00014020832895766944
of O 0 5.491536285262555e-06
C5D B-Disease 1 0.9999994039535522
serum O 0 0.0001565317070344463
contain O 0 4.1002806483447785e-07
a O 0 1.317555643254309e-06
factor O 0 5.280366508486622e-07
( O 0 1.5525749574862857e-07
or O 0 3.2821770901136915e-07
factors O 0 1.1587842863036713e-07
) O 0 9.117425747717789e-08
interfering O 0 3.674805384434876e-07
at O 0 4.824473762710113e-07
some O 0 2.929703768472791e-08
step O 0 6.696686227769533e-07
in O 0 4.252405290117167e-07
the O 0 1.6702747416275088e-06
hemolytic O 0 0.0059303101152181625
assay O 0 8.730612898943946e-05
of O 0 4.521398011547717e-07
C5 O 0 0.0016402306500822306
, O 0 4.660973900172394e-07
rather O 0 3.424582573074986e-08
than O 0 2.674862287221913e-08
a O 0 8.572251317673363e-07
true O 0 4.942350187775446e-06
C5 O 0 0.0007465637754648924
inhibitor O 0 3.707318319357e-05
or O 0 3.460045036263182e-06
inactivator O 0 0.0003082422190345824
. O 0 1.0543207281443756e-05

Of O 0 2.869039417419117e-05
clinical O 0 0.00018718653882388026
interest O 0 3.2888492569327354e-06
are O 0 6.0820241287729e-07
( O 0 4.2663378962970455e-07
a O 0 1.938431751113967e-06
) O 0 3.919218727332918e-07
the O 0 1.416179173929777e-07
documentation O 0 2.0157576727797277e-06
of O 0 2.610464207464247e-06
membranous O 1 0.6642758250236511
glomerulonephritis B-Disease 1 0.9999998807907104
, O 0 0.03548303619027138
vasculitis B-Disease 1 0.9999997615814209
, O 0 0.0033427320886403322
and O 0 0.3006613850593567
arthritis B-Disease 1 1.0
in O 0 7.637820090167224e-06
an O 0 4.086818535142811e-06
individual O 0 1.287949203288008e-06
lacking O 0 1.096710821002489e-05
C5 O 0 0.0029698829166591167
( O 0 4.610359098933259e-07
and O 0 1.9594740763295704e-07
its O 0 1.0945153690045117e-06
biologic O 0 1.989443990169093e-05
functions O 0 2.1981993825193058e-07
) O 0 3.368526790836768e-07
, O 0 4.222858933644602e-07
and O 0 1.6070905530796153e-06
( O 0 6.866387138870778e-07
b O 0 3.2346076750400243e-06
) O 0 9.673384226971393e-08
a O 0 6.069369646866107e-07
remarkable O 0 3.040586989300209e-06
propensity O 0 7.2302165790461e-05
to O 0 0.00034452686668373644
bacterial B-Disease 1 0.9999983310699463
infections I-Disease 1 0.9999996423721313
in O 0 2.5674644348328e-06
the O 0 1.1450846386651392e-06
proband O 0 0.0006442953599616885
, O 0 7.07812375821959e-07
even O 0 7.339190233324189e-08
during O 0 5.8122928692228015e-08
periods O 0 3.945115523151799e-08
of O 0 3.187061281550996e-08
low O 0 5.434062586573418e-06
- O 0 7.28112063370645e-05
dose O 0 7.04816147845122e-06
or O 0 1.070599040531306e-07
alternate O 0 9.189046181745653e-07
- O 0 3.698243745020591e-05
day O 0 1.2502971003414132e-05
corticosteroid O 0 0.0007946679252199829
therapy O 0 4.7774399718036875e-05
. O 0 3.2550437936151866e-06

Other O 0 5.168159077584278e-06
observations O 0 2.6657089620130137e-05
indicate O 0 5.26813164469786e-06
that O 0 4.194970131266018e-07
the O 0 9.671887255535694e-07
C5D B-Disease 1 0.999994158744812
state O 0 1.4451745755650336e-06
is O 0 1.5517593965341803e-07
compatible O 0 5.244433509687951e-07
with O 0 1.5680623732805543e-07
normal O 0 1.7760592072590953e-06
coagulation O 0 2.2205283585208235e-06
function O 0 2.398976164386113e-07
and O 0 2.9920008159933786e-07
the O 0 1.6198666230593517e-07
capacity O 0 1.8926745326552918e-07
to O 0 2.0287413349251437e-07
mount O 0 1.3209539247327484e-05
a O 0 2.376429438299965e-05
neutrophilic O 0 0.14080411195755005
leukocytosis O 0 0.09832394868135452
during O 0 0.00015010782226454467
pyogenic B-Disease 1 0.9006063938140869
infection I-Disease 0 0.057840727269649506
. O 0 3.5613127238320885e-06
. O 0 8.583559974795207e-06

Susceptibility O 1 0.8984630703926086
to O 0 0.033899012953042984
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.6149142384529114
twins O 0 0.16136227548122406
: O 0 8.091375889307528e-07
the O 0 1.0846123643659666e-07
role O 0 1.9013947394341812e-07
of O 0 5.915929435218459e-08
genes O 0 1.2449920632207068e-06
, O 0 1.3323812027010717e-06
HLA O 0 6.509443483082578e-05
, O 0 3.4100287393812323e-07
and O 0 3.725086230588204e-07
the O 0 9.761066621649661e-07
environment O 0 2.008287083299365e-05
. O 0 8.754389455134515e-06

OBJECTIVE O 0 7.905266102170572e-05
To O 0 1.3740358326685964e-06
determine O 0 9.297070278080355e-07
the O 0 1.4734150965978188e-07
relative O 0 1.0272502777297632e-06
effects O 0 3.1033557661430677e-06
of O 0 1.8301585669178166e-07
genetic O 0 2.103553015331272e-05
and O 0 5.4985271162877325e-06
environmental O 0 9.675239198259078e-06
factors O 0 4.210437225538044e-07
in O 0 1.996861328734667e-06
susceptibility O 0 0.03983204439282417
to O 1 0.5104626417160034
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0077793290838599205
AS B-Disease 1 0.9996354579925537
) O 0 1.2323604096309282e-05
. O 0 7.46915702620754e-06

METHODS O 0 0.0004449422121979296
Twins O 0 0.002119929762557149
with O 0 7.494350938941352e-06
AS B-Disease 1 0.9654654860496521
were O 0 4.5407750803860836e-06
identified O 0 1.7641614249441773e-06
from O 0 7.333285623190022e-08
the O 0 6.7587410512715e-07
Royal O 0 5.651010724250227e-05
National O 0 9.194803169521037e-06
Hospital O 0 0.0002836257917806506
for O 0 4.5152886741561815e-05
Rheumatic B-Disease 1 0.9999489784240723
Diseases I-Disease 0 0.27978673577308655
database O 0 8.147161133820191e-05
. O 0 3.089257006649859e-05

Clinical O 0 0.005492932628840208
and O 0 2.383569699304644e-05
radiographic O 0 0.0004823060007765889
examinations O 0 3.6511290090857074e-05
were O 0 7.58484657126246e-06
performed O 0 8.253834494098555e-06
to O 0 5.115764452057192e-07
establish O 0 8.133842129609548e-06
diagnoses O 0 0.07971984148025513
, O 0 1.4803837984800339e-05
and O 0 0.0013178009539842606
disease O 0 0.0475124791264534
severity O 0 0.0005939871771261096
was O 0 0.0005711147678084671
assessed O 0 5.83583732804982e-06
using O 0 4.4304169932729565e-07
a O 0 1.3935057268099627e-06
combination O 0 4.211861323710764e-06
of O 0 1.6896736099170084e-07
validated O 0 6.207641945366049e-06
scoring O 0 1.2281262797841919e-06
systems O 0 3.3184216590598226e-05
. O 0 8.586933290644083e-06

HLA O 0 0.01381604839116335
typing O 0 0.00025066069792956114
for O 0 5.276347110338975e-06
HLA O 0 0.0007981829112395644
- O 0 0.0002702363417483866
B27 O 0 2.368600689806044e-05
, O 0 1.1186643860128243e-06
HLA O 0 4.2916490201605484e-05
- O 0 2.1260986613924615e-05
B60 O 0 3.4456322737241862e-06
, O 0 2.767299349670793e-07
and O 0 5.788887165181222e-07
HLA O 0 0.00035314945853315294
- O 0 0.001548967557027936
DR1 O 0 0.4915464520454407
was O 0 2.7467449399409816e-05
performed O 0 9.865573247225257e-07
by O 0 5.71375160518528e-08
polymerase O 0 2.816055712173693e-06
chain O 0 1.24591451822198e-05
reaction O 0 1.114619365694125e-07
with O 0 2.5202597342399713e-08
sequence O 0 2.0106321585444675e-07
- O 0 7.757994353596587e-06
specific O 0 2.0082232765616936e-07
primers O 0 1.2024179341096897e-05
, O 0 5.197252903599292e-07
and O 0 7.186400239334034e-07
zygosity O 0 0.00010621109686326236
was O 0 2.6053354304167442e-05
assessed O 0 2.39612313635007e-06
using O 0 2.36377127293963e-06
microsatellite O 0 0.00028066980303265154
markers O 0 0.0002094482770189643
. O 0 1.7592554286238737e-05

Genetic O 0 0.0021651387214660645
and O 0 2.3546597731183283e-05
environmental O 0 9.370968655275647e-06
variance O 0 1.8953094240714563e-06
components O 0 9.5094010248431e-06
were O 0 3.350691940795514e-06
assessed O 0 4.046280537295388e-06
with O 0 2.9088465680615627e-07
the O 0 8.689607966516633e-07
program O 0 1.332175315837958e-06
Mx O 0 2.9526956950576277e-06
, O 0 5.075667175447052e-08
using O 0 7.232507925891696e-08
data O 0 3.862296580336988e-07
from O 0 2.4810731247271178e-08
this O 0 4.6569834211140915e-08
and O 0 5.003690830562846e-07
previous O 0 7.753704267088324e-06
studies O 0 3.696160888466693e-07
of O 0 1.1596000604185974e-07
twins O 0 6.237091292859986e-05
with O 0 4.015056219941471e-06
AS B-Disease 1 0.9995972514152527
. O 0 5.269824032438919e-05

RESULTS O 0 0.00041007183608599007
Six O 0 3.867603936669184e-06
of O 0 8.503968160766817e-07
8 O 0 3.7644593248842284e-05
monozygotic O 0 0.00024218250473495573
( O 0 7.657863534404896e-06
MZ O 0 0.33931899070739746
) O 0 3.387425294931745e-06
twin O 0 9.250983566744253e-05
pairs O 0 1.8273056411999278e-05
were O 0 4.0791594074107707e-05
disease O 0 5.6006239901762456e-05
concordant O 0 2.5512295906082727e-05
, O 0 1.803680561351939e-06
compared O 0 6.661626912318752e-07
with O 0 8.329028133857719e-08
4 O 0 3.937188466807129e-06
of O 0 1.739285835355986e-07
15 O 0 2.0542215679597575e-06
B27 O 0 9.025564395415131e-06
- O 0 0.00012039381545037031
positive O 0 3.0211344892450143e-06
dizygotic O 0 8.509456165484153e-06
( O 0 9.790956028155051e-07
DZ O 0 0.09191441535949707
) O 0 2.1748815015598666e-06
twin O 0 7.522732630604878e-05
pairs O 0 4.6108962123980746e-06
( O 0 7.457118726961198e-07
27 O 0 3.6686321891465923e-06
% O 0 2.310860054421937e-07
) O 0 5.9227037496611956e-08
and O 0 1.3292320488744735e-07
4 O 0 1.3640113820656552e-06
of O 0 1.5606833869696857e-07
32 O 0 3.2291336538037285e-06
DZ O 0 0.12502765655517578
twin O 0 0.0009531874093227088
pairs O 0 4.540489953797078e-06
overall O 0 2.9488004656741396e-05
( O 0 1.5225019467379752e-07
12 O 0 3.0850554821881815e-07
. O 0 1.312911734885347e-07
5 O 0 1.19456547054142e-06
% O 0 5.728973633267742e-07
) O 0 6.257411087062792e-07
. O 0 4.34912544733379e-06

Nonsignificant O 0 0.0032006679102778435
increases O 0 3.0512179364450276e-05
in O 0 8.78142941473925e-07
similarity O 0 1.4038995459486614e-06
with O 0 2.2910668917575094e-07
regard O 0 4.27011144665812e-07
to O 0 2.2650974642601795e-06
age O 0 2.770277660602005e-06
at O 0 4.326693670009263e-05
disease O 0 0.0004311330849304795
onset O 0 1.2245906873431522e-05
and O 0 4.118091965210624e-07
all O 0 1.9543747953321144e-08
of O 0 1.1420359413705228e-07
the O 0 1.90533774002688e-05
disease O 0 0.008173428475856781
severity O 0 4.5874057832406834e-05
scores O 0 5.843311100761639e-06
assessed O 0 1.2699716535280459e-05
were O 0 1.1089601912317448e-06
noted O 0 9.45639840210788e-06
in O 0 1.696994513622485e-05
disease O 0 0.004602361936122179
- O 0 0.028462087735533714
concordant O 0 0.0695381760597229
MZ O 1 0.9974397420883179
twins O 0 0.002632878255099058
compared O 0 2.1745208869106136e-05
with O 0 4.983089638699312e-06
concordant O 0 0.02326161228120327
DZ O 1 0.9993746876716614
twins O 0 0.0144981499761343
. O 0 5.09292003698647e-05

HLA O 0 0.2990444004535675
- O 0 0.0017416203627362847
B27 O 0 2.7053018129663542e-05
and O 0 1.5170652432061615e-06
B60 O 0 2.6545278615230927e-06
were O 0 4.164100175785279e-07
associated O 0 1.6405515168571583e-07
with O 0 1.6846937000991602e-07
the O 0 6.350937383103883e-06
disease O 0 7.185485446825624e-05
in O 0 5.161963940736314e-07
probands O 0 8.974187221610919e-05
, O 0 7.8018041449468e-07
and O 0 2.4790443831079756e-07
the O 0 2.0554784896376077e-07
rate O 0 3.761961352211074e-06
of O 0 4.3163728946638e-07
disease O 0 2.7678648621076718e-05
concordance O 0 7.376319899776718e-06
was O 0 4.447391984285787e-05
significantly O 0 3.858776381093776e-06
increased O 0 1.1507070212246617e-06
among O 0 5.373349267756566e-07
DZ O 0 0.18052878975868225
twin O 0 0.00032430721330456436
pairs O 0 1.2326274827501038e-06
in O 0 4.2585577375575667e-07
which O 0 5.66951825931028e-07
the O 0 1.0362732609792147e-06
co O 0 0.002393959788605571
- O 0 0.0026931557804346085
twin O 0 0.005062000826001167
was O 0 3.424118403927423e-05
positive O 0 9.395224509489708e-08
for O 0 6.085586079507266e-08
both O 0 2.0838868408645794e-07
B27 O 0 1.884529228846077e-05
and O 0 1.374649946228601e-05
DR1 O 0 0.10141807794570923
. O 0 1.7001872038235888e-05

Additive O 0 0.00021663118968717754
genetic O 0 0.000572979508433491
effects O 0 0.00010648866737028584
were O 0 2.31708418141352e-06
estimated O 0 1.4051397556613665e-06
to O 0 1.781659619837228e-07
contribute O 0 1.2837867302550876e-07
97 O 0 3.102028074408736e-07
% O 0 7.21166628636638e-08
of O 0 3.1924884069667314e-08
the O 0 5.882758387087961e-07
population O 0 1.959998826350784e-06
variance O 0 5.034612058807397e-06
. O 0 5.8086629906028975e-06

CONCLUSION O 0 0.00033854955108836293
Susceptibility O 0 0.0011110324412584305
to O 0 1.2389924449962564e-05
AS B-Disease 0 0.4752312898635864
is O 0 8.842955026011623e-07
largely O 0 5.609144295704027e-07
genetically O 0 1.2145142136432696e-05
determined O 0 4.225274551572511e-06
, O 0 2.728330059653672e-07
and O 0 2.2122372911326238e-07
the O 0 3.9157069409156975e-07
environmental O 0 4.371154773252783e-06
trigger O 0 6.032850706105819e-06
for O 0 6.408037620531104e-07
the O 0 2.1278752683429047e-05
disease O 0 0.00043670576997101307
is O 0 6.540160484291846e-07
probably O 0 2.5434935650991974e-06
ubiquitous O 0 2.468328057148028e-05
. O 0 6.059935003577266e-06

HLA O 0 0.2032015025615692
- O 0 0.0021881316788494587
B27 O 0 6.062555257813074e-05
accounts O 0 2.1719631604355527e-06
for O 0 1.1651715681182395e-07
a O 0 2.4952350941020995e-07
minority O 0 8.630689194433216e-07
of O 0 1.0406689909814304e-07
the O 0 6.985814025028958e-07
overall O 0 0.0003261265519540757
genetic O 0 0.0009380347328260541
susceptibility O 0 0.00057567487237975
to O 0 1.0861564987862948e-05
AS B-Disease 1 0.9940853118896484
. O 0 7.492199074476957e-05

Cell O 0 0.0012680159416049719
cycle O 0 0.0002178229478886351
- O 0 0.000344887055689469
dependent O 0 1.4274117347667925e-05
colocalization O 0 2.42557634919649e-05
of O 0 2.1521987036976498e-07
BARD1 O 0 0.00014703570923302323
and O 0 3.4290155781491194e-06
BRCA1 O 0 2.1286303308443166e-05
proteins O 0 1.5809125386567757e-07
in O 0 9.547383683639055e-08
discrete O 0 2.590613576103351e-06
nuclear O 0 0.0001642200513742864
domains O 0 1.24662756206817e-05
. O 0 6.449301054090029e-06

Germ O 0 0.06899187713861465
- O 0 0.0010868820827454329
line O 0 3.422486042836681e-05
mutations O 0 9.687297279015183e-06
of O 0 1.291318767471239e-07
the O 0 1.0811811534949811e-06
BRCA1 O 0 0.00024084714823402464
gene O 0 1.5572695701848716e-05
predispose O 0 1.2347284609859344e-05
women O 0 9.484164706918818e-07
to O 0 3.132771269065415e-07
early O 0 1.1594996067287866e-05
- O 1 0.8859137892723083
onset O 1 0.7846569418907166
breast B-Disease 1 0.9999048709869385
and I-Disease 1 0.9975048899650574
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
by O 0 6.841535764579021e-07
compromising O 0 1.4625901712861378e-05
the O 0 4.7120809654188633e-07
genes O 0 2.3374716420221375e-06
presumptive O 0 0.0006224344833754003
function O 0 6.530661949000205e-07
as O 0 7.847531833249377e-07
a O 0 2.6724645067588426e-05
tumor B-Disease 0 0.006088113412261009
suppressor O 0 0.001592398388311267
. O 0 2.3012213205220178e-05

Although O 0 1.097991753340466e-05
the O 0 1.057546569427359e-06
biochemical O 0 5.387329110817518e-06
properties O 0 9.213878001901321e-06
of O 0 9.876879403236671e-07
BRCA1 O 0 0.000890078314114362
polypeptides O 0 1.1037112017220352e-05
are O 0 3.5631128980639915e-07
not O 0 1.4565368644525734e-07
understood O 0 2.7726935059035895e-07
, O 0 8.914089733025321e-08
their O 0 6.861982626560348e-08
expression O 0 1.9379018567633466e-07
pattern O 0 2.869634499802487e-06
and O 0 4.528803287939809e-07
subcellular O 0 4.184564204479102e-06
localization O 0 8.190711923816707e-06
suggest O 0 7.120628993106948e-07
a O 0 5.534704996534856e-07
role O 0 1.0387240081399796e-06
in O 0 1.4832999113423284e-06
cell O 0 0.0002181133022531867
- O 0 0.0038555869832634926
cycle O 0 0.0001972589234355837
regulation O 0 2.41667094087461e-05
. O 0 8.789558705757372e-06

When O 0 3.294941416243091e-05
resting O 0 6.178361945785582e-05
cells O 0 1.4315356565930415e-05
are O 0 4.198055876258877e-07
induced O 0 1.2371104276098777e-05
to O 0 7.746438086542184e-07
proliferate O 0 7.907008694019169e-06
, O 0 2.061412800458129e-07
the O 0 4.6636678519007546e-08
steady O 0 6.644573659286834e-06
- O 0 9.311159374192357e-06
state O 0 1.2500908042056835e-07
levels O 0 6.735975688343387e-08
of O 0 3.645908464022796e-08
BRCA1 O 0 1.851053639256861e-05
increase O 0 9.252641461898747e-07
in O 0 2.729837262904766e-07
late O 0 4.200421244604513e-06
G1 O 0 0.00010022290371125564
and O 0 4.389069374610699e-07
reach O 0 2.3852697950133006e-07
a O 0 5.405312322181999e-07
maximum O 0 1.0444823601574171e-06
during O 0 2.3653499283682322e-06
S O 0 0.0008244774071499705
phase O 0 1.9547871488612145e-05
. O 0 6.4185728660959285e-06

Moreover O 0 9.210203279508278e-05
, O 0 2.745030769801815e-06
in O 0 8.020602422220691e-07
S O 0 0.005193741526454687
phase O 0 1.446072019462008e-05
cells O 0 8.343532499566209e-06
, O 0 5.451443598758487e-07
BRCA1 O 0 1.8180789993493818e-05
polypeptides O 0 1.5822865861991886e-06
are O 0 1.0082507628794701e-07
hyperphosphorylated O 0 1.9469693143037148e-05
and O 0 1.1380158184692846e-06
accumulate O 0 1.1878336181325722e-06
into O 0 1.2186590936380526e-07
discrete O 0 2.8353449579299195e-06
subnuclear O 0 0.00011090658517787233
foci O 0 0.0001069800418918021
termed O 0 8.274754509329796e-05
" O 0 2.5876657673506998e-05
BRCA1 O 0 0.00024708276032470167
nuclear O 0 0.00017785023374017328
dots O 0 0.0006832486833445728
. O 0 2.0536812371574342e-05

" O 0 0.0021078146528452635
BRCA1 O 0 0.03221733495593071
associates O 0 0.2534118592739105
in O 0 1.0057737199531402e-05
vivo O 0 0.00031685439171269536
with O 0 8.485125135848648e-07
a O 0 2.0226079868734814e-05
structurally O 0 0.01166227925568819
related O 0 1.7602254956727847e-05
protein O 0 4.958787758368999e-05
termed O 0 0.000328374735545367
BARD1 O 0 0.037286434322595596
. O 0 2.8541040592244826e-05

Here O 0 1.9174705812474713e-05
we O 0 1.5809985143278027e-06
show O 0 6.900845619384199e-07
that O 0 4.9466414964172145e-08
the O 0 5.98917040406377e-08
steady O 0 7.436966370732989e-06
- O 0 1.2455606338335201e-05
state O 0 1.3190073389068857e-07
levels O 0 5.8704515026875015e-08
of O 0 3.097921208450316e-08
BARD1 O 0 5.605668411590159e-05
, O 0 2.480723537701124e-07
unlike O 0 4.6078227455836895e-08
those O 0 1.6178404393940582e-08
of O 0 7.77073765334535e-08
BRCA1 O 0 0.00020301037875469774
, O 0 1.4815071835982963e-06
remain O 0 2.1729088928168494e-07
relatively O 0 9.949773271955564e-08
constant O 0 2.4096289052977227e-07
during O 0 1.2234783071107813e-06
cell O 0 0.00016106039402075112
cycle O 0 0.0002993627858813852
progression O 0 0.0005447490839287639
. O 0 1.9515087842592038e-05

However O 0 4.2064613808179274e-05
, O 0 6.666751232842216e-06
immunostaining O 0 0.00011336802708683535
revealed O 0 3.145085429423489e-05
that O 0 2.3005253524388536e-07
BARD1 O 0 7.736328552709892e-05
resides O 0 5.761570264439797e-06
within O 0 1.9404872375616833e-07
BRCA1 O 0 8.546580647816882e-05
nuclear O 0 6.59906945656985e-05
dots O 0 7.361162715824321e-05
during O 0 8.572401384299155e-06
S O 0 0.00047720089787617326
phase O 0 1.5316578583224327e-06
of O 0 5.0051610855916806e-08
the O 0 2.3999461973289726e-07
cell O 0 3.976951848017052e-05
cycle O 0 1.837994386733044e-05
, O 0 3.704386983827135e-07
but O 0 8.255153005620741e-08
not O 0 4.339974779554723e-08
during O 0 8.058648148789871e-08
the O 0 3.363778944276419e-07
G1 O 0 0.00020240234152879566
phase O 0 2.7495463655213825e-05
. O 0 7.890074812166858e-06

Nevertheless O 0 0.00039076534449122846
, O 0 6.81118035572581e-06
BARD1 O 0 0.0001256160467164591
polypeptides O 0 1.0359232874179725e-05
are O 0 1.8491340370019316e-07
found O 0 3.626828402047977e-07
exclusively O 0 1.2651655367790227e-07
in O 0 9.360488206766604e-08
the O 0 4.4717062053223344e-08
nuclear O 0 2.14040778701019e-06
fractions O 0 1.648539154075479e-07
of O 0 3.4827209560717165e-08
both O 0 1.7535458596285025e-07
G1 O 0 0.00014400752843357623
- O 0 8.923872519517317e-05
and O 0 3.4549375413917005e-06
S O 0 0.001283134100958705
- O 0 4.133196489419788e-05
phase O 0 1.1693115084199235e-05
cells O 0 1.3550028597819619e-05
. O 0 4.106227152078645e-06

Therefore O 0 4.10757347708568e-05
, O 0 2.8096553705836413e-06
progression O 0 9.509592018730473e-06
to O 0 1.0777006309581338e-06
S O 0 0.005598816554993391
phase O 0 7.434336112055462e-06
is O 0 3.087733944084903e-07
accompanied O 0 2.238073477656144e-07
by O 0 3.0478918944254474e-08
the O 0 3.34275185309707e-08
aggregation O 0 3.9920996641740203e-07
of O 0 9.547438395429708e-08
nuclear O 0 2.996893090312369e-05
BARD1 O 0 8.088613685686141e-05
polypeptides O 0 5.151998266228475e-06
into O 0 1.9767842331930296e-06
BRCA1 O 0 0.00037889170926064253
nuclear O 0 0.00016714053344912827
dots O 0 0.00047243834706023335
. O 0 1.8889662896981463e-05

This O 0 7.978490430105012e-06
cell O 0 5.857333235326223e-05
cycle O 0 6.681654485873878e-05
- O 0 9.221504296874627e-05
dependent O 0 4.78666470371536e-06
colocalization O 0 1.8382819689577445e-05
of O 0 1.6334450947397272e-07
BARD1 O 0 0.000161737683811225
and O 0 7.364117664110381e-06
BRCA1 O 0 0.0001538721116958186
indicates O 0 9.632738056097878e-07
a O 0 1.9843535881136631e-07
role O 0 5.750957257077971e-07
for O 0 3.891163373737072e-07
BARD1 O 0 0.00038394148577935994
in O 0 8.15159273770405e-06
BRCA1 O 0 0.00564199173822999
- O 0 0.06883754581212997
mediated O 0 0.4300073981285095
tumor B-Disease 0 0.481205552816391
suppression O 0 4.849996548728086e-05
. O 0 9.914205293171108e-06

Ethnic O 0 5.162207526154816e-05
differences O 0 3.9432692574337125e-05
in O 0 2.332456915610237e-06
the O 0 1.5673402913307655e-06
HFE O 0 0.0009398006368428469
codon O 0 4.615014040609822e-05
282 O 0 0.00011147563782287762
( O 0 8.164624887285754e-06
Cys O 0 0.17024923861026764
/ O 0 0.0019337630365043879
Tyr O 0 0.001135293859988451
) O 0 3.233414190617623e-06
polymorphism O 0 6.25088723609224e-05
. O 0 1.184641496365657e-05

Recent O 0 4.3648877181112766e-05
studies O 0 5.999316726956749e-06
have O 0 9.903761792884325e-07
shown O 0 1.6301351934089325e-05
that O 0 0.002447292674332857
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.8616852760314941
HH B-Disease 1 0.9997513890266418
) O 0 7.453488706232747e-06
is O 0 7.289871746252174e-07
likely O 0 1.0636964589139097e-06
to O 0 3.396938552668871e-07
be O 0 7.876969334574824e-07
caused O 0 9.896226629280136e-07
by O 0 1.0188426102786252e-07
homozygosity O 0 1.161263480753405e-05
for O 0 1.3488347860857175e-07
a O 0 1.325132757301617e-06
Cys282Tyr O 0 9.525463974568993e-05
mutation O 0 4.0555719351687e-06
in O 0 1.4298585426786303e-07
the O 0 4.333308254445001e-07
HFE O 0 0.0002693546121008694
gene O 0 6.567425771208946e-06
located O 0 3.15289389618556e-06
4 O 0 2.1102498067193665e-05
. O 0 1.0848501005966682e-05

5 O 0 0.00010149396257475019
Mb O 0 0.0007677418179810047
telomeric O 0 0.000738898350391537
to O 0 1.9612625692388974e-05
HLA O 0 0.005265882238745689
- O 0 0.0004419650067575276
A O 0 6.82238896843046e-05
. O 0 1.859847725427244e-05

Population O 0 5.731069904868491e-05
studies O 0 5.462213266582694e-06
of O 0 2.1222719226443587e-07
this O 0 1.917374987669973e-07
polymorphism O 0 8.941759006120265e-06
are O 0 1.0928354754469183e-07
facilitated O 0 8.763559549151978e-07
by O 0 2.4290119426950696e-07
the O 0 2.2918295883300743e-07
fact O 0 1.9290621366963023e-07
that O 0 7.170176274939877e-08
the O 0 1.4876643206207518e-07
Cys282Tyr O 0 5.359722854336724e-05
mutation O 0 4.501942385104485e-06
creates O 0 5.471548547575367e-07
a O 0 1.1675357427520794e-06
Rsal O 0 5.588214844465256e-05
restriction O 0 2.208941168646561e-06
site O 0 1.5086745406733826e-05
. O 0 5.766181857325137e-06

We O 0 8.638028702989686e-06
have O 0 1.2018982715744642e-06
studied O 0 1.1984120646957308e-06
the O 0 4.816841965293861e-07
codon O 0 1.1689702660078183e-05
282 O 0 3.947795994463377e-05
( O 0 6.5867197918123566e-06
Cys O 0 0.11533955484628677
/ O 0 0.0016194707714021206
Tyr O 0 0.00020440961816348135
) O 0 4.387441094877431e-07
polymorphism O 0 1.0765368188003777e-06
in O 0 6.734126145602204e-08
different O 0 1.0496234637002999e-07
ethnic O 0 1.8074413219437702e-06
groups O 0 1.580690877744928e-06
. O 0 3.879490577674005e-06

In O 0 2.916982521128375e-05
agreement O 0 2.213479092461057e-06
with O 0 4.501039825299813e-07
previous O 0 4.556643489195267e-06
observations O 0 3.267092097303248e-06
the O 0 7.381925115623744e-07
Tyr O 0 4.277634070604108e-05
allele O 0 5.292877631291049e-06
appeared O 0 5.278385287965648e-06
to O 0 1.710778292363102e-07
be O 0 1.8493599895919033e-07
rare O 0 5.140535108694166e-07
or O 0 5.765983246419637e-07
absent O 0 4.171340151515324e-06
in O 0 1.8069312091029133e-06
Asiatic O 0 2.9908942451584153e-05
( O 0 1.4891689659179974e-07
Indian O 0 1.0644885151123162e-07
, O 0 6.89860968350331e-08
Chinese O 0 5.078979725681165e-08
) O 0 3.7513353845497477e-07
populations O 0 2.1068860860395944e-06
. O 0 4.370092028693762e-06

The O 0 1.243699443875812e-05
highest O 0 7.904384801804554e-06
allele O 0 1.311569576500915e-05
frequency O 0 1.6146494090207852e-05
( O 0 5.810325092170388e-07
7 O 0 2.7326814233674668e-06
. O 0 2.2939441635116964e-07
5 O 0 1.3810970358463237e-06
% O 0 6.551753131134319e-07
) O 0 2.469996616127901e-07
was O 0 5.87371641813661e-06
found O 0 1.740539914862893e-06
in O 0 8.768851671447919e-07
Swedes O 0 0.0003259500372223556
. O 0 1.1315679330436978e-05

Saamis O 0 0.005415908060967922
( O 0 1.08912936411798e-05
2 O 0 5.555441475735279e-06
% O 0 8.614505873083544e-07
) O 0 1.53518229240035e-07
and O 0 5.980848527542548e-07
Mordvinians O 0 5.276239971863106e-05
( O 0 1.590902201087374e-07
1 O 0 5.892325702916423e-07
. O 0 1.1416113210316325e-07
8 O 0 1.6331100596289616e-06
% O 0 2.897787965139287e-07
) O 0 1.1496590701653986e-07
had O 0 1.6678204701747745e-06
significantly O 0 2.210804268543143e-06
lower O 0 6.997969421718153e-07
frequencies O 0 4.77450953439984e-07
of O 0 8.682437169227342e-08
the O 0 1.7701188426144654e-06
Tyr O 0 0.00038598559331148863
allele O 0 3.109387762378901e-05
. O 0 4.662903847929556e-06

Comparisons O 0 2.760836468951311e-05
with O 0 2.1177158942009555e-06
allele O 0 8.573594641347881e-06
frequencies O 0 4.1131715988740325e-06
based O 0 4.215647095406894e-06
on O 0 2.3636997866560705e-05
prevalence O 0 0.0005100390990264714
estimates O 0 6.670207949355245e-05
of O 0 2.2927331428945763e-06
HH B-Disease 1 0.9465058445930481
showed O 0 6.597497122129425e-05
some O 0 5.1978076953673735e-08
disagreements O 0 1.6061130736488849e-06
with O 0 2.768133242625481e-07
the O 0 7.291165502465446e-07
RFLP O 0 8.538256224710494e-05
data O 0 4.298038220440503e-06
, O 0 2.2739749283573474e-07
particularly O 0 2.2360060825121764e-07
in O 0 4.1458727650933724e-07
Finns O 0 0.00027123966719955206
. O 0 1.3468876204569824e-05

The O 0 1.4258595001592766e-05
newly O 0 3.813069633906707e-05
described O 0 5.709327160730027e-05
HFE O 0 0.0002817457134369761
marker O 0 2.1345582354115322e-05
provides O 0 2.9385412858573545e-07
a O 0 2.440440312057035e-07
new O 0 3.1431588354280393e-07
approach O 0 4.455025077731989e-07
to O 0 1.8256609735090024e-07
the O 0 5.7953339904770473e-08
screening O 0 3.131307835246844e-07
of O 0 1.5030761346679355e-07
HH B-Disease 0 0.018926143646240234
as O 0 2.0950385533069493e-06
well O 0 3.242021193727851e-07
as O 0 3.662671872461942e-07
studies O 0 4.255106489381433e-08
of O 0 1.754819933807994e-08
the O 0 3.139920181638445e-07
relationship O 0 9.376514071846032e-07
between O 0 5.751615503868379e-07
the O 0 1.788345912245859e-06
HFE O 0 0.0006937796133570373
Tyr O 0 0.00011497480591060594
allele O 0 7.025981176411733e-06
and O 0 8.026647151382349e-07
different O 0 1.7717791251925519e-06
disorders O 0 0.00907642487436533
including O 0 0.00011928992171306163
cancer B-Disease 1 0.5853133797645569

Autosomal B-Disease 1 0.9997357726097107
dominant I-Disease 1 0.988350510597229
neurohypophyseal I-Disease 1 0.9999879598617554
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9998815059661865
associated O 0 0.00020333330030553043
with O 0 1.5727815707577975e-06
a O 0 1.055854227161035e-05
missense O 0 0.00043554254807531834
mutation O 0 1.5371044355561025e-05
encoding O 0 6.207369551702868e-06
Gly23 O 0 0.00030443008290603757
- O 0 0.0013896707678213716
- O 0 0.004811407532542944
> O 0 4.2858409869950265e-05
Val O 0 0.0003932039253413677
in O 0 7.310769888135837e-06
neurophysin O 0 0.0010659528197720647
II O 0 0.0010714877862483263
. O 0 1.5808891475899145e-05

Autosomal B-Disease 1 0.9998270869255066
dominant I-Disease 1 0.9951063394546509
neurohypophyseal I-Disease 1 0.99998939037323
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999740123748779
( O 0 0.0002616285055410117
ADNDI B-Disease 0 0.28348711133003235
) O 0 2.3555940060759895e-05
is O 0 7.380316219496308e-06
an O 0 0.013620738871395588
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.004060748964548111
by O 0 1.030684870784171e-05
progressive O 0 0.06973373144865036
degeneration O 0 0.08062123507261276
of O 0 2.4527295749976474e-07
the O 0 1.0405493640064378e-06
magnocellular O 0 5.636984860757366e-05
neurons O 0 1.4594664207834285e-05
of O 0 7.96819605852761e-08
the O 0 5.983027904221672e-07
hypothalamus O 0 4.257698492438067e-06
leading O 0 3.960522008128464e-06
to O 0 7.424463319694041e-07
decreased O 0 4.1736839193617925e-06
ability O 0 2.0509902753929055e-07
to O 0 1.7366041049626801e-07
produce O 0 1.180516733256809e-06
the O 0 1.8417333649267675e-06
hormone O 0 1.4219052900443785e-05
arginine O 0 4.313970566727221e-05
vasopressin O 0 3.128256503259763e-05
( O 0 8.507942652613565e-07
AVP O 0 0.00011345074017299339
) O 0 1.2781225677827024e-06
. O 0 3.0373962545127142e-06

Affected O 0 8.400164369959384e-05
individuals O 0 1.2833428399972036e-06
are O 0 2.1521186965856032e-07
not O 0 4.3750318923230225e-07
symptomatic O 0 1.2320878340688068e-05
at O 0 2.3601904103998095e-05
birth O 0 0.0001221086859004572
, O 0 2.99777843792981e-06
but O 0 1.3687312048205058e-06
usually O 0 2.31967987929238e-06
develop O 0 0.00015034820535220206
diabetes B-Disease 1 0.9426926374435425
insipidus I-Disease 0 0.0048380689695477486
at O 0 8.672009244037326e-06
1 O 0 1.385271389153786e-05
- O 0 0.001559492782689631
6 O 0 0.00010298912093276158
yr O 0 0.0009033143287524581
of O 0 5.738970116908604e-07
age O 0 5.027189672546228e-06
. O 0 4.702533260569908e-06

The O 0 1.203346073452849e-05
genetic O 0 4.578717198455706e-05
locus O 0 3.067574289161712e-05
of O 0 1.3576290029959637e-06
the O 0 3.1883817428024486e-05
disease O 0 0.0034725251607596874
is O 0 7.965155077727104e-07
the O 0 1.1001171742464066e-06
AVP O 0 0.005265240091830492
- O 0 0.023815155029296875
neurophysin O 0 0.004231477156281471
II O 0 0.001245145103894174
( O 0 5.301083660924633e-07
NPII O 0 5.343326483853161e-05
) O 0 3.070376806135755e-07
gene O 0 5.441989969767747e-07
, O 0 1.9206602530630335e-07
and O 0 7.738344720564783e-07
mutations O 0 7.027992069197353e-06
that O 0 8.432126037405396e-07
cause O 0 5.275612238619942e-06
ADNDI B-Disease 0 0.006143717560917139
have O 0 1.6821326198623865e-06
been O 0 1.8265784547111252e-06
found O 0 5.748293006035965e-07
in O 0 8.008940710624302e-08
both O 0 3.673879689358728e-08
the O 0 6.09711179322403e-08
signal O 0 1.1850919463540777e-06
peptide O 0 1.3578190305452154e-07
of O 0 1.5206062187189673e-08
the O 0 1.5463716351860057e-07
prepro O 0 5.3507039410760626e-05
- O 0 9.524337656330317e-05
AVP O 0 0.00019188229634892195
- O 0 3.851695510093123e-05
NPII O 0 3.617307447711937e-05
precursor O 0 2.247684733447386e-06
and O 0 1.302441177131186e-07
within O 0 1.8615089913964766e-07
NPII O 0 0.00018946558702737093
itself O 0 2.5829025616985746e-05
. O 0 9.967426194634754e-06

An O 0 2.772612242551986e-05
affected O 0 7.72846306063002e-06
girl O 0 0.00030341651290655136
who O 0 1.1809034731413703e-05
presented O 0 2.877002998502576e-06
at O 0 1.4332144928630441e-06
9 O 0 5.964477168163285e-06
months O 0 8.493804557474505e-07
of O 0 5.8031648819678594e-08
age O 0 8.878860739969241e-07
and O 0 9.334285664408526e-07
her O 0 1.566064020153135e-05
similarly O 0 7.33960632715025e-06
affected O 0 5.856538223270036e-07
younger O 0 1.4881201195748872e-06
brother O 0 1.2082227840437554e-05
and O 0 2.896361820603488e-06
father O 0 9.496015991317108e-06
were O 0 3.735210327704408e-07
all O 0 1.8046179661723727e-08
found O 0 3.2646858016960323e-07
to O 0 1.3938789322764933e-07
have O 0 1.7811923669341923e-07
a O 0 2.11084420698171e-06
novel O 0 1.8107150026480667e-05
missense O 0 0.000198322391952388
mutation O 0 2.8367996492306702e-05
( O 0 5.217952434577455e-07
G1758 O 0 7.435590759996558e-06
- O 0 0.0029562858399003744
- O 0 0.026175135746598244
> O 0 1.0268447113048751e-05
T O 0 5.88109833188355e-05
) O 0 2.1009975981201023e-08
encoding O 0 3.761892841680492e-08
the O 0 2.078089167412145e-08
amino O 0 1.6052433693403145e-07
acid O 0 5.711898438676144e-07
substitution O 0 1.7996995893554413e-07
Gly23 O 0 1.0464791557751596e-05
- O 0 3.918943548342213e-05
- O 0 0.00014811304572504014
> O 0 7.23584389561438e-06
Val O 0 2.29909346671775e-05
within O 0 7.519140012846037e-07
NPII O 0 0.0005065100849606097
. O 0 8.627532224636525e-06

The O 0 4.0739032556302845e-05
mutation O 0 0.00017537061648909003
was O 0 4.445899321581237e-05
confirmed O 0 1.591232285136357e-05
by O 0 4.205268737678125e-07
restriction O 0 2.989364929817384e-06
endonuclease O 0 0.00023842368682380766
analysis O 0 3.566652230801992e-05
. O 0 1.357906967314193e-05

A O 0 0.00010171368921874091
T1 O 0 0.01744239404797554
- O 0 0.00027537596179172397
weighted O 0 5.7679085330164526e-06
magnetic O 0 5.285180122882593e-06
resonance O 0 6.3067805058381055e-06
imaging O 0 9.326698636868969e-05
of O 0 2.1093659086091066e-07
the O 0 4.54206610811525e-06
fathers O 0 6.85960694681853e-05
pituitary O 0 0.00018229895795229822
gland O 0 0.00014222801837604493
demonstrates O 0 3.894362635037396e-06
an O 0 1.1106991451015347e-06
attenuated O 0 0.00023024642723612487
posterior O 0 0.0016373199177905917
pituitary O 0 0.0013164825504645705
bright O 0 9.932382090482861e-05
spot O 0 0.00018230800924357027
. O 0 1.282457378692925e-05

This O 0 2.859249980247114e-05
mutation O 0 0.0001437598984921351
may O 0 2.7789310479420237e-05
be O 0 1.4289656746768742e-07
valuable O 0 1.220066252471952e-07
for O 0 1.0530082761306403e-07
developing O 0 3.9329745504801394e-07
models O 0 3.0142707601044094e-06
of O 0 4.077359960774629e-07
dominantly B-Disease 0 0.009523672051727772
inherited I-Disease 1 0.9973968267440796
neurodegeneration I-Disease 1 1.0
, O 0 3.330313484184444e-05
as O 0 6.9366075194921e-07
the O 0 1.3785439989533188e-07
early O 0 3.68538007933239e-06
age O 0 2.448244913466624e-07
of O 0 9.347945706394967e-08
onset O 0 2.5811961677391082e-05
of O 0 3.3239537060580915e-06
symptoms O 0 0.00011219675798201934
suggests O 0 1.3785194141746615e-06
that O 0 2.1702871322304418e-07
this O 0 1.6079169995464326e-07
mutation O 0 9.152652637567371e-06
may O 0 5.396765118348412e-06
be O 0 1.2505223878633842e-07
particularly O 0 2.157424461302071e-07
deleterious O 0 4.99257885167026e-06
to O 0 4.212577948692342e-07
the O 0 7.204516805359162e-07
magnocellular O 0 0.00021732198365498334
neuron O 0 0.00029056501807644963
. O 0 1.4663895626654266e-06
. O 0 4.399093995743897e-06

Frequent O 0 0.0010783636244013906
inactivation O 0 0.022305883467197418
of O 0 9.463309652346652e-06
PTEN O 0 0.14884530007839203
/ O 0 0.002437642775475979
MMAC1 O 0 0.006940317340195179
in O 0 0.00018360136891715229
primary O 1 0.945041298866272
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 9.71837725955993e-05

Sporadic B-Disease 1 0.9875097274780273
prostate I-Disease 1 0.9999984502792358
carcinoma I-Disease 1 1.0
is O 0 3.424288297537714e-05
the O 0 3.532927621563431e-07
most O 0 1.2072430877196894e-07
common O 0 1.7902724493978894e-06
male B-Disease 0 4.3387128243921325e-05
cancer I-Disease 0 0.00018432701472193003
in O 0 1.1097573349161394e-07
the O 0 1.6264888813566358e-07
Western O 0 2.2761539639759576e-06
world O 0 2.387846961937612e-06
, O 0 2.130596499227977e-07
yet O 0 2.7492951915064623e-08
many O 0 3.0745093138051516e-09
of O 0 7.52364304190678e-09
the O 0 1.3920059416250297e-07
major O 0 7.239200954245462e-07
genetic O 0 3.7466591038537445e-06
events O 0 2.389058124663279e-07
involved O 0 2.850033808954322e-07
in O 0 3.233085692500026e-07
the O 0 6.929123514964886e-07
progression O 0 7.705853931838647e-06
of O 0 7.711545180200119e-08
this O 0 1.3009109807171626e-06
often O 0 3.2171126804314554e-05
fatal O 1 0.9734331369400024
cancer B-Disease 0 0.11635798960924149
remain O 0 2.927117520812317e-06
to O 0 8.15874159343366e-07
be O 0 1.1940724107262213e-06
elucidated O 0 0.0001673826336627826
. O 0 1.0737584489106666e-05

Numerous O 0 5.98680526309181e-05
cytogenetic O 0 0.0032160913106054068
and O 0 5.6919412600109354e-05
allelotype O 0 0.005579660646617413
studies O 0 1.584318306413479e-05
have O 0 4.492832431424176e-06
reported O 0 3.952459155698307e-05
frequent O 0 8.623961548437364e-06
loss O 0 4.1345094359712675e-05
of O 0 5.827834002047894e-07
heterozygosity O 0 0.0003941773029509932
on O 0 0.0036424067802727222
chromosomal O 1 0.571514368057251
arm O 0 0.003910460509359837
10q O 0 0.00017139218107331544
in O 0 3.0907951440894976e-05
sporadic B-Disease 1 0.9710623025894165
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 4.641681880457327e-05

Deletion O 0 0.0011328976834192872
mapping O 0 0.0005066105513833463
studies O 0 2.4948094505816698e-05
have O 0 2.235623242086149e-06
unambiguously O 0 7.840311445761472e-05
identified O 0 1.1401589290471748e-05
a O 0 1.4454806205321802e-06
region O 0 1.2282701391086448e-05
of O 0 8.085589797701687e-07
chromosome O 0 7.26442740415223e-05
10q23 O 0 4.885277576249791e-06
to O 0 4.563113407130004e-07
be O 0 1.468802111048717e-07
the O 0 7.957352465837175e-08
minimal O 0 7.360891345342679e-07
area O 0 2.0344600670796353e-06
of O 0 1.153865355263406e-06
loss O 0 0.0003200976934749633
. O 0 1.895097375381738e-05

A O 0 6.0965412558289245e-05
new O 0 4.729869033326395e-05
tumor B-Disease 0 0.0008477942901663482
suppressor O 0 0.00018461671425029635
gene O 0 2.554389720899053e-05
, O 0 3.615557034208905e-06
PTEN O 0 0.0031040040776133537
/ O 0 0.0003394527011550963
MMAC1 O 0 0.00048181062447838485
, O 0 2.264825297970674e-06
was O 0 5.201440217206255e-06
isolated O 0 1.4801642009842908e-06
recently O 0 8.964206244854722e-06
at O 0 7.560730637123925e-07
this O 0 5.711604700309181e-08
region O 0 1.0947836699415348e-06
of O 0 3.056129571632482e-07
chromosome O 0 8.506211452186108e-05
10q23 O 0 6.840284186182544e-06
and O 0 8.751349582780676e-07
found O 0 4.432880871263478e-07
to O 0 1.3081100291856274e-07
be O 0 1.8467532925114938e-07
inactivated O 0 5.829490419273498e-07
by O 0 5.35335047402441e-08
mutation O 0 1.0728532515713596e-06
in O 0 1.1882913213412394e-06
three O 0 0.05556757375597954
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
cell O 0 0.0025734396185725927
lines O 0 0.00020609601051546633
. O 0 1.6429044990218244e-05

We O 0 2.1954703697701916e-05
screened O 0 6.757825758541003e-05
80 O 0 0.0001226580934599042
prostate B-Disease 1 0.9994413256645203
tumors I-Disease 1 0.9999994039535522
by O 0 2.725669446590473e-06
microsatellite O 0 0.0001291955850319937
analysis O 0 7.877120879129507e-06
and O 0 4.511643055593595e-06
found O 0 8.252834959421307e-06
chromosome O 0 3.533410563250072e-05
10q23 O 0 3.658716423160513e-06
to O 0 4.324588758208847e-07
be O 0 6.902241977968515e-08
deleted O 0 6.023113883202313e-07
in O 0 3.760512470307731e-07
23 O 0 8.23530263005523e-06
cases O 0 9.408141750100185e-07
. O 0 2.8252877655177144e-06

We O 0 7.724314855295233e-06
then O 0 8.855977284838445e-07
proceeded O 0 4.282676684397302e-07
with O 0 3.3961313761210477e-08
sequence O 0 1.0531930882962115e-07
analysis O 0 1.1438988423151386e-07
of O 0 4.0846568793995175e-08
the O 0 4.1614325141381414e-07
entire O 0 7.082410775183234e-06
PTEN O 0 0.00732469605281949
/ O 0 6.363308057188988e-05
MMAC1 O 0 6.514013512060046e-05
coding O 0 3.9401533285854384e-05
region O 0 7.727792763034813e-06
and O 0 2.7730002329917625e-06
tested O 0 3.034535666301963e-06
for O 0 2.2402045374292356e-07
homozygous O 0 1.7730636727719684e-06
deletion O 0 2.672170694495435e-06
with O 0 2.327483485942139e-07
new O 0 6.3386905821971595e-06
intragenic O 0 0.00019053897995036095
markers O 0 2.182215393986553e-05
in O 0 9.614300324756186e-07
these O 0 1.5001661779479036e-07
23 O 0 3.4717163543973584e-06
cases O 0 1.5710635636878578e-07
with O 0 2.932717961812159e-07
10q23 O 0 7.111847662599757e-05
loss O 0 3.694380211527459e-05
of O 0 1.962516535058967e-06
heterozygosity O 0 0.0009585506049916148
. O 0 2.9193312002462335e-05

The O 0 3.933442712877877e-06
identification O 0 2.038869070020155e-06
of O 0 1.5276185649781837e-07
the O 0 2.835259067524021e-07
second O 0 7.020810244284803e-06
mutational O 0 2.8536331228679046e-05
event O 0 2.6974516913469415e-06
in O 0 4.816589580514119e-07
10 O 0 5.25405539519852e-07
( O 0 6.159940113548146e-08
43 O 0 1.0215508154942654e-06
% O 0 2.0777263216587016e-06
) O 0 1.4473384908342268e-05
tumors B-Disease 1 0.9999974966049194
establishes O 0 0.00011847393761854619
PTEN O 0 0.030190449208021164
/ O 0 7.905047095846385e-05
MMAC1 O 0 3.47430250258185e-05
as O 0 8.748114765921855e-08
a O 0 1.5407690057145373e-07
main O 0 3.932204890588764e-06
inactivation O 0 0.00012101096945116296
target O 0 2.926007027781452e-06
of O 0 1.3941129850536527e-07
10q O 0 1.1980568160652183e-05
loss O 0 4.966733467881568e-05
in O 0 1.5091350178408902e-05
sporadic B-Disease 1 0.9918261766433716
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 7.74465843278449e-06
. O 0 1.1747344615287147e-05

Risk O 0 0.004939836449921131
reversals O 0 0.0007912046276032925
in O 0 5.009935648558894e-06
predictive O 0 0.00022447522496804595
testing O 0 0.00022369984071701765
for O 0 0.002216730499640107
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999980926513672
. O 0 8.979109406936914e-05

The O 0 8.51583627081709e-06
first O 0 3.6293167795520276e-06
predictive O 0 2.2074769731261767e-05
testing O 0 1.93495270650601e-05
for O 0 0.00044910263386555016
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 4.0260492824018e-06
HD B-Disease 0 0.024622464552521706
) O 0 1.1443946732470067e-06
was O 0 6.381657840393018e-06
based O 0 2.0716761355288327e-06
on O 0 3.6043716136191506e-06
analysis O 0 6.447564260270156e-07
of O 0 1.1438323355150715e-07
linked O 0 3.472026946838014e-05
polymorphic O 0 1.3696629139303695e-05
DNA O 0 6.998787284828722e-05
markers O 0 2.9915960112703033e-05
to O 0 1.6341460877811187e-06
estimate O 0 1.478149260947248e-05
the O 0 2.4583616209383763e-07
likelihood O 0 1.048161493599764e-06
of O 0 8.825728059491666e-08
inheriting O 0 7.2723782977845985e-06
the O 0 1.1544012750164256e-06
mutation O 0 8.047516530496068e-06
for O 0 1.0228717428617529e-06
HD B-Disease 0 0.004128271713852882
. O 0 1.1429438018240035e-05

Limits O 0 2.4600798496976495e-05
to O 0 3.1244696856447263e-06
accuracy O 0 5.822162165713962e-06
included O 0 3.6753871768269164e-07
recombination O 0 7.371759238594677e-07
between O 0 2.5215487653440505e-07
the O 0 4.7249824319806066e-07
DNA O 0 2.2822250684839673e-05
markers O 0 1.5398438335978426e-05
and O 0 1.5548673673038138e-06
the O 0 5.186884663999081e-07
mutation O 0 3.1315219075622736e-06
, O 0 3.8726238926756196e-07
pedigree O 0 3.3947503652598243e-06
structure O 0 3.0505607355735265e-06
, O 0 9.577109949532314e-07
and O 0 3.9014710750961967e-07
whether O 0 1.0122607108087323e-07
DNA O 0 2.6474792775843525e-06
samples O 0 6.062306283638463e-07
were O 0 1.1258818233272905e-07
available O 0 5.5290499290094886e-08
from O 0 6.885476722118256e-08
family O 0 1.2259239383638487e-06
members O 0 1.1044166967622004e-06
. O 0 4.430604349181522e-06

With O 0 5.76306456423481e-06
direct O 0 5.641995358018903e-06
tests O 0 2.855681259461562e-06
for O 0 2.0728684546611476e-07
the O 0 3.3656883147159533e-07
HD B-Disease 0 0.0018744112458080053
mutation O 0 4.707697826233925e-06
, O 0 3.1453146220883355e-07
we O 0 7.606439567098278e-08
have O 0 6.847810141152877e-08
assessed O 0 8.025468218875176e-07
the O 0 1.49153549955372e-07
accuracy O 0 1.1901356629095972e-05
of O 0 5.492005357154994e-07
results O 0 1.2903003153041936e-05
obtained O 0 1.15195655325806e-06
by O 0 1.5057690916364663e-07
linkage O 0 3.963325525546679e-06
approaches O 0 4.473865374166053e-06
when O 0 7.872238256823039e-07
requested O 0 1.845614008288976e-07
to O 0 1.2092203860447626e-07
do O 0 3.39059731402358e-08
so O 0 2.0235718878325315e-08
by O 0 3.411881976944642e-08
the O 0 1.1960150914092083e-07
test O 0 8.226739964811713e-07
individuals O 0 3.282800093984406e-07
. O 0 2.7212799977860413e-06

For O 0 3.0843866625218652e-06
six O 0 1.5722821444796864e-06
such O 0 1.2374641755741322e-07
individuals O 0 6.91315094059064e-08
, O 0 5.405590854934417e-07
there O 0 1.3393812992035237e-07
was O 0 1.9596736819949e-05
significant O 0 6.426630534406286e-07
disparity O 0 2.8504925921879476e-06
between O 0 3.002230641868664e-07
the O 0 3.1701756597612984e-06
tests O 0 8.455643182969652e-06
. O 0 6.3253692133002914e-06

Three O 0 1.2733477888104971e-05
went O 0 1.4192012713465374e-05
from O 0 3.3810144373092044e-07
a O 0 2.5050730982911773e-06
decreased O 0 0.00010621099499985576
risk O 0 3.9608012230019085e-06
to O 0 2.8108485139455297e-07
an O 0 1.2017355857096845e-06
increased O 0 7.702210496063344e-06
risk O 0 5.7701035984791815e-06
, O 0 2.441816207010561e-07
while O 0 1.4018630167811352e-07
in O 0 5.4727394172005006e-08
another O 0 2.1530014748805115e-07
three O 0 3.8592000350945455e-07
the O 0 3.853709131362848e-06
risk O 0 1.3437736924970523e-05
was O 0 3.215582182747312e-05
decreased O 0 6.057788050384261e-05
. O 0 8.302132300741505e-06

Knowledge O 0 1.1481614819786046e-05
of O 0 5.987103008919803e-07
the O 0 9.551368975735386e-07
potential O 0 1.0616765848681098e-06
reasons O 0 2.46816938442862e-07
for O 0 1.042097039771761e-07
these O 0 2.717213298808474e-08
changes O 0 1.1179728431898184e-07
in O 0 9.701485623736517e-07
results O 0 1.7167751138913445e-05
and O 0 8.372205684281653e-07
impact O 0 2.945589301361906e-07
of O 0 3.949082838516915e-08
these O 0 2.570102708432387e-07
risk O 0 2.585899210316711e-06
reversals O 0 4.585738224704983e-06
on O 0 1.5375795555883087e-05
both O 0 5.484235316544073e-06
patients O 0 4.773335149366176e-06
and O 0 2.719803831041645e-07
the O 0 2.787564881145954e-07
counseling O 0 3.3277206057391595e-07
team O 0 1.3057518799541867e-07
can O 0 1.4459802244459752e-08
assist O 0 2.6245919215739377e-08
in O 0 9.651710541902503e-08
the O 0 5.638885625103285e-08
development O 0 8.640655835279176e-08
of O 0 3.488744226842755e-08
strategies O 0 5.515167345038208e-07
for O 0 2.13197253629005e-07
the O 0 6.430051371353329e-07
prevention O 0 2.1069545255159028e-06
and O 0 1.1292686394881457e-06
, O 0 3.662542553684034e-07
where O 0 2.9817775271112623e-07
necessary O 0 2.1537427130624565e-07
, O 0 5.616724365609116e-07
management O 0 4.253622023497883e-07
of O 0 3.0886937452123675e-08
a O 0 1.1219156476727221e-05
risk O 0 1.046381385094719e-05
reversal O 0 1.2808112842321862e-05
in O 0 3.584697765290912e-07
any O 0 1.1067007932297201e-07
predictive O 0 4.049612471135333e-06
testing O 0 2.0098607365071075e-06
program O 0 7.610254328938026e-07
. O 0 4.6285845201055054e-07
. O 0 1.9369904293853324e-06

A O 0 0.00013207296433392912
novel O 0 3.5945282434113324e-05
common O 0 1.3137728274159599e-05
missense O 0 0.0003377710236236453
mutation O 0 3.192105214111507e-05
G301C O 0 1.3439159374684095e-05
in O 0 5.281706307869172e-07
the O 0 3.483871182652365e-07
N O 0 0.0005246984073892236
- O 0 0.0004680377896875143
acetylgalactosamine O 0 0.00020638093701563776
- O 0 9.570979455020279e-05
6 O 0 2.6636507755029015e-05
- O 0 0.0005462348344735801
sulfate O 0 4.493442247621715e-05
sulfatase O 0 3.462959284661338e-05
gene O 0 3.005071675943327e-06
in O 0 1.0320146657250007e-06
mucopolysaccharidosis B-Disease 0 0.0007374064298346639
IVA I-Disease 0 0.3423689901828766
. O 0 3.4168017009506e-05

Mucopolysaccharidosis B-Disease 1 0.9153761863708496
IVA I-Disease 1 0.9999649524688721
( O 0 0.020412428304553032
MPS B-Disease 1 0.9999850988388062
IVA I-Disease 1 0.9999998807907104
) O 0 4.236227323417552e-05
is O 0 1.5286256029867218e-06
an O 0 1.3131540981703438e-05
autosomal B-Disease 1 0.9837188124656677
recessive I-Disease 1 0.9935548901557922
lysosomal I-Disease 1 0.9997901320457458
storage I-Disease 1 0.9999464750289917
disorder I-Disease 1 0.9969916343688965
caused O 0 3.727176954271272e-05
by O 0 1.1820150120911421e-06
a O 0 0.0011640983866527677
genetic B-Disease 1 0.9999988079071045
defect I-Disease 1 0.9999854564666748
in O 0 3.246725782446447e-06
N O 0 0.015563697554171085
- O 0 0.0022450501564890146
acetylgalactosamine O 0 0.004470190033316612
- O 0 0.002274581231176853
6 O 0 0.00019414945563767105
- O 0 0.3209339678287506
sulfate O 0 0.0023919413797557354
sulfatase O 0 0.00038198314723558724
( O 0 1.2312199260122725e-06
GALNS O 0 0.00010920523345703259
) O 0 2.2426679606724065e-06
. O 0 4.674167939811014e-06

In O 0 2.5058159735635854e-05
previous O 0 3.634183667600155e-05
studies O 0 3.7125355447642505e-06
, O 0 7.971219702085364e-07
we O 0 1.2424710860159394e-07
have O 0 6.716705769349574e-08
found O 0 8.488736824574517e-08
two O 0 8.998186018516208e-08
common O 0 2.9942068522359477e-06
mutations O 0 9.844578926276881e-06
in O 0 4.794147798747872e-07
Caucasians O 0 1.0483751793799456e-05
and O 0 9.921666332957102e-07
Japanese O 0 5.3459807531908154e-06
, O 0 1.2574840866363957e-06
respectively O 0 9.924251571646892e-06
. O 0 3.688896185849444e-06

To O 0 1.52706397784641e-05
characterize O 0 6.055667836335488e-05
the O 0 1.430153361070552e-06
mutational O 0 7.656668458366767e-05
spectrum O 0 7.368430942733539e-06
in O 0 2.1626979673783353e-07
various O 0 3.153826710899921e-08
ethnic O 0 1.8242006660784682e-07
groups O 0 8.275126361922958e-08
, O 0 3.8635158716715523e-07
mutations O 0 6.458025723077299e-07
in O 0 5.381576073659744e-08
the O 0 1.7316361322627927e-07
GALNS O 0 0.00016898111789487302
gene O 0 4.765670837514335e-06
in O 0 6.83835878589889e-07
Colombian O 0 4.272521982784383e-05
MPS B-Disease 1 0.9998119473457336
IVA I-Disease 1 1.0
patients O 0 0.0008210965897887945
were O 0 1.3557994407165097e-06
investigated O 0 8.402990715694614e-06
, O 0 6.266463969950564e-07
and O 0 8.186597710846399e-07
genetic O 0 2.7487769784784177e-06
backgrounds O 0 6.247036026252317e-07
were O 0 5.911823564019869e-07
extensively O 0 1.6391969666074147e-06
analyzed O 0 3.213392801626469e-06
to O 0 3.002863309120585e-07
identify O 0 1.2882243254352943e-06
racial O 0 4.0806003198667895e-07
origin O 0 5.54976850253297e-07
, O 0 3.7841738276256365e-07
based O 0 6.022005436534528e-07
on O 0 7.778426152071916e-06
mitochondrial O 0 0.00012786497245542705
DNA O 0 0.0008288259850814939
( O 0 1.1511559705468244e-06
mtDNA O 0 6.663255135208601e-06
) O 0 9.272985153074842e-07
lineages O 0 8.444200830126647e-06
. O 0 3.573120920918882e-06

Three O 0 3.578812174964696e-05
novel O 0 3.611254214774817e-05
missense O 0 0.0007884337683208287
mutations O 0 0.0006354197394102812
never O 0 4.291698496672325e-05
identified O 0 9.055560440174304e-06
previously O 0 3.582531689971802e-06
in O 0 3.4455689501555753e-07
other O 0 2.297295935704824e-07
populations O 0 8.272252216556808e-07
and O 0 1.1637650914053665e-06
found O 0 8.46858483782853e-07
in O 0 1.5478293846626912e-07
16 O 0 4.3730088350457663e-07
out O 0 7.152937797627601e-08
of O 0 1.0877572265144408e-07
19 O 0 1.3130664228810929e-05
Colombian O 0 7.483852095901966e-05
MPS B-Disease 1 0.9983277916908264
IVA I-Disease 1 0.9999979734420776
unrelated O 0 6.961916369618848e-05
alleles O 0 8.023830559977796e-06
account O 0 3.5966527320852038e-06
for O 0 1.7431096921427525e-06
84 O 0 2.180563569709193e-05
. O 0 9.595883057045285e-06

2 O 0 5.436848005047068e-05
% O 0 1.4301479041023413e-06
of O 0 8.244971638760035e-08
the O 0 1.1734134375274152e-07
alleles O 0 1.101200496123056e-06
in O 0 4.068026839831873e-07
this O 0 3.7546033127000555e-07
study O 0 2.7042437977797817e-06
. O 0 6.429171207855688e-06

The O 0 1.2440173122740816e-05
G301C O 0 5.4976913816062734e-05
and O 0 5.782101197837619e-06
S162F O 0 4.97540422657039e-05
mutations O 0 5.130034332978539e-05
account O 0 2.027379196078982e-06
for O 0 1.022449396259617e-06
68 O 0 4.9752048653317615e-05
. O 0 1.680607419984881e-05

4 O 0 0.0001414988946635276
% O 0 7.429325250996044e-06
and O 0 2.2899625946593005e-06
10 O 0 4.242195700498996e-06
. O 0 6.906995622557588e-06

5 O 0 4.535096377367154e-05
% O 0 2.9141299364709994e-06
of O 0 2.479961835888389e-07
mutations O 0 1.5223280570353381e-05
, O 0 1.2920322660647798e-06
respectively O 0 5.8679938774730545e-06
, O 0 2.4675080112501746e-07
whereas O 0 1.4955679716877057e-07
the O 0 4.2106702125011e-08
remaining O 0 1.0234562068944797e-06
F69V O 0 0.00016638585657346994
is O 0 1.5163305988608045e-07
limited O 0 7.024280535006255e-08
to O 0 5.098926081359423e-08
a O 0 5.074990099274146e-07
single O 0 1.7636466509429738e-05
allele O 0 6.0987851611571386e-05
. O 0 1.0237070455332287e-05

The O 0 3.4599888749653473e-05
skewed O 0 0.0001748910144669935
prevalence O 0 0.00014822775847278535
of O 0 3.4957659522660833e-07
G301C O 0 8.185433216567617e-06
in O 0 8.173374794750998e-07
only O 0 1.4272522719238623e-07
Colombian O 0 1.0356002348999027e-05
patients O 0 3.861611276079202e-06
and O 0 7.810276656528004e-07
haplotype O 0 4.355390774435364e-05
analysis O 0 9.06812545053981e-07
by O 0 9.497399844349275e-08
restriction O 0 3.694145220833889e-07
fragment O 0 2.0104656869079918e-05
length O 0 1.2116634934500325e-05
polymorphisms O 0 4.5426884753396735e-05
in O 0 4.269606392881542e-07
the O 0 4.7531750624330016e-07
GALNS O 0 0.0002506762684788555
gene O 0 3.619976496338495e-06
suggest O 0 5.303389798427816e-07
that O 0 5.1486797048028166e-08
G301C O 0 1.5281445939763216e-06
originated O 0 3.063748863496585e-07
from O 0 5.10392723640507e-08
a O 0 4.479397546219843e-07
common O 0 4.676442131312797e-06
ancestor O 0 4.627494854503311e-05
. O 0 1.327294285147218e-05

Investigation O 0 3.46571505360771e-05
of O 0 1.004923319669615e-06
the O 0 7.792517067173321e-07
genetic O 0 1.3502609363058582e-05
background O 0 2.279812406413839e-06
by O 0 1.9221353397824714e-07
means O 0 1.7093056214889657e-07
of O 0 5.3841631597606465e-08
mtDNA O 0 2.200912831540336e-06
lineages O 0 1.7090119399654213e-06
indicate O 0 1.7365092617183109e-06
that O 0 9.060477879074824e-08
all O 0 2.6956460175142638e-08
our O 0 1.343973849543545e-06
patients O 0 1.5923911860227236e-06
are O 0 2.0474171691375886e-08
probably O 0 2.2952922051899805e-07
of O 0 9.157562885775405e-08
native O 0 6.605093858524924e-06
American O 0 2.4441105779260397e-05
descent O 0 0.0007246696623042226

Low O 0 8.490134496241808e-05
frequency O 0 4.406399966683239e-05
of O 0 3.898130671586841e-06
BRCA1 O 0 0.001733400858938694
germline O 0 0.001979860942810774
mutations O 0 0.00013478670734912157
in O 0 1.3359259583012317e-06
45 O 0 2.008465162361972e-05
German O 1 0.9987210631370544
breast B-Disease 1 0.9999980926513672
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 1.6543313904548995e-05
. O 0 1.4743535757588688e-05

In O 0 1.38629429784487e-05
this O 0 4.1243566784032737e-07
study O 0 3.719513017585996e-07
we O 0 2.2515391151500808e-07
investigated O 0 3.3986307244049385e-06
45 O 0 5.659234830091009e-06
German O 1 0.9972777962684631
breast B-Disease 1 0.9999986886978149
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 6.542562687172904e-07
for O 0 7.848280461075774e-07
germline O 0 0.0003083369228988886
mutations O 0 4.679950143327005e-05
in O 0 5.034843297835323e-07
the O 0 3.5495943393470952e-06
BRCA1 O 0 0.006060066167265177
gene O 0 7.737058331258595e-05
. O 0 7.697121873206925e-06

We O 0 1.49672569023096e-05
identified O 0 7.249478585436009e-06
four O 0 1.1555832770682173e-06
germline O 0 0.00011822025408037007
mutations O 0 3.595344242057763e-05
in O 0 1.809283162401698e-06
three O 0 0.0001555264025228098
breast B-Disease 1 0.9996861219406128
cancer I-Disease 0 0.08114572614431381
families O 0 3.7248869944050966e-07
and O 0 1.0963342447212199e-06
in O 0 1.8599471331981476e-06
one O 0 0.0017177639529109001
breast B-Disease 1 0.999997615814209
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 8.362905646208674e-06
. O 0 1.34118479877543e-07
among O 0 3.1931218558156615e-08
these O 0 1.1896238660824565e-08
were O 0 2.3985458597053366e-07
one O 0 6.149294335955346e-07
frameshift O 0 0.00030877432436682284
mutation O 0 1.0337076673749834e-05
, O 0 4.3980315922453883e-07
one O 0 3.85630073651555e-07
nonsense O 0 1.1974105291301385e-05
mutation O 0 4.531344984570751e-06
, O 0 2.073665257285029e-07
one O 0 1.5171217171427998e-07
novel O 0 9.511301755082968e-07
splice O 0 0.00025660046958364546
site O 0 7.617290248163044e-05
mutation O 0 9.771099939825945e-06
, O 0 3.933949983547791e-07
and O 0 3.969041415530228e-07
one O 0 1.8410345319352928e-06
missense O 0 0.0002882682019844651
mutation O 0 0.00011591337533900514
. O 0 1.3247764400148299e-05

The O 0 2.640539241838269e-05
missense O 0 0.0015315383207052946
mutation O 0 0.0002519925474189222
was O 0 8.698037709109485e-05
also O 0 4.721523055195576e-06
found O 0 1.6611564888080466e-06
in O 0 8.865052336659573e-07
2 O 0 3.892383392667398e-05
. O 0 1.6590238374192268e-05

8 O 0 5.419341323431581e-05
% O 0 1.2964547977389884e-06
of O 0 8.542221507923387e-08
the O 0 4.006455185390223e-07
general O 0 8.521283803020197e-07
population O 0 1.8204207208327716e-07
, O 0 1.2854505371251435e-07
suggesting O 0 6.982050422266184e-07
that O 0 8.026465536659089e-08
it O 0 4.4546638378051284e-07
is O 0 2.0772567950189114e-06
not O 0 7.088464826665586e-06
disease O 0 0.00014653046673629433
associated O 0 5.595628863375168e-06
. O 0 6.14508826402016e-06

The O 0 1.5930603694869205e-05
average O 0 3.646510958787985e-05
age O 0 7.22346021575504e-06
of O 0 2.8326585379545577e-06
disease O 0 0.0029375317972153425
onset O 0 0.00010242118878522888
in O 0 2.2413573788071517e-06
those O 0 3.175045435455104e-07
families O 0 8.535549795851693e-07
harbouring O 0 0.0004100020451005548
causative O 0 0.0005848153959959745
mutations O 0 0.00026479168445803225
was O 0 1.5156572771957144e-05
between O 0 1.050325977303146e-06
32 O 0 3.055469278478995e-05
. O 0 1.3550959010899533e-05

3 O 0 0.0002027322188951075
and O 0 8.554009582439903e-06
37 O 0 3.83349834010005e-05
. O 0 1.3336994015844539e-05

4 O 0 0.00020990008488297462
years O 0 1.4670436030428391e-05
, O 0 5.405926231105695e-07
whereas O 0 3.0725385613550316e-07
the O 0 2.4877837745407305e-07
family O 0 6.1578302847919986e-06
harbouring O 0 0.00019169434381183237
the O 0 3.2100786029332085e-06
missense O 0 0.0001354099513264373
mutation O 0 1.979378066607751e-05
had O 0 4.627429007086903e-06
an O 0 5.119605361869617e-07
average O 0 2.8211090921104187e-06
age O 0 3.2035660524343257e-07
of O 0 1.2208285227188753e-07
onset O 0 1.7873444448923692e-05
of O 0 9.75656234913913e-07
51 O 0 4.9277132347924635e-05
. O 0 1.1854235708597116e-05

2 O 0 0.0002773531887214631
years O 0 6.47863998892717e-05
. O 0 2.329914968868252e-05

These O 0 6.562785983987851e-06
findings O 0 2.109070737787988e-05
show O 0 1.4927928532415535e-05
that O 0 6.595284958166303e-07
BRCA1 O 0 0.00017168447084259242
is O 0 2.240981075374293e-06
implicated O 0 6.224465778359445e-06
in O 0 1.6266906754935917e-07
a O 0 1.1620943496382097e-07
small O 0 1.931735340576779e-07
fraction O 0 1.2127582067478215e-06
of O 0 1.4859736438666005e-05
breast B-Disease 1 0.9999959468841553
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 9.535951335237769e-07
suggesting O 0 1.048845547302335e-06
the O 0 1.8116176647708926e-07
involvement O 0 1.8045650449494133e-06
of O 0 2.642011338593875e-07
another O 0 2.5182636818499304e-05
susceptibility O 0 0.0040525286458432674
gene O 0 0.00010326348274247721
( O 0 5.597561084869085e-06
s O 0 0.03032848611474037
) O 0 2.5308647309429944e-05

Paternal O 0 0.45481082797050476
transmission O 1 0.8085187673568726
of O 0 0.01719689555466175
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.022388460114598274

We O 0 4.819953392143361e-05
report O 0 8.03074271971127e-06
a O 0 7.743084324829397e-07
rare O 0 2.9166737931518583e-06
case O 0 8.564409654354677e-06
of O 0 1.055471602739999e-05
paternally O 1 0.9935286641120911
transmitted O 1 0.9999933242797852
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9867401123046875
DM B-Disease 1 1.0
) O 0 0.0002098342520184815
. O 0 2.6106477889698e-05

The O 0 1.1477673979243264e-05
proband O 0 0.00013430381659418344
is O 0 6.918941153344349e-07
a O 0 6.487018708867254e-07
23 O 0 5.221364972385345e-06
year O 0 1.5549888985333382e-06
old O 0 0.00010623895650496706
, O 0 0.00018516693671699613
mentally B-Disease 1 0.999998927116394
retarded I-Disease 1 0.9999947547912598
male O 0 0.021578313782811165
who O 0 0.04131515696644783
suffers O 1 0.9994692206382751
severe O 0 0.422971248626709
muscular B-Disease 1 0.9396790862083435
weakness I-Disease 1 0.5684007406234741
. O 0 2.9971959520480596e-05

He O 0 9.993623098125681e-05
presented O 0 2.967209366033785e-05
with O 0 2.578266321506817e-05
respiratory O 1 0.8327524065971375
and O 0 5.468389281304553e-05
feeding O 0 0.00010139180085388944
difficulties O 0 4.01980614697095e-05
at O 0 3.106743679381907e-05
birth O 0 0.00023294452694244683
. O 0 2.1464837118401192e-05

His O 0 0.00015600229380652308
two O 0 6.834070518380031e-05
sibs O 1 0.9389069676399231
suffer O 0 0.08236391097307205
from O 0 1.9013319615623914e-05
childhood O 0 0.0042273420840501785
onset O 1 0.7910715341567993
DM B-Disease 1 0.9999998807907104
. O 0 0.00047099340008571744

Their O 0 1.8565993741503917e-05
late O 0 5.441059693112038e-05
father O 0 1.3182670954847708e-05
had O 0 2.91041101263545e-06
the O 0 9.04845762761397e-08
adult O 0 6.043177336323424e-07
type O 0 2.2455164980783593e-06
of O 0 2.8964252578589367e-06
DM B-Disease 1 1.0
, O 0 8.460193384962622e-06
with O 0 1.2054661056026816e-06
onset O 0 1.4268674931372516e-05
around O 0 2.7071703811998304e-07
30 O 0 2.0196850982756587e-06
years O 0 1.2639223996302462e-06
. O 0 2.6540039925748715e-06

Only O 0 3.6034298318554647e-06
six O 0 1.1137028650409775e-06
other O 0 1.4095995481966384e-07
cases O 0 8.186989930436539e-08
of O 0 7.208461738628102e-08
paternal O 0 8.423152758041397e-05
transmission O 0 0.02238866314291954
of O 0 0.010421976447105408
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0027098681312054396
been O 0 4.8021563998190686e-05
reported O 0 0.00013071755529381335
recently O 0 4.423050631885417e-05
. O 0 7.588457265228499e-06

We O 0 1.77120109583484e-05
review O 0 2.936820237664506e-06
the O 0 4.1148254581457877e-07
sex O 0 1.0671815289242659e-06
related O 0 1.3671865417563822e-06
effects O 0 1.0808875231305137e-05
on O 0 8.31980723887682e-05
transmission O 0 0.22111988067626953
of O 0 0.005397978704422712
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.0010468106484040618

Decreased O 0 0.0014439263613894582
fertility O 0 0.00047497672494500875
of O 0 1.0429038184156525e-06
males O 0 1.444429130970093e-06
with O 0 6.753032835149497e-07
adult O 0 0.0001259435957763344
onset O 0 0.041009340435266495
DM B-Disease 1 1.0
and O 0 8.427460124948993e-05
contraction O 0 1.2008502380922437e-05
of O 0 5.988793105871082e-08
the O 0 3.8168153082551726e-07
repeat O 0 1.2902793059765827e-05
upon O 0 3.2929497706390976e-07
male O 0 1.454005655432411e-06
transmission O 0 4.448382242117077e-06
contribute O 0 7.390773504312165e-08
to O 0 5.875761033280469e-08
the O 0 8.185678268546326e-08
almost O 0 2.8439953325687384e-07
absent O 0 9.70342853179318e-07
occurrence O 0 1.2348169775577844e-06
of O 0 2.4896158379306144e-07
paternal O 0 9.17428988032043e-05
transmission O 0 0.05249654874205589
of O 0 0.0033971513621509075
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.001011254033073783

Also O 0 3.2715492125134915e-05
the O 0 1.0862992212423705e-06
fathers O 0 1.6873979120646254e-06
of O 0 1.718825899388321e-07
the O 0 2.2572696707356954e-06
reported O 0 0.003090103156864643
congenitally O 0 0.005202021449804306
affected O 0 6.634696092078229e-06
children O 0 3.271244850111543e-06
showed O 0 8.408233043155633e-06
, O 0 1.5670369180043053e-07
on O 0 1.7627032775635598e-06
average O 0 2.852681745935115e-06
, O 0 4.881389372712874e-07
shorter O 0 1.2272094863874372e-05
CTG O 0 5.3052612202009186e-05
repeat O 0 8.400106707995292e-06
lengths O 0 2.6633815650711767e-05
and O 0 2.3644995508220745e-06
hence O 0 1.8048971242023981e-06
less O 0 6.081842911953572e-06
severe O 0 0.0015249589923769236
clinical O 0 0.0005754126468673348
symptoms O 0 3.7389319913927466e-05
than O 0 1.1979877001522254e-07
the O 0 6.202756139828125e-07
mothers O 0 2.578609610282001e-06
of O 0 3.4159461392846424e-07
children O 0 2.912679519795347e-05
with O 0 0.0071082208305597305
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.0021147856023162603

We O 0 2.907223824877292e-05
conclude O 0 2.769000275293365e-05
that O 0 6.616723453589657e-07
paternal O 0 4.1356648580404e-05
transmission O 0 0.0050533912144601345
of O 0 0.0007478326442651451
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.002416384406387806
rare O 0 9.230069736076985e-06
and O 0 1.4763112403670675e-06
preferentially O 0 2.954506726382533e-06
occurs O 0 1.6203317443341803e-07
with O 0 1.963027784768201e-07
onset O 0 2.8011372705805115e-05
of O 0 2.932946699729655e-06
DM B-Disease 1 1.0
past O 0 1.5014648852229584e-05
30 O 0 2.573406391093158e-06
years O 0 4.975786396244075e-07
in O 0 8.032361620280426e-08
the O 0 3.626433908721083e-07
father O 0 1.795329080778174e-05
. O 0 8.849274308886379e-07
. O 0 3.5300213312439155e-06

The O 0 4.483409065869637e-05
RB1 O 0 0.0041359830647706985
gene O 0 5.904744830331765e-05
mutation O 0 2.1482203010236844e-05
in O 0 1.0473362408447429e-06
a O 0 7.819451639079489e-06
child O 0 0.00013483698421623558
with O 0 0.00013203039998188615
ectopic B-Disease 1 0.9999986886978149
intracranial I-Disease 1 0.9999680519104004
retinoblastoma I-Disease 1 0.9963059425354004
. O 0 0.00017362854850944132

The O 0 7.213249045889825e-05
RB1 O 0 0.006488807499408722
gene O 0 0.00022004902712069452
mutation O 0 0.00011729969264706597
was O 0 3.9822574763093144e-05
investigated O 0 2.3718897864455357e-05
in O 0 1.159199200628791e-06
a O 0 8.165830877260305e-06
child O 0 7.355085836024955e-05
with O 0 4.43309654656332e-05
ectopic B-Disease 1 0.9999899864196777
intracranial I-Disease 1 0.998431384563446
retinoblastoma I-Disease 0 0.10064346343278885
using O 0 1.4241691133065615e-05
DNA O 0 0.00018686057592276484
obtained O 0 3.4713357308646664e-06
from O 0 1.5657342089525628e-07
both O 0 2.3132237458867166e-07
the O 0 1.334945295639045e-06
pineal B-Disease 0 0.0023209231439977884
and I-Disease 0 0.0004993510665372014
retinal I-Disease 1 0.9451693892478943
tumours I-Disease 1 0.9999998807907104
of O 0 2.8335664410406025e-06
the O 0 1.5502682799706236e-05
patient O 0 0.00017501981346867979
. O 0 1.800521022232715e-05

A O 0 9.981222683563828e-05
nonsense O 0 0.00014290363469626755
mutation O 0 2.8321337595116347e-05
in O 0 2.2119577351986663e-06
exon O 0 0.0001255339157069102
17 O 0 2.216985376435332e-05
( O 0 3.549224913967919e-07
codon O 0 7.961904771036643e-07
556 O 0 8.220339964282175e-07
) O 0 1.0316549037270306e-07
of O 0 4.889281868258877e-08
the O 0 1.6347727296306402e-06
RB1 O 0 0.0009168070973828435
gene O 0 3.4719216728262836e-06
was O 0 7.228325557662174e-06
found O 0 5.188868499317323e-07
to O 0 2.3117681280382385e-07
be O 0 1.0530022365173863e-07
present O 0 1.379814591473405e-07
homozygously O 0 1.5128959603316616e-05
in O 0 2.1016433038312243e-07
both O 0 1.8708132643041608e-07
the O 0 1.0054322956420947e-06
retinal B-Disease 0 0.0009163197828456759
and I-Disease 0 1.0143833605980035e-05
the I-Disease 0 2.029776806011796e-05
pineal I-Disease 1 0.8058514595031738
tumours I-Disease 1 0.9999991655349731
. O 0 6.329320603981614e-05

The O 0 5.8288173931941856e-06
same O 0 2.7309617962600896e-06
mutation O 0 7.881637429818511e-06
was O 0 8.778927622188348e-06
present O 0 3.5359542494006746e-07
heterozygously O 0 2.28763328777859e-05
in O 0 3.026591457455652e-07
the O 0 3.2167426411433553e-07
DNA O 0 1.284309291804675e-05
from O 0 1.7005743302433984e-07
the O 0 1.8145675539926742e-07
constitutional O 0 2.6241872319587856e-07
cells O 0 5.208734705774987e-07
of O 0 7.223849252113723e-08
the O 0 2.231831331300782e-06
patient O 0 1.715004509605933e-05
, O 0 6.546325721501489e-07
proving O 0 2.48232845478924e-06
it O 0 2.2335103722070926e-07
to O 0 1.1127203691785326e-07
be O 0 9.671096989904981e-08
of O 0 1.5888356585946894e-07
germline O 0 6.598074833163992e-05
origin O 0 6.783972821722273e-06
. O 0 6.242656581889605e-06

The O 0 1.1883346815011464e-05
initial O 0 1.610695107956417e-05
mutation O 0 1.6994252291624434e-05
was O 0 1.1629435903159901e-05
shown O 0 9.192736456498096e-07
to O 0 1.5823576404727646e-07
have O 0 1.6683453907262447e-07
occurred O 0 3.992301174093882e-07
in O 0 1.1727288296015104e-07
the O 0 4.5527460201810754e-07
paternally O 0 4.056539910379797e-05
derived O 0 2.1491483494173735e-05
RB1 O 0 0.0011790890712291002
allele O 0 7.178807572927326e-05
. O 0 9.920466254698113e-06

The O 0 1.2072368917870335e-05
mutation O 0 2.020377723965794e-05
is O 0 8.594368523517915e-07
in O 0 2.5154912464131485e-07
an O 0 3.0208300927370146e-07
area O 0 4.770004125020932e-07
of O 0 4.343834092424004e-08
the O 0 1.9604910050929902e-07
gene O 0 5.454189704323653e-07
that O 0 4.375999651529128e-08
encodes O 0 1.8106727850408788e-07
the O 0 5.218450027655308e-08
protein O 0 9.225635722032166e-07
- O 0 2.1036352336523123e-05
binding O 0 3.0855369459459325e-06
region O 0 2.775939947241568e-06
known O 0 1.6188548670470482e-06
as O 0 1.669403815185433e-07
the O 0 2.7445233286016446e-07
pocket O 0 0.004523353185504675
region O 0 1.210664413520135e-05
and O 0 3.176385689585004e-06
has O 0 2.7695220978785073e-06
been O 0 7.010801823525981e-07
detected O 0 1.9810534013231518e-06
in O 0 1.1816234035677553e-07
other O 0 6.816065933890059e-08
cases O 0 8.819400676429723e-08
of O 0 1.8219665776086913e-07
retinoblastoma B-Disease 0 0.0014032685430720448
. O 0 6.063056389393751e-06
. O 0 6.299116193986265e-06

Low O 0 9.932003013091162e-05
levels O 0 4.08898267778568e-06
of O 0 2.0129151323544647e-07
beta O 0 1.0870224969039555e-06
hexosaminidase O 0 6.264931926125428e-06
A O 0 1.9003319948751596e-06
in O 0 1.4981560525484383e-06
healthy O 0 2.461489202687517e-06
individuals O 0 6.311230293931658e-08
with O 0 3.311136879347032e-06
apparent O 0 0.36780866980552673
deficiency O 0 0.06885487586259842
of O 0 2.5500071387796197e-07
this O 0 7.148927352318424e-07
enzyme O 0 2.2244610590860248e-05
. O 0 6.7719943217525724e-06

Appreciable O 0 0.0011530739720910788
beta O 0 9.071706153918058e-05
hexosaminidase O 0 0.0004009998810943216
A O 0 4.328402064857073e-05
( O 0 2.2121794245322235e-06
hex O 0 4.974227704224177e-05
A O 0 1.1794740203185938e-05
) O 0 3.4895339240392786e-07
activity O 0 1.7167961630093487e-07
has O 0 3.087795903411461e-07
been O 0 5.833383056597086e-07
detected O 0 2.583020204838249e-06
in O 0 4.368136217181018e-07
cultured O 0 0.0005600959993898869
skin O 1 0.8197781443595886
fibroblasts O 0 0.00025599522632546723
and O 0 0.0004824566130992025
melanoma B-Disease 1 0.9999161958694458
tissue O 0 0.002515047322958708
from O 0 1.5107156059457338e-06
healthy O 0 3.1434904030902544e-06
individuals O 0 3.484674238052321e-08
previously O 0 1.4239625670597889e-05
reported O 0 0.00010380609455751255
as O 0 4.4243006414035335e-06
having O 0 7.819696475053206e-05
deficiency B-Disease 0 0.00014381569053512067
of I-Disease 0 7.080277697468773e-08
hex I-Disease 0 7.125356933102012e-05
A I-Disease 0 5.825666448799893e-06
activity O 0 5.176502213544154e-07
indistinguishable O 0 8.441242584922293e-07
from O 0 3.987540253547195e-08
that O 0 3.48731390431567e-08
of O 0 2.3651777780742123e-07
patients O 0 7.609944532305235e-06
with O 0 0.0006368402391672134
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9850881695747375
( O 0 3.406483301660046e-06
TSD B-Disease 0 0.000573102617636323
) O 0 3.233966253901599e-06
. O 0 5.243191026238492e-06

Identification O 0 0.00011015908239642158
and O 0 1.7287502487306483e-05
quantitation O 0 0.0003686685231514275
of O 0 2.3548634544567904e-06
hex O 0 0.0003348303434904665
A O 0 2.5476143491687253e-05
, O 0 1.1709121281455737e-06
amounting O 0 1.345920964013203e-06
to O 0 2.9652343869202014e-07
3 O 0 8.774910384090617e-06
. O 0 7.763523171888664e-06

5 O 0 7.846998778404668e-05
% O 0 9.23306288314052e-06
- O 0 0.00017295373254455626
6 O 0 5.0097794883186e-05
. O 0 9.971152394427918e-06

9 O 0 0.00014489788736682385
% O 0 3.1092479275685037e-06
of O 0 1.4821429772382544e-07
total O 0 3.0329479727697617e-07
beta O 0 8.171754188879277e-07
hexosaminidase O 0 7.995590749487747e-06
activity O 0 4.876289949606871e-07
, O 0 2.586355378753069e-07
has O 0 2.42826843077637e-07
been O 0 2.1932262939117209e-07
obtained O 0 2.0907923214963375e-07
by O 0 1.0900709668248965e-07
cellulose O 0 0.00011674243432935327
acetate O 0 7.09426385583356e-05
gel O 0 9.327995940111578e-05
electrophoresis O 0 1.0337234925827943e-05
, O 0 2.578417763743346e-07
DEAE O 0 2.5736919269547798e-05
- O 0 2.4438564651063643e-05
cellulose O 0 7.930265564937145e-05
ion O 0 1.0609089258650783e-05
- O 0 1.4127493159321602e-05
exchange O 0 1.5389862255688058e-06
chromatography O 0 2.9546081350417808e-06
, O 0 2.8095834636587824e-07
radial O 0 2.541278809076175e-05
immunodiffusion O 0 4.309263022150844e-05
, O 0 6.848488283139886e-07
and O 0 1.171420421997027e-06
radioimmunoassay O 0 0.00029424316016957164
. O 0 6.0797551668656524e-06

Previous O 0 0.00023638023412786424
family O 0 9.656779729994014e-05
studies O 0 7.486507456633262e-06
suggested O 0 4.394393727125134e-06
that O 0 2.562718748322368e-07
these O 0 6.069080171755559e-08
individuals O 0 4.230925298998045e-08
may O 0 1.8674172679311596e-06
be O 0 8.955637298413421e-08
compound O 0 2.6805423658515792e-06
heterozygotes O 0 1.6389250276915845e-06
for O 0 7.648570488072437e-08
the O 0 1.898296488889173e-07
common O 0 1.9414862890698714e-06
mutant O 0 1.6700816559023224e-05
TSD B-Disease 0 9.981451148632914e-05
gene O 0 3.713590558618307e-06
and O 0 4.5706960349889414e-07
a O 0 3.2299099075316917e-06
rare O 0 1.3409600796876475e-05
( O 0 1.0480246146471472e-06
allelic O 0 6.872290214232635e-06
) O 0 6.264725698201801e-07
mutant O 0 6.643344477197388e-06
gene O 0 1.682791844359599e-05
. O 0 5.79452125748503e-06

Thus O 0 1.903866541397292e-05
, O 0 8.358850891454495e-07
the O 0 2.4155096411959676e-07
postulated O 0 6.41225869912887e-06
rate O 0 3.481935436866479e-06
mutant O 0 2.5906604150804924e-06
gene O 0 1.7695839460429852e-06
appears O 0 8.238116038228327e-07
to O 0 6.017647535827564e-08
code O 0 4.702200229189657e-08
for O 0 4.459602820361397e-08
the O 0 7.794815815032052e-08
expression O 0 2.2832865909094835e-07
of O 0 6.409443642496626e-08
low O 0 2.2973624709266005e-06
amounts O 0 2.1583217346687888e-07
of O 0 2.0386988808240858e-07
hex O 0 0.00016441983461845666
A O 0 5.66377020732034e-05
. O 0 1.93043324543396e-05

Heterozygotes O 0 0.0007694641244597733
for O 0 5.968636742181843e-06
the O 0 6.02972306751326e-07
rare O 0 3.342081527080154e-06
mutant O 0 5.128409975441173e-05
may O 0 2.204134398198221e-05
be O 0 2.0511839693426737e-07
indistinguishable O 0 1.2992892379770637e-06
from O 0 1.0909986514207048e-07
heterozygotes O 0 2.1148016458027996e-06
for O 0 1.5070678216488886e-07
the O 0 6.823258900112705e-07
common O 0 2.0668550860136747e-05
TSD B-Disease 0 0.0012552447151392698
mutant O 0 0.0001727869239402935
. O 0 1.0722808838181663e-05

However O 0 4.078540951013565e-05
, O 0 1.6065819181676488e-06
direct O 0 9.335238360108633e-07
visualization O 0 1.12947091110982e-05
and O 0 3.1094346013560425e-06
quantitation O 0 0.00012079883163096383
of O 0 4.1885942891894956e-07
hex O 0 3.8637332181679085e-05
A O 0 2.9047848784102825e-06
by O 0 1.3219604966252518e-07
the O 0 1.885896381281782e-07
methods O 0 3.533780272846343e-06
described O 0 0.00011401250958442688
may O 0 4.968345820088871e-06
prevent O 0 3.366234011537017e-07
false O 0 3.3583185086172307e-06
- O 0 0.0004862231726292521
positive O 0 3.89030174119398e-06
prenatal O 0 0.0008372606243938208
diagnosis O 0 0.0005663941847160459
of O 0 4.1728932842488575e-07
TSD B-Disease 0 0.0018352929037064314
in O 0 1.5989324310794473e-05
fetuses O 0 0.00010218910028925166
having O 0 4.195474616608408e-07
the O 0 4.336061465437524e-07
incomplete O 0 8.178628377208952e-06
hex B-Disease 0 0.008931309916079044
A I-Disease 0 0.06646355241537094
deficiency I-Disease 0 0.002917615231126547
of O 0 8.084820990461594e-08
the O 0 8.076988819993858e-07
type O 0 1.05812423498719e-05
described O 0 1.9802033421001397e-05
in O 0 2.4930110953391704e-07
the O 0 3.3028257462319743e-07
four O 0 5.891286036785459e-06
healthy O 0 3.154886871925555e-05
individuals O 0 5.177137154532829e-06

The O 0 8.176050323527306e-05
tumor B-Disease 0 0.002626172499731183
suppressor O 0 0.0005976403481326997
gene O 0 0.00015318274381570518
Smad4 O 0 0.00131130067165941
/ O 0 0.0014627038035541773
Dpc4 O 0 0.00012213323498144746
is O 0 4.2610844275259296e-07
required O 0 1.0483569212738075e-07
for O 0 1.7608103064503666e-07
gastrulation O 0 1.3628759006678592e-05
and O 0 3.069646709263907e-06
later O 0 7.257419383677188e-06
for O 0 3.9875678226053424e-07
anterior O 0 1.4122456377663184e-05
development O 0 4.4818759192821744e-07
of O 0 1.403594040993994e-07
the O 0 1.8101185332852765e-06
mouse O 0 9.371274063596502e-05
embryo O 0 0.0002270212717121467
. O 0 1.866158527263906e-05

Mutations O 0 0.0013352474197745323
in O 0 6.80326002111542e-06
the O 0 1.8561285060059163e-06
SMAD4 O 0 0.04077152907848358
/ O 0 0.03112943097949028
DPC4 O 0 0.020527690649032593
tumor B-Disease 0 0.0005514724762178957
suppressor O 0 4.0063310734694824e-05
gene O 0 6.132326689112233e-06
, O 0 1.7729188073190016e-07
a O 0 2.0627500418868294e-07
key O 0 2.0592724467860535e-06
signal O 0 5.424784376373282e-06
transducer O 0 7.680595444981009e-06
in O 0 4.828892201658164e-07
most O 0 3.2663828619661217e-07
TGFbeta O 0 6.388431211235002e-05
- O 0 0.00018713409372139722
related O 0 1.430954171155463e-06
pathways O 0 8.804842650533828e-07
, O 0 5.42544910331344e-07
are O 0 1.2752774836144454e-08
involved O 0 3.363383882515336e-08
in O 0 6.761346327266438e-08
50 O 0 2.5933451297532883e-07
% O 0 3.248898394758726e-07
of O 0 2.0936545297445264e-06
pancreatic B-Disease 1 0.9995822310447693
cancers I-Disease 1 0.9568535685539246
. O 0 2.639398917381186e-05

Homozygous O 0 0.0028557111509144306
Smad4 O 0 0.004127038177102804
mutant O 0 0.0044808294624090195
mice O 0 0.2786470651626587
die O 0 0.10658872127532959
before O 0 3.920911240129499e-06
day O 0 2.433206645946484e-06
7 O 0 8.950153642217629e-06
. O 0 8.130383321258705e-06

5 O 0 0.00017845378897618502
of O 0 1.4279237802838907e-05
embryogenesis O 0 0.0007859606994315982
. O 0 4.8685880756238475e-05

Mutant O 0 0.00039279108750633895
embryos O 0 0.00022323707526084036
have O 0 2.9073455607431242e-06
reduced O 0 2.849092879841919e-06
size O 0 2.004577254410833e-06
, O 0 8.718960771147977e-07
fail O 0 2.3125032839743653e-06
to O 0 3.238584724840621e-07
gastrulate O 0 5.8761423133546486e-05
or O 0 5.661073601004318e-07
express O 0 1.69843463027064e-06
a O 0 6.510755952149339e-07
mesodermal O 0 2.315135316166561e-05
marker O 0 5.901975600863807e-05
, O 0 1.8478662013876601e-06
and O 0 1.9220963167754235e-06
show O 0 4.0105664083966985e-05
abnormal O 0 1.9993110981886275e-05
visceral O 0 9.673302884039003e-06
endoderm O 0 0.0002014404599322006
development O 0 7.850086149119306e-06
. O 0 1.098572010960197e-05

Growth B-Disease 1 0.9999767541885376
retardation I-Disease 1 0.9999964237213135
of O 0 3.9973820094019175e-06
the O 0 3.832100901490776e-06
Smad4 O 0 0.012715481221675873
- O 0 0.35701969265937805
deficient O 0 0.0019753018859773874
embryos O 0 1.4007636309543159e-05
results O 0 3.4720540043053916e-06
from O 0 1.2100082358301734e-07
reduced O 0 3.414732191231451e-06
cell O 0 8.816013723844662e-05
proliferation O 0 3.3285818972217385e-06
rather O 0 1.147596364603487e-07
than O 0 9.21789933272521e-08
increased O 0 3.3013186566677177e-06
apoptosis O 0 3.54877847712487e-05
. O 0 8.499172508891206e-06

Aggregation O 0 0.00018412870122119784
of O 0 5.724594757339219e-06
mutant O 0 6.83452672092244e-05
Smad4 O 0 0.0003736705402843654
ES O 0 0.000610464601777494
cells O 0 8.154446732078213e-06
with O 0 2.696845058380859e-07
wild O 0 8.577357220929116e-06
- O 0 0.00031159637728706
type O 0 1.1587225344555918e-05
tetraploid O 0 9.374706860398874e-05
morulae O 0 0.0003140401386190206
rescues O 0 0.00016461152699775994
the O 0 5.3564122026728e-06
gastrulation B-Disease 0 0.0009870901703834534
defect I-Disease 0 0.0007799894083291292
. O 0 1.2931755918543786e-05

These O 0 1.5178166904661339e-05
results O 0 3.89436972909607e-05
indicate O 0 3.319442839710973e-06
that O 0 2.9683522484447167e-07
Smad4 O 0 3.39064936270006e-05
is O 0 5.858013309989474e-07
initially O 0 5.846638373441237e-07
required O 0 2.6620059045967537e-08
for O 0 3.1403807554397645e-08
the O 0 3.286210770170328e-08
differentiation O 0 1.5260765451330371e-07
of O 0 3.9012213903788506e-08
the O 0 2.563708676461829e-07
visceral O 0 3.007052782777464e-06
endoderm O 0 3.538917735568248e-05
and O 0 7.324967441491026e-07
that O 0 5.867775954015997e-08
the O 0 2.2041592728783144e-07
gastrulation B-Disease 0 3.667306009447202e-05
defect I-Disease 0 2.4440894776489586e-05
in O 0 1.7464729751281993e-07
the O 0 3.3953739375647274e-07
epiblast O 0 5.482769847731106e-05
is O 0 5.247820809017867e-07
secondary O 0 4.168582279362454e-07
and O 0 5.80938888106175e-07
non O 0 2.75150978268357e-06
- O 0 0.0001885091041913256
cell O 0 0.00034693392808549106
autonomous O 0 3.274302071076818e-05
. O 0 2.1152223780518398e-05

Rescued O 0 0.014830582775175571
embryos O 0 0.005640688817948103
show O 0 0.008806096389889717
severe O 0 0.1292485147714615
anterior O 0 0.030980335548520088
truncations O 0 0.002095865085721016
, O 0 2.3470733140129596e-05
indicating O 0 4.739903033623705e-06
a O 0 1.3593119092547568e-06
second O 0 5.73126453673467e-06
important O 0 1.380266070327707e-07
role O 0 7.412966169795254e-07
for O 0 7.953055956022581e-07
Smad4 O 0 0.0001558041403768584
in O 0 3.719289907166967e-06
anterior O 0 0.0003901794261764735
patterning O 0 0.008023431524634361
during O 0 5.540776328416541e-05
embryogenesis O 0 0.00026702083414420485
. O 0 1.9640870959847234e-05

Prevalence O 0 0.003732431447133422
of O 0 6.362783551594475e-06
p16 O 0 5.784858876722865e-05
and O 0 9.750870958669111e-06
CDK4 O 0 0.002781566232442856
germline O 0 0.0014290062244981527
mutations O 0 9.24299456528388e-05
in O 0 2.0576703718688805e-06
48 O 0 0.00030818054801784456
melanoma B-Disease 1 0.9999592304229736
- O 1 0.5889531373977661
prone O 0 0.006441605277359486
families O 0 2.0718439373013098e-06
in O 0 1.913553205667995e-06
France O 0 0.00017220697191078216
. O 0 1.3620053323393222e-05

The O 0 3.530140747898258e-05
French O 0 0.0010138640645891428
Familial B-Disease 1 0.9316655993461609
Melanoma I-Disease 1 0.9999946355819702
Study O 0 0.00017118343384936452
Group O 0 0.00017022117390297353
. O 0 1.5093106412678026e-05

Germline O 0 0.09732753038406372
mutations O 0 0.0025012551341205835
in O 0 3.578522864700062e-06
the O 0 5.059342811364331e-07
p16 O 0 4.798081590706715e-06
and O 0 1.7859819081422756e-06
CDK4 O 0 0.00021681883663404733
genes O 0 2.6572076876618667e-06
have O 0 3.2933078841779206e-07
been O 0 9.205351716445875e-07
reported O 0 3.033849907296826e-06
in O 0 3.996967379293892e-08
a O 0 1.9415737995132076e-07
subset O 0 5.430951546259166e-07
of O 0 2.168703304050723e-06
melanoma B-Disease 1 0.998079776763916
pedigrees O 0 6.242856761673465e-05
, O 0 1.8026831867246074e-06
but O 0 2.8247711725271074e-07
their O 0 7.909035844022583e-07
prevalence O 0 2.8794549507438205e-05
is O 0 3.932708523279871e-07
not O 0 1.5933451891214645e-07
well O 0 5.460590841721569e-07
known O 0 7.1266531449509785e-06
. O 0 7.850003385101445e-06

We O 0 7.872622518334538e-06
searched O 0 6.941015271877404e-06
for O 0 3.729451236722525e-07
such O 0 1.0997777621923888e-07
germline O 0 7.334340625675395e-05
mutations O 0 2.409390071989037e-05
in O 0 1.3335786661627935e-06
48 O 0 2.59172356891213e-05
French O 0 0.0062090023420751095
melanoma B-Disease 1 0.9999799728393555
- O 1 0.6320187449455261
prone O 0 0.00010735794785432518
families O 0 1.8377245680767373e-07
selected O 0 1.0304907505087613e-07
according O 0 5.148473292138078e-08
to O 0 4.3446874542496516e-08
two O 0 9.092713781910788e-08
major O 0 3.296827628673782e-07
criteria O 0 4.997891664970666e-07
families O 0 1.847610597849325e-08
with O 0 7.787281219862052e-08
at O 0 1.1397612524888245e-06
least O 0 2.2027197132956644e-07
three O 0 8.455688771391578e-07
affected O 0 4.180684527455014e-07
members O 0 1.1463527727073597e-07
( O 0 7.315808403518531e-08
n O 0 5.878938281966839e-06
= O 0 6.086653229431249e-06
20 O 0 1.2849336599174421e-06
) O 0 8.73344347951388e-08
or O 0 2.9795598877058183e-08
families O 0 1.1132081922937687e-08
with O 0 6.190717272147594e-08
two O 0 1.396544348608586e-06
affected O 0 5.718994771086727e-07
members O 0 1.4398366943169094e-07
, O 0 5.044051221148038e-08
one O 0 2.134449950119688e-08
of O 0 1.6907963029666462e-08
them O 0 6.621230852488225e-08
affected O 0 8.186756161876474e-08
before O 0 1.2779990754552273e-07
the O 0 7.035812643607642e-08
age O 0 8.695147357684618e-08
of O 0 1.7931409246330077e-08
50 O 0 5.852646722814825e-07
( O 0 1.5676661746510945e-07
n O 0 1.8603872376843356e-05
= O 0 1.1709831596817821e-05
28 O 0 6.362055501085706e-06
) O 0 1.8234894127999723e-07
, O 0 1.1509293784683905e-07
and O 0 1.3520507025077677e-07
one O 0 2.2903438434696e-07
additional O 0 8.175222774298163e-07
minor O 0 2.584340791145223e-06
criterion O 0 5.893483103136532e-05
. O 0 7.012432888586773e-06

Sixteen O 0 5.848882210557349e-05
different O 0 4.50403786089737e-06
p16 O 0 4.949716822011396e-05
germline O 0 0.0004428915272001177
mutations O 0 0.00015701170195825398
were O 0 2.0666363980126334e-06
found O 0 1.045048406922433e-06
in O 0 7.051153829706891e-07
21 O 0 5.0971061682503205e-06
families O 0 1.2502708557349251e-07
, O 0 1.999392651441667e-07
while O 0 2.6206959091723547e-07
one O 0 6.517124120364315e-07
germline O 0 3.9683975046500564e-05
mutation O 0 5.9674534895748366e-06
, O 0 4.590471576193522e-07
Arg24His O 0 1.818859345803503e-05
, O 0 5.938891263213009e-07
was O 0 5.396847427618923e-06
detected O 0 1.9135002276016166e-06
in O 0 1.035402377169703e-07
the O 0 7.001314088483923e-07
CDK4 O 0 0.0012961444444954395
gene O 0 4.824050120078027e-05
. O 0 7.725301657046657e-06

The O 0 6.189234682096867e-06
frequency O 0 5.7215329434257e-06
of O 0 2.1812698491885385e-07
p16 O 0 3.825294697890058e-06
gene O 0 3.582275212465902e-06
mutation O 0 2.3152751964516938e-06
in O 0 2.6233615812998323e-07
our O 0 1.914484641929448e-07
sample O 0 6.563290639860497e-07
( O 0 1.4676049886475084e-07
44 O 0 4.254279417637008e-07
% O 0 2.8155326958767546e-07
) O 0 4.557893973355931e-08
is O 0 2.5846015105912556e-08
among O 0 1.2498292178975134e-08
the O 0 1.0033627262373557e-07
highest O 0 4.848411208513426e-06
rates O 0 9.492448043602053e-06
yet O 0 7.59368901981361e-07
reported O 0 6.943517291801982e-06
and O 0 1.358314989374776e-07
the O 0 2.2711661529228877e-07
CDK4 O 0 0.00026837788755074143
mutation O 0 2.1998343981977087e-06
is O 0 3.9475239077546576e-08
the O 0 4.4178982250286936e-08
second O 0 9.142167073150631e-06
mutation O 0 5.8765849644260015e-06
detected O 0 2.166749709431315e-06
in O 0 9.593163952104078e-08
this O 0 2.015748776784676e-07
gene O 0 6.230452072486514e-06
worldwide O 0 4.446329512575176e-06
. O 0 4.462131528271129e-06

In O 0 0.00013141192903276533
summary O 0 8.991971117211506e-05
, O 0 2.2117953903944e-06
our O 0 6.478666136899847e-07
results O 0 1.8530687384554767e-06
show O 0 1.911275148813729e-06
frequent O 0 5.320035256772826e-07
involvement O 0 7.053588433336699e-07
of O 0 4.109750051384253e-08
the O 0 1.4729558017734234e-07
p16 O 0 1.0509631920285756e-06
gene O 0 1.8866388700189418e-06
in O 0 9.8832299499918e-07
familial B-Disease 0 0.0761728286743164
melanoma I-Disease 1 0.9999948740005493
and O 0 4.7692603402538225e-05
confirm O 0 1.533100294182077e-05
the O 0 9.467323280887285e-08
role O 0 3.6878583387078834e-07
of O 0 5.118912227430883e-08
the O 0 3.2000482974581246e-07
CDK4 O 0 0.00013128055434208363
gene O 0 1.6895507997105597e-06
as O 0 3.0127998229545483e-07
a O 0 2.6320012693759054e-05
melanoma B-Disease 1 0.9998190999031067
- O 0 0.024273080751299858
predisposing O 0 0.00015095870185177773
gene O 0 2.1464755263878033e-05
. O 0 1.5456183746209717e-06
. O 0 3.8792168197687715e-06

Progression O 0 0.001187506248243153
of O 0 8.821653864288237e-06
somatic O 0 0.00016926656826399267
CTG O 0 0.0013904287479817867
repeat O 0 0.00018613538122735918
length O 0 1.714466452540364e-05
heterogeneity O 0 3.930617094738409e-05
in O 0 1.4005884168000193e-06
the O 0 1.2772367199431756e-06
blood O 0 9.418504487257451e-05
cells O 0 0.0001702763547655195
of O 0 0.0002174797118641436
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.523873507976532
. O 0 1.9877390514011495e-05

The O 0 1.0016692613135092e-05
genetic O 0 2.911935189331416e-05
basis O 0 1.0514701898500789e-05
of O 0 0.00042983226012438536
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8267541527748108
DM B-Disease 1 1.0
) O 0 8.19357046566438e-06
is O 0 1.0878942191538954e-07
the O 0 3.7406284292273995e-08
expansion O 0 3.5928192687606497e-07
of O 0 7.287383851917184e-08
an O 0 2.604404244266334e-06
unstable O 0 0.0005640781600959599
CTG O 0 0.00024567966465838253
repeat O 0 1.9895463992725126e-05
in O 0 1.7422425457880308e-07
the O 0 1.2196021259569534e-07
34 O 0 8.429264539699943e-07
UTR O 0 2.1496956833289005e-05
of O 0 2.399870595581888e-07
the O 0 4.787691977981012e-06
DM B-Disease 1 0.9999972581863403
protein O 0 3.369848127476871e-05
kinase O 0 4.7908259148243815e-05
gene O 0 6.0532579482242e-06
on O 0 1.3500433851731941e-05
chromosome O 0 0.0003825079184025526
19 O 0 7.143346010707319e-05
. O 0 7.667524187127128e-06

One O 0 6.9411344156833366e-06
of O 0 3.5953488008999557e-07
the O 0 2.105973067045852e-07
principal O 0 1.904023633869656e-06
features O 0 5.772717486252077e-07
of O 0 1.481423765881118e-07
the O 0 3.127299351035617e-05
DM B-Disease 1 1.0
mutation O 0 9.671912266639993e-05
is O 0 5.836855621055292e-07
an O 0 2.369630038856485e-07
extraordinarily O 0 4.481077667151112e-06
high O 0 1.625234290258959e-06
level O 0 3.1837322467254126e-07
of O 0 9.591279592768842e-08
somatic O 0 1.0145130545424763e-05
mosaicism O 0 0.0002848200383596122
, O 0 1.9563349269446917e-06
due O 0 9.458042882215523e-07
to O 0 2.781234229587426e-07
an O 0 8.299909950437723e-07
extremely O 0 1.4198657254382852e-06
high O 0 1.8554842426965479e-06
degree O 0 1.3016195907766814e-06
of O 0 1.90086538509604e-07
somatic O 0 4.468499173526652e-05
instability O 0 7.4501422204775736e-06
both O 0 2.523199214010674e-07
within O 0 9.971716963264043e-08
and O 0 4.495420000694139e-07
between O 0 3.3362431395289605e-07
different O 0 9.436150207875471e-07
tissues O 0 4.8006128054112196e-05
. O 0 7.903690857347101e-06

This O 0 1.6128287825267762e-05
instability O 0 3.92786278098356e-05
appears O 0 6.369280072249239e-06
to O 0 4.969925271325337e-07
be O 0 1.1791491516532915e-07
biased O 0 1.2782688827428501e-06
towards O 0 1.4593135233553767e-07
further O 0 1.53970404426218e-07
expansion O 0 4.160258129104477e-07
and O 0 2.111511605562555e-07
continuous O 0 5.090802233098657e-07
throughout O 0 8.87623912149138e-08
the O 0 7.805482482581283e-08
life O 0 1.7612016733892233e-07
of O 0 2.286622269309646e-08
an O 0 3.4279099736522767e-07
individual O 0 1.0744059864009614e-07
, O 0 1.7634167193136818e-07
features O 0 1.1135350632685004e-06
that O 0 1.106531499317498e-06
could O 0 1.159519797511166e-06
be O 0 1.159549185558717e-07
associated O 0 2.3402948556849879e-07
with O 0 1.1087797702202806e-07
the O 0 2.473433823979576e-06
progressive O 0 6.606140959775075e-05
nature O 0 1.6914435718717868e-06
of O 0 5.117877321936248e-07
the O 0 3.6425837606657296e-05
disease O 0 0.001346354023553431
. O 0 7.005842235230375e-06

Although O 0 1.5300523955374956e-05
increasing O 0 1.8919288322649663e-06
measured O 0 4.987272859580116e-06
allele O 0 4.54217888545827e-06
size O 0 1.8348243884247495e-06
between O 0 2.729974994508666e-06
patients O 0 2.313552613486536e-05
clearly O 0 1.2754838962791837e-06
correlates O 0 1.1167297770953155e-06
with O 0 3.7094952176630613e-07
an O 0 3.559322976798285e-06
increased O 0 1.3717911315325182e-05
severity O 0 0.00014727537927683443
of O 0 6.14434975432232e-06
symptoms O 0 0.00036245904630050063
and O 0 6.863696739856096e-07
an O 0 1.0280656397299026e-06
earlier O 0 2.227144068456255e-05
age O 0 4.677538640862622e-07
of O 0 1.6751036469031533e-07
onset O 0 1.3094349014863838e-05
, O 0 4.3199310084673925e-07
this O 0 5.705420136337125e-08
correlation O 0 7.284521075234807e-07
is O 0 4.1819765783657203e-07
not O 0 1.3183306180053478e-07
precise O 0 3.171711796312593e-06
and O 0 3.252021542721195e-06
measured O 0 1.059895566868363e-05
allele O 0 2.1032444692536956e-06
length O 0 6.086589564802125e-06
cannot O 0 1.269826839234156e-06
be O 0 4.934033626113887e-08
used O 0 2.179635316679196e-07
as O 0 2.2054754822420364e-07
an O 0 2.7428171733845375e-07
accurate O 0 4.0091556002153084e-05
predictor O 0 0.0007446928066201508
of O 0 9.353150289825862e-07
age O 0 3.350196493556723e-06
of O 0 1.5306736713682767e-06
onset O 0 0.0006613516015931964
. O 0 2.5046263544936664e-05

In O 0 2.0150630007265136e-05
order O 0 2.6077718757733237e-06
to O 0 5.346371381165227e-07
further O 0 3.4929064440802904e-07
characterize O 0 6.635315912717488e-06
the O 0 9.53762537392322e-07
dynamics O 0 7.266034663189203e-05
of O 0 7.428899607475614e-06
DM B-Disease 1 0.9999998807907104
CTG O 0 0.015613960102200508
repeat O 0 6.841269350843504e-05
somatic O 0 1.838460775616113e-05
instability O 0 7.719992026977707e-06
, O 0 5.827333779961918e-07
we O 0 1.3824053723965335e-07
have O 0 7.189581197053485e-08
studied O 0 5.008838002140692e-07
repeat O 0 4.281457677279832e-06
length O 0 1.5518837699346477e-06
changes O 0 1.7080932934732118e-07
over O 0 1.5399243125102657e-07
time O 0 9.13201688490517e-07
in O 0 2.858095285773743e-06
111 O 0 0.025306660681962967
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0006611141143366694
with O 0 2.912094316798175e-07
varying O 0 7.757608727843035e-06
clinical O 0 0.00038845176459290087
severity O 0 0.000367144588381052
and O 0 1.2345647519396152e-05
CTG O 0 0.0008819266222417355
repeat O 0 1.4097185157879721e-05
size O 0 3.8271522839750105e-07
over O 0 1.2797517001672531e-07
time O 0 1.1924025500320568e-07
intervals O 0 2.136313810296997e-07
of O 0 3.379395607794322e-08
1 O 0 3.421022938709939e-06
- O 0 7.073675078572705e-05
7 O 0 2.6561194317764603e-05
years O 0 3.507959945636685e-06
. O 0 3.5443983961158665e-06

We O 0 1.7263613699469715e-05
have O 0 5.867887011845596e-07
found O 0 2.2004668664976634e-07
a O 0 1.5249054285959573e-07
direct O 0 5.811111805087421e-07
progression O 0 6.699613550154027e-06
of O 0 7.950237090881274e-08
the O 0 2.2733721039003285e-07
size O 0 1.7112315617850982e-06
heterogeneity O 0 4.625646397471428e-06
over O 0 5.296606673255155e-07
time O 0 5.826789220009232e-07
related O 0 3.4419562666698766e-07
to O 0 3.5351317251297587e-07
initial O 0 3.728736601260607e-06
CTG O 0 4.756329508381896e-05
repeat O 0 6.000426765240263e-06
size O 0 7.949416271912924e-07
and O 0 4.047138588703092e-07
the O 0 1.0133889105645721e-07
time O 0 3.815341358404112e-07
interval O 0 6.066186983844091e-07
and O 0 5.372324380914506e-07
always O 0 4.811690814676695e-07
biased O 0 2.465311581545393e-06
towards O 0 5.376691092351393e-07
further O 0 1.2504048072514706e-06
expansion O 0 1.241893187398091e-05
. O 0 7.889924745541066e-06

Attempts O 0 0.00012058063293807209
to O 0 8.58902967593167e-06
mathematically O 0 2.6470843295101076e-05
model O 0 6.7427631620375905e-06
the O 0 1.0226366384813446e-06
dynamics O 0 5.615041663986631e-05
have O 0 1.248470994141826e-06
proved O 0 3.368962097738404e-06
only O 0 1.3904150364396628e-07
partially O 0 1.6527119441889226e-05
successful O 0 3.7642080314981285e-06
suggesting O 0 1.2436273664206965e-06
that O 0 4.063954506250411e-08
individual O 0 1.9484717839191035e-08
specific O 0 5.354229060117177e-08
genetic O 0 7.361828465946019e-06
and O 0 1.0554142136243172e-05
/ O 0 0.0004799377638846636
or O 0 1.5919068800940295e-06
environmental O 0 1.2186642379674595e-06
factors O 0 1.4767886113986606e-07
also O 0 3.2743329825279943e-07
play O 0 1.1712523217966009e-07
a O 0 6.796735192438064e-07
role O 0 2.4565924832131714e-06
in O 0 1.2797116824003751e-06
somatic O 0 3.1710882467450574e-05
mosaicism O 0 0.00038277162821032107
. O 0 2.1422538338811137e-06
. O 0 5.112421604280826e-06

Aspartylglucosaminuria B-Disease 1 0.9993247985839844
among O 0 4.7040808567544445e-05
Palestinian O 0 0.00031239772215485573
Arabs O 0 0.00021489796927198768
. O 0 2.880009742511902e-05

Aspartylglucosaminuria B-Disease 1 0.9999955892562866
( O 1 0.786414623260498
AGU B-Disease 1 0.9999992847442627
) O 0 2.6325235012336634e-05
is O 0 8.210523674279102e-07
a O 0 3.858865056827199e-06
rare O 0 8.160137076629326e-05
disorder B-Disease 0 0.00160815694835037
of I-Disease 0 8.237252018261643e-07
glycoprotein I-Disease 0 0.003291650675237179
metabolism I-Disease 0 0.017993874847888947
caused O 0 6.668898276984692e-05
by O 0 1.0075843874801649e-06
the O 0 2.3502785552409478e-05
deficiency B-Disease 0 0.0008301023626700044
of I-Disease 0 9.484800500558777e-08
the I-Disease 0 2.3384191081277095e-06
lysosomal I-Disease 0 0.0009857226395979524
enzyme I-Disease 0 8.230793901020661e-05
aspartylglucosaminidase I-Disease 0 0.0012756644282490015
( O 0 1.4629436009272467e-06
AGA O 0 0.00019502836221363395
) O 0 2.5771591936063487e-06
. O 0 4.4755724957212806e-06

AGU B-Disease 1 0.9999918937683105
is O 0 0.0007511868025176227
inherited O 0 0.0022676780354231596
as O 0 8.323283509525936e-06
an O 0 2.4548628061893396e-05
autosomal O 1 0.9820621609687805
recessive O 1 0.9828298687934875
trait O 0 0.019882844761013985
and O 0 1.97422195924446e-05
occurs O 0 3.8081907405285165e-07
with O 0 1.1735679095181695e-07
a O 0 1.636966203477641e-06
high O 0 5.5145123951660935e-06
frequency O 0 7.973029823915567e-06
in O 0 8.148415417963406e-07
Finland O 0 0.00010900039342232049
because O 0 1.4001594195178768e-07
of O 0 3.419700433937578e-08
a O 0 3.5280022530059796e-06
founder O 0 0.0004051023570355028
effect O 0 1.0233771718048956e-05
. O 0 4.164475285506342e-06

While O 0 1.8538783479016274e-05
very O 0 1.463538069401693e-06
few O 0 1.4337448419610155e-06
patients O 0 7.720750545558985e-06
with O 0 5.3816038416698575e-06
AGU B-Disease 1 0.9999996423721313
have O 0 1.4577387446479406e-05
been O 0 3.767458110814914e-06
reported O 0 1.160766350949416e-05
from O 0 6.604833657775089e-08
non O 0 5.577257411459868e-07
- O 0 2.5299887056462467e-05
Finnish O 0 5.907532249693759e-05
origin O 0 1.1559756103451946e-06
, O 0 1.229094095833716e-06
we O 0 1.4755611346117803e-06
diagnosed O 0 0.0019566609989851713
the O 0 2.053344132946222e-06
disorder O 0 0.00020388601114973426
in O 0 1.7749382550391601e-06
8 O 0 5.268658060231246e-05
patients O 0 1.3591653669209336e-06
originating O 0 1.295085212404956e-07
from O 0 1.438663161934528e-07
3 O 0 4.123623057239456e-06
unrelated O 0 1.5652162801416125e-06
families O 0 1.31887389898111e-07
, O 0 1.0501160119247288e-07
all O 0 1.3105294627280273e-08
Palestinian O 0 4.992678896087455e-06
Arabs O 0 2.2129431727080373e-06
from O 0 1.3630136663778103e-07
the O 0 2.1197595856392581e-07
region O 0 3.1264848985301796e-06
of O 0 6.752878789484384e-07
Jerusalem O 0 0.003079281421378255
. O 0 3.563483551261015e-05

The O 0 5.3066374675836414e-05
clinical O 0 0.0010436703450977802
diagnosis O 1 0.550366222858429
of O 0 4.2321971704950556e-05
AGU B-Disease 1 0.9999998807907104
is O 0 2.928432331827935e-05
often O 0 1.3055456520305597e-06
difficult O 0 1.5359730696218321e-06
, O 0 5.530583848667447e-07
in O 0 1.832778337984564e-07
particular O 0 7.576177551982255e-08
early O 0 1.5575296856695786e-06
in O 0 1.5148374643558782e-07
the O 0 1.53914768930008e-07
course O 0 2.0994489204895217e-06
of O 0 2.390749216374388e-07
the O 0 2.4870558263501152e-05
disease O 0 0.0007569051231257617
, O 0 2.3789679914898443e-07
and O 0 1.4890838428982534e-07
most O 0 1.5158223121147785e-08
of O 0 1.7468986257540564e-08
the O 0 1.2050086297676899e-06
patients O 0 7.189819370978512e-06
are O 0 3.953152827307349e-07
diagnosed O 0 0.0004715567047242075
after O 0 1.3581988014266244e-06
the O 0 2.087692081431669e-07
age O 0 2.4468562287438544e-07
of O 0 6.189867463035625e-08
5 O 0 6.415671577997273e-06
years O 0 3.3510625598864863e-06
. O 0 4.3632999222609214e-06

However O 0 5.067877646069974e-05
, O 0 3.22796995533281e-06
since O 0 8.866117582329025e-07
these O 0 6.668364704864871e-08
patients O 0 1.1230438303755363e-06
excrete O 0 6.237285106180934e-07
early O 0 3.123165868146316e-07
large O 0 1.0233161873429708e-07
amounts O 0 1.7472459035161592e-07
of O 0 1.1629325058493123e-07
aspartylglucosamine O 0 5.679027526639402e-05
in O 0 1.6767960460128961e-06
urine O 0 8.562089533370454e-06
, O 0 2.583661000699067e-07
biochemical O 0 7.404769348795526e-07
screening O 0 7.459885296157154e-07
is O 0 1.6363934207674902e-07
easy O 0 8.680042355990736e-07
by O 0 6.540784056596749e-07
urine O 0 2.4264971216325648e-05
chromatography O 0 3.915401975973509e-05
. O 0 1.7880815903481562e-06
. O 0 3.4858096569223562e-06

Detection O 0 9.736279753269628e-05
of O 0 2.894793169616605e-06
heterozygous O 0 1.4276336514740251e-05
carriers O 0 4.464694029593375e-06
of O 0 1.6129326922964538e-06
the O 0 0.0006332530174404383
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 2.0027364371344447e-05
ATM O 0 0.00022419117158278823
) O 0 3.903201672983414e-07
gene O 0 7.282221758941887e-07
by O 0 2.7772506427936605e-07
G2 O 0 0.0005289092659950256
phase O 0 6.256922642933205e-05
chromosomal O 0 0.007554891984909773
radiosensitivity O 0 0.0008330222335644066
of O 0 5.544342457142193e-06
peripheral O 0 0.011497327126562595
blood O 0 0.0036568602081388235
lymphocytes O 0 0.0009411819046363235
. O 0 1.851984234235715e-05

In O 0 0.35384905338287354
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 1.0
( O 0 0.005066756159067154
A B-Disease 1 0.9999867677688599
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
) O 0 2.3313506972044706e-05
patients O 0 2.983938884426607e-06
, O 0 2.421330975721503e-07
mutations O 0 7.795586611791805e-07
in O 0 4.8323474999278915e-08
a O 0 4.05998093810922e-07
single O 0 8.306922609335743e-06
gene O 0 2.888880317186704e-06
, O 0 3.552299858711194e-07
ATM O 0 2.6710427846410312e-05
, O 0 7.031572977211908e-07
result O 0 9.016119406624057e-07
in O 0 7.84038184065139e-06
an O 0 0.4624658524990082
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.0854420906980522e-05
embraces O 0 5.498364316736115e-06
a O 0 1.2059352911819587e-06
variety O 0 2.2198223348368629e-07
of O 0 1.6293330418193364e-07
clinical O 0 7.14326961315237e-06
features O 0 1.368430457659997e-05
and O 0 7.22980075806845e-06
manifests O 0 1.7145581296063028e-05
extreme O 0 1.712954690447077e-05
radiosensitivity O 0 0.0001432160206604749
and O 0 7.475539405277232e-07
a O 0 1.0251627600155189e-06
strong O 0 1.5230930330289993e-06
pre O 0 6.531691178679466e-05
- O 0 0.0018791032489389181
disposition O 0 0.0001331632665824145
to O 0 1.6502977814525366e-05
malignancy B-Disease 0 0.003758965991437435
. O 0 9.464916729484685e-06

Heterozygotes O 0 0.0006333290948532522
for O 0 2.95756262858049e-06
the O 0 5.766191861766856e-07
ATM O 0 5.5773973144823685e-05
gene O 0 4.731024546344997e-06
have O 0 1.9437061382632237e-07
no O 0 2.679340980193956e-07
clinical O 0 8.424024144915165e-07
expression O 0 2.0518453425211192e-07
of O 0 3.6371574196891743e-07
A B-Disease 1 0.9999935626983643
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
but O 0 7.63181087677367e-05
may O 0 3.276670031482354e-05
be O 0 5.102932846057229e-06
cancer B-Disease 0 0.0005303581128828228
prone O 0 2.7143905754201114e-06
with O 0 1.3678707944109192e-07
a O 0 3.1737451990920817e-06
moderate O 0 5.407674325397238e-05
increase O 0 3.7843576592422323e-06
in O 0 8.156430908456969e-07
in O 0 3.0716907986061415e-06
vitro O 0 0.00036629365058615804
radiosensitivity O 0 0.0010712203802540898
. O 0 1.317034457315458e-05

We O 0 3.164565714541823e-05
performed O 0 1.4838806237094104e-05
a O 0 3.638146154116839e-06
blind O 0 9.783390123629943e-05
chromosomal O 0 0.0017786802491173148
analysis O 0 9.78798016149085e-06
on O 0 3.27961788570974e-05
G2 O 0 0.026003697887063026
- O 0 0.001578603987582028
phase O 0 1.2428718946466688e-05
lymphocytes O 0 8.01713849796215e-06
from O 0 1.566044858236637e-07
7 O 0 5.490514922712464e-06
unrelated O 0 2.076745658996515e-05
A B-Disease 1 0.9999649524688721
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 0.002629227004945278
, O 0 3.9459814615838695e-07
13 O 0 8.351352676072565e-07
obligate O 0 1.0086372412843048e-06
A B-Disease 1 0.998979389667511
- I-Disease 1 0.9999903440475464
T I-Disease 1 1.0
heterozygotes O 0 0.00011999690468655899
( O 0 2.820948452608718e-07
parents O 0 4.851094104196818e-08
of O 0 3.4312975571992865e-08
the O 0 4.217745754431235e-06
patients O 0 1.0479433512955438e-05
) O 0 1.7373992022839957e-07
, O 0 1.7115321782057435e-07
and O 0 2.4529728648303717e-07
14 O 0 5.896806101191032e-07
normal O 0 2.9840390425306396e-07
controls O 0 1.936489979925682e-06
following O 0 8.909668167689233e-07
X O 0 0.0006104925414547324
- O 0 6.718430813634768e-05
irradiation O 0 1.553914103169518e-06
with O 0 2.000241323685259e-07
1 O 0 3.6620465380110545e-06
Gy O 0 3.490072413114831e-05
in O 0 1.548992969446772e-07
order O 0 6.300693655703071e-08
to O 0 1.051936280305199e-07
evaluate O 0 4.651506344544032e-07
this O 0 5.517251366882192e-08
cytogenetic O 0 3.990419827459846e-06
method O 0 6.119493036749191e-07
as O 0 1.198120145318171e-07
a O 0 2.235850615761592e-07
tool O 0 2.0918264453939628e-06
for O 0 1.1080504691562965e-07
detection O 0 1.1757842912629712e-06
of O 0 3.0087571190051676e-07
ATM O 0 0.0005802144878543913
carriers O 0 8.552362487534992e-06
. O 0 5.162991328688804e-06

Both O 0 6.217025656951591e-05
A B-Disease 1 0.9957212209701538
- I-Disease 1 0.999927282333374
T I-Disease 1 0.999998927116394
homozygotes O 0 0.0008119586855173111
and O 0 3.68532369066088e-06
heterozygotes O 0 8.151717338478193e-06
showed O 0 6.513583684863988e-06
significantly O 0 7.747353834020032e-07
increased O 0 1.3414087618457415e-07
levels O 0 1.5810451259312686e-07
of O 0 2.1804025607252697e-07
radiation O 0 0.0035667873453348875
- O 0 0.23048226535320282
induced O 0 0.010357344523072243
chromatid O 0 0.1009085550904274
damage O 0 0.0007238814141601324
relative O 0 2.6170421278948197e-06
to O 0 3.824043801614607e-07
that O 0 8.51871035933982e-08
of O 0 1.294396270168363e-07
normal O 0 3.0382304885279154e-06
controls O 0 8.488637104164809e-05
. O 0 9.330092325399164e-06

These O 0 6.118365035945317e-06
results O 0 9.308336302638054e-06
show O 0 1.8582964003144298e-06
that O 0 1.0972739517001173e-07
the O 0 1.6306465511206625e-07
G2 O 0 0.0004081942606717348
- O 0 0.00012321701797191054
phase O 0 1.1419174370530527e-05
chromosomal O 0 0.00014428379654418677
radiosensitivity O 0 5.676488217432052e-05
assay O 0 2.1998357624397613e-05
can O 0 1.9706656928519806e-07
be O 0 3.2321171516969116e-08
used O 0 8.673978868500853e-08
for O 0 4.27916546641427e-08
the O 0 9.890418084523844e-08
detection O 0 4.011978944618022e-06
of O 0 1.0239325547445333e-06
A B-Disease 1 0.9998583793640137
- I-Disease 1 0.999983549118042
T I-Disease 1 0.9999994039535522
heterozygotes O 0 0.0004208625468891114
. O 0 8.008884833543561e-06

In O 0 1.9990024156868458e-05
combination O 0 7.034321697574342e-06
with O 0 1.118466002481e-06
molecular O 0 6.401970313163474e-05
genetic O 0 0.00013560002844315022
analyses O 0 1.84050095413113e-05
, O 0 1.3762939943262609e-06
this O 0 2.0066630668225116e-07
test O 0 1.5309014997910708e-06
may O 0 1.663237867433054e-06
be O 0 2.5401035941285954e-08
of O 0 1.0946877182504977e-08
value O 0 3.1290034030462266e-07
in O 0 4.991889568373153e-07
studies O 0 2.474112932304706e-07
of O 0 8.945838203544554e-08
familial B-Disease 0 5.5904856708366424e-05
and I-Disease 0 1.9382714526727796e-05
sporadic I-Disease 0 0.0005425129784271121
cancers I-Disease 0 0.14707311987876892
aimed O 0 4.5168353608460166e-06
at O 0 6.5293997977278195e-06
determination O 0 3.1306558412325103e-06
of O 0 6.669026220151864e-08
the O 0 3.819742744326504e-07
potential O 0 6.557935421369621e-07
involvement O 0 4.834098490391625e-07
of O 0 1.3749964011822158e-07
ATM O 0 0.002146477345377207
mutations O 0 7.138973160181195e-05
in O 0 1.3206164112489205e-05
tumor B-Disease 0 0.3443964421749115
risk O 0 1.8159407773055136e-05
or O 0 8.337912049682927e-07
development O 0 9.07723631371482e-07
. O 0 1.8582537677502842e-06
. O 0 5.947188128629932e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999947547912598
telangiectasia I-Disease 1 0.9999995231628418
: O 0 2.554857564973645e-05
identification O 0 3.4821480312530184e-06
and O 0 5.909512310608989e-07
detection O 0 2.1182611362746684e-06
of O 0 2.6205759695585584e-07
founder O 0 0.00024730994482524693
- O 0 0.0029221377335488796
effect O 0 9.356717782793567e-06
mutations O 0 2.6418399556860095e-06
in O 0 6.296933463545429e-08
the O 0 1.0879024614496302e-07
ATM O 0 8.009075099835172e-05
gene O 0 3.1358670184999937e-06
in O 0 2.0940768763466622e-07
ethnic O 0 3.682702754304046e-06
populations O 0 7.1046119956008624e-06
. O 0 5.785785560874501e-06

To O 0 9.609060725779273e-06
facilitate O 0 2.801249365802505e-06
the O 0 4.180221822025487e-07
evaluation O 0 6.598990580641839e-07
of O 0 1.1515804487771675e-07
ATM O 0 4.6695986384293064e-05
heterozygotes O 0 5.928183782089036e-06
for O 0 2.737783972861507e-07
susceptibility O 0 1.3057213436695747e-05
to O 0 9.9072758530383e-07
other O 0 2.3004997729003662e-06
diseases O 0 7.719820132479072e-05
, O 0 3.4621467648321413e-07
such O 0 6.208075831182214e-08
as O 0 0.00016444287030026317
breast B-Disease 1 0.9990653395652771
cancer I-Disease 0 0.11701324582099915
, O 0 1.0560127066128189e-06
we O 0 1.0398256478083567e-07
have O 0 4.0158269598578045e-08
attempted O 0 1.8124503640137846e-06
to O 0 1.1619280826380418e-07
define O 0 2.073131497581926e-07
the O 0 6.765191074009635e-08
most O 0 1.6651789280786033e-07
common O 0 1.1379909210518235e-06
mutations O 0 2.5215972527803387e-06
and O 0 1.7517339756523143e-07
their O 0 4.2812882838916266e-07
frequencies O 0 1.9042678104597144e-05
in O 0 0.0010859309695661068
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 0 0.0009096208959817886
A B-Disease 1 0.9999945163726807
- I-Disease 1 0.9999977350234985
T I-Disease 1 1.0
) O 0 3.6682404243038036e-06
homozygotes O 0 7.564555744465906e-06
from O 0 7.917596178685926e-08
10 O 0 2.449218925448804e-07
ethnic O 0 2.4857065454853e-06
populations O 0 4.900947715213988e-06
. O 0 6.495545676443726e-06

Both O 0 3.7840796721866354e-05
genomic O 0 0.00016162746760528535
mutations O 0 0.0002215525892097503
and O 0 3.7242409689497435e-06
their O 0 2.009381432799273e-06
effects O 0 5.699334906239528e-06
on O 0 2.384274466749048e-06
cDNA O 0 9.13875010155607e-06
were O 0 3.883621957356809e-06
characterized O 0 3.420459688641131e-05
. O 0 9.136911103269085e-06

Protein O 0 0.00018600409384816885
- O 0 0.0002453030610922724
truncation O 0 4.308346615289338e-05
testing O 0 1.5632471104254364e-06
of O 0 3.59411735928461e-08
the O 0 5.351982323986704e-08
entire O 0 3.760157483156945e-07
ATM O 0 1.114910173782846e-05
cDNA O 0 2.4878172553144395e-06
detected O 0 4.716654075309634e-06
92 O 0 1.201773329739808e-06
( O 0 8.244216331831922e-08
66 O 0 2.304669806107995e-06
% O 0 5.840230414833059e-07
) O 0 1.412412018453324e-07
truncating O 0 6.14718646829715e-06
mutations O 0 1.4358220141730271e-05
in O 0 2.7561952720134286e-07
140 O 0 1.244194436367252e-06
mutant O 0 3.746398942894302e-05
alleles O 0 1.9681277990457602e-05
screened O 0 9.59793251240626e-05
. O 0 1.4293747881310992e-05

The O 0 1.3738177585764788e-05
haplotyping O 0 0.00018696891493164003
of O 0 1.042046847032907e-06
patients O 0 6.750419288437115e-06
with O 0 5.225442123446555e-07
identical O 0 0.00011160517897224054
mutations O 0 0.00014229855150915682
indicates O 0 5.3657990974897984e-06
that O 0 1.510095017920321e-07
almost O 0 3.8035082638998574e-08
all O 0 6.093923587968675e-09
of O 0 9.45730249668486e-09
these O 0 1.805564764367773e-08
represent O 0 1.5215540827284713e-07
common O 0 1.411745529367181e-06
ancestry O 0 8.828050340525806e-06
and O 0 2.9729746984230587e-06
that O 0 3.9417690800291894e-07
very O 0 2.014993327748016e-07
few O 0 4.740124666113843e-07
spontaneously O 0 5.618751401925692e-06
recurring O 0 2.0321846022852696e-05
ATM O 0 0.0006942740292288363
mutations O 0 0.00011225796333746985
exist O 0 4.579790129355388e-06
. O 0 4.5417368710332084e-06

Assays O 0 0.0005275998264551163
requiring O 0 2.5172214009216987e-05
minimal O 0 9.22637354960898e-06
amounts O 0 1.0080062793349498e-06
of O 0 1.663945710106418e-07
genomic O 0 4.431656634551473e-06
DNA O 0 6.039853906258941e-05
were O 0 1.2770856301358435e-06
designed O 0 1.5301803841794026e-06
to O 0 1.5456609503416985e-07
allow O 0 9.342205942175497e-08
rapid O 0 7.437083695549518e-07
screening O 0 3.3863969406411343e-07
for O 0 9.251806432075682e-08
common O 0 1.1666209047689335e-06
ethnic O 0 1.2993080417800229e-05
mutations O 0 0.00011701502808136865
. O 0 8.85953431861708e-06

These O 0 8.086970410658978e-06
rapid O 0 1.4724426364409737e-05
assays O 0 2.3115962903830223e-05
detected O 0 2.6443090973771177e-05
mutations O 0 7.116859251254937e-06
in O 0 4.0619323726787115e-07
76 O 0 4.7080256990739144e-06
% O 0 2.2136323707400152e-07
of O 0 5.052428164731282e-08
Costa O 0 1.2310847523622215e-05
Rican O 0 1.750182309478987e-05
patients O 0 5.03503906656988e-06
( O 0 8.449612920458094e-08
3 O 0 1.6272441598630394e-06
) O 0 1.7794555162709003e-07
, O 0 6.519088202594503e-08
50 O 0 5.177059492211811e-08
% O 0 5.1879030849022456e-08
of O 0 6.235108429564207e-08
Norwegian O 1 0.739777147769928
patients O 0 4.1339179006172344e-05
( O 0 1.8346635499710828e-07
1 O 0 3.1643824058846803e-06
) O 0 3.173202003381448e-07
, O 0 1.492268353331383e-07
25 O 0 9.578646853469763e-08
% O 0 7.645129329603151e-08
of O 0 1.0008817241669021e-07
Polish O 0 0.2341882437467575
patients O 0 4.930960858473554e-05
( O 0 1.2869433874129754e-07
4 O 0 2.958109917017282e-06
) O 0 2.725022625327256e-07
, O 0 2.2030705792985827e-07
and O 0 3.723573058778129e-07
14 O 0 5.585662279372627e-07
% O 0 5.343720488326653e-08
of O 0 3.582373153676599e-08
Italian O 0 0.0003922439937014133
patients O 0 9.250645234715194e-06
( O 0 9.886250040835876e-08
1 O 0 1.7511038095108233e-06
) O 0 2.012920958804898e-07
, O 0 1.3657930253430095e-07
as O 0 8.379477378639422e-08
well O 0 1.1389796128469243e-07
as O 0 3.800894319283543e-07
in O 0 5.654102892549417e-07
patients O 0 5.892393346584868e-07
of O 0 5.52055645641758e-08
Amish O 0 0.0002488848986104131
/ O 0 0.0002747568069025874
Mennonite O 0 6.537143781315535e-05
and O 0 4.39339646618464e-06
Irish O 0 1.0953425771731418e-05
English O 0 4.070039722137153e-06
backgrounds O 0 1.3152420251572039e-05
. O 0 9.462713023822289e-06

Additional O 0 2.4713148377486505e-05
mutations O 0 8.865161362336949e-05
were O 0 1.8294812207386713e-06
observed O 0 1.1025559842892108e-06
in O 0 1.953294628265212e-07
Japanese O 0 1.6443513004560373e-06
, O 0 3.206659471288731e-07
Utah O 0 1.8838035202861647e-06
Mormon O 0 8.80240804690402e-07
, O 0 2.0099994912925467e-07
and O 0 2.6428429578118084e-07
African O 0 4.6910656692489283e-07
American O 0 4.704470939032035e-06
patients O 0 7.755367732897867e-06
. O 0 2.803552661134745e-06

These O 0 4.8251727093884256e-06
assays O 0 1.0976462363032624e-05
should O 0 3.102373966612504e-07
facilitate O 0 1.6580369788243843e-07
screening O 0 9.265125981983147e-07
for O 0 1.2807116718249745e-06
A B-Disease 1 0.9997957348823547
- I-Disease 1 0.9999783039093018
T I-Disease 1 0.9999997615814209
heterozygotes O 0 2.0250918169040233e-05
in O 0 3.0022593477951887e-07
the O 0 3.243183925860649e-07
populations O 0 1.2603211416717386e-06
studied O 0 1.5803170754224993e-06
. O 0 1.234853471032693e-06
. O 0 4.57940132037038e-06

The O 0 0.00014118057151790708
von B-Disease 1 0.9771248698234558
Hippel I-Disease 1 0.9979749321937561
- I-Disease 1 0.9945623278617859
Lindau I-Disease 1 0.9991463422775269
tumor I-Disease 0 0.1763850450515747
suppressor O 0 0.0002871203178074211
gene O 0 2.525531454011798e-05
is O 0 2.961278084967489e-07
required O 0 1.873103769867157e-07
for O 0 2.7667030622069433e-07
cell O 0 4.3381172872614115e-05
cycle O 0 2.1112964532221667e-05
exit O 0 4.6170480345608667e-05
upon O 0 1.3407683354671462e-06
serum O 0 2.2270422050496563e-05
withdrawal O 0 6.491379463113844e-05
. O 0 8.497842827637214e-06

The O 0 3.2387593819294125e-05
inactivation O 0 0.0008256727596744895
of O 0 1.2897511396658956e-06
the O 0 6.16208353676484e-06
von B-Disease 1 0.9951223731040955
Hippel I-Disease 1 0.9995384216308594
- I-Disease 1 0.9976860284805298
Lindau I-Disease 1 0.9993661046028137
( I-Disease 0 5.9879192122025415e-05
VHL I-Disease 0 0.0017999688861891627
) I-Disease 0 1.6665719158481807e-05
tumor I-Disease 0 0.0004064128443133086
suppressor O 0 0.00027499505085870624
gene O 0 4.165736027061939e-05
predisposes O 0 0.00011765547242248431
affected O 0 2.5357192043884424e-06
individuals O 0 1.0358883173466893e-07
to O 0 5.486440386448521e-07
the O 0 8.228284059441648e-06
human O 0 0.0014866853598505259
VHL B-Disease 1 0.999994158744812
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999973773956299
and O 0 1.8942881069961004e-05
is O 0 3.146129529341124e-06
associated O 0 3.7775498640257865e-06
with O 0 5.7111092246486805e-06
sporadic B-Disease 1 0.6644151210784912
renal I-Disease 1 0.9999991655349731
cell I-Disease 1 0.9999947547912598
carcinomas I-Disease 1 1.0
( O 0 0.001035879016853869
RCC B-Disease 1 0.9290695786476135
) O 0 1.2891516234958544e-05
and O 0 6.139410834293813e-05
brain B-Disease 0 0.01926879584789276
hemangioblastomas I-Disease 0 0.00790480338037014
. O 0 2.797570232360158e-05

VHL O 0 0.23725321888923645
- O 0 0.005570077802985907
negative O 0 5.973928637104109e-05
786 O 0 0.00014329908299259841
- O 0 0.001050853286869824
0 O 0 3.5620258131530136e-05
RCC B-Disease 0 0.0006432918598875403
cells O 0 6.619388386752689e-06
are O 0 7.015724889924968e-08
tumorigenic O 0 2.8946913516847417e-05
in O 0 3.591114136725082e-06
nude O 0 0.001072784885764122
mice O 0 0.0008585699833929539
which O 0 2.9098669074301142e-06
is O 0 4.855861561736674e-07
suppressed O 0 3.2973304087136057e-07
by O 0 4.2194734817257995e-08
the O 0 1.7279491260069335e-07
reintroduction O 0 3.767989983316511e-05
of O 0 2.414536311334814e-06
VHL B-Disease 0 0.0007261009886860847
. O 0 1.782904473657254e-05

Remarkably O 0 0.0010897248284891248
, O 0 8.166781299223658e-06
this O 0 2.4688520738891384e-07
occurs O 0 2.60344791058742e-07
without O 0 1.1324765836207007e-07
affecting O 0 2.58615074244517e-07
the O 0 2.0430857716746686e-07
growth O 0 9.352791494166013e-06
rate O 0 4.035093752463581e-06
and O 0 6.269309551498736e-07
cell O 0 2.854428021237254e-05
cycle O 0 1.2720492122753058e-05
profile O 0 2.9629293294419767e-06
of O 0 6.594422785610732e-08
these O 0 1.2182954378658906e-07
cells O 0 2.4838914214342367e-06
in O 0 3.7137215258553624e-07
culture O 0 3.536369376888615e-06
. O 0 4.908473783871159e-06

The O 0 1.680498280620668e-05
786 O 0 0.00011096656089648604
- O 0 0.0005127093172632158
0 O 0 1.4383066627488006e-05
cell O 0 3.0167297154548578e-05
line O 0 7.408481451420812e-06
, O 0 2.28682353053955e-07
like O 0 9.077983520455746e-08
many O 0 4.3190411247451266e-07
cancer B-Disease 0 0.00010594476043479517
cells O 0 2.873421863114345e-06
, O 0 5.753722120971361e-07
fails O 0 2.7826004043163266e-06
to O 0 1.4606305853703816e-07
exit O 0 4.8269675971823744e-06
the O 0 3.413998683754471e-07
cell O 0 3.138290412607603e-05
cycle O 0 1.577443617861718e-05
upon O 0 3.1405299978359835e-06
serum O 0 5.171648081159219e-05
withdrawal O 0 7.641400588909164e-05
. O 0 8.712263479537796e-06

Here O 0 2.3645294277230278e-05
, O 0 2.6819589038495906e-06
it O 0 2.0522112720300356e-07
is O 0 9.491134278505342e-08
shown O 0 1.985025477324598e-07
that O 0 8.296461828649626e-08
reintroduction O 0 1.791700356079673e-06
of O 0 5.166899086361809e-08
the O 0 1.4703914530400652e-07
wild O 0 3.197271098542842e-06
- O 0 0.0004468710976652801
type O 0 1.2450023859855719e-05
VHL B-Disease 0 5.191769014345482e-05
gene O 0 3.55236443283502e-06
restores O 0 9.85354017757345e-06
the O 0 1.2918953018470347e-07
ability O 0 3.2581323239355697e-07
of O 0 2.739787134942162e-07
VHL O 0 0.0010680248960852623
- O 0 0.09272453188896179
negative O 0 5.6615292123751715e-05
RCC B-Disease 1 0.5035229325294495
cancer I-Disease 0 0.005310459528118372
cells O 0 1.8002401702688076e-06
to O 0 2.398731169250823e-07
exit O 0 7.024467322480632e-06
the O 0 3.3427016887799255e-07
cell O 0 3.689824006869458e-05
cycle O 0 1.2666020666074473e-05
and O 0 1.6600384924458922e-06
enter O 0 1.2958490742676076e-06
G0 O 0 0.00010943279630737379
/ O 0 2.6452549718669616e-05
quiescence O 0 2.849793054338079e-05
in O 0 1.2618942264452926e-06
low O 0 2.8149011995992623e-05
serum O 0 0.00013796502025797963
. O 0 1.24024090837338e-05

Both O 0 6.806740566389635e-05
VHL O 0 0.004093450959771872
- O 0 0.0010585770942270756
positive O 0 6.791293799324194e-06
and O 0 4.375910066301003e-06
VHL O 0 0.0007880792254582047
- O 0 0.0009442524751648307
negative O 0 9.191980097966734e-06
RCC B-Disease 0 0.00020063883857801557
cells O 0 3.595318503357703e-06
exit O 0 3.622808662839816e-06
the O 0 3.502794356791128e-07
cell O 0 2.9284517950145528e-05
cycle O 0 1.2171484740974847e-05
by O 0 5.253098152024904e-07
contact O 0 6.308681349764811e-06
inhibition O 0 1.2010770660708658e-05
. O 0 6.129379471531138e-06

The O 0 1.118833006330533e-05
cyclin O 0 0.00018174428259953856
- O 0 0.00013389973901212215
dependent O 0 1.1691085092024878e-05
kinase O 0 4.6280285459943116e-05
inhibitor O 0 9.064779987966176e-06
, O 0 4.22783188014364e-07
p27 O 0 3.627849309850717e-06
, O 0 1.8710559857026965e-07
accumulates O 0 9.873790531855775e-07
upon O 0 2.2037136204744456e-07
serum O 0 3.46828778674535e-06
withdrawal O 0 8.396742487093434e-06
, O 0 2.0229165897944767e-07
only O 0 1.6011190595577318e-08
in O 0 4.791834484763058e-08
the O 0 5.375512657224135e-08
presence O 0 9.83755086281235e-08
of O 0 1.421480533281283e-07
VHL B-Disease 0 5.009243977838196e-05
, O 0 8.887569720172905e-07
as O 0 1.2031811991164432e-07
a O 0 4.5692968342336826e-07
result O 0 2.2933359389298857e-07
of O 0 1.717963193925698e-08
the O 0 2.2522284837123152e-07
stabilization O 0 1.7485222087998409e-06
of O 0 5.0689919817159534e-08
the O 0 3.0688281071888923e-07
protein O 0 1.5416673704748973e-05
. O 0 6.537288300023647e-06

We O 0 1.3287330148159526e-05
propose O 0 1.214354324474698e-05
that O 0 4.622329470294062e-07
the O 0 1.9888285862634802e-07
loss O 0 6.213932010723511e-06
of O 0 1.5239807282796392e-07
wild O 0 1.7581924112164415e-05
- O 0 0.006969096604734659
type O 0 1.8834045476978645e-05
VHL B-Disease 0 7.750638906145468e-05
gene O 0 5.485103429236915e-06
results O 0 1.7050153928721556e-06
in O 0 6.36898462857971e-08
a O 0 5.523578465727041e-07
specific O 0 4.011911585166672e-07
cellular O 0 0.00016346361371688545
defect O 0 9.353096538688987e-05
in O 0 2.4020396267587785e-06
serum O 0 2.9837066904292442e-05
- O 0 0.00011752797581721097
dependent O 0 1.3069472515780944e-05
growth O 0 1.552653338876553e-05
control O 0 2.532164444346563e-06
, O 0 4.841619443141099e-07
which O 0 1.8858977455238346e-06
may O 0 5.2628683988587e-06
initiate O 0 7.454078513546847e-06
tumor B-Disease 0 0.0002891768526751548
formation O 0 1.8950217054225504e-05
. O 0 8.195618647732772e-06

This O 0 1.4124045264907181e-05
is O 0 2.3721268007648177e-06
corrected O 0 2.364267857046798e-05
by O 0 1.5710260470314097e-07
the O 0 1.388501686960808e-07
reintroduction O 0 6.320135071291588e-06
of O 0 2.4337884951819433e-07
wild O 0 8.519175935362e-06
- O 0 0.004008996766060591
type O 0 2.8749662305926904e-05
VHL B-Disease 0 0.00030097394483163953
, O 0 2.173923348891549e-06
implicating O 0 5.506720845005475e-05
VHL B-Disease 0 6.909006333444268e-05
as O 0 8.781103133514989e-07
the O 0 2.873658218049968e-07
first O 0 9.98260838969145e-06
tumor B-Disease 0 6.0947037127334625e-05
suppressor O 0 3.4491895348764956e-05
involved O 0 7.313994387914136e-07
in O 0 1.6965763904863707e-07
the O 0 9.524357125201277e-08
regulation O 0 3.715124137215753e-07
of O 0 1.5760262783715007e-07
cell O 0 5.773214070359245e-05
cycle O 0 3.365085649420507e-05
exit O 0 4.417962554725818e-05
, O 0 5.461018304231402e-07
which O 0 2.6304260813958535e-07
is O 0 1.094126602652068e-07
consistent O 0 3.582735814688931e-07
with O 0 1.572651058268093e-07
its O 0 4.323502253100742e-06
gatekeeper O 0 2.673856397450436e-05
function O 0 2.0117771271088714e-07
in O 0 3.3516587905069173e-07
the O 0 8.256731234723702e-06
kidney O 0 0.09792965650558472
. O 0 3.0794487884122645e-06
. O 0 5.763042736361967e-06

Piebaldism B-Disease 1 0.9999747276306152
with O 1 0.7912359237670898
deafness B-Disease 1 1.0
: O 0 9.838814003160223e-05
molecular O 0 0.00014758874021936208
evidence O 0 1.1027243999706116e-05
for O 0 1.8232786942462553e-06
an O 0 1.051778053806629e-05
expanded O 0 0.002385238651186228
syndrome O 1 0.9996862411499023
. O 0 2.5759680283954367e-05

In O 0 8.116097887977958e-06
a O 0 2.472490450600162e-06
South O 0 2.198445827161777e-06
African O 0 8.236231110458903e-07
girl O 0 1.755675839376636e-05
of O 0 1.7898715043429547e-07
Xhosa O 0 0.0007012282148934901
stock O 0 0.00010654106154106557
with O 0 4.179148618277395e-06
severe O 0 0.0013142938259989023
piebaldism B-Disease 0 0.08423386514186859
and O 0 0.0011894515482708812
profound O 0 0.17265021800994873
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.0004219576367177069
identified O 0 1.6295056411763653e-05
a O 0 1.557875862090441e-06
novel O 0 2.0222482817189302e-06
missense O 0 3.2721777643018868e-06
substitution O 0 2.031575832006638e-07
at O 0 4.795930976797536e-07
a O 0 2.7411749670136487e-07
highly O 0 2.847059192845336e-07
conserved O 0 5.095271262689494e-07
residue O 0 1.80995618848101e-06
in O 0 6.073109659610054e-08
the O 0 4.138389897434536e-08
intracellular O 0 4.92671745178086e-07
kinase O 0 6.22889547230443e-06
domain O 0 3.335886731292703e-07
of O 0 6.395838880735027e-08
the O 0 4.81820620734652e-07
KIT O 0 0.0001354631531285122
proto O 0 0.0004771942913066596
- O 0 0.00034316221717745066
oncogene O 0 0.00016706690075807273
, O 0 7.234107215481345e-07
R796G O 0 2.523725743230898e-05
. O 0 5.263671937427716e-06

Though O 0 0.00013341517478693277
auditory B-Disease 0 0.00083086674567312
anomalies I-Disease 0 0.33813464641571045
have O 0 5.7429515436524525e-06
been O 0 1.9859601252392167e-06
observed O 0 1.7696177110337885e-06
in O 0 1.007431592370267e-06
mice O 0 2.7977945137536153e-05
with O 0 1.3110941381455632e-06
dominant O 0 0.00014684292546007782
white O 0 0.0007094590691849589
spotting O 0 0.015091256238520145
( O 0 1.367613731417805e-05
W O 0 0.42339104413986206
) O 0 8.507992106387974e-07
due O 0 8.518984486727277e-07
to O 0 9.978982689062832e-07
KIT O 0 0.06887111812829971
mutations O 0 0.00133250851649791
, O 0 9.061141463462263e-05
deafness B-Disease 1 1.0
is O 0 5.333453373168595e-06
not O 0 4.813664418179542e-07
typical O 0 1.4764337947781314e-06
in O 0 2.0042102732986677e-06
human O 0 3.6291576179792173e-06
piebaldism B-Disease 0 0.0006999149336479604
. O 0 1.3323124221642502e-05

Thus O 0 3.197741898475215e-05
, O 0 1.9682233869389165e-06
the O 0 5.50784022834705e-07
occurrence O 0 1.279995558434166e-05
of O 0 1.0833158739842474e-05
sensorineural B-Disease 1 0.999996542930603
deafness I-Disease 1 1.0
in O 0 0.0006449106731452048
this O 0 4.571869794744998e-06
patient O 0 1.0805217243614607e-05
extends O 0 1.285221628677391e-06
considerably O 0 4.234225343680009e-06
the O 0 1.9265581840954837e-07
phenotypic O 0 1.0485824759598472e-06
range O 0 4.173028571585746e-07
of O 0 1.482773512861968e-07
piebaldism B-Disease 0 5.08768753206823e-05
due O 0 1.4328509223560104e-06
to O 0 2.739264743922831e-07
KIT O 0 2.297517676197458e-05
gene O 0 1.8451897858540178e-06
mutation O 0 1.0247316595268785e-06
in O 0 1.7906090477026737e-07
humans O 0 1.9394234129777033e-07
and O 0 1.149941226685769e-06
tightens O 0 0.0002635308774188161
the O 0 2.236092313978588e-06
clinical O 0 4.875285412708763e-06
similarity O 0 6.48716707019048e-07
between O 0 6.445866915782972e-07
piebaldism B-Disease 0 0.0010661839041858912
and O 0 7.008515581219399e-07
the O 0 3.9688288211436884e-08
various O 0 2.7247281764175568e-08
forms O 0 3.116637117273058e-06
of O 0 4.9929189117392525e-05
Waardenburg B-Disease 1 0.9999955892562866
syndrome I-Disease 1 0.9999686479568481
. O 0 4.85997088617296e-06
. O 0 7.64744163461728e-06

Cycloheximide O 0 0.0017803600057959557
facilitates O 0 7.164698763517663e-05
the O 0 2.3313541532843374e-06
identification O 0 2.1574935544776963e-06
of O 0 2.946873678411066e-07
aberrant O 0 2.6625741156749427e-05
transcripts O 0 2.0933648556820117e-05
resulting O 0 1.717755480967753e-06
from O 0 1.3486200600709708e-07
a O 0 6.876840075165092e-07
novel O 0 3.4225304261781275e-06
splice O 0 0.001029305742122233
- O 0 0.0034340478014200926
site O 0 2.851562931027729e-05
mutation O 0 3.154141950290068e-06
in O 0 1.9338384049660817e-07
COL17A1 O 0 0.00013082004443276674
in O 0 9.586063924871269e-07
a O 0 6.135824605735252e-06
patient O 0 4.0508803067496046e-05
with O 0 7.944558092276566e-06
generalized O 0 0.004381169565021992
atrophic B-Disease 1 0.9999339580535889
benign I-Disease 1 0.9981546998023987
epidermolysis I-Disease 1 0.9992315769195557
bullosa I-Disease 1 0.9915237426757812
. O 0 0.00022490131959784776

Patients O 0 0.028191540390253067
with O 0 3.660416041384451e-05
generalized O 0 0.006885305978357792
atrophic B-Disease 1 0.9999598264694214
benign I-Disease 1 0.9996689558029175
epidermolysis I-Disease 1 0.999692440032959
bullosa I-Disease 1 0.9970360994338989
often O 0 0.00012008241901639849
show O 0 3.8059417420299724e-05
decreased O 0 7.081545845721848e-06
expression O 0 4.3623495571409876e-07
of O 0 3.16911325626279e-07
type O 0 5.3141826356295496e-05
XVII O 0 0.00112200400326401
collagen O 0 9.43871564231813e-05
, O 0 4.149875962866645e-07
a O 0 4.6471609493892174e-07
transmembrane O 0 7.547002496721689e-06
hemidesmosomal O 0 1.954371327883564e-05
protein O 0 1.3766301663054037e-06
encoded O 0 8.008082659216598e-07
by O 0 7.03662408341188e-07
COL17A1 O 0 0.0009917152347043157
. O 0 1.71802967088297e-05

This O 0 1.24333419080358e-05
report O 0 9.830113413045183e-06
documents O 0 8.884747444426466e-07
a O 0 6.637465617131966e-07
novel O 0 2.3526858967670705e-06
splice O 0 0.0004147156432736665
- O 0 0.008549874648451805
site O 0 3.0609400710090995e-05
mutation O 0 3.0523360692313872e-06
in O 0 1.9705643694578612e-07
COL17A1 O 0 0.00012558443995658308
in O 0 6.600249093935417e-07
a O 0 5.195005542191211e-06
patient O 0 1.9913382857339457e-05
with O 0 8.177973541023675e-06
generalized O 0 0.0021293337922543287
atrophic B-Disease 1 0.9998965263366699
benign I-Disease 1 0.9917669892311096
epidermolysis I-Disease 1 0.979616641998291
bullosa I-Disease 0 0.48468470573425293
, O 0 1.2777392839780077e-05
and O 0 6.129726557446702e-07
applies O 0 8.620244074108996e-08
a O 0 1.418274138131892e-07
new O 0 9.037105996867467e-07
methodology O 0 1.2963521385245258e-06
to O 0 3.1369481234833074e-07
define O 0 1.1007930424966617e-06
and O 0 6.544409529851691e-07
characterize O 0 7.837690645828843e-06
the O 0 4.883298743152409e-07
resulting O 0 2.2383326268027304e-06
mRNA O 0 7.1208373810804915e-06
splice O 0 0.0004162755503784865
variants O 0 7.06278151483275e-05
. O 0 1.031625743053155e-05

Mutational O 0 0.002064252970740199
analysis O 0 5.414119004854001e-05
of O 0 2.947768962258124e-06
COL17A1 O 0 0.0015717159258201718
identified O 0 7.919412746559829e-05
a O 0 4.746326339954976e-06
maternally O 0 0.00034277085796929896
inherited O 0 0.02311217226088047
G O 0 0.35666346549987793
- O 0 0.0030306666158139706
to O 0 1.1860772247018758e-05
- O 0 0.0025159541983157396
T O 0 0.001099419896490872
transversion O 0 1.1644061487459112e-05
at O 0 2.4366613615711685e-07
the O 0 6.068593449981563e-08
- O 0 3.14641465593013e-06
1 O 0 9.90449848359276e-07
position O 0 4.92706021759659e-07
of O 0 9.355687069501073e-08
exon O 0 1.3988254977448378e-05
32 O 0 3.153525312882266e-06
. O 0 3.208670705134864e-06

This O 0 5.66714061278617e-06
acceptor O 0 8.41235578263877e-06
splice O 0 0.00022169543080963194
- O 0 0.00043112426646985114
site O 0 1.1999687558272853e-05
mutation O 0 1.7592823269296787e-06
led O 0 2.951162514364114e-07
to O 0 6.447317701940847e-08
the O 0 1.1689669321413021e-07
formation O 0 5.46519686395186e-07
of O 0 7.549923708438655e-08
aberrant O 0 3.303711991975433e-06
transcripts O 0 2.0329223389126128e-06
present O 0 2.8742036306539376e-07
at O 0 1.124873506341828e-06
extremely O 0 8.125833232952573e-07
low O 0 7.81432208896149e-06
levels O 0 3.874093636113685e-06
. O 0 5.742338089476107e-06

Based O 0 4.527629062067717e-05
on O 0 3.5938890050601913e-06
our O 0 6.822659770477912e-07
recent O 0 7.509752322221175e-07
finding O 0 6.32691012469877e-07
that O 0 4.0661998923496867e-07
cycloheximide O 0 8.88633803697303e-05
stabilized O 0 0.00017270719399675727
mutant O 0 9.492285244050436e-06
COL17A1 O 0 8.814551256364211e-05
transcripts O 0 9.396778295922559e-06
in O 0 5.985995699120394e-07
keratinocytes O 0 7.096659828675911e-05
homozygous O 0 5.149090611666907e-06
for O 0 2.676343058283237e-07
a O 0 3.068596242883359e-06
frameshift O 0 0.004823409486562014
mutation O 0 1.8594982975628227e-05
, O 0 2.668470244771015e-07
the O 0 1.1024618373767225e-07
effects O 0 5.521545745068579e-07
of O 0 3.0543983342568026e-08
the O 0 2.809087789046316e-07
splice O 0 0.0008461806573905051
- O 0 0.0003740214160643518
site O 0 1.5007634829089511e-05
mutation O 0 1.2168943612778094e-06
on O 0 4.715938359822758e-07
splicing O 0 3.4974905247509014e-06
of O 0 1.5172619782788388e-07
COL17A1 O 0 0.00016885549121070653
transcripts O 0 6.209009370650165e-06
were O 0 3.200372020728537e-07
determined O 0 1.734204317926924e-07
using O 0 2.4018146405069274e-07
reverse O 0 1.5577195881633088e-05
transcriptase O 0 2.6726531359599903e-05
polymerase O 0 7.154300419642823e-06
chain O 0 1.160394458565861e-05
reaction O 0 2.2212644523733616e-07
of O 0 2.5356841959478515e-08
total O 0 2.4036890522438625e-07
RNA O 0 3.0801450066064717e-06
from O 0 4.2155801338594756e-07
keratinocytes O 0 1.426588642061688e-05
incubated O 0 4.566492407320766e-06
for O 0 4.6987938162601495e-07
2 O 0 8.94566528586438e-06
. O 0 7.165170700318413e-06

5 O 0 0.00013005414803046733
h O 0 0.00027670053532347083
in O 0 8.931625643526786e-07
the O 0 1.995184959469043e-07
presence O 0 3.0399354500332265e-07
or O 0 1.7972503485452762e-07
absence O 0 2.4078920546344307e-07
of O 0 4.2442614756055264e-08
10 O 0 1.0483065580046969e-06
microg O 0 8.099019032670185e-05
cycloheximide O 0 4.9179572670254856e-05
per O 0 3.609717168728821e-06
ml O 0 0.00013029768888372928
. O 0 3.4321401471970603e-06

Using O 0 1.580242496856954e-05
this O 0 7.353734190473915e-07
approach O 0 1.8536377410782734e-06
, O 0 7.244415201057564e-07
an O 0 8.124647479235136e-07
abnormally O 0 5.2306164434412494e-05
spliced O 0 0.0007119891815818846
transcript O 0 0.002102634636685252
was O 0 8.116576645988971e-05
identified O 0 3.640325758169638e-06
that O 0 6.23006854993946e-08
contains O 0 2.0413422063825237e-08
an O 0 5.0096303993996116e-08
extra O 0 1.9745843360396975e-07
264 O 0 3.185542425399035e-07
bases O 0 1.4863937281006656e-07
upstream O 0 2.5701885419948667e-07
from O 0 9.345217932832384e-08
exon O 0 2.294189926033141e-06
32 O 0 1.1950793350479216e-06
, O 0 3.137441524359019e-07
resulting O 0 3.8277215708149015e-07
in O 0 3.724066743870935e-07
a O 0 1.606102887308225e-05
premature O 0 0.0003129602409899235
termination O 0 1.9207025616196916e-05
codon O 0 6.244216820050497e-06
27 O 0 1.4932697922631633e-05
bp O 0 0.00013612289330922067
downstream O 0 2.777319423330482e-06
from O 0 1.2621573830529087e-07
the O 0 4.158599722359213e-07
cryptic O 0 5.671579856425524e-05
splice O 0 0.0020522293634712696
site O 0 0.00019240831898059696
. O 0 1.5440165952895768e-05

Three O 0 3.679939936773735e-06
other O 0 2.437116961573338e-07
splice O 0 4.339668885222636e-05
variants O 0 1.0351065611757804e-05
, O 0 3.4822966199499206e-07
including O 0 5.562230853684014e-08
one O 0 1.2717680419882527e-07
derived O 0 2.5430372829760017e-07
from O 0 5.843795847226829e-08
the O 0 5.741992836760801e-08
skipping O 0 4.474828756428906e-07
of O 0 5.0501157033977506e-08
exon O 0 6.296299943642225e-06
32 O 0 1.4958375231799437e-06
, O 0 2.0994539795538003e-07
were O 0 3.241328556669032e-07
also O 0 2.4602641133242287e-06
identified O 0 1.4842824384686537e-05
. O 0 5.410189260146581e-06

These O 0 1.1658528819680214e-05
results O 0 1.7705591744743288e-05
indicate O 0 2.1495272903848672e-06
the O 0 1.1305321123700196e-07
usefulness O 0 7.3229278996223e-07
of O 0 1.4034320372502407e-07
cycloheximide O 0 0.0002452319604344666
treatment O 0 8.84168275661068e-06
in O 0 2.1185570631132578e-07
evaluating O 0 5.434334866549762e-07
the O 0 2.8248359740246087e-07
abnormal O 0 2.0581198896252317e-06
processing O 0 1.9507646698002645e-07
of O 0 2.5164744954508933e-08
mRNA O 0 3.4257072911714204e-07
due O 0 3.263039332068729e-07
to O 0 1.7203295499257365e-07
splice O 0 0.00012597952445503324
- O 0 0.005529838614165783
site O 0 5.616670023300685e-05
mutations O 0 1.0445090993016493e-05
, O 0 7.22809375020006e-07
because O 0 2.506344003450067e-07
( O 0 2.977206179366476e-07
i O 0 1.2250732197571779e-06
) O 0 1.6757284981849807e-07
aberrant O 0 1.2027583125018282e-06
splicing O 0 1.0967275557050016e-05
often O 0 4.07163611271244e-07
generates O 0 7.062904501253797e-07
a O 0 3.966074473282788e-06
premature O 0 5.916909140069038e-05
termination O 0 5.892432000109693e-06
codon O 0 7.980408554431051e-06
, O 0 2.3003506157692755e-06
( O 0 3.354664670496277e-07
ii O 0 1.137517665483756e-05
) O 0 2.6632432081896695e-07
transcripts O 0 9.663045830166084e-07
with O 0 8.085312401817646e-07
premature O 0 3.562314668670297e-05
termination O 0 2.0646505163313122e-06
codons O 0 1.5945081486279378e-06
can O 0 1.4207202525540197e-07
occur O 0 7.280993230551758e-08
at O 0 4.1920631588254764e-07
low O 0 2.91064952762099e-06
or O 0 9.39074254802108e-07
undetectable O 0 5.763229182775831e-06
levels O 0 1.7969077248380927e-07
due O 0 1.593586773651623e-07
to O 0 2.0175873771677288e-07
nonsense O 0 2.025971980401664e-06
- O 0 7.149437806219794e-06
mediated O 0 5.118285571370507e-06
mRNA O 0 6.465290880441898e-07
decay O 0 3.5003135963052046e-06
, O 0 7.870871741033625e-07
and O 0 1.4334017350847716e-06
( O 0 4.1576399212317483e-07
iii O 0 5.8857654948951676e-05
) O 0 3.1615363127457385e-07
the O 0 8.438515664010993e-08
levels O 0 1.0313048193211216e-07
of O 0 1.0142799489187837e-08
these O 0 1.70027512069737e-08
transcripts O 0 5.770306188424001e-07
can O 0 4.8234888083698024e-08
be O 0 4.9894335774069987e-08
increased O 0 2.740500519848865e-07
by O 0 9.883023039947147e-07
cycloheximide O 0 0.0005600872100330889
. O 0 1.3634492461278569e-05

A O 0 0.00010212256165686995
deletion O 0 0.00036855871439911425
mutation O 0 3.985053626820445e-05
in O 0 2.1077582914585946e-06
COL17A1 O 0 0.0016078040935099125
in O 0 1.8510428390072775e-06
five O 0 1.2633414598894888e-06
Austrian O 0 0.00035757586010731757
families O 0 1.185978362627793e-06
with O 0 4.092044946446549e-06
generalized O 0 0.0006606397219002247
atrophic B-Disease 1 0.9998598098754883
benign I-Disease 1 0.9907468557357788
epidermolysis I-Disease 1 0.9937257170677185
bullosa I-Disease 1 0.5327272415161133
represents O 0 2.5990126232500188e-05
propagation O 0 7.530862148996675e-06
of O 0 3.0063162625992845e-07
an O 0 1.5575059251204948e-06
ancestral O 0 0.000122932338854298
allele O 0 0.0003568324900697917
. O 0 2.1877622202737257e-05

Patients O 0 0.030879132449626923
with O 0 3.131452831439674e-05
generalized O 0 0.007072633132338524
atrophic B-Disease 1 0.9999790191650391
benign I-Disease 1 0.9997578263282776
epidermolysis I-Disease 1 0.9998024106025696
bullosa I-Disease 1 0.9860748648643494
, O 0 2.4959850634331815e-05
a O 0 1.7480122096458217e-06
usually O 0 8.103414756988059e-07
nonlethal O 0 5.485004294314422e-06
form O 0 1.3289344451550278e-06
of O 0 1.7862748791230842e-06
junctional B-Disease 1 0.8822058439254761
epidermolysis I-Disease 1 0.9955162405967712
bullosa I-Disease 1 0.8156116008758545
, O 0 6.72972282700357e-06
have O 0 3.2638672564644367e-07
generalized O 0 2.7964417768089334e-06
blistering B-Disease 0 0.0008586563053540885
, O 0 0.00020280663738958538
nail B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999741315841675
, O 0 9.875331306830049e-05
patchy B-Disease 1 0.6573549509048462
alopecia I-Disease 1 0.9999958276748657
, O 0 4.4920794607605785e-05
and O 0 0.00020748407405335456
dental B-Disease 1 0.9890066385269165
abnormalities I-Disease 1 0.9953988194465637
. O 0 5.271160989650525e-05

Skin B-Disease 1 0.9998681545257568
fragility I-Disease 1 0.8700774312019348
in O 0 2.4871744244592264e-05
most O 0 9.297992278334277e-07
cases O 0 5.390779733716045e-07
is O 0 3.991695791683014e-07
due O 0 2.550477120166761e-06
to O 0 1.6900761465876712e-06
mutations O 0 3.544472974681412e-06
in O 0 1.1447096426309145e-07
the O 0 2.9342427865231e-07
gene O 0 2.3604552552569658e-06
encoding O 0 3.5437765291135293e-06
type O 0 0.00010072265285998583
XVII O 0 0.022844217717647552
collagen O 0 0.002022698987275362
( O 0 3.994889539171709e-06
COL17A1 O 0 0.0005872451583854854
) O 0 2.4894145553844282e-06
. O 0 3.737466158781899e-06

Recently O 0 0.0003143124049529433
, O 0 3.7138881907594623e-06
we O 0 3.3446087854827056e-07
reported O 0 1.8071758631776902e-06
five O 0 2.1563754160069948e-07
Austrian O 0 0.00012036281987093389
families O 0 9.697646419226658e-07
with O 0 4.608315521181794e-06
generalized O 0 0.0008983000298030674
atrophic B-Disease 1 0.9998193383216858
benign I-Disease 1 0.9947658777236938
epidermolysis I-Disease 1 0.9977678060531616
bullosa I-Disease 1 0.9664337038993835
who O 0 0.00013350145309232175
share O 0 8.967122084868606e-06
the O 0 8.629931471659802e-07
same O 0 3.676133928820491e-06
COL17A1 O 0 0.020429937168955803
mutation O 0 0.0002930007758550346
. O 0 1.80611004907405e-05

Affected O 0 0.00011953939974773675
individuals O 0 1.0413316431368003e-06
in O 0 5.173200747776718e-07
three O 0 4.602105150297575e-07
families O 0 2.06758713261479e-07
are O 0 7.633239818005677e-08
homozygous O 0 6.77086973155383e-07
for O 0 2.8232520321580523e-07
4003delTC O 0 1.4881150491419248e-05
, O 0 3.6033432593285397e-07
whereas O 0 1.7040922273281467e-07
those O 0 2.0026533320560702e-08
in O 0 3.7102164895941314e-08
two O 0 3.486649688966281e-07
others O 0 2.242191158075002e-06
are O 0 1.6306715622249612e-07
compound O 0 2.756411959126126e-05
heterozygotes O 0 9.366877930006012e-05
. O 0 5.554059043788584e-06

To O 0 2.9819544579368085e-05
determine O 0 6.577316526090726e-06
if O 0 1.8146073443858768e-07
the O 0 1.4569717166068585e-07
occurrence O 0 5.380528023124498e-07
of O 0 1.1204662087038741e-07
4003delTC O 0 2.213204061263241e-05
in O 0 7.866107125664712e-07
these O 0 3.45435324788923e-08
unrelated O 0 6.166465595924819e-07
families O 0 9.31391710423668e-08
signifies O 0 1.7641850718064234e-06
propagation O 0 1.2668294857576257e-06
of O 0 9.887230589811224e-08
an O 0 3.597502882257686e-07
ancestral O 0 7.556617219961481e-06
allele O 0 1.0062553883471992e-05
or O 0 3.432803907799098e-07
a O 0 1.2685909496212844e-06
mutational O 0 3.859417120111175e-05
hot O 0 3.155747617711313e-05
spot O 0 4.6369299525395036e-05
, O 0 1.198004042635148e-06
haplotypes O 0 7.924582860141527e-06
were O 0 9.378624099554145e-07
determined O 0 1.5214583299894002e-06
for O 0 5.921212959947297e-07
polymorphisms O 0 4.5039869291940704e-05
both O 0 4.672375837344589e-07
within O 0 3.3506296404084424e-07
and O 0 6.651154762948863e-06
flanking O 0 0.000688597618136555
COL17A1 O 0 0.1947198212146759
. O 0 3.9120466681197286e-05

Five O 0 5.471707117976621e-05
intragenic O 0 0.0009859143756330013
polymorphisms O 0 0.00040477694710716605
were O 0 5.661232080456102e-06
chosen O 0 1.0845725455510546e-06
based O 0 7.906788823675015e-07
on O 0 2.6201414584647864e-06
their O 0 2.127306515831151e-06
informativeness O 0 0.000788938079494983
. O 0 8.121332029986661e-06

One O 0 5.094015705253696e-06
of O 0 4.4625471673498396e-07
these O 0 1.7129185891917587e-07
, O 0 3.9965868836588925e-07
not O 0 1.8240824317672377e-07
previously O 0 7.5468801696843e-06
reported O 0 3.159753032377921e-05
, O 0 5.398908911047329e-07
was O 0 4.273001650290098e-06
2988 O 0 2.08453798222763e-06
A O 0 3.998632564616855e-06
or O 0 9.181740097119473e-07
C O 0 2.1716505216318183e-05
that O 0 7.987658534602815e-08
introduces O 0 3.5651217444865324e-07
a O 0 1.9157245390033495e-07
new O 0 3.2391528748121345e-07
restriction O 0 6.512227912480739e-08
site O 0 6.00930377459008e-07
for O 0 2.285142528535289e-07
Eco0109 O 0 9.177282663586084e-06
I O 0 1.078412515198579e-05
. O 0 3.5637181099446025e-06

All O 0 4.222011739329901e-06
the O 0 1.0461462807143107e-06
4003delTC O 0 1.5438266927958466e-05
alleles O 0 4.521476967056515e-06
showed O 0 5.103813691675896e-06
the O 0 1.4531612180235243e-07
same O 0 2.6764601557260903e-07
haplotype O 0 2.1508461941266432e-05
for O 0 2.653596595791896e-07
these O 0 7.273691693399087e-08
five O 0 1.1891053190993262e-06
polymorphic O 0 8.642444299766794e-05
markers O 0 0.00023274117847904563
. O 0 1.6469832189613953e-05

Fourteen O 0 0.0001957931963261217
microsatellite O 0 0.0008481324184685946
polymorphisms O 0 0.000996729708276689
were O 0 8.506437552568968e-06
selected O 0 7.376077064691344e-07
based O 0 9.189159868583374e-07
on O 0 1.794554464140674e-06
their O 0 7.486098070330627e-07
high O 0 9.117039553530049e-06
heterozygosity O 0 2.3161619537859224e-05
and O 0 6.125109734966827e-07
their O 0 1.736597425860964e-07
location O 0 1.648233933337906e-06
within O 0 1.4120725211341778e-07
10q23 O 0 3.679209839901887e-06
- O 0 4.167420047451742e-05
q25 O 0 1.8468446796759963e-05
near O 0 2.775778921204619e-05
COL17A1 O 0 0.0010778799187391996
. O 0 1.4012192877999041e-05

Three O 0 1.599470851942897e-05
families O 0 4.840308520215331e-06
shared O 0 5.0497392294346355e-06
microsatellite O 0 0.00039379679947160184
polymorphisms O 0 0.0008258467423729599
covering O 0 4.5717144530499354e-05
at O 0 1.6254223737632856e-05
most O 0 5.150998276803875e-07
19 O 0 5.007977051718626e-06
cM O 0 1.5141922631300986e-05
, O 0 5.333884018909885e-07
whereas O 0 2.617244092562032e-07
the O 0 1.60800894377644e-07
others O 0 3.462536426468432e-07
shared O 0 8.821301378247881e-08
smaller O 0 3.0974015885476547e-07
regions O 0 5.531559850169288e-07
consistent O 0 2.2191859443410067e-06
with O 0 3.300149273854913e-07
cross O 0 6.502597898361273e-06
- O 0 5.4872838518349454e-05
over O 0 2.1534460756811313e-06
events O 0 2.0283195567571966e-07
during O 0 2.3746906663291156e-07
passage O 0 1.4763942601803137e-07
of O 0 3.021503403033421e-08
this O 0 7.8601324560168e-08
mutation O 0 5.352253538148943e-07
through O 0 8.340123969219349e-08
several O 0 4.303466880628548e-07
generations O 0 5.4455849749501795e-06
. O 0 5.326367954694433e-06

These O 0 1.6179865269805305e-05
results O 0 4.769865336129442e-05
indicate O 0 3.197228579665534e-06
that O 0 3.2336589583792374e-07
4003delTC O 0 2.3172357032308355e-05
occurs O 0 2.958692277843511e-07
on O 0 3.266956412062427e-07
a O 0 5.385764438869955e-07
single O 0 7.623222700203769e-06
ancestral O 0 3.045711673621554e-05
allele O 0 3.1765906896907836e-05
. O 0 1.4292207879407215e-06
. O 0 3.254156126786256e-06

The O 0 3.4638313081813976e-05
haptoglobin O 0 0.0007384126074612141
- O 0 0.0026585813611745834
gene O 0 9.949236118700355e-05
deletion O 0 0.0001332199026364833
responsible O 0 1.3181575923226774e-05
for O 0 3.4787756248988444e-06
anhaptoglobinemia B-Disease 0 0.002670109272003174
. O 0 3.772196578211151e-05

We O 0 1.94676158571383e-05
have O 0 7.568427236037678e-07
found O 0 4.936094910590327e-07
an O 0 2.386748860772059e-07
allelic O 0 5.717801741411677e-06
deletion O 0 1.8721048036240973e-05
of O 0 2.6586599233269226e-07
the O 0 2.266873707412742e-06
haptoglobin O 0 0.00021875080710742623
( O 0 8.665113000461133e-07
Hp O 0 1.3838692211720627e-05
) O 0 1.1372819841426463e-07
gene O 0 2.694294778393669e-07
from O 0 3.916953517091315e-08
an O 0 2.5971564809879055e-07
individual O 0 2.2787726550177467e-07
with O 0 4.999082193535287e-06
anhaptoglobinemia B-Disease 0 0.010417300276458263
. O 0 2.6200259526376612e-05

The O 0 8.139164492604323e-06
Hp O 0 0.00010917982581304386
gene O 0 1.2086584320059046e-05
cluster O 0 4.264290055289166e-06
consists O 0 3.0234295422815194e-07
of O 0 9.200526562835876e-08
coding O 0 1.6808462532935664e-05
regions O 0 6.132837029326765e-07
of O 0 6.452743406271111e-08
the O 0 2.2751136441456765e-07
alpha O 0 1.0503299563424662e-06
chain O 0 1.8519943978390074e-06
and O 0 2.0417321877630457e-07
beta O 0 2.0022318381052173e-07
chain O 0 5.649354193337786e-07
of O 0 2.624647166271643e-08
the O 0 3.707033613409294e-07
haptoglobin O 0 2.3081225663190708e-05
gene O 0 2.933380301328725e-06
( O 0 1.6153035176103003e-07
Hp O 0 9.368609426019248e-06
) O 0 8.046299626585096e-08
and O 0 5.0152522135249455e-08
of O 0 1.8889918962372576e-08
the O 0 2.1682367901121324e-07
alpha O 0 1.6189721918635769e-06
chain O 0 2.454833747833618e-06
and O 0 2.6372885031378246e-07
beta O 0 2.1862888388568535e-07
chain O 0 4.2197109451080905e-07
of O 0 1.9463989531232073e-08
the O 0 2.949716133571201e-07
haptoglobin O 0 2.347364352317527e-05
- O 0 0.00020145659800618887
related O 0 4.306720256863628e-06
gene O 0 5.921013780607609e-06
( O 0 7.823575742804678e-07
Hpr O 0 2.776663313852623e-05
) O 0 4.5056526687403675e-07
, O 0 9.74575797840771e-08
in O 0 9.394238986715209e-08
tandem O 0 2.7889977900485974e-06
from O 0 1.471024120291986e-07
the O 0 4.5326572717385716e-07
5 O 0 9.070659871213138e-06
side O 0 1.5189347323030233e-05
. O 0 1.902710209833458e-05

Southern O 0 0.000348500267136842
blot O 0 0.008711249567568302
and O 0 1.322307525697397e-05
PCR O 0 9.711984603200108e-05
analyses O 0 6.926051810296485e-06
have O 0 5.778136937806266e-07
indicated O 0 3.3827120660134824e-06
that O 0 5.242982936692897e-08
the O 0 5.1588830984883316e-08
individual O 0 5.052572760178009e-08
with O 0 6.050587444406119e-07
anhaptoglobinemia B-Disease 0 0.0004492597945500165
was O 0 1.6954722013906576e-05
homozygous O 0 5.015787678530614e-07
for O 0 9.267171208193759e-08
the O 0 1.1610408279238982e-07
gene O 0 1.9471901850920403e-06
deletion O 0 3.7373094983195188e-06
and O 0 7.207746079984645e-07
that O 0 9.522613453327722e-08
the O 0 1.9507720594447164e-07
gene O 0 2.801526761686546e-06
deletion O 0 1.2127109584980644e-05
was O 0 6.99209158483427e-06
included O 0 1.51821296867638e-07
at O 0 5.510908636097156e-07
least O 0 7.494656273365763e-08
from O 0 4.675718656699246e-08
the O 0 2.3550940397853992e-07
promoter O 0 4.31624248449225e-05
region O 0 3.0564431199309183e-06
of O 0 1.853233584370173e-07
Hp O 0 1.6082547517726198e-05
to O 0 4.5588157604470325e-07
Hpr O 0 5.964812771708239e-06
alpha O 0 1.2502630397648318e-06
but O 0 7.465722973165612e-08
not O 0 4.65487879353077e-08
to O 0 1.795105788460205e-07
Hpr O 0 4.264820017851889e-05
beta O 0 4.1840617086563725e-06
( O 0 4.324556073243002e-07
Hpdel O 0 3.777192978304811e-05
) O 0 9.64307787398866e-07
. O 0 3.6944977637176635e-06

In O 0 1.9844757844111882e-05
addition O 0 2.686715106392512e-06
, O 0 1.6240721834037686e-06
we O 0 1.2978485131043271e-07
found O 0 1.4567855544100894e-07
seven O 0 1.3297872669681965e-07
individuals O 0 6.711811106896448e-09
with O 0 4.977106016212929e-08
hypohaptoglobinemia B-Disease 0 3.944999843952246e-05
in O 0 6.239783942874055e-07
three O 0 6.184664016473107e-07
families O 0 1.1867834359691187e-07
, O 0 1.4329464192996966e-07
and O 0 1.6464699115203985e-07
the O 0 1.9607153944889433e-07
genotypes O 0 1.1887367463714327e-06
of O 0 2.8300986443241527e-08
six O 0 2.49750144121208e-07
of O 0 3.7310588396621824e-08
the O 0 3.816392961653037e-07
seven O 0 1.0681234243747895e-06
individuals O 0 1.115831427256353e-08
were O 0 1.3871833459688787e-07
found O 0 1.7401883667389484e-07
to O 0 1.6457416052162444e-07
be O 0 5.447795388136001e-07
Hp2 O 0 0.00012334210623521358
/ O 0 0.00011884654668392614
Hpdel O 0 0.000134227258968167
. O 0 9.466161827731412e-06

The O 0 2.090729321935214e-05
phenotypes O 0 0.0001325341872870922
and O 0 9.803749890124891e-06
genotypes O 0 3.17329031531699e-05
in O 0 1.6822739326016745e-06
one O 0 2.7010688086193113e-07
of O 0 7.955895142686131e-08
these O 0 5.261776436782384e-08
three O 0 3.4940293858198856e-07
families O 0 2.5287300786658307e-07
showed O 0 5.281728590489365e-06
the O 0 3.5333385994817945e-07
father O 0 6.929579740244662e-06
to O 0 5.211527422943618e-07
be O 0 8.780441476119449e-07
hypohaptoglobinemic B-Disease 0 6.643908272963017e-05
( O 0 3.0566366149287205e-07
Hp2 O 0 8.464083293802105e-06
) O 0 1.1876031891233652e-07
and O 0 3.3805631005634496e-07
Hp2 O 0 5.681258699041791e-05
/ O 0 4.080264625372365e-05
Hpdel O 0 9.646476428315509e-06
, O 0 1.578888912945331e-07
the O 0 1.1353596107710473e-07
mother O 0 2.3872141809988534e-06
to O 0 1.4598911945995496e-07
be O 0 1.1161426272110475e-07
Hp2 O 0 6.776595000701491e-06
- O 0 9.20573620533105e-06
1 O 0 3.876177288475446e-06
and O 0 1.4306580169431982e-06
Hp1 O 0 3.498056321404874e-05
/ O 0 1.8236061805509962e-05
Hp2 O 0 4.7386101869051345e-06
, O 0 7.319101769098779e-08
one O 0 1.496420409807797e-08
of O 0 1.0748954615280581e-08
the O 0 1.7896870474487514e-07
two O 0 1.0823056300068856e-06
children O 0 9.001187208923511e-07
to O 0 1.8529631518049428e-07
be O 0 2.416380482372915e-07
hypohaptoglobinemic B-Disease 0 3.06485453620553e-05
( O 0 1.4280161053648044e-07
Hp2 O 0 6.8239432948757894e-06
) O 0 1.398299218635657e-07
and O 0 3.9994961298361886e-07
Hp2 O 0 2.9115102734067477e-05
/ O 0 2.6805506422533654e-05
Hpdel O 0 1.2182401405880228e-05
, O 0 2.4715706103961566e-07
and O 0 8.153050856662958e-08
the O 0 4.4711345736914154e-08
other O 0 7.170545757162472e-08
child O 0 6.215564098965842e-07
to O 0 1.0731115906992272e-07
be O 0 8.795043271447867e-08
Hp1 O 0 7.233732048916863e-06
and O 0 9.635410833652713e-07
Hp1 O 0 4.821359834750183e-05
/ O 0 2.7145897547597997e-05
Hpdel O 0 1.758306098054163e-05
, O 0 5.382832455325115e-07
showing O 0 1.1659079746095813e-06
an O 0 4.058169054133032e-07
anomalous O 0 2.2363468815456145e-05
inheritance O 0 1.2443329069355968e-05
of O 0 1.3958544968772912e-06
Hp O 0 0.0017223811009898782
phenotypes O 0 1.9765939214266837e-05
in O 0 5.180220910006028e-07
the O 0 8.229289960581809e-07
child O 0 7.161181201809086e-06
with O 0 1.8074723584504682e-06
Hp1 O 0 0.0014949169708415866
. O 0 1.3232650417194236e-05

The O 0 4.8470650654053316e-05
Hp2 O 0 0.0016915857559069991
/ O 0 0.002249686513096094
Hpdel O 0 0.0002372521994402632
individuals O 0 6.075815122130734e-07
had O 0 6.476358066720422e-06
an O 0 8.538374913769076e-07
extremely O 0 1.1151929584229947e-06
low O 0 1.8746313799056225e-06
level O 0 3.4508042290326557e-07
of O 0 1.6251833301339502e-07
Hp O 0 5.055897054262459e-05
( O 0 1.694199625035253e-07
mean O 0 2.7832481919176644e-07
+ O 0 7.8571110861958e-06
/ O 0 1.7026046407409012e-05
- O 0 2.343829874007497e-05
SD O 0 0.00021782149269711226
= O 0 5.632206466543721e-06
0 O 0 4.91294656512764e-07
. O 0 1.0715919529502571e-07
049 O 0 3.130876848445041e-06
+ O 0 4.624323082680348e-06
/ O 0 6.709485660394421e-06
- O 0 6.475963346019853e-06
0 O 0 1.8339758298679953e-06
. O 0 3.780757822369196e-07
043 O 0 8.044663445616607e-06
mg O 0 0.0001082342496374622
/ O 0 1.5471163351321593e-05
ml O 0 1.7768805264495313e-05
; O 0 4.45353407485527e-07
n O 0 9.533919183013495e-06
= O 0 7.5520356404013e-06
6 O 0 5.561447323998436e-06
) O 0 2.006435266821427e-07
, O 0 7.806450241787388e-08
compared O 0 2.4936841214184824e-07
with O 0 3.997790898324638e-08
the O 0 3.998088686785195e-07
level O 0 1.163315687335853e-06
( O 0 4.971062494973921e-08
1 O 0 2.6112905970876454e-07
. O 0 6.462276758156804e-08
64 O 0 1.8581320659905032e-07
+ O 0 4.242750037519727e-06
/ O 0 6.158276391943218e-06
- O 0 5.533472176466603e-06
1 O 0 1.5411790172947804e-06
. O 0 1.5653012042093906e-07
07 O 0 1.7953401538761682e-06
mg O 0 4.826153235626407e-05
/ O 0 9.484594556852244e-06
ml O 0 7.832773917471059e-06
) O 0 5.073818698519972e-08
obtained O 0 8.841768561751451e-08
from O 0 5.29266799276229e-08
52 O 0 5.411293386714533e-06
healthy O 0 8.450948030258587e-07
volunteers O 0 4.5657165514967346e-07
having O 0 6.229640803212533e-07
phenotype O 0 1.2749494089803193e-05
Hp2 O 0 2.5641937099862844e-05
, O 0 4.331275249569444e-07
whereas O 0 2.1637254121742444e-07
the O 0 2.3396432879962958e-07
serum O 0 3.351446139276959e-06
Hp O 0 3.989909600932151e-06
level O 0 4.540756748383501e-08
of O 0 1.7484719450067132e-08
an O 0 2.2361811602422677e-07
individual O 0 6.487346837502628e-08
with O 0 4.082601492427784e-07
Hp1 O 0 0.0004450541746336967
/ O 0 9.312728070653975e-05
Hpdel O 0 5.532075010705739e-05
was O 0 1.717942905088421e-05
0 O 0 9.33899536903482e-06
. O 0 1.064504795067478e-05

50 O 0 9.368575410917401e-05
mg O 0 0.0012837168760597706
/ O 0 0.0003169459232594818
ml O 0 0.00011105123849119991
, O 0 7.975827429618221e-07
which O 0 9.763749631019891e-08
was O 0 9.269218139706936e-07
approximately O 0 4.115908325275086e-08
half O 0 8.36863165432078e-08
the O 0 2.937991183671329e-08
level O 0 5.090753774084078e-08
of O 0 3.2050078146994565e-08
Hp O 0 7.434513008774957e-06
in O 0 3.345016921230126e-07
control O 0 2.12685199585394e-06
sera O 0 1.4296829249360599e-05
from O 0 1.0074779766000574e-07
the O 0 2.6810690201273246e-07
Hp1 O 0 0.00011822341184597462
phenotype O 0 3.621655923780054e-05
( O 0 8.96096850055983e-08
1 O 0 4.64093403707011e-07
. O 0 1.0489349477893484e-07
26 O 0 5.194081609261048e-07
+ O 0 3.932666459149914e-06
/ O 0 4.3229579205217306e-06
- O 0 6.220406703505432e-06
0 O 0 1.0271885457768803e-06
. O 0 1.9184248856163322e-07
33 O 0 1.720170303087798e-06
mg O 0 8.1819154729601e-05
/ O 0 1.5607993191224523e-05
ml O 0 8.100168997771107e-06
; O 0 1.6455688012229075e-07
n O 0 7.006496616668301e-06
= O 0 7.292400368896779e-06
9 O 0 5.168149073142558e-06
) O 0 1.1131130150943136e-07
, O 0 5.7697789657140675e-08
showing O 0 3.685759395466448e-07
a O 0 9.748450793267693e-07
gene O 0 8.437808901362587e-06
- O 0 0.0010401549516245723
dosage O 0 0.0002337947371415794
effect O 0 9.718703950056806e-06
. O 0 5.071437044534832e-06

The O 0 1.0307035154255573e-05
other O 0 1.191578917314473e-06
allele O 0 2.1862442736164667e-05
( O 0 1.3056961734037031e-06
Hp2 O 0 3.208322959835641e-05
) O 0 2.898031254972011e-07
of O 0 2.836080525980833e-08
individuals O 0 2.3130114712444083e-08
with O 0 2.3226715484270244e-07
Hp2 O 0 0.0016479163896292448
/ O 0 0.0003683316463138908
Hpdel O 0 3.135436418233439e-05
was O 0 1.1255623576289508e-05
found O 0 5.059526415607252e-07
to O 0 1.0881556278263815e-07
have O 0 1.7496988391485502e-07
, O 0 1.5088438942711946e-07
in O 0 5.372847766693667e-08
all O 0 3.6412171056099396e-08
exons O 0 5.729953045374714e-06
, O 0 4.0737492668085906e-07
no O 0 1.077661053727752e-07
mutation O 0 6.195479045345564e-07
, O 0 1.0165637576164954e-07
by O 0 1.5742702430543432e-07
DNA O 0 2.3688107830821536e-05
sequencing O 0 4.480630741454661e-05
. O 0 7.972139428602532e-06

On O 0 3.6422850826056674e-05
the O 0 4.6858428959239973e-07
basis O 0 2.529612856960739e-07
of O 0 8.10282188012934e-08
the O 0 2.899131459344062e-07
present O 0 6.355053869810945e-07
study O 0 4.14320084018982e-07
, O 0 9.407274603745464e-08
the O 0 3.418467997562402e-08
mechanism O 0 1.1265284172168322e-07
of O 0 1.453708762255701e-07
anhaptoglobinemia B-Disease 0 6.692272290820256e-05
and O 0 5.189091325519257e-07
the O 0 9.349585639029101e-08
mechanism O 0 1.815514423242348e-07
of O 0 1.4231801515052211e-07
anomalous O 0 2.67582836386282e-05
inheritance O 0 1.650785816309508e-05
of O 0 1.0992110901497654e-06
Hp O 0 0.0003375904052518308
phenotypes O 0 1.9517841792549007e-05
were O 0 1.1749772284019855e-06
well O 0 9.921968739945441e-07
explained O 0 1.3835760910296813e-05
. O 0 5.531524948310107e-06

However O 0 2.622950887598563e-05
, O 0 7.76019021486718e-07
the O 0 9.862481675781964e-08
mechanism O 0 5.78340745960304e-07
of O 0 5.01683075526671e-07
hypohaptoglobinemia B-Disease 0 0.0006909047951921821
remains O 0 0.0001495107135269791
unknown O 0 0.00012369190517347306

ATM O 0 0.007762203458696604
mutations O 0 0.001181621802970767
and O 0 4.2064773879246786e-05
phenotypes O 0 0.0014082203852012753
in O 0 0.012231997214257717
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
families O 0 6.507221405627206e-05
in O 0 3.114123501291033e-06
the O 0 1.9470769530016696e-06
British O 0 7.282613660208881e-05
Isles O 0 3.6644010833697394e-05
: O 0 9.67157660625162e-08
expression O 0 3.398528747311502e-08
of O 0 1.8510355914713728e-08
mutant O 0 1.5262016859196592e-06
ATM O 0 1.7665757695795037e-05
and O 0 5.027904990129173e-07
the O 0 4.5327180941967526e-07
risk O 0 3.3652370348136174e-06
of O 0 2.1563805603364017e-06
leukemia B-Disease 1 0.9994649291038513
, O 0 0.18974237143993378
lymphoma B-Disease 1 1.0
, O 0 0.0012747335713356733
and O 0 0.042088575661182404
breast B-Disease 1 0.9998735189437866
cancer I-Disease 0 0.4803485572338104
. O 0 1.6808893633424304e-05

We O 0 3.261916572228074e-05
report O 0 3.947376626456389e-06
the O 0 1.0984528842072905e-07
spectrum O 0 1.0207307923337794e-06
of O 0 1.2443872776657372e-07
59 O 0 6.611856861127308e-06
ATM O 0 0.0002742734213825315
mutations O 0 6.0300357290543616e-05
observed O 0 1.5534709746134467e-05
in O 0 0.00028300643316470087
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0027065083850175142
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 3.6546189221553504e-05
patients O 0 3.381747546882252e-06
in O 0 1.6121839507832192e-07
the O 0 1.2199037655591383e-06
British O 0 0.0001042196890921332
Isles O 0 0.00036387855652719736
. O 0 1.9321167201269418e-05

Of O 0 6.7666751419892535e-06
51 O 0 6.388736073859036e-05
ATM O 0 0.00039751044823788106
mutations O 0 9.020225115818903e-05
identified O 0 9.515497367829084e-06
in O 0 4.948802256876661e-07
families O 0 1.0792387428182337e-07
native O 0 8.631281502857746e-07
to O 0 2.892202815019118e-07
the O 0 6.914679602232354e-07
British O 0 3.2143067073775455e-05
Isles O 0 2.6492463803151622e-05
, O 0 1.1743386494345032e-06
11 O 0 1.1958032928305329e-06
were O 0 6.367551463881682e-07
founder O 0 4.4570766476681456e-05
mutations O 0 5.64151650905842e-06
, O 0 4.180564872058312e-07
and O 0 2.1362852464790194e-07
2 O 0 1.2317343589529628e-06
of O 0 5.154220872327642e-08
these O 0 5.264497104917609e-08
11 O 0 1.5953780803101836e-06
conferred O 0 1.6273063465632731e-06
a O 0 4.140635155636119e-06
milder O 0 0.0010318588465452194
clinical O 0 7.728114724159241e-05
phenotype O 0 4.250766505720094e-05
with O 0 7.504053769480379e-07
respect O 0 4.085845830559265e-07
to O 0 2.2131457626528572e-06
both O 0 1.3843760825693607e-05
cerebellar B-Disease 1 0.7125069499015808
degeneration I-Disease 1 0.9918819069862366
and O 0 2.4037715775193647e-05
cellular O 0 0.00021140224998816848
features O 0 8.51006552693434e-05
. O 0 1.8910390281234868e-05

We O 0 5.8804194850381464e-05
report O 0 1.0680087143555284e-05
, O 0 4.178851042979659e-07
in O 0 1.2395713611113024e-07
two O 0 2.6806189907802036e-06
A B-Disease 1 0.9999794960021973
- I-Disease 1 0.9999840259552002
T I-Disease 1 0.9999998807907104
families O 0 2.0009674699394964e-06
, O 0 2.522243960356718e-07
an O 0 2.4064297576842364e-07
ATM O 0 0.0007365355268120766
mutation O 0 1.4631508747697808e-05
( O 0 1.6126345769862382e-07
7271T O 0 3.4111517379642464e-06
- O 0 8.210193482227623e-05
- O 0 0.001337800407782197
> O 0 5.690287252946291e-06
G O 0 0.0046255276538431644
) O 0 4.154647399445821e-07
that O 0 4.026972248993843e-07
may O 0 2.0132602003286593e-06
be O 0 9.102395637228256e-08
associated O 0 1.0440049891258241e-07
with O 0 1.0720702903199708e-07
an O 0 1.166614197245508e-06
increased O 0 7.702658876951318e-06
risk O 0 7.178281975939171e-06
of O 0 2.671609991011792e-06
breast B-Disease 1 0.9976929426193237
cancer I-Disease 0 0.024902796372771263
in O 0 6.222117576726305e-07
both O 0 1.4449899481405737e-06
homozygotes O 0 8.922748384065926e-05
and O 0 5.914506800763775e-06
heterozygotes O 0 9.92114746622974e-06
( O 0 1.8416123737097223e-07
relative O 0 1.5393634384963661e-06
risk O 0 4.376853212306742e-06
12 O 0 2.6417594654049026e-06
. O 0 5.453440508063068e-07
7 O 0 7.658622962480877e-06
; O 0 2.114841890943353e-06
P O 0 0.09661166369915009
= O 0 7.194233330665156e-05
. O 0 1.2913598084196565e-06
0025 O 0 4.6676200327055994e-06
) O 0 1.2168868579465197e-07
, O 0 7.203856711157641e-08
although O 0 4.636094530496848e-08
there O 0 1.8864209749835936e-08
is O 0 9.82324408482782e-08
a O 0 2.290399379489827e-06
less O 0 1.839365722844377e-05
severe O 0 0.002469254657626152
A B-Disease 1 0.9999961853027344
- I-Disease 1 0.9999985694885254
T I-Disease 1 1.0
phenotype O 0 0.00846155546605587
in O 0 7.383571869468142e-07
terms O 0 2.2868908899909002e-07
of O 0 5.120024937355083e-08
the O 0 5.964159868199204e-07
degree O 0 1.2111829164496157e-05
of O 0 8.528596481482964e-06
cerebellar B-Disease 1 0.9958332777023315
degeneration I-Disease 1 0.9996740818023682
. O 0 7.873689901316538e-05

This O 0 2.4397997549385764e-05
mutation O 0 7.573810580652207e-05
( O 0 1.722764295664092e-06
7271T O 0 1.6220528777921572e-05
- O 0 0.0003065419150516391
- O 0 0.0009232254233211279
> O 0 8.24340258986922e-06
G O 0 0.0012108266819268465
) O 0 1.537464981993253e-07
also O 0 8.427144138067888e-08
allows O 0 2.1239275227458165e-08
expression O 0 4.37156160160157e-08
of O 0 1.1126689791751687e-08
full O 0 1.5453750279448286e-07
- O 0 3.0644171147287125e-06
length O 0 7.117118911992293e-07
ATM O 0 4.960264050168917e-06
protein O 0 3.5008503118660883e-07
at O 0 1.3278776123115676e-07
a O 0 9.06303583292356e-08
level O 0 9.820884372402361e-08
comparable O 0 3.6681106507785444e-07
with O 0 1.0577064557537597e-07
that O 0 5.157727400728618e-07
in O 0 1.430000565960654e-06
unaffected O 0 4.636885932995938e-05
individuals O 0 5.560459044318122e-07
. O 0 2.7877799766429234e-06

In O 0 2.043578751909081e-05
addition O 0 1.6251382248810842e-06
, O 0 6.850133900115907e-07
we O 0 9.183730753647978e-08
have O 0 7.791827272285445e-08
studied O 0 1.197857841361838e-06
18 O 0 1.3907992070016917e-05
A B-Disease 1 0.9999885559082031
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.00019045689259655774
, O 0 1.9908095794107794e-07
in O 0 8.192550637886598e-08
15 O 0 4.0272448131872807e-07
families O 0 8.72307168719999e-08
, O 0 5.992541787236405e-07
who O 0 8.540185262972955e-06
developed O 0 0.0006588625255972147
leukemia B-Disease 1 0.9995414018630981
, O 0 0.05948245897889137
lymphoma B-Disease 1 1.0
, O 0 4.2933850636472926e-05
preleukemic O 0 0.002483280608430505
T O 0 0.0599023662507534
- O 0 0.002479838440194726
cell O 0 0.0031027677468955517
proliferation O 0 1.6944506569416262e-05
, O 0 3.877153176290449e-06
or O 0 0.003878484247252345
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 3.32688468915876e-05
mostly O 0 6.576674422831275e-07
in O 0 1.68868405125977e-06
childhood O 0 4.0634931792737916e-05
. O 0 1.445771431463072e-05

A O 0 3.1651812605559826e-05
wide O 0 4.556304702418856e-06
variety O 0 6.192524892867368e-07
of O 0 1.6089018117781961e-07
ATM O 0 0.00024338922230526805
mutation O 0 9.785936526895966e-06
types O 0 5.228174018157006e-07
, O 0 2.4266478249046486e-07
including O 0 2.4961107669696503e-07
missense O 0 6.950029637664557e-05
mutations O 0 3.706014103954658e-05
and O 0 2.0733878045575693e-06
in O 0 1.638173444007407e-06
- O 0 0.00046990232658572495
frame O 0 0.0026152993086725473
deletions O 0 3.505663698888384e-05
, O 0 1.2938412510266062e-06
were O 0 2.1729088928168494e-07
seen O 0 8.551152177460608e-07
in O 0 3.592110147110361e-07
these O 0 5.648443561767635e-07
patients O 0 7.933708729979116e-06
. O 0 3.3637770684435964e-06

We O 0 2.4571862013544887e-05
also O 0 3.6001943044539075e-06
show O 0 1.7767775943866582e-06
that O 0 5.412467984911018e-08
25 O 0 5.566646166244027e-08
% O 0 3.8789249146020666e-08
of O 0 2.1783423065357965e-08
all O 0 2.3639285018361988e-07
A B-Disease 1 0.9999526739120483
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
patients O 0 4.19969619542826e-05
carried O 0 1.117848569265334e-06
in O 0 3.4835920814657584e-07
- O 0 3.432235462241806e-05
frame O 0 0.0002363718958804384
deletions O 0 1.923626405186951e-05
or O 0 2.2233571144170128e-06
missense O 0 3.637619738583453e-05
mutations O 0 1.730865187710151e-05
, O 0 1.651026622084828e-07
many O 0 1.0541854500445424e-08
of O 0 4.102044215414935e-08
which O 0 4.1337307266076095e-06
were O 0 1.9658918972709216e-06
also O 0 2.1237349301372888e-06
associated O 0 2.981134912261041e-07
with O 0 6.852343403807026e-08
expression O 0 3.997871544925147e-07
of O 0 1.4341426890496223e-07
mutant O 0 7.1091935751610436e-06
ATM O 0 0.0001305484038311988
protein O 0 3.0025397791177966e-05
. O 0 8.790229003352579e-06

The O 0 1.4538680261466652e-05
DMPK O 0 0.0010839113965630531
gene O 0 5.378005880629644e-05
of O 0 9.649438652559184e-06
severely O 1 0.9904292821884155
affected O 1 0.5598211884498596
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9837216734886169
is O 0 6.7525120357458945e-06
hypermethylated O 0 0.00034816315746866167
proximal O 0 0.00030711377621628344
to O 0 2.2284539227257483e-06
the O 0 5.85596865221305e-07
largely O 0 3.2518789794266922e-06
expanded O 0 9.500165106146596e-06
CTG O 0 0.0005193370161578059
repeat O 0 0.00012387061724439263
. O 0 9.269977454096079e-06

Using O 0 1.7038912119460292e-05
methylation O 0 0.00012443223386071622
- O 0 0.000229010489420034
sensitive O 0 9.341088116343599e-06
restriction O 0 6.996408501436235e-07
enzymes O 0 4.6781542550888844e-07
, O 0 2.7322332130097493e-07
we O 0 1.1149957401812571e-07
characterized O 0 5.774644478151458e-07
the O 0 9.573459891498715e-08
methylation O 0 4.080540747963823e-06
pattern O 0 8.769296982791275e-06
on O 0 1.1142819857923314e-05
the O 0 8.041802175284829e-07
5 O 0 1.4620899264627951e-06
side O 0 3.0049375254748156e-07
of O 0 6.465272406330769e-08
the O 0 7.423719807775342e-07
CTG O 0 4.236582390149124e-05
repeat O 0 5.230760052654659e-06
in O 0 1.4267187964378536e-07
the O 0 1.600501633447493e-07
DMPK O 0 5.346104080672376e-05
gene O 0 6.779050067962089e-07
of O 0 4.2981099568351055e-08
normal O 0 3.271938737725577e-07
individuals O 0 1.5932654306993754e-08
and O 0 2.9057551387268177e-07
of O 0 9.415367117071582e-07
patients O 0 4.149357118876651e-05
affected O 0 3.477707423371612e-06
with O 0 0.001276531838811934
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.414809321431676e-05
showing O 0 6.504148586827796e-06
expansions O 0 2.8427853067114484e-06
of O 0 1.7411478836493188e-07
the O 0 1.042364942804852e-06
repetitive O 0 7.639178511453792e-05
sequence O 0 1.4867361642245669e-05
. O 0 8.51288132253103e-06

The O 0 1.1401460142224096e-05
gene O 0 1.5908104614936747e-05
segment O 0 1.4615471627621446e-05
analyzed O 0 4.489213552005822e-06
corresponds O 0 1.3238898191048065e-06
to O 0 1.7679631980627164e-07
the O 0 2.5969731609620794e-07
genomic O 0 4.021126187581103e-06
SacI O 0 5.312693247105926e-05
- O 0 3.3162039471790195e-05
HindIII O 0 2.069691072392743e-05
fragment O 0 4.8350302677135915e-06
carrying O 0 6.421625471375592e-07
exons O 0 1.2395905287121423e-05
11 O 0 3.261230176576646e-06
- O 0 3.076400753343478e-05
15 O 0 7.047388862702064e-06
. O 0 6.768546882085502e-06

There O 0 9.095580935536418e-06
is O 0 8.638948543193692e-07
constitutive O 0 6.48780678602634e-06
methylation O 0 9.688812497188337e-06
in O 0 2.1215848846622976e-06
intron O 0 0.00020739369210787117
12 O 0 5.764867637481075e-06
at O 0 3.538497992394696e-07
restriction O 0 6.387841011701312e-08
sites O 0 9.682226220775192e-08
of O 0 4.0682511581735525e-08
SacII O 0 2.132110603270121e-05
and O 0 1.9819487988570472e-06
HhaI O 0 2.147146915376652e-05
, O 0 3.1859252658250625e-07
localized O 0 7.169396667450201e-07
1 O 0 1.6762571704020957e-06
, O 0 3.6585871043826046e-07
159 O 0 1.4683473636978306e-06
- O 0 2.3015834813122638e-05
1 O 0 6.0975467022217344e-06
, O 0 3.38940850497238e-07
232 O 0 5.527382995751395e-07
bp O 0 4.849524702876806e-05
upstream O 0 6.916618531249696e-07
of O 0 7.150414660372917e-08
the O 0 4.943245812683017e-07
CTG O 0 5.6067485274979845e-05
repeat O 0 1.1373680536053143e-05
, O 0 1.8948816205011099e-07
whereas O 0 6.471947244790499e-08
most O 0 3.48628326207745e-08
, O 0 1.5277933584911807e-07
if O 0 3.7205268199613784e-08
not O 0 1.7162992804742316e-08
all O 0 4.152058252770985e-09
, O 0 2.027852907815486e-08
of O 0 3.481437582664171e-09
the O 0 2.5856321528294757e-08
other O 0 1.8922914790664436e-08
sites O 0 6.199982749421906e-08
of O 0 4.825412247555505e-08
SacII O 0 2.1981772079016082e-05
, O 0 7.17378725312301e-07
HhaI O 0 8.484043974021915e-06
, O 0 3.0555148100575025e-07
and O 0 1.786924457292116e-07
HpaII O 0 6.1987689150555525e-06
in O 0 2.042444862127013e-07
this O 0 5.093531285638164e-08
region O 0 1.0278009767716867e-06
are O 0 8.743143098399742e-08
unmethylated O 0 3.5679825032275403e-06
, O 0 3.260780658820295e-07
in O 0 8.700440190523295e-08
normal O 0 3.6809717585128965e-07
individuals O 0 1.6095178523301e-08
and O 0 8.30634192539037e-08
most O 0 4.307630163680187e-08
of O 0 8.431613451875819e-08
the O 0 6.698258857795736e-06
patients O 0 2.5207840735674836e-05
. O 0 6.2281001191877294e-06

In O 0 5.891949058423052e-06
a O 0 6.836787633801578e-07
number O 0 2.736202020514611e-07
of O 0 2.1546877349010174e-07
young O 0 6.450833097915165e-06
and O 0 2.9567860110546462e-05
severely O 0 0.13881711661815643
affected O 0 1.395316212438047e-05
patients O 0 7.774332516419236e-06
, O 0 3.870246132464672e-07
however O 0 2.3607023535987537e-07
, O 0 9.528645250611589e-08
complete O 0 2.2523079223901732e-07
methylation O 0 1.2034835208396544e-06
of O 0 3.319010488667118e-08
these O 0 3.7429124688515e-08
restriction O 0 5.207840558796306e-08
sites O 0 1.9914135407361755e-07
was O 0 4.7910398279782385e-06
found O 0 3.48381803405573e-07
in O 0 1.087819541112367e-07
the O 0 3.4048846941914235e-07
mutated O 0 1.5020678802102339e-05
allele O 0 2.704770304262638e-05
. O 0 5.6315029723919e-06

In O 0 9.376045454700943e-06
most O 0 6.023113883202313e-07
of O 0 2.3189379305676994e-07
these O 0 2.9917612209828803e-07
patients O 0 3.148825271637179e-06
, O 0 1.4905899092809705e-07
the O 0 3.388541927051847e-07
onset O 0 1.8037419067695737e-05
of O 0 9.410591701453086e-07
the O 0 0.00020261917961761355
disease O 1 0.7514837384223938
was O 0 0.1394243836402893
congenital O 1 0.999992847442627
. O 0 6.493224645964801e-05

Preliminary O 0 0.0003447147901169956
in O 0 4.128721775487065e-05
vivo O 0 0.001244285493157804
footprinting O 0 0.0025791150983422995
data O 0 1.9679457182064652e-05
gave O 0 2.2799604266765527e-06
evidence O 0 3.739437488547992e-07
for O 0 1.0534502337122831e-07
protein O 0 1.3813618124913773e-06
- O 0 9.463373862672597e-05
DNA O 0 3.5837263567373157e-05
contact O 0 8.839658107717696e-07
in O 0 2.9582693628071866e-07
normal O 0 5.324344556356664e-07
genes O 0 3.92961936768188e-07
at O 0 6.31338480161503e-07
an O 0 3.5070323178842955e-07
Sp1 O 0 2.0874123947578482e-05
consensus O 0 2.3990216391212016e-07
binding O 0 3.9042555499690934e-07
site O 0 9.290351954405196e-07
upstream O 0 2.817332358517888e-07
of O 0 4.824537924719152e-08
the O 0 3.760889342174778e-07
CTG O 0 5.770137067884207e-05
repeat O 0 9.469990800425876e-06
and O 0 2.454695220421854e-07
for O 0 3.980473550768693e-08
a O 0 2.8843442123616114e-07
significant O 0 4.22894459006784e-07
reduction O 0 2.1545881736528827e-06
of O 0 3.3212266714599536e-08
this O 0 3.979471685511271e-08
interaction O 0 4.51809611945464e-08
in O 0 3.4014931316050934e-07
cells O 0 5.605385240414762e-07
with O 0 1.3114639330069622e-07
a O 0 7.0850855991011485e-06
hypermethylated O 0 0.0005050714826211333
DMPK O 0 0.0002553477534092963
gene O 0 7.215818641270744e-06
. O 0 6.801566314607044e-07
. O 0 3.077338078583125e-06

The O 0 0.00014855236804578453
hemochromatosis B-Disease 1 0.9999854564666748
gene O 0 0.00017716966976877302
product O 0 5.356932888389565e-06
complexes O 0 1.3543882459998713e-06
with O 0 2.9292493763932725e-07
the O 0 6.264324952098832e-07
transferrin O 0 1.1948916835535783e-05
receptor O 0 1.616192321307608e-06
and O 0 4.63003232198389e-07
lowers O 0 1.4337108041218016e-05
its O 0 2.3748287958369474e-07
affinity O 0 3.2496421908945194e-07
for O 0 9.775396137001735e-08
ligand O 0 5.718990450986894e-06
binding O 0 1.8274486137670465e-05
. O 0 8.857904504111502e-06

We O 0 5.5375323427142575e-05
recently O 0 4.7709301725262776e-05
reported O 0 1.3614898307423573e-05
the O 0 1.3287719013987953e-07
positional O 0 3.0333580980368424e-06
cloning O 0 2.605285999379703e-06
of O 0 5.893472376783393e-08
a O 0 2.546323457863764e-06
candidate O 0 2.9239286959636956e-05
gene O 0 6.715869676554576e-05
for O 0 0.0004338911676313728
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9753456115722656
HFE O 1 0.911022424697876
. O 0 5.197040081839077e-05

The O 0 6.721385034325067e-06
gene O 0 8.710552720003761e-06
product O 0 3.5429993658908643e-06
, O 0 2.3658184034047736e-07
a O 0 2.4358527639378735e-07
member O 0 3.7286261544977606e-07
of O 0 2.0594020710973382e-08
the O 0 2.566769126133295e-07
major O 0 8.954831969276711e-07
histocompatibility O 0 2.1110736270202324e-06
complex O 0 9.59003273237613e-07
class O 0 6.550847047037678e-07
I O 0 8.736741619941313e-06
- O 0 5.926712401560508e-05
like O 0 5.656529538100585e-07
family O 0 2.4577195745223435e-06
, O 0 8.40127938772639e-07
was O 0 5.4116958381200675e-06
found O 0 3.303846085600526e-07
to O 0 1.1793437693086162e-07
have O 0 6.120391304875739e-08
a O 0 6.304979365268082e-07
mutation O 0 2.9786901905026753e-06
, O 0 5.346764169189555e-07
Cys O 0 0.00028717698296532035
- O 0 0.00010080508218379691
282 O 0 1.3497151485353243e-05
- O 0 0.0021320669911801815
- O 0 0.015225039795041084
> O 0 1.3302607840159908e-05
Tyr O 0 3.494455086183734e-05
( O 0 1.6806882285891334e-07
C282Y O 0 1.0211533663095906e-06
) O 0 6.540696517731703e-08
, O 0 6.114417061553468e-08
in O 0 5.715767770197999e-08
85 O 0 4.161587128237443e-07
% O 0 1.823579793835961e-07
of O 0 2.1359450386171375e-07
patient O 0 2.2005177015671507e-05
chromosomes O 0 3.791968629229814e-05
. O 0 1.768606853147503e-05

This O 0 1.6351486920029856e-05
mutation O 0 2.9144774089218117e-05
eliminates O 0 1.2875862012151629e-05
the O 0 7.163983468672086e-07
ability O 0 8.910203632694902e-07
of O 0 2.406693795364845e-07
HFE O 0 9.812841017264873e-05
to O 0 1.594953573658131e-06
associate O 0 3.0091525786701823e-06
with O 0 5.722880018765863e-07
beta2 O 0 0.01111812237650156
- O 0 0.1915643811225891
microglobulin O 0 0.005730925593525171
( O 0 8.320753863699792e-07
beta2m O 0 2.3065074856276624e-05
) O 0 1.5959913923779823e-07
and O 0 2.4277798615912616e-07
prevents O 0 5.406297418630857e-07
cell O 0 0.0001163561173598282
- O 0 0.00031661250977776945
surface O 0 0.00017331246635876596
expression O 0 1.567907747812569e-05
. O 0 1.0173363079957198e-05

A O 0 7.991239544935524e-05
second O 0 6.565212243003771e-05
mutation O 0 2.149457941413857e-05
that O 0 6.601098903047387e-07
has O 0 9.649369303588173e-07
no O 0 5.03640876559075e-07
effect O 0 7.839349223104364e-07
on O 0 2.3016822524368763e-05
beta2m O 0 0.0011017475044354796
association O 0 9.899700899040909e-07
, O 0 3.3085760264839337e-07
H63D O 0 0.0001433293946320191
, O 0 2.4353867047466338e-06
was O 0 8.83950724528404e-06
found O 0 5.800442863801436e-07
in O 0 9.308482162850851e-08
eight O 0 1.9416090424329013e-07
out O 0 2.2104596553162992e-07
of O 0 1.1775747310593943e-07
nine O 0 1.3174462765164208e-05
patients O 0 4.057954811287345e-06
heterozygous O 0 5.791769694951654e-07
for O 0 1.1548831935215276e-07
the O 0 7.164597946029971e-07
C282Y O 0 4.982174505130388e-05
mutant O 0 6.121381011325866e-05
. O 0 1.3052534086455125e-05

In O 0 4.665174492402002e-05
this O 0 2.122196065101889e-06
report O 0 4.089906724402681e-06
, O 0 1.9407592333209323e-07
we O 0 8.372384030508329e-08
demonstrate O 0 2.1473643130320852e-07
in O 0 1.469065580295137e-07
cultured O 0 1.855843402154278e-05
293 O 0 1.2006705219391733e-05
cells O 0 1.47051187013858e-05
overexpressing O 0 3.535557334544137e-05
wild O 0 4.210415681882296e-06
- O 0 4.284999522496946e-05
type O 0 3.1115794172364986e-06
or O 0 5.849906870025734e-07
mutant O 0 2.6893710582953645e-06
HFE O 0 1.165202684205724e-05
proteins O 0 1.6662337998241128e-07
that O 0 3.935135239885312e-08
both O 0 2.375933760845328e-08
the O 0 1.712650714580377e-07
wild O 0 4.445752892934252e-06
- O 0 0.0003652912564575672
type O 0 9.22244907997083e-06
and O 0 1.6082128695416031e-06
H63D O 0 0.00014627024938818067
HFE O 0 3.049076985917054e-05
proteins O 0 1.7036714439200296e-07
form O 0 1.3102425100441906e-07
stable O 0 4.999911652703304e-06
complexes O 0 4.86073133743048e-07
with O 0 2.2676901778595493e-07
the O 0 2.208220848842757e-06
transferrin O 0 5.33902166353073e-05
receptor O 0 9.557762496115174e-06
( O 0 1.3297711802806589e-06
TfR O 0 4.713996531791054e-05
) O 0 1.6777685232227668e-06
. O 0 3.7703730413340963e-06

The O 0 1.0511684195080306e-05
C282Y O 0 5.492613126989454e-05
mutation O 0 2.463655073370319e-05
nearly O 0 3.2627078780933516e-06
completely O 0 7.2558968895464204e-06
prevents O 0 9.67773644333647e-07
the O 0 3.1084985607776616e-07
association O 0 1.554161599415238e-07
of O 0 2.179647395905704e-08
the O 0 3.182038597060455e-07
mutant O 0 1.1929059837711975e-05
HFE O 0 0.00010054472659248859
protein O 0 3.112638978564064e-06
with O 0 3.968954445099371e-07
the O 0 4.796901066583814e-06
TfR O 0 0.0008198156720027328
. O 0 1.2674285244429484e-05

Studies O 0 9.0406509116292e-05
on O 0 2.680253965081647e-05
cell O 0 0.0003484936023596674
- O 0 0.0006465226761065423
associated O 0 8.619653272035066e-06
transferrin O 0 8.881504072633106e-06
at O 0 1.6873207187018124e-06
37 O 0 1.1417129144319915e-06
degrees O 0 4.695927600550931e-06
C O 0 4.315378100727685e-05
suggest O 0 6.747226848347054e-07
that O 0 7.989334704916473e-08
the O 0 2.476664633377368e-07
overexpressed O 0 3.6075023672310635e-05
wild O 0 4.767553036799654e-06
- O 0 0.0001360879687126726
type O 0 6.2071922002360225e-06
HFE O 0 9.032739762915298e-05
protein O 0 6.637252681684913e-06
decreases O 0 1.0358819508837769e-06
the O 0 4.164488487390372e-08
affinity O 0 2.0502862696503144e-07
of O 0 5.97530629420362e-08
the O 0 8.771235684434942e-07
TfR O 0 4.803855699719861e-05
for O 0 1.7022372276187525e-06
transferrin O 0 6.846425094408914e-05
. O 0 7.617612482135883e-06

The O 0 2.0544412109302357e-05
overexpressed O 0 0.0003014958056155592
H63D O 0 0.0007445970550179482
protein O 0 3.5574026696849614e-05
does O 0 8.595663416599564e-07
not O 0 1.111541010345718e-07
have O 0 4.0871270812203875e-08
this O 0 4.457833924220722e-08
effect O 0 3.932029812858673e-07
, O 0 1.4662661840247893e-07
providing O 0 3.2901304791721486e-08
the O 0 3.098045198157706e-08
first O 0 5.126602218297194e-07
direct O 0 3.208690770861722e-07
evidence O 0 9.421852382729412e-07
for O 0 1.0418526130706596e-07
a O 0 1.1384847766748862e-06
functional O 0 2.064705768134445e-06
consequence O 0 9.972684438253054e-07
of O 0 7.86272664754506e-08
the O 0 2.7735661660699407e-06
H63D O 0 0.10130048543214798
mutation O 0 0.00011212765821255744
. O 0 4.524410087469732e-06

Addition O 0 1.131787030317355e-05
of O 0 1.1174488463439047e-06
soluble O 0 1.8646251191967167e-05
wild O 0 1.0545199074840639e-05
- O 0 0.0007326363120228052
type O 0 3.663052848423831e-05
HFE O 0 0.000570162374060601
/ O 0 8.235238055931404e-05
beta2m O 0 4.764755431097001e-05
heterodimers O 0 1.001206965156598e-05
to O 0 8.320722599819419e-07
cultured O 0 3.4345179301453754e-05
cells O 0 1.9190640159649774e-05
also O 0 3.112692411377793e-06
decreased O 0 3.770488319787546e-06
the O 0 2.595505179669999e-07
apparent O 0 2.429635742373648e-06
affinity O 0 2.874557196719252e-07
of O 0 1.137121472538638e-07
the O 0 9.277991352973913e-07
TfR O 0 1.7006055713864043e-05
for O 0 1.3677326649030874e-07
its O 0 3.1218436902236135e-07
ligand O 0 1.039139192471339e-06
under O 0 2.6037608336082485e-07
steady O 0 1.210004211316118e-05
- O 0 6.07068941462785e-05
state O 0 6.10931238043122e-07
conditions O 0 2.3310649339691736e-06
, O 0 1.806860723263526e-07
both O 0 3.676417392739495e-08
in O 0 1.4771462986118422e-07
293 O 0 9.19991009595833e-07
cells O 0 2.536662350394181e-06
and O 0 5.388590125221526e-07
in O 0 9.796129916139762e-07
HeLa O 0 0.0004907441325485706
cells O 0 6.436372495954856e-05
. O 0 5.056659119873075e-06

Furthermore O 0 9.445207979297265e-05
, O 0 6.892611054354347e-06
at O 0 1.7377849417243851e-06
4 O 0 3.920488779840525e-06
degrees O 0 1.4658521649835166e-05
C O 0 0.00012344776769168675
, O 0 3.3142444522127334e-07
the O 0 1.8066228335555934e-07
added O 0 1.994341573663405e-06
soluble O 0 2.0798952391487546e-06
complex O 0 5.170951453692396e-07
of O 0 6.016833253852383e-07
HFE O 0 0.0026423134841024876
/ O 0 7.38232847652398e-05
beta2m O 0 2.6475490813027136e-05
inhibited O 0 3.407854592296644e-06
binding O 0 8.541502438674797e-07
of O 0 1.2198509580230166e-07
transferrin O 0 1.1697788067976944e-05
to O 0 1.6237717090916703e-06
HeLa O 0 0.00020025810226798058
cell O 0 0.00015425097080878913
TfR O 0 3.866472252411768e-05
in O 0 3.368279521964723e-07
a O 0 2.2653134692518506e-06
concentration O 0 6.091879913583398e-05
- O 0 0.00023879267973825336
dependent O 0 1.6585050616413355e-05
manner O 0 8.84749442775501e-06
. O 0 9.89584168564761e-06

Scatchard O 0 0.0012961148750036955
plots O 0 0.00012381108535919338
of O 0 1.903489874166553e-06
these O 0 3.9368174498122244e-07
data O 0 2.6987383989762748e-06
indicate O 0 9.012782697936927e-07
that O 0 7.444890570695861e-08
the O 0 1.1253258236365582e-07
added O 0 2.85579562842031e-06
heterodimer O 0 5.236954166321084e-06
substantially O 0 7.029815151327057e-06
reduced O 0 8.900402690414921e-07
the O 0 7.604364782309858e-08
affinity O 0 5.526012500922661e-07
of O 0 3.041625973310147e-07
TfR O 0 5.618266368401237e-05
for O 0 1.8669720702746417e-06
transferrin O 0 0.00010766243940452114
. O 0 1.2082527064194437e-05

These O 0 7.3760802479228005e-06
results O 0 8.387602065340616e-06
establish O 0 7.560657877547783e-07
a O 0 1.0306641797797056e-06
molecular O 0 1.6694255464244634e-05
link O 0 4.5056967792334035e-05
between O 0 4.1339553717989475e-06
HFE O 0 0.0012574488064274192
and O 0 3.3198323308170075e-06
a O 0 1.2878116422143648e-06
key O 0 2.505966676835669e-06
protein O 0 1.8392252059129532e-06
involved O 0 2.7354349185770843e-07
in O 0 7.588830612803577e-07
iron O 0 0.004135794471949339
transport O 0 2.1942312741884962e-05
, O 0 5.963408966636052e-07
the O 0 2.0389924770825019e-07
TfR O 0 1.2334680832282174e-05
, O 0 4.0570236592429865e-07
and O 0 2.1259424443087482e-07
raise O 0 3.2774664759926964e-07
the O 0 1.6509525835317618e-07
possibility O 0 2.005654664571921e-07
that O 0 1.6106672262594657e-07
alterations O 0 2.9766968054900644e-06
in O 0 2.9278388069542416e-07
this O 0 1.1205858641005761e-07
regulatory O 0 5.797223820991348e-07
mechanism O 0 5.457087581817177e-07
may O 0 1.8198703628513613e-06
play O 0 6.541295505257949e-08
a O 0 3.530579704147385e-07
role O 0 5.607224125014909e-07
in O 0 3.9261880147023476e-07
the O 0 2.4487285372742917e-06
pathogenesis O 0 0.010755202732980251
of O 0 0.00024550542002543807
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0003097644366789609
. O 0 1.628839163458906e-05

Genomic O 0 0.00033012437052093446
organization O 0 1.1280005310254637e-05
of O 0 6.08071331953397e-07
the O 0 2.017709675783408e-06
UBE3A O 0 0.0015157271409407258
/ O 0 0.00043752326746471226
E6 O 0 0.0064192223362624645
- O 0 0.022367682307958603
AP O 0 0.0008176686242222786
gene O 0 6.635493264184333e-06
and O 0 1.1032839211111423e-06
related O 0 4.991993137082318e-06
pseudogenes O 0 6.139586184872314e-05
. O 0 1.5217604413919616e-05

The O 0 3.406708856346086e-05
UBE3A O 0 0.000612625852227211
gene O 0 2.1352505427785218e-05
encodes O 0 9.917447641782928e-06
the O 0 5.822678303957218e-07
E6 O 0 0.0005499457474797964
- O 0 0.002756093628704548
AP O 0 0.00014937507512513548
ubiquitin O 0 3.971422302129213e-06
- O 0 1.1308310604363214e-05
protein O 0 9.162190508504864e-07
ligase O 0 4.678573759520077e-07
and O 0 2.999288710725523e-07
has O 0 4.952112249156926e-07
recently O 0 2.5690467282402096e-06
been O 0 3.256970728671149e-07
shown O 0 8.737025325444847e-08
to O 0 7.543863489445357e-08
be O 0 5.131101943334215e-07
mutated O 0 0.00015054902178235352
in O 0 0.14267666637897491
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.1562385857105255
who O 0 1.3672537534148432e-05
lack O 0 1.4314114196167793e-06
15q11 O 0 1.6362968381145038e-05
- O 0 0.0001034153247019276
q13 O 0 2.800343827402685e-05
deletions O 0 2.9319811801542528e-05
or O 0 6.481944183178712e-06
chromosome O 0 0.0004642413987312466
15 O 0 4.751410961034708e-05
paternal O 0 0.0004489025450311601
uniparental B-Disease 0 0.16112083196640015
disomy I-Disease 0 0.25777968764305115
. O 0 0.00010348064097343013

Previous O 0 7.974126492626965e-05
UBE3A O 0 0.0004605604917742312
cDNA O 0 7.139857916627079e-05
analysis O 0 8.067642738751601e-06
has O 0 1.4159888905851403e-06
shown O 0 3.129032961624034e-07
a O 0 6.490898840638692e-07
coding O 0 5.806446279166266e-05
region O 0 7.736685802228749e-06
of O 0 2.7280361791781615e-07
approximately O 0 1.382995037602086e-06
2 O 0 1.3019291145610623e-05
. O 0 9.105483513849322e-06

6 O 0 0.00027633379795588553
kb O 0 0.0009139821049757302
and O 0 3.4992726796190254e-06
a O 0 1.0286943279425032e-06
3 O 0 3.6221568734617904e-05
- O 0 0.03938476741313934
untranslated O 0 0.03416140004992485
region O 0 8.508418977726251e-05
( O 0 6.380693662322301e-07
UTR O 0 3.7143818190088496e-05
) O 0 1.11225993748576e-07
of O 0 3.852462882036889e-08
< O 0 1.232374643223011e-06
50 O 0 4.911948963126633e-07
bp O 0 6.682622915832326e-05
, O 0 1.9094410674824758e-07
whereas O 0 1.5331850988786755e-07
Northern O 0 5.252612140793644e-07
analysis O 0 9.61880346039834e-07
has O 0 5.639535629597958e-07
indicated O 0 6.50993058570748e-07
mRNA O 0 1.322568294881421e-07
sizes O 0 1.6946600567280257e-07
of O 0 4.1470421763278864e-08
5 O 0 2.9628558877448086e-06
- O 0 0.00011917643860215321
8 O 0 2.3892409444670193e-05
kb O 0 0.00027290420257486403
. O 0 6.772827873646747e-06

We O 0 9.753280210134108e-06
have O 0 6.910572665219661e-07
analyzed O 0 9.438094252800511e-07
additional O 0 1.3015447564157512e-07
cDNA O 0 1.754686309141107e-06
clones O 0 1.3859241335012484e-05
and O 0 5.439883352664765e-07
provide O 0 1.2495461021444498e-07
evidence O 0 2.3678363447743322e-07
for O 0 9.039383996878314e-08
an O 0 3.7741077107966703e-07
additional O 0 9.383276164953713e-07
0 O 0 2.1083769752294756e-05
. O 0 1.0966773515974637e-05

5 O 0 3.890412699547596e-05
kb O 0 0.00018514452676754445
of O 0 8.27181054319226e-07
5 O 0 7.5713032856583595e-06
- O 0 0.00015080851153470576
UTR O 0 0.00015909018111415207
and O 0 1.8029204511549324e-06
> O 0 5.580018296313938e-07
2 O 0 6.923574460415693e-07
kb O 0 9.186257557303179e-06
of O 0 9.089384178651017e-08
3 O 0 1.7745283912518062e-05
- O 0 0.004062772262841463
UTR O 0 0.015505039133131504
. O 0 1.3821518223267049e-05

We O 0 2.242677510366775e-05
have O 0 9.248856258636806e-07
established O 0 4.387273691008886e-07
the O 0 2.603239579457295e-07
genomic O 0 3.3011738196364604e-06
organization O 0 3.4081983812939143e-07
of O 0 1.393459001519659e-07
UBE3A O 0 4.316102422308177e-05
and O 0 3.53878817804798e-07
the O 0 5.25130978701327e-08
sequence O 0 2.0239083653450507e-07
of O 0 2.443274524921435e-07
intron O 0 0.0009064033511094749
- O 0 0.0004111921589355916
exon O 0 0.000216284446651116
borders O 0 2.123318517988082e-05
. O 0 7.546419510617852e-06

We O 0 1.8655357052921318e-05
have O 0 7.133304507078719e-07
also O 0 3.87457788519896e-07
mapped O 0 2.8753684091498144e-06
two O 0 3.178381007273856e-07
highly O 0 5.861589897904196e-07
homologous O 0 1.871446556833689e-06
processed O 0 7.241145340231014e-06
pseudogenes O 0 7.642863238288555e-06
, O 0 7.932497965157381e-07
UBE3AP1 O 0 7.131841994123533e-05
and O 0 1.6298503169309697e-06
UBE3AP2 O 0 0.00011208330397494137
, O 0 3.269954902407335e-07
to O 0 5.58581234599842e-08
chromosomes O 0 3.372480534835631e-07
2 O 0 2.536161673560855e-06
and O 0 2.232014367109514e-06
21 O 0 3.362260031281039e-06
, O 0 3.1244678666553227e-07
respectively O 0 1.0824109040186158e-06
, O 0 1.658230104339964e-07
and O 0 3.7863108559577086e-07
determined O 0 1.8911675851995824e-06
their O 0 1.6409862837463152e-06
genomic O 0 1.7836324332165532e-05
organization O 0 6.026082701282576e-06
. O 0 7.90169451647671e-06

These O 0 9.481465895078145e-06
results O 0 1.3227062481746543e-05
will O 0 2.2810122857208626e-07
form O 0 7.97617971670661e-08
the O 0 4.468866521278869e-08
basis O 0 1.2669899263073603e-07
for O 0 1.26547803347421e-07
studies O 0 1.5039320544474322e-07
of O 0 1.5531702501903055e-07
mutation O 0 6.644586392212659e-06
and O 0 1.3827286693413043e-06
imprinting O 0 7.829067180864513e-05
of O 0 2.891217491196585e-06
UBE3A O 0 0.00243547884747386
. O 0 1.7629672584007494e-05

Mutation O 0 0.0011515322839841247
spectrum O 0 0.0001157064107246697
and O 0 2.0086374206584878e-05
genotype O 0 0.005505377426743507
- O 0 0.29792192578315735
phenotype O 0 0.011374888010323048
analyses O 0 3.5114586353302e-05
in O 0 1.13584737846395e-05
Cowden B-Disease 1 0.9975354671478271
disease I-Disease 0 0.2625926733016968
and O 0 3.309143357910216e-05
Bannayan B-Disease 1 0.9459307193756104
- I-Disease 1 0.9999926090240479
Zonana I-Disease 1 0.9999964237213135
syndrome I-Disease 1 0.9999949932098389
, O 0 3.5778232359007234e-06
two O 0 2.3879812943050638e-05
hamartoma B-Disease 1 0.9975703358650208
syndromes I-Disease 1 0.8845946192741394
with O 0 8.184350008377805e-05
germline O 1 0.8260610103607178
PTEN O 1 0.9721695780754089
mutation O 0 0.0012373838108032942
. O 0 2.3783153665135615e-05

The O 0 0.00036520016146823764
tumour B-Disease 1 0.9999951124191284
suppressor O 0 0.02500358782708645
gene O 0 0.0005730996490456164
PTEN O 0 0.014612127095460892
, O 0 3.843087597488193e-06
which O 0 3.6008012216370844e-07
maps O 0 6.927062258910155e-06
to O 0 2.8890290195704438e-06
10q23 O 0 9.285096894018352e-05
. O 0 1.0443795872561168e-05

3 O 0 4.2838721128646284e-05
and O 0 1.1350006161592319e-06
encodes O 0 2.089573399643996e-06
a O 0 4.204398464935366e-07
403 O 0 5.184026008464571e-07
amino O 0 7.470963510058937e-07
acid O 0 3.7687771055061603e-06
dual O 0 3.6592189189832425e-06
specificity O 0 5.11317284690449e-06
phosphatase O 0 0.007008835207670927
( O 0 6.503241820610128e-07
protein O 0 1.259554437638144e-06
tyrosine O 0 1.4596056644222699e-05
phosphatase O 0 0.008936531841754913
; O 0 2.9780542263324605e-06
PTPase O 0 3.240748992539011e-05
) O 0 3.794277745328145e-07
, O 0 2.8554151754178747e-07
was O 0 3.3955598155444022e-06
shown O 0 6.060913051442185e-07
recently O 0 1.3453562814902398e-06
to O 0 1.244324465687896e-07
play O 0 1.3177978530620749e-07
a O 0 4.804967943528027e-07
broad O 0 2.3428456188412383e-06
role O 0 5.705066996597452e-06
in O 0 6.70958797854837e-06
human O 0 9.028775821207091e-06
malignancy B-Disease 0 0.020534807816147804
. O 0 1.5712788808741607e-05

Somatic O 0 0.0032663545571267605
PTEN O 0 0.019156748428940773
deletions O 0 0.0005262274644337595
and O 0 3.987266245530918e-05
mutations O 0 5.805920227430761e-05
were O 0 1.2276835832381039e-06
observed O 0 1.265444552700501e-06
in O 0 1.3839239727531094e-06
sporadic B-Disease 0 0.0008908401359803975
breast I-Disease 1 0.9933632612228394
, I-Disease 0 0.00012010554200969636
brain I-Disease 0 0.05794873461127281
, I-Disease 0 0.00010513982124393806
prostate I-Disease 1 0.9943965673446655
and I-Disease 0 0.019908791407942772
kidney I-Disease 1 0.9992480874061584
cancer I-Disease 0 0.3825434744358063
cell O 0 0.00017789483536034822
lines O 0 4.528259523794986e-05
and O 0 3.711990075316862e-06
in O 0 6.187189001138904e-07
several O 0 1.3085408454571734e-06
primary O 0 0.0011303041828796268
tumours B-Disease 1 0.9999985694885254
such O 0 7.460881192855595e-07
as O 0 5.425422568805516e-05
endometrial B-Disease 1 0.9987932443618774
carcinomas I-Disease 1 1.0
, O 1 0.9957478642463684
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9971514344215393
thyroid B-Disease 1 0.9999986886978149
tumours I-Disease 1 0.9999998807907104
. O 0 0.00023343588691204786

In O 0 2.5164245016640052e-05
addition O 0 2.4074727207334945e-06
, O 0 2.6476459424884524e-06
PTEN O 0 0.0004603541165124625
was O 0 4.086873013875447e-05
identified O 0 1.8063590232486604e-06
as O 0 1.4158510452944029e-07
the O 0 2.2411661859678134e-07
susceptibility O 0 1.8800055840983987e-05
gene O 0 1.9654644347610883e-06
for O 0 8.251152507909865e-07
two O 0 0.0001446023816242814
hamartoma B-Disease 1 0.9999632835388184
syndromes I-Disease 1 0.999941349029541
Cowden B-Disease 1 0.999985933303833
disease I-Disease 1 0.9958904385566711
( O 0 1.020759100356372e-05
CD B-Disease 0 0.0021035862155258656
; O 0 1.556154529680498e-05
MIM O 0 0.026407137513160706
158350 O 0 5.4733562137698755e-05
) O 0 4.105559128220193e-07
and O 0 5.690802140634332e-07
Bannayan B-Disease 0 0.0007044529193080962
- I-Disease 0 0.1703057587146759
Zonana I-Disease 0 0.059474583715200424
( I-Disease 0 6.561469945154386e-07
BZS I-Disease 0 1.5779129171278328e-05
) I-Disease 0 2.2354431905569072e-07
or I-Disease 0 5.297222855915606e-07
Ruvalcaba I-Disease 0 0.00019037209858652204
- I-Disease 0 0.011003068648278713
Riley I-Disease 0 0.0042777713388204575
- I-Disease 1 0.9990789890289307
Smith I-Disease 1 0.9990817308425903
syndrome I-Disease 1 0.9999184608459473
( O 0 8.187275852833409e-06
MIM O 0 0.08353231102228165
153480 O 0 0.00017779716290533543
) O 0 2.306725718881353e-06
. O 0 3.6220624224370113e-06

Constitutive O 0 0.0004498522321227938
DNA O 0 0.00032300231396220624
from O 0 2.2476676804217277e-06
37 O 0 3.204077984264586e-06
CD B-Disease 0 1.8274415197083727e-05
families O 0 5.835096885675739e-07
and O 0 5.85277518894145e-07
seven O 0 1.2724536873065517e-06
BZS B-Disease 0 4.719002390629612e-05
families O 0 5.319492402122705e-07
was O 0 4.635202913050307e-06
screened O 0 1.0193756679655053e-05
for O 0 3.829371507890755e-06
germline O 0 0.0016613337211310863
PTEN O 0 0.2301350086927414
mutations O 0 0.001143943052738905
. O 0 1.3265060260891914e-05

PTEN O 1 0.711715042591095
mutations O 0 0.006173132453113794
were O 0 1.0168871995119844e-05
identified O 0 5.939269613008946e-06
in O 0 3.9380040561809437e-07
30 O 0 5.642785367854231e-07
of O 0 8.871617751537997e-08
37 O 0 9.449438948649913e-06
( O 0 5.522641117750027e-07
81 O 0 1.762896772561362e-06
% O 0 3.377015218575252e-07
) O 0 6.909156979872932e-08
CD B-Disease 0 9.246286936104298e-06
families O 0 1.9170020948422462e-07
, O 0 1.092027090976444e-07
including O 0 1.3946568344636034e-07
missense O 0 1.0005397598433774e-05
and O 0 2.2144843114801915e-06
nonsense O 0 1.610702929610852e-05
point O 0 1.104586226574611e-05
mutations O 0 1.2286521268833894e-05
, O 0 3.25082623930939e-07
deletions O 0 2.1451855900522787e-06
, O 0 4.523597567640536e-07
insertions O 0 7.226147317851428e-06
, O 0 8.074524657786242e-07
a O 0 1.9410272216191515e-06
deletion O 0 9.90903572528623e-05
/ O 0 6.591899727936834e-05
insertion O 0 7.659017683181446e-06
and O 0 2.8871452286693966e-06
splice O 0 0.003785984357818961
site O 0 0.0004705832398030907
mutations O 0 0.00025436977739445865
. O 0 8.186290870071389e-06

These O 0 9.440161193197127e-06
mutations O 0 4.12674926337786e-05
were O 0 8.062820597842801e-07
scattered O 0 4.515649152381229e-07
over O 0 4.520108802807954e-07
the O 0 2.1110324155415583e-07
entire O 0 2.7609831931840745e-07
length O 0 2.2112596980150556e-06
of O 0 4.95571669034689e-07
PTEN O 0 0.0011729208054021
, O 0 2.8359298198665783e-07
with O 0 3.5726834823890385e-08
the O 0 1.0721930010504366e-07
exception O 0 1.1875136607386594e-07
of O 0 4.53173250036798e-08
the O 0 2.887988443944778e-07
first O 0 2.5243666641472373e-06
, O 0 8.425285500379687e-07
fourth O 0 1.2452243936422747e-05
and O 0 1.5159863551161834e-06
last O 0 1.1290540896879975e-05
exons O 0 0.00013863785716239363
. O 0 7.14283351044287e-06

A O 0 4.4674892706098035e-05
hot O 0 5.4381958761950955e-05
spot O 0 2.8900907636852935e-05
for O 0 1.7191714505315758e-06
PTEN O 0 0.00039754516910761595
mutation O 0 8.049006282817572e-06
in O 0 8.945135618887434e-07
CD B-Disease 0 0.00022395125415641814
was O 0 6.0302947531454265e-05
identified O 0 1.8405552282274584e-06
in O 0 1.7329328727555549e-07
exon O 0 6.611654498556163e-06
5 O 0 1.473818656450021e-06
that O 0 4.3011691985839207e-08
contains O 0 2.0769638453543848e-08
the O 0 1.0119634197280902e-07
PTPase O 0 7.502317657781532e-06
core O 0 6.326828952296637e-06
motif O 0 3.5018729249713942e-06
, O 0 9.863535410659097e-08
with O 0 2.580020996845178e-08
13 O 0 3.596240105707693e-07
of O 0 6.623290005336457e-08
30 O 0 1.4534260799337062e-06
( O 0 7.937207158192905e-08
43 O 0 7.635640599801263e-07
% O 0 2.3606865795500198e-07
) O 0 1.10247867723956e-07
CD B-Disease 0 3.777257734327577e-05
mutations O 0 1.0279313755745534e-05
identified O 0 2.5562651444488438e-06
in O 0 1.327339447243503e-07
this O 0 5.282270194584271e-07
exon O 0 0.0003082969051320106
. O 0 1.1306025044177659e-05

Seven O 0 2.1822279450134374e-05
of O 0 1.1893388318640064e-06
30 O 0 5.953957952442579e-06
( O 0 4.06290894261474e-07
23 O 0 2.956400749098975e-06
% O 0 2.873540267955832e-07
) O 0 4.925777830067091e-08
were O 0 3.301401463318143e-08
within O 0 9.105447951185397e-09
the O 0 6.088732362741212e-08
core O 0 5.593398782366421e-06
motif O 0 8.859238732839003e-06
, O 0 4.13374067420591e-07
the O 0 1.1988711889898696e-07
majority O 0 3.064242548589391e-07
( O 0 4.2724455084908186e-08
five O 0 4.605819370340214e-08
of O 0 5.264085700673604e-08
seven O 0 8.333253163073095e-07
) O 0 1.1938840316361166e-07
of O 0 2.2897733487070582e-08
which O 0 7.972998332661518e-07
were O 0 1.0707476576499175e-06
missense O 0 3.1161383958533406e-05
mutations O 0 1.1432925930421334e-05
, O 0 5.429465659290145e-07
possibly O 0 1.0064675279863877e-06
pointing O 0 1.9916767541872105e-06
to O 0 1.3386853936481202e-07
the O 0 9.547784429742023e-08
functional O 0 5.006951369068702e-07
significance O 0 2.663182101514394e-07
of O 0 1.1797666843449406e-07
this O 0 1.3712552799916011e-06
region O 0 6.776333611924201e-05
. O 0 2.122747537214309e-05

Germline O 0 0.26612451672554016
PTEN O 1 0.7907646894454956
mutations O 0 0.0065101818181574345
were O 0 2.2119675122667104e-05
identified O 0 6.323463367152726e-06
in O 0 2.960563847409503e-07
four O 0 3.5237277984379034e-07
of O 0 1.7271320018608094e-07
seven O 0 2.8984618438698817e-06
( O 0 4.3800497451229603e-07
57 O 0 2.0235218016750878e-06
% O 0 4.6462926661661186e-07
) O 0 2.809430554862047e-07
BZS B-Disease 0 1.5374855138361454e-05
families O 0 7.000967343628872e-07
studied O 0 4.619139872374944e-06
. O 0 5.276035153656267e-06

Interestingly O 0 0.000475223088869825
, O 0 4.57255828223424e-06
none O 0 5.30189311120921e-07
of O 0 7.260815237941642e-08
these O 0 1.3692621791960846e-07
mutations O 0 1.2335362043813802e-05
was O 0 1.8535798517405055e-05
observed O 0 1.5575446923321579e-06
in O 0 1.2184906950096774e-07
the O 0 4.656437511130207e-07
PTPase O 0 6.712155300192535e-05
core O 0 5.4526739404536784e-05
motif O 0 8.310379053000361e-05
. O 0 9.783220775716472e-06

It O 0 1.065940159605816e-05
is O 0 4.7085998744478275e-07
also O 0 3.282784462044219e-07
worthy O 0 1.3639954943300836e-07
of O 0 5.0925891059705464e-08
note O 0 1.5980093621692504e-06
that O 0 6.065110369490867e-08
a O 0 3.038005331745808e-07
single O 0 5.129182227392448e-06
nonsense O 0 5.224981123319594e-06
point O 0 3.1404370020027272e-06
mutation O 0 1.850740886766289e-06
, O 0 1.8927900669041264e-07
R233X O 0 7.362070277849853e-07
, O 0 2.6866206326303654e-07
was O 0 2.370028369114152e-06
observed O 0 1.973963179580096e-07
in O 0 7.412061364675537e-08
the O 0 2.2552245582119212e-07
germline O 0 1.0218908755632583e-05
DNA O 0 9.022320227813907e-06
from O 0 1.1448843650896379e-07
two O 0 3.9210578961501596e-07
unrelated O 0 1.9271697055955883e-06
CD B-Disease 0 0.00010432329872855917
families O 0 3.8269260471679445e-07
and O 0 4.845550165555323e-07
one O 0 1.05595427157823e-06
BZS B-Disease 0 0.00015334495401475579
family O 0 7.30922192815342e-06
. O 0 6.856003437860636e-06

Genotype O 0 0.36046484112739563
- O 0 0.4143614172935486
phenotype O 0 0.01352966483682394
studies O 0 1.1216117854928598e-05
were O 0 1.8658150793271489e-06
not O 0 3.3470655580458697e-07
performed O 0 2.0931595372530865e-06
on O 0 1.6222455769820954e-06
this O 0 5.815785897311798e-08
small O 0 3.530845731347654e-07
group O 0 1.1512314813444391e-05
of O 0 3.6172258432998206e-07
BZS B-Disease 0 0.00014679560263175517
families O 0 3.2610466860205634e-06
. O 0 6.656738605670398e-06

However O 0 6.35335745755583e-05
, O 0 7.851740519981831e-06
genotype O 0 0.00030868779867887497
- O 0 0.0017046802677214146
phenotype O 0 0.0002478701062500477
analysis O 0 2.6544519187154947e-06
inthe O 0 5.220295861363411e-05
group O 0 9.454829523747321e-06
of O 0 1.0111935466738942e-07
CD B-Disease 0 8.295683801406994e-05
families O 0 7.182755439316679e-07
revealed O 0 5.4255865507002454e-06
two O 0 1.8087190767346328e-07
possible O 0 1.4697829442411603e-07
associations O 0 2.4715605562164455e-08
worthy O 0 1.0645717196666737e-07
of O 0 2.9596114003993534e-08
follow O 0 4.630500711755303e-07
- O 0 1.3984760698804166e-05
up O 0 3.2714322060201084e-06
in O 0 1.4322129118227167e-06
independent O 0 5.601357770501636e-06
analyses O 0 9.873293493001256e-06
. O 0 5.277715899865143e-06

The O 0 1.4258758710639086e-05
first O 0 1.9221337424824014e-05
was O 0 2.5096540412050672e-05
an O 0 1.8413153384244652e-06
association O 0 1.1402222526157857e-06
noted O 0 1.0945121857730555e-06
in O 0 8.273579510387208e-08
the O 0 1.283198116652784e-07
group O 0 4.214384716760833e-06
of O 0 2.9671342716142135e-08
CD B-Disease 0 5.227379369898699e-05
families O 0 1.019423280013143e-06
with O 0 4.702586738858372e-05
breast B-Disease 1 0.999527096748352
disease I-Disease 0 0.010283203795552254
. O 0 1.0691654097172432e-05

A O 0 0.00012078513100277632
correlation O 0 5.84997033001855e-05
was O 0 4.981514211976901e-05
observed O 0 1.57771785325167e-06
between O 0 1.321694327316436e-07
the O 0 4.089350511549128e-07
presence O 0 6.359134090416774e-07
/ O 0 3.8528640288859606e-05
absence O 0 2.455575724980008e-07
of O 0 3.503989276509856e-08
a O 0 8.545937816961668e-06
PTEN O 0 0.010943927802145481
mutation O 0 1.0633379133651033e-05
and O 0 8.465871701446304e-07
the O 0 2.3009597782674973e-07
type O 0 6.131285772426054e-06
of O 0 6.017337454977678e-06
breast O 1 0.9257647395133972
involvement O 0 0.00010602843394735828
( O 0 3.296825525467284e-06
unaffected O 0 5.8183857618132606e-05
versus O 0 0.0004806328797712922
benign O 0 0.04835764691233635
versus O 0 0.02714223600924015
malignant O 1 0.9736734628677368
) O 0 8.536619134247303e-06
. O 0 8.452660949842539e-06

Specifically O 0 1.769523078110069e-05
and O 0 2.202578116339282e-06
more O 0 1.0655631399458798e-07
directly O 0 3.973980255977949e-07
, O 0 7.77247009864368e-07
an O 0 1.1082358923886204e-06
association O 0 1.066101276592235e-06
was O 0 1.2055053957737982e-05
also O 0 2.3077027435647324e-06
observed O 0 3.9236013549270865e-07
between O 0 3.300797146721379e-08
the O 0 1.0591397625603349e-07
presence O 0 7.205726149095426e-08
of O 0 6.833392518501569e-08
a O 0 1.4296092558652163e-05
PTEN O 1 0.5939661264419556
mutation O 0 0.0007770871161483228
and O 0 0.004533682018518448
malignant B-Disease 1 0.9999984502792358
breast I-Disease 1 0.9999969005584717
disease I-Disease 1 0.8697074055671692
. O 0 2.4252549337688833e-05

Secondly O 0 0.005828540772199631
, O 0 1.0323205060558394e-05
there O 0 3.687837306642905e-07
appeared O 0 2.173937900806777e-06
to O 0 1.2382162140056607e-07
be O 0 9.897173924855451e-08
an O 0 3.313786010039621e-07
interdependent O 0 0.00013171276077628136
association O 0 9.562688774167327e-07
between O 0 3.033668178886728e-07
mutations O 0 4.8734814299677964e-06
upstream O 0 1.3706605841434794e-06
and O 0 4.250645702086331e-07
within O 0 4.242286877342849e-08
the O 0 1.0083623180889845e-07
PTPase O 0 6.663674867013469e-06
core O 0 4.227249519317411e-06
motif O 0 3.6160811305308016e-06
, O 0 6.501468163833124e-08
the O 0 1.945070238207336e-08
core O 0 7.909699775154877e-07
motif O 0 6.210124752215052e-07
containing O 0 1.0968219754659003e-07
the O 0 3.208885601679867e-08
majority O 0 6.941691310657916e-08
of O 0 7.939856772054554e-08
missense O 0 5.015850183553994e-05
mutations O 0 1.2609639270522166e-05
, O 0 3.7519473039537843e-07
and O 0 3.340767307236092e-07
the O 0 2.3378856894851197e-07
involvement O 0 1.41275302212307e-06
of O 0 4.6753264371091063e-08
all O 0 1.0576378173254852e-07
major O 0 3.223392468498787e-06
organ O 0 0.002162669552490115
systems O 0 0.00011105335579486564
( O 0 6.186964469634404e-07
central O 0 1.5544210327789187e-06
nervous O 0 8.181538760254625e-06
system O 0 1.76096432369377e-06
, O 0 1.0178312550124247e-05
thyroid O 0 0.3645719289779663
, O 0 6.713275797665119e-05
breast O 1 0.8006529808044434
, O 0 0.0002472071791999042
skin O 1 0.9995456337928772
and O 1 0.6785253882408142
gastrointestinal O 1 0.9952358603477478
tract O 0 0.4493847191333771
) O 0 2.066362321784254e-05
. O 0 1.645036718400661e-05

However O 0 3.61441052518785e-05
, O 0 1.9473666270641843e-06
these O 0 5.220192278443392e-08
observations O 0 9.666242704042816e-07
would O 0 3.2613777989354276e-07
need O 0 6.606017421972865e-08
to O 0 1.848368924584065e-07
be O 0 2.715882487791532e-07
confirmed O 0 1.800731297407765e-06
by O 0 2.3870262211289628e-08
studying O 0 4.220769156404458e-08
a O 0 1.4896008337927924e-07
larger O 0 2.2261419019287132e-07
number O 0 1.4847587692656816e-07
of O 0 1.0640196279609881e-07
CD B-Disease 0 0.00010804729390656576
families O 0 2.511366346880095e-06
. O 0 4.053445081808604e-06

Molecular O 0 0.42648234963417053
defects O 1 0.9992368221282959
leading O 0 9.376600792165846e-05
to O 0 2.0769259663211415e-06
human O 0 7.189814255070814e-07
complement B-Disease 0 1.0275589374941774e-05
component I-Disease 0 0.02542092278599739
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
in O 0 4.663944764615735e-06
an O 0 1.2003794154225034e-06
African O 0 1.3699221881324775e-06
- O 0 5.3253534133546054e-05
American O 0 8.912795237847604e-06
family O 0 1.553257789055351e-05
. O 0 8.854864063323475e-06

Complement B-Disease 0 0.001995268976315856
component I-Disease 1 0.6049280166625977
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.873749564168975e-05
C6D B-Disease 0 0.12702009081840515
) O 0 1.7758387912181206e-05
was O 0 0.0003338849055580795
diagnosed O 0 0.009386863559484482
in O 0 1.7414086528333428e-07
a O 0 8.667906286063953e-07
16 O 0 6.338938419503393e-06
- O 0 5.827764471177943e-05
year O 0 3.969839781348128e-06
- O 0 8.891808647604194e-06
old O 0 7.121312592062168e-06
African O 0 2.3379838864912017e-07
- O 0 6.840864898549626e-06
American O 0 1.3179854931877344e-06
male O 0 2.297833589182119e-06
with O 0 2.626605419209227e-05
meningococcal B-Disease 1 0.9999970197677612
meningitis I-Disease 1 0.9999797344207764
. O 0 6.446802581194788e-05

The O 0 0.00010832334373844787
patients O 0 0.0002858586667571217
father O 0 2.9106997317285277e-05
and O 0 2.7991047772957245e-06
two O 0 7.270553851412842e-06
brothers O 0 0.0048515754751861095
also O 0 9.622476682125125e-06
had O 0 1.684612470853608e-05
C6D B-Disease 0 0.0009723887778818607
, O 0 1.2299173022256582e-06
but O 0 1.3473511728534504e-07
gave O 0 8.53753590490669e-07
no O 0 1.5647609075131186e-07
history O 0 2.3156979978011805e-07
of O 0 3.637480176621466e-06
meningitis B-Disease 1 0.9995269775390625
or O 0 4.905993137072073e-06
other O 0 4.841775989916641e-06
neisserial B-Disease 0 0.32202303409576416
infection I-Disease 0 0.0033574607223272324
. O 0 9.91538672678871e-06

By O 0 6.523007868963759e-06
using O 0 3.105031282757409e-06
exon O 0 5.109713310957886e-05
- O 0 3.8429345295298845e-05
specific O 0 6.717615406159894e-07
polymerase O 0 7.337177976296516e-06
chain O 0 2.998064701387193e-05
reaction O 0 1.6645851701468928e-06
( O 0 1.572722965192952e-07
PCR O 0 3.82247935704072e-06
) O 0 1.8667213907974656e-07
/ O 0 1.2785089893441182e-06
single O 0 6.76160368584533e-07
- O 0 2.1958179786452092e-05
strand O 0 0.00015717916539870203
conformation O 0 4.665626420319313e-06
polymorphism O 0 1.2084196896466892e-06
as O 0 6.905165150783432e-08
a O 0 6.735770341492753e-08
screening O 0 2.2557321699423483e-07
step O 0 1.488193674958893e-07
and O 0 6.830942567148668e-08
nucleotide O 0 2.1278329143115116e-07
sequencing O 0 2.779805186037265e-07
of O 0 3.384982250054236e-08
target O 0 2.4565529201936442e-06
exons O 0 1.3937083167547826e-05
, O 0 5.564469347518752e-07
we O 0 6.714400058172032e-08
determined O 0 1.709877892608347e-07
that O 0 2.617787764336299e-08
the O 0 8.722489042156667e-08
proband O 0 4.66317796963267e-05
was O 0 2.940659442174365e-06
a O 0 2.3301885221371776e-07
compound O 0 3.505311269691447e-06
heterozygote O 0 3.820897745754337e-06
for O 0 2.4335912485184963e-07
two O 0 1.9047973864871892e-06
C6 O 1 0.5359869003295898
gene O 0 0.00022655940847471356
mutations O 0 0.00022574455942958593
. O 0 7.996139174792916e-06

The O 0 8.452806468994822e-06
first O 0 3.267512738602818e-06
, O 0 5.862428338332393e-07
1195delC O 0 4.932386673317524e-06
located O 0 9.074129252439889e-07
in O 0 3.4765230338962283e-07
exon O 0 1.407934269082034e-05
7 O 0 1.8542124962550588e-05
, O 0 4.087626734872174e-07
is O 0 5.0355826175518814e-08
a O 0 4.6325277480718796e-07
novel O 0 2.522698878237861e-06
mutation O 0 2.824732519002282e-06
, O 0 1.4978131446241605e-07
while O 0 1.2362232837404008e-07
the O 0 1.0032918851266004e-07
second O 0 9.009740097098984e-06
, O 0 5.973210477350221e-07
1936delG O 0 1.7600577848497778e-06
in O 0 1.3370853935157356e-07
exon O 0 4.316572358220583e-06
12 O 0 2.9605257623188663e-06
, O 0 4.513754845447693e-07
has O 0 8.859000786287652e-07
been O 0 1.2088288485756493e-06
described O 0 6.025128641340416e-06
before O 0 9.063966217581765e-07
to O 0 8.887764693099598e-07
cause O 0 2.72253100774833e-06
C6D B-Disease 0 0.00021836986707057804
in O 0 5.217395369072619e-07
an O 0 6.202761824170011e-07
unrelated O 0 2.1864129848836455e-06
African O 0 7.477036092495837e-07
- O 0 3.2593918149359524e-05
American O 0 3.650017788459081e-06
individual O 0 8.49404727887304e-07
. O 0 5.612672794086393e-06

Both O 0 5.738825348089449e-05
mutations O 0 0.0004640400584321469
result O 0 1.4700701285619289e-05
in O 0 1.3433560525299981e-05
premature O 0 0.0012538202572613955
termination O 0 0.00010438339813845232
codons O 0 6.878373096697032e-05
and O 0 2.3133407012210228e-05
C6 O 0 0.37279295921325684
null O 0 0.0028972544241696596
alleles O 0 0.00013459715410135686
. O 0 2.4985474738059565e-05

Allele O 0 0.00045533134834840894
- O 0 0.0001853504654718563
specific O 0 1.516596626061073e-06
PCR O 0 3.3416636142646894e-05
indicated O 0 8.389154572796542e-06
that O 0 5.28260279963888e-08
the O 0 5.668367464295443e-08
probands O 0 2.1542926333495416e-05
two O 0 2.364569581914111e-06
brothers O 0 0.00028265159926377237
also O 0 9.905084880301729e-06
inherited O 0 1.2571913430292625e-05
the O 0 2.615986716136831e-07
1195delC O 0 1.1946387530770153e-05
mutation O 0 9.445251976103464e-07
from O 0 4.932396180379328e-08
their O 0 3.372850585492415e-07
heterozygous O 0 2.1575572191068204e-06
mother O 0 9.28844565351028e-06
and O 0 2.0418509905084647e-07
the O 0 1.5211928428016108e-07
1936delG O 0 8.171205990947783e-06
mutation O 0 1.4619924968428677e-06
from O 0 7.208983987538886e-08
their O 0 1.1212662229809212e-06
homozygous O 0 2.18826717173215e-05
father O 0 2.2509351765620522e-05
. O 0 1.2916763125758735e-06
. O 0 4.262143193045631e-06

PAX6 O 1 0.8365675806999207
mutations O 0 0.1439611166715622
reviewed O 0 0.000977526418864727
. O 0 0.00011281803745077923

Mutations O 0 0.0027332024183124304
in O 0 1.7646494598011486e-05
PAX6 O 0 0.0016862144693732262
are O 0 1.6314303366016247e-06
responsible O 0 3.856135208479827e-06
for O 0 1.2051062867612927e-06
human O 0 2.493208967280225e-06
aniridia B-Disease 1 0.9999947547912598
and O 0 4.8250669351546094e-05
have O 0 9.786662076294306e-07
also O 0 3.302036475361092e-06
been O 0 8.069897603490972e-07
found O 0 1.540998255222803e-06
in O 0 2.701060793697252e-06
patients O 0 6.879968623252353e-06
with O 0 1.1680241186695639e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999995231628418
, O 0 8.921745757106692e-05
with O 0 0.034315332770347595
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999994039535522
, O 0 4.263510345481336e-05
with O 0 2.509498517611064e-05
autosomal B-Disease 1 0.9469529986381531
dominant I-Disease 0 0.4405806362628937
keratitis I-Disease 1 0.996588945388794
, O 0 6.9608490775863174e-06
and O 0 1.5165878721745685e-06
with O 0 8.009496013983153e-06
isolated B-Disease 0 0.2080642729997635
foveal I-Disease 1 0.9999996423721313
hypoplasia I-Disease 1 0.9999996423721313
. O 0 0.0002446971193421632

No O 0 1.0724536878115032e-05
locus O 0 1.1860093763971236e-05
other O 0 4.780086442224274e-07
than O 0 5.47536956219119e-07
chromosome O 0 6.782404670957476e-05
11p13 O 0 1.8989290765603073e-05
has O 0 5.69215399082168e-06
been O 0 1.433545321560814e-06
implicated O 0 8.959189472079743e-06
in O 0 7.399866717605619e-06
aniridia B-Disease 1 0.9999959468841553
, O 0 1.0499120435270015e-05
and O 0 1.6218619975916226e-06
PAX6 O 0 3.3932432415895164e-05
is O 0 7.91134425526252e-07
clearly O 0 2.733825965606229e-07
the O 0 4.9314557770685497e-08
major O 0 4.004010634162114e-07
, O 0 3.069934564337018e-07
if O 0 5.601453167969339e-08
not O 0 2.4518495678194085e-08
only O 0 3.6553988280729754e-08
, O 0 3.7374337580331485e-07
gene O 0 4.881640506937401e-06
responsible O 0 9.634027264837641e-06
. O 0 7.167986495915102e-06

Twenty O 0 6.155732262413949e-05
- O 0 5.018625233788043e-05
eight O 0 3.0375729238585336e-06
percent O 0 1.2108249393349979e-05
of O 0 1.7202016522332997e-07
identified O 0 7.115488642739365e-06
PAX6 O 0 0.00017260480672121048
mutations O 0 4.691031062975526e-05
are O 0 4.470388716981688e-07
C O 0 0.00010066290997201577
- O 0 0.008996492251753807
T O 0 0.009837061166763306
changes O 0 2.8794300988010946e-07
at O 0 8.259418677880603e-07
CpG O 0 8.695429642102681e-06
dinucleotides O 0 3.102655318798497e-05
, O 0 2.8975503596484486e-07
20 O 0 7.66630208204333e-08
% O 0 3.477636312254617e-08
are O 0 1.3388367747779739e-08
splicing O 0 4.157467628829181e-06
errors O 0 9.604973456589505e-06
, O 0 2.391848568095156e-07
and O 0 9.390834776468182e-08
more O 0 1.6730211882531876e-08
than O 0 4.627763416920061e-08
30 O 0 2.3682451910644886e-07
% O 0 1.5253068852416618e-07
are O 0 3.2680713246691084e-08
deletion O 0 2.9373520646913676e-06
or O 0 5.731782835027843e-07
insertion O 0 1.854530637501739e-05
events O 0 3.736261533049401e-06
. O 0 8.416079253947828e-06

There O 0 8.584558599977754e-06
is O 0 4.7233604050234135e-07
a O 0 4.892378910881234e-07
noticeably O 0 1.4293992535385769e-05
elevated O 0 1.1604353858274408e-05
level O 0 2.7688409431902983e-07
of O 0 5.329317787072796e-08
mutation O 0 8.522396797161491e-07
in O 0 8.227817005490579e-08
the O 0 8.95743070827848e-08
paired O 0 2.6029888431367e-06
domain O 0 6.257267841647263e-07
compared O 0 6.985587219787703e-07
with O 0 4.847098722393639e-08
the O 0 2.532941891786322e-07
rest O 0 2.0563626890179876e-07
of O 0 5.3661704413343614e-08
the O 0 8.95116102128668e-07
gene O 0 1.6668293028487824e-05
. O 0 4.7140051719907206e-06

Increased O 0 9.184356167679653e-05
mutation O 0 7.355997513514012e-05
in O 0 1.3888516150473151e-06
the O 0 4.1507308878863114e-07
homeodomain O 0 6.141694757388905e-05
is O 0 1.760390091476438e-06
accounted O 0 1.8390902596365777e-06
for O 0 8.965567133145669e-08
by O 0 6.744512148770809e-08
the O 0 6.035465389686578e-07
hypermutable O 0 0.00033849308965727687
CpG O 0 7.939284841995686e-05
dinucleotide O 0 2.764076998573728e-05
in O 0 4.918708214063372e-07
codon O 0 8.519703442289028e-06
240 O 0 3.6464480217546225e-06
. O 0 4.503316176851513e-06

Very O 0 1.1079338037234265e-05
nearly O 0 2.327839411009336e-06
all O 0 2.209879994552466e-07
mutations O 0 6.1642108448722865e-06
appear O 0 2.095466243190458e-06
to O 0 2.7143337320012506e-06
cause O 0 1.0610101526253857e-05
loss O 0 7.645735422556754e-06
of O 0 6.252567175124568e-08
function O 0 1.1858545434506595e-07
of O 0 8.821066188602344e-08
the O 0 5.255638484413794e-07
mutant O 0 4.2700276026153006e-06
allele O 0 3.494729980957345e-06
, O 0 1.693635738320154e-07
and O 0 5.707575567726053e-08
more O 0 1.6183372864020384e-08
than O 0 2.3994054743070592e-08
80 O 0 8.148355590265055e-08
% O 0 6.893413484476696e-08
of O 0 5.930480995175458e-08
exonic O 0 1.8177481251768768e-05
substitutions O 0 2.185443690905231e-06
result O 0 9.142133308159828e-07
in O 0 5.959219038231822e-07
nonsense O 0 3.6782585084438324e-05
codons O 0 4.22283228544984e-05
. O 0 7.590751465613721e-06

In O 0 1.7808486518333666e-05
a O 0 2.309499450348085e-06
gene O 0 1.474105374654755e-06
with O 0 1.449471227488175e-07
such O 0 7.962696457752827e-08
extraordinarily O 0 8.09341963758925e-06
high O 0 1.4898282643116545e-06
sequence O 0 3.510606347845169e-07
conservation O 0 1.967300846672515e-07
throughout O 0 3.3325854076338146e-08
evolution O 0 1.6343612685432163e-07
, O 0 6.548410880213851e-08
there O 0 1.923575965179225e-08
are O 0 6.210906633441482e-08
presumed O 0 6.187818507896736e-05
undiscovered O 0 0.00020674332336056978
missense O 0 8.745627565076575e-05
mutations O 0 2.902531014115084e-05
, O 0 3.955102556574275e-07
these O 0 2.381214514457497e-08
are O 0 4.006660958566499e-08
hypothesized O 0 1.8746313799056225e-06
to O 0 3.4494684086894267e-07
exist O 0 1.7585833234079473e-07
in O 0 1.5291432475805777e-07
as O 0 1.2006656788798864e-06
- O 0 0.0006336327642202377
yet O 0 6.439627213694621e-06
unidentified O 0 0.0001620456314412877
phenotypes O 0 2.911035880970303e-05
. O 0 1.5563507531624055e-06
. O 0 3.818100140051683e-06

Genetic O 0 0.006084591615945101
heterogeneity O 0 0.0010272710351273417
and O 0 2.3200216674013063e-05
penetrance O 0 0.00023868888092692941
analysis O 0 3.0151361443131464e-06
of O 0 1.558797322331884e-07
the O 0 1.3478887694873265e-06
BRCA1 O 0 0.0010496096219867468
and O 0 1.9387834981898777e-05
BRCA2 O 0 0.0031782023143023252
genes O 0 3.276726056355983e-05
in O 0 0.00014274223940446973
breast B-Disease 1 0.9999055862426758
cancer I-Disease 0 0.20928260684013367
families O 0 4.314028956287075e-06
. O 0 1.1491407349240035e-05

The O 0 0.18123850226402283
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.999998927116394
Linkage O 0 0.009757126681506634
Consortium O 0 0.0008125160820782185
. O 0 6.493385444628075e-05

The O 0 6.021268745826092e-06
contribution O 0 4.06428762289579e-06
of O 0 8.392655104216828e-07
BRCA1 O 0 0.0008557350956834853
and O 0 9.344735008198768e-05
BRCA2 O 0 0.4675489664077759
to O 0 0.08669118583202362
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.08947600424289703
assessed O 0 3.7250170862535015e-05
by O 0 4.272208968814084e-07
linkage O 0 3.3959498978219926e-05
and O 0 1.6446696463390253e-05
mutation O 0 4.944678948959336e-06
analysis O 0 6.709509534630342e-07
in O 0 3.065514135869307e-07
237 O 0 7.859021025069524e-07
families O 0 1.3755327188391675e-07
, O 0 6.694604337553756e-08
each O 0 1.4543695137092527e-08
with O 0 1.3674548426934052e-07
at O 0 1.2993734799238155e-06
least O 0 1.3007679910970182e-07
four O 0 5.546016836888157e-07
cases O 0 3.061362576772808e-07
of O 0 3.2916482268774416e-06
breast B-Disease 1 0.9982238411903381
cancer I-Disease 0 0.08145522326231003
, O 0 2.1399658578502567e-07
collected O 0 3.265859618295508e-07
by O 0 8.99217866390245e-07
the O 0 0.005597526207566261
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999969005584717
Linkage O 0 0.0003187562106177211
Consortium O 0 6.299057713476941e-05
. O 0 8.22447873360943e-06

Families O 0 7.495615136576816e-05
were O 0 6.894510988786351e-06
included O 0 4.7023442562021955e-07
without O 0 1.3066450321730372e-07
regard O 0 1.502859703350623e-07
to O 0 9.030354419792275e-08
the O 0 2.159816574476281e-07
occurrence O 0 6.400112852134043e-06
of O 0 7.524989086959977e-06
ovarian B-Disease 1 0.9056493639945984
or I-Disease 0 6.899352229083888e-06
other I-Disease 0 7.220616225822596e-06
cancers I-Disease 0 0.06963599473237991
. O 0 1.4493245544144884e-05

Overall O 0 0.014417547732591629
, O 0 0.00044406973756849766
disease O 0 0.007410909049212933
was O 0 3.3504897146485746e-05
linked O 0 3.805081723839976e-05
to O 0 5.671098733728286e-06
BRCA1 O 0 0.00041257429984398186
in O 0 1.091122044272197e-06
an O 0 5.273064971333952e-07
estimated O 0 1.6217816209973535e-06
52 O 0 1.3057410797046032e-06
% O 0 6.443003286449311e-08
of O 0 1.6599001284589576e-08
families O 0 6.89816204157978e-08
, O 0 2.756597439201869e-07
to O 0 4.7218293275363976e-07
BRCA2 O 0 4.293508027330972e-05
in O 0 3.6092586697122897e-07
32 O 0 5.090122385809082e-07
% O 0 8.705220722049489e-08
of O 0 2.2872066907098088e-08
families O 0 1.1284799938948709e-07
, O 0 2.680506554497697e-07
and O 0 3.772110517274996e-07
to O 0 2.0630352537409635e-07
neither O 0 4.330610465785867e-07
gene O 0 4.599024805429508e-07
in O 0 1.4754357380297733e-07
16 O 0 1.1155269703522208e-06
% O 0 3.4981005114786967e-07
( O 0 2.6302698685753967e-08
95 O 0 1.790417769598207e-07
% O 0 1.7739419888584962e-07
confidence O 0 7.337846454902319e-07
interval O 0 2.0924089767504483e-06
[ O 0 2.471563902872731e-06
CI O 0 0.0005830647423863411
] O 0 6.804829126849654e-07
6 O 0 9.060907473212865e-07
% O 0 3.2871642474674445e-07
- O 0 2.0551760826492682e-05
28 O 0 9.47737953538308e-06
% O 0 4.7001023517623253e-07
) O 0 9.050563676282763e-08
, O 0 1.5178916612512694e-07
suggesting O 0 8.603980177213089e-07
other O 0 4.287073238629091e-07
predisposition O 0 6.928588845767081e-05
genes O 0 1.583730772836134e-05
. O 0 1.4912789083609823e-05

The O 0 1.2772544323524926e-05
majority O 0 5.874063390365336e-06
( O 0 9.150733717433468e-07
81 O 0 2.4274911538668675e-06
% O 0 3.3470112725808576e-07
) O 0 4.651887763884588e-08
of O 0 8.971947806912794e-08
the O 0 5.40254040970467e-05
breast B-Disease 1 0.9999953508377075
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 7.792643259563192e-07
were O 0 7.223517854981765e-07
due O 0 9.624106951378053e-07
to O 0 8.375720312869817e-07
BRCA1 O 0 0.000368558889022097
, O 0 7.250200155795028e-07
with O 0 1.8725930317486927e-07
most O 0 7.633674954377057e-07
others O 0 3.4423214856360573e-06
( O 0 1.7667042584434967e-07
14 O 0 1.3114755574861192e-06
% O 0 3.7225646565275383e-07
) O 0 1.8847312333036825e-07
due O 0 9.483857184022781e-07
to O 0 5.845406576554524e-06
BRCA2 O 0 0.006056077778339386
. O 0 1.2919255823362619e-05

Conversely O 0 0.0003663952520582825
, O 0 2.071593144137296e-06
the O 0 1.231036321769352e-07
majority O 0 1.0478092349330836e-07
of O 0 3.6650959600592614e-08
families O 0 6.781248629295078e-08
with O 0 2.4244548058049986e-07
male B-Disease 0 8.763059668126516e-06
and I-Disease 0 1.0712648872868158e-05
female I-Disease 0 0.005061334930360317
breast I-Disease 1 0.9968758821487427
cancer I-Disease 0 0.08063989132642746
were O 0 2.09946097129432e-06
due O 0 2.2747001366951736e-06
to O 0 2.994532223965507e-06
BRCA2 O 0 0.002403753576800227
( O 0 6.636200282628124e-07
76 O 0 4.2899141590169165e-06
% O 0 7.560629455838352e-07
) O 0 5.758349743700819e-07
. O 0 3.3169712878589053e-06

The O 0 1.2579946996993385e-05
largest O 0 3.5704906622413546e-05
proportion O 0 8.59492956806207e-06
( O 0 6.751133696525358e-07
67 O 0 5.512324605660979e-06
% O 0 2.78198001524288e-07
) O 0 4.237240602833481e-08
of O 0 2.3026053952435177e-08
families O 0 1.0440527375976671e-07
due O 0 6.594473234144971e-07
to O 0 1.3564522305387072e-07
other O 0 6.370490979179522e-08
genes O 0 6.348602710204432e-07
was O 0 1.7659458535490558e-05
found O 0 1.3307532071848982e-06
in O 0 2.0889228835585527e-07
families O 0 3.159064476676576e-08
with O 0 9.206565465547101e-08
four O 0 8.12429902907752e-07
or O 0 3.442901856942626e-07
five O 0 2.4155050937224587e-07
cases O 0 6.72196023288052e-08
of O 0 3.657540617041377e-07
female O 0 0.010847225785255432
breast B-Disease 1 0.9972871541976929
cancer I-Disease 0 0.014088442549109459
only O 0 1.4503937109111575e-06
. O 0 5.037589744461002e-06

These O 0 1.4320095033326652e-05
estimates O 0 5.714065991924144e-05
were O 0 2.61712693827576e-06
not O 0 3.0082148327892355e-07
substantially O 0 2.798997911668266e-06
affected O 0 2.958263394248206e-07
either O 0 1.2308942132222e-07
by O 0 9.048267912703523e-08
changing O 0 9.072476245819416e-07
the O 0 4.854713324675686e-07
assumed O 0 6.847868462500628e-06
penetrance O 0 1.2731560673273634e-05
model O 0 4.533575065579498e-06
for O 0 7.836127338123333e-07
BRCA1 O 0 7.626658771187067e-05
or O 0 3.732760376351507e-07
by O 0 1.0629870672573816e-07
including O 0 2.1788498827390868e-07
or O 0 2.0223621959303273e-06
excluding O 0 0.00013246267917566001
BRCA1 O 0 0.00865271408110857
mutation O 0 0.00010703932639444247
data O 0 1.6018870155676268e-05
. O 0 1.0875163752643857e-05

Among O 0 1.3762726666755043e-05
those O 0 1.1491673603813979e-06
families O 0 7.394184535769455e-07
with O 0 9.518646947981324e-06
disease O 0 0.0029792743735015392
due O 0 7.545656899310416e-06
to O 0 4.265612005838193e-06
BRCA1 O 0 0.0011678822338581085
that O 0 1.4563564718628186e-06
were O 0 7.962800623317889e-07
tested O 0 7.77275204200123e-07
by O 0 3.073291310329296e-08
one O 0 2.951195199329959e-08
of O 0 1.1855375348091002e-08
the O 0 6.453753087498626e-08
standard O 0 6.819876148256299e-07
screening O 0 1.7236388316632656e-07
methods O 0 3.3588838732612203e-07
, O 0 2.594361774299614e-07
mutations O 0 1.2714590411633253e-06
were O 0 2.685034985461243e-07
detected O 0 9.583632163412403e-07
in O 0 8.202417234315362e-08
the O 0 9.997407346418186e-08
coding O 0 7.0251903707685415e-06
sequence O 0 2.947607242731465e-07
or O 0 9.799421718525991e-08
splice O 0 1.6834081179695204e-05
sites O 0 6.136382353361114e-07
in O 0 1.0508293257771584e-07
an O 0 1.6247230405497248e-07
estimated O 0 1.864116597971588e-06
63 O 0 2.6982338567904662e-06
% O 0 1.323855371992977e-07
( O 0 2.994224246322119e-08
95 O 0 2.616021390622336e-07
% O 0 3.492773430480156e-07
CI O 0 0.00012130210234317929
51 O 0 2.915444611062412e-06
% O 0 4.777091930918687e-07
- O 0 2.164709076168947e-05
77 O 0 5.052696906204801e-06
% O 0 7.675400865991833e-07
) O 0 9.075989737539203e-07
. O 0 4.548342531052185e-06

The O 0 2.01770308194682e-05
estimated O 0 1.541251185699366e-05
sensitivity O 0 4.321766937209759e-06
was O 0 1.6644578863633797e-05
identical O 0 2.3386401153402403e-06
for O 0 2.4035927026488935e-07
direct O 0 5.917452767789655e-07
sequencing O 0 3.7822144349775044e-06
and O 0 5.874404678252176e-07
other O 0 1.9859685096434987e-07
techniques O 0 1.0957427548419219e-05
. O 0 1.2037006854370702e-05

The O 0 2.664290695975069e-05
penetrance O 0 0.0003699017397593707
of O 0 8.252055522461887e-06
BRCA2 O 0 0.0037373744416981936
was O 0 3.7984325899742544e-05
estimated O 0 1.0160903229916585e-06
by O 0 1.230434207855069e-07
maximizing O 0 1.7838201529229991e-06
the O 0 1.3591576362159685e-06
LOD O 0 0.023329569026827812
score O 0 3.599891897465568e-06
in O 0 2.3392913135467097e-06
BRCA2 O 0 0.007221979554742575
- O 0 0.02431468665599823
mutation O 0 1.4749315596418455e-05
families O 0 1.591006792978078e-07
, O 0 8.935402462384445e-08
over O 0 9.930170108418679e-08
all O 0 6.087827131295853e-08
possible O 0 1.131425619860238e-06
penetrance O 0 0.00010235741501674056
functions O 0 2.3444683847628767e-06
. O 0 4.005029040854424e-06

The O 0 1.2808698556909803e-05
estimated O 0 2.1029773051850498e-05
cumulative O 0 2.73134410235798e-05
risk O 0 1.5470810467377305e-05
of O 0 8.038390660658479e-06
breast B-Disease 1 0.9998117089271545
cancer I-Disease 1 0.5608434081077576
reached O 0 1.1258587619522586e-05
28 O 0 5.022632194595644e-06
% O 0 1.6323254214967164e-07
( O 0 1.7283719344618476e-08
95 O 0 1.497134860528604e-07
% O 0 1.906802395978957e-07
CI O 0 0.00011502020788611844
9 O 0 2.717830511755892e-06
% O 0 1.1563489721311271e-07
- O 0 2.9931334211141802e-06
44 O 0 5.337435595720308e-07
% O 0 1.0653517534819912e-07
) O 0 3.939235426742016e-08
by O 0 2.8136074803342126e-08
age O 0 1.486680218931724e-07
50 O 0 1.2881577049483894e-07
years O 0 5.529449822461174e-07
and O 0 3.727808461917448e-07
84 O 0 7.568066848762101e-07
% O 0 1.3893985340018844e-07
( O 0 2.5998248887049158e-08
95 O 0 1.6856546380950022e-07
% O 0 2.704146027099341e-07
CI O 0 6.37756020296365e-05
43 O 0 8.274674314634467e-07
% O 0 1.0977344544471634e-07
- O 0 2.4310913886438357e-06
95 O 0 1.1032755082851509e-06
% O 0 1.3893958339394885e-07
) O 0 5.155046878257963e-08
by O 0 9.008523704778781e-08
age O 0 3.413021829601348e-07
70 O 0 5.682319965671923e-07
years O 0 1.8525738596508745e-06
. O 0 3.0268504360719817e-06

The O 0 0.00018699247448239475
corresponding O 0 0.4288792908191681
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.006504800170660019
were O 0 7.3354781306989025e-06
0 O 0 1.861215969256591e-05
. O 0 9.770949873200152e-06

4 O 0 9.546541696181521e-05
% O 0 1.019527371681761e-05
( O 0 6.710571938128851e-07
95 O 0 1.4901820577506442e-06
% O 0 8.533962159162911e-07
CI O 0 0.00031477512675337493
0 O 0 3.1442398267245153e-06
% O 0 3.5713765100808814e-07
- O 0 7.93893832451431e-06
1 O 0 3.7515503663598793e-06
% O 0 2.816620394696656e-07
) O 0 2.9309443760894283e-08
by O 0 3.3495300755248536e-08
age O 0 1.0505047498554632e-07
50 O 0 8.333032042173727e-08
years O 0 3.8555143078156107e-07
and O 0 4.852195161220152e-07
27 O 0 2.8934077818121295e-06
% O 0 1.1957779122440115e-07
( O 0 1.8927895695242114e-08
95 O 0 1.5693160548835294e-07
% O 0 2.5419996063646977e-07
CI O 0 8.713130227988586e-05
0 O 0 1.9439189600234386e-06
% O 0 2.3588886222114525e-07
- O 0 7.235567409225041e-06
47 O 0 8.711133887118194e-06
% O 0 2.745863412201288e-07
) O 0 4.626924976491864e-08
by O 0 7.884682418080047e-08
age O 0 2.409114188139938e-07
70 O 0 7.514007620557095e-07
years O 0 2.2632189029536676e-06
. O 0 3.010871978403884e-06

The O 0 2.2577307390747592e-05
lifetime O 0 0.00011272780830040574
risk O 0 3.4408938518026844e-05
of O 0 1.0876316082431003e-05
breast B-Disease 1 0.9998408555984497
cancer I-Disease 0 0.2930290997028351
appears O 0 3.100782123510726e-06
similar O 0 2.0333803263383743e-07
to O 0 3.515444007007318e-07
the O 0 9.25609128898941e-07
risk O 0 3.0004212021594867e-06
in O 0 9.729235443955986e-07
BRCA1 O 0 0.00010932047007372603
carriers O 0 1.7369399074596004e-06
, O 0 6.714240043947939e-07
but O 0 2.181939748879813e-07
there O 0 3.0998005939864015e-08
was O 0 1.3245693253338686e-06
some O 0 1.583534370297457e-08
suggestion O 0 1.2494852796862688e-07
of O 0 2.7475234531948445e-08
a O 0 2.7255655368207954e-06
lower O 0 0.00047322100726887584
risk O 0 1.0999599908245727e-05
in O 0 1.6164821090569603e-06
BRCA2 O 0 0.0001721714943414554
carriers O 0 1.0110496759807575e-06
< O 0 8.627101237834722e-07
50 O 0 2.2873513216836727e-07
years O 0 1.8354249675667234e-07
of O 0 1.3718698710363242e-07
age O 0 2.944240122815245e-06
. O 0 6.754824426025152e-06

Eye B-Disease 1 0.9917932152748108
movement I-Disease 0 0.00887070968747139
abnormalities I-Disease 1 0.9866466522216797
correlate O 0 0.00014739984180778265
with O 0 1.4098960491537582e-05
genotype O 0 0.21454057097434998
in O 0 0.0002508404722902924
autosomal O 1 0.9995342493057251
dominant O 1 0.994675874710083
cerebellar B-Disease 1 0.9999797344207764
ataxia I-Disease 1 0.9999971389770508
type I-Disease 0 0.06894943863153458
I I-Disease 0 0.00135785061866045
. O 0 3.690165249281563e-05

We O 0 4.299103966332041e-05
compared O 0 2.680264151422307e-05
horizontal O 0 0.0002566888288129121
eye O 1 0.5481741428375244
movements O 0 0.00010087932605529204
( O 0 2.1516641481866827e-06
visually O 0 4.78982474305667e-06
guided O 0 1.7204612959176302e-05
saccades O 0 0.00042442980338819325
, O 0 5.27462634636322e-06
antisaccades O 0 3.736544385901652e-05
, O 0 4.976973286829889e-07
and O 0 2.991741325786279e-07
smooth O 0 1.0060193744720891e-05
pursuit O 0 4.073278250871226e-05
) O 0 6.277506372498465e-07
in O 0 3.351601378653868e-07
control O 0 3.7898037135164486e-06
subjects O 0 2.460857785990811e-06
( O 0 5.854756750522938e-07
n O 0 8.895742212189361e-05
= O 0 5.0774411647580564e-05
14 O 0 7.427270702464739e-06
) O 0 4.878834261035081e-07
and O 0 1.3645292256114772e-06
patients O 0 5.814188739350357e-07
with O 0 3.877926246786956e-08
three O 0 3.7381255424406845e-07
forms O 0 1.5270286439772462e-06
of O 0 3.4804945698851952e-06
autosomal O 0 0.4360758066177368
dominant O 0 0.004123964812606573
cerebellar B-Disease 0 0.08496349304914474
ataxias I-Disease 0 0.026679672300815582
type I-Disease 0 7.14841517037712e-05
I I-Disease 0 6.87561187078245e-05
spinocerebellar B-Disease 0 0.10715248435735703
ataxias I-Disease 0 0.0011685325298458338
1 I-Disease 0 1.786199391062837e-05
and I-Disease 0 3.1076915547600947e-06
2 I-Disease 0 1.852415152825415e-05
( O 0 4.6688390398230695e-07
SCA1 B-Disease 0 6.867585034342483e-05
, O 0 1.2879344239991042e-06
n O 0 1.5037218872748781e-05
= O 0 9.04369335330557e-06
11 O 0 3.4461088489479152e-06
; O 0 7.56231713694433e-07
SCA2 B-Disease 0 7.856282900320366e-05
, O 0 5.947772478975821e-07
n O 0 1.0929040399787482e-05
= O 0 7.814248419890646e-06
10 O 0 4.968489406564913e-07
) O 0 1.9914932636311278e-07
and O 0 3.5573887089412892e-06
SCA3 B-Disease 1 0.9999957084655762
/ O 0 0.004077911842614412
Machado B-Disease 0 9.319043601863086e-05
- I-Disease 0 0.08139151334762573
Joseph I-Disease 0 0.26533469557762146
disease I-Disease 0 0.08979673683643341
( O 0 9.268775102100335e-06
MJD B-Disease 1 0.999998927116394
) O 0 8.732876267458778e-06
( O 0 4.470508088161296e-07
n O 0 3.2210515200858936e-05
= O 0 3.436038241488859e-05
16 O 0 6.7166047301725484e-06
) O 0 9.713612598716281e-07
. O 0 3.4978475014213473e-06

In O 0 3.92929396184627e-05
SCA1 B-Disease 0 0.0007856146548874676
, O 0 4.581096163747134e-06
saccade O 0 2.6160339984926395e-05
amplitude O 0 2.916690618803841e-06
was O 0 6.146354280645028e-06
significantly O 0 2.9510852073144633e-06
increased O 0 9.778638059287914e-07
, O 0 4.952967174176592e-07
resulting O 0 1.391691512253601e-06
in O 0 3.4756187687889906e-06
hypermetria B-Disease 0 0.0011755279265344143
. O 0 1.3227477211330552e-05

The O 0 1.2624343071365729e-05
smooth O 0 9.023270104080439e-05
pursuit O 0 0.0001599700190126896
gain O 0 0.0002833658072631806
was O 0 0.00010507286788197234
decreased O 0 0.0001110206576413475
. O 0 1.2318881090322975e-05

In O 0 5.557413169299252e-05
SCA2 B-Disease 0 0.0011216357816010714
, O 0 5.755013262387365e-06
saccade O 0 0.0001185024157166481
velocity O 0 7.739354623481631e-05
was O 0 5.897563823964447e-05
markedly O 0 0.0001842896017478779
decreased O 0 0.0001404657814418897
. O 0 1.3681133168574888e-05

The O 0 1.4495622963295318e-05
percentage O 0 3.385828676982783e-05
of O 0 1.2374244988677674e-06
errors O 0 2.6636153052095324e-05
in O 0 1.8295806967216777e-06
antisaccades O 0 0.0016304835444316268
was O 0 6.548993405885994e-05
greatly O 0 9.956719395631808e-07
increased O 0 1.0108470860359375e-06
and O 0 1.066362642632157e-06
was O 0 1.3537693121179473e-05
significantly O 0 2.8108881906518945e-06
correlated O 0 2.5317708605143707e-06
with O 0 1.1277854810032295e-06
age O 0 9.42195674724644e-06
at O 0 5.785432949778624e-05
disease O 0 0.005107381381094456
onset O 0 0.0005041165859438479
. O 0 2.3155525923357345e-05

In O 0 1.7756119632394984e-05
addition O 0 1.9192573290638393e-06
, O 0 3.3589833492442267e-07
a O 0 3.0073715606704354e-07
correlation O 0 1.754821823851671e-06
between O 0 5.154633981874213e-07
smooth O 0 4.9631449655862525e-05
pursuit O 0 6.397575634764507e-05
gain O 0 5.5770458857296035e-05
and O 0 8.709420171726379e-07
the O 0 6.733984747597788e-08
number O 0 1.5969794731063303e-07
of O 0 2.3750327216021105e-07
trinucleotide O 0 0.00013557184138335288
repeats O 0 9.187737305182964e-05
was O 0 2.325608511455357e-05
found O 0 6.542059054481797e-06
. O 0 4.639660801331047e-06

In O 0 0.00017050054157152772
SCA3 B-Disease 1 0.9999363422393799
, O 0 9.251035953639075e-05
gaze B-Disease 0 0.000552986515685916
- I-Disease 0 0.003927337005734444
evoked I-Disease 0 7.05389684299007e-05
nystagmus I-Disease 0 0.0007863276987336576
was O 0 2.3562928618048318e-05
often O 0 2.441722983803629e-07
present O 0 1.6881982389804762e-07
as O 0 3.5194491943002504e-07
was O 0 4.729598913399968e-06
saccade O 0 1.9401910321903415e-05
hypometria O 0 5.534940282814205e-05
and O 0 1.6592375686741434e-06
smooth O 0 1.3696446330868639e-05
pursuit O 0 3.753382770810276e-05
gain O 0 6.450344517361373e-05
was O 0 4.7076711780391634e-05
markedly O 0 0.0001430628908565268
decreased O 0 0.00013567801215685904
. O 0 1.4885692507959902e-05

Three O 0 1.406042338203406e-05
major O 0 8.269552381534595e-06
criteria O 0 3.790396476688329e-06
, O 0 7.943610853544669e-07
saccade O 0 1.8149921743315645e-05
amplitude O 0 2.358605570407235e-06
, O 0 4.3472738298078184e-07
saccade O 0 9.119265996559989e-06
velocity O 0 5.053439053881448e-06
, O 0 2.4363546913264145e-07
and O 0 1.0620608748013183e-07
presence O 0 6.815012909555662e-08
of O 0 8.16970668893191e-08
gaze B-Disease 0 6.11562209087424e-05
- I-Disease 0 0.0010952657321467996
evoked I-Disease 0 1.1864242878800724e-05
nystagmus I-Disease 0 4.653067298932001e-05
, O 0 1.8739275731149974e-07
permitted O 0 3.712871077254931e-08
the O 0 9.964815461671606e-08
correct O 0 7.000338882789947e-06
assignment O 0 2.804304415349179e-07
of O 0 2.1596182619987303e-08
90 O 0 6.80680329878669e-08
% O 0 4.056806091057297e-08
of O 0 9.34976096544915e-09
the O 0 1.598096304178398e-07
SCA1 B-Disease 0 0.00011772640573326498
, O 0 1.9781522553330433e-07
90 O 0 3.589164521144994e-08
% O 0 1.929028492497764e-08
of O 0 8.140056628747061e-09
the O 0 2.710278295126045e-07
SCA2 B-Disease 0 0.00017581899010110646
, O 0 4.928827479488973e-07
and O 0 1.716404796070492e-07
93 O 0 2.6043170464618015e-07
% O 0 3.771175016709094e-08
of O 0 2.5377790535685563e-08
the O 0 9.843704447121127e-07
patients O 0 1.4459218391493778e-06
with O 0 3.3187512826771126e-07
SCA3 B-Disease 1 0.9999889135360718
to O 0 2.010707930821809e-06
their O 0 1.5050670754135353e-06
genetically O 0 8.820168295642361e-05
confirmed O 0 0.0002328568371012807
patient O 0 8.983273801277392e-06
group O 0 7.3664637056936044e-06
and O 0 2.605778036013362e-06
, O 0 1.2513318097262527e-06
therefore O 0 2.2789508591358754e-07
, O 0 5.442784072329232e-07
may O 0 1.2890440075352672e-06
help O 0 1.701023677469493e-07
orient O 0 0.016639219596982002
diagnoses O 0 0.0017155804671347141
of O 0 5.054809548710182e-07
SCA1 B-Disease 0 0.005985170137137175
, O 0 3.4290060284547508e-06
SCA2 B-Disease 0 0.00014762095815967768
, O 0 1.1762373333112919e-06
and O 0 1.4721974821441108e-06
SCA3 B-Disease 1 0.9999082088470459
at O 0 8.582798727729823e-06
early O 0 6.688007943012053e-06
clinical O 0 2.363428620810737e-06
stages O 0 1.5041200640553143e-06
of O 0 3.4233687529194867e-07
the O 0 4.074832031619735e-05
diseases O 0 0.006580756511539221
. O 0 1.957421090992284e-06
. O 0 7.806025678291917e-06

Genetic O 0 0.0005212870892137289
basis O 0 1.447377053409582e-05
and O 0 1.0229477993561886e-05
molecular O 0 0.0001903850061353296
mechanism O 0 0.0001100264853448607
for O 0 0.011715490370988846
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999985694885254
fibrillation I-Disease 1 0.9999998807907104
. O 0 0.0030212667770683765

Ventricular B-Disease 1 0.9998677968978882
fibrillation I-Disease 1 0.9999802112579346
causes O 0 0.003156426828354597
more O 0 1.7146850268545677e-06
than O 0 3.4758400602186157e-07
300 O 0 4.6798052721896966e-07
, O 0 4.280234975340136e-07
000 O 0 6.837837531747937e-07
sudden O 0 8.322251233039424e-06
deaths O 0 4.922922016703524e-06
each O 0 6.62220358549348e-08
year O 0 7.348854751398903e-07
in O 0 2.016017930372982e-07
the O 0 6.41688075120328e-07
USA O 0 0.00016383937327191234
alone O 0 6.059507541067433e-06
. O 0 3.1947777188179316e-06

In O 0 1.1041069228667766e-05
approximately O 0 1.8944203930004733e-06
5 O 0 2.820189365593251e-06
- O 0 2.668949673534371e-05
12 O 0 1.4733773241459858e-06
% O 0 5.656443846646653e-08
of O 0 1.1350841155888247e-08
these O 0 3.842167117795725e-08
cases O 0 1.5204022929538041e-07
, O 0 1.547594621342796e-07
there O 0 3.994071207102934e-08
are O 0 3.433778772432561e-08
no O 0 9.833627245825483e-07
demonstrable O 0 0.005055829882621765
cardiac O 0 0.473173052072525
or O 0 8.202952813007869e-06
non O 0 9.68889580690302e-05
- O 1 0.9944692850112915
cardiac O 1 0.9975019097328186
causes O 0 1.1797485058195889e-05
to O 0 9.9017870525131e-07
account O 0 1.1560990742509603e-06
for O 0 4.088422258519131e-07
the O 0 9.689242688182276e-07
episode O 0 4.376006836537272e-05
, O 0 9.936950391420396e-07
which O 0 3.8383296896427055e-07
is O 0 4.258963883785327e-07
therefore O 0 1.0089584066008683e-06
classified O 0 3.2988777093123645e-05
as O 0 0.005336058791726828
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999991655349731
fibrillation I-Disease 1 1.0
( O 0 0.384591668844223
IVF B-Disease 1 0.9999998807907104
) O 0 3.373484287294559e-05
. O 0 1.6805272025521845e-05

A O 0 4.5622677134815603e-05
distinct O 0 1.204522868647473e-05
group O 0 3.974616265622899e-05
of O 0 4.2326264519942924e-06
IVF B-Disease 1 1.0
patients O 0 0.019733376801013947
has O 0 4.561974492389709e-06
been O 0 1.399956772729638e-06
found O 0 5.496422090800479e-07
to O 0 9.576528015031727e-08
present O 0 4.4178477764944546e-08
with O 0 7.64839569455944e-08
a O 0 5.224473170528654e-06
characteristic O 0 0.00025737081887200475
electrocardiographic O 0 0.03933684155344963
pattern O 0 0.0003767237067222595
. O 0 2.0143923393334262e-05

Because O 0 6.5599642766756006e-06
of O 0 2.101024136891283e-07
the O 0 1.707503685111078e-07
small O 0 1.1214432760198179e-07
size O 0 5.206321134210157e-07
of O 0 4.4593814862992076e-08
most O 0 9.829579283859857e-08
pedigrees O 0 1.711189156594628e-06
and O 0 3.3674348287604516e-07
the O 0 3.2316705755874864e-07
high O 0 1.4721395018568728e-05
incidence O 0 6.891319208079949e-05
of O 0 1.104237639992789e-06
sudden B-Disease 0 0.00018520330195315182
death I-Disease 0 0.00038704974576830864
, O 0 4.0765087305771885e-07
however O 0 2.1998920374244335e-07
, O 0 1.0633947056248871e-07
molecular O 0 4.25882353738416e-06
genetic O 0 1.729713403619826e-05
studies O 0 1.4421951846088632e-06
of O 0 2.5589849883544957e-06
IVF B-Disease 1 1.0
have O 0 9.717183274915442e-06
not O 0 4.626404290775099e-07
yet O 0 3.5738838732868317e-07
been O 0 1.003703118840349e-06
done O 0 1.601429744368943e-06
. O 0 3.907256541424431e-06

Because O 0 0.004023352637887001
IVF B-Disease 1 0.9999994039535522
causes O 1 0.6855729222297668
cardiac O 1 0.999419093132019
rhythm O 1 0.5915298461914062
disturbance O 0 0.003248642897233367
, O 0 9.803263310459442e-06
we O 0 7.465571911779989e-07
investigated O 0 5.546431111724814e-06
whether O 0 7.993904773684335e-07
malfunction O 0 7.017573079792783e-05
of O 0 1.509095852725295e-07
ion O 0 1.2687188245763537e-05
channels O 0 2.837990678017377e-06
could O 0 3.862885478156386e-06
cause O 0 3.023495082743466e-06
the O 0 2.304891950188903e-06
disorder O 0 4.947857451043092e-05
by O 0 8.957550790000823e-08
studying O 0 4.637713288957457e-07
mutations O 0 2.773312417048146e-06
in O 0 2.276774324627695e-07
the O 0 3.6540229757520137e-06
cardiac O 0 0.05858280882239342
sodium O 0 8.080518455244601e-05
channel O 0 9.317132935393602e-05
gene O 0 2.006495196837932e-05
SCN5A O 0 0.0003555546572897583
. O 0 8.08757158665685e-06

We O 0 2.4638267859700136e-05
have O 0 1.4001849422129453e-06
now O 0 4.3841285446433176e-07
identified O 0 7.040335958663491e-07
a O 0 6.218410248948203e-07
missense O 0 7.189159077825025e-05
mutation O 0 9.354362191515975e-06
, O 0 1.613020543800303e-07
a O 0 2.875868005958182e-07
splice O 0 0.0023714967537671328
- O 0 0.02647596038877964
donor O 0 3.818138429778628e-05
mutation O 0 1.5056777556310408e-05
, O 0 3.228839489111124e-07
and O 0 2.9740647278231336e-07
a O 0 2.6280245037924033e-06
frameshift O 0 0.0005662026815116405
mutation O 0 5.991660600557225e-06
in O 0 2.2014366152234288e-07
the O 0 2.3587917041822948e-07
coding O 0 4.8599733418086544e-05
region O 0 4.9050577217713e-06
of O 0 3.2521288062525855e-07
SCN5A O 0 0.0006434089737012982
in O 0 2.967901309602894e-06
three O 0 1.5970548702171072e-05
IVF B-Disease 1 0.9999973773956299
families O 0 6.976332770136651e-06
. O 0 9.288808541896287e-06

We O 0 2.378297176619526e-05
show O 0 3.0129517654131632e-06
that O 0 1.630113217743201e-07
sodium O 0 4.858872557633731e-07
channels O 0 2.1039835473857238e-07
with O 0 4.540436293609673e-08
the O 0 1.84751243637038e-07
missense O 0 3.690531593747437e-05
mutation O 0 1.1460042514954694e-05
recover O 0 2.9147855457267724e-05
from O 0 6.013396500748058e-07
inactivation O 0 5.86449823458679e-05
more O 0 6.685430520292357e-08
rapidly O 0 2.222253954187181e-07
than O 0 3.845048368589232e-08
normal O 0 2.4359667349926895e-07
and O 0 2.482695151684311e-07
that O 0 1.3291217726418836e-07
the O 0 4.1815857798610523e-07
frameshift O 0 0.0008892751066014171
mutation O 0 7.3421269917162135e-06
causes O 0 6.036731292624609e-07
the O 0 9.438871018119244e-08
sodium O 0 3.5807520362141076e-06
channel O 0 4.141219505982008e-06
to O 0 1.2291933160213375e-07
be O 0 8.630772896367489e-08
non O 0 4.903636181552429e-07
- O 0 2.4067581762210466e-05
functional O 0 1.1606877706071828e-05
. O 0 8.183636964531615e-06

Our O 0 4.125931081944145e-05
results O 0 2.8720449336105958e-05
indicate O 0 3.101751872236491e-06
that O 0 7.369537797785597e-07
mutations O 0 7.011068646534113e-06
in O 0 2.4204498458857415e-06
cardiac O 0 0.016947176307439804
ion O 0 0.00010024020593846217
- O 0 0.00016112888988573104
channel O 0 1.774888914951589e-05
genes O 0 1.9494294178912241e-07
contribute O 0 5.626981547379728e-08
to O 0 5.5134112386667766e-08
the O 0 2.724630121520022e-07
risk O 0 1.0165623507418786e-06
of O 0 2.3384140490634309e-07
developing O 0 5.332244836608879e-05
IVF B-Disease 1 0.9999977350234985
. O 0 5.029150543123251e-06
. O 0 5.036331003793748e-06

Molecular O 0 0.00043467068462632596
heterogeneity O 0 0.0006358702667057514
in O 0 2.134387250407599e-05
mucopolysaccharidosis B-Disease 0 0.0021694512106478214
IVA I-Disease 1 0.8091657757759094
in O 0 1.2149358553870115e-05
Australia O 0 3.880704298353521e-06
and O 0 7.495799536627601e-07
Northern O 0 2.596346803329652e-06
Ireland O 0 9.44165549299214e-06
: O 0 2.3813967686692195e-07
nine O 0 4.5617471755576844e-07
novel O 0 2.979963255711482e-06
mutations O 0 3.999605269200401e-06
including O 0 1.3191292680403421e-07
T312S O 0 5.849733952345559e-06
, O 0 2.1631167612667923e-07
a O 0 3.608653003084328e-07
common O 0 1.0182233154409914e-06
allele O 0 5.721548859582981e-06
that O 0 4.353148597147083e-07
confers O 0 8.637509381514974e-06
a O 0 3.9942533476278186e-05
mild O 0 0.0036750936415046453
phenotype O 0 0.004164478275924921
. O 0 3.68143773812335e-05

Mucopolysaccharidosis B-Disease 1 0.8610693216323853
IVA I-Disease 1 0.9998918771743774
( O 0 0.008529325015842915
MPS B-Disease 1 0.9999663829803467
IVA I-Disease 1 0.9999998807907104
) O 0 3.906637357431464e-05
is O 0 1.2315674666751875e-06
an O 0 9.423538358532824e-06
autosomal B-Disease 1 0.9859345555305481
recessive I-Disease 1 0.9990981817245483
lysosomal I-Disease 1 0.9999865293502808
storage I-Disease 1 0.9999939203262329
disorder I-Disease 1 0.9997884631156921
caused O 0 9.18045116122812e-05
by O 0 2.2050771804060787e-06
a O 0 0.0031110914424061775
genetic B-Disease 1 0.9999994039535522
defect I-Disease 1 0.9999834299087524
in O 0 7.887200808909256e-06
N O 0 0.017040302976965904
- O 0 0.0056394850835204124
acetylgalactosamine O 0 0.005268244072794914
- O 0 0.0027534514665603638
6 O 0 0.00019380102457944304
- O 0 0.2024228572845459
sulfate O 0 0.00038319622399285436
sulfatase O 0 0.0001572881592437625
( O 0 8.554382588954468e-07
GALNS O 0 0.00010830578685272485
) O 0 1.6513288301212015e-06
. O 0 3.322442125863745e-06

Previous O 0 0.00012406233872752637
studies O 0 7.092549367371248e-06
of O 0 6.599972266485565e-07
patients O 0 1.1592784176173154e-05
from O 0 1.4384683311163826e-07
a O 0 6.1106679822842125e-06
British O 0 0.0006048756767995656
- O 0 0.04306160286068916
Irish O 0 0.0001143928020610474
population O 0 5.556239557336085e-07
showed O 0 1.9955077732447535e-06
that O 0 7.725132888936059e-08
the O 0 8.467004164458558e-08
I113F O 0 5.3223611757857725e-06
mutation O 0 1.6107053397718119e-06
is O 0 4.700541467173025e-08
the O 0 2.6691441945558836e-08
most O 0 7.59917426762513e-08
common O 0 3.007474731475668e-07
single O 0 1.1971410458500031e-05
mutation O 0 2.0819290512008592e-05
among O 0 6.456895334849833e-06
MPS B-Disease 1 0.9998676776885986
IVA I-Disease 1 1.0
patients O 0 0.0013259192928671837
and O 0 1.395660206071625e-06
produces O 0 2.1550775272771716e-05
a O 0 0.00010774398106150329
severe O 0 0.08706705272197723
clinical O 0 0.0004723559832200408
phenotype O 0 0.006330958101898432
. O 0 5.0407845264999196e-05

We O 0 3.2699554139981046e-05
studied O 0 1.9623439584393054e-05
mutations O 0 1.9256764062447473e-05
in O 0 6.142740858194884e-07
the O 0 3.9793735595594626e-07
GALNS O 0 0.0003526087966747582
gene O 0 5.49631477042567e-06
from O 0 2.143896011830293e-07
23 O 0 5.200860414333874e-06
additional O 0 2.8534734610730084e-06
MPS B-Disease 1 0.9999758005142212
IVA I-Disease 1 1.0
patients O 0 0.011950519867241383
( O 0 1.6749166320551012e-07
15 O 0 2.760946529178909e-07
from O 0 1.266000708710635e-07
Australia O 0 1.915749862746452e-06
, O 0 4.101755450847122e-07
8 O 0 1.1098817367383162e-06
from O 0 6.733097990263559e-08
Northern O 0 2.24086147682101e-06
Ireland O 0 1.7708851373754442e-05
) O 0 3.181704926191742e-07
, O 0 4.246658491524613e-08
with O 0 4.4481176075805706e-08
various O 0 2.4503401618858334e-07
clinical O 0 3.232208837289363e-05
phenotypes O 0 0.00012710277223959565
( O 0 1.2547309779620264e-05
severe O 0 0.0006272858590818942
, O 0 2.3088894067768706e-06
16 O 0 2.7692317416949663e-06
cases O 0 3.0540724083039095e-07
; O 0 1.636374662439266e-07
intermediate O 0 1.4849445051368093e-06
, O 0 6.683632136628148e-07
4 O 0 1.1772848665714264e-05
cases O 0 9.175954005513631e-07
; O 0 1.943473989740596e-06
mild O 0 2.9414530217763968e-05
, O 0 1.4690868965772097e-06
3 O 0 1.594647255842574e-05
cases O 0 2.1161836230021436e-06
) O 0 9.491936907579657e-07
. O 0 3.845646460831631e-06

We O 0 1.3575780030805618e-05
found O 0 2.4833584575389978e-06
two O 0 2.497218076769059e-07
common O 0 1.4923750768502941e-06
mutations O 0 7.495651971112238e-06
that O 0 1.1383508535800502e-07
together O 0 2.464944088842458e-07
accounted O 0 2.2624699340667576e-06
for O 0 8.956679664606781e-08
32 O 0 4.028669877698121e-07
% O 0 5.0554358921317544e-08
of O 0 1.2396701443151414e-08
the O 0 2.1959638729640574e-07
44 O 0 7.311037393264996e-07
unrelated O 0 8.855579949340608e-07
alleles O 0 8.984497981145978e-07
in O 0 7.248388556035934e-07
these O 0 1.3928679436503444e-06
patients O 0 3.467612623353489e-05
. O 0 9.195733582600951e-06

One O 0 1.4424247638089582e-05
is O 0 1.0695932814996922e-06
the O 0 2.6819054710358614e-07
T312S O 0 8.925111615099013e-06
mutation O 0 4.155240276304539e-06
, O 0 2.3347885758084885e-07
a O 0 4.888050852969172e-07
novel O 0 2.9516932045225985e-06
mutation O 0 5.563213562709279e-06
found O 0 1.003505872176902e-06
exclusively O 0 7.222119506877789e-07
in O 0 2.777515419438714e-06
milder O 0 0.0010143985273316503
patients O 0 0.00010824229684658349
. O 0 6.9936122599756345e-06

The O 0 3.63526100954914e-06
other O 0 5.462143235490657e-07
is O 0 2.1675710115687252e-07
the O 0 1.509834248736297e-07
previously O 0 6.985533218539786e-06
described O 0 1.4027796169102658e-05
I113F O 0 5.459057319967542e-06
that O 0 2.727338994645834e-07
produces O 0 9.011459951580036e-06
a O 0 6.223966192919761e-05
severe O 0 0.015161952935159206
phenotype O 0 0.007366525940597057
. O 0 4.4709842768497765e-05

The O 0 7.149390057747951e-06
I113F O 0 2.3213628082885407e-05
and O 0 1.998968627958675e-06
T312S O 0 1.4340252164402045e-05
mutations O 0 2.3821427021175623e-05
accounted O 0 4.54084010925726e-06
for O 0 4.980183234692959e-07
8 O 0 6.990338533796603e-06
( O 0 3.26418444274168e-07
18 O 0 6.871051709822495e-07
% O 0 1.9669444384362578e-07
) O 0 9.558625890804251e-08
and O 0 1.3597060615211376e-06
6 O 0 1.725538277241867e-05
( O 0 2.649924510933488e-07
14 O 0 9.748581533131073e-07
% O 0 1.7745730929163983e-07
) O 0 5.1243336685047325e-08
of O 0 5.217892962150472e-08
44 O 0 1.5127542383197579e-06
unrelated O 0 3.577748202587827e-06
alleles O 0 3.086216793235508e-06
, O 0 1.1412448657210916e-06
respectively O 0 3.117942105745897e-05
. O 0 9.546703040541615e-06

The O 0 1.7207796190632507e-05
relatively O 0 7.4107424552494194e-06
high O 0 1.1987344805675093e-05
residual O 0 3.637730696937069e-05
GALNS O 0 0.00027945489273406565
activity O 0 1.09723589503119e-06
seen O 0 7.078427302076307e-07
when O 0 6.416929210217859e-08
the O 0 6.751745473820847e-08
T312S O 0 8.69330506247934e-07
mutant O 0 1.2758682714775205e-06
cDNA O 0 1.0214309895673068e-06
is O 0 1.5309174727917707e-07
overexpressed O 0 4.099911620869534e-06
in O 0 2.888803862788336e-07
mutant O 0 5.405449428508291e-06
cells O 0 2.9941268167021917e-06
provides O 0 1.7768644511306775e-07
an O 0 1.8628514908414218e-07
explanation O 0 2.841485127191845e-07
for O 0 1.4287708438587288e-07
the O 0 2.105279236275237e-06
mild O 0 0.00040283220005221665
phenotype O 0 0.0007611491600982845
in O 0 6.433022917917697e-06
patients O 0 2.211862693002331e-06
with O 0 1.3403908383224916e-07
this O 0 2.0801510345336283e-06
mutation O 0 4.867343886871822e-05
. O 0 6.497663434856804e-06

The O 0 5.429354587249691e-06
distribution O 0 1.9894253000529716e-06
and O 0 6.352115065055841e-07
relative O 0 2.6506222639000043e-07
frequencies O 0 2.7206212394048634e-07
of O 0 4.016447263666123e-08
the O 0 1.6128544189086824e-07
I113F O 0 2.655794105521636e-06
and O 0 7.018856535978557e-07
T312S O 0 2.627503135954612e-06
mutations O 0 1.6215991536228103e-06
in O 0 8.52275761076271e-08
Australia O 0 7.134338488867797e-07
corresponded O 0 5.323963705450296e-07
to O 0 1.4071738974053005e-07
those O 0 3.733763875857221e-08
observed O 0 4.6668984055031615e-07
in O 0 2.1794443227918237e-07
Northern O 0 1.6326927152476856e-06
Ireland O 0 9.472257261222694e-06
and O 0 6.463188242378237e-07
are O 0 1.3328924630684469e-08
unique O 0 2.5773060130518388e-08
to O 0 7.338882568319605e-08
these O 0 1.135328897561294e-08
two O 0 2.3382088443213433e-07
populations O 0 3.5889667060473585e-07
, O 0 1.8781302912884712e-07
suggesting O 0 3.6838304140474065e-07
that O 0 8.086902880677371e-08
both O 0 2.6078413384311716e-07
mutations O 0 3.3507621992612258e-06
were O 0 6.840264177299105e-07
probably O 0 3.3501856933071394e-07
introduced O 0 5.566719778471452e-07
to O 0 2.9187225436544395e-07
Australia O 0 6.215492476258078e-07
by O 0 4.854630120121328e-08
Irish O 0 1.2467695569284842e-06
migrants O 0 4.339623274063342e-07
during O 0 1.1380154774087714e-07
the O 0 1.5879841441801545e-07
19th O 0 9.821605090110097e-06
century O 0 1.137960407504579e-05
. O 0 1.0801117241499014e-05

Haplotype O 0 0.006166943348944187
analysis O 0 4.329367948230356e-05
using O 0 3.7467200399987632e-06
6 O 0 1.3535717698687222e-05
RFLPs O 0 2.1050158466096036e-05
provides O 0 1.9452397737040883e-07
additional O 0 7.09004837062821e-08
data O 0 3.5366457495911163e-07
that O 0 6.155501353077852e-08
the O 0 7.590801232026934e-08
I113F O 0 5.772376880486263e-06
mutation O 0 1.4935939134375076e-06
originated O 0 3.0889739832673513e-07
from O 0 3.780227331162678e-08
a O 0 5.219709464654443e-07
common O 0 5.885771315661259e-06
ancestor O 0 6.08066693530418e-05
. O 0 2.1807090888614766e-05

The O 0 9.291768037655856e-06
other O 0 7.427536274917657e-07
9 O 0 1.0687189387681428e-05
novel O 0 4.067703684995649e-06
mutations O 0 1.051293747877935e-05
identified O 0 6.370300070557278e-06
in O 0 3.89048437909878e-07
these O 0 1.0242710146712852e-07
23 O 0 2.8326796382316388e-05
patients O 0 1.6656173329465673e-06
were O 0 7.840248628099289e-08
each O 0 3.185299135566311e-08
limited O 0 2.1414069806269254e-07
to O 0 2.398040521711664e-07
a O 0 8.929334853746695e-07
single O 0 1.9772782252402976e-05
family O 0 5.807963680126704e-05
. O 0 1.3965010111860465e-05

These O 0 4.179925326752709e-06
data O 0 3.2494917832082137e-06
provide O 0 2.1759095147899643e-07
further O 0 2.76009075150796e-07
evidence O 0 3.6406171943781374e-07
for O 0 1.969577994032079e-07
extensive O 0 3.6505468870018376e-06
allelic O 0 3.4750872146105394e-05
heterogeneity O 0 0.00016162499377969652
in O 0 6.476262205978855e-05
MPS B-Disease 1 0.9997833371162415
IVA I-Disease 1 0.9999997615814209
in O 0 4.5231194235384464e-05
British O 0 0.00040830945363268256
- O 0 0.25548264384269714
Irish O 0 0.001355786807835102
patients O 0 1.0669672519725282e-05
and O 0 3.8089899589976994e-07
provide O 0 3.424550811814697e-07
evidence O 0 4.6771504003118025e-07
for O 0 9.840328374366436e-08
their O 0 5.107730203235405e-07
transmission O 0 1.4600595022784546e-05
to O 0 8.366459383069014e-07
Australia O 0 8.958052717389364e-07
by O 0 2.2980826486218575e-07
British O 0 1.1760661436710507e-05
- O 0 0.00038770888932049274
Irish O 0 1.5140651157707907e-05
migrants O 0 1.6833843119457015e-06
. O 0 6.036086688254727e-07
. O 0 3.5672342164616566e-06

Identification O 0 6.518002192024142e-05
of O 0 4.615044417732861e-06
constitutional O 0 1.5247034752974287e-05
WT1 O 0 0.021000266075134277
mutations O 0 0.0005066458252258599
, O 0 2.3093627987691434e-06
in O 0 2.1762341475550784e-06
patients O 0 6.638050308538368e-06
with O 0 2.0250950001354795e-06
isolated O 0 0.05846715345978737
diffuse B-Disease 1 0.9995158910751343
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.27284105878789e-05
and O 0 1.8328377109355642e-06
analysis O 0 9.360288686366403e-07
of O 0 1.0718255225583562e-06
genotype O 0 0.19464528560638428
/ O 0 0.21080665290355682
phenotype O 0 0.0005894562345929444
correlations O 0 1.8241784346173517e-05
by O 0 3.451297914125462e-07
use O 0 5.782127914244484e-07
of O 0 1.6586727724643424e-07
a O 0 7.937243026390206e-06
computerized O 0 0.0007440331974066794
mutation O 0 0.00011088110477430746
database O 0 1.9881503249052912e-05
. O 0 1.0061708962894045e-05

Constitutional O 0 0.0001615572109585628
mutations O 0 0.00013187174045015126
of O 0 1.3663327536050929e-06
the O 0 1.1485603863548022e-06
WT1 O 0 0.00030831192270852625
gene O 0 5.2998075261712074e-06
, O 0 1.3060844139545225e-07
encoding O 0 2.6689818355407624e-07
a O 0 1.4235727121558739e-06
zinc O 0 0.04185903072357178
- O 0 0.0007007475942373276
finger O 0 8.341048669535667e-05
transcription O 0 3.380164343980141e-06
factor O 0 4.988082764612045e-07
involved O 0 2.632140194691601e-07
in O 0 3.7961340240144636e-06
renal O 1 0.765591561794281
and O 0 2.2295604139799252e-05
gonadal O 0 0.0004460747877601534
development O 0 2.1771745650767116e-06
, O 0 4.725667110960785e-07
are O 0 2.9352465347187717e-08
found O 0 3.294991870461672e-07
in O 0 1.4526872860187723e-07
most O 0 5.821568151986867e-07
patients O 0 3.1941565339366207e-06
with O 0 5.979199613648234e-06
Denys B-Disease 1 0.9999643564224243
- I-Disease 1 0.9999985694885254
Drash I-Disease 1 0.9999988079071045
syndrome I-Disease 1 0.9999997615814209
( O 0 3.752892735064961e-05
DDS B-Disease 1 0.9999998807907104
) O 0 1.477113528380869e-05
, O 0 3.0374599191418383e-06
or O 0 4.617487866198644e-05
diffuse B-Disease 1 0.9968344569206238
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.0008743276703171432
DMS B-Disease 1 0.8656321167945862
) O 0 2.3212862743093865e-06
associated O 0 1.0955795914924238e-06
with O 0 2.998121544806054e-06
pseudohermaphroditism B-Disease 1 0.9999995231628418
and O 0 0.00026190176140516996
/ O 0 0.003230974543839693
or O 0 6.119152385508642e-05
Wilms B-Disease 1 0.9965596795082092
tumor I-Disease 1 0.9470378160476685
( O 0 2.99224066111492e-05
WT B-Disease 1 0.9999786615371704
) O 0 5.080160008219536e-06
. O 0 5.007509116694564e-06

Most O 0 3.6364581319503486e-05
mutations O 0 0.0008188312058337033
in O 0 0.0001061660295818001
DDS B-Disease 1 1.0
patients O 1 0.7406877279281616
lie O 0 0.00010383301560068503
in O 0 2.3741997665638337e-06
exon O 0 5.856037387275137e-05
8 O 0 8.237509973696433e-06
or O 0 2.5690172833492397e-07
exon O 0 5.292271907819668e-06
9 O 0 2.464338422214496e-06
, O 0 9.089193753197833e-08
encoding O 0 7.549721203758963e-07
zinc O 0 0.0012821825221180916
finger O 0 0.0003989214892499149
2 O 0 6.310228491201997e-05
or O 0 7.278852081071818e-06
zinc O 0 0.026450520381331444
finger O 0 0.0002746937097981572
3 O 0 1.4833005479886197e-05
, O 0 5.383458869800961e-07
respectively O 0 8.939116469264263e-07
, O 0 4.156331101512478e-08
with O 0 2.8487503911378553e-08
a O 0 1.3467375765685574e-06
hot O 0 7.080288196448237e-05
spot O 0 0.0003707186260726303
( O 0 3.900492799857602e-07
R394W O 0 1.2176952850495582e-06
) O 0 7.684484160108696e-08
in O 0 3.1953032930687186e-07
exon O 0 4.2030012991745025e-05
9 O 0 2.243665949208662e-05
. O 0 6.207878868735861e-06

We O 0 1.994630292756483e-05
analyzed O 0 5.778970262326766e-06
a O 0 4.256280021763814e-07
series O 0 1.0535361525398912e-06
of O 0 3.437783675508399e-07
24 O 0 5.665369099006057e-05
patients O 0 2.3717511794529855e-06
, O 0 1.3533535536680574e-07
10 O 0 4.0083318708639126e-07
with O 0 2.6747482024802594e-06
isolated B-Disease 0 0.009863613173365593
DMS I-Disease 1 0.9461444020271301
( O 0 4.590169737639371e-06
IDMS B-Disease 0 0.00037807159242220223
) O 0 1.2458708624762949e-06
, O 0 3.747927621589042e-07
10 O 0 3.9899910575513786e-07
with O 0 4.7007397370180115e-06
DDS B-Disease 1 1.0
, O 0 1.1867117791553028e-05
and O 0 1.5615260053891689e-06
4 O 0 8.289852303278167e-06
with O 0 1.0873017345147673e-05
urogenital B-Disease 1 0.8059388995170593
abnormalities I-Disease 1 0.9978025555610657
and O 0 9.739325469126925e-05
/ O 0 0.043768588453531265
or O 0 0.00010630187171045691
WT B-Disease 1 0.9999717473983765
. O 0 4.031330536236055e-05

We O 0 8.958112448453903e-05
report O 0 3.4699020034167916e-05
WT1 O 0 0.0003289055312052369
heterozygous O 0 6.592924910364673e-05
mutations O 0 6.960641621844843e-05
in O 0 3.7915426673862385e-06
16 O 0 0.00010795274283736944
patients O 0 2.027954178629443e-05
, O 0 3.597523345888476e-07
4 O 0 2.8457473035814473e-06
of O 0 4.954034693582798e-07
whom O 0 8.986916327557992e-06
presented O 0 9.290899470215663e-06
with O 0 1.289726969844196e-05
IDMS B-Disease 1 0.6316742897033691
. O 0 5.663014235324226e-05

One O 0 2.2076434106566012e-05
male O 0 1.1113126674899831e-05
and O 0 9.798541213967837e-07
two O 0 9.533832781016827e-07
female O 0 8.576952677685767e-05
IDMS B-Disease 0 0.21815620362758636
patients O 0 6.14884338574484e-05
with O 0 3.1133097309066216e-06
WT1 O 1 0.7710044384002686
mutations O 0 0.01671574078500271
underwent O 0 0.006050874013453722
normal O 0 4.7199835535138845e-05
puberty O 0 0.00016653967031743377
. O 0 1.7071897673304193e-05

Two O 0 7.716567779425532e-05
mutations O 0 0.000426106940722093
associated O 0 1.565197999298107e-05
with O 0 4.483860720938537e-06
IDMS B-Disease 0 0.017865313217043877
are O 0 3.256343177326926e-07
different O 0 4.1380111781563755e-08
from O 0 1.4519255842060375e-07
those O 0 1.9031072895359102e-07
described O 0 6.764988938812166e-05
in O 0 9.762422268977389e-05
DDS B-Disease 1 1.0
patients O 0 0.01888810656964779
. O 0 1.3655063412443269e-05

No O 0 8.108918700600043e-05
WT1 O 0 0.002136592287570238
mutations O 0 0.0003909978549927473
were O 0 4.020136657345574e-06
detected O 0 6.060010036890162e-06
in O 0 1.8089951936417492e-07
the O 0 1.4458774444392475e-07
six O 0 2.298670779055101e-06
other O 0 4.131555215280969e-06
IDMS B-Disease 1 0.6363605856895447
patients O 0 3.359685797477141e-05
, O 0 5.148355626261036e-07
suggesting O 0 5.681589755113237e-06
genetic O 0 1.3928804037277587e-05
heterogeneity O 0 4.104253093828447e-05
of O 0 2.7017408683605026e-06
this O 0 3.7855879782000557e-05
disease O 0 0.0077650174498558044
. O 0 1.3022493476455566e-05

We O 0 3.191551149939187e-05
analyzed O 0 0.000111015782749746
genotype O 0 0.003219044301658869
/ O 0 0.04467222839593887
phenotype O 0 0.000749919330701232
correlations O 0 0.00011758324399124831
, O 0 3.065232476728852e-06
on O 0 1.8060077309201006e-06
the O 0 1.169806722600697e-07
basis O 0 1.5664660679703957e-07
of O 0 4.837041345240323e-08
the O 0 3.9403855112141173e-07
constitution O 0 1.7468477153670392e-07
of O 0 2.85801871058311e-08
a O 0 1.8009993709711125e-06
WT1 O 0 0.00015844104927964509
mutation O 0 2.4161993223970057e-06
database O 0 2.2441584235366463e-07
of O 0 7.642533716989419e-08
84 O 0 8.132089533319231e-06
germ O 0 0.0004286090552341193
- O 0 0.0010203818092122674
line O 0 0.00013301466242410243
mutations O 0 4.693456048698863e-06
, O 0 6.982563860447044e-08
to O 0 1.0255984506102322e-07
compare O 0 2.6346467052462685e-07
the O 0 5.3704912517105186e-08
distribution O 0 5.281333983475633e-07
and O 0 8.020356858651212e-07
type O 0 9.258449154003756e-07
of O 0 3.024133263807016e-07
mutations O 0 9.732745638757478e-06
, O 0 2.3311999086672586e-07
according O 0 4.313483970008747e-08
to O 0 4.067265990670421e-08
the O 0 1.5028081179480068e-07
different O 0 1.2220183407407603e-06
symptoms O 0 6.671461596852168e-05
. O 0 2.9969578463351354e-06

This O 0 2.5272636776207946e-05
demonstrated O 0 5.506337765837088e-05
( O 0 1.7032440382536151e-06
1 O 0 4.4122325562057085e-06
) O 0 2.4419421151833376e-07
the O 0 1.7036973076756112e-07
association O 0 1.5656610230507795e-07
between O 0 9.895644836888096e-08
mutations O 0 1.5299089000109234e-06
in O 0 3.307572455923946e-07
exons O 0 1.1605173313000705e-05
8 O 0 7.123819159460254e-06
and O 0 1.4136775234874221e-06
9 O 0 1.5089421140146442e-05
and O 0 1.5615287338732742e-05
DMS B-Disease 0 0.02488149330019951
; O 0 1.9638907815533457e-06
( O 0 1.1103882968654943e-07
2 O 0 3.0287908430182142e-06
) O 0 4.6127294694997545e-07
among O 0 2.458181143083493e-07
patients O 0 7.913781701063272e-07
with O 0 5.03154069519951e-07
DMS B-Disease 0 0.04598076269030571
, O 0 1.7510058114567073e-07
a O 0 7.903880572257549e-08
higher O 0 2.0387726351600577e-07
frequency O 0 5.64990386919817e-07
of O 0 4.273472242743992e-08
exon O 0 9.14499287318904e-06
8 O 0 8.30270982987713e-06
mutations O 0 2.5458234631514642e-06
among O 0 1.4082411325944122e-07
46 O 0 3.310189867988811e-06
, O 0 3.2105992886499735e-06
XY O 0 0.0006399884005077183
patients O 0 2.0241952825017506e-06
with O 0 2.0826649915761664e-07
female O 0 1.0231019587081391e-05
phenotype O 0 2.399200457148254e-05
than O 0 2.2885731709720858e-07
among O 0 1.872230512844908e-07
46 O 0 4.816915406991029e-06
, O 0 4.411054760566913e-06
XY O 0 0.0024438216350972652
patients O 0 4.64931190435891e-06
with O 0 1.5435838918165246e-07
sexual O 0 6.282950266722764e-07
ambiguity O 0 9.989637419494102e-07
or O 0 2.4834578198351664e-06
male O 0 3.349602047819644e-05
phenotype O 0 0.0005069139879196882
; O 0 5.280917775962735e-06
and O 0 5.228445843385998e-06
( O 0 5.357477448342252e-07
3 O 0 7.852272574382368e-06
) O 0 5.297849838825641e-07
statistically O 0 1.0573187410045648e-06
significant O 0 1.4519171998017555e-07
evidence O 0 7.790874292368244e-07
that O 0 6.434627266571624e-07
mutations O 0 3.0802389119344298e-06
in O 0 2.5777049472708313e-07
exons O 0 1.2059883374604397e-05
8 O 0 3.2344657938665478e-06
and O 0 4.418336914113752e-07
9 O 0 1.6413854382335558e-06
preferentially O 0 8.703400453669019e-07
affect O 0 2.520755515433848e-07
amino O 0 2.2446121761277027e-07
acids O 0 1.858440441537823e-07
with O 0 2.5122062652371824e-08
different O 0 3.3809104849069627e-08
functions O 0 1.934649986878867e-07
. O 0 6.483616630248434e-07
. O 0 4.3288741835567635e-06

The O 0 2.0309580577304587e-05
185delAG O 0 0.00028235799982212484
BRCA1 O 0 0.001557391369715333
mutation O 0 3.348611789988354e-05
originated O 0 1.8707684148466797e-06
before O 0 4.620663389687252e-07
the O 0 6.971119859144892e-08
dispersion O 0 4.765793619299075e-06
of O 0 1.0765249669475452e-07
Jews O 0 1.1157642347825458e-06
in O 0 4.6566017886107147e-07
the O 0 3.43372391853336e-07
diaspora O 0 1.7253471469302895e-06
and O 0 1.2851469364250079e-06
is O 0 4.033575464745809e-07
not O 0 1.5437400691098446e-07
limited O 0 4.718930028957402e-07
to O 0 2.165390469599515e-06
Ashkenazim O 0 0.00013342409511096776
. O 0 1.3045490049989894e-05

The O 0 2.103378574247472e-05
185delAG O 0 0.0001791644172044471
mutation O 0 5.660190436174162e-05
in O 0 3.724322823472903e-06
BRCA1 O 0 0.0010564030380919576
is O 0 5.735223112424137e-06
detected O 0 1.5974386769812554e-05
in O 0 5.809876029161387e-07
Ashkenazi O 0 6.876287079649046e-05
Jews O 0 1.3574192507803673e-06
both O 0 3.056963180370076e-07
in O 0 5.15629471919965e-06
familial B-Disease 1 0.9096159338951111
breast I-Disease 1 0.9999991655349731
and I-Disease 1 0.9999916553497314
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.961662969231838e-06
in O 0 7.586421588712255e-07
the O 0 3.6569687722476374e-07
general O 0 1.13097144094354e-06
population O 0 1.0768427500806865e-06
. O 0 2.2050853658583947e-06

All O 0 1.3422495612758212e-05
tested O 0 6.243571260711178e-05
Ashkenazi O 0 0.0008052584016695619
mutation O 0 3.4053155104629695e-05
carriers O 0 3.5231871606811183e-06
share O 0 2.039857008639956e-06
the O 0 1.752232066110082e-07
same O 0 5.852847380083404e-07
allelic O 0 1.9238410459365696e-05
pattern O 0 4.2257728637196124e-05
at O 0 4.726965471490985e-06
the O 0 4.32681008533109e-06
BRCA1 O 0 0.0017778701148927212
locus O 0 0.00028817972633987665
. O 0 2.784836215141695e-05

Our O 0 2.3959992176969536e-05
previous O 0 1.95374341274146e-05
study O 0 3.364704298292054e-06
showed O 0 6.2637072915094905e-06
that O 0 9.497617270426417e-08
this O 0 1.478117326314532e-07
Ashkenazi O 0 0.00023682191385887563
mutation O 0 9.441205293114763e-06
also O 0 2.3411034817399923e-06
occurs O 0 1.0609129219574243e-07
in O 0 9.84883428145622e-08
Iraqi O 0 4.712755412583647e-07
Jews O 0 3.6310956375018577e-07
with O 0 1.2428999696112442e-07
a O 0 1.6600922663201345e-06
similar O 0 2.8509193725767545e-06
allelic O 0 0.00013613807095680386
pattern O 0 0.0002488300669938326
. O 0 2.368031709920615e-05

We O 0 6.17148180026561e-06
extended O 0 2.9221137083368376e-06
our O 0 6.187294729897985e-07
analysis O 0 4.2040053926939436e-07
to O 0 4.738357262112913e-08
other O 0 3.9178349453550254e-08
non O 0 4.820389563064964e-07
- O 0 2.0586558093782514e-05
Ashkenazi O 0 2.416689312667586e-05
subsets O 0 1.1246214626225992e-06
354 O 0 6.573852715519024e-07
of O 0 5.112472223345321e-08
Moroccan O 0 7.865928637329489e-06
origin O 0 7.659139100724133e-07
, O 0 1.199391448380993e-07
200 O 0 6.230139604213036e-08
Yemenites O 0 1.6966522480288404e-06
and O 0 1.668396265586125e-07
150 O 0 2.630837627748406e-07
Iranian O 0 1.5912889921310125e-06
Jews O 0 4.3630834625218995e-06
. O 0 5.4530787565454375e-06

Heteroduplex O 0 0.0017092882189899683
analysis O 0 1.2436400538717862e-05
complemented O 0 5.300787961459719e-06
by O 0 3.1528799127045204e-07
direct O 0 3.465337954366987e-07
DNA O 0 3.4799436434695963e-06
sequencing O 0 1.5129851362871705e-06
of O 0 2.1736737210176216e-07
abnormally O 0 2.0052995751029812e-05
migrating O 0 7.69113285059575e-07
bands O 0 2.515069581932039e-06
were O 0 1.2654987813220941e-06
employed O 0 3.738336090464145e-06
. O 0 3.347689471411286e-06

Four O 0 1.2235494068590924e-05
of O 0 9.715558917378075e-07
Moroccan O 0 6.056355414330028e-05
origin O 0 6.8932031354052015e-06
( O 0 4.235115795836464e-07
1 O 0 9.048817446455359e-07
. O 0 6.808686237036454e-08
1 O 0 5.252752544038231e-07
% O 0 2.358620747600071e-07
) O 0 6.74726550187188e-08
and O 0 2.4161246869880415e-07
none O 0 7.107501431846686e-08
of O 0 1.8197711781908765e-08
the O 0 3.998020190465468e-07
Yemenites O 0 7.476775863324292e-06
or O 0 2.6138494035876647e-07
Iranians O 0 3.706291522576066e-07
was O 0 7.05477248175157e-07
a O 0 4.262072081928636e-07
carrier O 0 1.8870456415243098e-06
of O 0 7.273219893022542e-08
the O 0 1.3702057231057552e-06
185delAG O 0 0.00023953652998898178
mutation O 0 4.825029827770777e-05
. O 0 7.00614236848196e-06

BRCA1 O 0 0.022838585078716278
allelic O 0 0.0009107769001275301
patterns O 0 0.0003111291734967381
were O 0 1.2490600056480616e-05
determined O 0 2.2285560135060223e-06
for O 0 1.645112206460908e-07
four O 0 2.691865290671558e-07
of O 0 5.263653690690262e-08
these O 0 6.368546934254482e-08
individuals O 0 9.443999360314592e-09
and O 0 1.3397837506090582e-07
for O 0 7.607396668163346e-08
12 O 0 2.2186264914125786e-07
additional O 0 1.6017445148008846e-07
non O 0 1.7193634676004876e-06
- O 0 4.871141936746426e-05
Ashkenazi O 0 0.00016608186706434935
185delAG O 0 8.553047337045427e-06
mutation O 0 3.349583039380377e-06
carriers O 0 7.683076432840608e-07
who O 0 7.3814353527268395e-06
had O 0 0.026024775579571724
breast B-Disease 1 0.9999903440475464
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 5.1083294238196686e-05

Six O 0 3.6654917494161054e-05
non O 0 3.0120007068035193e-05
- O 0 0.0017996055539697409
Ashkenazi O 0 0.001163732260465622
individuals O 0 2.1260437677028676e-07
shared O 0 2.863492341020901e-07
the O 0 2.7678615310833266e-07
common O 0 8.074747711361852e-06
Ashkenazi O 0 0.004124079830944538
haplotype O 0 0.00029013428138569
, O 0 1.026815425575478e-06
four O 0 6.040037305865553e-07
had O 0 4.004448328487342e-06
a O 0 9.382864618601161e-07
closely O 0 6.5082435867225286e-06
related O 0 3.59232626578887e-06
pattern O 0 6.521993782371283e-05
, O 0 2.8983401989535196e-06
and O 0 6.888694201734324e-07
the O 0 6.564130217157071e-07
rest O 0 1.8895810853791772e-06
( O 0 2.0019282942485006e-07
n O 0 1.542230529594235e-05
= O 0 1.4072737030801363e-05
6 O 0 8.103692380245775e-06
) O 0 1.418205073377976e-07
displayed O 0 1.8065573215153563e-07
a O 0 1.384585289088136e-06
distinct O 0 1.28616375150159e-05
BRCA1 O 0 0.0010737342527136207
allelic O 0 0.0001151888063759543
pattern O 0 0.0002979396958835423
. O 0 1.5782379705342464e-05

We O 0 1.0187751286139246e-05
conclude O 0 6.232294708752306e-06
that O 0 2.814185222632659e-07
the O 0 1.6528746016319928e-07
185delAG O 0 4.549147706711665e-05
BRCA1 O 0 0.0006663998938165605
mutation O 0 1.2154561773058958e-05
occurs O 0 1.9349729996065435e-07
in O 0 3.920661129086511e-08
some O 0 2.513696983896807e-08
non O 0 1.2148766472819261e-06
- O 0 0.0002382896200288087
Ashkenazi O 0 0.0010672580683603883
populations O 0 7.371857577709306e-07
at O 0 4.989400395061239e-07
rates O 0 6.997349260018382e-07
comparable O 0 3.168792659380415e-07
with O 0 1.0356018975699044e-07
that O 0 4.1512453208270017e-07
of O 0 8.03942498350807e-07
Ashkenazim O 0 0.0005006292485632002
. O 0 1.7114882211899385e-05

The O 0 6.266145192057593e-06
majority O 0 1.2358796084299684e-06
of O 0 1.4957619498545682e-07
Jewish O 0 2.820270083248033e-06
185delAG O 0 5.60783373657614e-05
mutation O 0 1.3927317013440188e-05
carriers O 0 4.838476002078096e-07
have O 0 5.316363171914418e-08
a O 0 2.1821333007210342e-07
common O 0 2.178873728553299e-06
allelic O 0 1.9832723410218023e-05
pattern O 0 5.737895116908476e-05
, O 0 7.214107426989358e-07
supporting O 0 2.2880253425228148e-07
the O 0 2.4854168145793665e-07
founder O 0 3.9075908716768026e-05
effect O 0 6.152320679575496e-07
notion O 0 2.6793182428264117e-07
, O 0 2.1850632947462145e-07
but O 0 1.0493972979475075e-07
dating O 0 3.829298975688289e-07
the O 0 2.633355222769751e-07
mutations O 0 2.0454206151043763e-06
origin O 0 2.0287374979943706e-07
to O 0 1.7945238539596176e-07
an O 0 2.867496107228362e-07
earlier O 0 3.262203790654894e-06
date O 0 8.793474080448505e-06
than O 0 1.8174476679178042e-07
currently O 0 6.597278456865752e-07
estimated O 0 2.6761031222122256e-06
. O 0 4.636237008526223e-06

However O 0 1.9814498955383897e-05
, O 0 4.4011952127220866e-07
the O 0 6.901346694121457e-08
different O 0 4.294152233796922e-08
allelic O 0 2.143786787200952e-06
pattern O 0 6.496882633655332e-06
at O 0 2.3270224573934684e-06
the O 0 1.288076987293607e-06
BRCA1 O 0 0.00013474842126015574
locus O 0 6.940194452909054e-06
even O 0 2.7915794476029987e-07
in O 0 3.8147330627680276e-08
some O 0 1.540356819873523e-08
Jewish O 0 1.6102230802061968e-06
mutation O 0 5.5427940424124245e-06
carriers O 0 3.9416261188307544e-07
, O 0 2.6320421397940663e-07
might O 0 3.642544470494613e-07
suggest O 0 2.774330880583875e-07
that O 0 6.484389558636394e-08
the O 0 3.734818676548457e-07
mutation O 0 6.856539584987331e-06
arose O 0 1.7406262031727238e-06
independently O 0 3.600482386900694e-06
. O 0 7.946051141516364e-07
. O 0 4.5727460928901564e-06

Crystal O 0 0.00637810118496418
structure O 0 2.1084009858896025e-05
of O 0 1.3995788776810514e-06
the O 0 1.4179634490574244e-05
hemochromatosis B-Disease 1 0.9999986886978149
protein O 0 0.0002476197259966284
HFE O 0 0.000588484515901655
and O 0 4.4554981286637485e-06
characterization O 0 5.580812739935936e-06
of O 0 5.42151887827913e-08
its O 0 1.1435131455073133e-06
interaction O 0 4.197687530904659e-07
with O 0 7.785526463521819e-07
transferrin O 0 7.810679380781949e-05
receptor O 0 1.7496116925030947e-05
. O 0 8.648050425108522e-06

HFE O 0 0.014168989844620228
is O 0 2.520380076020956e-05
an O 0 1.8746563910099212e-06
MHC O 0 3.26862427755259e-05
- O 0 0.0002019585808739066
related O 0 1.7963985783353564e-06
protein O 0 7.137182933547592e-07
that O 0 8.20406000912044e-08
is O 0 5.887540055482532e-08
mutated O 0 4.90095260374801e-07
in O 0 1.3872137571979692e-07
the O 0 2.228615358035313e-06
iron B-Disease 1 0.9997938275337219
- I-Disease 1 0.9999983310699463
overload I-Disease 1 0.9999140501022339
disease I-Disease 1 0.9999514818191528
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.003804342122748494

HFE O 0 0.004662793595343828
binds O 0 8.780758798820898e-05
to O 0 5.515774319064803e-06
transferrin O 0 8.054462523432449e-05
receptor O 0 1.4673290934297256e-05
( O 0 1.158642135123955e-06
TfR O 0 1.5310040907934308e-05
) O 0 2.1677612949133618e-07
and O 0 2.0501454400800867e-07
reduces O 0 5.220650223236589e-07
its O 0 2.0616585061361548e-07
affinity O 0 2.5548951043674606e-07
for O 0 1.7220021675257158e-07
iron O 0 0.00048811922897584736
- O 0 8.825645636534318e-05
loaded O 0 7.077036570990458e-06
transferrin O 0 1.0031796591647435e-05
, O 0 8.115517289297713e-07
implicating O 0 6.816470704507083e-05
HFE O 0 0.0004514592874329537
in O 0 7.164637736423174e-06
iron O 0 0.3832911252975464
metabolism O 0 0.001711633987724781
. O 0 2.0582849174388684e-05

The O 0 2.550932731537614e-05
2 O 0 5.352184234652668e-05
. O 0 2.7982905521639623e-05

6 O 0 0.00019434670684859157
A O 0 1.5583436834276654e-05
crystal O 0 0.0007039278279989958
structure O 0 1.6802419850137085e-05
of O 0 1.0680695368137094e-06
HFE O 0 0.0007088396814651787
reveals O 0 1.7470774764660746e-05
the O 0 2.0149894908172428e-07
locations O 0 1.1511350521686836e-06
of O 0 4.95812673761975e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0034817527048289776
and O 0 3.486846708256053e-06
a O 0 9.076233254745603e-06
patch O 0 0.1425212025642395
of O 0 2.9036132218607236e-06
histidines O 0 0.0004480464558582753
that O 0 1.3136924508216907e-06
could O 0 6.08035406912677e-07
be O 0 4.7950251769179886e-08
involved O 0 9.29545933558984e-08
in O 0 5.947018166807538e-07
pH O 0 0.000190234393812716
- O 0 0.00821708608418703
dependent O 0 3.592219218262471e-05
interactions O 0 4.671449914894765e-06
. O 0 5.0341222959104925e-06

We O 0 1.8962253307108767e-05
also O 0 1.822406147766742e-06
demonstrate O 0 1.7903407751873601e-06
that O 0 3.4822565453396237e-07
soluble O 0 7.964677024574485e-06
TfR O 0 0.00011238263687118888
and O 0 5.226555913395714e-06
HFE O 0 0.00011701391485985368
bind O 0 3.246945425416925e-06
tightly O 0 4.295202415960375e-06
at O 0 1.016576902657107e-06
the O 0 7.727903295062788e-08
basic O 0 3.739102112376713e-07
pH O 0 1.8639246945895138e-06
of O 0 4.0357448938266316e-08
the O 0 3.79776736281201e-07
cell O 0 5.987850818200968e-05
surface O 0 2.7669861083268188e-05
, O 0 1.5718699160061078e-06
but O 0 9.069952966456185e-08
not O 0 2.6834984012680252e-08
at O 0 1.1434461555381858e-07
the O 0 3.204794438715908e-07
acidic O 0 0.00010399314487585798
pH O 0 3.604298035497777e-05
of O 0 6.108624575063004e-07
intracellular O 0 2.436869908706285e-05
vesicles O 0 0.00017552284407429397
. O 0 1.5532488760072738e-05

TfR O 0 0.41016989946365356
HFE O 0 0.11652117222547531
stoichiometry O 0 0.0005674841231666505
( O 0 1.3747155207965989e-05
2 O 0 1.177502690552501e-05
1 O 0 6.107999524829211e-06
) O 0 4.0141426893569587e-07
differs O 0 6.945511472622456e-07
from O 0 3.9022674513944366e-07
TfR O 0 2.430325184832327e-05
transferrin O 0 1.477489604440052e-05
stoichiometry O 0 4.019155767309712e-06
( O 0 3.515789330776897e-07
2 O 0 2.208995965702343e-06
2 O 0 1.0838843081728555e-05
) O 0 2.745575500284758e-07
, O 0 1.1541917643853594e-07
implying O 0 1.6227487265041418e-07
a O 0 4.0671881862408554e-08
different O 0 9.287428603954595e-09
mode O 0 2.187239971362942e-07
of O 0 3.417828864371586e-08
binding O 0 1.1606261978158727e-06
for O 0 1.7378910115439794e-06
HFE O 0 0.00012400085688568652
and O 0 2.47547495746403e-06
transferrin O 0 9.417887667950708e-06
to O 0 1.1651710565274698e-06
TfR O 0 2.0897026843158528e-05
, O 0 2.893910675538791e-07
consistent O 0 1.7761664139470668e-07
with O 0 5.197044572469167e-08
our O 0 2.781640091598092e-07
demonstration O 0 9.641164524509804e-07
that O 0 3.272232049766899e-07
HFE O 0 5.137157131684944e-05
, O 0 8.310277621603746e-07
transferrin O 0 5.3256057981343474e-06
, O 0 5.275534817883454e-07
and O 0 6.030977033333329e-07
TfR O 0 1.4556354472006205e-05
form O 0 5.293632057146169e-07
a O 0 4.172291028226027e-06
ternary O 0 1.484895619796589e-05
complex O 0 2.7660995328915305e-05
. O 0 1.629212056286633e-05

Identification O 0 2.618260077724699e-05
of O 0 1.4210090739652514e-06
three O 0 2.6742432055471e-06
novel O 0 1.0362690773035865e-05
mutations O 0 1.8174861907027662e-05
and O 0 6.147699309622112e-07
a O 0 8.709661187822348e-07
high O 0 3.846152594633168e-06
frequency O 0 2.2694521248922683e-06
of O 0 6.543504582623427e-08
the O 0 5.665340268024011e-07
Arg778Leu O 0 8.070008334470913e-05
mutation O 0 4.367037945485208e-06
in O 0 4.269663520517497e-07
Korean O 0 9.319332093582489e-06
patients O 0 5.609489107882837e-06
with O 0 3.4941367630381137e-06
Wilson B-Disease 0 0.013465512543916702
disease I-Disease 0 0.0007563694380223751
. O 0 6.440830929932417e-06

Four O 0 4.672779323300347e-05
mutations O 0 0.00035073337494395673
- O 0 0.0002531679638195783
- O 0 0.00026194771635346115
R778L O 0 7.394505701086018e-06
, O 0 1.6504220923252433e-07
A874V O 0 8.325524163410591e-07
, O 0 1.1205560213056742e-07
L1083F O 0 5.140932444192003e-07
, O 0 8.893574943158455e-08
and O 0 5.96211222614329e-08
2304delC O 0 1.4009035567141837e-06
- O 0 9.833423973759636e-06
- O 0 1.367243385175243e-05
in O 0 2.433925487821398e-07
the O 0 2.0785675758361322e-07
copper O 0 9.392225183546543e-05
- O 0 1.0727564585977234e-05
transporting O 0 1.8672106989470194e-06
enzyme O 0 1.0917287909251172e-06
, O 0 3.0178236443134665e-07
P O 0 0.0003839813871309161
- O 0 6.506464706035331e-05
type O 0 6.185328402352752e-06
ATPase O 0 8.238458394771442e-05
( O 0 4.338915573498525e-07
ATP7B O 0 3.735033897100948e-05
) O 0 1.7334288315851154e-07
, O 0 7.79536577510953e-08
were O 0 6.305502608938696e-08
identified O 0 5.532530167329242e-07
in O 0 3.0582930321543245e-07
Korean O 0 1.5638954209862277e-05
Patients O 0 6.202919394127093e-06
with O 0 4.152483143116115e-06
Wilson B-Disease 0 0.10912027955055237
disease I-Disease 0 0.0012278639478608966
. O 0 1.4525665392284282e-05

Arg778Leu O 0 0.002446991391479969
, O 0 1.1184915820194874e-05
the O 0 3.9449128053092863e-07
most O 0 1.7228663296009472e-07
frequently O 0 1.1252844842601917e-06
reported O 0 1.5024776075733826e-05
mutation O 0 4.5951142624289787e-07
of O 0 2.924176989438365e-08
this O 0 9.864551486771234e-08
enzyme O 0 1.0984681466652546e-06
, O 0 1.3243242165117408e-06
was O 0 6.310257958830334e-06
found O 0 4.789422405337973e-07
in O 0 4.1290075358801914e-08
six O 0 1.2952372685504088e-07
of O 0 5.8387158219375124e-08
eight O 0 1.8994495576407644e-06
unrelated O 0 1.7891692550620064e-05
patients O 0 7.004893177509075e-06
studied O 0 5.523884283320513e-07
, O 0 1.3966385381536384e-07
an O 0 1.417435697703695e-07
allele O 0 2.398944616288645e-06
frequency O 0 2.171739652112592e-06
of O 0 5.31694638539193e-07
37 O 0 2.9194816306699067e-05
. O 0 1.2777149095200002e-05

5 O 0 0.00013459241017699242
% O 0 1.9516985048539937e-05
, O 0 1.5818097836017841e-06
which O 0 2.0328840832917194e-07
is O 0 6.406852293139309e-08
considerably O 0 6.823557896495913e-07
higher O 0 3.801999923780386e-07
than O 0 6.840160438059684e-08
those O 0 2.146993161034061e-08
in O 0 7.036966565010516e-08
other O 0 1.4475510567990568e-07
Asian O 0 2.382769480391289e-06
populations O 0 7.4050626608368475e-06
. O 0 4.034401172248181e-06

The O 0 1.0968635251629166e-05
novel O 0 5.486228474183008e-06
single O 0 3.0597914246754954e-06
nucleotide O 0 1.2799881915270817e-05
deletion O 0 3.4994507586816326e-05
, O 0 1.2220987173350295e-06
2304delC O 0 2.0161392967565916e-05
, O 0 1.6381467276005424e-06
was O 0 5.907133981963852e-06
found O 0 8.236960979957075e-07
in O 0 3.5725787483897875e-07
one O 0 2.805654958137893e-06
patient O 0 3.329519313410856e-05
. O 0 6.302174824668327e-06

Since O 0 2.134452370228246e-05
a O 0 2.9699028800678207e-06
mutation O 0 5.707172931579407e-06
at O 0 1.5709678109487868e-06
cDNA O 0 1.169891493191244e-05
nucleotide O 0 6.834865780547261e-05
2302 O 0 0.00047176628140732646
( O 0 8.837770337777329e-07
2302insC O 0 8.260196409537457e-06
) O 0 4.2084138840436935e-07
had O 0 2.575405005700304e-06
been O 0 1.2321995654929196e-06
previously O 0 7.123378054529894e-06
described O 0 2.1542351532843895e-05
, O 0 5.71721727737895e-07
this O 0 3.1904917818792455e-08
region O 0 3.1542842293674767e-07
of O 0 3.542778870269103e-08
the O 0 6.557447136401606e-07
ATP7B O 0 0.0017668104264885187
gene O 0 1.790736314433161e-05
may O 0 5.646457793773152e-06
be O 0 2.8313979782979004e-07
susceptible O 0 1.2755769603245426e-05
to O 0 2.903275344579015e-06
gene O 0 0.00011093291686847806
rearrangements O 0 0.00653781509026885
causing O 0 0.042870450764894485
Wilson B-Disease 0 0.18538816273212433
disease I-Disease 0 0.008997486904263496
. O 0 1.3901414604333695e-05

Disruption O 0 0.0002817043277900666
of O 0 1.9571484699554276e-06
splicing O 0 3.0203107598936185e-05
regulated O 0 4.5572173803520855e-06
by O 0 2.9126221079422976e-07
a O 0 8.703424896339129e-07
CUG O 0 0.00040978813194669783
- O 0 0.00017426280828658491
binding O 0 1.4669219126517419e-05
protein O 0 9.181869972962886e-05
in O 0 9.60362667683512e-05
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.00021842023124918342

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9997363686561584
DM B-Disease 1 1.0
) O 0 0.001971516292542219
is O 0 7.444858056260273e-06
caused O 0 3.541519845384755e-06
by O 0 1.6890950860215526e-07
a O 0 1.512021526650642e-06
CTG O 0 3.647666017059237e-05
expansion O 0 1.787791688911966e-06
in O 0 2.914186438829347e-07
the O 0 2.332189410481078e-07
3 O 0 7.358557922998443e-06
untranslated O 0 0.00014283797645475715
region O 0 5.181345386517933e-06
of O 0 5.066991661806242e-07
the O 0 2.4921557269408368e-05
DM B-Disease 1 0.9999998807907104
gene O 0 0.00042867480078712106
. O 0 1.4371068573382217e-05

One O 0 1.2330398931226227e-05
model O 0 2.7329229851602577e-05
of O 0 8.081449777819216e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.31714269518852234
suggests O 0 9.900485565594863e-06
that O 0 3.0546726748070796e-07
RNAs O 0 2.081196953440667e-06
from O 0 5.7207955705962377e-08
the O 0 5.1651152688236834e-08
expanded O 0 2.913274954607914e-07
allele O 0 4.77818105082406e-07
create O 0 7.33050242729405e-08
a O 0 4.044831598548626e-07
gain O 0 9.214449164574035e-06
- O 0 1.202725343318889e-05
of O 0 2.1041181241798768e-07
- O 0 3.2642041333019733e-05
function O 0 4.119128789170645e-07
mutation O 0 2.9831741699126724e-07
by O 0 1.9919637495036113e-08
the O 0 1.1195881910452954e-07
inappropriate O 0 3.168738373915403e-07
binding O 0 2.3700118845226825e-07
of O 0 4.022151145477437e-08
proteins O 0 7.597246565183013e-08
to O 0 1.737813590807491e-07
the O 0 7.605248129038955e-07
CUG O 0 0.0008885501301847398
repeats O 0 0.0002232594124507159
. O 0 7.684580850764178e-06

Data O 0 0.00013126790872775018
presented O 0 1.3295428288984112e-05
here O 0 9.002595220408693e-07
indicate O 0 9.958428108802764e-07
that O 0 9.670469580669305e-08
the O 0 1.2295883777824201e-07
conserved O 0 1.1879808425874216e-06
heterogeneous O 0 1.3216520528658293e-05
nuclear O 0 4.1872510337270796e-05
ribonucleoprotein O 0 8.996966244012583e-06
, O 0 3.9737909673931426e-07
CUG O 0 2.0643414245569147e-05
- O 0 1.1202978384972084e-05
binding O 0 1.3508846450349665e-06
protein O 0 1.9537246771506034e-06
( O 0 1.59697350454735e-07
CUG O 0 0.0001097433632821776
- O 0 0.0059524597600102425
BP O 0 0.2045769840478897
) O 0 4.0128719547283254e-07
, O 0 2.3402434123909188e-07
may O 0 7.241796993184835e-07
mediate O 0 1.304690886172466e-05
the O 0 1.2478329836085322e-06
trans O 0 9.551059338264167e-05
- O 0 0.00023079240054357797
dominant O 0 9.299019438913092e-06
effect O 0 5.428917120298138e-07
of O 0 4.3833008334104306e-08
the O 0 3.0482848956125963e-07
RNA O 0 2.7489748390507884e-05
. O 0 7.694464329688344e-06

CUG O 0 0.3050684928894043
- O 1 0.6850199699401855
BP O 1 0.7241738438606262
was O 0 8.03960720077157e-05
found O 0 6.180878244776977e-07
to O 0 5.6538443260478743e-08
bind O 0 3.1798424515727675e-07
to O 0 3.0499219860757876e-07
the O 0 9.510848713034648e-07
human O 0 1.7386075342074037e-05
cardiac O 0 0.43073606491088867
troponin O 0 0.0038234805688261986
T O 0 0.13945338129997253
( O 0 5.420587854132464e-07
cTNT O 0 4.309711130190408e-06
) O 0 1.840867867031193e-07
pre O 0 2.9467710191966034e-06
- O 0 1.8955997802549973e-05
messenger O 0 3.620480811150628e-06
RNA O 0 7.680263252041186e-07
and O 0 7.278605096416868e-08
regulate O 0 2.474565974353027e-07
its O 0 4.44945840172295e-07
alternative O 0 3.322141083117458e-06
splicing O 0 8.102919673547149e-05
. O 0 7.3923620220739394e-06

Splicing O 0 0.0003523379855323583
of O 0 1.0327775271434803e-05
cTNT O 0 0.00040696572978049517
was O 0 0.00010388560622232035
disrupted O 0 0.00040770001942291856
in O 0 0.00011234630073886365
DM B-Disease 1 1.0
striated O 0 0.3985697329044342
muscle O 0 0.0016802680911496282
and O 0 2.672078835530556e-06
in O 0 3.2764728530310094e-07
normal O 0 2.005112719416502e-06
cells O 0 7.19144463801058e-06
expressing O 0 9.242789928975981e-07
transcripts O 0 2.756528829195304e-06
that O 0 2.5373878997925203e-07
contain O 0 2.104002987834974e-06
CUG O 0 0.002808245597407222
repeats O 0 0.0002084690349875018
. O 0 9.4429169621435e-06

Altered O 0 0.00024398587993346155
expression O 0 9.24914547795197e-06
of O 0 7.652108706679428e-07
genes O 0 1.9498625078995246e-06
regulated O 0 1.5665035562051344e-06
posttranscriptionally O 0 4.8874931962927803e-05
by O 0 1.3398608871284523e-06
CUG O 0 0.005731610581278801
- O 0 0.07064898312091827
BP O 0 0.2658019959926605
therefore O 0 1.8999442090716911e-06
may O 0 1.5106147657206748e-06
contribute O 0 4.0181640770242666e-07
to O 0 1.785550375643652e-05
DM B-Disease 1 1.0
pathogenesis O 0 0.2615737318992615
. O 0 5.158429303264711e-06
. O 0 6.751031378371408e-06

Identification O 0 1.9309745766804554e-05
of O 0 1.108119704440469e-06
a O 0 3.6431806620385032e-06
novel O 0 1.4828819075773936e-05
nonsense O 0 6.327497976599261e-05
mutation O 0 9.800739462662023e-06
and O 0 2.859382846054359e-07
a O 0 5.264723768050317e-07
missense O 0 5.244601197773591e-06
substitution O 0 3.2783137271508167e-07
in O 0 2.428069194593263e-07
the O 0 5.417621196102118e-07
vasopressin O 0 4.4455435272539034e-05
- O 0 0.0006297195795923471
neurophysin O 0 0.00017525027215015143
II O 0 3.5259748983662575e-05
gene O 0 5.430521810012578e-07
in O 0 4.4550457545255995e-08
two O 0 1.235093236573448e-07
Spanish O 0 1.2646627283174894e-06
kindreds O 0 2.5076951715163887e-05
with O 0 4.120548965147464e-06
familial B-Disease 1 0.636411726474762
neurohypophyseal I-Disease 1 0.9999624490737915
diabetes I-Disease 1 0.9999854564666748
insipidus I-Disease 1 0.9658475518226624
. O 0 7.782366446917877e-05

Familial B-Disease 1 0.9996336698532104
neurohypophyseal I-Disease 1 0.9999853372573853
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999839067459106
( O 0 0.12028501182794571
FNDI B-Disease 1 0.9999998807907104
) O 0 4.688133776653558e-05
is O 0 1.2244494200785994e-06
an O 0 5.203102318773745e-06
autosomal B-Disease 1 0.9634568691253662
dominant I-Disease 1 0.9975244402885437
disease I-Disease 1 0.9952183365821838
caused O 0 0.0006091249524615705
by O 0 2.8905647923238575e-05
deficiency O 0 0.017590418457984924
in O 0 9.094740107684629e-07
the O 0 7.096350600477308e-06
antidiuretic O 0 0.0007462195353582501
hormone O 0 1.530309054942336e-05
arginine O 0 2.0596258764271624e-05
vasopressin O 0 2.2530784917762503e-05
( O 0 2.5897145405906485e-07
AVP O 0 1.8035458197118714e-05
) O 0 5.4567809826266966e-08
encoded O 0 5.520430335081983e-08
by O 0 5.589020091179009e-08
the O 0 5.30696127043484e-07
AVP O 0 0.0006761313998140395
- O 0 0.004736825358122587
neurophysin O 0 0.0016026238445192575
II O 0 0.00015763334522489458
( O 0 3.698667967455549e-07
AVP O 0 6.287319411057979e-05
- O 0 0.00013413385022431612
NPII O 0 0.00018472483498044312
) O 0 1.82192323450181e-07
gene O 0 6.414115318875702e-07
on O 0 3.523086434142897e-06
chromosome O 0 0.0002803098759613931
20p13 O 0 5.3315889090299606e-05
. O 0 1.037270703818649e-05

In O 0 1.7009591829264536e-05
this O 0 5.797428457299247e-07
study O 0 4.986493991054886e-07
, O 0 4.352094151727215e-07
we O 0 9.800898936873637e-08
analyzed O 0 3.771873196001252e-07
two O 0 8.630114933794175e-08
families O 0 7.692007386594923e-08
with O 0 3.61655622782564e-07
FNDI B-Disease 1 0.9996647834777832
using O 0 5.732001113756269e-07
direct O 0 1.9488774682940857e-07
automated O 0 3.954411567974603e-06
fluorescent O 0 2.0067618606844917e-06
, O 0 1.442637795889823e-07
solid O 0 1.3616356682177866e-06
phase O 0 1.1491782743178192e-06
, O 0 1.9020765762434166e-07
single O 0 6.92859487116948e-07
- O 0 1.962460191862192e-05
stranded O 0 2.4003452381293755e-06
DNA O 0 3.016510845554876e-06
sequencing O 0 7.383079605460807e-07
of O 0 9.537409084714454e-08
PCR O 0 3.2366628147428855e-05
- O 0 7.340224692597985e-05
amplified O 0 6.368480535456911e-05
AVP O 0 0.0002791087608784437
- O 0 7.871198613429442e-05
NPII O 0 0.0002628047368489206
DNA O 0 8.478176459902897e-05
. O 0 6.898595529492013e-06

In O 0 5.8892860579362605e-06
one O 0 5.207215281188837e-07
of O 0 8.056419886770527e-08
the O 0 4.0292002267960925e-07
families O 0 4.7040754225236014e-07
, O 0 9.565032996761147e-07
affected O 0 1.3752821814705385e-07
individuals O 0 2.069955762351583e-08
presented O 0 4.794142682840175e-07
a O 0 1.1075989050368662e-06
novel O 0 6.44521833237377e-06
nonsense O 0 1.2460808648029342e-05
mutation O 0 1.4779257071495522e-06
in O 0 1.089476455717886e-07
exon O 0 2.2742835881217616e-06
3 O 0 1.0642686447681626e-06
of O 0 2.358473949470863e-08
the O 0 1.5855947310683405e-07
gene O 0 8.841605563247867e-07
, O 0 7.551349767709326e-08
consisting O 0 2.9791111799681858e-08
in O 0 8.069014967304611e-08
a O 0 1.8021297591985785e-06
G O 0 0.01288442313671112
to O 0 3.884480975102633e-06
T O 0 0.00012601172784343362
transition O 0 6.961532221794187e-07
at O 0 6.199650783855759e-07
nucleotide O 0 4.644260116037913e-06
2101 O 0 2.1405388906714506e-05
, O 0 4.944415081808984e-07
which O 0 1.1044065217902244e-07
produces O 0 3.375282915385469e-07
a O 0 2.9839026183253736e-07
stop O 0 1.2234036148583982e-06
signal O 0 1.9751655599975493e-06
in O 0 4.2826604840229265e-07
codon O 0 3.03411616187077e-06
82 O 0 8.352424629265442e-06
( O 0 5.124011863699707e-07
Glu O 0 0.00019400253950152546
) O 0 2.126932230339662e-07
of O 0 1.85028426358258e-07
NPII O 0 0.0010295046959072351
. O 0 1.1087772691098507e-05

The O 0 5.181965752854012e-05
premature O 0 0.0007927272235974669
termination O 0 2.131287328666076e-05
eliminates O 0 6.03488797423779e-06
part O 0 3.998245006187062e-07
of O 0 5.349563991785544e-08
the O 0 5.178748665457533e-07
C O 0 8.313003490911797e-05
- O 0 2.7051624783780426e-05
terminal O 0 6.112136816227576e-06
domain O 0 1.325821301634278e-07
of O 0 5.5824248335056836e-08
NPII O 0 5.216911813477054e-05
, O 0 1.0680332707124762e-07
including O 0 1.1053270299044016e-08
a O 0 8.320739652845077e-08
cysteine O 0 2.057784911357885e-07
residue O 0 3.197490514139645e-06
in O 0 4.6891960892025963e-07
position O 0 1.8714893030846724e-06
85 O 0 1.4752135939488653e-06
, O 0 4.440124428128911e-07
which O 0 3.211412149539683e-07
could O 0 4.881417225988116e-07
be O 0 5.897700816603901e-08
involved O 0 4.222549065957537e-08
in O 0 1.1570759284040832e-07
the O 0 2.931152209839638e-07
correct O 0 4.451316999620758e-05
folding O 0 8.546825483790599e-06
of O 0 2.8985783728785464e-07
the O 0 4.25541747972602e-06
prohormone O 0 0.002505002310499549
. O 0 2.1124566046637483e-05

In O 0 1.3476391359290574e-05
the O 0 2.896560772569501e-06
second O 0 2.0631054212572053e-05
family O 0 6.296901119640097e-06
, O 0 2.502269751403219e-07
a O 0 1.5517163376443932e-07
G279A O 0 6.672346444247523e-07
substitution O 0 8.608611068439131e-08
at O 0 7.353635851359286e-07
position O 0 1.1696376986947143e-06
- O 0 1.221059665112989e-05
1 O 0 1.09511472601298e-06
of O 0 1.606772670470491e-08
the O 0 1.1747290784569486e-07
signal O 0 3.8079692785686348e-06
peptide O 0 8.707659731044259e-07
was O 0 2.1791065591969527e-06
observed O 0 3.2244699355032935e-07
in O 0 6.983602673926725e-08
all O 0 6.794299167722784e-08
affected O 0 7.715566994193068e-07
individuals O 0 2.3249255320934026e-07
. O 0 2.716244807743351e-06

This O 0 2.5887766241794452e-05
missense O 0 0.0006348598399199545
mutation O 0 0.00019359712314326316
, O 0 3.6802591694140574e-06
which O 0 1.504286387898901e-06
replaces O 0 9.202573710354045e-05
Ala O 0 0.00022865115897729993
with O 0 2.735090447458788e-06
Thr O 0 0.012282725423574448
, O 0 1.2702471394732129e-06
is O 0 6.686131115429816e-08
frequent O 0 1.4363999980560038e-06
among O 0 2.0289130588935222e-06
FNDI B-Disease 1 0.9999998807907104
patients O 0 0.0004893045406788588
and O 0 1.2720715858449694e-06
is O 0 3.4773981383295904e-07
thought O 0 1.2222544398809987e-07
to O 0 5.415421355792205e-08
reduce O 0 5.710095365429879e-07
the O 0 7.00323781188672e-08
efficiency O 0 6.93306276389194e-07
of O 0 1.1508328867648743e-07
cleavage O 0 1.8779235688271e-05
by O 0 8.085790454970265e-07
signal O 0 1.6596664863754995e-05
peptidases O 0 4.8655620048521087e-05
. O 0 1.3610488167614676e-06
. O 0 2.72435977421992e-06

Genetic O 0 0.0013470964040607214
heterogeneity O 0 0.0006794328801333904
of O 0 1.3211126315582078e-05
Saethre B-Disease 1 0.6750951409339905
- I-Disease 1 0.9999033212661743
Chotzen I-Disease 1 0.9998832941055298
syndrome I-Disease 1 0.9999942779541016
, O 0 2.4913051674957387e-06
due O 0 1.361002091471164e-06
to O 0 3.6744899034601985e-07
TWIST O 0 6.29190108156763e-05
and O 0 1.171390886156587e-05
FGFR O 0 0.023403547704219818
mutations O 0 0.0001120411980082281
. O 0 4.556852218229324e-06

Thirty O 0 0.0001434936566511169
- O 0 0.00025892656412906945
two O 0 3.751557414943818e-06
unrelated O 0 2.348035923205316e-05
patients O 0 7.474152425857028e-06
with O 0 7.591510353677222e-08
features O 0 2.016365215240512e-06
of O 0 1.0125713743036613e-06
Saethre B-Disease 1 0.6035934090614319
- I-Disease 1 0.9993127584457397
Chotzen I-Disease 1 0.9968427419662476
syndrome I-Disease 1 0.998024582862854
, O 0 3.965764960867091e-07
a O 0 1.338522338301118e-06
common O 0 2.9330889447010122e-05
autosomal B-Disease 0 0.1629633605480194
dominant I-Disease 0 0.018832668662071228
condition I-Disease 0 0.012562681920826435
of O 0 8.61045191413723e-06
craniosynostosis B-Disease 1 0.9867061972618103
and O 0 0.05993976071476936
limb B-Disease 1 0.935713529586792
anomalies I-Disease 1 0.5652346014976501
, O 0 3.776249741349602e-06
were O 0 8.32269051898038e-07
screened O 0 2.8807096441596514e-06
for O 0 5.786789643025259e-07
mutations O 0 4.157340754318284e-06
in O 0 9.687524880064302e-07
TWIST O 0 0.00011954703222727403
, O 0 3.811638862316613e-06
FGFR2 O 0 0.0003216864133719355
, O 0 1.0575244004940032e-06
and O 0 1.248439957635128e-06
FGFR3 O 0 0.0008306344388984144
. O 0 1.0371143616794143e-05

Nine O 0 7.338509021792561e-05
novel O 0 1.9134791727992706e-05
and O 0 1.9655994947243016e-06
three O 0 2.523165676393546e-06
recurrent O 0 0.000574041623622179
TWIST O 0 0.005480623338371515
mutations O 0 0.00018628100224304944
were O 0 1.1020514421034022e-06
found O 0 1.0870516007344122e-06
in O 0 5.930322117819742e-07
12 O 0 5.996364507154794e-06
families O 0 2.547163830968202e-06
. O 0 8.223412805818953e-06

Seven O 0 5.519334081327543e-05
families O 0 4.446566890692338e-06
were O 0 3.5537061648938106e-06
found O 0 5.67235247217468e-07
to O 0 9.739830630905999e-08
have O 0 7.080250696844814e-08
the O 0 7.17474577527355e-08
FGFR3 O 0 9.305669664172456e-05
P250R O 0 5.304651949700201e-06
mutation O 0 1.7166779571198276e-06
, O 0 1.8614646535297652e-07
and O 0 2.935908298695722e-07
one O 0 2.491756276867818e-07
individual O 0 1.0371575598355776e-07
was O 0 4.55579865956679e-05
found O 0 1.584232791174145e-06
to O 0 1.7470293300902995e-07
have O 0 6.462634161152891e-08
an O 0 1.895441812393983e-07
FGFR2 O 0 0.0001744439941830933
VV269 O 0 1.7794225641409867e-05
- O 0 8.068884926615283e-05
270 O 0 2.18424538616091e-05
deletion O 0 0.00015556483413092792
. O 0 9.328117812401615e-06

To O 0 2.0598223272827454e-05
date O 0 1.4228276995709166e-05
, O 0 3.3877665828185854e-07
our O 0 1.6300930383295054e-07
detection O 0 9.931834483722923e-07
rate O 0 6.135188641565037e-07
for O 0 8.861741207510931e-08
TWIST O 0 2.2427630028687418e-05
or O 0 1.3804558420815738e-06
FGFR O 0 0.00027459184639155865
mutations O 0 1.0577267858025152e-05
is O 0 1.2270406557490787e-07
68 O 0 1.0845664064618177e-06
% O 0 8.558154718230071e-08
in O 0 6.08365979815062e-08
our O 0 1.0823840739249135e-06
Saethre B-Disease 0 0.014512920752167702
- I-Disease 1 0.9988393187522888
Chotzen I-Disease 1 0.999855637550354
syndrome I-Disease 1 0.9999877214431763
patients O 0 1.948763929249253e-05
, O 0 1.0355505963843825e-07
including O 0 3.420411331944706e-08
our O 0 1.968295464394032e-07
five O 0 2.946970880657318e-06
patients O 0 2.364172587476787e-06
elsewhere O 0 1.2258362858119654e-06
reported O 0 1.4883278709021397e-05
with O 0 7.552089869022893e-07
TWIST O 0 0.002345082815736532
mutations O 0 0.0002714644942898303
. O 0 5.454134679894196e-06

More O 0 3.916142759408103e-06
than O 0 7.772114258841611e-07
35 O 0 7.138524438232707e-07
different O 0 9.807930467786719e-08
TWIST O 0 1.6683830835972913e-05
mutations O 0 1.521927333669737e-05
are O 0 8.310145460654894e-08
now O 0 1.9278317608950601e-07
known O 0 5.142241548128368e-07
in O 0 2.070880640303585e-07
the O 0 6.63563014313695e-07
literature O 0 2.5271247068303637e-06
. O 0 3.903897322743433e-06

The O 0 3.1450617825612426e-06
most O 0 3.6363667277328204e-07
common O 0 3.787835112234461e-07
phenotypic O 0 2.9422612897178624e-06
features O 0 3.838483735307818e-06
, O 0 1.1666409136523725e-06
present O 0 1.038901871197595e-07
in O 0 8.936527251535153e-08
more O 0 2.013254452037927e-08
than O 0 2.480476801736131e-08
a O 0 3.325372972540208e-07
third O 0 2.379858187850914e-06
of O 0 1.1280754819154026e-07
our O 0 2.106516603816999e-06
patients O 0 1.0138794550584862e-06
with O 0 1.0870210331859198e-07
TWIST O 0 0.0007896157330833375
mutations O 0 6.363763532135636e-05
, O 0 1.7671406737918005e-07
are O 0 4.142117404626333e-08
coronal B-Disease 0 3.971055048168637e-05
synostosis I-Disease 0 0.00023301829060073942
, O 0 1.0082370636155247e-06
brachycephaly B-Disease 0 3.644022217486054e-05
, O 0 7.437047884195636e-07
low B-Disease 0 3.072879189858213e-05
frontal I-Disease 0 0.19601747393608093
hairline I-Disease 1 0.99997878074646
, O 0 0.001525765168480575
facial B-Disease 1 0.9948887228965759
asymmetry I-Disease 0 0.00607543159276247
, O 0 6.793745706090704e-05
ptosis B-Disease 1 0.8166759610176086
, O 0 2.426842002023477e-05
hypertelorism B-Disease 0 0.002862154506146908
, O 0 2.3326106202148367e-06
broad B-Disease 0 4.154249381826958e-06
great I-Disease 0 3.853790076391306e-06
toes I-Disease 0 0.0017084080027416348
, O 0 3.132080337309162e-06
and O 0 2.5263366296712775e-06
clinodactyly B-Disease 0 0.0003178994811605662
. O 0 6.6527277340355795e-06

Significant O 0 3.370731428731233e-05
intra O 0 0.00012380685075186193
- O 0 0.0015818449901416898
and O 0 8.263017662102357e-06
interfamilial O 0 0.000108642183477059
phenotypic O 0 3.895855479640886e-05
variability O 0 5.6524662795709446e-05
is O 0 5.524074140339508e-07
present O 0 1.788743446695662e-07
for O 0 2.634262159517675e-07
either O 0 1.0585939662632882e-06
TWIST O 0 0.0005112910876050591
mutations O 0 0.00025971702416427433
or O 0 5.437468644231558e-06
FGFR O 0 0.017535578459501266
mutations O 0 0.0003674549516290426
. O 0 1.1924533282581251e-05

The O 0 6.8968720370321535e-06
overlap O 0 1.0995781849487685e-05
in O 0 5.831386715726694e-06
clinical O 0 7.927363185444847e-06
features O 0 2.995180693687871e-06
and O 0 2.5137699140032055e-06
the O 0 2.0835709335642605e-07
presence O 0 1.7616065406400594e-07
, O 0 1.0029054209326205e-07
in O 0 1.8575857296809772e-08
the O 0 2.5154283989081705e-08
same O 0 9.466582184813888e-08
genes O 0 1.7393720952441072e-07
, O 0 9.903423858759197e-08
of O 0 3.941820736486079e-08
mutations O 0 1.4713764358020853e-06
for O 0 4.944679332652413e-08
more O 0 3.749221377802314e-08
than O 0 7.40095842388655e-08
one O 0 1.3664083553521778e-06
craniosynostotic B-Disease 0 0.0003234956820961088
condition I-Disease 0 1.44098930832115e-05
- O 0 5.1907663873862475e-06
such O 0 3.694454875358133e-08
as O 0 5.556165092457377e-07
Saethre B-Disease 0 3.247001222916879e-05
- I-Disease 0 0.00013569535803981125
Chotzen I-Disease 0 2.0783427316928282e-05
, I-Disease 0 3.930140053398645e-07
Crouzon I-Disease 0 5.684434654540382e-06
, I-Disease 0 4.485981150992302e-07
and I-Disease 0 6.460887107095914e-06
Pfeiffer I-Disease 1 0.6462070941925049
syndromes I-Disease 0 0.00727086840197444
- O 0 5.858980512130074e-05
support O 0 1.0482824563950999e-06
the O 0 4.230909382840764e-07
hypothesis O 0 2.6712712042353814e-06
that O 0 1.469352781668931e-07
TWIST O 0 1.4876793102303054e-05
and O 0 1.9625390450528357e-06
FGFRs O 0 1.0402822226751596e-05
are O 0 2.1727238674884575e-08
components O 0 1.480231901496154e-07
of O 0 1.7661829332382695e-08
the O 0 6.571784894049415e-08
same O 0 1.7265523410969763e-07
molecular O 0 1.3289712796904496e-06
pathway O 0 4.1730604039003083e-07
involved O 0 2.2729689419520582e-07
in O 0 2.1375304015691654e-07
the O 0 2.0042607218329067e-07
modulation O 0 5.651295396091882e-06
of O 0 3.1032136575959157e-06
craniofacial O 1 0.9966527819633484
and O 0 0.002246347488835454
limb O 0 0.0029276711866259575
development O 0 1.9897631773346802e-06
in O 0 1.528118332316808e-06
humans O 0 1.4291471188698779e-06
. O 0 1.663807552176877e-06
. O 0 5.068274731456768e-06

Mutation O 0 0.00044413114665076137
analysis O 0 2.96509333566064e-05
of O 0 9.658184353611432e-06
UBE3A O 1 0.9897301197052002
in O 1 0.9795290231704712
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.7977535724639893
. O 0 3.9063837903086096e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.4121728539466858
AS B-Disease 1 0.9999310970306396
) O 0 6.474922702182084e-05
is O 0 3.980192559538409e-06
caused O 0 6.455676157202106e-06
by O 0 1.1453805655037286e-06
chromosome O 0 0.00023531055194325745
15q11 O 0 3.064509655814618e-05
- O 0 8.10315104899928e-05
q13 O 0 5.198648523219163e-06
deletions O 0 1.5922530565148918e-06
of O 0 1.0448056997347521e-07
maternal O 0 8.089453331194818e-06
origin O 0 2.54893780038401e-06
, O 0 7.124085641407873e-07
by O 0 6.963146006455645e-07
paternal O 0 0.00013091402070131153
uniparental B-Disease 0 0.10073377937078476
disomy I-Disease 1 0.7473386526107788
( O 0 3.06719375657849e-05
UPD B-Disease 1 0.9999520778656006
) O 0 2.358733809160185e-06
15 O 0 5.412622385847499e-07
, O 0 1.443007988655154e-07
by O 0 2.945165533674299e-07
imprinting O 0 0.03576713427901268
defects O 1 0.9944370985031128
, O 0 2.625524075483554e-06
and O 0 9.99874941953749e-07
by O 0 5.797477911073656e-07
mutations O 0 5.7066231420321856e-06
in O 0 4.748952164845832e-07
the O 0 2.301768290635664e-06
UBE3A O 0 0.002481683623045683
gene O 0 9.559075988363475e-05
. O 0 1.3312176633917261e-05

UBE3A O 0 0.005195575300604105
encodes O 0 0.00011654088302748278
a O 0 7.722650479990989e-06
ubiquitin O 0 2.4918277631513774e-05
- O 0 7.057019683998078e-05
protein O 0 4.705520950665232e-06
ligase O 0 1.7442404214307317e-06
and O 0 9.288695537179592e-07
shows O 0 3.2970331176329637e-06
brain O 0 5.7289664255222306e-05
- O 0 6.51030641165562e-05
specific O 0 3.0748092285648454e-06
imprinting O 0 0.0003326401056256145
. O 0 1.3091976143186912e-05

Here O 0 2.433217377983965e-05
we O 0 1.9822002741420874e-06
describe O 0 3.069447757297894e-06
UBE3A O 0 0.0002244347706437111
coding O 0 0.00043868509237654507
- O 0 0.006926423404365778
region O 0 0.0001024789089569822
mutations O 0 7.4925490480382e-05
detected O 0 7.2708244260866195e-06
by O 0 1.4847532270323427e-07
SSCP O 0 8.301120396936312e-05
analysis O 0 2.0825827959924936e-06
in O 0 1.2959009154656087e-06
13 O 0 1.6880991097423248e-05
AS B-Disease 1 0.99204421043396
individuals O 0 1.5476625492283347e-07
or O 0 1.1210834145458648e-06
families O 0 1.3534830713979318e-06
. O 0 4.398779765324434e-06

Two O 0 2.1837247913936153e-05
identical O 0 3.743406341527589e-05
de O 0 2.8478043532231823e-05
novo O 0 5.8192788856104016e-05
5 O 0 1.0029405530076474e-05
- O 0 9.197853796649724e-05
bp O 0 0.0001916276232805103
duplications O 0 4.269865257811034e-06
in O 0 3.311423029117577e-07
exon O 0 9.719046829559375e-06
16 O 0 1.9992203306173906e-06
were O 0 1.1942352102778386e-06
found O 0 3.5415737329458352e-06
. O 0 7.696263310208451e-06

Among O 0 4.2580882109177765e-06
the O 0 5.377465299716278e-07
other O 0 1.399087494746709e-07
11 O 0 6.539748937939294e-07
unique O 0 3.5157725619683333e-07
mutations O 0 9.178499567497056e-06
, O 0 5.384521841733658e-07
8 O 0 1.4336601452669129e-06
were O 0 1.2903154811283457e-07
small O 0 8.201619294823104e-08
deletions O 0 2.600046400402789e-06
or O 0 4.94789617278002e-07
insertions O 0 2.1156542061362416e-05
predicted O 0 0.0003797871177084744
to O 0 2.9518030260078376e-06
cause O 0 4.765612175106071e-06
frameshifts O 0 0.00011238627484999597
, O 0 1.1288163932476891e-06
1 O 0 2.9096063371980563e-06
was O 0 9.188579497276805e-06
a O 0 1.1520004363774206e-06
mutation O 0 1.4076721299716155e-06
to O 0 6.602414970302561e-08
a O 0 2.0795272348550498e-07
stop O 0 1.1119975624751532e-06
codon O 0 8.533612572136917e-07
, O 0 1.5653505158752523e-07
1 O 0 4.837843903260364e-07
was O 0 1.7455716943004518e-06
a O 0 6.152391165414883e-07
missense O 0 2.629462323966436e-05
mutation O 0 4.650611117540393e-06
, O 0 4.27573894512534e-07
and O 0 5.14606313117838e-07
1 O 0 1.1623093087109737e-05
was O 0 0.0003258362994529307
predicted O 0 4.7500929213128984e-05
to O 0 8.989477464638185e-07
cause O 0 6.738712841070083e-07
insertion O 0 1.3230820741227944e-06
of O 0 1.4390198543878796e-07
an O 0 2.2737783638149267e-06
isoleucine O 0 0.005061611998826265
in O 0 1.1689083976307302e-06
the O 0 2.600604318558908e-07
hect O 0 8.617368621344212e-06
domain O 0 1.1671301081150887e-07
of O 0 2.4404467779959305e-08
the O 0 2.0941268985552597e-07
UBE3A O 0 3.190312781953253e-05
protein O 0 3.181509327987442e-06
, O 0 9.200508799267482e-08
which O 0 3.9012363117763016e-08
functions O 0 1.5853780510610704e-08
in O 0 8.270976081803383e-08
E2 O 0 4.0865223127184436e-05
binding O 0 4.250582605891395e-06
and O 0 9.76127125795756e-07
ubiquitin O 0 1.030019575409824e-05
transfer O 0 8.520662049704697e-06
. O 0 1.2965021596755832e-05

Eight O 0 6.326636139419861e-06
of O 0 4.2556669654914003e-07
the O 0 6.205885938470601e-07
cases O 0 5.930650104346569e-07
were O 0 1.1538345461303834e-06
familial O 0 4.519070716924034e-05
, O 0 3.2557425129198236e-06
and O 0 1.4717397789354436e-06
five O 0 1.2758853245031787e-06
were O 0 1.3572238231063238e-06
sporadic O 0 4.570934106595814e-05
. O 0 7.732201083854306e-06

In O 0 1.3642425983562134e-05
two O 0 3.6542044199450174e-06
familial O 0 0.0006078392034396529
cases O 0 1.1372725566616282e-05
and O 0 4.910168627247913e-06
one O 0 2.508266788936453e-06
sporadic O 0 3.2970063330139965e-05
case O 0 1.134304784500273e-05
, O 0 1.1613414017119794e-06
mosaicism O 0 4.0649429138284177e-05
for O 0 1.4688024521092302e-06
UBE3A O 0 0.00031565228709951043
mutations O 0 3.7759324186481535e-05
was O 0 1.5467418052139692e-05
detected O 0 4.277527750673471e-06
in O 0 3.2309031894328655e-07
the O 0 4.5498165945900837e-07
mother O 0 8.246626748587005e-06
of O 0 1.046127806603181e-07
three O 0 4.437035840965109e-06
AS B-Disease 1 0.9999741315841675
sons O 0 0.00964815728366375
, O 0 3.2590648402219813e-07
in O 0 1.1227102447719517e-07
the O 0 3.7745576264569536e-07
maternal O 0 7.081167495925911e-06
grandfather O 0 4.176048605586402e-06
of O 0 8.057526201810106e-08
two O 0 3.124618842775817e-06
AS B-Disease 1 0.9993594288825989
first O 0 3.6616627767216414e-05
cousins O 0 2.2095304302638397e-05
, O 0 7.244960897878627e-07
and O 0 4.6105571982479887e-07
in O 0 1.6092454302452097e-07
the O 0 3.770830119265156e-07
mother O 0 9.536264769849367e-06
of O 0 1.6887503306861618e-07
an O 0 9.69257416727487e-06
AS B-Disease 1 0.9997478127479553
daughter O 0 0.18090243637561798
. O 0 3.677326094475575e-05

The O 0 4.921968866256066e-06
frequencies O 0 3.7006229831604287e-06
with O 0 2.9507543786166934e-07
which O 0 3.6811400150327245e-07
we O 0 1.6741215347337857e-07
detected O 0 1.3820075537296361e-06
mutations O 0 1.0605978104649694e-06
were O 0 3.9082078728824854e-07
5 O 0 1.8592447759147035e-06
( O 0 1.7427160514671414e-07
14 O 0 7.344889922933362e-07
% O 0 1.4729093322785047e-07
) O 0 2.1188334642374684e-08
of O 0 9.687412649839189e-09
35 O 0 7.342592311943008e-07
in O 0 4.4998810722063354e-07
sporadic O 0 1.1619082215474918e-05
cases O 0 1.127679070123122e-06
and O 0 9.9751571269735e-07
8 O 0 5.1497681852197275e-06
( O 0 8.101971360474636e-08
80 O 0 1.4233050649181678e-07
% O 0 1.2882044586604025e-07
) O 0 2.4669404297128494e-08
of O 0 1.732940368981417e-08
10 O 0 9.366629001306137e-07
in O 0 2.0103630049561616e-06
familial O 0 0.0006018617423251271
cases O 0 6.752029548806604e-06
. O 0 9.930356554832542e-07
. O 0 5.37471032657777e-06

The O 0 0.00038974147173576057
hemochromatosis B-Disease 1 0.9999947547912598
845 O 0 0.007001530844718218
G O 1 0.8354655504226685
- O 0 0.0019828686490654945
- O 0 0.00019623036496341228
> O 0 1.2316662605371675e-06
A O 0 5.846716817359265e-07
and O 0 2.3398619930503628e-07
187 O 0 4.222488598770724e-07
C O 0 1.568568950460758e-05
- O 0 0.00024481542641296983
- O 0 0.0011582992738112807
> O 0 1.6598532965872437e-05
G O 0 0.012730604968965054
mutations O 0 1.586725738889072e-05
: O 0 3.706340976350475e-07
prevalence O 0 4.043912213091971e-06
in O 0 2.387841675499658e-07
non O 0 6.249710168049205e-06
- O 0 0.006820743437856436
Caucasian O 0 0.0005114256637170911
populations O 0 2.137059527740348e-05
. O 0 6.521235263790004e-06

Hemochromatosis B-Disease 1 0.9971169233322144
, O 0 0.000712370325345546
the O 0 0.0005261843325570226
inherited B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999998807907104
of I-Disease 0 1.6008119928301312e-05
iron I-Disease 1 0.990931510925293
metabolism I-Disease 0 0.033949483186006546
, O 0 3.6832157093158457e-06
leads O 0 7.063395969453268e-06
, O 0 2.1506548364413902e-06
if O 0 8.719152333469538e-07
untreated O 0 3.6094574170419946e-05
, O 0 3.150205145630025e-07
to O 0 7.045729262245004e-07
progressive O 0 0.0011358378687873483
iron B-Disease 1 0.9914295077323914
overload I-Disease 0 0.06593291461467743
and O 0 0.00016790855443105102
premature B-Disease 0 0.0015544468769803643
death I-Disease 0 0.00014334497973322868
. O 0 8.071128831943497e-06

The O 0 0.0005301958881318569
hemochromatosis B-Disease 1 0.9999969005584717
gene O 0 0.001387180294841528
, O 0 1.626737321203109e-05
HFE O 0 0.001200914615765214
, O 0 1.1326746061968151e-05
recently O 0 1.542211430205498e-05
has O 0 3.448893721724744e-06
been O 0 1.5429010318257497e-06
identified O 0 2.906685722336988e-06
, O 0 3.516523747748579e-07
and O 0 3.059637663227477e-07
characterization O 0 2.822209580699564e-06
of O 0 1.289557616246384e-07
this O 0 3.0302649633995316e-07
gene O 0 2.4100936570903286e-06
has O 0 2.196593413827941e-06
shown O 0 7.755055548841483e-07
that O 0 9.936763234463797e-08
it O 0 7.522540101945197e-08
contains O 0 2.7376994893302253e-08
two O 0 4.5331847786656e-07
mutations O 0 2.9230195650598034e-06
that O 0 8.489514158327438e-08
result O 0 1.0816230400223503e-07
in O 0 4.7764043387132915e-08
amino O 0 2.3312043140322203e-07
acid O 0 1.8583158407636802e-06
substitutions O 0 3.4271255344719975e-07
- O 0 1.199768234982912e-06
cDNA O 0 6.910599381626525e-07
nucleotides O 0 4.982529731023533e-07
845 O 0 1.245018097506545e-06
G O 0 9.676524496171623e-05
- O 0 6.053958713891916e-05
- O 0 8.848204015521333e-05
> O 0 8.012619900910067e-07
A O 0 2.6194818474323256e-06
( O 0 1.3881535210202856e-07
C282Y O 0 9.754886605151114e-07
) O 0 5.7362566252550096e-08
and O 0 9.3231946607375e-08
187 O 0 4.6349450144589355e-07
C O 0 1.8270580767421052e-05
- O 0 0.00021015481615904719
- O 0 0.005828977562487125
> O 0 3.149866824969649e-05
G O 0 0.008747567422688007
( O 0 1.0920183513007942e-06
H63D O 0 0.00018448385526426136
) O 0 2.802344624797115e-06
. O 0 3.712970737979049e-06

Although O 0 0.002103380858898163
hemochromatosis B-Disease 1 0.9999985694885254
is O 0 1.9369133951840922e-05
common O 0 4.361477749625919e-06
in O 0 3.5836899314745096e-06
Caucasians O 0 0.0001849433610914275
, O 0 4.011251803603955e-06
affecting O 0 9.062774211088254e-07
> O 0 2.242127038698527e-06
= O 0 1.985304697882384e-05
1 O 0 7.568633009213954e-06
/ O 0 5.053805580246262e-06
300 O 0 6.652955164554442e-08
individuals O 0 7.106902177866914e-09
of O 0 1.2845591257359956e-08
northern O 0 1.5214423001452815e-06
European O 0 2.9882335184083786e-06
origin O 0 9.976679393730592e-07
, O 0 5.201368935559003e-07
it O 0 2.346774152783837e-07
has O 0 6.193151307343214e-07
not O 0 9.881574669634574e-08
been O 0 1.9509506898884865e-07
recognized O 0 7.599014395509585e-08
in O 0 1.1771638241953042e-07
other O 0 4.579557639772247e-07
populations O 0 5.771798896603286e-06
. O 0 3.6135197660769336e-06

The O 0 8.850845006236341e-06
present O 0 2.228704715889762e-06
study O 0 7.512194883929624e-07
used O 0 3.4715003494056873e-07
PCR O 0 5.62361856282223e-06
and O 0 2.676891881492338e-07
restriction O 0 1.1823674128663697e-07
- O 0 6.0069423852837645e-06
enzyme O 0 7.935902885947144e-07
digestion O 0 6.315932523648371e-07
to O 0 1.2035094698603643e-07
analyze O 0 2.612361527098983e-07
the O 0 3.924633773522146e-08
frequency O 0 3.13140333219053e-07
of O 0 2.5422121296969635e-08
the O 0 3.0466370048998215e-07
845 O 0 7.011757134023355e-06
G O 0 0.0011072192573919892
- O 0 4.33156565122772e-05
- O 0 2.458250310155563e-05
> O 0 3.2318681064680277e-07
A O 0 6.972462074372743e-07
and O 0 3.337439409278886e-07
187 O 0 5.116481816003215e-07
C O 0 1.7012576790875755e-05
- O 0 4.804148920811713e-05
- O 0 0.0005788371781818569
> O 0 6.317839506664313e-06
G O 0 0.0005356921465136111
mutations O 0 5.513786618394079e-06
in O 0 1.962236098052017e-07
HLA O 0 2.8416814529919066e-05
- O 0 7.37270465833717e-06
typed O 0 9.401962302035827e-07
samples O 0 2.1108449743678648e-07
from O 0 6.712070188541475e-08
non O 0 5.847642228218319e-07
- O 0 6.745811697328463e-05
Caucasian O 0 4.245313903084025e-05
populations O 0 1.111254391616967e-06
, O 0 5.60743913524675e-08
comprising O 0 4.411978338225708e-08
Australian O 0 4.153351937929983e-07
Aboriginal O 0 2.1624815360610228e-07
, O 0 5.771584454805634e-08
Chinese O 0 1.75108176847516e-08
, O 0 1.0082507628794701e-07
and O 0 3.6230946420801047e-07
Pacific O 0 3.988714979641372e-06
Islanders O 0 1.3357882380660158e-05
. O 0 3.2294110496877693e-06

Results O 0 0.0006289099110290408
showed O 0 4.7342015022877604e-05
that O 0 2.3354878919690236e-07
the O 0 2.932228824192862e-07
845 O 0 1.3496894098352641e-05
G O 0 0.041772712022066116
- O 0 0.0010451390407979488
- O 0 0.00038154787034727633
> O 0 1.139582991527277e-06
A O 0 2.782465116979438e-06
mutation O 0 2.1641640159941744e-06
was O 0 2.9460713903972646e-06
present O 0 1.7176641620153532e-07
in O 0 1.8298810289252287e-07
these O 0 5.184391582702119e-08
populations O 0 3.8082851006038254e-07
( O 0 5.9129177998329396e-08
allele O 0 2.3207984156670136e-07
frequency O 0 6.38379788142629e-07
0 O 0 8.167593819052854e-07
. O 0 1.2199021170999913e-07
32 O 0 3.751954693598236e-07
% O 0 2.1457859133988677e-07
) O 0 8.935998607739748e-08
, O 0 1.5815881226899364e-07
and O 0 5.057557928012102e-07
, O 0 7.555734669040248e-07
furthermore O 0 8.337697181559633e-07
, O 0 2.723466252518847e-07
it O 0 3.380021382781706e-07
was O 0 8.888587217370514e-06
always O 0 1.955758790472828e-07
seen O 0 5.941559493294335e-07
in O 0 5.115671442013081e-08
conjunction O 0 2.768922797713458e-07
with O 0 1.0059848136734217e-06
HLA O 0 0.0005689041572622955
haplotypes O 0 1.4142292457108852e-05
common O 0 7.45827776427177e-07
in O 0 5.852819526808162e-07
Caucasians O 0 1.8757042198558338e-05
, O 0 8.051163717937015e-07
suggesting O 0 1.7502791251899907e-06
that O 0 2.0532723965516197e-07
845 O 0 4.222938059683656e-06
G O 0 0.04307320713996887
- O 0 0.004655171651393175
- O 0 0.00975481141358614
> O 0 2.4889611722755944e-06
A O 0 2.179811053792946e-05
may O 0 1.0714100426412188e-05
have O 0 6.380535921834962e-08
been O 0 6.824600262689273e-08
introduced O 0 7.545359892446868e-08
into O 0 3.5654270647000885e-08
these O 0 3.812521853774342e-08
populations O 0 2.596589467884769e-07
by O 0 4.0717992533245706e-07
Caucasian O 0 0.00013020914047956467
admixture O 0 0.00018701082444749773
. O 0 3.274186747148633e-05

187 O 0 0.00024347903672605753
C O 0 0.0006920794839970767
- O 0 0.0005519728292711079
- O 0 0.0013008811511099339
> O 0 1.981345849344507e-05
G O 0 0.00030196469742804766
was O 0 6.413860774046043e-06
present O 0 1.0899628222205138e-07
at O 0 2.1113928028171358e-07
an O 0 1.1257917265083961e-07
allele O 0 1.5118254168555723e-06
frequency O 0 1.529421865598124e-06
of O 0 2.5282287197114783e-07
2 O 0 3.090046811848879e-05
. O 0 1.7590004063094966e-05

68 O 0 0.0006684983382001519
% O 0 1.1235130841669161e-05
in O 0 5.58938154426869e-07
the O 0 1.9617813507011306e-07
two O 0 1.4962456589273643e-06
populations O 0 4.390854428493185e-06
analyzed O 0 1.4396789993043058e-05
( O 0 3.9708967847218446e-07
Australian O 0 9.648753120927722e-07
Aboriginal O 0 8.224104135479138e-07
and O 0 6.031885959600913e-07
Chinese O 0 1.8955648783958168e-07
) O 0 6.519560997730878e-07
. O 0 1.918492216645973e-06

In O 0 1.075453565135831e-05
the O 0 1.2954362773598405e-06
Australian O 0 2.465473698975984e-06
Aboriginal O 0 9.156216265182593e-07
samples O 0 6.227502353794989e-07
, O 0 1.4192157493653212e-07
187 O 0 3.0154905061863246e-07
C O 0 1.1685868230415508e-05
- O 0 0.00011546041059773415
- O 0 0.0004500469658523798
> O 0 5.1118659030180424e-06
G O 0 0.0011760813649743795
was O 0 1.995832826651167e-05
found O 0 6.822490945523896e-07
to O 0 1.203582939979242e-07
be O 0 9.392877586833492e-08
associated O 0 1.8594596440379974e-07
with O 0 4.505974686708214e-07
HLA O 0 0.003573212306946516
haplotypes O 0 1.6350895748473704e-05
common O 0 1.778564296728291e-06
in O 0 1.1044681968996883e-06
Caucasians O 0 2.2144411559565924e-05
, O 0 8.660065304866293e-07
suggesting O 0 1.3747671800956596e-06
that O 0 1.5611151127359335e-07
it O 0 2.3580091124131286e-07
was O 0 3.0444632557191653e-06
introduced O 0 1.1253102911723545e-06
by O 0 8.276578000732115e-08
recent O 0 1.2796068631359958e-06
admixture O 0 8.60096697579138e-05
. O 0 2.078766920021735e-05

In O 0 3.617940365074901e-06
the O 0 2.3352249911567924e-07
Chinese O 0 9.974856141070632e-08
samples O 0 6.693794034617895e-07
analyzed O 0 1.4208682159733144e-06
, O 0 9.88881510011197e-08
187 O 0 1.6801240576569398e-07
C O 0 6.857272182969609e-06
- O 0 4.7837045713094994e-05
- O 0 0.0005819446523673832
> O 0 4.4028884076396935e-06
G O 0 0.0013212102930992842
was O 0 9.255471923097502e-06
present O 0 1.908023108398993e-07
in O 0 8.350580742444436e-07
association O 0 1.0737852562670014e-07
with O 0 4.684484622430318e-08
a O 0 4.3530405946512474e-07
wide O 0 3.614866841417097e-07
variety O 0 4.437393954503932e-07
of O 0 4.974064609086781e-07
HLA O 0 0.0012552004773169756
haplotypes O 0 4.2697356548160315e-05
, O 0 5.433080900729692e-07
showing O 0 1.501589053987118e-06
this O 0 6.053368650782431e-08
mutation O 0 6.616647851842572e-07
to O 0 2.536855845391983e-07
be O 0 1.819459214402741e-07
widespread O 0 1.8819616798282368e-07
and O 0 4.863416052103275e-07
likely O 0 6.90296474203933e-07
to O 0 2.4147104227267846e-07
predate O 0 4.992912181478459e-06
the O 0 1.3445119861899002e-07
more O 0 8.703875664650695e-08
genetically O 0 1.5554130641248776e-06
restricted O 0 2.497618254437839e-07
845 O 0 4.031243406643625e-06
G O 0 0.0022637706715613604
- O 0 0.000693049980327487
- O 0 0.001522933249361813
> O 0 7.977174391271546e-06
A O 0 1.2994890312256757e-05
mutation O 0 8.365008397959173e-05
. O 0 6.3184115788317285e-06

Genotype O 1 0.7175859808921814
- O 1 0.568755030632019
phenotype O 0 0.0928557738661766
correlations O 0 0.0021083352621644735
in O 0 0.0006861854926683009
attenuated B-Disease 1 0.9990049004554749
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999969005584717
coli I-Disease 1 0.9999909400939941
. O 0 0.0003869641514029354

Germ O 0 0.10660117119550705
- O 0 0.0031332208309322596
line O 0 0.0001236963871633634
mutations O 0 1.5780831745360047e-05
of O 0 2.3532733450792875e-07
the O 0 3.166374654028914e-06
tumor B-Disease 0 0.0011441094102337956
suppressor O 0 0.00043392382212914526
APC O 0 0.00012771399633493274
are O 0 8.520365781805594e-07
implicated O 0 0.00010589830344542861
in O 0 9.312496695201844e-05
attenuated B-Disease 1 0.9995183944702148
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
( O 0 0.004353241994976997
AAPC B-Disease 1 0.9999995231628418
) O 0 1.64734465215588e-05
, O 0 4.0343334717363177e-07
a O 0 3.283640580775682e-06
variant O 0 0.035680536180734634
of O 0 0.002452473621815443
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 0.001450142590329051
FAP B-Disease 0 0.0011885302374139428
) O 0 7.552222541562514e-06
. O 0 7.972854291438125e-06

AAPC B-Disease 1 0.9999713897705078
is O 0 0.00010546214616624638
recognized O 0 5.518025773199042e-06
by O 0 5.90563615787687e-07
the O 0 4.0698117231841024e-07
occurrence O 0 3.811984015555936e-06
of O 0 3.0905886205800925e-07
< O 0 1.2206986866658553e-05
100 O 0 1.254201379197184e-06
colonic B-Disease 0 0.00013816617138218135
adenomas I-Disease 0 0.0005451914039440453
and O 0 9.201015700455173e-07
a O 0 2.2810781956650317e-06
later O 0 0.0002139407879440114
onset O 0 0.0044029271230101585
of O 1 0.6874187588691711
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 8.620500011602417e-06
age O 0 2.022597527684411e-06
> O 0 1.8405254422759754e-06
40 O 0 2.410949036857346e-06
years O 0 1.7029386754074949e-06
) O 0 9.096058306568011e-07
. O 0 4.048526989208767e-06

The O 0 8.561110007576644e-06
aim O 0 1.0876616215682589e-05
of O 0 2.988097378420207e-07
this O 0 2.3232654200455727e-07
study O 0 3.2273004535454675e-07
was O 0 3.850468601740431e-06
to O 0 1.2678930261245114e-06
assess O 0 2.6307214284315705e-05
genotype O 0 0.0007575689814984798
- O 0 0.03339263051748276
phenotype O 0 0.0008544599404558539
correlations O 0 0.00014931040641386062
in O 0 6.19222191744484e-05
AAPC B-Disease 1 0.9999969005584717
families O 0 0.00011950235057156533
. O 0 1.9354622054379433e-05

By O 0 1.262246587430127e-05
protein O 0 3.379879126441665e-05
- O 0 0.00012399919796735048
truncation O 0 0.00011849495786009356
test O 0 7.6319083746057e-06
( O 0 4.0775117327029875e-07
PTT O 0 3.0136643545120023e-05
) O 0 1.3241495366855816e-07
assay O 0 1.0706230568757746e-06
, O 0 5.7556331256591875e-08
the O 0 3.435993178868557e-08
entire O 0 2.995838315200672e-07
coding O 0 1.0848004421859514e-05
region O 0 1.4365507468028227e-06
of O 0 9.307381532153158e-08
the O 0 6.563716397067765e-07
APC B-Disease 0 1.4579375601897482e-05
gene O 0 1.2973576986041735e-06
was O 0 3.7231366150081158e-06
screened O 0 2.694053364393767e-06
in O 0 5.726100766878517e-07
affected O 0 3.727559771959932e-07
individuals O 0 2.6023252885920556e-08
from O 0 4.313081092277571e-07
11 O 0 2.8676988222287036e-05
AAPC B-Disease 1 0.9999362230300903
kindreds O 0 0.0002583145978860557
, O 0 6.755184358553379e-07
and O 0 1.463550347580167e-07
their O 0 2.892591624004126e-07
phenotypic O 0 7.492300028388854e-06
differences O 0 1.0351084711146541e-05
were O 0 1.9310720745124854e-05
examined O 0 0.00010544273391133174
. O 0 9.213755220116582e-06

Five O 0 4.684219311457127e-05
novel O 0 4.4298594730207697e-05
germ O 0 0.0017093907808884978
- O 0 0.000270108605036512
line O 0 9.482578025199473e-05
APC B-Disease 0 6.525110802613199e-05
mutations O 0 9.542934094497468e-06
were O 0 6.827307288403972e-07
identified O 0 2.184272489103023e-06
in O 0 6.830863412687904e-07
seven O 0 5.869762389920652e-06
kindreds O 0 0.0006902535678818822
. O 0 2.218294503109064e-05

Mutations O 0 0.001097506145015359
were O 0 6.810284048697213e-06
located O 0 8.896813028513861e-07
in O 0 2.3445304009328538e-07
three O 0 7.263709989047129e-08
different O 0 2.086962958003369e-08
regions O 0 1.6839145189351257e-07
of O 0 6.674358132841007e-08
the O 0 1.1087940947618335e-06
APC B-Disease 0 3.18409402098041e-05
gene O 0 2.0364711872389307e-06
( O 0 1.2970814111668005e-07
1 O 0 1.0595464345897199e-06
) O 0 1.3195182191338972e-07
at O 0 4.0774378362584685e-07
the O 0 2.0400524647357088e-07
5 O 0 2.764002147159772e-06
end O 0 1.5684887557654292e-06
spanning O 0 8.131244157993933e-07
exons O 0 7.996780368557665e-06
4 O 0 5.0640624067455065e-06
and O 0 7.932528092169377e-07
5 O 0 3.474021468719002e-06
, O 0 8.321245559272938e-07
( O 0 7.295047055322357e-08
2 O 0 1.1937626140934299e-06
) O 0 8.236861503974069e-08
within O 0 2.040656887913883e-08
exon O 0 2.152374236175092e-06
9 O 0 7.0763344410806894e-06
, O 0 5.925714390286885e-07
and O 0 4.954233077114623e-07
( O 0 7.965582682345484e-08
3 O 0 1.902566054923227e-06
) O 0 2.0754121976551687e-07
at O 0 3.918075037745439e-07
the O 0 2.044896802999574e-07
3 O 0 7.976702363521326e-06
distal O 0 3.423948510317132e-05
end O 0 4.718840500572696e-06
of O 0 1.0540813377701852e-07
the O 0 1.5022135357867228e-06
gene O 0 2.64363825408509e-05
. O 0 6.591633791686036e-06

Variability O 0 0.0010325020411983132
in O 0 3.6615192584577017e-06
the O 0 5.333400849849568e-07
number O 0 1.8183783367931028e-06
of O 0 0.0006879858556203544
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.030116669833660126
most O 0 6.801325866945263e-07
apparent O 0 1.1576764336496126e-05
in O 0 8.893301242096641e-07
individuals O 0 2.5299884853779986e-08
with O 0 3.3904427709785523e-07
mutations O 0 1.048251215252094e-05
in O 0 6.280320690166263e-07
region O 0 8.048238669289276e-06
1 O 0 1.853463072620798e-05
, O 0 1.8365400364928064e-06
and O 0 3.5226901218265994e-06
upper O 0 0.0016258405521512032
- O 1 0.9984787106513977
gastrointestinal O 0 0.1490090936422348
manifestations O 0 3.222753730369732e-05
were O 0 1.944773885043105e-06
more O 0 4.6608579395979177e-07
severe O 0 2.848505027941428e-05
in O 0 7.116182132449467e-07
them O 0 1.2697358897639788e-06
. O 0 1.350925685983384e-05

In O 0 1.4870623090246227e-05
individuals O 0 4.6249044771684567e-07
with O 0 7.791870189066685e-07
mutations O 0 1.0828613085323013e-05
in O 0 7.938809858387685e-07
either O 0 6.604619215977436e-07
region O 0 1.0983499123540241e-05
2 O 0 1.604630051588174e-05
or O 0 9.555596989230253e-07
region O 0 2.6298246211808873e-06
3 O 0 4.324590918258764e-06
, O 0 1.8500320209113852e-07
the O 0 2.904454987628924e-08
average O 0 1.5811356490758044e-07
number O 0 6.9041114159063e-08
of O 0 1.3939626342107658e-07
adenomas B-Disease 0 4.709282802650705e-05
tended O 0 3.0938761028664885e-06
to O 0 2.5720373741933145e-07
be O 0 1.1797363441701236e-07
lower O 0 1.3155053011359996e-06
than O 0 8.07877853503669e-08
those O 0 2.134262722108815e-08
in O 0 1.0004236372651576e-07
individuals O 0 8.45786374270574e-09
with O 0 2.553569800056721e-07
mutations O 0 1.149537547462387e-05
in O 0 7.675606639168109e-07
region O 0 6.0866477724630386e-06
1 O 0 1.2722845895041246e-05
, O 0 5.927534516558808e-07
although O 0 2.974702795199846e-07
age O 0 3.844982927603269e-07
at O 0 5.199075076234294e-06
diagnosis O 0 0.000998062314465642
was O 0 2.04223433684092e-05
similar O 0 4.3557993194554e-06
. O 0 1.1059048119932413e-05

In O 0 4.0809885831549764e-05
all O 0 6.300829227257054e-06
AAPC B-Disease 1 0.9998791217803955
kindreds O 0 0.0011623036116361618
, O 0 2.629322807479184e-06
a O 0 4.801963200407044e-07
predominance O 0 1.3770929399470333e-05
of O 0 1.6760222933953628e-06
right O 0 0.0006575311999768019
- O 1 0.9999752044677734
sided O 1 0.9999996423721313
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.02773008495569229
rectal B-Disease 1 0.999768078327179
polyp I-Disease 1 0.8818798661231995
sparing O 0 0.0004030984127894044
was O 0 0.0002325635141460225
observed O 0 3.348056270624511e-05
. O 0 1.1828758943011053e-05

No O 0 0.0003777315141633153
desmoid B-Disease 1 0.6593282222747803
tumors I-Disease 1 0.9999995231628418
were O 0 4.388310117064975e-05
found O 0 3.2023976928030606e-06
in O 0 8.128437798404775e-07
these O 0 5.47204933809553e-07
kindreds O 0 0.00033620611065998673
. O 0 1.641585913603194e-05

Our O 0 1.7378350094077177e-05
data O 0 6.33461786492262e-06
suggest O 0 1.744885935295315e-06
that O 0 1.705500238813329e-07
, O 0 6.84449275922816e-07
in O 0 3.885222213284578e-06
AAPC B-Disease 1 0.999994158744812
families O 0 1.7690912272882997e-06
, O 0 1.1918420028678156e-07
the O 0 2.924879716204032e-08
location O 0 7.089622044986754e-07
of O 0 1.16409424322228e-07
the O 0 1.9519554825819796e-06
APC B-Disease 0 0.0001764649205142632
mutation O 0 3.1297509849537164e-05
may O 0 9.268173926102463e-06
partially O 0 3.758816819754429e-05
predict O 0 7.658126378373709e-06
specific O 0 5.062890409135434e-07
phenotypic O 0 1.0812371328938752e-05
expression O 0 1.3992445019539446e-05
. O 0 1.3398631381278392e-05

This O 0 8.207460268749855e-06
should O 0 6.686711913062027e-07
help O 0 1.4761718603040208e-07
in O 0 1.4127164149613236e-07
the O 0 5.433921046460455e-08
design O 0 3.135182396363234e-06
of O 0 2.0751608076352568e-07
tailored O 0 5.5400152632500976e-05
clinical O 0 0.0001296464033657685
- O 0 0.0019556372426450253
management O 0 8.039118256419897e-06
protocols O 0 8.16629267319513e-07
in O 0 1.0937071692751488e-07
this O 0 2.6333722757954092e-08
subset O 0 2.5736716224855627e-07
of O 0 4.3605069777186145e-07
FAP B-Disease 0 0.00037188781425356865
patients O 0 2.3188604245660827e-05
. O 0 5.279596280161059e-07
. O 0 3.681705493363552e-06

Wilms B-Disease 1 0.9956607222557068
' I-Disease 0 0.09880322962999344
tumor I-Disease 0 0.006326238624751568
1 O 0 6.182061042636633e-06
and O 0 2.0871354990958935e-06
Dax O 0 0.04546181485056877
- O 0 9.623759251553565e-05
1 O 0 3.010860609720112e-06
modulate O 0 2.5102483505179407e-06
the O 0 2.4080208049781504e-07
orphan O 0 7.646508493053261e-06
nuclear O 0 2.7768963263952173e-05
receptor O 0 3.4970037177117774e-06
SF O 0 0.0030092629604041576
- O 0 1.4347611795528792e-05
1 O 0 1.0159352541450062e-06
in O 0 9.727947514193147e-08
sex O 0 1.6809511294013646e-07
- O 0 3.144011998301721e-06
specific O 0 2.6082440740538004e-07
gene O 0 2.400061248408747e-06
expression O 0 3.675878133435617e-06
. O 0 3.070607135668979e-06

Products O 0 9.397404210176319e-05
of O 0 1.4514840813717456e-06
steroidogenic O 0 8.79983781487681e-05
factor O 0 4.374340733193094e-06
1 O 0 9.816726560529787e-06
( O 0 2.259556822536979e-06
SF O 0 0.1073603630065918
- O 0 0.0001909187121782452
1 O 0 6.56255451758625e-06
) O 0 4.2237371644660016e-07
and O 0 2.8933359317306895e-06
Wilms B-Disease 0 0.06737066805362701
tumor I-Disease 0 0.010868093930184841
1 O 0 2.476377267157659e-05
( O 0 6.339061542348645e-07
WT1 O 0 3.5630655474960804e-05
) O 0 1.9851182742058882e-07
genes O 0 9.835881087383314e-08
are O 0 1.5413327503210894e-08
essential O 0 7.524262457536679e-08
for O 0 1.4767195466447447e-07
mammalian O 0 6.392707746272208e-06
gonadogenesis O 0 6.808649050071836e-05
prior O 0 1.1243533890592516e-06
to O 0 2.8898372761432256e-07
sexual O 0 8.812117471279635e-07
differentiation O 0 6.490913619927596e-06
. O 0 8.06355819804594e-06

In O 0 5.6762659369269386e-05
males O 0 2.9141550839995034e-05
, O 0 1.0277196452079806e-05
SF O 1 0.6113738417625427
- O 0 0.0005164580652490258
1 O 0 6.772834694857011e-06
participates O 0 7.423421948260511e-07
in O 0 1.6856368745266082e-07
sexual O 0 8.673217166688119e-08
development O 0 7.663845735805808e-08
by O 0 5.984031758998754e-08
regulating O 0 6.38060839719401e-07
expression O 0 2.495092417120759e-07
of O 0 4.321752200553419e-08
the O 0 3.78132398282105e-07
polypeptide O 0 3.042402386199683e-05
hormone O 0 7.247017492773011e-06
Mullerian O 0 2.8438258595997468e-05
inhibiting O 0 2.5801062292885035e-05
substance O 0 2.440106800349895e-05
( O 0 2.8316751468082657e-06
MIS O 0 0.024405263364315033
) O 0 3.4612630770425312e-06
. O 0 5.278657226881478e-06

Here O 0 4.2134237446589395e-05
, O 0 4.658929810830159e-06
we O 0 4.6247015461631236e-07
show O 0 1.6425645981144044e-06
that O 0 4.88993464387022e-07
WT1 O 0 0.0001315716654062271
- O 0 0.00014850277511868626
KTS O 0 0.00017565878806635737
isoforms O 0 2.037982540059602e-06
associate O 0 1.4610960761274328e-06
and O 0 1.2711787178432132e-07
synergize O 0 1.7896572899189778e-05
with O 0 7.002021447988227e-06
SF O 1 0.9756824970245361
- O 0 9.92569766822271e-05
1 O 0 2.4202606709877728e-06
to O 0 5.405307206274301e-07
promote O 0 3.461781489022542e-06
MIS O 0 0.005409767385572195
expression O 0 2.032449992839247e-05
. O 0 6.638063041464193e-06

In O 0 3.1191259040497243e-05
contrast O 0 3.870186264975928e-05
, O 0 6.0016909628757276e-06
WT1 O 0 0.0012690532021224499
missense O 0 0.0009017878328450024
mutations O 0 0.0002572940429672599
, O 0 2.096683601848781e-06
associated O 0 8.202345043173409e-07
with O 0 9.240850999958639e-07
male B-Disease 0 0.00017524842405691743
pseudohermaphroditism I-Disease 1 0.999998927116394
in O 0 0.00039242245838977396
Denys B-Disease 1 0.9994685053825378
- I-Disease 1 0.9999346733093262
Drash I-Disease 1 0.99985671043396
syndrome I-Disease 1 0.9999773502349854
, O 0 3.6167120924801566e-06
fail O 0 4.625390374712879e-06
to O 0 4.494905567753449e-07
synergize O 0 7.388132507912815e-05
with O 0 1.1303264727757778e-05
SF O 1 0.9974409341812134
- O 0 0.004979181569069624
1 O 0 4.191677726339549e-05
. O 0 4.72139709017938e-06

Additionally O 0 0.00015386140148621053
, O 0 2.9278323836479103e-06
the O 0 7.678864335503022e-07
X O 0 0.014204706065356731
- O 0 0.007168916054069996
linked O 0 9.563371713738889e-05
, O 0 2.9222374564596976e-07
candidate O 0 9.285781743528787e-07
dosage O 0 3.563235623005312e-06
- O 0 1.226851327373879e-05
sensitive O 0 4.1036587390408386e-06
sex O 0 8.818994388093415e-07
- O 0 1.1371901564416476e-05
reversal O 0 1.7808433767640963e-05
gene O 0 1.1187700010850676e-06
, O 0 2.9034339377176366e-07
Dax O 0 0.028537925332784653
- O 0 0.00011382187949493527
1 O 0 4.453628662304254e-06
, O 0 4.816777732230548e-07
antagonizes O 0 3.4292870623175986e-06
synergy O 0 1.4375182217918336e-06
between O 0 9.85755150395562e-07
SF O 0 0.49926748871803284
- O 0 0.00026461403467692435
1 O 0 1.0181740435655229e-05
and O 0 1.73026057836978e-06
WT1 O 0 3.050501982215792e-05
, O 0 1.6025298066324467e-07
most O 0 3.03612530672126e-08
likely O 0 5.0013436947438095e-08
through O 0 8.061411982396294e-09
a O 0 8.121079275724696e-08
direct O 0 1.6304336725170288e-07
interaction O 0 1.6672684921559267e-07
with O 0 4.292843641451327e-06
SF O 1 0.9973316192626953
- O 0 0.0032863705419003963
1 O 0 4.8130081268027425e-05
. O 0 9.487145689490717e-06

We O 0 1.2082803550583776e-05
propose O 0 1.1376272595953196e-05
that O 0 7.811937052792928e-07
WT1 O 0 0.0001218416218762286
and O 0 1.0579265108390246e-05
Dax O 1 0.5567193031311035
- O 0 0.0009416855173185468
1 O 0 6.857651442260249e-06
functionally O 0 1.976233988898457e-06
oppose O 0 1.4855449137485266e-07
each O 0 2.862825532190527e-08
other O 0 4.3535880678291505e-08
in O 0 1.9025519293336401e-07
testis O 0 4.543442264548503e-05
development O 0 5.901425197407661e-07
by O 0 9.325930818704364e-07
modulating O 0 0.00013822467008139938
SF O 1 0.9493510127067566
- O 0 0.0010747541673481464
1 O 0 2.265186412842013e-05
- O 0 0.00023089253227226436
mediated O 0 0.00020700626191683114
transactivation O 0 0.0002498325484339148
. O 0 1.8777786863211077e-06
. O 0 3.195277486156556e-06

A O 0 9.227090049535036e-05
mouse O 0 0.00014202632883097976
model O 0 0.00013915861200075597
for O 0 0.0001258608972420916
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
imprinting O 0 0.16510717570781708
- O 0 0.17394596338272095
centre O 0 0.0008290403638966382
mutations O 0 0.0006741680554114282
. O 0 8.540128874301445e-06

Imprinting O 0 0.0022046249359846115
in O 0 1.5621053535141982e-05
the O 0 1.2295442957110936e-06
15q11 O 0 2.9834278393536806e-05
- O 0 0.00016190078167710453
q13 O 0 1.4824606296315324e-05
region O 0 2.260306928292266e-06
involves O 0 3.89072937423407e-07
an O 0 8.322928124471218e-07
imprinting O 0 0.00012118752056267112
centre O 0 0.00021823582937940955
( O 0 1.8610738834468066e-06
IC O 0 0.00015126477228477597
) O 0 5.270842393656494e-07
, O 0 1.3053721659161965e-07
mapping O 0 1.0026908512372756e-06
in O 0 2.574233803898096e-07
part O 0 3.238807266825461e-07
to O 0 3.534444203978637e-07
the O 0 2.903049107771949e-07
promoter O 0 4.807150617125444e-05
and O 0 9.78003640739189e-07
first O 0 1.3265438383314176e-06
exon O 0 1.1010031812475063e-05
of O 0 6.86512407810369e-07
SNRPN O 0 0.0010292830411344767
. O 0 9.478337233304046e-06

Deletion O 0 0.0009969841921702027
of O 0 5.1273823373776395e-06
this O 0 1.9322119442222174e-06
IC O 0 0.0003276167844887823
abolishes O 0 6.539469177369028e-05
local O 0 1.3978901733935345e-06
paternally O 0 2.3835196770960465e-05
derived O 0 1.5340173149525071e-06
gene O 0 2.1713935893785674e-06
expression O 0 7.536327188972791e-07
and O 0 2.6838522444450064e-06
results O 0 0.0001083537281374447
in O 0 0.0024984371848404408
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0004886937676928937
PWS B-Disease 1 0.9999960660934448
) O 0 2.927058631030377e-05
. O 0 1.1638999239949044e-05

We O 0 1.859482472355012e-05
have O 0 5.706801857741084e-07
created O 0 2.0368990760744055e-07
two O 0 3.1804640343580104e-07
deletion O 0 4.681664358940907e-05
mutations O 0 3.368736361153424e-05
in O 0 2.2398978671844816e-06
mice O 0 0.00023686392523813993
to O 0 1.447292925149668e-05
understand O 0 1.2718187463178765e-05
PWS B-Disease 1 0.9999895095825195
and O 0 3.843534614134114e-06
the O 0 1.5270082087681658e-07
mechanism O 0 2.9175399163250404e-07
of O 0 1.280577066609112e-07
this O 0 1.0562342822595383e-06
IC O 0 0.0009253486641682684
. O 0 1.3287977708387189e-05

Mice O 0 0.19430816173553467
harbouring O 0 0.004381535574793816
an O 0 8.972648174676578e-06
intragenic O 0 0.0003672667662613094
deletion O 0 7.130305311875418e-05
in O 0 1.1294819159957115e-06
Snrpn O 0 6.78298674756661e-05
are O 0 2.681856585695641e-07
phenotypically O 0 9.575078365742229e-06
normal O 0 1.5927465710774413e-06
, O 0 2.6650192808119755e-07
suggesting O 0 4.876806087850127e-07
that O 0 1.6071949460183532e-07
mutations O 0 1.16980606890138e-06
of O 0 7.901604703874909e-08
SNRPN O 0 0.0014544375007972121
are O 0 1.7337015378871e-07
not O 0 1.4240993095882004e-07
sufficient O 0 2.2864091420160548e-07
to O 0 1.3254613122626324e-06
induce O 0 0.0001282844750676304
PWS B-Disease 1 0.9999529123306274
. O 0 7.675564847886562e-05

Mice O 0 0.008222135715186596
with O 0 2.061451368717826e-06
a O 0 1.784987375685887e-06
larger O 0 1.2672112461586948e-06
deletion O 0 1.3007896995986812e-05
involving O 0 3.287922822892142e-07
both O 0 4.992089657207543e-07
Snrpn O 0 7.863965583965182e-05
and O 0 2.3798399979568785e-06
the O 0 1.629707298889116e-06
putative O 0 0.003888038918375969
PWS O 1 0.9999988079071045
- O 0 0.1030297800898552
IC O 0 0.0004137783544138074
lack O 0 9.001908551908855e-07
expression O 0 1.6779496547769668e-07
of O 0 4.03169799767511e-08
the O 0 4.3276421024529554e-07
imprinted O 0 0.0002777490590233356
genes O 0 8.679920028953347e-06
Zfp127 O 0 7.313401147257537e-05
( O 0 3.152684371343639e-07
mouse O 0 1.6573019365750952e-06
homologue O 0 1.2884952411695849e-05
of O 0 5.075396529719001e-07
ZNF127 O 0 0.0009231234434992075
) O 0 7.487883522117045e-07
, O 0 4.171107548245345e-07
Ndn O 0 4.610799442161806e-05
and O 0 8.976652452474809e-07
Ipw O 0 2.5172696041408926e-05
, O 0 5.408308538790152e-07
and O 0 6.174562940941541e-07
manifest O 0 7.699081834289245e-06
several O 0 3.607971734709281e-07
phenotypes O 0 2.0692332327598706e-05
common O 0 1.4731618648511358e-05
to O 0 0.00010566166019998491
PWS B-Disease 1 0.9999997615814209
infants O 1 0.6951658129692078
. O 0 1.8767814253806137e-05

These O 0 3.3302269457635703e-06
data O 0 3.475757921478362e-06
demonstrate O 0 7.029547646197898e-07
that O 0 1.0114442972053439e-07
both O 0 6.765706928035797e-08
the O 0 8.633045922579186e-08
position O 0 6.324436867544136e-07
of O 0 2.8953895281347286e-08
the O 0 2.9424001013467205e-07
IC O 0 4.756515772896819e-05
and O 0 6.250933779483603e-07
its O 0 3.983284102559992e-07
role O 0 2.978095210437459e-07
in O 0 7.595899376156012e-08
the O 0 4.8802906604805685e-08
coordinate O 0 5.21184517765505e-07
expression O 0 1.267232789814443e-07
of O 0 2.923831132761734e-08
genes O 0 1.4263923731050454e-07
is O 0 7.478235630742347e-08
conserved O 0 1.8533394552378013e-07
between O 0 3.1933717536958284e-07
mouse O 0 1.8652155631571077e-05
and O 0 8.691815310157835e-06
human O 0 8.066319878707873e-07
, O 0 5.519808041754004e-07
and O 0 8.603520313954505e-07
indicate O 0 9.53690687310882e-07
that O 0 1.0529199556685853e-07
the O 0 1.4735866216142313e-07
mouse O 0 4.593309768097242e-06
is O 0 1.4882448340358678e-07
a O 0 1.9315196198022022e-07
suitable O 0 1.5536636510660173e-06
model O 0 6.291714271355886e-06
system O 0 5.069572353022522e-07
in O 0 2.0172218739844539e-07
which O 0 3.795605891809828e-07
to O 0 2.468315187797998e-07
investigate O 0 2.889222514568246e-07
the O 0 8.665114847872246e-08
molecular O 0 1.8412944200463244e-06
mechanisms O 0 2.1439450392790604e-07
of O 0 1.2577945085467945e-07
imprinting O 0 4.136710413149558e-05
in O 0 1.1758986602217192e-06
this O 0 1.3238478402399778e-07
region O 0 1.33887601805327e-06
of O 0 8.695180753193199e-08
the O 0 8.846776040627446e-07
genome O 0 5.567077096202411e-06
. O 0 8.977903007689747e-07
. O 0 3.0549017537850887e-06

Mutations O 0 0.000762604468036443
of O 0 2.17684032577381e-06
the O 0 1.0797261893458199e-06
ATM O 0 0.00015957956202328205
gene O 0 1.1545066627149936e-05
detected O 0 9.007678272610065e-06
in O 0 1.1772069683502195e-06
Japanese O 0 0.0052027045749127865
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.8417425751686096
: O 0 7.515599236285198e-07
possible O 0 6.258556481952837e-07
preponderance O 0 4.086164153704885e-06
of O 0 1.0723566390424821e-07
the O 0 3.943814306239801e-07
two O 0 3.499132390061277e-06
founder O 0 0.000760177499614656
mutations O 0 3.166558235534467e-05
4612del165 O 0 8.174854883691296e-06
and O 0 2.7571256850933423e-06
7883del5 O 0 6.513441621791571e-05
. O 0 6.7755736381514e-06

The O 0 2.0850446162512526e-05
ATM O 0 0.0013537516351789236
( O 0 1.7895652490551583e-05
A O 1 0.9873732924461365
- O 1 0.9998500347137451
T O 1 0.9999992847442627
, O 0 5.974440227873856e-06
mutated O 0 3.88143735108315e-06
) O 0 1.673960241532768e-07
gene O 0 7.645325013072579e-07
on O 0 5.010857876186492e-06
human O 0 4.452541361388285e-06
chromosome O 0 0.0003713891201186925
11q22 O 0 0.0001463656808482483
. O 0 1.2870816135546193e-05

3 O 0 0.00038780763861723244
has O 0 1.0042651410913095e-05
recently O 0 7.735284270893317e-06
been O 0 7.541057698290388e-07
identified O 0 9.723586344989599e-07
as O 0 6.36874162296408e-08
the O 0 9.797833655511567e-08
gene O 0 1.384545726068609e-06
responsible O 0 8.186902391571493e-07
for O 0 3.993607435859303e-07
the O 0 5.5793866522435565e-06
human O 0 0.0009537662263028324
recessive B-Disease 1 0.9999954700469971
disease I-Disease 1 0.999998927116394
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0039514112286269665
A B-Disease 1 0.9999877214431763
- I-Disease 1 0.999997615814209
T I-Disease 1 1.0
) O 0 1.282914945477387e-05
. O 0 5.253160907159327e-06

In O 0 1.891123793029692e-05
order O 0 1.5255759535648394e-06
to O 0 4.940785629514721e-07
define O 0 1.14247643523413e-06
the O 0 1.2039548380471388e-07
types O 0 4.6488855787174543e-07
of O 0 2.937005092462641e-06
disease O 0 0.01782311126589775
- O 0 0.0028311507776379585
causing O 0 2.620083250803873e-05
ATM O 0 0.00025452839327044785
mutations O 0 8.120681741274893e-06
in O 0 2.524171520690288e-07
Japanese O 0 1.0847301382455043e-05
A B-Disease 1 0.9999631643295288
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 5.770159623352811e-05
as O 0 2.495049500339519e-07
well O 0 8.946281582211668e-08
as O 0 1.5097708683242672e-07
to O 0 7.749660113631762e-08
look O 0 2.9859890560146596e-07
for O 0 7.155271930514573e-08
possible O 0 3.842153262212378e-07
mutational O 0 1.116998100769706e-05
hotspots O 0 9.108453923545312e-06
, O 0 5.245533998277097e-07
reverse O 0 2.143920210073702e-05
- O 0 5.202971078688279e-05
transcribed O 0 8.799757779343054e-06
RNA O 0 1.4278665503297816e-06
derived O 0 1.9178926891072479e-07
from O 0 7.302926974261936e-08
ten O 0 6.667817729066883e-07
patients O 0 6.056521897335188e-07
belonging O 0 2.7475661568132637e-07
to O 0 9.748993079483625e-08
eight O 0 3.4700505580076424e-07
unrelated O 0 1.7210121541211265e-06
Japanese O 0 9.141277587332297e-06
A B-Disease 1 0.9986916184425354
- I-Disease 1 0.9997186064720154
T I-Disease 1 0.9999997615814209
families O 0 3.365551719980431e-06
was O 0 1.4703772649227176e-05
analyzed O 0 2.640683987920056e-06
for O 0 5.170497274775698e-07
mutations O 0 2.8800391191907693e-06
by O 0 5.573902939204345e-08
the O 0 2.2092541485108086e-07
restriction O 0 1.108846959141374e-06
endonuclease O 0 3.525026477291249e-05
fingerprinting O 0 4.214001455693506e-05
method O 0 9.679355571279302e-06
. O 0 6.109712103352649e-06

As O 0 1.7762420611688867e-05
has O 0 3.3897877074196003e-06
been O 0 1.018921807371953e-06
reported O 0 3.81731342713465e-06
by O 0 1.1533852273259981e-07
others O 0 1.1301241329420009e-06
, O 0 5.173590125195915e-07
mutations O 0 8.140507929965679e-07
that O 0 9.701840042453114e-08
lead O 0 1.4845112445982522e-06
to O 0 3.454379964296095e-07
exon O 0 1.0577045031823218e-05
skipping O 0 4.054172222822672e-06
or O 0 1.813380436033185e-06
premature O 0 9.131448678090237e-06
protein O 0 1.8846247940018657e-06
truncation O 0 2.6931724278256297e-05
were O 0 1.017848603623861e-06
also O 0 7.306311431420909e-07
predominant O 0 3.6890580759063596e-06
in O 0 4.538617872640316e-07
our O 0 2.432784413031186e-06
mutants O 0 6.791205669287592e-05
. O 0 5.810524271510076e-06

Six O 0 1.3013009265705477e-05
different O 0 8.684306180839485e-07
mutations O 0 1.0036533240054268e-05
were O 0 1.4519492879117024e-06
identified O 0 2.508190391381504e-06
on O 0 1.9003682609763928e-06
12 O 0 1.7141749140137108e-06
of O 0 8.837367460046153e-08
the O 0 9.860033287623082e-07
16 O 0 1.1955618901993148e-05
alleles O 0 6.361120995279634e-06
examined O 0 4.477332913666032e-05
. O 0 1.1196196282980964e-05

Four O 0 3.552537600626238e-05
were O 0 5.6890280575316865e-06
deletions O 0 1.2848116057284642e-05
involving O 0 1.2574325864989078e-06
a O 0 1.0567568097030744e-05
loss O 0 0.00011014741903636605
of O 0 2.016021767303755e-07
a O 0 2.284519950990216e-06
single O 0 9.24989490158623e-06
exon O 0 3.37837846018374e-05
exon O 0 2.2882049961481243e-05
7 O 0 7.568791716039414e-06
, O 0 2.5854058094409993e-07
exon O 0 3.2849875424290076e-06
16 O 0 1.2105742825951893e-06
, O 0 1.0726552801543221e-07
exon O 0 3.3069461551349377e-06
33 O 0 1.0478247531864326e-06
or O 0 4.740029453387251e-07
exon O 0 2.6598074327921495e-05
35 O 0 3.961360562243499e-06
. O 0 3.7081229038449237e-06

The O 0 1.6443906133645214e-05
others O 0 6.556023890880169e-06
were O 0 8.793078336566396e-07
minute O 0 9.974568229154102e-07
deletions O 0 3.237811142753344e-06
, O 0 2.985636058383534e-07
4649delA O 0 3.8122786918393103e-06
in O 0 3.6173014450469054e-07
exon O 0 8.78004175319802e-06
33 O 0 1.963989916475839e-06
and O 0 4.5600330622619367e-07
7883del5 O 0 2.7151518224854954e-06
in O 0 4.682412679812842e-07
exon O 0 5.127540134708397e-05
55 O 0 2.0033268810948357e-05
. O 0 6.581162779184524e-06

The O 0 2.4172699340851977e-05
mutations O 0 5.770159623352811e-05
4612del165 O 0 2.183533251809422e-05
and O 0 1.8986381746799452e-06
7883del5 O 0 6.154237325972645e-06
were O 0 1.249040224138298e-06
found O 0 5.043021928941016e-07
in O 0 6.840512156713885e-08
more O 0 2.1539248606927686e-08
than O 0 4.4620446004728365e-08
two O 0 2.3285291206320835e-07
unrelated O 0 7.42832298783469e-07
families O 0 1.0908426162359319e-07
; O 0 1.620243637034946e-07
44 O 0 2.2164016399983666e-07
% O 0 1.2177285668713012e-07
( O 0 2.2645041397595378e-08
7 O 0 5.95138715198118e-07
of O 0 8.337850232464916e-08
16 O 0 1.7617874163988745e-06
) O 0 4.448524393296793e-08
of O 0 1.2670292370842162e-08
the O 0 2.7100170996163797e-07
mutant O 0 3.32734134644852e-06
alleles O 0 7.0939159968475e-07
had O 0 1.4002731631990173e-06
one O 0 4.7276145664909563e-08
of O 0 1.884601275037312e-08
the O 0 2.5675231540844834e-07
two O 0 7.256574917846592e-06
mutations O 0 0.0001474115124437958
. O 0 5.945600150880637e-06

The O 0 1.2423527550708968e-05
4612del165 O 0 6.528042285935953e-05
mutations O 0 2.8916234441567212e-05
in O 0 2.9292914405232295e-07
three O 0 9.199158057526802e-08
different O 0 3.056985775629073e-08
families O 0 7.662807632868862e-08
were O 0 9.62747819244214e-08
all O 0 2.222522610395572e-08
ascribed O 0 1.044189616550284e-06
to O 0 1.882096398730937e-07
the O 0 1.0928876292837231e-07
same O 0 8.505736559527577e-07
T O 0 0.0035182805731892586
- O 0 4.826594886253588e-05
- O 0 4.271804937161505e-05
> O 0 2.652217574450333e-07
A O 0 1.7348196479360922e-07
substitution O 0 8.493660885733334e-08
at O 0 2.1402861705155374e-07
the O 0 7.292584314200212e-08
splice O 0 9.924807818606496e-05
donor O 0 6.5903891481866594e-06
site O 0 5.276447609503521e-06
in O 0 1.2903688002552371e-06
intron O 0 0.0005381220253184438
33 O 0 2.0759851395268925e-05
. O 0 6.362055501085706e-06

Microsatellite O 0 0.0019289368065074086
genotyping O 0 0.0008725491934455931
around O 0 1.3039918485446833e-05
the O 0 1.0961125553876627e-06
ATM O 0 9.695089829619974e-05
locus O 0 2.425990351184737e-05
also O 0 1.1102819371444639e-05
indicated O 0 5.417939519247739e-06
that O 0 5.409144776535868e-08
a O 0 5.303106718201889e-07
common O 0 4.012120371044148e-06
haplotype O 0 0.00025641778483986855
was O 0 1.6602614778093994e-05
shared O 0 3.311101011149731e-07
by O 0 9.329082928388743e-08
the O 0 1.482263201069145e-07
mutant O 0 3.6029418879479636e-06
alleles O 0 1.121954028349137e-06
in O 0 2.5818997073656647e-07
both O 0 2.244996267108945e-06
mutations O 0 0.0001245191233465448
. O 0 1.1142586117784958e-05

This O 0 1.1265782632108312e-05
suggests O 0 5.503028205566807e-06
that O 0 1.7019306142174173e-07
these O 0 2.526116560375158e-08
two O 0 2.3257993575498404e-07
founder O 0 0.00016410986427217722
mutations O 0 2.9122684281901456e-05
may O 0 2.4188968836824642e-06
be O 0 7.297162341046715e-08
predominant O 0 1.7357576780341333e-06
among O 0 1.9245179316840222e-07
Japanese O 0 1.6158810467459261e-06
ATM O 0 0.00013217008381616324
mutant O 0 5.911043626838364e-05
alleles O 0 3.428166019148193e-05
. O 0 1.4656983694294468e-05

W474C O 0 0.0001595462381374091
amino O 0 1.662254726397805e-05
acid O 0 1.7246762581635267e-05
substitution O 0 9.278045354221831e-07
affects O 0 5.639745381813555e-07
early O 0 1.907713738091843e-07
processing O 0 1.6597900298620516e-07
of O 0 1.2838389018554608e-08
the O 0 4.723270308204519e-08
alpha O 0 2.7110095857096894e-07
- O 0 2.1300765240539477e-07
subunit O 0 5.916515988246829e-08
of O 0 1.4700628270247762e-08
beta O 0 1.658619055433519e-07
- O 0 2.845394647010835e-06
hexosaminidase O 0 3.2224272672465304e-06
A O 0 1.8110872588295024e-06
and O 0 1.0207269269812969e-06
is O 0 4.382899589927547e-07
associated O 0 1.2409261671564309e-06
with O 0 3.0724409043614287e-06
subacute O 0 0.12342769652605057
G B-Disease 1 0.7746968269348145
( I-Disease 0 2.711699835344916e-06
M2 I-Disease 0 0.002663359744474292
) I-Disease 0 3.055994511669269e-06
gangliosidosis I-Disease 0 0.00016418451559729874
. O 0 8.663776497996878e-06

Mutations O 0 0.001273247180506587
in O 0 6.178124294820009e-06
the O 0 1.2631595609491342e-06
HEXA O 0 0.0012232442386448383
gene O 0 6.942325853742659e-06
, O 0 8.176503030199456e-08
encoding O 0 7.879059893411977e-08
the O 0 3.687189575884986e-08
alpha O 0 3.000009485276678e-07
- O 0 3.173891798269324e-07
subunit O 0 1.2329125809174002e-07
of O 0 3.2496600965714606e-08
beta O 0 5.52931282982172e-07
- O 0 6.8215035753382836e-06
hexosaminidase O 0 1.2822165444958955e-05
A O 0 5.063579465058865e-06
( O 0 1.1879237149514665e-07
Hex O 0 4.839154371438781e-06
A O 0 8.668421287438832e-06
) O 0 2.670588514774863e-07
, O 0 8.768327575126023e-08
that O 0 4.599200309485241e-08
abolish O 0 4.5987795260771236e-07
Hex O 0 2.0832183054153575e-06
A O 0 9.568235554979765e-07
enzyme O 0 4.520666152529884e-06
activity O 0 1.1630279004748445e-05
cause O 0 0.007769264746457338
Tay B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9553070068359375
( O 0 3.184696652169805e-06
TSD B-Disease 0 0.00017162912990897894
) O 0 8.413875889345945e-07
, O 0 7.513363016187213e-07
the O 0 2.7064422738476424e-06
fatal O 0 0.435377836227417
infantile B-Disease 0 0.007942884229123592
form I-Disease 0 3.7243651149765356e-06
of I-Disease 0 1.7312064528596238e-06
G I-Disease 1 0.8547778129577637
( I-Disease 0 1.67412281371071e-06
M2 I-Disease 0 0.0044550406746566296
) I-Disease 0 8.933415074352524e-07
gangliosidosis I-Disease 0 2.388562097621616e-05
, I-Disease 0 3.3871916116368084e-07
Type I-Disease 0 9.367736879539734e-07
1 I-Disease 0 1.0783867764985189e-05
. O 0 6.639709226874402e-06

Less O 0 0.0009936714777722955
severe O 0 0.23013868927955627
, O 0 9.15829514269717e-05
subacute O 1 0.7187070250511169
( O 0 0.00012391159543767571
juvenile O 0 0.2170625627040863
- O 1 0.9947952628135681
onset O 1 0.502577543258667
) O 0 3.624731471063569e-05
and O 0 0.0024286473635584116
chronic O 1 0.7089795470237732
( O 0 1.8359323803451844e-06
adult O 0 1.575516398588661e-05
- O 0 0.4307739734649658
onset O 0 0.000980004551820457
) O 0 3.6610373399525997e-07
variants O 0 1.2078850204488845e-06
are O 0 5.599925501087455e-08
characterized O 0 6.179735123623686e-07
by O 0 9.877221884835308e-08
a O 0 1.2929863260069396e-06
broad O 0 5.1487468226696365e-06
spectrum O 0 3.499699687381508e-06
of O 0 8.168395311258791e-07
clinical O 0 1.6359816072508693e-05
manifestations O 0 9.040571057994384e-06
and O 0 2.9673692552023567e-06
are O 0 1.0662543559192272e-07
associated O 0 4.1980078435699397e-07
with O 0 2.9912820309618837e-07
residual O 0 3.885240948875435e-05
levels O 0 5.169333689991618e-07
of O 0 4.391803187786536e-08
Hex O 0 1.3163135918148328e-05
A O 0 4.6852269406372216e-06
enzyme O 0 7.908064617367927e-06
activity O 0 2.9281284241733374e-06
. O 0 4.9593513722356874e-06

We O 0 3.407700205571018e-05
identified O 0 6.7130436036677565e-06
a O 0 3.3918120152520714e-06
1422 O 0 0.00017570267664268613
G O 0 0.17653508484363556
- O 0 0.004344753921031952
- O 0 0.00033623812487348914
> O 0 2.4247840428870404e-06
C O 0 7.715862011536956e-06
( O 0 6.478146730160006e-08
amino O 0 1.5896159766271012e-07
acid O 0 8.917233458305418e-07
W474C O 0 6.048487080079212e-07
) O 0 1.237971325451781e-08
substitution O 0 1.8314045391321088e-08
in O 0 2.809430021954995e-08
the O 0 4.847089485338074e-08
first O 0 1.0356202437833417e-06
position O 0 7.275078814927838e-07
of O 0 5.995205043518581e-08
exon O 0 8.936081940191798e-06
13 O 0 7.536240218541934e-07
of O 0 5.764378130379555e-08
HEXA O 0 4.8880760004976764e-05
of O 0 5.424083937555224e-08
a O 0 1.004713453767181e-06
non O 0 3.5376715459278785e-06
- O 0 3.897999704349786e-05
Jewish O 0 1.297431026614504e-05
proband O 0 0.000392389134503901
who O 0 6.754148216714384e-06
manifested O 0 3.373681693119579e-06
a O 0 4.894282483292045e-06
subacute O 0 0.0008883548434823751
variant O 0 0.00024124313495121896
of O 0 3.0622784379374934e-06
G B-Disease 1 0.9153620004653931
( I-Disease 0 6.118178589531453e-06
M2 I-Disease 0 0.005090021528303623
) I-Disease 0 4.927487680106424e-06
gangliosidosis I-Disease 0 0.00016592087922617793
. O 0 8.980575330497231e-06

On O 0 4.5327877160161734e-05
the O 0 1.8185829731010017e-06
second O 0 1.9236944353906438e-05
maternally O 0 9.353167843073606e-05
inherited O 0 0.00020368762488942593
allele O 0 2.123557533195708e-05
, O 0 1.1672151458697044e-06
we O 0 1.1515563613784252e-07
identified O 0 6.095565368013922e-07
the O 0 2.3403840998525993e-07
common O 0 0.00022745309979654849
infantile O 1 0.99953293800354
disease O 1 0.8231685161590576
- O 0 0.025264468044042587
causing O 0 8.849250298226252e-05
4 O 0 2.937663157354109e-05
- O 0 0.00795680284500122
bp O 0 0.002868287730962038
insertion O 0 7.810544957465027e-06
, O 0 7.514394724239537e-07
+ O 0 7.91867478255881e-06
TATC O 0 0.00011463630653452128
1278 O 0 4.322041786508635e-05
, O 0 5.796748610009672e-07
in O 0 2.9733044470958703e-07
exon O 0 4.26497426815331e-05
11 O 0 7.218778137030313e-06
. O 0 4.4364687710185535e-06

Pulse O 0 0.005747864488512278
- O 0 0.001017397386021912
chase O 0 0.00015074582188390195
analysis O 0 2.2959388843446504e-06
using O 0 1.1473057384137064e-06
proband O 0 0.00010146221029572189
fibroblasts O 0 4.3152835132787004e-05
revealed O 0 2.242662594653666e-05
that O 0 7.140234004054946e-08
the O 0 7.569980908783691e-08
W474C O 0 1.9499850623105885e-06
- O 0 1.4580630249838578e-06
containing O 0 1.582402830990759e-07
alpha O 0 3.49981235103769e-07
- O 0 4.1105738546320936e-07
subunit O 0 1.5777661133142828e-07
precursor O 0 4.95475262596301e-07
was O 0 5.474398108162859e-07
normally O 0 4.860643088022698e-08
synthesized O 0 3.923429687802127e-07
, O 0 5.937351232887522e-08
but O 0 2.5348187548956957e-08
not O 0 1.3700061529675622e-08
phosphorylated O 0 1.2080745648290758e-07
or O 0 6.315082856644949e-08
secreted O 0 1.931797868337526e-07
, O 0 8.973076859319917e-08
and O 0 7.115585276551428e-08
the O 0 8.680085983314711e-08
mature O 0 1.1115755569335306e-06
lysosomal O 0 4.626025656762067e-06
alpha O 0 1.2324263707341743e-06
- O 0 1.4185636700858595e-06
subunit O 0 5.7537550901543e-07
was O 0 2.0725751710415352e-06
not O 0 5.298273890730343e-07
detected O 0 1.021960997604765e-05
. O 0 2.699237711567548e-06

When O 0 2.2375159460352734e-05
the O 0 1.5130630117710098e-06
W474C O 0 7.973675565153826e-06
- O 0 4.175825779384468e-06
containing O 0 2.896428838994325e-07
alpha O 0 4.62765768816098e-07
- O 0 8.243932256846165e-07
subunit O 0 3.2812414474392426e-07
was O 0 1.2984444310859544e-06
transiently O 0 2.3023917492537294e-06
co O 0 1.2250649888301268e-05
- O 0 5.3368166845757514e-06
expressed O 0 4.19462224954259e-08
with O 0 9.7183008307411e-09
the O 0 2.7471985575289182e-08
beta O 0 1.4011399684932258e-07
- O 0 4.072863646342739e-07
subunit O 0 8.700307319031708e-08
to O 0 7.656496592289841e-08
produce O 0 1.8456528039223485e-07
Hex O 0 2.701895482459804e-06
A O 0 3.7453874028869905e-06
( O 0 1.5794024932347384e-07
alphabeta O 0 5.671217877534218e-06
) O 0 1.6125376589570806e-07
in O 0 4.543563818515395e-07
COS O 0 0.003900128183886409
- O 0 5.485714427777566e-05
7 O 0 6.868712716823211e-06
cells O 0 6.602094231311639e-07
, O 0 3.690574246206779e-08
the O 0 3.653015312465868e-08
mature O 0 1.7349984204884095e-07
alpha O 0 2.522927218251425e-07
- O 0 4.891538765150472e-07
subunit O 0 1.4541122084210656e-07
was O 0 1.0896433195739519e-06
present O 0 5.705224737084791e-08
, O 0 5.8021690563236916e-08
but O 0 3.5014103616504144e-08
its O 0 9.588315919017987e-08
level O 0 1.8258072032040218e-07
was O 0 2.667414264578838e-06
much O 0 7.118340761280706e-08
lower O 0 9.635365358917625e-07
than O 0 3.602758624765556e-08
that O 0 4.2129514099542575e-08
from O 0 1.9486909863530855e-08
normal O 0 6.264349394768942e-08
alpha O 0 1.9452379262929753e-07
- O 0 7.340688057411171e-07
subunit O 0 1.7256304829516012e-07
transfections O 0 2.361855877097696e-06
, O 0 5.8324268081833e-08
although O 0 1.7000187924054444e-08
higher O 0 5.2390245031119775e-08
than O 0 2.4893349603871684e-08
in O 0 9.213943741315234e-08
those O 0 5.0277989771529974e-08
cells O 0 4.2687227619353507e-07
transfected O 0 2.0717986899398966e-06
with O 0 8.994136635465111e-08
an O 0 3.586632999486028e-07
alpha O 0 2.473745098541258e-06
- O 0 9.59386943577556e-06
subunit O 0 1.2671774811678915e-06
associated O 0 1.3980234143673442e-06
with O 0 2.3819334273866843e-06
infantile O 0 0.022377436980605125
TSD B-Disease 0 0.007088194135576487
. O 0 2.798410969262477e-05

Furthermore O 0 5.422742833616212e-05
, O 0 1.4102774912316818e-06
the O 0 1.2666649240600236e-07
precursor O 0 9.533569595987501e-07
level O 0 7.216894459816103e-08
of O 0 1.4344951004829909e-08
the O 0 4.0779777776833726e-08
W474C O 0 5.726062113353692e-07
alpha O 0 2.9994117767273565e-07
- O 0 3.181116312589438e-07
subunit O 0 1.3965880896193994e-07
was O 0 1.1250023135289666e-06
found O 0 1.3892712047436362e-07
to O 0 9.542249301830452e-08
accumulate O 0 1.0215781003353186e-06
in O 0 5.1565614000992355e-08
comparison O 0 1.223180277065694e-07
to O 0 3.8195164364651646e-08
the O 0 3.524957392642136e-08
normal O 0 2.5512233037261467e-07
alpha O 0 4.268124769168935e-07
- O 0 1.0410566346763517e-06
subunit O 0 9.181381415146461e-07
precursor O 0 4.2550518628559075e-06
levels O 0 1.454993139304861e-06
. O 0 1.7086094885598868e-06

We O 0 1.3396102076512761e-05
conclude O 0 1.6086643881862983e-05
that O 0 3.0934930350667855e-07
the O 0 3.641290788891638e-07
1422 O 0 7.592785550514236e-05
G O 0 0.10698585212230682
- O 0 0.0024804919958114624
- O 0 0.0017778481123968959
> O 0 5.827194854646223e-06
C O 0 1.8704668036662042e-05
mutation O 0 1.136379296440282e-06
is O 0 6.496757265495035e-08
the O 0 2.0734893269036547e-07
cause O 0 1.5282539607142098e-06
of O 0 1.4299608608325798e-07
Hex B-Disease 0 0.0042394474148750305
A I-Disease 0 0.16380806267261505
enzyme I-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999984502792358
in O 0 2.930944447143702e-06
the O 0 4.042041837237775e-06
proband O 0 0.002729792846366763
. O 0 2.441205651848577e-05

The O 0 1.5526460629189387e-05
resulting O 0 9.443834642297588e-06
W474C O 0 1.0168804692511912e-05
substitution O 0 1.2719078767986502e-06
clearly O 0 7.823352348168555e-07
interferes O 0 7.033564770608791e-07
with O 0 5.29619228473166e-08
alpha O 0 6.0264926560194e-07
- O 0 1.0511936352486373e-06
subunit O 0 1.927732569129148e-07
processing O 0 3.537880388648773e-07
, O 0 8.330124501298997e-08
but O 0 2.088902206764942e-08
because O 0 1.0821549878414771e-08
the O 0 1.5339624681587338e-08
base O 0 1.8276521984716965e-07
substitution O 0 1.5044916779061168e-07
falls O 0 1.8920673028333113e-05
at O 0 3.994719577349315e-07
the O 0 3.605680376495002e-08
first O 0 7.82821814482304e-07
position O 0 8.162430731317727e-07
of O 0 8.252665395502845e-08
exon O 0 6.899806066940073e-06
13 O 0 1.32243860662129e-06
, O 0 1.9949034424371348e-07
aberrant O 0 1.5144748886086745e-06
splicing O 0 3.247694985475391e-05
may O 0 2.2633983462583274e-05
also O 0 5.698231007045251e-07
contribute O 0 1.145222867648954e-07
to O 0 2.2978349534241715e-07
Hex B-Disease 0 0.00038420563214458525
A I-Disease 0 0.0575302392244339
deficiency I-Disease 0 0.00550795765593648
in O 0 4.6488014504575403e-07
this O 0 4.5276803462002135e-07
proband O 0 0.00027407315792515874
. O 0 1.510004153715272e-06
. O 0 4.922429070575163e-06

Two O 0 4.475190507946536e-05
frequent O 0 0.0001881253847386688
missense O 0 0.012852816842496395
mutations O 0 0.186264768242836
in O 0 0.011742917820811272
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 0.0004913981538265944

Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
is O 0 0.025289105251431465
an O 1 0.8353984951972961
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9750943779945374
by O 0 6.662122177658603e-05
early O 0 0.05763080343604088
childhood O 1 0.9958199262619019
deafness B-Disease 1 1.0
and O 1 0.9893963932991028
goiter B-Disease 1 1.0
. O 0 0.0006613644654862583

A O 0 3.188259870512411e-05
century O 0 5.2912118917447515e-06
after O 0 4.818753041035961e-06
its O 0 9.291264291277912e-07
recognition O 0 8.373228297386959e-07
as O 0 3.0114176752249477e-06
a O 0 0.0012629294069483876
syndrome O 1 0.9977747797966003
by O 0 1.42555086313223e-06
Vaughan O 0 3.9501690480392426e-05
Pendred O 0 5.644149860017933e-05
, O 0 1.9072220993621158e-06
the O 0 3.6776557408302324e-06
disease O 0 0.00012405407323967665
gene O 0 1.2161599443061277e-05
( O 0 1.2499100421337062e-06
PDS O 0 0.0011443794937804341
) O 0 5.384942483033228e-07
was O 0 7.980202099133749e-06
mapped O 0 1.3879135622119065e-05
to O 0 1.5501738062084769e-06
chromosome O 0 0.00010551384912105277
7q22 O 0 3.481410021777265e-05
- O 0 0.00016842357581481338
q31 O 0 7.652484782738611e-05
. O 0 8.165278813976329e-06

1 O 0 0.00015043681196402758
and O 0 7.775014637445565e-06
, O 0 1.1835943496407708e-06
recently O 0 7.627069862792268e-06
, O 0 1.5003793407686317e-07
found O 0 9.516185883740036e-08
to O 0 4.918079810067866e-08
encode O 0 5.386144721342134e-07
a O 0 3.103841208940139e-06
putative O 0 0.0004460862837731838
sulfate O 0 0.001394385821186006
transporter O 0 0.00566440261900425
. O 0 2.2342963347909972e-05

We O 0 3.0241755666793324e-05
performed O 0 1.3610056157631334e-05
mutation O 0 4.169125077169156e-06
analysis O 0 4.063947471877327e-07
of O 0 9.626614883018192e-08
the O 0 8.126328907565039e-07
PDS B-Disease 0 0.0029166925232857466
gene O 0 8.08217464509653e-06
in O 0 1.1460055020506843e-06
patients O 0 1.4255942915042397e-06
from O 0 8.491004166444327e-08
14 O 0 1.3003949561607442e-06
Pendred B-Disease 0 1.8582592019811273e-05
families O 0 1.1186276793750949e-07
originating O 0 8.191957334702238e-08
from O 0 3.9249634653515386e-08
seven O 0 1.9177007004600455e-07
countries O 0 3.04589882205164e-08
and O 0 4.310400072427001e-07
identified O 0 4.119311142858351e-06
all O 0 2.673164658517635e-07
mutations O 0 2.9015236577834003e-05
. O 0 2.8230360840098e-06

The O 0 2.3784969016560353e-05
mutations O 0 3.827704495051876e-05
include O 0 3.5177546919840097e-07
three O 0 4.791803007719864e-07
single O 0 4.346239620645065e-06
base O 0 3.3185026495630154e-06
deletions O 0 3.4536790280981222e-06
, O 0 1.6092300825221173e-07
one O 0 1.0237359049369843e-07
splice O 0 0.00012559210881590843
site O 0 3.4859014704125e-05
mutation O 0 7.304623068193905e-06
and O 0 1.5596999674016843e-06
10 O 0 5.16549789608689e-06
missense O 0 0.0004148854350205511
mutations O 0 0.0002739320625551045
. O 0 9.858164958131965e-06

One O 0 4.9413782107876614e-05
missense O 0 0.002356038661673665
mutation O 0 0.00045564412721432745
( O 0 6.098424364608945e-06
L236P O 0 3.3398609957657754e-05
) O 0 3.283518481111969e-06
was O 0 6.019260126777226e-06
found O 0 7.206206760201894e-07
in O 0 2.1205683253811003e-07
a O 0 1.8583070868771756e-06
homozygous O 0 3.423868975005462e-06
state O 0 9.025205827128957e-08
in O 0 1.1923332010610466e-07
two O 0 5.010089694224007e-07
consanguineous O 0 1.8796972653944977e-05
families O 0 6.27883537163143e-07
and O 0 6.506070349132642e-07
in O 0 3.052660417779407e-07
a O 0 2.2925275970919756e-06
heterozygous O 0 1.0572723567747744e-06
state O 0 1.1756458206946263e-07
in O 0 6.994213919142567e-08
five O 0 1.3884209693060257e-07
additional O 0 4.2678354361669335e-07
non O 0 4.141899353271583e-06
- O 0 0.00014847713464405388
consanguineous O 0 0.0001733635290293023
families O 0 5.7429515436524525e-06
. O 0 8.791965228738263e-06

Another O 0 0.00013553861936088651
missense O 0 0.004511848092079163
mutation O 0 0.0005693657440133393
( O 0 7.597812782478286e-06
T416P O 0 2.5587951313355006e-05
) O 0 2.3331645024882164e-06
was O 0 1.2532840628409758e-05
found O 0 1.1201365168744815e-06
in O 0 1.5085547033777402e-07
a O 0 2.4631212909298483e-06
homozygous O 0 4.769476618093904e-06
state O 0 1.768870561136282e-07
in O 0 4.4152031364319555e-07
one O 0 8.778482651905506e-07
family O 0 2.687791720745736e-06
and O 0 9.720462230689009e-07
in O 0 2.1952476458864112e-07
a O 0 8.984232522379898e-07
heterozygous O 0 5.960031330687343e-07
state O 0 1.0142068163077056e-07
in O 0 1.998515699597192e-07
four O 0 1.1749950772355078e-06
families O 0 2.713096591833164e-06
. O 0 5.579498974839225e-06

Pendred B-Disease 0 0.28220072388648987
patients O 0 0.007049391977488995
in O 0 1.9488195448502665e-06
three O 0 1.2109322824471747e-06
non O 0 8.678529411554337e-06
- O 0 0.0003803839208558202
consanguineous O 0 5.883105768589303e-05
families O 0 5.786464498669375e-07
were O 0 3.056371440379735e-07
shown O 0 2.0337139972070872e-07
to O 0 8.272490958916023e-08
be O 0 8.481001145810296e-08
compound O 0 1.6514704839210026e-06
heterozygotes O 0 2.2632921172771603e-06
for O 0 1.2911623059608246e-07
L236P O 0 5.085812517791055e-06
and O 0 1.9528640677890508e-06
T416P O 0 4.348746006144211e-05
. O 0 7.110210390237626e-06

In O 0 2.4148439479176886e-05
total O 0 4.5133429011912085e-06
, O 0 1.01962950793677e-06
one O 0 7.896512244087717e-08
or O 0 5.6425648153890506e-08
both O 0 2.6128791574819843e-08
of O 0 3.90462346899767e-08
these O 0 1.2749799793709826e-07
mutations O 0 6.588409632968251e-06
were O 0 7.62508932439232e-07
found O 0 5.111858172313077e-07
in O 0 7.327176376747957e-08
nine O 0 2.1186015430885163e-07
of O 0 6.15890698441035e-08
the O 0 5.431951421996928e-07
14 O 0 4.232921128277667e-06
families O 0 5.800536655442556e-07
analyzed O 0 1.467681704525603e-05
. O 0 5.6817302720446605e-06

The O 0 3.378820338184596e-06
identification O 0 1.0966018635372166e-06
of O 0 1.5143059783895296e-07
two O 0 5.661570412485162e-07
frequent O 0 1.7996831957134418e-05
PDS B-Disease 0 0.034714002162218094
mutations O 0 5.40587461728137e-05
will O 0 1.815315187059241e-07
facilitate O 0 2.3097098278412886e-07
the O 0 8.659073955641361e-07
molecular O 0 0.0003092625120189041
diagnosis O 1 0.5911852121353149
of O 0 0.0020042238757014275
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.849857840687037e-05

Insertional O 0 0.007489780895411968
mutation O 0 0.0003314318601042032
by O 0 2.181141780965845e-06
transposable O 0 9.30677997530438e-05
element O 0 7.638709575985558e-06
, O 0 2.613059450595756e-06
L1 O 0 0.00020750108524225652
, O 0 1.104292323361733e-06
in O 0 3.53628479388135e-07
the O 0 3.8142497942317277e-06
DMD B-Disease 1 0.9999991655349731
gene O 0 8.860987145453691e-05
results O 0 1.521920148661593e-05
in O 0 2.5745234779606108e-06
X B-Disease 1 0.9895826578140259
- I-Disease 1 0.9990631937980652
linked I-Disease 1 0.9993244409561157
dilated I-Disease 1 0.9999172687530518
cardiomyopathy I-Disease 1 0.9999995231628418
. O 0 0.00024185945221688598

X B-Disease 1 0.9993526339530945
- I-Disease 1 0.9996256828308105
linked I-Disease 1 0.9871833324432373
dilated I-Disease 1 0.9999680519104004
cardiomyopathy I-Disease 1 1.0
( O 0 0.0028351948130875826
XLDCM B-Disease 1 0.5543484687805176
) O 0 3.2193677270697663e-06
is O 0 2.1660419236013695e-07
a O 0 5.222042545938166e-06
clinical O 0 3.1606963602826e-05
phenotype O 0 8.203861943911761e-05
of O 0 1.1389246310500312e-06
dystrophinopathy B-Disease 0 0.02131771855056286
which O 0 6.805544671806274e-06
is O 0 1.3070666682324372e-06
characterized O 0 8.968610018200707e-06
by O 0 1.32863544877182e-06
preferential O 0 0.0003204815147910267
myocardial B-Disease 1 0.994949221611023
involvement I-Disease 0 1.8018745322478935e-05
without O 0 6.44203282718081e-07
any O 0 1.9201876000352058e-07
overt O 0 9.60971101449104e-06
clinical O 0 2.4098910216707736e-05
signs O 0 3.1389037758344784e-05
of O 0 0.00011452224862296134
skeletal B-Disease 1 0.9999998807907104
myopathy I-Disease 1 1.0
. O 0 0.0027715335600078106

To O 0 1.8423905203235336e-05
date O 0 1.765745400916785e-05
, O 0 3.7009473885518673e-07
several O 0 2.681452713204635e-07
mutations O 0 6.615918209718075e-06
in O 0 9.487068268754228e-07
the O 0 3.355689477757551e-05
Duchenne B-Disease 1 0.9999908208847046
muscular I-Disease 1 0.9995189905166626
dystrophy I-Disease 1 0.9998757839202881
gene O 0 0.0010563075775280595
, O 0 3.6492176150204614e-05
DMD O 1 0.9999995231628418
, O 0 1.4478769116976764e-05
have O 0 5.881411766495148e-07
been O 0 1.010073447105242e-06
identified O 0 4.871488272328861e-06
in O 0 1.4778439663132303e-06
patients O 0 1.5321985529226367e-06
with O 0 2.3934231307976006e-07
XLDCM B-Disease 0 0.021682260558009148
, O 0 1.214577764585556e-06
but O 0 3.207967935736633e-08
a O 0 1.4340045595417905e-07
pathogenic O 0 2.748519989381748e-07
correlation O 0 3.2639044889037905e-07
of O 0 7.606715257679753e-08
these O 0 2.897918136568478e-07
cardiospecific O 0 0.0016149007715284824
mutations O 0 8.272339618997648e-05
in O 0 5.2799609875364695e-06
DMD O 1 0.9999994039535522
with O 0 8.32083878776757e-06
the O 0 7.636305781488772e-06
XLDCM B-Disease 0 0.3071548342704773
phenotype O 0 0.0011440776288509369
has O 0 5.5727978178765625e-06
remained O 0 6.160961220302852e-06
to O 0 6.525606863760913e-07
be O 0 1.4957776102164644e-06
elucidated O 0 0.00022962073853705078
. O 0 1.567079743836075e-05

We O 0 5.602215969702229e-05
report O 0 5.251267339190235e-06
here O 0 1.569160446024398e-07
the O 0 3.695420147664663e-08
identification O 0 2.1842403441496572e-07
of O 0 3.9537027873848274e-08
a O 0 6.036783588569961e-07
unique O 0 1.368170046589512e-06
de O 0 6.812420906499028e-06
novo O 0 1.46717229654314e-05
L1 O 0 2.3210706785903312e-05
insertion O 0 2.321556394235813e-06
in O 0 1.9626534708550025e-07
the O 0 1.5621964166712132e-07
muscle O 0 1.650658077778644e-06
exon O 0 9.722355571284425e-06
1 O 0 8.615478691353928e-06
in O 0 4.820729827770265e-06
DMD O 1 0.9999983310699463
in O 0 3.477104201010661e-06
three O 0 3.7703587167925434e-06
XLDCM B-Disease 0 0.21101978421211243
patients O 0 9.72267116594594e-06
from O 0 3.865225295385244e-08
two O 0 2.8712776156680775e-07
unrelated O 0 3.6302237731433706e-06
Japanese O 0 5.0542294047772884e-06
families O 0 8.253788905676629e-07
. O 0 5.646893896482652e-06

The O 0 8.930544026952703e-06
insertion O 0 1.856783637776971e-05
was O 0 9.069890438695438e-06
a O 0 5.382262315833941e-07
5 O 0 2.9914781407569535e-06
- O 0 1.1571796676435042e-05
truncated O 0 1.6324823945979006e-06
form O 0 1.610075912594766e-07
of O 0 9.067427697573294e-08
human O 0 3.7256580753819435e-07
L1 O 0 2.65632970695151e-05
inversely O 0 2.222252760475385e-06
integrated O 0 3.893902430718299e-06
in O 0 2.872203310744226e-07
the O 0 2.946533470549184e-07
5 O 0 6.765694706700742e-06
- O 0 0.0002294255536980927
untranslated O 0 0.0007958099013194442
region O 0 1.090946352633182e-05
in O 0 6.10343590778939e-07
the O 0 2.5101115852521616e-07
muscle O 0 3.1082843179319752e-06
exon O 0 9.52226127992617e-06
1 O 0 7.995980013220105e-06
, O 0 3.502680385736312e-07
which O 0 2.0724216653889016e-07
affected O 0 4.1505792580665e-08
the O 0 2.9534477974380025e-08
transcription O 0 8.085728495643707e-07
or O 0 2.531777738568053e-07
the O 0 1.0483709900199756e-07
stability O 0 1.6181340924958931e-06
of O 0 8.50336974167476e-08
the O 0 6.009607318446797e-07
muscle O 0 2.1613507215079153e-06
form O 0 1.9130170869630092e-07
of O 0 8.767140258214567e-08
dystrophin O 0 7.595269835292129e-06
transcripts O 0 2.9322081900318153e-06
but O 0 1.748918094790497e-07
not O 0 3.4651289837484e-08
that O 0 2.0875919659602005e-08
of O 0 3.8145877567785647e-08
the O 0 1.7266246459257673e-06
brain O 0 0.00010482848301762715
or O 0 1.7939298686542315e-06
Purkinje O 0 0.002126401523128152
cell O 0 0.0003257959324400872
form O 0 3.5980247048428282e-06
, O 0 2.8593492515938124e-06
probably O 0 2.5562676455592737e-06
due O 0 3.170382569805952e-07
to O 0 8.686627950282855e-08
its O 0 5.321268190527917e-07
unique O 0 1.7508403971078224e-07
site O 0 2.768149215626181e-06
of O 0 1.3443401769563934e-07
integration O 0 6.288259100983851e-06
. O 0 5.926284757151734e-06

We O 0 2.6271765818819404e-05
speculate O 0 1.1615803487075027e-05
that O 0 1.8088606168475962e-07
this O 0 3.411309634770987e-08
insertion O 0 5.485038627739414e-07
of O 0 9.851764559698495e-08
an O 0 6.120228022155061e-07
L1 O 0 0.0001487527770223096
sequence O 0 6.263934665184934e-06
in O 0 2.3243268515216187e-05
DMD O 1 0.9999998807907104
is O 0 1.704749411146622e-05
responsible O 0 2.732540451688692e-06
for O 0 6.495245230553337e-08
some O 0 1.271587990459011e-08
of O 0 2.6859460433570348e-08
the O 0 1.6851676321039122e-07
population O 0 8.934158302054129e-08
of O 0 3.704311879459965e-08
Japanese O 0 8.098060789052397e-06
patients O 0 7.446764129781513e-07
with O 0 2.5313406126770133e-07
XLDCM B-Disease 0 0.001184761757031083
. O 0 4.064380391355371e-06
. O 0 6.046513135515852e-06

Severe O 1 0.6604155898094177
early O 0 0.0014582249568775296
- O 1 0.9993593096733093
onset O 1 0.9998003840446472
obesity B-Disease 1 0.9999998807907104
, O 0 0.19223564863204956
adrenal B-Disease 1 0.9999995231628418
insufficiency I-Disease 1 0.9999997615814209
and O 0 0.00018139819439966232
red O 0 0.008352475240826607
hair O 1 0.9997720122337341
pigmentation O 1 0.9077943563461304
caused O 0 0.0001543705875519663
by O 0 3.46301953868533e-06
POMC O 0 0.05929911509156227
mutations O 0 0.0001719100255286321
in O 0 1.987752739296411e-06
humans O 0 6.3243678596336395e-06
. O 0 7.826806722732726e-06

Sequential O 0 0.00020318212045822293
cleavage O 0 6.476954149547964e-05
of O 0 4.781244342666469e-07
the O 0 3.338333840474661e-07
precursor O 0 2.618724920466775e-06
protein O 0 1.3027286058786558e-06
pre O 0 9.280955055146478e-06
- O 0 6.481012678705156e-05
pro O 0 2.008334922720678e-05
- O 0 0.00026962385163642466
opiomelanocortin O 0 0.0001423931389581412
( O 0 4.841443796976819e-07
POMC O 0 2.376180054852739e-05
) O 0 1.2501133994646807e-07
generates O 0 2.638317369019205e-07
the O 0 2.0397099831370724e-07
melanocortin O 0 2.9238199203973636e-05
peptides O 0 6.867547199362889e-06
adrenocorticotrophin O 0 0.00016279614646919072
( O 0 1.8216103399026906e-06
ACTH O 0 3.08000307995826e-05
) O 0 1.7615157332784293e-07
, O 0 1.5520969043336663e-07
melanocyte O 0 1.5946197891025804e-05
- O 0 0.0001442931534256786
stimulating O 0 3.062125688302331e-05
hormones O 0 6.40074722468853e-06
( O 0 1.0965437269305767e-07
MSH O 0 8.587113370595034e-06
) O 0 4.753220395059543e-08
alpha O 0 9.651232346641336e-08
, O 0 2.004250809761743e-08
beta O 0 3.8167417670820214e-08
and O 0 1.814935579602661e-08
gamma O 0 6.220165715831172e-08
as O 0 1.545560124327494e-08
well O 0 9.780278809046195e-09
as O 0 1.590032283615983e-08
the O 0 3.957331884407722e-08
opioid O 0 9.012439363687008e-07
- O 0 3.2586342513241107e-06
receptor O 0 4.839343432649912e-07
ligand O 0 1.9274195892649004e-06
beta O 0 3.187759602951701e-06
- O 0 5.5620148486923426e-05
endorphin O 0 0.00021111300156917423
. O 0 5.996216259518405e-06

While O 0 9.357323506264947e-06
a O 0 1.2920262406623806e-06
few O 0 3.0221582392186974e-07
cases O 0 2.82680588270523e-07
of O 0 5.583361257777142e-07
isolated O 0 0.05416075512766838
ACTH B-Disease 1 0.9997770190238953
deficiency I-Disease 1 0.6506046652793884
have O 0 3.929929789592279e-06
been O 0 1.1857718163810205e-05
reported O 0 0.0003963282215408981
( O 0 1.746214365994092e-06
OMIM O 0 0.00035486213164404035
201400 O 0 1.4811265828029718e-05
) O 0 2.9107505383763055e-07
, O 0 3.2075772082862386e-07
an O 0 3.710408009283128e-06
inherited O 0 0.3640355169773102
POMC O 1 0.9854970574378967
defect O 0 0.08334635198116302
has O 0 6.422699698305223e-06
not O 0 3.4505376333981985e-07
been O 0 8.396265229748678e-07
described O 0 4.4003486436849926e-06
so O 0 3.3921668318726006e-07
far O 0 1.334741568825848e-06
. O 0 4.7162043301796075e-06

Recent O 0 0.00010980304068652913
studies O 0 6.213819688127842e-06
in O 0 6.010971560499456e-07
animal O 0 2.3707020773144905e-06
models O 0 4.441278179001529e-06
elucidated O 0 6.437238880607765e-06
a O 0 6.234608918020967e-07
central O 0 5.271692202768463e-07
role O 0 2.6308552492082526e-07
of O 0 6.479901770717333e-08
alpha O 0 2.877093493225402e-06
- O 0 5.510072878678329e-05
MSH O 0 6.545882934005931e-05
in O 0 8.402747653235565e-08
the O 0 2.2445984626529025e-08
regulation O 0 1.116223486974377e-07
of O 0 3.5379439822236236e-08
food O 0 2.0678119483363844e-07
intake O 0 3.7702190525124024e-07
by O 0 2.817640520902387e-08
activation O 0 1.1420610945833687e-07
of O 0 5.4022574857981454e-08
the O 0 2.8099448172724806e-06
brain O 0 0.00023057661019265652
melanocortin O 0 8.098949183477089e-05
- O 0 7.2718714363873e-05
4 O 0 1.3795089216728229e-05
- O 0 4.447620813152753e-05
receptor O 0 1.6035020280469325e-06
( O 0 1.9605396062161162e-07
MC4 O 0 2.870473326765932e-05
- O 0 3.805277810897678e-05
R O 0 0.00013371995009947568
; O 0 3.0691734309584717e-07
refs O 0 1.9142814835504396e-06
3 O 0 1.7195109194290126e-06
- O 0 2.488702375558205e-05
5 O 0 4.121920937905088e-06
) O 0 7.234066856653953e-08
and O 0 5.394185365048543e-08
the O 0 1.4394701963738044e-07
linkage O 0 8.044594324019272e-06
of O 0 8.877192385625676e-07
human O 0 2.472903906891588e-05
obesity B-Disease 1 0.9991588592529297
to O 0 3.44203294844192e-06
chromosome O 0 3.577989264158532e-05
2 O 0 5.736634648201289e-06
in O 0 2.498413778084796e-07
close O 0 6.33727893273317e-07
proximity O 0 6.473712232946127e-07
to O 0 9.87872567748127e-07
the O 0 1.5680459455325035e-06
POMC O 0 0.00012821011478081346
locus O 0 8.291765880130697e-06
, O 0 3.9852105260251847e-07
led O 0 1.1698780610913673e-07
to O 0 9.484981688956395e-08
the O 0 9.324723748704855e-08
proposal O 0 7.534113706242351e-07
of O 0 1.0338552414168589e-07
an O 0 2.068339881589054e-06
association O 0 6.895122623973293e-07
of O 0 3.675674520309258e-07
POMC O 0 0.0006001953152008355
with O 0 8.297492968267761e-06
human O 0 0.00013058650074526668
obesity B-Disease 1 0.9991410970687866
. O 0 3.1991909054340795e-05

The O 0 4.953107691108016e-06
dual O 0 1.1850223017972894e-05
role O 0 1.985638164114789e-06
of O 0 2.1285595153130998e-07
alpha O 0 1.049792808771599e-05
- O 0 0.00010715207463363186
MSH O 0 0.0001311794330831617
in O 0 4.040975625230203e-07
regulating O 0 7.923727594061347e-07
food O 0 3.8400028756768734e-07
intake O 0 6.815363917667128e-07
and O 0 1.192048216580588e-06
influencing O 0 1.5714496839791536e-05
hair O 1 0.6850275993347168
pigmentation O 0 0.08717161417007446
predicts O 0 0.002997762756422162
that O 0 6.874951168356347e-07
the O 0 6.908338718858431e-07
phenotype O 0 7.99683402874507e-05
associated O 0 2.403093503744458e-06
with O 0 4.553288874831196e-07
a O 0 2.2011348846717738e-05
defect O 0 0.00013902201317250729
in O 0 2.5103774987655925e-06
POMC O 0 0.0002325856767129153
function O 0 7.352556394835119e-07
would O 0 1.6106039311125642e-06
include O 0 3.7964925923006376e-06
obesity B-Disease 1 0.9996206760406494
, O 0 3.2784837458166294e-06
alteration O 0 3.005473263328895e-05
in O 0 1.736327430990059e-05
pigmentation O 1 0.8684541583061218
and O 0 0.09159275144338608
ACTH B-Disease 1 0.9906923174858093
deficiency I-Disease 0 0.14072194695472717
. O 0 1.0711178219935391e-05

The O 0 8.834164873405825e-06
observation O 0 1.4750117770745419e-05
of O 0 7.178434202614881e-07
these O 0 9.129465183832508e-07
symptoms O 0 1.724120375001803e-05
in O 0 2.399355878424103e-07
two O 0 7.890939173194056e-07
probands O 0 0.00011335797171341255
prompted O 0 1.4525558071909472e-06
us O 0 3.990813013388106e-07
to O 0 6.642899563757965e-08
search O 0 2.6916265483123425e-07
for O 0 1.9018045804841677e-07
mutations O 0 2.7694534310285235e-06
within O 0 1.2525288184406236e-07
their O 0 2.3105524178390624e-06
POMC O 0 0.003033924149349332
genes O 0 3.0863120628055185e-05
. O 0 9.930869055096991e-06

Patient O 0 0.041959840804338455
1 O 0 0.00013761853915639222
was O 0 3.9700858906144276e-05
found O 0 9.708890047477325e-07
to O 0 1.3813708221732668e-07
be O 0 3.410951876503532e-08
a O 0 1.1392022969403115e-07
compound O 0 3.021304564754246e-06
heterozygote O 0 3.5173961805412546e-06
for O 0 1.234631525903751e-07
two O 0 7.668363082302676e-07
mutations O 0 5.170071744942106e-06
in O 0 2.850498503903509e-07
exon O 0 2.3689757654210553e-05
3 O 0 1.4977194950915873e-05
( O 0 3.4101458368240856e-07
G7013T O 0 2.134158421540633e-06
, O 0 8.562495281694282e-07
C7133delta O 0 1.116083421948133e-05
) O 0 1.7940686802830896e-07
which O 0 1.119442956110106e-07
interfere O 0 1.1508152653050274e-07
with O 0 4.2708077074848916e-08
appropriate O 0 1.2603987897819025e-07
synthesis O 0 2.4415608095296193e-06
of O 0 8.320555480167968e-07
ACTH O 0 0.00014280786854214966
and O 0 1.8339444523007842e-06
alpha O 0 1.2443708328646608e-05
- O 0 0.0002278350730193779
MSH O 0 0.000967555504757911
. O 0 6.533043688250473e-06

Patient O 0 0.03663229942321777
2 O 0 0.00010347146599087864
was O 0 2.360253347433172e-05
homozygous O 0 2.432798282825388e-06
for O 0 1.7818635456023912e-07
a O 0 2.3530337784904987e-06
mutation O 0 7.341104719671421e-06
in O 0 1.349738568023895e-06
exon O 0 7.627575541846454e-05
2 O 0 4.216888191876933e-05
( O 0 6.180018203849613e-07
C3804A O 0 5.853171842318261e-06
) O 0 4.896598397863272e-07
which O 0 2.1300286334735574e-06
abolishes O 0 0.0003066769859287888
POMC O 0 0.001179910614155233
translation O 0 5.480239633470774e-05
. O 0 6.7565897552412935e-06

These O 0 1.3300983482622541e-05
findings O 0 1.1297445780655835e-05
represent O 0 5.045398552283586e-07
the O 0 1.1031644220338421e-07
first O 0 5.705626335839042e-07
examples O 0 1.9336631851274433e-07
of O 0 1.6500680999342876e-07
a O 0 0.0010607101721689105
genetic B-Disease 1 0.9999972581863403
defect I-Disease 1 0.9997064471244812
within O 0 3.754273905087757e-07
the O 0 1.2017241033390746e-06
POMC O 0 0.0002990943321492523
gene O 0 3.122965381407994e-06
and O 0 2.755028276624216e-07
define O 0 8.53640472087136e-07
a O 0 4.501001967582852e-06
new O 0 0.00021555567218456417
monogenic B-Disease 1 0.9961666464805603
endocrine I-Disease 1 0.9996956586837769
disorder I-Disease 0 0.3570674955844879
resulting O 0 9.728569239086937e-06
in O 0 2.095074705721345e-06
early O 0 0.00021840297267772257
- O 1 0.9998314380645752
onset O 1 0.9993988275527954
obesity B-Disease 1 1.0
, O 0 0.03331100568175316
adrenal B-Disease 1 0.9999991655349731
insufficiency I-Disease 1 0.9999996423721313
and O 0 8.903726848075166e-05
red O 0 0.0005553224473260343
hair O 1 0.9958735108375549
pigmentation O 0 0.11204911768436432
. O 0 6.137732725619571e-06
. O 0 4.298186013329541e-06

A O 0 9.681461961008608e-05
European O 0 5.4737789469072595e-05
multicenter O 0 0.0012739887461066246
study O 0 1.8220503989141434e-05
of O 0 3.381284841452725e-05
phenylalanine B-Disease 1 0.9999998807907104
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 7.080789600877324e-06
classification O 0 7.605526661791373e-06
of O 0 2.1513326942113054e-07
105 O 0 5.7197489695681725e-06
mutations O 0 9.291396054322831e-06
and O 0 4.234186690155184e-07
a O 0 6.257972131606948e-07
general O 0 1.568388370287721e-07
system O 0 1.928569162146232e-07
for O 0 5.286947271088138e-07
genotype O 0 8.656747377244756e-05
- O 0 0.000441107404185459
based O 0 3.068662772420794e-05
prediction O 0 4.8169109504669905e-05
of O 0 2.2651749986835057e-06
metabolic O 0 0.022060619667172432
phenotype O 0 0.003794129239395261
. O 0 2.887523078243248e-05

Phenylketonuria B-Disease 1 0.9989783763885498
( O 0 0.0032973706256598234
PKU B-Disease 0 0.3683593273162842
) O 0 4.4404921936802566e-05
and O 0 6.257949280552566e-05
mild B-Disease 1 0.5124856233596802
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.00880605448037386
MHP B-Disease 1 0.9999997615814209
) O 0 9.996631888498086e-06
are O 0 1.3825849691784242e-06
allelic B-Disease 0 0.014236170798540115
disorders I-Disease 1 0.9645692706108093
caused O 0 3.3058313420042396e-05
by O 0 2.968277840409428e-06
mutations O 0 2.9083495974191464e-05
in O 0 3.937853705338057e-07
the O 0 1.3970704912935616e-06
gene O 0 1.3668182873516344e-05
encoding O 0 1.7851572920335457e-05
phenylalanine O 0 0.01910228468477726
hydroxylase O 1 0.9578126072883606
( O 0 7.323381578316912e-05
PAH O 0 0.08821553736925125
) O 0 7.531781648140168e-06
. O 0 5.187327133171493e-06

Previous O 0 0.00016072686412371695
studies O 0 1.7661646779743023e-05
have O 0 5.386863790590724e-07
suggested O 0 1.5546952454315033e-06
that O 0 8.191988598582611e-08
the O 0 1.9484015467696736e-07
highly O 0 2.2759629700885853e-06
variable O 0 8.810736471787095e-05
metabolic O 0 0.05637185648083687
phenotypes O 0 0.0007063574157655239
of O 0 7.97966422396712e-05
PAH B-Disease 1 0.9999977350234985
deficiency I-Disease 1 0.9829555153846741
correlate O 0 8.864662959240377e-05
with O 0 4.386811997392215e-05
PAH O 1 0.9932780861854553
genotypes O 0 0.0019096997566521168
. O 0 2.4142314941855147e-05

We O 0 2.1624353394145146e-05
identified O 0 8.098299986158963e-06
both O 0 8.657951866553049e-07
causative O 0 5.174001125851646e-05
mutations O 0 0.00014953552454244345
in O 0 5.627556674880907e-06
686 O 0 0.001820429926738143
patients O 0 9.742957627167925e-05
from O 0 2.8939575713593513e-07
seven O 0 8.009670864339569e-07
European O 0 7.54017537474283e-06
centers O 0 3.097087756032124e-06
. O 0 3.8744583434890956e-06

On O 0 2.406546991551295e-05
the O 0 5.388261001826322e-07
basis O 0 2.0907643261125486e-07
of O 0 6.005104324913191e-08
the O 0 1.8476745822226803e-07
phenotypic O 0 2.2594233541894937e-06
characteristics O 0 7.793966574354272e-07
of O 0 1.5306707723539148e-07
297 O 0 1.4844438737782184e-05
functionally O 0 0.0001035446985042654
hemizygous O 0 0.003386675613000989
patients O 0 1.9765466277021915e-05
, O 0 5.2030948438641644e-08
105 O 0 9.412982393541824e-08
of O 0 3.1989127791121064e-08
the O 0 6.615171059820568e-07
mutations O 0 4.9546006266609766e-06
were O 0 1.1340026162542927e-07
assigned O 0 1.1612435457664105e-07
to O 0 3.670090720220287e-08
one O 0 3.794950131918995e-08
of O 0 3.02244878014335e-08
four O 0 8.010756005205621e-07
arbitrary O 0 1.5063427781569771e-05
phenotype O 0 0.00016736444376874715
categories O 0 8.81102641869802e-06
. O 0 6.971411949052708e-06

We O 0 1.4837618437013589e-05
proposed O 0 2.450499550832319e-06
and O 0 2.2001365778123727e-06
tested O 0 1.8127803969036904e-06
a O 0 3.316859533697425e-07
simple O 0 2.493714816864667e-07
model O 0 2.1438254407257773e-06
for O 0 2.1954485873720841e-07
correlation O 0 1.6371379842894385e-06
between O 0 1.9146611975884298e-06
genotype O 0 0.00019631680333986878
and O 0 5.3982939789420925e-06
phenotypic O 0 3.4357824915787205e-05
outcome O 0 2.5895520593621768e-05
. O 0 9.926900929713156e-06

The O 0 2.9551343686762266e-05
observed O 0 2.9170381822041236e-05
phenotype O 0 0.00015944037295412272
matched O 0 6.389601185219362e-05
the O 0 5.394922936829971e-06
predicted O 0 0.0002877613005694002
phenotype O 0 6.244732503546402e-05
in O 0 1.9986482584499754e-06
79 O 0 4.638337941287318e-06
% O 0 1.4236282197543915e-07
of O 0 2.6665642138823387e-08
the O 0 1.1043281347156153e-06
cases O 0 8.540720273231273e-07
, O 0 5.570958023781714e-07
and O 0 3.0979688858678855e-07
in O 0 1.1264575761060769e-07
only O 0 5.5608097682124935e-08
5 O 0 5.189150442674872e-07
of O 0 9.018167901331253e-08
184 O 0 6.716847565257922e-06
patients O 0 6.701115125906654e-06
was O 0 2.780716840788955e-06
the O 0 3.256734260048688e-07
observed O 0 4.242054274072871e-06
phenotype O 0 7.527078196289949e-06
more O 0 4.611620951777695e-08
than O 0 3.768535705717113e-08
one O 0 1.20399619163436e-07
category O 0 2.543653465636453e-07
away O 0 2.5078026055780356e-07
from O 0 1.1560303647684123e-07
that O 0 3.052788315471844e-07
expected O 0 5.773593329649884e-06
. O 0 5.050875643064501e-06

Among O 0 9.272293937101495e-06
the O 0 1.0240107712888857e-06
seven O 0 8.391518235839612e-07
contributing O 0 1.341726488135464e-06
centers O 0 2.1553699980358942e-07
, O 0 1.3451980862555502e-07
the O 0 9.618484142492889e-08
proportion O 0 5.877873263671063e-07
of O 0 3.081283068695484e-07
patients O 0 4.834251285501523e-06
for O 0 6.793378588554333e-07
whom O 0 4.000303306384012e-06
the O 0 1.1227868981222855e-06
observed O 0 1.738246101012919e-05
phenotype O 0 5.3052812290843576e-05
did O 0 2.1282316993165296e-06
not O 0 1.133324687430104e-07
match O 0 4.825844825973036e-07
the O 0 6.753934940206818e-07
predicted O 0 8.960077684605494e-05
phenotype O 0 1.4376387298398186e-05
was O 0 3.686399395519402e-06
4 O 0 2.5368776732648257e-06
% O 0 2.622706176680367e-07
- O 0 3.125793591607362e-05
23 O 0 7.63940806791652e-06
% O 0 6.135656462902261e-07
( O 0 1.656210173450745e-07
P O 0 0.0008299591718241572
< O 0 3.0242131288105156e-06
. O 0 3.5048222457589873e-07
0001 O 0 9.744670933287125e-06
) O 0 1.1296052093712206e-07
, O 0 8.126811934516809e-08
suggesting O 0 3.2103804414873593e-07
that O 0 4.8021824738953e-08
differences O 0 1.9334565592998842e-07
in O 0 2.1214604828401207e-07
methods O 0 5.531696842808742e-07
used O 0 8.456124191980052e-07
for O 0 4.7211449327733135e-07
mutation O 0 2.005139322136529e-06
detection O 0 5.10779682372231e-06
or O 0 3.999654836661648e-06
phenotype O 0 0.0003578373871278018
classification O 0 0.0010317827109247446
may O 0 0.0001434729783795774
account O 0 8.816472245598561e-07
for O 0 7.27095965658009e-08
a O 0 5.307801984599791e-07
considerable O 0 5.442446422421199e-07
proportion O 0 1.998566403926816e-06
of O 0 1.1085552387157804e-06
genotype O 0 0.03825909271836281
- O 1 0.7802325487136841
phenotype O 0 0.0554467998445034
inconsistencies O 0 0.0007642253185622394
. O 0 2.1772180843981914e-05

Our O 0 1.9281113054603338e-05
data O 0 1.1822962733276654e-05
indicate O 0 2.244150664409972e-06
that O 0 2.2958219858537632e-07
the O 0 7.510755608564068e-07
PAH O 0 0.10776318609714508
- O 0 0.007834788411855698
mutation O 0 1.0555671906331554e-05
genotype O 0 5.888955001864815e-06
is O 0 3.7821383358505045e-08
the O 0 2.055030812186942e-08
main O 0 8.099211186163302e-07
determinant O 0 8.72596774570411e-06
of O 0 5.490821308740124e-07
metabolic O 0 0.007548052351921797
phenotype O 0 0.00029352394631132483
in O 0 2.7715088890545303e-06
most O 0 1.0313444363418967e-05
patients O 0 6.583030335605145e-05
with O 0 4.206525773042813e-05
PAH B-Disease 1 0.9999916553497314
deficiency I-Disease 1 0.9001676440238953
. O 0 1.3650519576913211e-05

In O 0 9.48091474128887e-06
the O 0 8.326906595357286e-07
present O 0 7.163354780459485e-07
study O 0 4.969432438883814e-07
, O 0 1.4595417496821028e-07
the O 0 7.637434151774869e-08
classification O 0 3.9160981941677164e-06
of O 0 2.9056775474600727e-07
105 O 0 1.5623198123648763e-05
PAH O 0 0.08267885446548462
mutations O 0 6.589994882233441e-05
may O 0 1.8641646875039442e-06
allow O 0 3.8738754426503874e-08
the O 0 1.6067734520675003e-07
prediction O 0 1.4207057574822102e-05
of O 0 5.8709666461709276e-08
the O 0 8.939747431213618e-07
biochemical O 0 2.822023816406727e-05
phenotype O 0 6.2625935242977e-05
in O 0 1.605659690540051e-06
> O 0 2.733932660703431e-06
10 O 0 1.025494270834315e-06
, O 0 2.024276994916363e-07
000 O 0 2.5864466124403407e-07
genotypes O 0 1.7200145521201193e-06
, O 0 5.618583145405864e-07
which O 0 1.6380437273255666e-06
may O 0 2.454580908306525e-06
be O 0 3.437993001398354e-08
useful O 0 2.80974088440189e-08
for O 0 1.0982412135263075e-07
the O 0 4.510088729148265e-07
management O 0 5.326397968019592e-06
of O 0 5.519634669326479e-07
hyperphenylalaninemia B-Disease 1 0.99998939037323
in O 0 3.784606451517902e-05
newborns O 0 0.00021919759456068277
. O 0 4.5288566070667e-06

Somatic O 0 0.00137475342489779
instability O 0 0.0002004839334404096
of O 0 1.9052042716793949e-06
the O 0 3.2202890452026622e-06
CTG O 0 0.000731157255358994
repeat O 0 0.0001377975131617859
in O 0 1.5171058294072282e-06
mice O 0 2.5892852136166766e-05
transgenic O 0 1.8525230188970454e-05
for O 0 3.7166164474911056e-06
the O 0 9.58659074967727e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.002702604979276657
is O 0 3.2723776257626014e-06
age O 0 6.235893579287222e-07
dependent O 0 9.810229357753997e-07
but O 0 2.5020574412337737e-07
not O 0 6.164347610138066e-08
correlated O 0 2.1859531784684805e-07
to O 0 7.550600145123099e-08
the O 0 8.97254679443904e-08
relative O 0 6.121979936324351e-07
intertissue O 0 2.126865365426056e-05
transcription O 0 6.762636530766031e-06
levels O 0 2.1147673123778077e-06
and O 0 2.638274963828735e-06
proliferative O 0 0.002689783228561282
capacities O 0 4.703304512077011e-05
. O 0 9.709254300105385e-06

A O 0 0.0005711306002922356
( O 0 2.835560735547915e-05
CTG O 0 0.0004868950054515153
) O 0 1.1686765901686158e-06
nexpansion O 0 8.967096619016957e-06
in O 0 1.5963522059792012e-07
the O 0 1.9614971336068265e-07
3 O 0 3.663248207885772e-05
- O 0 0.014185242354869843
untranslated O 0 0.0557936429977417
region O 0 0.00012695766054093838
( O 0 1.1129129688924877e-06
UTR O 0 0.00013089293497614563
) O 0 1.2498082924139453e-07
of O 0 2.1389491067225208e-08
the O 0 4.591347533278167e-06
DM O 1 0.9999997615814209
protein O 0 6.868776836199686e-05
kinase O 0 0.00013001682236790657
gene O 0 1.2864251402788796e-05
( O 0 5.83050223212922e-07
DMPK O 0 0.00013321380538400263
) O 0 4.62694714542522e-07
is O 0 1.9339250911798445e-07
responsible O 0 5.001986664865399e-06
for O 0 3.6850418837275356e-05
causing O 1 0.9825707077980042
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.22059786319732666
DM B-Disease 1 1.0
) O 0 3.629961429396644e-05
. O 0 1.2175385563750751e-05

Major O 0 0.00023419142235070467
instability O 0 0.0001326672063441947
, O 0 1.0148711453439319e-06
with O 0 2.484049730355764e-07
very O 0 1.7519479911243252e-07
large O 0 1.2252689884917345e-07
expansions O 0 1.370917971144081e-06
between O 0 1.537913760785159e-07
generations O 0 5.035159915678378e-07
and O 0 5.546741590478632e-07
high O 0 9.397157327839523e-07
levels O 0 1.6379219403006573e-07
of O 0 5.5082821859286923e-08
somatic O 0 4.791108494828222e-06
mosaicism O 0 0.00011734914005501196
, O 0 9.86451027529256e-07
is O 0 2.824418459113076e-07
observed O 0 1.5178236481006024e-06
in O 0 2.0634261090890504e-06
patients O 0 1.6888541722437367e-05
. O 0 6.483724973804783e-06

There O 0 1.6468859030283056e-05
is O 0 1.0964304237859324e-06
a O 0 6.144158533061272e-07
good O 0 1.9768519905483117e-06
correlation O 0 3.4483543913665926e-06
between O 0 1.59892101692094e-06
repeat O 0 4.9052458052756265e-05
size O 0 4.711492692877073e-06
( O 0 4.392347818793496e-07
at O 0 7.408174269585288e-07
least O 0 1.982660506882894e-07
in O 0 4.753619293751399e-07
leucocytes O 0 0.00019603248802013695
) O 0 1.0712051334849093e-06
, O 0 2.142684934369754e-06
clinical O 0 1.0190375178353861e-05
severity O 0 2.5876362997223623e-05
and O 0 3.772085165110184e-06
age O 0 1.974581664399011e-06
of O 0 1.3151942539479933e-06
onset O 0 0.00034094543661922216
. O 0 2.3282645997824147e-05

The O 0 4.398616511025466e-05
trinucleotide O 0 0.0019141536904498935
repeat O 0 0.0004110126756131649
instability O 0 3.792171264649369e-05
mechanisms O 0 8.544894626538735e-06
involved O 0 7.077954251144547e-06
in O 0 4.233085201121867e-05
DM B-Disease 1 1.0
and O 0 6.540111644426361e-05
other O 0 3.5391360597714083e-06
human O 0 5.170276926946826e-05
genetic B-Disease 1 0.9999980926513672
diseases I-Disease 1 0.9999995231628418
are O 0 3.7005167996539967e-06
unknown O 0 7.213661592686549e-05
. O 0 1.6417425285908394e-05

We O 0 2.4126091375364922e-05
studied O 0 1.2820258234569337e-05
somatic O 0 5.835572301293723e-05
instability O 0 3.0590348615078256e-05
by O 0 8.690089430274384e-07
measuring O 0 8.570142381358892e-05
the O 0 8.254463864432182e-06
CTG O 0 0.0003519596648402512
repeat O 0 2.7404132197261788e-05
length O 0 1.7650937707003322e-06
at O 0 5.63893877369992e-07
several O 0 6.29396694762363e-08
ages O 0 3.716931473718432e-07
in O 0 8.737991663565481e-08
various O 0 3.345794752362963e-08
tissues O 0 1.1081851880589966e-06
of O 0 1.1840622704539783e-07
transgenic O 0 4.1275132389273494e-05
mice O 0 4.5567809138447046e-05
carrying O 0 1.3007199868297903e-06
a O 0 6.0085521909059025e-06
( O 0 1.2670506066569942e-06
CTG O 0 7.273452501976863e-05
) O 0 2.9980421345499053e-07
55expansion O 0 4.2346246118540876e-06
surrounded O 0 8.695676569914212e-07
by O 0 9.81801875354904e-08
45 O 0 2.3677505112118524e-07
kb O 0 1.082163453247631e-05
of O 0 5.679340731035154e-08
the O 0 1.913284904730972e-06
human O 0 3.2410796848125756e-05
DM B-Disease 1 1.0
region O 0 5.244956264505163e-05
, O 0 2.5172386131089297e-07
using O 0 1.6264625912754127e-07
small O 0 2.621478358832974e-07
- O 0 7.718099368503317e-05
pool O 0 1.8864568119170144e-05
PCR O 0 0.0001283035526284948
. O 0 3.885185378749156e-06

These O 0 7.769782314426266e-06
mice O 0 0.00015153270214796066
have O 0 6.13600832366501e-07
been O 0 3.346242181123671e-07
shown O 0 2.918677921570634e-07
to O 0 2.7076791297986347e-07
reproduce O 0 2.3913041786727263e-06
the O 0 1.5274976306045573e-07
intergenerational O 0 1.288165913138073e-05
and O 0 1.7877065374705126e-06
somatic O 0 4.902653472527163e-06
instability O 0 1.0253661457682028e-06
of O 0 4.3051414877481875e-08
the O 0 3.962612140639976e-07
55 O 0 5.288623924570857e-06
CTG O 0 8.106877066893503e-05
repeat O 0 3.2800089684315026e-05
suggesting O 0 1.4803180192757281e-06
that O 0 7.434105953052494e-08
surrounding O 0 1.2322472286996344e-07
sequences O 0 1.4921886304364307e-07
and O 0 2.9447494398482377e-07
the O 0 1.5860015878388367e-07
chromatin O 0 1.2198165677546058e-06
environment O 0 1.4676753608000581e-06
are O 0 5.822812099154362e-08
involved O 0 2.8857445499852474e-07
in O 0 1.1432034625613596e-06
instability O 0 1.897699803521391e-05
mechanisms O 0 1.883743971120566e-05
. O 0 1.1563038242456969e-05

As O 0 2.7144214982399717e-05
observed O 0 3.945393473259173e-06
in O 0 1.5050656543280638e-07
some O 0 2.1465346833338117e-08
of O 0 2.6089749027846665e-08
the O 0 6.29125452178414e-07
tissues O 0 2.040848085016478e-05
of O 0 1.5989355233614333e-05
DM B-Disease 1 1.0
patients O 0 0.019414136186242104
, O 0 7.831996526874718e-07
there O 0 5.43461560198466e-08
is O 0 9.214910079435867e-08
a O 0 1.072282543645997e-06
tendency O 0 4.101569629710866e-06
for O 0 7.087276117090369e-07
repeat O 0 1.1739361070794985e-05
length O 0 2.5632955384935485e-06
and O 0 6.804284566896968e-07
somatic O 0 1.0314665814803448e-06
mosaicism O 0 7.945513061713427e-06
to O 0 1.7807067820285738e-07
increase O 0 2.5055626906578254e-07
with O 0 9.909338416491664e-08
the O 0 4.881640620624239e-07
age O 0 2.825304648013116e-07
of O 0 3.897666189800475e-08
the O 0 1.4056437294129864e-06
mouse O 0 7.66208759159781e-05
. O 0 1.153928769781487e-05

Furthermore O 0 0.0001761021849233657
, O 0 9.343769306724425e-06
we O 0 5.443012582873052e-07
observed O 0 3.895028442002513e-07
no O 0 7.456898742930207e-08
correlation O 0 3.8920208567105874e-07
between O 0 1.48517798947978e-07
the O 0 3.487857043182885e-07
somatic O 0 1.5383715435746126e-05
mutation O 0 1.3334742106962949e-05
rate O 0 6.617186045332346e-06
and O 0 5.483111181092681e-06
tissue O 0 0.0003262142708990723
proliferation O 0 2.9944443667773157e-05
capacity O 0 3.1708773349237163e-06
. O 0 5.192855951463571e-06

The O 0 6.3442062128160615e-06
somatic O 0 3.046917299798224e-05
mutation O 0 2.3273745682672597e-05
rates O 0 3.733333869604394e-06
in O 0 2.3095161338915204e-07
different O 0 6.255656614939653e-08
tissues O 0 4.691030426329235e-06
were O 0 1.1559866379684536e-06
also O 0 1.1028463404727518e-06
not O 0 9.024173408533898e-08
correlated O 0 3.6112626844442275e-07
to O 0 8.321691780110996e-08
the O 0 4.3283680639660815e-08
relative O 0 4.801541990673286e-07
inter O 0 8.636158781882841e-06
- O 0 0.006898432970046997
tissue O 0 3.655058389995247e-05
difference O 0 5.716399300581543e-07
in O 0 8.345455171365757e-08
transcriptional O 0 3.0076640200604743e-07
levels O 0 8.720908795112337e-08
of O 0 1.0081100398906528e-08
the O 0 1.1700064561637191e-07
three O 0 9.316685805060843e-07
genes O 0 1.3112942269799532e-06
( O 0 1.6641995159716316e-07
DMAHP O 0 8.766268729232252e-05
, O 0 1.3055766885372577e-06
DMPK O 0 8.167509804479778e-05
and O 0 1.6095383443825995e-06
59 O 0 4.42162627223297e-06
) O 0 6.951322717441144e-08
surrounding O 0 1.4851893581635522e-07
the O 0 6.707871875732963e-07
repeat O 0 6.090497117838822e-05
. O 0 1.212399865835323e-06
. O 0 4.420791356096743e-06

A O 0 6.956540892133489e-05
novel O 0 4.017172977910377e-05
missense O 0 0.0004854898143094033
mutation O 0 0.00013446003140415996
in O 0 8.093828910205048e-06
patients O 0 1.980273191293236e-05
from O 0 3.3291965451098804e-07
a O 0 1.0712444236560259e-05
retinoblastoma B-Disease 0 0.07762531191110611
pedigree O 0 0.005797937512397766
showing O 0 0.00016203144332394004
only O 0 2.1725595615862403e-06
mild O 0 1.607031299499795e-05
expression O 0 5.327031544766214e-07
of O 0 4.069967189934687e-07
the O 0 4.193452332401648e-05
tumor B-Disease 0 0.48703742027282715
phenotype O 0 0.0031921686604619026
. O 0 2.2816722776042297e-05

We O 0 1.0953624951071106e-05
have O 0 4.106984476948128e-07
used O 0 2.8104867055844807e-07
single O 0 9.483838994128746e-07
strand O 0 5.80562737013679e-05
conformation O 0 5.496141966432333e-06
polymorphism O 0 3.4894151212938596e-06
analysis O 0 6.75666626648308e-07
to O 0 2.3557591077860707e-07
study O 0 9.030715375502041e-08
the O 0 1.0276779960349813e-07
27 O 0 1.888051770038146e-06
exons O 0 1.5961999224600731e-06
of O 0 5.869712182970943e-08
the O 0 9.370533007313497e-07
RB1 O 0 0.00016428255185019225
gene O 0 1.466799403715413e-06
in O 0 1.8021212611074588e-07
individuals O 0 1.344312750006793e-08
from O 0 4.5869182230262595e-08
a O 0 6.305217084445758e-06
family O 0 7.776491111144423e-05
showing O 0 0.0003727030416484922
mild O 0 3.222108352929354e-05
expression O 0 6.06382684509299e-07
of O 0 1.5300271627438633e-07
the O 0 4.749776508106152e-06
retinoblastoma B-Disease 0 0.04142038896679878
phenotype O 0 0.004305685870349407
. O 0 2.9699836886720732e-05

In O 0 1.4452584764512721e-05
this O 0 6.799535867685336e-07
family O 0 4.822716164198937e-06
affected O 0 1.4098243354965234e-06
individuals O 0 8.418950159239103e-08
developed O 0 2.057599886029493e-05
unilateral B-Disease 0 0.20060475170612335
tumors I-Disease 1 1.0
and O 0 8.525100565748289e-05
, O 0 1.365693151456071e-06
as O 0 1.7666772578195378e-07
a O 0 5.005895786780457e-07
result O 0 7.506902193199494e-07
of O 0 1.218451046725022e-07
linkage O 0 3.496075078146532e-05
analysis O 0 5.176574632059783e-06
, O 0 1.021266371026286e-06
unaffected O 0 7.990071935637388e-06
mutation O 0 2.3533457351732068e-06
carriers O 0 4.343527848504891e-07
were O 0 2.8499985660346283e-07
also O 0 7.816833544893598e-07
identified O 0 1.4261056549003115e-06
within O 0 1.0874626354961947e-07
the O 0 1.1041490779462038e-06
pedigree O 0 0.00018739979714155197
. O 0 1.8656637621461414e-05

A O 0 4.666118184104562e-05
single O 0 1.3468413271766622e-05
band O 0 1.1893130249518435e-05
shift O 0 2.5656875095592113e-06
using O 0 5.062653940512973e-07
SSCP O 0 0.00013087346451357007
was O 0 2.0362407667562366e-05
identified O 0 4.098918452655198e-06
in O 0 5.581104005614179e-07
exon O 0 3.6550965887727216e-05
21 O 0 1.1399263712519314e-05
which O 0 8.062859251367627e-07
resulted O 0 7.24062260815117e-07
in O 0 1.6527862101156643e-07
a O 0 1.8184581449531834e-06
missense O 0 5.2378589316504076e-05
mutation O 0 2.613184051369899e-06
converting O 0 1.1342182233420317e-06
a O 0 4.8135452743736096e-06
cys O 0 0.10367309302091599
- O 0 0.0037631443701684475
- O 0 0.0014094911748543382
> O 0 5.115099156682845e-06
arg O 0 5.392659659264609e-06
at O 0 2.2078998540564498e-07
nucleotide O 0 8.802273896435509e-07
position O 0 1.3727260466112057e-06
28 O 0 8.386054446418711e-07
in O 0 1.352445337943209e-07
the O 0 8.37998641145532e-07
exon O 0 0.00021441292483359575
. O 0 1.1000985068676528e-05

The O 0 1.7163380107376724e-05
mutation O 0 4.2556381231406704e-05
destroyed O 0 3.45008447766304e-05
an O 0 1.2119292023271555e-06
NdeI O 0 5.904891440877691e-05
restriction O 0 2.3456445887859445e-06
enzyme O 0 4.98941381010809e-06
site O 0 9.304776540375315e-06
. O 0 5.4126971917867195e-06

Analysis O 0 2.831766687449999e-05
of O 0 5.698894369743357e-07
all O 0 1.7226082604793191e-07
family O 0 1.4217315538189723e-06
members O 0 2.488879999873461e-07
demonstrated O 0 4.054455473578855e-07
that O 0 4.488873983632402e-08
the O 0 1.3452108760247938e-07
missense O 0 2.9033335522399284e-05
mutation O 0 9.360732292407192e-06
co O 0 4.8399888328276575e-05
- O 0 2.1229985577519983e-05
segregated O 0 9.342007274426578e-07
with O 0 2.7253418011241592e-06
patients O 0 1.4870964150759391e-05
with O 0 2.3833832528907806e-05
tumors B-Disease 1 1.0
or O 0 3.255974661442451e-05
who O 0 2.496970773790963e-05
, O 0 3.917716355772427e-07
as O 0 1.0930877181181131e-07
a O 0 6.561701297869149e-07
result O 0 6.43514340481488e-07
of O 0 9.029665193338587e-08
linkage O 0 5.567428161157295e-05
analysis O 0 1.1128811820526607e-05
had O 0 3.5324170312378556e-05
been O 0 2.5070758056244813e-06
predicted O 0 1.2483515092753805e-05
to O 0 1.425991058567888e-07
carry O 0 5.039522079641756e-07
the O 0 1.0068879419122823e-06
predisposing O 0 0.00013276617391966283
mutation O 0 7.444255606969818e-05
. O 0 8.571632861276157e-06

These O 0 5.098783731227741e-06
observations O 0 6.601599125133362e-06
point O 0 3.499142167129321e-06
to O 0 4.280863379335642e-07
another O 0 2.611270701891044e-07
region O 0 1.4179415757098468e-06
of O 0 1.3105500329402275e-07
the O 0 7.472588094969979e-07
RB1 O 0 8.44359674374573e-05
gene O 0 9.767239816937945e-07
where O 0 5.291668685458717e-07
mutations O 0 6.356490303005558e-07
only O 0 2.023170431186827e-08
modify O 0 3.272506887697091e-07
the O 0 5.69377718306896e-08
function O 0 3.529370573573942e-08
of O 0 1.634711210840578e-08
the O 0 1.5891220073172008e-07
gene O 0 1.539198933642183e-06
and O 0 4.6981486434560793e-07
raise O 0 4.4704910351356375e-07
important O 0 5.0070514845401703e-08
questions O 0 8.055421574226784e-08
for O 0 2.08715462690634e-07
genetic O 0 6.888143161631888e-06
counseling O 0 7.829860351193929e-07
in O 0 2.3403194404636452e-07
families O 0 6.312156841659089e-08
with O 0 2.370809824014941e-07
these O 0 3.04016481322833e-07
distinctive O 0 9.672078886069357e-05
phenotypes O 0 0.0001789141388144344
. O 0 3.0694830002175877e-06
. O 0 8.166593943315092e-06

Maternal B-Disease 0 0.08613963425159454
disomy I-Disease 1 0.5497684478759766
and O 0 0.2746046781539917
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
consistent O 0 0.00010766151535790414
with O 0 1.5996805586837581e-06
gamete O 0 7.3653893196024e-05
complementation O 0 0.0009282123064622283
in O 0 2.1955795546091394e-06
a O 0 3.7889074064878514e-06
case O 0 2.9350169370445656e-06
of O 0 3.088867970291176e-07
familial O 0 0.000231629004701972
translocation O 0 0.006555970758199692
( O 0 4.054705641465262e-06
3 O 0 8.10193068900844e-06
; O 0 2.1979008124617394e-06
15 O 0 3.0996350233181147e-06
) O 0 5.013664576836163e-07
( O 0 1.2325668308221793e-07
p25 O 0 1.3661230013894965e-06
; O 0 3.823992926754727e-07
q11 O 0 2.177168198613799e-06
. O 0 3.6188092167321884e-07
2 O 0 3.7038782920717495e-06
) O 0 6.025273933119024e-07
. O 0 2.1704349819628987e-06

Maternal B-Disease 1 0.8237713575363159
uniparental I-Disease 1 0.976650595664978
disomy I-Disease 1 0.99039626121521
( I-Disease 0 0.0009185680537484586
UPD I-Disease 1 0.9999852180480957
) I-Disease 0 1.8550719687482342e-05
for I-Disease 0 1.3261416142995586e-06
chromosome I-Disease 0 0.00014111016935203224
15 I-Disease 0 9.230931937054265e-06
is O 0 1.129148017753323e-06
responsible O 0 2.552805653976975e-06
for O 0 4.390731191961095e-07
an O 0 8.01352939561184e-07
estimated O 0 2.201521738243173e-06
30 O 0 4.7251083401533833e-07
% O 0 8.951760577247114e-08
of O 0 5.74371235018134e-08
cases O 0 8.172073648893274e-07
of O 0 4.5151937229093164e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0005357115878723562
PWS B-Disease 1 0.9999972581863403
) O 0 2.9195623937994242e-05
. O 0 1.893561966426205e-05

We O 0 4.7613582864869386e-05
report O 0 6.063600267225411e-06
on O 0 5.760601879956084e-07
an O 0 2.2599181193072582e-07
unusual O 0 2.953544537831476e-07
case O 0 6.34629600426706e-07
of O 0 2.4046704538704944e-07
maternal B-Disease 0 3.8473124732263386e-05
disomy I-Disease 0 0.0005585808539763093
15 I-Disease 0 2.3699927623965777e-05
in O 0 1.1541597814357374e-05
PWS B-Disease 1 0.9999946355819702
that O 0 3.692951395350974e-06
is O 0 2.6220959625788964e-07
most O 0 5.839494932047273e-08
consistent O 0 2.957056324248697e-07
with O 0 1.1250768494619479e-07
adjacent O 0 4.878345862380229e-06
- O 0 0.0003506220818962902
1 O 0 3.6297183214628603e-06
segregation O 0 3.0737314204998256e-07
of O 0 2.5395610947498426e-08
a O 0 2.116463974743965e-06
paternal O 0 4.479489871300757e-05
t O 0 0.00808822363615036
( O 0 2.120859647902762e-07
3 O 0 3.076123221035232e-06
; O 0 1.1017824590453529e-06
15 O 0 1.5470118341909256e-06
) O 0 4.1963747321460687e-07
( O 0 5.977723560590675e-08
p25 O 0 8.76901083302073e-07
; O 0 2.884641219225159e-07
q11 O 0 1.3581197890744079e-06
. O 0 1.7857098555396078e-07
2 O 0 6.27225233529316e-07
) O 0 3.7297638755262597e-08
with O 0 4.551552024167904e-08
simultaneous O 0 1.0247550562780816e-05
maternal O 0 6.2929218984209e-05
meiotic O 0 0.00015207694377750158
nondisjunction O 0 0.0005075482768006623
for O 0 3.4760164453473408e-06
chromosome O 0 0.00019329646602272987
15 O 0 1.3165823474992067e-05
. O 0 6.811323601141339e-06

The O 0 6.118988676462322e-05
patient O 0 0.00043562662904150784
( O 0 8.795101166469976e-06
J O 0 0.11504632234573364
. O 0 2.466028718117741e-06
B O 0 1.9171578969690017e-05
. O 0 2.367540616887709e-07
) O 0 7.635482290879736e-08
, O 0 4.0339592999316665e-08
a O 0 2.584375522474147e-07
17 O 0 4.408522727317177e-06
- O 0 0.00010527334961807355
year O 0 6.897266302985372e-06
- O 0 9.300107922172174e-05
old O 0 2.5207096769008785e-05
white O 0 8.468814485240728e-06
male O 0 3.4192548810096923e-06
with O 0 4.5711717575613875e-06
PWS B-Disease 1 0.9999951124191284
, O 0 1.465748755435925e-05
was O 0 1.1005171472788788e-05
found O 0 4.5224371092444926e-07
to O 0 1.7862566892290488e-07
have O 0 9.567801129151121e-08
47 O 0 1.1039448963856557e-06
chromosomes O 0 4.6393898855967564e-07
with O 0 7.479633268303587e-08
a O 0 3.933218067686539e-06
supernumerary O 0 0.0014979514526203275
, O 0 9.55994073592592e-06
paternal O 0 6.42376544419676e-05
der O 1 0.9832435250282288
( O 0 7.148436225179466e-07
15 O 0 5.36937420747563e-07
) O 0 3.0436801523592294e-08
consisting O 0 1.8914866117825113e-08
of O 0 4.3437012209324166e-08
the O 0 1.0324773711545276e-06
short O 0 1.0876025044126436e-05
arm O 0 0.0001718035200610757
and O 0 1.748623844832764e-06
the O 0 7.240270747388422e-07
proximal O 0 0.0001043292650138028
long O 0 5.921345655224286e-05
arm O 0 0.00012934597907587886
of O 0 6.137892683000246e-07
chromosome O 0 0.00012864707969129086
15 O 0 3.920989456673851e-06
, O 0 4.816171781385492e-07
and O 0 4.218566573399585e-06
distal O 0 0.05430813878774643
chromosome O 0 0.35231101512908936
arm O 0 0.027083372697234154
3p O 0 0.028628911823034286
. O 0 3.099786408711225e-05

The O 0 7.447045936714858e-05
t O 0 0.0022538932971656322
( O 0 8.475581694256107e-07
3 O 0 3.1435683922609314e-06
; O 0 3.8875617747180513e-07
15 O 0 7.381756290669728e-07
) O 0 1.9328334133206226e-07
was O 0 1.9219312434870517e-06
present O 0 6.603674762573064e-08
in O 0 8.011048180378566e-08
the O 0 8.094804115899024e-08
balanced O 0 4.366454959381372e-06
state O 0 4.6870320602465654e-07
in O 0 3.886316335410811e-07
the O 0 2.5106648990913527e-06
patients O 0 7.153140813898062e-06
father O 0 2.5139136141660856e-06
and O 0 1.0450204399603535e-06
a O 0 6.473635039583314e-06
sister O 0 0.0003066684876102954
. O 0 1.3281135579745751e-05

Fluorescent O 0 0.00020545872393995523
in O 0 6.0110796766821295e-06
situ O 0 2.691246845643036e-05
hybridization O 0 6.256294000195339e-06
analysis O 0 1.877295403573953e-06
demonstrated O 0 1.786366851774801e-06
that O 0 2.3228022882904042e-07
the O 0 1.539802497063647e-06
PWS B-Disease 1 0.9999864101409912
critical O 0 2.0301329641370103e-05
region O 0 9.341560144093819e-06
resided O 0 4.896247901342576e-06
on O 0 2.911310275521828e-06
the O 0 3.5725309999179444e-07
derivative O 0 6.101490725995973e-06
chromosome O 0 3.3090011129388586e-05
3 O 0 1.063447507476667e-05
and O 0 1.559253746563627e-06
that O 0 2.1968016028495185e-07
there O 0 5.716574591474455e-08
was O 0 4.6227883103711065e-06
no O 0 2.1146995266008162e-07
deletion O 0 1.157979340860038e-06
of O 0 1.7387320383477345e-07
the O 0 8.935458936321083e-06
PWS B-Disease 1 0.9999971389770508
region O 0 2.3858256099629216e-05
on O 0 7.160047516663326e-06
the O 0 2.2063842664010735e-07
normal O 0 5.035707317802007e-07
pair O 0 9.798970950214425e-07
of O 0 9.57247365818148e-08
15s O 0 6.124011520114436e-07
present O 0 2.7660328782985744e-07
in O 0 1.0617586667649448e-06
J O 0 0.11127883195877075
. O 0 1.8504129911889322e-05

B O 0 0.004140145145356655
. O 0 0.00013438271707855165

Methylation O 0 0.00022664041898678988
analysis O 0 1.5862990039750002e-05
at O 0 2.6871355203184066e-06
exon O 0 6.4646460486983415e-06
alpha O 0 8.908563700060768e-07
of O 0 4.3042053476938236e-08
the O 0 7.421935777074395e-08
small O 0 2.944291850326408e-07
nuclear O 0 3.3147367503261194e-05
ribonucleoprotein O 0 1.706356488284655e-05
- O 0 0.00012489418440964073
associated O 0 3.852283498417819e-06
polypeptide O 0 5.4597553571511526e-06
N O 0 0.00011512005585245788
( O 0 1.84882026132982e-07
SNRPN O 0 2.330239294678904e-05
) O 0 2.1515747050671052e-07
gene O 0 6.28335214969411e-07
showed O 0 1.0395049230282893e-06
a O 0 2.450260581099428e-07
pattern O 0 8.725384759600274e-06
characteristic O 0 3.835625648207497e-06
of O 0 1.75640963107071e-07
only O 0 1.8633241438692494e-07
the O 0 8.045315667004616e-07
maternal O 0 1.8171189367421903e-05
chromosome O 0 7.232948701130226e-05
15 O 0 4.162006007391028e-06
in O 0 3.6103367619944038e-06
J O 0 0.15913689136505127
. O 0 2.0018698705825955e-05

B O 0 0.005155241582542658
. O 0 0.0004517770139500499

Maternal B-Disease 0 0.0871247798204422
disomy I-Disease 0 0.06922265142202377
was O 0 0.0006421274156309664
confirmed O 0 2.212668005086016e-05
by O 0 2.678140447187616e-07
polymerase O 0 6.898016636114335e-06
chain O 0 2.6509902454563417e-05
reaction O 0 6.365511353578768e-07
analysis O 0 4.425716610967356e-07
of O 0 1.0986665444079335e-07
microsatellite O 0 1.4619849025621079e-05
repeats O 0 1.1405004443076905e-05
at O 0 5.75298713556549e-07
the O 0 6.647246664215345e-08
gamma O 0 2.6473203433852177e-06
- O 0 2.592695273051504e-05
aminobutyric O 0 1.9923185391235165e-05
acid O 0 3.0869025522406446e-06
receptor O 0 5.524095172404486e-07
beta3 O 0 3.6236137930245604e-06
subunit O 0 1.4762352975594695e-06
( O 0 5.633950195260695e-07
GABRB3 O 0 8.716546290088445e-05
) O 0 1.0671245718185673e-06
locus O 0 2.5766659746295772e-05
. O 0 7.3950131991296075e-06

A O 0 0.001047364086844027
niece O 0 0.11248944699764252
( O 0 2.397887692495715e-05
B O 0 7.565379200968891e-05
. O 0 8.305024721266818e-07
B O 0 6.7112132455804385e-06
. O 0 1.1801335375594135e-07
) O 0 3.449869012683848e-08
with O 0 3.68951837970144e-08
45 O 0 1.912287643790478e-07
chromosomes O 0 4.334391121574299e-07
and O 0 3.488881645807851e-07
the O 0 1.244152372237295e-07
derivative O 0 1.525468292129517e-06
3 O 0 2.6531508865446085e-06
but O 0 3.836960900116537e-07
without O 0 9.669584244420548e-08
the O 0 1.3850435607309919e-06
der O 1 0.8986210823059082
( O 0 2.9668126444448717e-07
15 O 0 5.434417857941298e-07
) O 0 5.668194447139285e-08
demonstrated O 0 2.0934818678597367e-07
a O 0 1.9423162029852392e-06
phenotype O 0 7.317992276512086e-05
consistent O 0 3.366033070051344e-06
with O 0 9.71074200606381e-07
that O 0 3.3774704206734896e-06
reported O 0 2.454462446621619e-05
for O 0 2.8732415557897184e-07
haploinsufficiency O 0 3.9610396925127134e-05
of O 0 4.304850165226526e-07
distal O 0 0.00020595946989487857
3 O 0 0.0002162240562029183
p O 0 0.008039637468755245
. O 0 1.1263023225183133e-05

Uniparental B-Disease 1 0.9998795986175537
disomy I-Disease 1 0.9999686479568481
associated O 0 0.0008606824558228254
with O 0 5.4929714679019526e-06
unbalanced O 0 0.0003207618137821555
segregation O 0 8.346357390109915e-06
of O 0 3.385428044566652e-07
non O 0 5.444032467494253e-06
- O 0 0.00019813168910332024
Robertsonian O 0 0.000165215038578026
translocations O 0 9.113393753068522e-05
has O 0 6.6946954575541895e-06
been O 0 2.6687171157391276e-06
reported O 0 1.8265320250065997e-05
previously O 0 3.184891056662309e-06
but O 0 4.0335677908842626e-07
has O 0 7.966872317410889e-07
not O 0 1.1342989836293782e-07
, O 0 5.8064312469241486e-08
to O 0 3.7225998283929584e-08
our O 0 4.596130764866757e-08
knowledge O 0 7.88486289593493e-08
, O 0 2.2999923032784864e-07
been O 0 2.3628150813692628e-07
observed O 0 3.1940419376041973e-07
in O 0 1.2641669400181854e-07
a O 0 2.5389279016962973e-06
case O 0 1.7672666217549704e-05
of O 0 5.849003173352685e-06
PWS B-Disease 1 0.9999949932098389
. O 0 7.990568701643497e-05

Furthermore O 0 0.0002506145683582872
, O 0 9.896681149257347e-06
our O 0 1.355407675873721e-06
findings O 0 1.6998686760416604e-06
are O 0 4.182064117230766e-08
best O 0 3.8189961060197675e-07
interpreted O 0 4.873970169683162e-07
as O 0 2.669727621196216e-07
true O 0 1.2667956070799846e-06
gamete O 0 1.7026372006512247e-05
complementation O 0 0.000274334306595847
resulting O 0 2.2733056539436802e-05
in O 0 1.0925059541477822e-05
maternal B-Disease 0 0.001468365779146552
UPD I-Disease 1 0.9999949932098389
15 I-Disease 0 0.0004760214942507446
and O 0 0.00030031154165044427
PWS B-Disease 1 0.9999738931655884

Schwartz B-Disease 1 0.9961353540420532
- I-Disease 1 0.998668909072876
Jampel I-Disease 1 0.9987824559211731
syndrome I-Disease 1 0.9999833106994629
type I-Disease 0 1.7449843653594144e-05
2 I-Disease 0 2.1633966753142886e-05
and O 0 1.889816667244304e-05
Stuve B-Disease 0 0.401620477437973
- I-Disease 1 0.9999833106994629
Wiedemann I-Disease 1 0.9999969005584717
syndrome I-Disease 1 0.9999802112579346
: O 0 5.9972524013574e-07
a O 0 2.249945055154967e-06
case O 0 4.327148417360149e-06
for O 0 1.0061670536742895e-06
" O 0 6.2161961977835745e-06
lumping O 0 1.1013875337084755e-05
" O 0 1.0616163308441173e-05
. O 0 4.452346274774754e-06

Recent O 0 7.40533578209579e-05
studies O 0 1.841043558670208e-05
demonstrated O 0 3.4206379950774135e-06
the O 0 2.0334347539119335e-07
existence O 0 4.318687274462718e-07
of O 0 6.348657421995085e-08
a O 0 1.6324823945979006e-06
genetically O 0 1.2814245565095916e-05
distinct O 0 9.047627145264414e-07
, O 0 4.2626942331480677e-07
usually O 0 1.0945899475700571e-07
lethal O 0 3.309068006274174e-07
form O 0 7.082763175958462e-08
of O 0 7.963152626189185e-08
the O 0 7.328954325203085e-06
Schwartz B-Disease 1 0.7231820821762085
- I-Disease 1 0.9994937181472778
Jampel I-Disease 1 0.9998918771743774
syndrome I-Disease 1 0.999994158744812
( O 0 1.7310301700490527e-05
SJS B-Disease 0 0.22736619412899017
) O 0 7.004566668911139e-07
of O 0 7.532353265560232e-07
myotonia B-Disease 1 0.9223348498344421
and O 0 0.0005041557014919817
skeletal B-Disease 1 0.9644253253936768
dysplasia I-Disease 1 0.9999290704727173
, O 0 8.797525879344903e-06
which O 0 1.3114292869431665e-06
we O 0 4.4203176230439567e-07
called O 0 1.476962734159315e-05
SJS B-Disease 0 0.18155869841575623
type I-Disease 0 4.370596343505895e-06
2 I-Disease 0 1.0631574696162716e-05
. O 0 5.604782927548513e-06

This O 0 0.00017345580272376537
disorder O 0 0.015363522805273533
is O 0 1.2143113963247743e-06
reminiscent O 0 5.753739969804883e-06
of O 0 4.01338468236645e-07
another O 0 1.1277274097665213e-05
rare O 0 3.7119814805919304e-05
condition O 0 0.0002131391956936568
, O 0 1.3364458482101327e-06
the O 0 4.152665042056469e-06
Stuve B-Disease 1 0.9337440133094788
- I-Disease 1 0.9999986886978149
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999991655349731
( O 0 2.725169906625524e-05
SWS B-Disease 1 0.7417171001434326
) O 0 1.089906277229602e-06
, O 0 1.891121144126373e-07
which O 0 1.0909570136163893e-07
comprises O 0 8.44724397097707e-08
campomelia B-Disease 0 1.973378675756976e-05
at O 0 3.1117840535443975e-06
birth O 0 2.0129366021137685e-05
with O 0 9.466856681683566e-06
skeletal B-Disease 1 0.9685354828834534
dysplasia I-Disease 1 0.9999741315841675
, O 0 3.9032154745655134e-05
contractures B-Disease 0 0.04353949427604675
, O 0 2.922250359915779e-06
and O 0 3.149840495098033e-06
early B-Disease 0 2.5946883397409692e-05
death I-Disease 0 0.00011482886475278065
. O 0 7.65101685828995e-06

To O 0 2.3214513930724934e-05
test O 0 5.338073606253602e-06
for O 0 3.8211385344766313e-07
possible O 0 7.339708076870011e-07
nosologic O 0 6.735841452609748e-05
identity O 0 9.769963071448728e-06
between O 0 1.6782901184342336e-06
these O 0 4.374453965283465e-06
disorders O 0 0.012986273504793644
, O 0 1.6400757658630027e-06
we O 0 3.7781228456879035e-07
reviewed O 0 4.450340895800764e-07
the O 0 9.683593304998794e-08
literature O 0 1.0396016136837716e-07
and O 0 5.553612254516338e-07
obtained O 0 4.281059489130712e-07
a O 0 3.310684064672387e-07
follow O 0 2.608114755275892e-07
- O 0 6.18386548012495e-06
up O 0 3.43126544066763e-07
of O 0 1.5830934785299178e-08
the O 0 7.388320710788321e-08
only O 0 4.762821959047869e-08
two O 0 7.133345434340299e-07
surviving O 0 6.292645412031561e-05
patients O 0 2.506843884475529e-06
, O 0 9.63787698537999e-08
one O 0 1.2516105130089272e-07
with O 0 7.855304033910215e-07
SJS B-Disease 0 0.11012991517782211
type I-Disease 0 1.8369377130511566e-06
2 I-Disease 0 4.710827852250077e-06
at O 0 3.3340402296744287e-06
age O 0 3.506443988499086e-07
10 O 0 1.8852058758511703e-07
years O 0 2.6163058919337345e-07
and O 0 1.5549576914963836e-07
another O 0 3.5212420357311203e-07
with O 0 1.9146245904266834e-06
SWS B-Disease 0 0.36549943685531616
at O 0 6.050222054909682e-06
age O 0 4.597981444476318e-07
7 O 0 3.340876901347656e-06
years O 0 2.8139352252765093e-06
. O 0 2.9388093025772832e-06

Patients O 0 0.3815283179283142
reported O 0 0.0005517210811376572
as O 0 2.461029225742095e-06
having O 0 6.8930185079807416e-06
either O 0 3.570024637156166e-05
neonatal O 1 0.9999849796295166
SJS B-Disease 1 0.999981164932251
or O 0 0.00012031348887830973
SWS B-Disease 0 0.37736430764198303
presented O 0 3.1396675694850273e-06
a O 0 2.7536205493561283e-07
combination O 0 1.2265296618352295e-06
of O 0 2.051444170092509e-07
a O 0 7.567674038000405e-05
severe O 0 0.00920421164482832
, O 0 2.057523488474544e-05
prenatal O 1 0.5716149806976318
- O 1 0.9999148845672607
onset O 1 0.9991408586502075
neuromuscular B-Disease 1 0.9999922513961792
disorder I-Disease 1 0.9988057613372803
( O 0 1.0648673196556047e-05
with O 0 0.0007506214897148311
congenital B-Disease 1 0.9999998807907104
joint I-Disease 1 0.952497661113739
contractures I-Disease 1 0.9999890327453613
, O 0 0.06698335707187653
respiratory O 1 0.7024481892585754
and O 0 1.5385519873234443e-05
feeding O 0 3.232054950785823e-05
difficulties O 0 1.583967787155416e-05
, O 0 1.3485791896528099e-06
tendency O 0 1.710578999336576e-06
to O 0 2.4684004529262893e-06
hyperthermia B-Disease 0 0.07128679752349854
, O 0 1.6266175180135178e-06
and O 0 1.3920405308454065e-06
frequent O 0 1.2626172974705696e-05
death O 0 0.00041393021820113063
in O 0 8.646491551189683e-06
infancy O 0 5.9946203691652045e-05
) O 0 6.68076438614662e-08
with O 0 3.586632502106113e-08
a O 0 2.0420604869286763e-06
distinct O 0 1.1122424439236056e-05
campomelic B-Disease 0 0.02149016037583351
- I-Disease 1 0.5727022290229797
metaphyseal I-Disease 1 0.8467205762863159
skeletal I-Disease 1 0.9515399932861328
dysplasia I-Disease 1 0.999804675579071
. O 0 0.00010294953972334042

The O 0 6.30365366305341e-06
similarity O 0 6.073832537367707e-06
of O 0 4.1485068891233823e-07
the O 0 2.1139849195606075e-06
clinical O 0 3.41067134286277e-05
and O 0 4.845855073654093e-06
radiographic O 0 0.000590178300626576
findings O 0 4.160733078606427e-05
is O 0 4.2944390088450746e-07
so O 0 1.2242330171829963e-07
extensive O 0 7.964448514030664e-07
that O 0 2.3312695702770725e-06
these O 0 2.391917632849072e-06
disorders O 0 0.0011117105605080724
appear O 0 2.2976626041781856e-06
to O 0 2.7434660410108336e-07
be O 0 1.6045255790686497e-07
a O 0 8.225774763559457e-07
single O 0 1.8980164895765483e-05
entity O 0 3.829026172752492e-05
. O 0 8.605526090832427e-06

The O 0 4.694888502854155e-06
follow O 0 1.6991037909974693e-06
- O 0 2.07538359973114e-05
up O 0 7.951524025884282e-07
observation O 0 6.852695833003963e-07
of O 0 2.818161881634751e-08
an O 0 1.853684210573192e-07
identical O 0 3.3191356578754494e-06
and O 0 1.0112917152582668e-06
unique O 0 8.731217349122744e-07
pattern O 0 4.521333903539926e-05
of O 0 7.830346476112027e-06
progressive O 1 0.9449036717414856
bone B-Disease 1 0.9997847676277161
dysplasia I-Disease 1 0.9999489784240723
in O 0 2.8878370358143002e-05
the O 0 3.2134114462678554e-06
two O 0 5.318654439179227e-05
patients O 0 3.532767004799098e-05
( O 0 1.2604313326392003e-07
one O 0 3.5213460591876355e-07
with O 0 3.1331946956925094e-06
SJS B-Disease 1 0.7833936810493469
type I-Disease 0 5.66038943361491e-06
2 I-Disease 0 6.511074388981797e-06
, O 0 4.831131263927091e-07
one O 0 2.0676127121532772e-07
with O 0 2.7502610464580357e-06
SWS B-Disease 0 0.4699341952800751
) O 0 6.77423486195039e-07
surviving O 0 4.045628884341568e-06
beyond O 0 2.4071628104138654e-06
infancy O 0 8.634643563709687e-06
adds O 0 1.7593310985830612e-06
to O 0 9.94603510662273e-08
the O 0 1.140882091021922e-07
evidence O 0 4.3695024487533374e-07
in O 0 1.4235141065910284e-07
favor O 0 3.5233716744187404e-07
of O 0 2.1950049244878755e-07
identity O 0 3.602709693950601e-05
. O 0 8.711350346857216e-06

The O 0 2.1307141651050188e-05
hypothesis O 0 9.503353794571012e-05
that O 0 4.3391037252149545e-06
SWS B-Disease 0 0.2797366976737976
and O 0 2.9314920539036393e-05
SJS B-Disease 0 0.44009366631507874
type I-Disease 0 2.7542191674001515e-06
2 I-Disease 0 2.5250747057725675e-06
are O 0 2.6716294954098885e-08
the O 0 1.921129069160088e-07
same O 0 5.109994162921794e-06
disorder O 0 0.0001332509273197502
should O 0 1.6730314200685825e-07
be O 0 5.7846328616051323e-08
testable O 0 7.952183977977256e-07
by O 0 9.836556102982286e-08
molecular O 0 7.465653652616311e-06
methods O 0 1.3180960195313673e-05
. O 0 2.0723025500046788e-06
. O 0 4.385743977763923e-06

A O 0 0.00010754320828709751
mouse O 0 0.00019748286285903305
model O 0 8.429807348875329e-05
of O 0 3.115880099358037e-05
severe O 1 0.9986560344696045
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.14319726824760437
defects O 1 0.999369204044342
in O 0 9.303567640017718e-05
hemostasis O 1 0.9921561479568481
and O 0 0.05698280781507492
thrombosis B-Disease 1 0.9976893663406372
. O 0 7.775275298627093e-05

von B-Disease 1 0.9993896484375
Willebrand I-Disease 1 0.9973650574684143
factor I-Disease 0 0.0009796746307983994
( I-Disease 0 8.5453997598961e-05
vWf I-Disease 0 0.005342239513993263
) I-Disease 0 0.011920725926756859
deficiency I-Disease 1 0.9911081790924072
causes O 0 0.20014002919197083
severe O 1 0.9999277591705322
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.00011022412945749238
humans O 0 3.646733603090979e-05
. O 0 1.4018675756233279e-05

We O 0 4.9635009418125264e-06
generated O 0 9.192613106279168e-07
a O 0 2.8174693511573423e-07
mouse O 0 3.288758307462558e-06
model O 0 3.494443262752611e-06
for O 0 4.0054581518234045e-07
this O 0 6.204998044267995e-07
disease O 0 1.1503830137371551e-05
by O 0 5.421674131866894e-08
using O 0 8.579791597185249e-07
gene O 0 6.8889175963704474e-06
targeting O 0 1.8866152458940633e-05
. O 0 6.252237653825432e-06

vWf B-Disease 0 0.11380854994058609
- I-Disease 1 0.9821714162826538
deficient I-Disease 1 0.779883086681366
mice O 0 0.003006800776347518
appeared O 0 4.837894084630534e-05
normal O 0 2.8551257855724543e-06
at O 0 5.679969490302028e-06
birth O 0 2.2155692931846716e-05
; O 0 5.122535640111892e-07
they O 0 1.1079151107651342e-07
were O 0 2.602221798042592e-07
viable O 0 5.009448159398744e-06
and O 0 1.8187704426964046e-06
fertile O 0 7.494192686863244e-05
. O 0 2.330001734662801e-05

Neither O 0 0.0008469929452985525
vWf O 0 0.002067600144073367
nor O 0 0.00030979159055277705
vWf O 0 0.0016721984138712287
propolypeptide O 0 0.02711574360728264
( O 0 9.314326598541811e-05
von B-Disease 1 0.9407130479812622
Willebrand I-Disease 1 0.947869598865509
antigen O 0 0.005965328309684992
II O 0 0.005747188348323107
) O 0 1.5978082501533208e-06
were O 0 5.550350579142105e-07
detectable O 0 1.3360380535232252e-06
in O 0 2.0334347539119335e-07
plasma O 0 1.7104068319895305e-05
, O 0 1.798860466806218e-06
platelets O 0 1.267464722332079e-05
, O 0 5.343027851267834e-07
or O 0 2.990221048548847e-07
endothelial O 0 9.213852536049671e-06
cells O 0 2.1382575141615234e-06
of O 0 7.318055139649005e-08
the O 0 1.4874985936330631e-06
homozygous O 0 4.881949644186534e-05
mutant O 0 8.952033385867253e-05
mice O 0 0.0005525118322111666
. O 0 1.15717748485622e-05

The O 0 1.9548093405319378e-05
mutant O 0 0.00041971230530180037
mice O 0 0.04508642852306366
exhibited O 0 0.022565796971321106
defects O 1 0.9918515086174011
in O 0 1.5187913049885537e-05
hemostasis O 0 0.008551854640245438
with O 0 2.734467216214398e-06
a O 0 2.7321855668560602e-05
highly O 0 0.00012916357081849128
prolonged O 0 0.06082994118332863
bleeding O 1 0.7223007678985596
time O 0 2.324928345842636e-06
and O 0 3.4029376365651842e-06
spontaneous O 0 1.3207422853156459e-05
bleeding O 0 0.00335456570610404
events O 0 2.9375240728768404e-07
in O 0 2.395663329934905e-07
approximately O 0 2.041835358568278e-07
10 O 0 3.8448106920441205e-07
% O 0 2.190724046613468e-07
of O 0 3.8111519984340703e-07
neonates O 0 0.0003358655667398125
. O 0 1.5954443369992077e-05

As O 0 2.4966802811832167e-05
in O 0 3.409590590308653e-06
the O 0 2.5714978164614877e-06
human O 0 1.0432666385895573e-05
disease O 0 0.00013186105934437364
, O 0 4.0733377204560384e-07
the O 0 4.462036429231375e-07
factor O 0 9.000156637739565e-07
VIII O 0 6.567793025169522e-05
level O 0 1.0285177722835215e-06
in O 0 6.34237551366823e-07
these O 0 1.9213985069654882e-07
mice O 0 4.344832996139303e-05
was O 0 2.8388183636707254e-05
reduced O 0 2.4134335490089143e-06
strongly O 0 5.667658911079343e-07
as O 0 1.4740419373993063e-07
a O 0 5.074714408692671e-07
result O 0 3.196839486463432e-07
of O 0 4.445335477498702e-08
the O 0 4.574572471938154e-07
lack O 0 4.755532927447348e-07
of O 0 1.7320539313914196e-07
protection O 0 2.068353751383256e-06
provided O 0 6.723537353536813e-07
by O 0 1.3123776625434402e-06
vWf O 0 6.63830287521705e-05
. O 0 7.651527084817644e-06

Defective O 1 0.9880324602127075
thrombosis B-Disease 1 0.9992332458496094
in O 0 0.0001181677434942685
mutant O 0 0.0006202668300829828
mice O 0 0.008834960870444775
was O 0 5.782487278338522e-05
also O 0 2.500218442946789e-06
evident O 0 7.328628726099851e-07
in O 0 2.4867685510798765e-07
an O 0 6.514079018415941e-07
in O 0 2.2107578843133524e-06
vivo O 0 0.0003958216984756291
model O 0 1.5116960639716126e-05
of O 0 9.985141332435887e-06
vascular B-Disease 1 0.9996669292449951
injury I-Disease 0 0.05189405381679535
. O 0 6.747477891622111e-05

In O 0 1.1509668183862232e-05
this O 0 3.8716527228643827e-07
model O 0 2.30884302254708e-06
, O 0 2.008589063962063e-07
the O 0 2.0140635115240002e-07
exteriorized O 0 5.3067185945110396e-05
mesentery O 0 5.005767525290139e-05
was O 0 9.521135325485375e-06
superfused O 0 1.4874311091261916e-05
with O 0 4.120708467780787e-07
ferric O 0 3.6877139791613445e-05
chloride O 0 1.0073719749925658e-05
and O 0 3.9936375628712995e-07
the O 0 1.4475868681529391e-07
accumulation O 0 1.095802076633845e-06
of O 0 1.95623272247758e-07
fluorescently O 0 0.0001248202461283654
labeled O 0 0.00011772527068387717
platelets O 0 0.00013040867634117603
was O 0 2.0230554582667537e-05
observed O 0 1.004039177132654e-06
by O 0 2.875823952308565e-07
intravital O 0 8.008532313397154e-05
microscopy O 0 2.3703769329586066e-05
. O 0 7.028259460639674e-06

We O 0 3.364841904840432e-05
conclude O 0 1.4519032447424252e-05
that O 0 2.3093267031981668e-07
these O 0 8.104645132789301e-08
mice O 0 8.767138751863968e-06
very O 0 6.161650958347309e-07
closely O 0 1.755220364429988e-05
mimic O 0 0.013492207042872906
severe O 0 0.1900620311498642
human O 0 0.0136619433760643
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
and O 0 2.895497891586274e-05
will O 0 3.1002734885987593e-06
be O 0 1.8970730764067412e-07
very O 0 6.677872477212077e-08
useful O 0 6.137342012380032e-08
for O 0 1.9299748998946598e-07
investigating O 0 4.1372109649273625e-07
the O 0 1.2056530351856054e-07
role O 0 2.1159462448849808e-07
of O 0 4.727524682834883e-08
vWf O 0 2.7205171591049293e-06
in O 0 5.035150252297171e-07
normal O 0 2.0088066321477527e-06
physiology O 0 1.3988134014653042e-05
and O 0 7.5829225352208596e-06
in O 0 1.2135138604207896e-05
disease O 0 8.228974184021354e-05
models O 0 9.7787715276354e-06
. O 0 1.098356051443261e-06
. O 0 3.1376500828628195e-06

Oral O 0 0.007312761154025793
contraceptives O 0 0.19676043093204498
and O 0 1.0317191481590271e-05
the O 0 3.3181293019879377e-06
risk O 0 4.286936382413842e-05
of O 0 8.68852948769927e-05
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00011452552280388772

Hereditary B-Disease 1 0.9999972581863403
Ovarian I-Disease 1 0.9999997615814209
Cancer I-Disease 1 0.9999785423278809
Clinical O 0 0.004127269610762596
Study O 0 6.730370660079643e-05
Group O 0 0.00021478203416336328
. O 0 3.7356323446147144e-05

BACKGROUND O 0 0.0003600583004299551
Women O 0 3.0300474463729188e-05
with O 0 1.0204290674664662e-06
mutations O 0 9.764765309228096e-06
in O 0 2.6018221888080006e-07
either O 0 3.491055053927994e-07
the O 0 7.776599773023918e-07
BRCA1 O 0 0.00018640590133145452
or O 0 8.676574339006038e-07
the O 0 7.424823706969619e-07
BRCA2 O 0 0.0001775014097802341
gene O 0 1.930023927343427e-06
have O 0 8.463128864377722e-08
a O 0 5.620834144792752e-07
high O 0 2.4566284992033616e-05
lifetime O 0 0.00010850158287212253
risk O 0 9.779156243894249e-05
of O 0 0.0008170093642547727
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 3.537689190125093e-05

Oral O 0 0.0032225335016846657
contraceptives O 1 0.6623064279556274
protect O 0 0.005388711113482714
against O 1 0.9301801323890686
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.1889978597755544e-05
general O 0 2.0927882360410877e-06
, O 0 6.938043384252524e-07
but O 0 1.877326241128685e-07
it O 0 1.3817727051446127e-07
is O 0 1.6611883779660275e-07
not O 0 5.409309977721932e-08
known O 0 4.1944582562791766e-07
whether O 0 1.1874536198774877e-07
they O 0 1.4377276613686263e-07
also O 0 1.8749855144051253e-06
protect O 0 8.882146858013584e-07
against O 0 1.9174167391611263e-06
hereditary B-Disease 0 0.004183477256447077
forms I-Disease 0 6.207511614775285e-05
of I-Disease 0 0.21461425721645355
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 5.021722608944401e-05

METHODS O 0 9.724105620989576e-05
We O 0 2.905092287619482e-06
enrolled O 0 2.1881674001633655e-06
207 O 0 6.0547417888301425e-06
women O 0 6.629294148297049e-06
with O 0 0.000128781350213103
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.013912520254962e-06
161 O 0 1.2066760746165528e-06
of O 0 1.0109968684446358e-07
their O 0 2.123591002600733e-06
sisters O 0 3.162001303280704e-05
as O 0 6.255095854612591e-07
controls O 0 2.6023433292721165e-06
in O 0 4.77486480576772e-07
a O 0 2.85689088741492e-06
case O 0 1.2937945939484052e-05
- O 0 0.0009916145354509354
control O 0 3.3317490306217223e-05
study O 0 3.6972787711420096e-06
. O 0 3.81478457711637e-06

All O 0 2.7353564746590564e-06
the O 0 2.257054575238726e-06
patients O 0 4.129522494622506e-06
carried O 0 4.832794502362958e-07
a O 0 1.113590315071633e-06
pathogenic O 0 5.8508389884082135e-06
mutation O 0 6.891559223731747e-06
in O 0 1.0153008815905196e-06
either O 0 3.485543402348412e-06
BRCA1 O 0 0.00727852713316679
( O 0 1.5010421066108393e-06
179 O 0 2.020341980824014e-06
women O 0 2.3576137664349517e-06
) O 0 4.2035125602524204e-07
or O 0 2.6925608835881576e-06
BRCA2 O 0 0.007769162300974131
( O 0 1.8189438151239301e-06
28 O 0 1.2597307431860827e-05
women O 0 1.6055648757173913e-06
) O 0 6.34299226476287e-07
. O 0 3.2608134006295586e-06

The O 0 1.6863132259459235e-05
control O 0 1.8485627151676454e-05
women O 0 3.264706265326822e-06
were O 0 6.357533379741653e-07
enrolled O 0 5.394729214458494e-07
regardless O 0 1.033413639106584e-07
of O 0 2.9643624444020134e-08
whether O 0 2.0407179590620217e-07
or O 0 2.699976846542995e-07
not O 0 1.8508401922190387e-07
they O 0 8.71359304710495e-08
had O 0 1.8968754602610716e-06
either O 0 1.4610668586101383e-06
mutation O 0 2.0962954295100644e-05
. O 0 5.383307779993629e-06

Lifetime O 0 0.00044813589192926884
histories O 0 5.5791097111068666e-05
of O 0 4.478407845454058e-06
oral O 0 0.00012181025522295386
- O 0 0.0016902172937989235
contraceptive O 0 0.0008262083865702152
use O 0 8.198270506909466e-07
were O 0 3.684047840124549e-07
obtained O 0 2.4794510977699247e-07
by O 0 1.0312398757150731e-07
interview O 0 2.43918093474349e-05
or O 0 9.43269782283096e-08
by O 0 6.374307304213289e-08
written O 0 2.329488637542454e-07
questionnaire O 0 2.217067702758868e-07
and O 0 3.5018823041355063e-07
were O 0 4.23625067469402e-07
compared O 0 1.0587333463263349e-06
between O 0 6.359043140946596e-07
patients O 0 5.810596576338867e-06
and O 0 1.3192367305236985e-06
control O 0 5.928772225161083e-06
women O 0 2.454197101542377e-06
, O 0 2.879762348584336e-07
after O 0 7.364963607869868e-07
adjustment O 0 5.291668685458717e-07
for O 0 1.7373726279856783e-07
year O 0 5.242562792773242e-07
of O 0 1.384868966169961e-07
birth O 0 2.235161628050264e-05
and O 0 2.845294147846289e-06
parity O 0 1.2145326763857156e-05
. O 0 1.2963513654540293e-05

RESULTS O 0 0.0005831416929140687
The O 0 4.129908120376058e-06
adjusted O 0 0.00048550183419138193
odds O 0 0.00028735416708514094
ratio O 0 0.0001215213633258827
for O 1 0.7181928753852844
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 4.0495351640856825e-06
with O 0 1.3440529755825992e-07
any O 0 1.0253089754996836e-07
past O 0 1.9555369590307237e-07
use O 0 7.990650487954554e-07
of O 0 5.442944939204608e-07
oral O 0 9.998769382946193e-05
contraceptives O 0 0.00343784736469388
was O 0 4.221942072035745e-05
0 O 0 1.8109862139681354e-05
. O 0 6.069490154914092e-06

5 O 0 0.0001321922754868865
( O 0 2.650404667292605e-06
95 O 0 3.6050005292054266e-06
percent O 0 5.688648161594756e-05
confidence O 0 2.4868329546734458e-06
interval O 0 8.274461720247928e-07
, O 0 4.5954124061609036e-07
0 O 0 5.439364372250566e-07
. O 0 9.062188865982534e-08
3 O 0 6.700602170894854e-07
to O 0 2.221952968284313e-07
0 O 0 1.6820091559566208e-06
. O 0 4.0089625485961733e-07
8 O 0 1.5695480897193193e-06
) O 0 9.79047058535798e-07
. O 0 2.7397688882047078e-06

The O 0 7.513377204304561e-05
risk O 0 0.00010563466639723629
decreased O 0 8.492236702295486e-06
with O 0 2.405948009709391e-07
increasing O 0 2.978492545935296e-07
duration O 0 1.1329632343404228e-06
of O 0 6.159870480360041e-08
use O 0 1.09521602098539e-06
( O 0 4.67950172833298e-07
P O 0 0.00013063794176559895
for O 0 2.851371334600117e-07
trend O 0 3.17328522214666e-06
, O 0 1.9853644062095555e-07
< O 0 3.3960733958338096e-07
0 O 0 7.874250513850711e-07
. O 0 2.5609253384573094e-07
001 O 0 1.4016412706041592e-06
) O 0 1.0228829694369779e-07
; O 0 2.1989475129657876e-08
use O 0 3.003347259777911e-08
for O 0 8.39795717411107e-08
six O 0 5.568556957769033e-07
or O 0 2.418787516944576e-07
more O 0 8.967926845571128e-08
years O 0 1.1678208693410852e-06
was O 0 3.236490101699019e-06
associated O 0 1.3332896742213052e-07
with O 0 3.7415347264868615e-08
a O 0 1.0876831311179558e-06
60 O 0 1.289388364966726e-06
percent O 0 2.5330089556518942e-05
reduction O 0 8.299115506815724e-06
in O 0 3.1808540370548144e-06
risk O 0 1.7521697373013012e-05
. O 0 5.88761849940056e-06

Oral O 0 0.001229047542437911
- O 0 0.0012978973099961877
contraceptive O 0 0.0015741056995466352
use O 0 1.3922881407779641e-05
protected O 0 0.00013463848154060543
against O 0 0.2860162854194641
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
both O 0 5.013119448449288e-07
for O 0 3.5720373148251383e-07
carriers O 0 1.8320881167710468e-07
of O 0 6.630228455151155e-08
the O 0 3.5239131648268085e-06
BRCA1 O 0 0.042384643107652664
mutation O 0 5.256893564364873e-05
( O 0 5.664448963216273e-07
odds O 0 1.6044463336584158e-05
ratio O 0 2.7024004793929635e-06
, O 0 6.637383762608806e-07
0 O 0 8.756925922170922e-07
. O 0 1.508084324086667e-07
5 O 0 3.641641512786009e-07
; O 0 8.960797970303247e-08
95 O 0 3.2189825560635654e-07
percent O 0 2.009334639296867e-05
confidence O 0 1.2523797749963705e-06
interval O 0 5.338769710760971e-07
, O 0 1.4494794697839097e-07
0 O 0 2.3404935234339064e-07
. O 0 6.474824232327592e-08
3 O 0 6.371584504449856e-07
to O 0 2.718105349686084e-07
0 O 0 1.4441220628214069e-06
. O 0 4.870080942964705e-07
9 O 0 3.6196659038978396e-06
) O 0 4.1162063979527375e-08
and O 0 3.7299773936183556e-08
for O 0 4.0199498840820524e-08
carriers O 0 1.1099965036009962e-07
of O 0 4.7612779496830626e-08
the O 0 3.2943491987680318e-06
BRCA2 O 0 0.03976205363869667
mutation O 0 2.8169044526293874e-05
( O 0 4.1088023294832965e-07
odds O 0 1.5766376236570068e-05
ratio O 0 2.3538621007901384e-06
, O 0 4.513776730163954e-07
0 O 0 8.124608825710311e-07
. O 0 1.290180193791457e-07
4 O 0 1.1195705837963033e-06
; O 0 1.0621177182201791e-07
95 O 0 2.8453246159187984e-07
percent O 0 9.864277672022581e-06
confidence O 0 7.42424333566305e-07
interval O 0 4.103511912489921e-07
, O 0 1.835923768567227e-07
0 O 0 4.0679955759514996e-07
. O 0 5.834185046182938e-08
2 O 0 6.122113518358674e-07
to O 0 1.8619724073687394e-07
1 O 0 1.0887924872804433e-06
. O 0 1.473044193289752e-07
1 O 0 1.4317732848212472e-06
) O 0 5.248426191428734e-07
. O 0 2.128601181539125e-06

CONCLUSIONS O 0 0.0010032659629359841
Oral O 0 0.00029030832229182124
- O 0 0.0016182245453819633
contraceptive O 0 0.0009495947742834687
use O 0 2.653834371812991e-06
may O 0 3.0086105198279256e-06
reduce O 0 7.034618079160282e-07
the O 0 8.82836047821911e-07
risk O 0 1.8992224795510992e-05
of O 0 0.0002808833960443735
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
in O 0 1.8658756744116545e-06
women O 0 6.809594310652756e-07
with O 0 3.02948762964661e-07
pathogenic O 0 4.339033239375567e-06
mutations O 0 8.053443707467522e-06
in O 0 3.3858287906696205e-07
the O 0 3.4754398257064167e-06
BRCA1 O 0 0.012298996560275555
or O 0 0.00013512271107174456
BRCA2 O 0 0.1172512024641037
gene O 0 0.0011191506637260318

A O 0 4.835970685235225e-05
Japanese O 0 2.1755577108706348e-05
family O 0 2.9353806894505396e-05
with O 0 2.1503148673218675e-05
adrenoleukodystrophy B-Disease 1 0.9999994039535522
with O 0 3.112917966063833e-06
a O 0 5.168582902115304e-06
codon O 0 1.1406124031054787e-05
291 O 0 8.262930350610986e-06
deletion O 0 1.8264432583237067e-05
: O 0 2.3399555004743888e-07
a O 0 1.7550728443893604e-06
clinical O 0 1.848116698965896e-05
, O 0 2.196400600951165e-06
biochemical O 0 2.1292658857419156e-05
, O 0 5.184755991649581e-06
pathological O 0 0.00010679494880605489
, O 0 2.5873198410408804e-06
and O 0 1.1204773727513384e-05
genetic O 0 0.0002464369754306972
report O 0 8.079725375864655e-05
. O 0 1.2031738151563331e-05

We O 0 1.8229906345368363e-05
report O 0 3.7531033285631565e-06
a O 0 5.590591740656237e-07
Japanese O 0 5.122191851114621e-06
family O 0 2.1122028556419536e-05
with O 0 0.0006383293657563627
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.26693570613861084
ALD B-Disease 1 1.0
) O 0 3.175592155457707e-06
with O 0 1.6176697670289286e-07
a O 0 1.9069346990363556e-06
three O 0 2.083820390907931e-06
base O 0 5.454519396153046e-06
pair O 0 2.481053161318414e-05
deletion O 0 5.9159159718547016e-05
( O 0 2.6943720854433195e-07
delGAG O 0 3.989875494880835e-06
291 O 0 1.372507426822267e-06
) O 0 1.521366925771872e-07
in O 0 5.150550919097441e-07
the O 0 2.191746716562193e-05
ALD B-Disease 1 0.9999997615814209
gene O 0 0.0003451416559983045
. O 0 8.824885298963636e-06

A O 0 2.3515989596489817e-05
variety O 0 2.9924283353466308e-06
of O 0 9.284806878895324e-07
phenotypes O 0 5.0882888899650425e-05
were O 0 3.0068576961639337e-06
observed O 0 1.679683350630512e-06
within O 0 1.5185490553903946e-07
this O 0 4.999117209081305e-07
family O 0 1.570032509334851e-05
. O 0 1.6656535080983303e-05

While O 0 4.2068466427735984e-05
the O 0 4.514621650741901e-06
proband O 0 0.0013608412118628621
( O 0 7.728617674729321e-06
patient O 0 1.3302227671374567e-05
1 O 0 7.778486178722233e-06
) O 0 8.138226235132606e-07
was O 0 9.275211596104782e-06
classified O 0 1.7499953628430376e-06
as O 0 3.709693316977791e-07
having O 0 3.9274499386010575e-07
a O 0 1.0137257504538866e-06
rare O 0 1.2214007938382565e-06
intermediate O 0 4.847191121370997e-06
type O 0 1.7090380879380973e-06
of O 0 2.850060809578281e-07
adult O 0 2.0660096197389066e-05
cerebral O 0 0.00011840008664876223
and O 0 1.0873909559450112e-05
cerebello O 0 0.1395178735256195
- O 1 0.9176549911499023
brain O 0 0.046405989676713943
stem O 0 1.14540434879018e-05
forms O 0 9.43394525165786e-07
, O 0 2.1723899408243597e-06
his O 0 1.3298904377734289e-05
younger O 0 4.0742648707237095e-05
brother O 0 0.00021129322703927755
( O 0 1.2934809774378664e-06
patient O 0 3.6980932236474473e-06
2 O 0 1.2477932614274323e-05
) O 0 8.871513728081482e-07
and O 0 5.531039732886711e-06
nephew O 0 0.01627950742840767
( O 0 6.528720859932946e-06
patient O 0 1.0572890460025519e-05
3 O 0 8.189289474103134e-06
) O 0 5.363469313124369e-07
had O 0 9.179164408124052e-06
a O 0 0.00010903156362473965
childhood O 0 0.11634857207536697
ALD B-Disease 1 0.9999998807907104
type O 0 0.0009229774586856365
. O 0 2.098785807902459e-05

Another O 0 0.0003019810828845948
nephew O 0 0.08897025138139725
( O 0 6.755685899406672e-05
patient O 0 7.154983177315444e-05
4 O 0 1.9524319213815033e-05
) O 0 8.762456786826078e-07
of O 0 2.284279787545529e-07
patient O 0 1.298183633480221e-05
1 O 0 1.3996822417539079e-05
was O 0 5.6244036386488006e-05
classified O 0 4.612132215697784e-06
as O 0 5.983974915579893e-07
having O 0 6.574730377906235e-07
an O 0 1.781948185453075e-06
adolescent O 0 3.2486175769008696e-05
form O 0 9.107428923016414e-06
. O 0 1.7980570191866718e-05

The O 0 6.8201502472220454e-06
tau O 0 1.4259656381909736e-05
level O 0 1.7286937463723007e-06
in O 0 8.258537036454072e-07
the O 0 5.291363322612597e-06
cerebrospinal O 0 0.005913111846894026
fluid O 0 0.001321611343882978
( O 0 5.3576179197989404e-05
CSF O 1 0.9679014086723328
) O 0 5.801964107376989e-06
in O 0 3.891578217007918e-06
patient O 0 1.4147231013339479e-05
1 O 0 9.89548243524041e-06
was O 0 2.740611853369046e-05
as O 0 5.798545430479862e-07
high O 0 1.1943639037781395e-06
as O 0 2.3355501355126762e-07
that O 0 1.027019607136026e-07
of O 0 2.9913078947174654e-07
patients O 0 1.4983438632043544e-05
with O 0 6.833509542047977e-05
Alzheimers B-Disease 1 0.9999985694885254
disease I-Disease 1 0.851894199848175
( O 0 2.083317667711526e-06
AD B-Disease 0 0.00011746937525458634
) O 0 3.372256514921901e-06
. O 0 4.009955318906577e-06

His O 0 0.0005306230741553009
brain O 0 0.004066265653818846
magnetic O 0 0.00016132353630382568
resonance O 0 0.00016879271424841136
image O 0 0.001916969777084887
( O 0 1.2059388609486632e-05
MRI O 0 0.03634176030755043
) O 0 1.4318061403173488e-05
showed O 0 0.0008363304659724236
abnormalities B-Disease 0 0.01984531246125698
in I-Disease 0 8.015401817829115e-07
the I-Disease 0 1.6475441952934489e-06
bilateral I-Disease 0 3.727944931597449e-05
cerebellar I-Disease 0 0.1813701093196869
hemispheres I-Disease 0 0.0050367251969873905
and O 0 0.00014308553363662213
brain O 0 0.014451274648308754
stem O 0 8.566628821427003e-05
, O 0 2.959204721264541e-06
but O 0 3.6568920336321753e-07
not O 0 8.642073368037018e-08
in O 0 1.746802666957592e-07
the O 0 2.6265211090503726e-06
cerebral O 0 0.0002538335684221238
white O 0 2.3739512471365742e-05
matter O 0 7.779062798363157e-07
, O 0 1.8072587693040987e-07
where O 0 1.4242215229387511e-07
marked O 0 1.1716202834577416e-06
reductions O 0 8.265759788628202e-06
of O 0 1.6104475264455687e-07
the O 0 5.424205028248252e-06
cerebral O 0 0.0017976561794057488
blood O 0 2.5876708605210297e-05
flow O 0 4.469222403713502e-06
and O 0 2.386635742368526e-06
oxygen O 0 3.258183596699382e-06
metabolism O 0 4.854166945733596e-06
were O 0 2.780194847673556e-07
clearly O 0 2.8058883572157356e-07
demonstrated O 0 2.4708612045287737e-07
by O 0 1.3001925935895997e-07
positron O 0 0.0002716434246394783
emission O 0 0.0003371907223481685
tomography O 0 0.025390058755874634
( O 0 2.718509676924441e-06
PET O 0 0.0003502218169160187
) O 0 4.491067556955386e-06
. O 0 6.741207016602857e-06

In O 0 0.00021901623404119164
patients O 0 0.0003353533102199435
2 O 0 1.9041042833123356e-05
and O 0 3.7661686747014755e-06
3 O 0 1.0745052350102924e-05
, O 0 7.478633961000014e-07
the O 0 1.769435357346083e-06
autopsy O 0 0.03895699977874756
findings O 0 3.775615550694056e-05
showed O 0 6.727406434947625e-05
massive O 0 5.464917921926826e-05
demyelination B-Disease 1 0.9999852180480957
of I-Disease 0 3.4386598599667195e-06
the I-Disease 0 3.326262958580628e-05
cerebral I-Disease 0 0.007938573136925697
white I-Disease 0 4.6052809921093285e-05
matter I-Disease 0 2.345284002558401e-07
with O 0 1.5819048826415383e-07
sparing O 0 5.443998816190287e-07
of O 0 9.123427702206754e-08
the O 0 8.66018922351941e-07
U O 0 0.003882010467350483
- O 0 0.009465581737458706
fibers O 0 0.00011937286762986332
, O 0 2.2234941354781768e-07
compatible O 0 3.0399962724914076e-07
with O 0 9.748789153718462e-08
the O 0 1.2092151564502274e-06
findings O 0 6.245943950489163e-06
of O 0 2.7314983981341356e-06
childhood O 0 0.009193004108965397
ALD B-Disease 1 0.9999997615814209
. O 0 0.0001983713882509619

Oleic O 0 0.03266526758670807
and O 0 0.000170127532328479
erucic O 0 0.013092238456010818
acids O 0 0.00014934714999981225
( O 0 2.528469849494286e-06
Lorenzos O 0 4.920866194879636e-05
Oil O 0 3.1858100555837154e-05
) O 0 2.8312953759268567e-07
were O 0 1.660936419511927e-07
administered O 0 1.029286522680195e-07
to O 0 7.82060624260339e-07
patients O 0 8.926771783990262e-07
1 O 0 1.4030281363375252e-06
and O 0 1.3523463167075533e-06
4 O 0 5.112860435474431e-06
, O 0 5.165381935512414e-07
but O 0 1.4247282820178953e-07
sufficient O 0 1.8639853749391477e-07
effectiveness O 0 1.4151747791402158e-06
was O 0 6.526106972160051e-06
not O 0 4.707028153916326e-07
obtained O 0 3.7752881780761527e-06
. O 0 5.181320830160985e-06

The O 0 2.1630748960888013e-05
findings O 0 1.6986154150799848e-05
in O 0 7.026424668765685e-07
this O 0 1.5552261345419538e-07
family O 0 3.351075292812311e-06
suggest O 0 1.3421142739389325e-06
that O 0 1.4590629859867477e-07
delGAG291 O 0 3.91437652069726e-06
is O 0 1.579132913320791e-07
part O 0 6.647044159535653e-08
of O 0 3.338419318765773e-08
the O 0 7.397358672278642e-07
cause O 0 3.1723229767521843e-06
of O 0 3.426095815939334e-07
Japanese O 0 0.0001056593464454636
ALD B-Disease 1 0.9999988079071045
with O 0 1.0121723789779935e-05
phenotypic O 0 6.198467599460855e-05
variations O 0 0.00013374788977671415
. O 0 1.8855611415347084e-05

Moreover O 0 0.00015274911129381508
, O 0 2.902062760767876e-06
although O 0 2.627402579946647e-07
the O 0 6.807893981886082e-08
scale O 0 2.023106844717404e-06
of O 0 9.01295820199266e-08
the O 0 7.660834171474562e-07
study O 0 7.086627533681167e-07
is O 0 2.1811159456319729e-07
limited O 0 3.22709723832304e-07
, O 0 2.3173572571977274e-07
there O 0 1.5504317829595493e-08
is O 0 2.441051982771114e-08
a O 0 6.795490321565012e-07
possibility O 0 4.447244066341227e-07
that O 0 2.7312304951010447e-07
PET O 0 2.6218154744128697e-05
can O 0 5.238704829935159e-07
detect O 0 9.19326066650683e-06
an O 0 3.858688160107704e-06
insidious B-Disease 0 0.0007198522216640413
lesion I-Disease 1 0.758336067199707
which O 0 5.073256033938378e-06
is O 0 8.30218993996823e-07
undetectable O 0 2.2874351088830736e-06
by O 0 1.0366018443619396e-07
computed O 0 6.3818038142926525e-06
tomogram O 0 0.0003568858955986798
( O 0 3.1722534004074987e-06
CT O 1 0.914955735206604
) O 0 1.0027443977378425e-06
or O 0 5.857096994077438e-07
MRI O 0 0.0006712202448397875
analysis O 0 1.4698281347591546e-06
, O 0 2.6289816901226004e-07
and O 0 2.5224750288543873e-07
that O 0 4.115484131261837e-08
the O 0 3.393088121583787e-08
higher O 0 2.200181370426435e-07
level O 0 6.932032192707993e-08
of O 0 3.143904692137767e-08
tau O 0 6.09453707056673e-07
reflects O 0 1.9122201422305807e-07
the O 0 4.033798006730649e-08
process O 0 1.788654770962239e-07
of O 0 1.0372559700044803e-06
neuronal B-Disease 0 0.02119293063879013
degeneration I-Disease 1 0.9987162351608276
in O 0 0.002635375829413533
ALD B-Disease 1 0.9999998807907104
. O 0 0.0005277253221720457

Lorenzos O 0 0.002876432379707694
Oil O 0 0.0001848874962888658
should O 0 8.860918683240016e-07
be O 0 6.02423924078721e-08
given O 0 2.829078482591285e-08
in O 0 3.5555256516772715e-08
the O 0 1.3556038425122097e-07
early O 0 3.68979704035155e-06
stage O 0 1.2649880773096811e-05
. O 0 1.076813987310743e-06
. O 0 3.2910895697568776e-06

Nonsense O 0 0.0008224741322919726
mutation O 0 0.00019710474589373916
in O 0 3.981760528404266e-06
exon O 0 2.9483506295946427e-05
4 O 0 5.068448899692157e-06
of O 0 1.907915674337346e-07
human O 0 3.69101456954013e-07
complement O 0 9.271207659367064e-07
C9 O 0 0.00010094726167153567
gene O 0 8.109962436719798e-06
is O 0 1.1954790579693508e-07
the O 0 1.3536995879803726e-07
major O 0 8.019270580916782e-07
cause O 0 7.382558351309854e-07
of O 0 8.667065287681908e-08
Japanese O 0 9.605239938537125e-06
complement B-Disease 0 4.6240184019552544e-05
C9 I-Disease 1 0.8689159750938416
deficiency I-Disease 0 0.21356424689292908
. O 0 1.546104613225907e-05

Deficiency B-Disease 1 0.9860141277313232
of I-Disease 0 1.7590676861800603e-06
the I-Disease 0 1.044996565724432e-06
ninth I-Disease 0 1.3812453289574478e-05
component I-Disease 0 1.488084649281518e-06
of I-Disease 0 1.2094476176116586e-07
human I-Disease 0 4.4066132431908045e-07
complement I-Disease 0 2.3045797661325196e-06
( O 0 7.767875445097161e-07
C9 O 0 3.6370161978993565e-05
) O 0 4.872821932622173e-07
is O 0 4.1058871858012935e-08
the O 0 4.578788903586428e-08
most O 0 2.586091625289555e-07
common O 0 3.1212861358653754e-05
complement B-Disease 1 0.9999337196350098
deficiency I-Disease 1 0.9999966621398926
in O 0 2.298293793501216e-06
Japan O 0 9.843002771958709e-06
but O 0 6.649402166658547e-07
is O 0 2.5925760382961016e-07
rare O 0 2.9697113745896786e-07
in O 0 1.1917556719254208e-07
other O 0 9.535590805853644e-08
countries O 0 2.1077572398553457e-07
. O 0 2.1930663933744654e-06

We O 0 1.668050572334323e-05
studied O 0 2.3762409000482876e-06
the O 0 2.1672508410119917e-07
molecular O 0 3.7764043554489035e-06
basis O 0 1.2308794339332962e-06
of O 0 1.9201434042770416e-06
C9 B-Disease 1 0.9738636016845703
deficiency I-Disease 0 0.3440825641155243
in O 0 4.403983098200115e-07
four O 0 7.708675866524572e-07
Japanese O 0 1.6365731426049024e-05
C9 B-Disease 0 0.012680433690547943
- I-Disease 1 0.9783086180686951
deficient I-Disease 1 0.7858901023864746
patients O 0 0.00010912465222645551
who O 0 1.1943481695197988e-05
had O 0 0.0012280931696295738
suffered O 1 0.9236380457878113
from O 0 0.00024450820637866855
meningococcal B-Disease 1 0.9999986886978149
meningitis I-Disease 1 0.9999933242797852
. O 0 5.553562004934065e-05

Direct O 0 1.0328691132599488e-05
sequencing O 0 2.1755577108706348e-05
of O 0 8.622256473245216e-07
amplified O 0 1.9119217540719546e-05
C9 O 0 0.00011332143185427412
cDNA O 0 1.3908495930081699e-05
and O 0 2.5968024601752404e-06
DNA O 0 2.781916737149004e-05
revealed O 0 1.5226110917865299e-05
a O 0 6.567273089785886e-07
nonsense O 0 4.494889708439587e-06
substitution O 0 7.060891107357747e-07
( O 0 3.924821498912934e-07
CGA O 0 1.5153450476645958e-05
- O 0 0.00013311553630046546
- O 0 0.00014496063522528857
> O 0 3.591360837162938e-06
TGA O 0 1.5325389540521428e-05
) O 0 7.742627872175945e-08
at O 0 7.374411126193081e-08
codon O 0 2.566639238921198e-07
95 O 0 1.2482882993936073e-07
in O 0 5.448700335364265e-08
exon O 0 1.4058099395697354e-06
4 O 0 9.16893839075783e-07
in O 0 1.0083912371783299e-07
the O 0 1.9188878752629535e-07
four O 0 2.8225515507074306e-06
C9 B-Disease 0 0.018478723242878914
- I-Disease 1 0.9175047278404236
deficient I-Disease 0 0.058082740753889084
individuals O 0 5.904397539779893e-07
. O 0 3.6409194308362203e-06

An O 0 1.4700295650982298e-05
allele O 0 6.0351558204274625e-05
- O 0 8.893968333723024e-05
specific O 0 5.794637445433182e-07
polymerase O 0 6.9377460931718815e-06
chain O 0 1.7880536688608117e-05
reaction O 0 5.578438049269607e-07
system O 0 1.835538654404445e-07
designed O 0 1.09223810795811e-06
to O 0 4.469992518352228e-07
detect O 0 2.4372893676627427e-06
exclusively O 0 1.1445415992739072e-07
only O 0 2.1855463216979842e-08
one O 0 2.1827800011919862e-08
of O 0 1.3433746559599058e-08
the O 0 1.4953484139823559e-07
normal O 0 8.57725524383568e-07
and O 0 8.039226031542057e-07
mutant O 0 2.5015588107635267e-06
alleles O 0 7.055552941892529e-07
indicated O 0 2.179041985073127e-06
that O 0 4.5171049123382545e-08
all O 0 8.324243516710794e-09
the O 0 9.71072608990653e-08
four O 0 3.788473804888781e-06
patients O 0 2.3623156266694423e-06
were O 0 1.1350802253673464e-07
homozygous O 0 4.220443372560112e-07
for O 0 1.0449492293673757e-07
the O 0 4.401883586524491e-07
mutation O 0 2.7679800496116513e-06
in O 0 2.472806102105096e-07
exon O 0 1.002449971565511e-05
4 O 0 6.992865564825479e-06
and O 0 5.111789960210444e-07
that O 0 9.110524246125351e-08
the O 0 1.3046739866240387e-07
parents O 0 1.849426922717612e-07
of O 0 1.0450130361050469e-07
patient O 0 3.5109985674353084e-06
2 O 0 5.033416528021917e-06
were O 0 2.3680945560045075e-06
heterozygous O 0 6.771142125217011e-06
. O 0 3.5055886655754875e-06

The O 0 1.1176119187439326e-05
common O 0 7.755449587421026e-06
mutation O 0 1.4289331375039183e-05
at O 0 1.4131518355497974e-06
codon O 0 2.287810275447555e-06
95 O 0 8.483733040520747e-07
in O 0 1.576753874132919e-07
exon O 0 4.680707661464112e-06
4 O 0 9.40576137509197e-06
might O 0 5.63422986488149e-07
be O 0 4.982244661277946e-08
responsible O 0 2.496948923180753e-07
for O 0 1.508687148543686e-07
most O 0 7.193771693891904e-07
Japanese O 0 5.237799268797971e-05
C9 B-Disease 1 0.9269465804100037
deficiency I-Disease 0 0.10356203466653824
. O 0 1.2997315934626386e-06
. O 0 5.322691322362516e-06

BRCA1 O 0 0.007046068087220192
required O 0 1.1071606422774494e-05
for O 0 1.6800612456790986e-06
transcription O 0 2.3585118469782174e-05
- O 0 0.0015965711791068316
coupled O 0 9.00611121323891e-05
repair O 0 0.0007195525104179978
of O 0 2.3350455649051582e-06
oxidative O 0 0.0003196384641341865
DNA O 0 0.04190259799361229
damage O 0 0.019865792244672775
. O 0 2.8693921194644645e-05

The O 0 0.00038443811354227364
breast B-Disease 1 0.9997890591621399
and I-Disease 1 0.9971936941146851
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.09332545101642609
gene O 0 0.00011996110697509721
BRCA1 O 0 0.00043949129758402705
encodes O 0 1.696533217909746e-05
a O 0 1.6548930943827145e-05
zinc O 0 0.046067457646131516
finger O 0 0.00016309897182509303
protein O 0 9.538275662634987e-06
of O 0 3.332528706323501e-07
unknown O 0 8.850304766383488e-06
function O 0 5.482734650286147e-06
. O 0 7.8342827691813e-06

Association O 0 2.9861261282349005e-05
of O 0 6.291746785791474e-07
the O 0 8.244254559031106e-07
BRCA1 O 0 6.866052717668936e-05
protein O 0 2.607105216156924e-06
with O 0 1.8997235429196735e-07
the O 0 5.839405616825388e-07
DNA O 0 4.502664160099812e-05
repair O 0 0.0005472786724567413
protein O 0 1.2340385183051694e-05
Rad51 O 0 5.0813261623261496e-05
and O 0 1.106883928514435e-06
changes O 0 1.0253754112454772e-07
in O 0 3.374873358552577e-08
the O 0 2.9420792913015248e-08
phosphorylation O 0 2.437637647290103e-07
and O 0 1.1025559842892108e-06
cellular O 0 3.591251015677699e-06
localization O 0 8.184599664673442e-07
of O 0 3.001531823088044e-08
the O 0 1.797759523469722e-07
protein O 0 2.0348250018287217e-06
after O 0 5.452896857605083e-06
exposure O 0 3.199586217306205e-06
to O 0 3.3149240152852144e-07
DNA O 0 4.91722603328526e-05
- O 0 0.014787498861551285
damaging O 0 7.12304754415527e-05
agents O 0 8.989932211989071e-07
are O 0 2.4820954180881927e-08
consistent O 0 1.8455612860179826e-07
with O 0 8.24824368805821e-08
a O 0 2.1459529762068996e-06
role O 0 1.8179916878580116e-06
for O 0 2.9286757126101293e-06
BRCA1 O 0 0.0004409604298416525
in O 0 3.953653504140675e-06
DNA O 0 0.001120828790590167
repair O 0 0.07802953571081161
. O 0 5.820727892569266e-05

Here O 0 2.8446909709600732e-05
, O 0 2.217470182586112e-06
it O 0 2.0245472853730462e-07
is O 0 6.134590790907168e-08
shown O 0 1.7575992217189196e-07
that O 0 7.898876930312326e-08
mouse O 0 3.7072707073093625e-06
embryonic O 0 2.9772856578347273e-05
stem O 0 5.8871242799796164e-05
cells O 0 0.00010790870146593079
deficient B-Disease 0 0.0006593427387997508
in I-Disease 0 2.274314056194271e-06
BRCA1 I-Disease 0 0.00014004303375259042
are O 0 2.454313801081298e-07
defective O 0 9.033056812768336e-06
in O 0 3.169203921515873e-07
the O 0 1.8315692784653947e-07
ability O 0 1.9720908994713682e-07
to O 0 8.106067639346293e-08
carry O 0 1.466050889575854e-07
out O 0 7.587139094766826e-08
transcription O 0 2.1701496280002175e-06
- O 0 0.00012141017214162275
coupled O 0 4.8649031668901443e-05
repair O 0 0.0004445958184078336
of O 0 6.963723535591271e-07
oxidative O 0 7.087225094437599e-05
DNA O 0 0.017306825146079063
damage O 0 0.0028066879604011774
, O 0 1.3949470485385973e-06
and O 0 6.809133310525795e-07
are O 0 9.626725017142235e-08
hypersensitive O 0 2.0794905140064657e-05
to O 0 1.771934648786555e-06
ionizing O 0 5.065968798589893e-05
radiation O 0 0.00011247353540966287
and O 0 2.4763651254033903e-06
hydrogen O 0 3.33169155055657e-05
peroxide O 0 0.004120389930903912
. O 0 1.6748808775446378e-05

These O 0 1.4246606951928698e-05
results O 0 2.3907678041723557e-05
suggest O 0 2.7778175990533782e-06
that O 0 4.79480604553828e-07
BRCA1 O 0 8.461917605018243e-05
participates O 0 3.17637341140653e-06
, O 0 4.491957383834233e-07
directly O 0 1.079440465900916e-07
or O 0 2.9918240329607215e-07
indirectly O 0 1.5176050283116638e-06
, O 0 2.5375814516337414e-07
in O 0 1.5580349099764135e-07
transcription O 0 5.001857516617747e-06
- O 0 0.002549597527831793
coupled O 0 0.00014884756819810718
repair O 0 0.002331277821213007
of O 0 1.9962824353569886e-06
oxidative O 0 0.00021882464352529496
DNA O 0 0.06044211611151695
damage O 0 0.014830206520855427
. O 0 7.141035439417465e-06
. O 0 8.267573321063537e-06

Truncation O 0 0.004809231963008642
mutations O 0 0.0019543571397662163
in O 0 3.082005150645273e-06
the O 0 8.284142154479923e-07
transactivation O 0 0.00020145755843259394
region O 0 3.5682580346474424e-05
of O 0 1.3047564380030963e-06
PAX6 O 0 0.0005907301674596965
result O 0 5.7123947954096366e-06
in O 0 5.301736223373155e-07
dominant O 0 3.3921496651601046e-05
- O 0 0.0010853409767150879
negative O 0 2.3165950551629066e-05
mutants O 0 0.000119121337775141
. O 0 8.830441402096767e-06

PAX6 O 0 0.011499689891934395
is O 0 7.937076588859782e-06
a O 0 9.473172895013704e-07
transcription O 0 2.3779614366503665e-06
factor O 0 5.475745865624049e-07
with O 0 6.647424299899285e-08
two O 0 2.857267418221454e-07
DNA O 0 2.43458453041967e-05
- O 0 0.00010742605081759393
binding O 0 2.1922676296526333e-06
domains O 0 8.056771321207634e-07
( O 0 1.0483869772315302e-07
paired O 0 2.047755060630152e-06
box O 0 1.149377476394875e-05
and O 0 3.8022210446797544e-06
homeobox O 0 1.386813983117463e-05
) O 0 1.0699233854438717e-07
and O 0 1.0053875598714512e-07
a O 0 7.459914286300773e-07
proline O 0 8.875007188180462e-05
- O 0 8.406222332268953e-05
serine O 0 5.418095679488033e-05
- O 0 0.0008471934706903994
threonine O 0 0.000803061353508383
( O 0 2.3396437427436467e-06
PST O 0 0.0004397988668642938
) O 0 3.738859959412366e-07
- O 0 8.30168846732704e-06
rich O 0 2.9974123663123464e-06
transactivation O 0 6.211692380020395e-05
domain O 0 9.646550097386353e-06
. O 0 5.888713531021494e-06

PAX6 O 0 0.19132307171821594
regulates O 0 0.0023107402957975864
eye O 0 0.08410416543483734
development O 0 8.215370144171175e-06
in O 0 2.9989450922585092e-06
animals O 0 6.153917411211296e-07
ranging O 0 1.2354306591078057e-06
from O 0 2.1861782784071693e-07
jellyfish O 0 1.3397803968473454e-06
to O 0 2.2482970507553546e-07
Drosophila O 0 5.172184387447487e-07
to O 0 5.811444907521945e-07
humans O 0 1.5598754998791264e-06
. O 0 4.322949735069415e-06

Heterozygous O 0 0.0010332213714718819
mutations O 0 0.0004818650777451694
in O 0 2.7718156161427032e-06
the O 0 1.4186178987074527e-06
human O 0 1.5588701671731542e-06
PAX6 O 0 0.00028976029716432095
gene O 0 2.4308466890943237e-05
result O 0 1.3266854921312188e-06
in O 0 1.6273330061267188e-07
various O 0 1.0882470036222003e-07
phenotypes O 0 1.7450260202167556e-05
, O 0 2.47026559918595e-06
including O 0 3.901135642081499e-06
aniridia B-Disease 1 0.9999997615814209
, O 0 0.009383570402860641
Peters B-Disease 1 0.9999996423721313
anomaly I-Disease 1 0.9999978542327881
, O 0 0.00013419844617601484
autosomal B-Disease 0 0.19226062297821045
dominant I-Disease 0 0.03693239018321037
keratitis I-Disease 1 0.9990925788879395
, O 0 2.701831363083329e-05
and O 0 4.586071372614242e-05
familial B-Disease 1 0.698803186416626
foveal I-Disease 1 0.9994233846664429
dysplasia I-Disease 1 0.9999886751174927
. O 0 0.0003422088921070099

It O 0 2.5911132979672402e-05
is O 0 1.4910747268004343e-06
believed O 0 1.4571761539627914e-06
that O 0 7.04665055195619e-08
the O 0 7.250601896657827e-08
mutated O 0 2.6037064344563987e-06
allele O 0 2.173915163439233e-06
of O 0 1.9951545482399524e-07
PAX6 O 0 7.905122765805572e-05
produces O 0 4.138740223424975e-06
an O 0 3.812406248471234e-07
inactive O 0 1.098552957046195e-06
protein O 0 2.433306235616328e-06
and O 0 8.18763510324061e-06
aniridia B-Disease 1 0.9999977350234985
is O 0 2.4050605134107172e-05
caused O 0 1.5076807358127553e-05
due O 0 3.6169330996926874e-06
to O 0 2.016388179981732e-06
genetic O 0 8.905256254365668e-05
haploinsufficiency O 0 0.003086167387664318
. O 0 1.920546856126748e-05

However O 0 3.0476234314846806e-05
, O 0 1.1636274166448857e-06
several O 0 2.2862521120714518e-07
truncation O 0 3.657949127955362e-05
mutations O 0 4.1356688598170877e-05
have O 0 7.846005587452964e-07
been O 0 1.3472732689479017e-06
found O 0 1.249662204827473e-06
to O 0 4.809708684661018e-07
occur O 0 1.2115451397676225e-07
in O 0 1.2100682056370715e-07
the O 0 3.827860552974016e-07
C O 0 0.0001462016225559637
- O 0 0.0001022100550471805
terminal O 0 2.6255311240674928e-05
half O 0 3.3960023415602336e-07
of O 0 1.1095688989826158e-07
PAX6 O 0 6.232126179384068e-05
in O 0 2.8888914584968006e-06
patients O 0 3.3159085432998836e-06
with O 0 8.402016646869015e-07
Aniridia B-Disease 1 0.999954342842102
resulting O 0 1.1902071491931565e-05
in O 0 4.6560555233554624e-07
mutant O 0 1.1178443628523382e-06
proteins O 0 9.800824329886382e-08
that O 0 6.963571763662912e-08
retain O 0 7.54196321395284e-07
the O 0 2.2733460980361997e-07
DNA O 0 8.507143320457544e-06
- O 0 2.6412997613078915e-05
binding O 0 1.613483505025215e-06
domains O 0 5.579103117270279e-07
but O 0 3.3764229101507226e-07
have O 0 1.7283134923218313e-07
lost O 0 2.690843530217535e-06
most O 0 2.6160456911838992e-08
of O 0 3.8607751662311784e-08
the O 0 5.715603492717491e-07
transactivation O 0 8.64190878928639e-05
domain O 0 9.55072755459696e-06
. O 0 8.692113624420017e-06

It O 0 1.5004342458269093e-05
is O 0 8.970678777586727e-07
not O 0 2.0647478038426925e-07
clear O 0 4.856371447203855e-07
whether O 0 1.6924683166053e-07
such O 0 4.294783195746277e-08
mutants O 0 1.4029375051904935e-05
really O 0 1.5361663372459589e-06
behave O 0 8.477910000692646e-07
as O 0 4.8813382136359e-07
loss O 0 4.391377387946704e-06
- O 0 6.546602435264504e-06
of O 0 2.752638579295308e-07
- O 0 3.2742522307671607e-05
function O 0 8.207031783058483e-07
mutants O 0 8.564311428926885e-06
as O 0 6.448369731515413e-07
predicted O 0 1.3150011909601744e-05
by O 0 5.742408006881305e-07
haploinsufficiency O 0 0.0002378621866228059
. O 0 1.0955546713375952e-05

Contrary O 0 5.2211522415746003e-05
to O 0 1.8062936533169704e-06
this O 0 1.3797475162391493e-07
theory O 0 3.3296126389359415e-07
, O 0 1.3100826379286445e-07
our O 0 1.1628836915633656e-07
data O 0 1.495647893534624e-06
showed O 0 1.1370860875103972e-06
that O 0 3.029767370321679e-08
these O 0 1.0380378334673424e-08
mutants O 0 6.870762945254683e-07
are O 0 1.9604492251801275e-08
dominant O 0 2.0433501504157903e-06
- O 0 2.8786153052351438e-05
negative O 0 9.023240750138939e-07
in O 0 2.2626956308613444e-07
transient O 0 3.2013931559049524e-06
transfection O 0 9.515696001471952e-05
assays O 0 7.035489034024067e-06
when O 0 2.8277898422857106e-07
they O 0 3.637628509522983e-08
are O 0 1.4250865376652655e-08
coexpressed O 0 3.7976622024871176e-06
with O 0 2.401065728463436e-07
wild O 0 1.0085937901749276e-05
- O 0 0.0029252031818032265
type O 0 8.619950676802546e-05
PAX6 O 0 0.0011349578853696585
. O 0 1.5409676052513532e-05

We O 0 1.9063720174017362e-05
found O 0 1.6342987692041788e-06
that O 0 8.907223048026935e-08
the O 0 7.453955674918689e-08
dominant O 0 5.2040800255781505e-06
- O 0 0.0008753187721595168
negative O 0 5.22316304341075e-06
effects O 0 4.208007339912001e-06
result O 0 3.6285928217694163e-07
from O 0 6.766132543134518e-08
the O 0 8.986985733372421e-08
enhanced O 0 2.8756480787706096e-06
DNA O 0 2.1063009626232088e-05
binding O 0 1.5856838899708237e-06
ability O 0 3.9936608686730324e-07
of O 0 7.163300352885926e-08
these O 0 3.405745303552976e-07
mutants O 0 6.517492874991149e-05
. O 0 5.576248440775089e-06

Kinetic O 0 0.0001303230383200571
studies O 0 1.076272292266367e-05
of O 0 2.2425963663863513e-07
binding O 0 3.1946924536896404e-06
and O 0 7.199556421255693e-06
dissociation O 0 3.771124829654582e-05
revealed O 0 4.6452947572106495e-05
that O 0 7.262421775067196e-08
various O 0 2.0411240697626454e-08
truncation O 0 6.5858025664056186e-06
mutants O 0 1.65014043886913e-05
have O 0 4.573412297759205e-07
3 O 0 1.957581616807147e-06
- O 0 1.8747759895632043e-05
5 O 0 3.5881050735042663e-06
- O 0 1.1089591680502053e-05
fold O 0 1.2711547014987445e-06
higher O 0 9.956683300060831e-08
affinity O 0 4.0980946636182125e-08
to O 0 2.527422537923485e-08
various O 0 1.2018023021198587e-08
DNA O 0 1.3750739071838325e-06
- O 0 6.521552222693572e-06
binding O 0 5.473323199112201e-07
sites O 0 1.623553771423758e-07
when O 0 1.7442225441755e-07
compared O 0 2.595116370684991e-07
with O 0 3.301300921521033e-08
the O 0 2.7805157287730253e-07
wild O 0 9.148237040790264e-06
- O 0 0.0008573919767513871
type O 0 4.7773584810784087e-05
PAX6 O 0 0.0007219702238216996
. O 0 1.2367164345050696e-05

These O 0 1.0848398233065382e-05
results O 0 6.12172698311042e-06
provide O 0 2.809953230098472e-07
a O 0 2.3091725154245069e-07
new O 0 1.542115569463931e-06
insight O 0 2.1952278075332288e-06
into O 0 7.655955869267927e-08
the O 0 6.285917208970204e-08
role O 0 2.673378673989646e-07
of O 0 1.878257336329625e-07
mutant O 0 1.4030498277861625e-05
PAX6 O 0 0.0002777975460048765
in O 0 9.15134387469152e-06
causing O 0 0.00010268473852192983
aniridia B-Disease 1 0.9999557733535767
. O 0 6.646589099545963e-06
. O 0 4.630351213563699e-06

Reversal O 0 0.007821740582585335
of O 0 0.0005182629683986306
severe O 1 0.9994825124740601
hypertrophic B-Disease 1 0.9999979734420776
cardiomyopathy I-Disease 1 1.0
and O 0 0.022245274856686592
excellent O 0 0.00019779040303546935
neuropsychologic O 0 0.009588110260665417
outcome O 0 2.5590074073988944e-05
in O 0 9.448018545299419e-07
very B-Disease 0 5.124793460709043e-07
- I-Disease 0 0.0003046821220777929
long I-Disease 0 2.134698661393486e-05
- I-Disease 0 0.00014470693713519722
chain I-Disease 0 3.8780373870395124e-05
acyl I-Disease 0 3.996558461949462e-06
- I-Disease 0 3.553448914317414e-05
coenzyme I-Disease 0 8.600644832768012e-06
A I-Disease 0 3.9496488170698285e-05
dehydrogenase I-Disease 0 0.0814688578248024
deficiency I-Disease 0 0.08605758100748062
. O 0 1.4767528227821458e-05

Very B-Disease 0 3.477308200672269e-05
- I-Disease 0 0.00029217120027169585
long I-Disease 0 1.7387568732374348e-05
- I-Disease 0 8.17262043710798e-05
chain I-Disease 0 1.276757575396914e-05
acyl I-Disease 0 1.7720325331538334e-06
- I-Disease 0 8.756761417316739e-06
coenzyme I-Disease 0 1.3677213246410247e-06
A I-Disease 0 2.554837010393385e-06
dehydrogenase I-Disease 0 3.492210089461878e-05
( I-Disease 0 3.0556388992408756e-06
VLCAD I-Disease 0 0.016351576894521713
) I-Disease 0 0.00013049959670752287
deficiency I-Disease 0 0.00035875968751497567
is O 0 5.92561832490901e-07
a O 0 1.999425694521051e-05
disorder O 0 0.0005420007510110736
of O 0 3.4430266282470257e-07
fatty O 0 2.4987142751342617e-05
acid O 0 2.8954093068023212e-05
beta O 0 1.071705924005073e-06
oxidation O 0 1.5545053884125082e-06
that O 0 3.357151570071437e-07
reportedly O 0 7.036334409349365e-06
has O 0 4.6108206674944086e-07
high O 0 1.1893604323631735e-06
rates O 0 3.2444447697344003e-06
of O 0 9.62663989412249e-07
morbidity O 0 0.1446451097726822
and O 0 7.086015830282122e-05
mortality O 0 0.0007052543223835528
. O 0 1.144846282841172e-05

We O 0 7.894756890891585e-06
describe O 0 2.1081764316477347e-06
the O 0 1.1043770342666903e-07
outcome O 0 4.4658253273155424e-07
of O 0 2.101033658163942e-08
a O 0 7.259311587404227e-07
5 O 0 6.452475190599216e-06
- O 0 6.51411319267936e-05
year O 0 8.529100341547746e-06
- O 0 0.00024021303397603333
old O 0 7.356867718044668e-05
girl O 0 0.0021675259340554476
with O 0 0.00015555042773485184
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
who O 0 2.1357105651986785e-05
was O 0 9.540222890791483e-06
first O 0 1.419676323166641e-06
seen O 0 1.7882128986457246e-06
at O 0 1.1386097185095423e-06
5 O 0 3.1208603559207404e-06
months O 0 5.326807581695903e-07
of O 0 7.061531448471214e-08
age O 0 1.3926606925451779e-06
with O 0 2.5597542844479904e-05
severe O 1 0.9793700575828552
hypertrophic B-Disease 1 0.9999878406524658
cardiomyopathy I-Disease 1 1.0
, O 1 0.9002748727798462
hepatomegaly B-Disease 1 1.0
, O 0 0.3124995231628418
encephalopathy B-Disease 1 0.9938566088676453
, O 0 7.468686817446724e-06
and O 0 2.1676094547729008e-05
hypotonia B-Disease 0 0.0720805898308754
. O 0 3.60256562998984e-05

Biochemical O 0 0.008203933015465736
studies O 0 0.0013665290316566825
indicated O 1 0.8756840825080872
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.000624781649094075
by O 0 5.822323032589338e-07
a O 0 3.258652895965497e-06
stable O 0 0.0001371388352708891
yet O 0 7.0147202677617315e-06
inactive O 0 9.94135916698724e-06
enzyme O 0 1.8301254385733046e-05
. O 0 6.27770123173832e-06

Molecular O 0 0.0013391872635111213
genetic O 0 0.0005031979526393116
analysis O 0 1.7059821402654052e-05
of O 0 1.7074040670195245e-06
her O 0 0.0002309037809027359
VLCAD O 0 0.3693101704120636
gene O 0 7.8578494139947e-05
revealed O 0 3.717081926879473e-05
a O 0 2.1258806555124465e-06
T1372C O 0 5.450209937407635e-05
( O 0 8.594253699811816e-07
F458L O 0 1.1732119673979469e-05
) O 0 6.786023050153744e-07
missense O 0 2.5849969460978173e-05
mutation O 0 1.2992040865356103e-05
and O 0 3.200425453542266e-06
a O 0 8.650483505334705e-05
1668 O 1 0.6681329011917114
ACAG O 0 0.3433910608291626
1669 O 0 0.001038233982399106
splice O 0 0.015259630046784878
site O 0 0.0005327345570549369
mutation O 0 0.0002701345947571099
. O 0 1.1265728971920907e-05

After O 0 0.00015349827299360186
initial O 0 4.420213008415885e-05
treatment O 0 1.3560420484282076e-05
with O 0 7.098978471731243e-07
intravenous O 0 1.836732917581685e-05
glucose O 0 0.0003549843095242977
and O 0 1.2359713764453772e-05
carnitine O 0 2.1005200323997997e-05
, O 0 7.189073585323058e-07
the O 0 3.510780288706883e-07
patient O 0 6.0772276810894255e-06
has O 0 7.468042895197868e-07
thrived O 0 8.16695433059067e-07
on O 0 7.057046786940191e-07
a O 0 6.179593583510723e-07
low O 0 7.97308257460827e-06
- O 0 0.0003311406180728227
fat O 0 5.7499128160998225e-05
diet O 0 3.8264951740529796e-07
supplemented O 0 1.5488483029457711e-07
with O 0 4.324918378983966e-08
medium O 0 2.5506790279905545e-06
- O 0 5.750515992986038e-05
chain O 0 3.195644239895046e-05
triglyceride O 0 6.904769634274999e-06
oil O 0 1.5249157513608225e-05
and O 0 1.2258304877832416e-06
carnitine O 0 9.52860227698693e-06
and O 0 4.463049378955475e-07
avoidance O 0 4.612281372828875e-06
of O 0 8.626261660538148e-07
fasting O 0 2.766149555100128e-05
. O 0 6.523487172671594e-06

Her O 0 0.015715328976511955
ventricular O 1 0.9034770131111145
hypertrophy O 1 0.5834352970123291
resolved O 0 0.0002718470641411841
significantly O 0 1.8494338291930035e-05
over O 0 8.676822176312271e-07
1 O 0 7.293971975741442e-06
year O 0 3.734366600838257e-06
, O 0 4.751348683385004e-07
and O 0 2.2860740500618704e-06
cognitively O 0 1.3102569027978461e-05
, O 0 8.062889946813812e-07
she O 0 2.318244469279307e-06
is O 0 1.0175783415888873e-07
in O 0 8.734409817634514e-08
the O 0 4.01546742523351e-07
superior O 0 9.335201866633724e-06
range O 0 2.775826033030171e-06
for O 0 1.7999896044784691e-06
age O 0 1.997825165744871e-06
. O 0 5.5328123380604666e-06

Clinical O 0 0.0031295695807784796
recognition O 0 5.465110734803602e-05
of O 0 0.0004905608366243541
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 7.068402283039177e-06
important O 0 3.67263311318311e-07
because O 0 2.0304678116644936e-07
it O 0 2.49280901698512e-07
is O 0 8.363541326161794e-08
one O 0 3.595632591668618e-08
of O 0 1.385814307752753e-08
the O 0 1.788472303587696e-07
few O 0 2.440310140627844e-07
directly O 0 3.281699491708423e-06
treatable O 0 0.04103599488735199
causes O 0 1.1025330422853585e-05
of O 0 7.439016826538136e-06
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 0.00011370049469405785
children O 0 2.1610008843708783e-05
. O 0 1.671433210503892e-06
. O 0 4.506568529905053e-06

Cloning O 0 0.00014711102994624525
of O 0 1.205176431540167e-06
a O 0 3.370452986928285e-06
novel O 0 4.810947302757995e-06
member O 0 6.312716323009226e-07
of O 0 3.540948156910417e-08
the O 0 2.058179404684779e-07
low O 0 6.7244750425743405e-06
- O 0 5.875626811757684e-05
density O 0 3.530115463945549e-06
lipoprotein O 0 4.908006303594448e-05
receptor O 0 7.446149993484141e-06
family O 0 1.0412072697363328e-05
. O 0 6.164517344586784e-06

A O 0 3.6200326576363295e-05
gene O 0 1.7641379599808715e-05
encoding O 0 5.137279913469683e-06
a O 0 2.7044786747865146e-06
novel O 0 4.2452270463400055e-06
transmembrane O 0 1.910295759444125e-05
protein O 0 1.1250805073359516e-05
was O 0 1.1840022125397809e-05
identified O 0 1.3590720300271641e-06
by O 0 4.6571432932296375e-08
DNA O 0 8.587437605456216e-07
sequence O 0 1.665075757273371e-07
analysis O 0 1.1351841777695881e-07
within O 0 2.0381440535288675e-08
the O 0 1.0533351542107994e-06
insulin B-Disease 1 0.6798049211502075
- I-Disease 1 0.9997327923774719
dependent I-Disease 1 0.9998376369476318
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.731580000021495e-05
IDDM B-Disease 0 0.011396716348826885
) O 0 1.3336498341232073e-06
locus O 0 9.828538168221712e-06
IDDM4 O 0 0.0005504903965629637
on O 0 6.422821752494201e-05
chromosome O 0 0.0008039824897423387
11q13 O 0 0.00019036122830584645
. O 0 1.6673126083333045e-05

Based O 0 7.440948684234172e-05
on O 0 6.8224530878069345e-06
its O 0 4.862822152063018e-06
chromosomal O 0 0.0009877094998955727
position O 0 2.7543623218662106e-05
, O 0 5.876859177078586e-07
this O 0 5.353074783442935e-08
gene O 0 3.360671883001487e-07
is O 0 5.933196334240165e-08
a O 0 5.001897420697787e-07
candidate O 0 1.6551869066461222e-06
for O 0 2.385297079854354e-07
conferring O 0 1.6833759218570776e-05
susceptibility O 0 0.012620657682418823
to O 0 0.0001503598177805543
diabetes B-Disease 1 0.9331560134887695
. O 0 2.6130841433769092e-05

The O 0 1.071115730155725e-05
gene O 0 2.73217519861646e-05
, O 0 1.2415547416821937e-06
termed O 0 7.9536557677784e-06
low O 0 6.7145419961889274e-06
- O 0 7.151510362746194e-05
density O 0 3.6355593238113215e-06
lipoprotein O 0 2.9680979423574172e-05
receptor O 0 2.8169260986032896e-06
related O 0 1.434130581401405e-06
protein O 0 2.4531182134523988e-06
5 O 0 3.903033302776748e-06
( O 0 2.816158541918412e-07
LRP5 O 0 4.327353599364869e-05
) O 0 1.5284550158867205e-07
, O 0 3.6540537706741816e-08
encodes O 0 1.1372625152716864e-07
a O 0 1.3715624902488344e-07
protein O 0 4.6279930643322587e-07
of O 0 1.0870748923252904e-07
1615 O 0 2.5452707632211968e-05
amino O 0 2.0488391783146653e-06
acids O 0 7.699976549702114e-07
that O 0 1.7796210727283324e-08
contains O 0 1.6318638884627035e-08
conserved O 0 1.041248722799537e-07
modules O 0 4.048389428135124e-07
which O 0 9.520270793927921e-08
are O 0 1.0069359568376512e-08
characteristic O 0 1.5249374030190666e-07
of O 0 3.2874144295647056e-08
the O 0 4.593331084379315e-07
low O 0 2.163598946935963e-05
- O 0 0.0010264149168506265
density O 0 1.4130510862742085e-05
lipoprotein O 0 0.0003817258111666888
( O 0 7.270235073519871e-06
LDL O 0 0.0004724957689177245
) O 0 2.5662966436357237e-06
receptor O 0 3.748489234567387e-06
family O 0 1.088663066184381e-05
. O 0 8.756360330153257e-06

These O 0 5.052017513662577e-06
modules O 0 5.283789505483583e-06
include O 0 5.63460559988016e-07
a O 0 7.874881475800066e-07
putative O 0 1.0565532647888176e-05
signal O 0 3.9412229853041936e-06
peptide O 0 4.463406639843015e-07
for O 0 4.476988735291343e-08
protein O 0 1.6677743985837878e-07
export O 0 2.8478169156187505e-07
, O 0 1.004036533913677e-07
four O 0 2.7923726975132013e-07
epidermal O 0 2.3009009964880534e-05
growth O 0 1.1174989595019724e-05
factor O 0 9.280841481995594e-07
( O 0 2.0772814934844064e-07
EGF O 0 4.021394488518126e-06
) O 0 2.820138718107046e-07
repeats O 0 1.4262428749134415e-06
with O 0 1.834756346852373e-07
associated O 0 9.499227076048555e-07
spacer O 0 1.43411007229588e-05
domains O 0 1.599396796336805e-06
, O 0 4.5517737135014613e-07
three O 0 6.718153713336505e-07
LDL O 0 0.00042158050928264856
- O 0 0.0018905990291386843
receptor O 0 6.3120874074229505e-06
( O 0 4.3218923906351847e-07
LDLR O 0 7.675337838009e-05
) O 0 3.7505452610275825e-07
repeats O 0 1.8865416677726898e-06
, O 0 5.298779015561195e-08
a O 0 1.1618748629871334e-07
single O 0 2.335025328648044e-06
transmembrane O 0 4.537615495792124e-06
spanning O 0 1.3289040907693561e-06
domain O 0 9.777313607628457e-07
, O 0 2.3217283739995764e-07
and O 0 2.517557788905833e-07
a O 0 1.6209590967264376e-06
cytoplasmic O 0 5.8489604271017015e-05
domain O 0 4.379956590128131e-05
. O 0 1.2191839232400525e-05

The O 0 4.150922904955223e-06
encoded O 0 3.902222033502767e-06
protein O 0 4.299268312024651e-06
has O 0 3.0010485829734534e-07
a O 0 2.2974450075707864e-07
unique O 0 3.0511438353642006e-07
organization O 0 2.950889381736488e-07
of O 0 1.2380094460695545e-07
EGF O 0 1.6481806596857496e-05
and O 0 6.03884291194845e-06
LDLR O 0 0.0007410544785670936
repeats O 0 2.4211252821260132e-05
; O 0 2.822361011567409e-07
therefore O 0 7.934195167536018e-08
, O 0 2.1274637163060106e-07
LRP5 O 0 5.0799015298252925e-05
likely O 0 1.0365183698013425e-06
represents O 0 1.5871515302023909e-07
a O 0 2.112272738941101e-07
new O 0 1.5480818547075614e-06
category O 0 1.1344714039296377e-06
of O 0 8.323866751425157e-08
the O 0 1.7966916630030028e-06
LDLR O 0 0.013753252103924751
family O 0 3.1073570426087826e-05
. O 0 7.4597392085706815e-06

Both O 0 1.5803858332219534e-05
human O 0 4.28907969762804e-06
and O 0 2.1049540919193532e-06
mouse O 0 1.814694405766204e-05
LRP5 O 0 0.0006771768094040453
cDNAs O 0 8.804386015981436e-05
have O 0 7.240664672281127e-07
been O 0 3.443548735049262e-07
isolated O 0 4.5981829543961794e-07
and O 0 1.66426445957768e-07
the O 0 3.545178373087765e-08
encoded O 0 1.2152214878824452e-07
mature O 0 1.9447705312813923e-07
proteins O 0 1.8222024777969636e-08
are O 0 1.0108691661514513e-08
95 O 0 8.792778771748999e-08
% O 0 9.097328046436814e-08
identical O 0 8.772790920374973e-07
, O 0 5.546751822294027e-07
indicating O 0 1.16900321245339e-06
a O 0 6.327422852336895e-07
high O 0 2.8906745228596264e-06
degree O 0 1.1343578307787539e-06
of O 0 2.2980563585406344e-07
evolutionary O 0 6.5265362536592875e-06
conservation O 0 6.767281774955336e-06
. O 0 1.777828401827719e-06
. O 0 3.778407290155883e-06

The O 0 1.544221413496416e-05
APC B-Disease 0 6.0567537730094045e-05
variants O 0 9.302097168983892e-06
I1307K O 0 1.1283544154139236e-05
and O 0 5.8001103298011e-07
E1317Q O 0 5.232680450717453e-06
are O 0 3.9940948681760347e-07
associated O 0 1.6835749192978255e-05
with O 1 0.9428129196166992
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.001866689883172512
but O 0 1.8501639260648517e-06
not O 0 1.5185663926331472e-07
always O 0 6.34270236332668e-08
with O 0 1.366935862279206e-07
a O 0 5.573654107138282e-06
family O 0 2.541104367992375e-05
history O 0 6.506319550680928e-06
. O 0 1.1394416105758864e-05

Classical O 1 0.7663848996162415
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 1.0
( O 0 0.18474876880645752
FAP B-Disease 0 0.0014763448853045702
) O 0 4.556300609692698e-06
is O 0 2.217568777496126e-07
a O 0 1.968829565157648e-06
high O 0 0.00017957041563931853
- O 1 0.9871004819869995
penetrance O 1 0.9374487996101379
autosomal B-Disease 1 0.9899771213531494
dominant I-Disease 0 0.4416666030883789
disease I-Disease 0 0.03532030060887337
that O 0 5.900361088606587e-07
predisposes O 0 5.523501840798417e-06
to O 0 2.3840283347453806e-07
hundreds O 0 1.9154890651407186e-07
or O 0 1.8622405661972152e-07
thousands O 0 7.000726327532902e-07
of O 0 0.00010459781333338469
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9937270879745483
carcinoma I-Disease 1 1.0
and O 0 0.0017354657175019383
that O 0 1.9950091427745065e-06
results O 0 4.442209956323495e-06
from O 0 1.7761969672847044e-07
truncating O 0 3.252995156799443e-05
mutations O 0 3.3933243685169145e-05
in O 0 3.161306949550635e-07
the O 0 1.371527332594269e-06
APC B-Disease 0 0.0001675087696639821
gene O 0 2.46211675403174e-05
. O 0 5.096872882859316e-06

A O 0 8.616752893431112e-05
variant O 0 0.0002801992523018271
of O 0 4.087528395757545e-06
FAP B-Disease 0 0.0027678643818944693
is O 0 0.00019316858379170299
attenuated B-Disease 1 0.8583809733390808
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999974966049194
coli I-Disease 1 0.9999995231628418
, O 0 3.535739961080253e-05
which O 0 2.1963712697470328e-06
results O 0 7.131874554033857e-06
from O 0 8.391726282752643e-07
germ O 0 0.003513430943712592
- O 0 0.0025706272572278976
line O 0 0.00044132606126368046
mutations O 0 5.7126671890728176e-06
in O 0 8.029282838606377e-08
the O 0 1.214610847455333e-07
5 O 0 1.7417669369024225e-06
and O 0 3.651688587069657e-07
3 O 0 1.0650769581843633e-06
regions O 0 1.526938291362967e-07
of O 0 4.6288842980857225e-08
the O 0 1.6340650290658232e-06
APC B-Disease 0 9.028331987792626e-05
gene O 0 1.7382079022354446e-05
. O 0 4.689178695116425e-06

Attenuated B-Disease 1 0.999669075012207
adenomatous I-Disease 1 0.9999984502792358
polyposis I-Disease 1 0.9999990463256836
coli I-Disease 1 0.9999997615814209
patients O 1 0.9678948521614075
have O 0 1.917388362926431e-05
" O 0 3.206738256267272e-05
multiple O 0 0.00032141568954102695
" O 1 0.9983364939689636
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
( O 0 2.574850805103779e-05
typically O 0 9.143842589764972e-07
fewer O 0 2.6957033583130396e-07
than O 0 7.14170482751797e-08
100 O 0 1.7689295361833501e-07
) O 0 7.697965997977008e-08
without O 0 7.081898445449042e-08
the O 0 2.792236841742124e-07
florid O 0 0.0002348004636587575
phenotype O 0 9.734756895340979e-05
of O 0 4.257250054706674e-07
classical O 0 2.589280302345287e-05
FAP B-Disease 0 0.00042259847396053374
. O 0 1.2429737580532674e-05

Another O 0 2.1333005861379206e-05
group O 0 2.6299088858650066e-05
of O 0 1.176793944068777e-06
patients O 0 6.7973196564707905e-06
with O 0 3.256538718687807e-07
multiple O 0 5.752424112870358e-05
adenomas B-Disease 0 0.09569147229194641
has O 0 9.805788067751564e-06
no O 0 1.067098196472216e-06
mutations O 0 1.9542146674211835e-06
in O 0 1.5239400852351537e-07
the O 0 1.749685480945118e-07
APC B-Disease 0 8.32966725283768e-06
gene O 0 1.0132707757293247e-06
, O 0 1.6247075507180853e-07
and O 0 2.2223683515676385e-07
their O 0 2.5831188850133913e-06
phenotype O 0 0.00018205268133897334
probably O 0 6.735616352671059e-06
results O 0 1.966204990822007e-06
from O 0 5.3467992700007017e-08
variation O 0 1.0468419304743293e-06
at O 0 3.7557026644208236e-06
a O 0 2.4568737444496946e-06
locus O 0 1.4840136827842798e-05
, O 0 7.911155535111902e-07
or O 0 2.0648559484470752e-07
loci O 0 7.366509748862882e-07
, O 0 2.1684145679046196e-07
elsewhere O 0 3.6986926943427534e-07
in O 0 1.4223537903035322e-07
the O 0 1.1972650781899574e-06
genome O 0 2.0250530724297278e-05
. O 0 1.0808453225763515e-05

Recently O 0 0.0006228457787074149
, O 0 5.8828532019106206e-06
however O 0 6.334952331599197e-07
, O 0 1.4054799635232484e-07
a O 0 4.6111199480947107e-07
missense O 0 3.6572757380781695e-05
variant O 0 6.457287236116827e-05
of O 0 2.455191861372441e-06
APC B-Disease 0 0.00025173870380967855
( O 0 9.491674859418708e-07
I1307K O 0 6.278479759203037e-06
) O 0 4.5096331291460956e-07
was O 0 6.133215720183216e-06
described O 0 3.969635145040229e-06
that O 0 1.3942324983418075e-07
confers O 0 7.901949174993206e-07
an O 0 6.050390766176861e-07
increased O 0 8.029487617022824e-06
risk O 0 0.00015574930876027793
of O 0 0.1507386565208435
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.9730287021957338e-05
including O 0 1.0556723282206804e-06
multiple O 0 4.5211229007691145e-05
adenomas B-Disease 0 0.041117388755083084
, O 0 3.35749223268067e-06
in O 0 3.886819740728242e-06
Ashkenazim O 0 0.0006780385156162083
. O 0 1.5984171113814227e-05

We O 0 2.006833892664872e-05
have O 0 3.9019550968077965e-07
studied O 0 2.5279007331846515e-07
a O 0 1.2613597277777444e-07
set O 0 9.42190638397733e-07
of O 0 1.8050469918762246e-07
164 O 0 2.2764083041693084e-05
patients O 0 1.486279688833747e-05
with O 0 8.081904525170103e-06
multiple O 1 0.9996780157089233
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.08574949204921722
/ I-Disease 0 0.4556029736995697
or I-Disease 0 0.0018266096012666821
carcinoma I-Disease 1 1.0
and O 0 0.0001860000193119049
analyzed O 0 4.03951526095625e-05
codons O 0 1.8008644474321045e-05
1263 O 0 0.0001513304014224559
- O 0 0.004066142253577709
1377 O 0 0.00045051262713968754
( O 0 5.593573177975486e-07
exon O 0 9.105032404477242e-06
15G O 0 1.1009842637577094e-05
) O 0 1.216623530808647e-07
of O 0 1.906220070679865e-08
the O 0 1.825452073944689e-07
APC B-Disease 0 1.6327427147189155e-05
gene O 0 2.0836912426602794e-06
for O 0 5.656011694554763e-07
germ O 0 0.00046579769696108997
- O 0 0.0001817247102735564
line O 0 6.748777377652004e-05
variants O 0 2.182042589993216e-05
. O 0 4.458018338482361e-06

Three O 0 6.266930722631514e-05
patients O 0 4.697974873124622e-05
with O 0 2.0792435861949343e-07
the O 0 2.961707252779888e-07
I1307K O 0 1.029986196954269e-05
allele O 0 7.236747933347942e-06
were O 0 1.0407339914308977e-06
detected O 0 2.274070993735222e-06
, O 0 8.127618400521897e-08
each O 0 4.1225391100851994e-08
of O 0 2.935185818842001e-07
Ashkenazi O 0 0.0013789742952212691
descent O 0 0.0002968531916849315
. O 0 1.3509771633835044e-05

Four O 0 0.00021338727674447
patients O 0 0.0002434221823932603
had O 0 1.0830029168573674e-05
a O 0 6.197397397045279e-06
germ O 0 0.00793171115219593
- O 0 0.0004355442360974848
line O 0 4.513553358265199e-05
E1317Q O 0 5.747641353082145e-06
missense O 0 1.0199503776675556e-05
variant O 0 7.100601578713395e-06
of O 0 4.0014376168073795e-07
APC O 0 4.400983016239479e-05
that O 0 1.234066985489335e-06
was O 0 6.409030447684927e-06
not O 0 1.7919636263741268e-07
present O 0 7.680410618604583e-08
in O 0 1.9447297461283597e-07
controls O 0 6.133005172159756e-06
; O 0 8.197425813705195e-07
one O 0 9.662541344823694e-08
of O 0 3.406017512475046e-08
these O 0 6.155089948833847e-08
individuals O 0 1.5787874119155276e-08
had O 0 1.135419552156236e-06
an O 0 3.812093325450405e-07
unusually O 0 1.6683358126101666e-06
large O 0 1.8112876887244056e-07
number O 0 2.561365022302198e-07
of O 0 2.2140018529626104e-07
metaplastic B-Disease 0 0.003707039635628462
polyps I-Disease 0 0.00030047193286009133
of I-Disease 0 3.008467501786072e-07
the I-Disease 0 2.403341341050691e-06
colorectum I-Disease 0 0.0011406607227399945
. O 0 1.3624729945149738e-05

There O 0 1.2836138012062293e-05
is O 0 1.333728732788586e-06
increasing O 0 7.496443004129105e-07
evidence O 0 9.411587598151527e-07
that O 0 1.8158259251777054e-07
there O 0 1.2275239669179427e-07
exist O 0 5.504605269379681e-07
germ O 0 0.00012550794053822756
- O 0 3.243850733269937e-05
line O 0 6.5766266743594315e-06
variants O 0 5.085299790152931e-07
of O 0 3.827728178862344e-08
the O 0 2.1645220726895786e-07
APC B-Disease 0 5.154076916369377e-06
gene O 0 5.891909609090362e-07
that O 0 6.680267716774324e-08
predispose O 0 4.511319104949507e-07
to O 0 7.476837993181107e-08
the O 0 6.267623575695325e-08
development O 0 5.94899802308646e-07
of O 0 4.131216428504558e-06
multiple O 1 0.9982051849365234
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9955020546913147
carcinoma I-Disease 1 1.0
, O 0 8.092101779766381e-05
but O 0 4.3863661858267733e-07
without O 0 1.2690105677393149e-07
the O 0 2.9212344543338986e-07
florid O 0 0.00022887671366333961
phenotype O 0 7.77723325882107e-05
of O 0 1.7755753844994615e-07
classical O 0 3.7021125081082573e-06
FAP B-Disease 0 1.2994121789233759e-05
, O 0 5.69672067740612e-07
and O 0 1.8115520106221084e-07
possibly O 0 1.198016263970203e-07
with O 0 1.7421312747956108e-07
importance O 0 1.7867290807771496e-05
for O 1 0.9971551895141602
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 6.947922520339489e-05
in O 0 3.1083712315194134e-07
the O 0 5.505634135261062e-07
general O 0 7.66321591072483e-07
population O 0 2.836616772583511e-07
. O 0 5.756620566899073e-07
. O 0 3.3502669793961104e-06

Genomic O 0 0.0006136402953416109
structure O 0 3.7025558413006365e-05
of O 0 1.7639040379435755e-06
the O 0 2.3269572920980863e-05
human O 0 0.024222897365689278
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999991655349731
diarrhea I-Disease 1 1.0
( O 0 0.0003153352881781757
CLD B-Disease 0 0.19124644994735718
) O 0 1.1135754903079942e-05
gene O 0 3.3844466088339686e-05
. O 0 6.3299071371147875e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999994039535522
diarrhea I-Disease 1 1.0
( O 0 0.1548800766468048
CLD B-Disease 1 0.9920899868011475
) O 0 5.2623818191932514e-05
is O 0 2.2898270799487364e-06
caused O 0 6.110878075560322e-06
by O 0 1.035233026414062e-06
mutations O 0 1.1311698472127318e-05
in O 0 4.377239406494482e-07
a O 0 3.629981392805348e-06
gene O 0 7.437973636115203e-06
which O 0 1.3727208170166705e-06
encodes O 0 1.6597756257397123e-05
an O 0 3.6677996831713244e-05
intestinal O 0 0.01748039573431015
anion O 0 0.0007204805733636022
transporter O 0 0.04452289640903473
. O 0 2.1595091311610304e-05

We O 0 3.5067972930846736e-05
report O 0 6.13830661677639e-06
here O 0 1.1325683857421609e-07
the O 0 5.2024994090515975e-08
complete O 0 1.0084197583637433e-06
genomic O 0 4.859215096075786e-06
organization O 0 2.2028142154795205e-07
of O 0 6.886829595487143e-08
the O 0 1.003106035568635e-06
human O 0 2.2402887225325685e-06
CLD B-Disease 0 0.00021024642046540976
gene O 0 8.155659998010378e-06
which O 0 4.6969748268566036e-07
spans O 0 2.1005062080803327e-06
approximately O 0 6.832179337834532e-07
39kb O 0 3.812124123214744e-05
, O 0 4.561416631077009e-07
and O 0 2.557805771630228e-07
comprises O 0 5.518134571502742e-07
21 O 0 3.875548827636521e-06
exons O 0 7.548573921667412e-05
. O 0 5.562407295656158e-06

All O 0 1.2255511137482245e-05
exon O 0 0.00047057741903699934
/ O 0 0.00039223654312081635
intron O 0 0.0002708639367483556
boundaries O 0 3.997709427494556e-06
conform O 0 7.747443305561319e-06
to O 0 7.030902224869351e-07
the O 0 8.525990438101871e-07
GT O 0 0.0045304978266358376
/ O 0 0.009972053579986095
AG O 1 0.9999203681945801
rule O 0 1.5569874449283816e-05
. O 0 6.876000952615868e-06

An O 0 1.885388519440312e-05
analysis O 0 3.547942469595e-06
of O 0 2.9024150194345566e-07
the O 0 5.943945211583923e-07
putative O 0 3.149038093397394e-05
promoter O 0 7.415001891786233e-05
region O 0 3.6992255445511546e-06
sequence O 0 3.2067816846392816e-07
shows O 0 3.1516142939835845e-07
a O 0 8.903026582629536e-07
putative O 0 2.0812422008020803e-05
TATA O 0 0.033045198768377304
box O 0 2.6831488867173903e-05
and O 0 2.1605490019283025e-06
predicts O 0 1.8348911908105947e-05
multiple O 0 6.390607723005814e-07
transcription O 0 2.1976075004204176e-06
factor O 0 8.513007401234063e-07
binding O 0 3.8184934965102e-06
sites O 0 4.775826255354332e-06
. O 0 8.152876034728251e-06

The O 0 1.1300355254206806e-05
genomic O 0 3.432900120969862e-05
structure O 0 1.0843061318155378e-05
was O 0 1.4610008292947896e-05
determined O 0 6.071233542570553e-07
using O 0 2.8457370149226335e-07
DNA O 0 3.7098880056873895e-06
from O 0 5.120396551205886e-08
several O 0 4.904084960344335e-08
sources O 0 2.8649947125813924e-07
including O 0 4.032821010468979e-08
multiple O 0 5.565339620261511e-07
large O 0 1.1641535593298613e-06
- O 0 0.0010411543771624565
insert O 0 6.229963037185371e-05
libaries O 0 2.725510421441868e-05
and O 0 4.999727138965682e-07
genomic O 0 1.9456142581475433e-06
DNA O 0 1.3741479051532224e-05
from O 0 1.041716018335137e-06
Finnish O 0 0.1152089387178421
CLD B-Disease 1 0.9427980780601501
patients O 0 0.00011020373494829983
and O 0 1.8183576457886375e-06
controls O 0 5.125926327309571e-05
. O 0 1.5766134310979396e-05

Exon O 0 0.000691268069203943
- O 0 0.0001424811634933576
specific O 0 1.3246677781353355e-06
primers O 0 1.747530586726498e-05
developed O 0 3.648131496447604e-06
in O 0 3.5927405406255275e-07
this O 0 8.321914179987289e-08
study O 0 1.0235113734324841e-07
will O 0 6.205306135598221e-08
facilitate O 0 1.0601119271314019e-07
mutation O 0 6.619083592340758e-07
screening O 0 6.167130663925491e-07
studies O 0 2.460866710407572e-07
of O 0 1.613608304751324e-07
patients O 0 3.381947408342967e-06
with O 0 7.074580139487807e-07
the O 0 7.848825043765828e-05
disease O 0 0.005998401902616024
. O 0 1.3054524060862605e-05

Genomic O 0 0.0002907695306930691
sequencing O 0 4.97138244099915e-05
of O 0 1.5672640074626543e-06
a O 0 1.0629272765072528e-05
BAC O 0 0.0014728527748957276
clone O 0 0.01088287215679884
H O 1 0.9999973773956299
_ O 0 5.354328095563687e-06
RG364P16 O 0 4.3377094698371366e-06
revealed O 0 6.098500307416543e-06
the O 0 4.130000164082048e-08
presence O 0 3.2094000346205576e-08
of O 0 1.5868785396833118e-08
another O 0 4.0128028899744095e-07
, O 0 2.1703718289245444e-07
highly O 0 8.693871222931193e-08
homologous O 0 3.271348987254896e-07
gene O 0 6.932256155778305e-07
3 O 0 9.967036476155045e-07
of O 0 5.8455572826687785e-08
the O 0 2.126024583049002e-06
CLD B-Disease 0 0.0008892717305570841
gene O 0 5.1310512390045915e-06
, O 0 9.082123142434284e-08
with O 0 2.2444957892275852e-08
a O 0 4.638102382159559e-07
similar O 0 5.343486009223852e-07
genomic O 0 3.823383394774282e-06
structure O 0 7.050830390653573e-06
, O 0 2.0460997802729253e-06
recently O 0 6.438890068238834e-06
identified O 0 1.996663286263356e-06
as O 0 5.941780045759515e-07
the O 0 0.00011151922808494419
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00020509820024017245
( O 0 2.361982069487567e-06
PDS B-Disease 0 0.0011309281690046191
) O 0 1.2205973689560778e-06
. O 0 6.80724440371705e-07
. O 0 2.888015387725318e-06

The O 0 7.312038633244811e-06
APCI1307K O 0 0.00046582616050727665
allele O 0 0.00013018988829571754
and O 0 0.00031123863300308585
cancer B-Disease 0 0.1619420200586319
risk O 0 5.311256700224476e-06
in O 0 2.8268192409086623e-07
a O 0 1.5586011841151048e-06
community O 0 1.3081540828352445e-06
- O 0 0.0019211821490898728
based O 0 2.0344510630820878e-05
study O 0 2.7219888920626545e-07
of O 0 1.8313509997369692e-07
Ashkenazi O 0 0.0004370989336166531
Jews O 0 1.3697492249775678e-05
. O 0 6.701370693917852e-06

Mutations O 0 0.002791937906295061
in O 0 1.677064210525714e-05
APC O 0 0.00036223488859832287
are O 0 2.33654441217368e-06
classically O 0 0.005095803644508123
associated O 0 0.0001904775999719277
with O 0 0.003693596925586462
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.0047980742529034615
FAP B-Disease 0 0.0005986253381706774
) O 0 2.417061296000611e-06
, O 0 3.7702585586885107e-07
a O 0 3.845338596875081e-06
highly O 0 0.00017949340690393
penetrant O 1 0.9975784420967102
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999948740005493
disorder I-Disease 1 1.0
characterized O 0 0.01285506784915924
by O 0 1.650785816309508e-05
multiple O 0 0.03007747419178486
intestinal O 1 0.998571515083313
polyps B-Disease 1 0.7207821011543274
and O 0 1.0191190995101351e-05
, O 0 9.606308140064357e-07
without O 0 3.05888505636176e-07
surgical O 0 5.5988191888900474e-05
intervention O 0 3.3940466437343275e-07
, O 0 1.224438506142178e-07
the O 0 9.56843990707057e-08
development O 0 6.441125606215792e-06
of O 1 0.7868244647979736
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.9622096159728244e-05
CRC B-Disease 0 0.0034007553476840258
) O 0 2.203782059950754e-06
. O 0 4.945075033901958e-06

APC B-Disease 0 0.0018057972192764282
is O 0 7.124158855731366e-06
a O 0 3.4043121559079736e-05
tumour O 1 0.9999994039535522
- O 0 0.11132533848285675
suppressor O 0 0.0005509374313987792
gene O 0 1.5080919183674268e-05
, O 0 3.8210217212508724e-07
and O 0 8.451802955278254e-07
somatic O 0 4.554851693683304e-05
loss O 0 0.0004912538570351899
occurs O 0 1.0553991160122678e-05
in O 0 5.230736132944003e-05
tumours B-Disease 1 0.9999997615814209
. O 0 7.963821553857997e-05

The O 0 4.003982030553743e-05
germline O 0 0.001034050015732646
T O 0 0.0036987890489399433
- O 0 6.267086428124458e-05
to O 0 9.253029134015378e-07
- O 0 1.790398164303042e-05
A O 0 4.798511781700654e-06
transversion O 0 3.8352751289494336e-05
responsible O 0 1.2545459640023182e-06
for O 0 5.90885882445491e-08
the O 0 2.0406848477705353e-07
APC O 0 3.7580814478133107e-06
I1307K O 0 1.0021364005297073e-06
allele O 0 5.568695087276865e-07
converts O 0 4.1033123920897197e-07
the O 0 9.00467611586464e-08
wild O 0 1.0619278327794746e-06
- O 0 1.3211441910243593e-05
type O 0 5.737755373047548e-07
sequence O 0 1.7893322024065128e-07
to O 0 2.577434656814148e-07
a O 0 9.289729860029183e-06
homopolymer O 1 0.6183504462242126
tract O 0 0.07035300880670547
( O 0 4.377871391625376e-06
A8 O 0 0.2727760672569275
) O 0 2.6862899176194333e-06
that O 0 5.989421651975135e-07
is O 0 1.8885795043388498e-06
genetically O 0 0.00010431354166939855
unstable O 0 0.024749476462602615
and O 0 2.7557680368772708e-05
prone O 0 0.00011280029139015824
to O 0 3.8055877666920424e-06
somatic O 0 0.00015974078269209713
mutation O 0 0.00011626318155322224
. O 0 1.047571549861459e-05

The O 0 2.2151341909193434e-05
I1307K O 0 9.994576248573139e-05
allele O 0 9.467688505537808e-05
was O 0 3.931723040295765e-05
found O 0 3.618057462517754e-06
in O 0 1.055928123605554e-06
6 O 0 5.048366074333899e-05
. O 0 1.596025686012581e-05

1 O 0 3.4726992453215644e-05
% O 0 2.497316017979756e-06
of O 0 3.977096980634087e-07
unselected O 0 0.00010300896246917546
Ashkenazi O 0 0.0010250215418636799
Jews O 0 1.2069261174474377e-05
and O 0 1.7228874185093446e-06
higher O 0 9.672679652794614e-07
proportions O 0 1.5349684190368862e-06
of O 0 1.5558225641143508e-07
Ashkenazim O 0 4.366827488411218e-05
with O 0 4.526118573267013e-06
family O 0 2.3239810616360046e-05
or O 0 2.4028554435062688e-06
personal O 0 4.817723947780905e-06
histories O 0 7.706067663093563e-06
of O 0 4.92992239742307e-06
CRC B-Disease 0 0.15561005473136902
( O 0 4.3471181925269775e-06
ref O 0 0.0001643138675717637
. O 0 4.872906060882087e-07
2 O 0 2.891857320719282e-06
) O 0 9.813466022023931e-07
. O 0 2.4168562049453612e-06

To O 0 1.129985957959434e-05
evaluate O 0 1.0385673704149667e-05
the O 0 3.264327688157209e-07
role O 0 4.907724928671087e-07
of O 0 1.0437780417760223e-07
I1307K O 0 1.1606158295762725e-05
in O 0 3.284375270595774e-05
cancer B-Disease 0 0.004764345474541187
, O 0 5.160290470485052e-07
we O 0 1.3370892304465087e-07
genotyped O 0 1.1351942703186069e-05
5 O 0 1.8810981146089034e-06
, O 0 4.4374704089023e-07
081 O 0 1.5219403394439723e-05
Ashkenazi O 0 5.5030726798577234e-05
volunteers O 0 5.177445245863055e-07
in O 0 1.7033870847171784e-07
a O 0 2.3682073333475273e-06
community O 0 2.4929211122071138e-06
survey O 0 3.6510977224679664e-05
. O 0 6.7074001890432555e-06

Risk O 0 0.00041141995461657643
of O 0 5.305359081830829e-06
developing O 0 0.0011323958169668913
colorectal B-Disease 1 1.0
, I-Disease 0 0.013509728945791721
breast I-Disease 1 0.724798321723938
and I-Disease 0 1.1919632925128099e-05
other I-Disease 0 2.7844002943311352e-06
cancers I-Disease 0 0.02143409289419651
were O 0 8.477635446979548e-07
compared O 0 1.1270426512055565e-06
between O 0 2.1530485128096188e-07
genotyped O 0 9.471119119552895e-05
I1307K O 0 5.4513684517587535e-06
carriers O 0 3.404092581149598e-07
and O 0 1.3247647245862026e-07
non O 0 3.2948378247965593e-07
- O 0 2.6281841201125644e-05
carriers O 0 4.483671318666893e-07
and O 0 7.696365855736076e-08
their O 0 1.1041432657066252e-07
first O 0 3.3506439649499953e-06
- O 0 0.000877200742252171
degree O 0 2.2762867956771515e-05
relatives O 0 1.596342190168798e-05
. O 0 6.210697392816655e-06

Sperm O 0 0.0008594056707806885
DNA O 0 0.0002795817272271961
analysis O 0 9.324435268354136e-06
in O 0 1.934900410560658e-06
a O 0 6.313304038485512e-05
Friedreich B-Disease 1 0.9972643852233887
ataxia I-Disease 1 0.9997429251670837
premutation O 0 0.31905704736709595
carrier O 0 0.0004982774262316525
suggests O 0 6.580717126780655e-06
both O 0 3.752999475636898e-07
meiotic O 0 3.9481954445363954e-05
and O 0 2.0437828425201587e-06
mitotic O 0 1.5899535355856642e-05
expansion O 0 3.2513639780518133e-06
in O 0 4.2454112758605334e-07
the O 0 7.24768369764206e-07
FRDA B-Disease 0 0.0021978833246976137
gene O 0 3.2632233342155814e-05
. O 0 3.999639375251718e-06

Friedreich B-Disease 1 0.9998536109924316
ataxia I-Disease 1 0.9999868869781494
is O 0 0.00036805905983783305
usually O 0 1.8888600607169792e-05
caused O 0 2.3358350517810322e-05
by O 0 2.419911311335454e-07
an O 0 2.9606709972540557e-07
expansion O 0 1.5597936453559669e-06
of O 0 2.454856939948513e-07
a O 0 1.0820715942827519e-05
GAA O 0 0.0002988085034303367
trinucleotide O 0 0.0002027716691372916
repeat O 0 1.609569699212443e-05
in O 0 3.752913642074418e-07
intron O 0 3.9782680687494576e-05
1 O 0 1.043900851982471e-06
of O 0 8.122194117277104e-08
the O 0 9.900833219944616e-07
FRDA B-Disease 0 0.0010165248531848192
gene O 0 4.439790063770488e-05
. O 0 5.153399342816556e-06

Occasionally O 0 7.206620648503304e-05
, O 0 1.9860585780406836e-06
a O 0 4.91313869588339e-07
fully O 0 7.118571261344186e-07
expanded O 0 3.955325098559115e-07
allele O 0 1.3478219216267462e-06
has O 0 1.2592230405061855e-06
been O 0 7.860879804866272e-07
found O 0 6.598304480576189e-07
to O 0 2.767283433513512e-07
arise O 0 2.1790658877307578e-07
from O 0 2.899727924443596e-08
a O 0 3.8966632587289496e-07
premutation O 0 1.595706089574378e-05
of O 0 9.752396579187916e-08
100 O 0 5.099500413052738e-07
or O 0 8.697152793502028e-07
less O 0 1.933518888108665e-06
triplet O 0 0.009334643371403217
repeats O 0 0.0006763248238712549
. O 0 8.850591257214546e-06

We O 0 2.3597538529429585e-05
have O 0 1.512230596745212e-06
examined O 0 2.3496120320487535e-06
the O 0 1.2953915984326159e-07
sperm O 0 6.694388957839692e-06
DNA O 0 7.3154078563675284e-06
of O 0 9.506371156930982e-08
a O 0 4.3206991904298775e-06
premutation O 0 0.001835063099861145
carrier O 0 7.63912103138864e-05
. O 0 6.478594514192082e-06

This O 0 6.234862667042762e-06
mans O 0 0.00010821618343470618
leucocyte O 0 0.00038310495438054204
DNA O 0 0.00014823058154433966
showed O 0 8.065680958679877e-06
one O 0 2.045526912297646e-07
normal O 0 4.3177809061489825e-07
allele O 0 1.2700775187113322e-06
and O 0 3.53176204725969e-07
one O 0 1.7762425841283402e-07
allele O 0 1.1343113328621257e-06
of O 0 8.016459673854115e-08
approximately O 0 6.87377792019106e-07
100 O 0 1.5849930150579894e-06
repeats O 0 5.471821714309044e-05
. O 0 4.3870950321434066e-06

His O 0 8.712067210581154e-05
sperm O 0 0.00024289519933518022
showed O 0 1.8375494619249366e-05
an O 0 2.3496382084431389e-07
expanded O 0 3.664768257749529e-07
allele O 0 1.0383763537902269e-06
in O 0 1.97123156908674e-07
a O 0 8.392623271902266e-07
tight O 0 9.199460691888817e-06
range O 0 2.168159426219063e-06
centering O 0 1.7182536566906492e-06
on O 0 6.242180916160578e-06
a O 0 5.997961238790595e-07
size O 0 8.83616905866802e-07
of O 0 1.5948532450238417e-07
approximately O 0 1.7874542663776083e-06
320 O 0 1.470985898777144e-05
trinucleotide O 0 0.0003613636363297701
repeats O 0 9.927155042532831e-05
. O 0 6.166903858684236e-06

His O 0 0.0008938648970797658
affected O 0 0.0002798620262183249
son O 0 0.001061300397850573
has O 0 7.52411369830952e-06
repeat O 0 1.3180821952119004e-05
sizes O 0 2.323494527445291e-06
of O 0 2.4865977366062e-07
1040 O 0 5.5546584917465225e-05
and O 0 3.8099087760201655e-06
540 O 0 1.894387423817534e-05
. O 0 5.258182682155166e-06

These O 0 5.035149570176145e-06
data O 0 4.909784820483765e-06
suggest O 0 6.76834588375641e-07
that O 0 8.27561521532516e-08
expansion O 0 4.5421643335430417e-07
occurs O 0 1.0592609811510556e-07
in O 0 1.1194151738891378e-07
two O 0 3.135064048365166e-07
stages O 0 1.0905906492553186e-05
, O 0 3.982494263254921e-07
the O 0 5.468419317367079e-08
first O 0 9.936590004144819e-07
during O 0 3.522407325817767e-07
meiosis O 0 1.629233707944877e-07
followed O 0 1.312114363827277e-07
by O 0 2.5711635487368767e-08
a O 0 1.5679756870667916e-07
second O 0 4.350884410087019e-06
mitotic O 0 3.7619149225065485e-05
expansion O 0 1.354243158857571e-05
. O 0 5.4300844567478634e-06

We O 0 2.21322934521595e-05
also O 0 1.8318031607122975e-06
show O 0 1.8753055428533116e-06
that O 0 6.249383943668363e-08
in O 0 3.1099926189881444e-08
all O 0 1.7418711806271858e-08
informative O 0 6.717718292748032e-07
carrier O 0 1.3658488569490146e-05
father O 0 3.98179872718174e-06
to O 0 8.772975093052082e-07
affected O 0 6.999031256782473e-07
child O 0 5.237923232925823e-06
transmissions O 0 1.874114605016075e-05
, O 0 2.1714939180128567e-07
with O 0 4.176483869855474e-08
the O 0 1.4904705381013628e-07
notable O 0 3.4161874395977065e-07
exception O 0 5.53978516393272e-08
of O 0 2.7250452561133898e-08
the O 0 5.258326041257533e-07
premutation O 0 8.891491597751155e-05
carrier O 0 4.464216999622295e-06
, O 0 9.271113299291756e-08
the O 0 2.5474154341509347e-08
expansion O 0 4.667761857035657e-07
size O 0 2.6948241611535195e-06
decreases O 0 6.231890438357368e-06
. O 0 8.973297553893644e-07
. O 0 3.7827448977623135e-06

The O 0 1.0146988643100485e-05
R496H O 0 3.801907951128669e-05
mutation O 0 1.292185697820969e-05
of O 0 3.3774469443415e-07
arylsulfatase O 0 0.00014727411326020956
A O 0 3.294328780611977e-05
does O 0 5.537172000913415e-06
not O 0 4.212472049403004e-06
cause O 0 0.00016449227405246347
metachromatic B-Disease 1 0.9999915361404419
leukodystrophy I-Disease 1 0.9999967813491821
. O 0 8.892459300113842e-05

Deficiency B-Disease 1 0.9975053668022156
of I-Disease 0 8.816876288619824e-06
arylsulfatase I-Disease 0 0.0017643427709117532
A I-Disease 0 0.0002940491249319166
( O 0 1.998638254008256e-05
ARSA O 0 0.007400099653750658
) O 0 2.0998013496864587e-06
enzyme O 0 1.0964765351673122e-05
activity O 0 1.2594568033819087e-05
causes O 0 0.000803450180683285
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 0.0004782701435033232
MLD B-Disease 1 0.9999842643737793
) O 0 1.9781420633080415e-05
. O 0 1.0582977665762883e-05

A O 0 2.1854624719708227e-05
number O 0 2.480951025063405e-06
of O 0 1.5526771903751069e-06
ARSA O 0 0.18597671389579773
gene O 0 0.0002059785183519125
mutations O 0 0.00018561098841018975
responsible O 0 4.824339703191072e-05
for O 0 4.290147262508981e-05
MLD B-Disease 1 0.9999983310699463
have O 0 4.03341073251795e-05
been O 0 8.231023457483388e-06
identified O 0 4.4561285903910175e-05
. O 0 7.235732937260764e-06

Recently O 0 0.00032051632297225296
, O 0 1.8767565279631526e-06
the O 0 1.580728650196761e-07
R496H O 0 5.516174041986233e-06
mutation O 0 3.0749795314477524e-06
of O 0 2.1702683739022177e-07
ARSA O 0 0.01585462875664234
was O 0 2.4735874831094407e-05
proposed O 0 5.740447477364796e-07
to O 0 3.5289943411953573e-07
be O 0 1.589625213682666e-07
a O 0 2.283261210322962e-06
cause O 0 9.407071047462523e-06
of O 0 7.039650427032029e-06
MLD B-Disease 1 0.9999992847442627
( O 0 1.9118815544061363e-05
Draghia O 0 0.0004273749073036015
et O 0 0.05168618634343147
al O 0 0.0001593659253558144
. O 0 1.364396553071856e-06
, O 0 7.914113666629419e-07
1997 O 0 3.6470355553319678e-06
) O 0 6.838985200374736e-07
. O 0 3.141848083032528e-06

We O 0 2.5877745429170318e-05
have O 0 7.420230190291477e-07
investigated O 0 1.6551191492908401e-06
the O 0 1.3206839355461852e-07
R496H O 0 5.099046120449202e-06
mutation O 0 3.3039516438293504e-06
and O 0 4.3698776153178187e-07
found O 0 5.563742320191523e-07
this O 0 8.186287203670872e-08
mutation O 0 1.0149939271286712e-06
at O 0 4.20437032744303e-07
a O 0 5.417905413196422e-07
relatively O 0 2.4756894845268107e-07
high O 0 7.052431669762882e-07
frequency O 0 1.953788114406052e-06
in O 0 6.619790724471386e-07
an O 0 6.087699375711964e-07
African O 0 1.7474792457505828e-07
American O 0 1.2643154150282498e-06
population O 0 2.1464204280619015e-07
( O 0 8.3862246924582e-08
f O 0 6.360951374517754e-06
= O 0 3.1675133413955336e-06
0 O 0 8.417487720180361e-07
. O 0 2.4643378537803073e-07
09 O 0 9.376281582262891e-07
, O 0 2.575220889866614e-07
n O 0 9.027957275975496e-06
= O 0 1.735703153826762e-05
61 O 0 9.372416570840869e-06
subjects O 0 1.6091487395897275e-06
) O 0 1.1319253871988622e-06
. O 0 4.705852916231379e-06

The O 0 3.984939758083783e-05
ARSA O 0 0.001727823750115931
enzyme O 0 1.6978638086584397e-05
activity O 0 1.5839593743294245e-06
in O 0 3.9799652995498036e-07
subjects O 0 2.7021664550375135e-07
with O 0 3.1333033234659524e-07
and O 0 2.184372533520218e-06
without O 0 1.6509305567069532e-07
the O 0 1.9721416322227014e-07
R496H O 0 1.3858871170668863e-05
mutation O 0 5.4196862038224936e-06
was O 0 9.561016668158118e-06
determined O 0 3.3650283057795605e-06
and O 0 8.041166097427777e-07
found O 0 1.0833507531060604e-06
to O 0 2.2615998318542552e-07
be O 0 2.8960695885871246e-07
normal O 0 2.371642722209799e-06
. O 0 5.01205749969813e-06

It O 0 2.2431351681007072e-05
is O 0 1.0934960528174997e-06
therefore O 0 6.806841383877327e-07
concluded O 0 1.8888063095801044e-06
that O 0 4.6874340853264584e-08
the O 0 7.075931307554129e-08
R496H O 0 5.745493126596557e-06
mutation O 0 2.683399088709848e-06
of O 0 1.766505448586031e-07
ARSA O 0 0.008127736859023571
does O 0 1.6922567738220096e-06
not O 0 1.3152101985269837e-07
negatively O 0 3.116215907539299e-07
influence O 0 1.0107154224670012e-07
the O 0 1.0240561465479914e-07
activity O 0 2.1127321758740436e-07
of O 0 1.2418337291819626e-07
ARSA O 0 0.04588896036148071
and O 0 4.869997155765304e-06
is O 0 3.92950312289031e-07
not O 0 1.6016086590298073e-07
a O 0 3.3775058909668587e-06
cause O 0 3.0985596822574735e-05
of O 0 1.9372622773516923e-05
MLD B-Disease 1 0.9999823570251465

Down O 0 0.00012043159222230315
- O 0 0.00013080336793791503
regulation O 0 3.642228875833098e-06
of O 0 6.235322302927671e-07
transmembrane O 0 4.2881674744421616e-05
carbonic O 0 0.0001870556006906554
anhydrases O 0 0.0004821788752451539
in O 0 5.073027205071412e-05
renal B-Disease 1 0.9996800422668457
cell I-Disease 1 0.9997045397758484
carcinoma I-Disease 1 1.0
cell O 1 0.8089824318885803
lines O 0 9.193347068503499e-05
by O 0 7.350572559516877e-07
wild O 0 1.1766113857447635e-05
- O 0 0.007951497100293636
type O 0 0.00020342424977570772
von B-Disease 1 0.9882708191871643
Hippel I-Disease 1 0.9919517040252686
- I-Disease 1 0.8902367353439331
Lindau I-Disease 1 0.9373648166656494
transgenes O 0 0.003546613035723567
. O 0 3.414466482354328e-05

To O 0 2.0185538232908584e-05
discover O 0 5.5636701290495694e-05
genes O 0 7.3842588790284935e-06
involved O 0 2.5906235805450706e-06
in O 0 8.781531505519524e-06
von B-Disease 1 0.9991714954376221
Hippel I-Disease 1 0.9999560117721558
- I-Disease 1 0.9999785423278809
Lindau I-Disease 1 0.9998853206634521
( O 0 2.1361831386457197e-05
VHL B-Disease 0 0.0004427839012350887
) O 0 2.337400474061724e-06
- O 0 0.00018416944658383727
mediated O 0 0.0005710995756089687
carcinogenesis O 0 0.024394622072577477
, O 0 1.5612685047017294e-06
we O 0 1.80887440137667e-07
used O 0 2.459563620504923e-05
renal B-Disease 1 0.9979621171951294
cell I-Disease 1 0.9987454414367676
carcinoma I-Disease 1 1.0
cell O 1 0.8342781066894531
lines O 0 0.0001983725233003497
stably O 0 0.00015550402167718858
transfected O 0 7.5626747275237e-05
with O 0 1.085757503460627e-06
wild O 0 2.8978678528801538e-05
- O 0 0.003675109473988414
type O 0 0.00011371047730790451
VHL O 0 0.0026383958756923676
- O 0 0.0019462504424154758
expressing O 0 2.4336466594832018e-05
transgenes O 0 0.00021626116358675063
. O 0 1.540882294648327e-05

Large O 0 2.603095526865218e-05
- O 0 7.73399806348607e-05
scale O 0 7.983720024640206e-06
RNA O 0 4.1802245505095925e-06
differential O 0 2.1684531930077355e-06
display O 0 7.506358201680996e-07
technology O 0 1.9344502106832806e-06
applied O 0 3.834608719444077e-07
to O 0 8.601094236837525e-08
these O 0 4.802201303277798e-08
cell O 0 1.0138534889847506e-05
lines O 0 1.498645269748522e-05
identified O 0 3.073680545639945e-06
several O 0 9.205968609649062e-08
differentially O 0 2.3369900645775488e-06
expressed O 0 2.1106419012539845e-07
genes O 0 2.2719069647791912e-07
, O 0 9.970518988211552e-08
including O 0 8.255027239556512e-08
an O 0 6.484340246970532e-07
alpha O 0 1.0550660590524785e-05
carbonic O 0 5.534238516702317e-05
anhydrase O 0 4.9417645641369745e-05
gene O 0 5.30914530827431e-06
, O 0 8.467567340630922e-07
termed O 0 3.093749546678737e-05
CA12 O 0 0.0015247442061081529
. O 0 2.1640733393724076e-05

The O 0 7.397919489449123e-06
deduced O 0 1.039816106640501e-05
protein O 0 2.519806457712548e-06
sequence O 0 1.0510693755350076e-06
was O 0 2.9142161110939924e-06
classified O 0 8.451561370748095e-07
as O 0 1.6732147400944086e-07
a O 0 3.104478309978731e-07
one O 0 1.15551927137858e-06
- O 0 0.00017683260375633836
pass O 0 3.816170647041872e-06
transmembrane O 0 4.169956446276046e-05
CA O 0 2.0750747353304178e-05
possessing O 0 1.10946041331772e-06
an O 0 3.7408534581118147e-07
apparently O 0 4.471929059945978e-06
intact O 0 3.5808236589218723e-06
catalytic O 0 2.427437948426814e-06
domain O 0 8.03812213234778e-07
in O 0 2.191823256225689e-07
the O 0 3.94884608567736e-07
extracellular O 0 8.399337275477592e-06
CA O 0 9.691669401945546e-05
module O 0 0.0001291430089622736
. O 0 7.144277788029285e-06

Reintroduced O 0 0.00044174346840009093
wild O 0 0.00011007466673618183
- O 0 0.0005951378843747079
type O 0 3.223792737117037e-05
VHL B-Disease 0 0.00020569944172166288
strongly O 0 3.0007417990418617e-06
inhibited O 0 2.555723995101289e-06
the O 0 1.7613965042073687e-07
overexpression O 0 2.343873575227917e-06
of O 0 5.252561763313679e-08
the O 0 3.107947179614712e-07
CA12 O 0 0.0002297762403031811
gene O 0 2.3642785436095437e-06
in O 0 1.3524827124911099e-07
the O 0 1.0328111557100783e-06
parental O 0 0.00019030676048714668
renal B-Disease 1 0.9999256134033203
cell I-Disease 1 0.9999454021453857
carcinoma I-Disease 1 1.0
cell O 1 0.9904584884643555
lines O 0 0.002066993387416005
. O 0 3.674069375847466e-05

Similar O 0 7.352799730142578e-05
results O 0 0.00010587012366158888
were O 0 2.496661409168155e-06
obtained O 0 3.0865435292071197e-06
with O 0 2.500237542335526e-06
CA9 O 0 0.003362559247761965
, O 0 3.90205173061986e-07
encoding O 0 2.794722604448907e-07
another O 0 1.6125235333674937e-06
transmembrane O 0 3.3667740353848785e-05
CA O 0 1.2865330063505098e-05
with O 0 9.345217932832384e-08
an O 0 1.022733272293408e-06
intact O 0 1.8630858903634362e-05
catalytic O 0 2.6994362997356802e-05
domain O 0 1.6924159353948198e-05
. O 0 5.321422122506192e-06

Although O 0 1.4847016245767009e-05
both O 0 9.045900810633611e-07
domains O 0 1.102324745261285e-06
of O 0 1.1417311185368817e-07
the O 0 4.259995591837651e-07
VHL B-Disease 0 3.2976480724755675e-05
protein O 0 1.4831074395260657e-06
contribute O 0 1.1497731833287617e-07
to O 0 7.301296989226103e-08
regulation O 0 1.6924136048146465e-07
of O 0 8.874461343566509e-08
CA12 O 0 4.864532093051821e-05
expression O 0 5.119439947520732e-07
, O 0 5.1535820944081934e-08
the O 0 4.3261234594638154e-08
elongin O 0 5.1614997573778965e-06
binding O 0 7.602905611747701e-07
domain O 0 1.0652515811671037e-06
alone O 0 1.444830104446737e-06
could O 0 6.84697965880332e-07
effectively O 0 3.4661716199479997e-06
regulate O 0 2.1180723706493154e-05
CA9 O 0 0.0014748070389032364
expression O 0 1.9805960619123653e-05
. O 0 9.718981345940847e-06

We O 0 7.876363815739751e-05
mapped O 0 0.00027690743445418775
CA12 O 0 0.002271178876981139
and O 0 2.5971441573346965e-05
CA9 O 0 0.0017064915737137198
loci O 0 1.4759545592823997e-05
to O 0 1.8662813090486452e-06
chromosome O 0 7.178061787271872e-05
bands O 0 1.4738980098627508e-05
15q22 O 0 4.2061485146405175e-05
and O 0 7.391643066512188e-06
17q21 O 0 8.96108613233082e-05
. O 0 1.3157739886082709e-05

2 O 0 0.00016288869665004313
respectively O 0 3.6698009353131056e-05
, O 0 1.1541382036739378e-06
regions O 0 2.2054343844502e-06
prone O 0 3.2739648304414004e-05
to O 0 1.4594459116779035e-06
amplification O 0 4.024903319077566e-05
in O 0 6.597222181881079e-07
some O 0 5.824589379699319e-07
human O 0 3.4829638025257736e-05
cancers B-Disease 0 0.1938430666923523
. O 0 1.7543234207550995e-05

Additional O 0 1.1927012565138284e-05
experiments O 0 2.102840880979784e-05
are O 0 3.274851394508005e-07
needed O 0 3.3147406952593883e-07
to O 0 8.66164526769353e-08
define O 0 6.672092354165216e-07
the O 0 2.7980482286693587e-07
role O 0 1.5719268731118063e-06
of O 0 8.692186383996159e-07
CA O 0 0.00011356895265635103
IX O 0 9.856251563178375e-05
and O 0 3.0011598937562667e-05
CA O 0 2.9554612410720438e-05
XII O 0 9.854207746684551e-06
enzymes O 0 6.235393925635435e-07
in O 0 1.3746043237006234e-07
the O 0 1.172627008827476e-07
regulation O 0 3.6956603821636236e-07
of O 0 1.172302717122875e-07
pH O 0 7.530352377216332e-06
in O 0 1.913867606617714e-07
the O 0 8.625671910067467e-08
extracellular O 0 5.452348545986752e-07
microenvironment O 0 3.1197535008686827e-06
and O 0 2.43699361135441e-07
its O 0 1.1541382036739378e-06
potential O 0 1.4868377320453874e-06
impact O 0 1.437723881281272e-06
on O 0 0.0001253598602488637
cancer B-Disease 0 0.0023984278086572886
cell O 0 0.0003055515990126878
growth O 0 4.585481292451732e-05
. O 0 7.620911219419213e-06

A O 0 2.472903906891588e-05
gene O 0 1.3494757695298176e-05
encoding O 0 3.1808781386644114e-06
a O 0 9.181363793686614e-07
transmembrane O 0 1.0544817087065894e-05
protein O 0 4.12780582337291e-06
is O 0 2.8244318173165084e-07
mutated O 0 5.9276130741636734e-06
in O 0 5.549266916204942e-06
patients O 0 0.0002348926936974749
with O 0 0.2249169796705246
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9990915060043335
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999889135360718
( O 0 0.22917312383651733
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 3.4614808100741357e-05
. O 0 1.6154994227690622e-05

Wolfram B-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
( O 0 0.06708286702632904
WFS B-Disease 1 0.9895614981651306
; O 0 0.0005696360603906214
OMIM O 0 0.1857667714357376
222300 O 0 0.00033878590329550207
) O 0 2.8285228381719207e-06
is O 0 5.879325613022957e-07
an O 0 2.7539523216546513e-05
autosomal B-Disease 1 0.9999254941940308
recessive I-Disease 1 0.9999988079071045
neurodegenerative I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9990326166152954
defined O 0 2.0111712728976272e-05
by O 0 2.3682796381763183e-06
young O 0 8.076880476437509e-06
- O 0 0.02542918734252453
onset O 0 0.00036382098915055394
non O 0 1.8656852262211032e-05
- O 0 0.09522494673728943
immune O 0 0.00014807633124291897
insulin B-Disease 1 0.5173285603523254
- I-Disease 1 0.9981704950332642
dependent I-Disease 1 0.998931348323822
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.04581134766340256
progressive O 1 0.9845151901245117
optic B-Disease 1 0.9999947547912598
atrophy I-Disease 1 0.9154623746871948
. O 0 2.8091142667108215e-05

Linkage O 0 0.0005725781666114926
to O 0 1.0135837328562047e-05
markers O 0 0.00017000040679704398
on O 0 0.0002573781821411103
chromosome O 0 0.0391584075987339
4p O 1 0.8522801399230957
was O 0 0.0005119347479194403
confirmed O 0 1.4935490980860777e-05
in O 0 3.6566652283909207e-07
five O 0 1.042531948769465e-06
families O 0 2.671385800567805e-06
. O 0 5.874926500837319e-06

On O 0 1.5264757166733034e-05
the O 0 6.674637802461802e-07
basis O 0 4.6423551225416304e-07
of O 0 2.3143755356613838e-07
meiotic O 0 0.0001564924605190754
recombinants O 0 0.05553704872727394
and O 0 0.0016068745171651244
disease O 0 0.005233481526374817
- O 0 0.0016574850305914879
associated O 0 2.1355110220611095e-05
haplotypes O 0 7.191915210569277e-05
, O 0 1.1327610991429538e-06
the O 0 7.246508744174207e-07
WFS B-Disease 0 0.0010701901046559215
gene O 0 1.4271138752519619e-05
was O 0 4.2320170905441046e-06
localized O 0 2.5106025987042813e-06
to O 0 6.234608918020967e-07
a O 0 6.683710580546176e-06
BAC O 0 0.0011102104326710105
/ O 0 5.739765765611082e-05
P1 O 0 0.0006047033239156008
contig O 0 5.3670883062295616e-05
of O 0 1.0303001118927568e-07
less O 0 1.7102188110129646e-07
than O 0 2.4072309656730795e-07
250 O 0 1.7374071603626362e-06
kb O 0 0.00035226039472036064
. O 0 1.1272531992290169e-05

Mutations O 0 0.001848667161539197
in O 0 7.0173159656405915e-06
a O 0 5.5350396905851085e-06
novel O 0 2.242144910269417e-05
gene O 0 1.74963497556746e-05
( O 0 6.808322154938651e-07
WFS1 O 0 4.648219692171551e-05
) O 0 1.2716030539650092e-07
encoding O 0 1.2135005533764343e-07
a O 0 2.6485426474209817e-07
putative O 0 7.038737294351449e-06
transmembrane O 0 5.800769031338859e-06
protein O 0 2.565486738603795e-06
were O 0 4.734170033771079e-07
found O 0 2.452434841870854e-07
in O 0 1.2375102187434095e-07
all O 0 4.985970747384272e-08
affected O 0 1.0304770370339611e-07
individuals O 0 1.1723895632087533e-08
in O 0 1.6319346229920484e-07
six O 0 3.4666675219341414e-06
WFS B-Disease 0 0.0009890979854390025
families O 0 4.4490681716524705e-07
, O 0 1.6708054317859933e-07
and O 0 1.9543195151072723e-07
these O 0 5.112316259214822e-08
mutations O 0 1.5871105460973922e-06
were O 0 2.6324966029278585e-07
associated O 0 3.4793521308529307e-07
with O 0 5.852127742400626e-07
the O 0 0.00014166912296786904
disease O 0 0.07398949563503265
phenotype O 0 0.0014166246401146054
. O 0 2.5018189262482338e-05

WFS1 O 0 0.013298303820192814
appears O 0 5.2689490985358134e-05
to O 0 6.689116389679839e-07
function O 0 2.7852505013470363e-07
in O 0 7.376435746664356e-07
survival O 0 4.506014738581143e-05
of O 0 6.101125791246886e-07
islet O 0 0.0002107007458107546
beta O 0 1.9009692550753243e-05
- O 0 7.963275129441172e-05
cells O 0 6.5785334300016984e-06
and O 0 1.3139706425135955e-06
neurons O 0 1.046972374751931e-05
. O 0 5.337669790606014e-07
. O 0 3.063476015086053e-06

Stable O 0 0.000436784845078364
interaction O 0 4.62519619759405e-06
between O 0 5.574917736339557e-07
the O 0 2.7871530505763076e-07
products O 0 1.0392421927463147e-06
of O 0 7.840562687988495e-08
the O 0 7.728300488452078e-07
BRCA1 O 0 0.0005868121515959501
and O 0 2.8017835575155914e-05
BRCA2 O 0 0.009679394774138927
tumor B-Disease 0 0.0002141446602763608
suppressor O 0 5.96071440668311e-05
genes O 0 3.2035463846114e-06
in O 0 3.6678520132227277e-07
mitotic O 0 7.438203465426341e-05
and O 0 2.676647090993356e-05
meiotic O 0 0.0022190678864717484
cells O 0 0.00044516706839203835
. O 0 1.937626257131342e-05

BRCA1 O 1 0.6198971271514893
and O 0 0.0004292088560760021
BRCA2 O 0 0.0034392853267490864
account O 0 9.526066605758388e-06
for O 0 5.550911623686261e-07
most O 0 1.4659963198937476e-07
cases O 0 1.5631306382601906e-07
of O 0 1.1019068324458203e-07
familial O 0 6.564486102433875e-05
, O 0 7.192329576355405e-06
early O 0 0.00013364972255658358
onset O 0 0.011953542940318584
breast B-Disease 0 0.4603237211704254
and I-Disease 0 0.00014345382805913687
/ I-Disease 1 0.8863336443901062
or I-Disease 1 0.8837863802909851
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
and O 0 7.356385935963772e-07
encode O 0 4.649679112844751e-07
products O 0 2.131894234480569e-06
that O 0 3.089359168484407e-08
each O 0 2.8564002718667325e-08
interact O 0 1.520635919405322e-07
with O 0 3.1580165682498773e-07
hRAD51 O 0 0.00016529223648831248
. O 0 1.0914801350736525e-05

Results O 0 0.00042561610462144017
presented O 0 1.703280213405378e-05
here O 0 1.213503310282249e-06
show O 0 6.021515673637623e-06
that O 0 6.544215693793376e-07
BRCA1 O 0 0.00011281728075118735
and O 0 1.40597257995978e-05
BRCA2 O 0 0.0006782191921956837
coexist O 0 1.587058613949921e-05
in O 0 3.180242913458642e-07
a O 0 1.914191898322315e-06
biochemical O 0 1.2157703167758882e-05
complex O 0 3.6706514947582036e-06
and O 0 5.0047351578541566e-06
colocalize O 0 0.0001273052184842527
in O 0 7.132284167710168e-07
subnuclear O 0 1.9696750314324163e-05
foci O 0 1.0349703188694548e-05
in O 0 2.868083868179383e-07
somatic O 0 3.4362799397058552e-06
cells O 0 7.551948783657281e-06
and O 0 4.793155312654562e-07
on O 0 1.6055923879321199e-06
the O 0 1.1157211332601946e-07
axial O 0 6.842312814114848e-07
elements O 0 3.7531106045207707e-07
of O 0 1.6687479842403263e-07
developing O 0 4.243996500008507e-06
synaptonemal O 0 0.00023185613099485636
complexes O 0 2.7830630642711185e-05
. O 0 1.1918700693058781e-05

Like O 0 0.00011858199286507443
BRCA1 O 0 0.004586223047226667
and O 0 3.142137938993983e-05
RAD51 O 0 0.006373473443090916
, O 0 2.070123446173966e-05
BRCA2 O 0 0.00033237444586120546
relocates O 0 3.9426489820471033e-05
to O 0 2.2217611785890767e-06
PCNA O 0 0.00012040552974212915
+ O 0 6.6682523538474925e-06
replication O 0 2.184922550441115e-06
sites O 0 3.1178032600109873e-07
following O 0 5.708570824936032e-07
exposure O 0 3.635919256339548e-06
of O 0 1.583299393814741e-07
S O 0 0.002590870950371027
phase O 0 9.568140740157105e-06
cells O 0 4.499127044255147e-06
to O 0 1.4831230146228336e-06
hydroxyurea O 0 0.0001051237850333564
or O 0 8.162810445355717e-06
UV O 0 0.0006692499737255275
irradiation O 0 2.842725189111661e-05
. O 0 8.269403224403504e-06

Thus O 0 6.488013605121523e-05
, O 0 1.5744648408144712e-05
BRCA1 O 0 0.0003876638365909457
and O 0 1.765501292538829e-05
BRCA2 O 0 0.00046464308979921043
participate O 0 7.596774480589374e-07
, O 0 3.3643115671111445e-07
together O 0 2.4413435539827333e-07
, O 0 4.218185836180055e-07
in O 0 1.653673962209723e-07
a O 0 2.0470638446568046e-06
pathway O 0 1.1348782209097408e-05
( O 0 4.683869065047475e-06
s O 0 0.042986225336790085
) O 0 9.150131745627732e-07
associated O 0 2.2789923548316438e-07
with O 0 3.797296344032475e-08
the O 0 1.3353128736071085e-07
activation O 0 3.6318263596513134e-07
of O 0 9.682651125331176e-08
double O 0 3.2789583201520145e-05
- O 0 0.0024124516639858484
strand O 0 0.06549672782421112
break O 0 9.49278473854065e-05
repair O 0 0.006495133973658085
and O 0 1.4044529052625876e-05
/ O 0 3.300913522252813e-05
or O 0 3.1934877142703044e-07
homologous O 0 3.887950242642546e-06
recombination O 0 2.2115540559752844e-05
. O 0 1.1240382264077198e-05

Dysfunction O 0 0.07936874777078629
of O 0 2.0375550775497686e-06
this O 0 3.47360639807448e-07
pathway O 0 2.9683114917133935e-06
may O 0 2.1882129658479244e-05
be O 0 1.503074571473917e-07
a O 0 6.261315093070152e-07
general O 0 3.30811815274501e-07
phenomenon O 0 4.984573251931579e-07
in O 0 1.3124861197866267e-07
the O 0 1.3741940563249955e-07
majority O 0 2.3408752269915567e-07
of O 0 6.759992743354815e-08
cases O 0 2.9355666697483684e-07
of O 0 1.2471631407606765e-06
hereditary B-Disease 1 0.9990333318710327
breast I-Disease 1 0.9977067708969116
and I-Disease 0 0.018452424556016922
/ I-Disease 1 0.9869788885116577
or I-Disease 1 0.9561139345169067
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 5.160382443136768e-06
. O 0 6.0819938880740665e-06

A O 0 7.222065323730931e-05
novel O 0 2.511414095351938e-05
Arg362Ser O 0 0.0002115653915097937
mutation O 0 1.9004619389306754e-05
in O 0 3.684272940063238e-07
the O 0 5.918547572036914e-07
sterol O 0 0.00031998875783756375
27 O 0 0.00021348617156036198
- O 0 0.011539706960320473
hydroxylase O 0 0.0009134754072874784
gene O 0 1.6617728761048056e-05
( O 0 5.339049948815955e-07
CYP27 O 0 6.097959339967929e-05
) O 0 2.5146161419797863e-07
: O 0 3.3216007722103313e-08
its O 0 2.6754116788652027e-07
effects O 0 5.566826075664721e-07
on O 0 2.468781985953683e-06
pre O 0 7.590983386762673e-06
- O 0 3.094820158366929e-06
mRNA O 0 4.5781251856169547e-07
splicing O 0 2.6657310172595317e-06
and O 0 3.8820343206680263e-07
enzyme O 0 4.057103978993837e-06
activity O 0 2.8202618977957172e-06
. O 0 3.8419116208388004e-06

A O 0 0.00014363080845214427
novel O 0 1.74638771568425e-05
C O 0 4.198038368485868e-05
to O 0 2.837423380697146e-07
A O 0 2.6015518415078986e-06
mutation O 0 2.5100471248151734e-06
in O 0 2.4573373025305045e-07
the O 0 2.5032960593307507e-07
sterol O 0 9.090453386306763e-05
27 O 0 9.836599929258227e-05
- O 0 0.003655001986771822
hydroxylase O 0 0.0007062840741127729
gene O 0 1.3427616067929193e-05
( O 0 3.703171671531891e-07
CYP27 O 0 0.00016064381634350866
) O 0 7.945823199406732e-07
was O 0 3.770006514969282e-06
identified O 0 8.98352936928859e-07
by O 0 6.414641262608711e-08
sequencing O 0 1.5489177940253285e-06
amplified O 0 6.333910732791992e-06
CYP27 O 0 6.92079629516229e-05
gene O 0 2.2726403585693333e-06
products O 0 1.8155711813960806e-06
from O 0 9.638612397111501e-08
a O 0 2.7760695502365706e-06
patient O 0 2.9430242648231797e-05
with O 0 2.8227454095031135e-05
cerebrotendinous B-Disease 1 0.9999997615814209
xanthomatosis I-Disease 1 0.9999994039535522
( O 0 4.0135848394129425e-05
CTX B-Disease 0 0.016172707080841064
) O 0 3.2621292120893486e-06
. O 0 4.342697138781659e-06

The O 0 1.8625298253027722e-05
mutation O 0 3.535982614266686e-05
changed O 0 3.5595674034993863e-06
the O 0 4.139772613598325e-07
adrenodoxin O 0 1.48525523400167e-05
cofactor O 0 3.324774752400117e-06
binding O 0 2.0808120098081417e-06
residue O 0 5.244115982350195e-06
362Arg O 0 1.1413926586101297e-05
to O 0 8.918339062802261e-07
362Ser O 0 2.4908418708946556e-05
( O 0 9.705428283268702e-07
CGT O 0 5.9168694861000404e-05
362Arg O 0 1.2841806892538443e-05
to O 0 8.613388331468741e-07
AGT O 0 0.00025453881244175136
362Ser O 0 2.5544799427734688e-05
) O 0 3.460747279859788e-07
, O 0 1.5689882104652497e-07
and O 0 4.4486523620435037e-07
was O 0 4.082198938704096e-05
responsible O 0 1.3923810911364853e-05
for O 0 4.5903641876066104e-05
deficiency O 0 0.00064257369376719
in O 0 3.406372286463011e-07
the O 0 4.981246775059844e-07
sterol O 0 0.00011517496750457212
27 O 0 6.019516513333656e-05
- O 0 8.495787187712267e-05
hydroxylase O 0 5.147916454006918e-05
activity O 0 5.098017368254659e-07
, O 0 9.373119524980211e-08
as O 0 9.105018250465946e-08
confirmed O 0 8.613552608949249e-07
by O 0 1.6081033393788857e-08
expression O 0 6.71461819479191e-08
of O 0 2.232681239888734e-08
mutant O 0 7.405687938444316e-07
cDNA O 0 9.528696978122753e-07
into O 0 8.26689756650012e-07
COS O 0 0.0018857598770409822
- O 0 6.321255932562053e-05
1 O 0 9.885654435493052e-06
cells O 0 1.557645373395644e-05
. O 0 4.580689619615441e-06

Quantitative O 0 0.0004728332569357008
analysis O 0 0.0001104456969187595
showed O 0 2.8241263862582855e-05
that O 0 2.243439354288057e-07
the O 0 6.951256636966718e-08
expression O 0 1.2810569671728445e-07
of O 0 5.9020219822514264e-08
CYP27 O 0 2.6632747903931886e-05
gene O 0 6.561963914464286e-07
mRNA O 0 2.962806320283562e-07
in O 0 1.2031112817112444e-07
the O 0 4.825955102205626e-07
patient O 0 9.512058568361681e-06
represented O 0 1.5445632470800774e-06
52 O 0 2.77742601610953e-05
. O 0 9.731167665449902e-06

5 O 0 2.7799856979981996e-05
% O 0 1.6173672747754608e-06
of O 0 1.2125310888677632e-07
the O 0 2.1212238721091126e-07
normal O 0 1.9650710783025716e-06
level O 0 3.693261305670603e-06
. O 0 1.007719856715994e-05

As O 0 8.838647772790864e-06
the O 0 1.6232855841735727e-06
mutation O 0 7.313844889722532e-06
occurred O 0 2.19315847971302e-06
at O 0 4.93135246415477e-07
the O 0 1.0577306142067755e-07
penultimate O 0 4.698310476669576e-06
nucleotide O 0 1.1268598427705001e-06
of O 0 9.743787643401447e-08
exon O 0 1.1079189789597876e-05
6 O 0 9.805769877857529e-06
( O 0 1.327200180867294e-07
- O 0 2.6158743366977433e-06
2 O 0 1.7819226059145876e-06
position O 0 7.561336019534792e-07
of O 0 6.450552803016762e-08
exon O 0 7.881516467023175e-06
6 O 0 5.937752121099038e-06
- O 0 2.3090206013876013e-05
intron O 0 4.158971569268033e-05
6 O 0 1.9592214357544435e-06
splice O 0 1.1417007954150904e-05
site O 0 2.0088182282052003e-06
) O 0 2.822788225387285e-08
of O 0 8.755037583796366e-09
the O 0 1.0589520371695471e-07
gene O 0 1.042117446559132e-06
, O 0 2.4097138862089196e-07
we O 0 8.079518210024617e-08
hypothesized O 0 6.061155772840721e-07
that O 0 7.09157674805283e-08
the O 0 3.7164036825743096e-07
mutation O 0 1.566591345181223e-05
may O 0 8.020058885449544e-06
partially O 0 1.6240388504229486e-05
affect O 0 2.352815613448911e-07
the O 0 5.015596471480421e-08
normal O 0 9.889550511843481e-08
splicing O 0 9.612410849513253e-07
efficiency O 0 8.788156833361427e-07
in O 0 1.473114394912045e-07
exon O 0 5.276890533423284e-06
6 O 0 4.1668990888865665e-06
and O 0 5.054616281086055e-07
cause O 0 2.3476469834804448e-07
alternative O 0 1.6958581738890643e-07
splicing O 0 7.428460776282009e-06
elsewhere O 0 2.4711584956094157e-06
, O 0 3.2089906198962126e-07
which O 0 3.0779321491536393e-07
resulted O 0 7.297328465938335e-07
in O 0 5.219998229222256e-07
decreased O 0 9.255119039153215e-06
transcript O 0 4.8688671085983515e-05
in O 0 7.041617777758802e-07
the O 0 3.0244671052059857e-06
patient O 0 6.743740232195705e-05
. O 0 7.509805072913878e-06

Transfection O 0 0.005076601170003414
of O 0 1.1360867574694566e-05
constructed O 0 5.24971037521027e-05
minigenes O 0 0.0008752829162403941
, O 0 9.986264331018901e-07
with O 0 1.0124228566610327e-07
or O 0 1.739232686759351e-07
without O 0 4.424720501106094e-08
the O 0 1.1641197517064938e-07
mutation O 0 8.593352163188683e-07
, O 0 1.2570569651870755e-07
into O 0 2.9278444912961277e-07
COS O 0 0.0026556963566690683
- O 0 3.151191776851192e-05
1 O 0 7.701027243456338e-06
cells O 0 2.2088906916906126e-06
confirmed O 0 1.4057147836865624e-06
that O 0 5.421291504603687e-08
the O 0 8.587881694666066e-08
mutant O 0 3.2542552617087495e-06
minigene O 0 6.989163375692442e-05
was O 0 2.7919044441659935e-05
responsible O 0 6.737260491718189e-07
for O 0 5.6680217852544956e-08
a O 0 3.043181493467273e-07
mRNA O 0 1.0374598105045152e-06
species O 0 2.0136639022894087e-07
alternatively O 0 8.48480965487397e-07
spliced O 0 5.841803067596629e-05
at O 0 2.1865027974854456e-06
an O 0 7.576899179184693e-07
activated O 0 7.868989996495657e-06
cryptic O 0 9.119057722273283e-06
5 O 0 1.4299951089924434e-06
splice O 0 4.6114066208247095e-05
site O 0 1.0165459570998792e-05
88 O 0 4.293548499845201e-06
bp O 0 4.774726039613597e-05
upstream O 0 7.111636364243168e-07
from O 0 5.1544965629091166e-08
the O 0 2.8250882522229404e-08
3 O 0 1.174643330159597e-06
end O 0 6.933082659088541e-07
of O 0 1.330030841018015e-07
exon O 0 3.758501406991854e-05
6 O 0 1.7189064237754792e-05
. O 0 4.796448138222331e-06

Our O 0 1.852999957918655e-05
data O 0 6.341175321722403e-06
suggest O 0 7.383417823803029e-07
that O 0 7.11443206569129e-08
the O 0 1.359613577278651e-07
C O 0 1.0534363354963716e-05
to O 0 1.2328314369369764e-07
A O 0 3.6344429190648952e-06
mutation O 0 1.5836270677027642e-06
at O 0 2.3664729553729558e-07
the O 0 7.69445804849056e-08
penultimate O 0 3.659086360130459e-06
nucleotide O 0 7.315542802643904e-07
of O 0 3.9349778546693415e-08
exon O 0 2.15502791434119e-06
6 O 0 7.389517691080982e-07
of O 0 2.4739234660842158e-08
the O 0 1.8714021621235588e-07
CYP27 O 0 0.00010334978287573904
gene O 0 2.4307946659973823e-06
not O 0 1.455480145295951e-07
only O 0 8.812960317072793e-08
causes O 0 1.0072741361000226e-06
the O 0 4.709165750682587e-06
deficiency B-Disease 0 0.0002705297083593905
in I-Disease 0 2.1866226518341136e-07
the I-Disease 0 6.352036052703625e-07
sterol I-Disease 0 0.00016757441335357726
27 I-Disease 0 3.270195520599373e-05
- I-Disease 0 0.00016045338998083025
hydroxylase I-Disease 0 5.403921750257723e-05
activity I-Disease 0 6.615146048716269e-07
, O 0 2.6205958647551597e-07
but O 0 1.1023693957668002e-07
also O 0 8.697235216459376e-07
partially O 0 5.3589055823977105e-06
leads O 0 1.2612360933417222e-06
to O 0 1.1420555523500298e-07
alternative O 0 3.437865814248653e-07
pre O 0 1.4920334479029407e-06
- O 0 1.0286345286658616e-06
mRNA O 0 2.2532876187142392e-07
splicing O 0 1.0591211321298033e-06
of O 0 5.45067528889831e-08
the O 0 3.6189717889101303e-07
gene O 0 1.0882779861276504e-05
. O 0 5.0024686970573384e-06

To O 0 1.529321525595151e-05
our O 0 1.6813788761282922e-06
knowledge O 0 7.457402944055502e-07
, O 0 2.061986918988623e-07
this O 0 2.8655076533823376e-08
is O 0 4.214365745269788e-08
the O 0 9.401767897543323e-08
first O 0 4.5308179323910736e-06
report O 0 6.714773007843178e-06
regarding O 0 2.273580150813359e-07
effects O 0 1.0333599220757606e-06
on O 0 2.9503451060008956e-06
pre O 0 9.335397407994606e-06
- O 0 2.6728434932010714e-06
mRNA O 0 1.6422906412572047e-07
splicing O 0 3.7969562072248664e-07
of O 0 1.851381625783688e-08
a O 0 2.2631360252489685e-07
mutation O 0 5.009019332646858e-07
at O 0 3.716931473718432e-07
the O 0 1.646374130359618e-07
- O 0 5.7954548537964e-05
2 O 0 7.896112037997227e-06
position O 0 9.254361543753475e-07
of O 0 3.4371471002714316e-08
a O 0 7.507088639613357e-07
5 O 0 2.9073871701257303e-06
splice O 0 0.00047660490963608027
site O 0 7.154341437853873e-05
. O 0 8.911503755371086e-06

ATM O 0 0.007261508610099554
germline O 0 0.03475639969110489
mutations O 0 0.0016170010203495622
in O 0 2.3650345610803925e-05
classical O 0 0.023995066061615944
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9176833033561707
in O 0 1.979963371923077e-06
the O 0 7.988060133357067e-07
Dutch O 0 0.00018672946316655725
population O 0 3.267440888521378e-06
. O 0 5.556951691687573e-06

Germline O 0 0.10634048283100128
mutations O 0 0.0011888336157426238
in O 0 2.1831210688105784e-06
the O 0 3.5404150366957765e-07
ATM O 0 9.837988181971014e-05
gene O 0 4.114992407266982e-06
are O 0 9.090371833053723e-08
responsible O 0 1.166610900327214e-06
for O 0 7.3115224950015545e-06
the O 1 0.7680025696754456
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.03793080896139145
A B-Disease 1 0.999993085861206
- I-Disease 1 0.9999971389770508
T I-Disease 1 0.9999998807907104
) O 0 2.7462812795420177e-05
. O 0 1.0567004210315645e-05

In O 0 2.1158035451662727e-05
our O 0 2.6691448056226363e-06
study O 0 9.458386216465442e-07
, O 0 2.5143762627521937e-07
we O 0 5.7554466081910505e-08
have O 0 3.0871561307321826e-08
determined O 0 1.8714057148372376e-07
the O 0 9.338785389445547e-08
ATM O 0 7.566085696453229e-05
mutation O 0 2.2637498204858275e-06
spectrum O 0 6.417076292564161e-07
in O 0 2.5434400185986306e-07
19 O 0 2.0964037048543105e-06
classical O 0 8.79655999597162e-06
A B-Disease 1 0.9999908208847046
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 0.00014584783639293164
, O 0 7.755663489206199e-08
including O 0 1.3870598003506984e-08
some O 0 1.2884483702180205e-08
immigrant O 0 1.9745270947169047e-06
populations O 0 5.276309025248338e-07
, O 0 1.6266223212824116e-07
as O 0 1.3185884029098816e-07
well O 0 1.2887561240404466e-07
as O 0 8.565470466237457e-08
12 O 0 1.3486663874573424e-07
of O 0 7.154507386530895e-08
Dutch O 0 1.2840361705457326e-05
ethnic O 0 2.6423315375723178e-06
origin O 0 7.449936219927622e-06
. O 0 8.220698873628862e-06

Both O 0 7.281010766746476e-06
the O 0 6.962316092540277e-07
protein O 0 3.0307296583487187e-06
truncation O 0 4.005612572655082e-05
test O 0 1.212486586155137e-05
( O 0 6.259207339098793e-07
PTT O 0 8.092062489595264e-05
) O 0 1.7310912880930118e-07
and O 0 1.383748156058573e-07
the O 0 1.3399242959621915e-07
restriction O 0 6.746196845597296e-07
endonuclease O 0 1.8971190002048388e-05
fingerprinting O 0 6.328801100607961e-05
( O 0 5.662952844431857e-07
REF O 0 6.749910971848294e-05
) O 0 8.491749525774139e-08
method O 0 1.2067526711234677e-07
were O 0 1.0879751499714985e-07
used O 0 3.153965622004762e-07
and O 0 4.0647384480507753e-07
compared O 0 4.2219934925924463e-07
for O 0 2.2005586686191236e-08
their O 0 5.815552839294469e-08
detection O 0 1.0574357247605803e-06
efficiency O 0 1.1550037015695125e-06
, O 0 1.7326867407518876e-07
identifying O 0 3.8625287857030344e-07
76 O 0 8.098415378299251e-07
% O 0 5.8931803437189956e-08
and O 0 7.000807045187685e-08
60 O 0 1.2120015924210747e-07
% O 0 4.428342492701631e-08
of O 0 1.6405680369757647e-08
the O 0 1.1495553735585418e-06
mutations O 0 3.060017843381502e-05
, O 0 1.0507266097192769e-06
respectively O 0 1.0415558790555224e-05
. O 0 6.17156365478877e-06

Most O 0 9.200836211675778e-05
patients O 0 0.0001717794220894575
were O 0 1.1391332463972503e-06
found O 0 6.579547857654688e-07
to O 0 2.189072176861373e-07
be O 0 3.7790380247315625e-07
compound O 0 1.773624899215065e-05
heterozygote O 0 0.0001947676355484873
. O 0 1.208981302625034e-05

Seventeen O 0 0.00031133153242990375
mutations O 0 0.0003366978489793837
were O 0 4.903242825093912e-06
distinct O 0 5.944784220446309e-07
, O 0 2.8796580409107264e-07
of O 0 1.0027140717738803e-07
which O 0 8.199967282962461e-07
10 O 0 8.502581181346613e-07
were O 0 8.407980089941702e-07
not O 0 6.604102509299992e-07
reported O 0 2.1301128072082065e-05
previously O 0 1.4416820704354905e-05
. O 0 5.954991593171144e-06

Mutations O 0 0.002410168992355466
are O 0 1.6246888208115706e-06
small O 0 1.0896671938098734e-06
deletions O 0 1.930354119394906e-05
or O 0 1.9020562831428833e-06
point O 0 1.7940285033546388e-05
mutations O 0 9.181187488138676e-05
frequently O 0 4.336758138379082e-06
affecting O 0 3.4096881336154183e-06
splice O 0 0.0013226948212832212
sites O 0 4.349413575255312e-05
. O 0 1.6193294868571684e-05

Moreover O 0 0.00020057705114595592
, O 0 7.213217486423673e-06
a O 0 4.592438017425593e-06
16 O 0 1.2416397112247068e-05
. O 0 1.120716751756845e-05

7 O 0 0.0005973544321022928
- O 0 0.0005785252433270216
kb O 0 0.0007881441852077842
genomic O 0 1.7474072592449374e-05
deletion O 0 8.031064680835698e-06
of O 0 1.893806711450452e-07
the O 0 3.388331890619156e-07
3 O 0 3.232554036003421e-06
end O 0 4.5409646531879844e-07
of O 0 3.7618498538449785e-08
the O 0 1.3649713537233765e-07
gene O 0 7.673176583011809e-07
, O 0 1.1162340740611398e-07
most O 0 4.241234918822556e-08
likely O 0 1.6073802555638395e-07
a O 0 4.50752622782602e-07
result O 0 2.658860296378407e-07
of O 0 2.013899624841997e-08
recombination O 0 5.732471777264436e-07
between O 0 2.2014596368080674e-07
two O 0 7.865536417739349e-07
LINE O 0 0.00016737273836042732
elements O 0 3.3182811876031337e-06
, O 0 2.9574837299151113e-06
was O 0 1.7758049580152147e-05
identified O 0 2.4399951144005172e-05
. O 0 3.3178444027726073e-06

The O 0 1.0482332072569989e-05
most O 0 1.0308303899364546e-06
frequently O 0 2.103886345139472e-06
found O 0 2.282357854710426e-06
mutation O 0 3.4028792015305953e-06
, O 0 8.996449878395651e-07
identified O 0 2.8883900995424483e-06
in O 0 1.2815617367323284e-07
three O 0 4.448278900781588e-07
unrelated O 0 3.934440883313073e-06
Turkish O 0 1.740541665640194e-05
A B-Disease 1 0.9999868869781494
- I-Disease 1 0.9999858140945435
T I-Disease 1 1.0
individuals O 0 6.087769861551351e-07
, O 0 5.516261580851278e-07
was O 0 1.126837196352426e-05
previously O 0 4.136175448365975e-06
described O 0 3.856006514979526e-06
to O 0 2.0730976757477038e-07
be O 0 7.522396572312573e-08
a O 0 4.900003887087223e-07
Turkish O 0 6.323451088974252e-06
A B-Disease 1 0.9997745156288147
- I-Disease 1 0.9999785423278809
T I-Disease 1 0.9999996423721313
founder O 0 0.019524864852428436
mutation O 0 8.971670467872173e-05
. O 0 5.089417300041532e-06

The O 0 6.520370334328618e-06
presence O 0 1.5712195136075024e-06
of O 0 2.3647244518087973e-07
a O 0 1.5706472140664118e-06
founder O 0 8.4077546489425e-05
mutation O 0 3.7496047298191115e-06
among O 0 9.560466907032605e-08
relatively O 0 1.0448495402215485e-07
small O 0 9.153738744771545e-08
ethnic O 0 3.0884788770890736e-07
population O 0 1.3086278727314493e-07
groups O 0 2.8566454091105697e-08
in O 0 4.580238766038747e-08
Western O 0 6.0783366961914e-07
Europe O 0 9.533073352940846e-06
could O 0 1.497361836300115e-06
indicate O 0 4.6306683998409426e-07
a O 0 2.416403503957554e-07
high O 0 3.71736769011477e-06
carrier O 0 5.988022167002782e-06
frequency O 0 3.4264105579495663e-06
in O 0 2.0129401434587635e-07
such O 0 1.0106999326353616e-07
communities O 0 1.4159767260935041e-06
. O 0 6.4995601860573515e-06

In O 0 0.00011880064266733825
patients O 0 5.0477021432016045e-05
of O 0 2.566025045780407e-07
Dutch O 0 3.117496089544147e-05
ethnic O 0 1.3403541743173264e-06
origin O 0 1.6734124983486254e-06
, O 0 6.770443974346563e-07
however O 0 4.831057367482572e-07
, O 0 1.2622777489923465e-07
no O 0 9.384174148863167e-08
significant O 0 1.922298480394602e-07
founder O 0 4.068518683197908e-05
effect O 0 2.544333028708934e-06
could O 0 1.3814197927786154e-06
be O 0 6.690979148515908e-07
identified O 0 1.8558257579570636e-05
. O 0 5.856946245330619e-06

The O 0 1.9611205061664805e-05
observed O 0 6.197734182933345e-05
genetic O 0 6.682049570372328e-05
heterogeneity O 0 2.4520175429643132e-05
including O 0 7.628587468389014e-07
the O 0 3.3891529938046006e-07
relative O 0 1.4205945717549184e-06
high O 0 2.2503099899040535e-06
percentage O 0 3.146033577650087e-06
of O 0 1.0796711080729438e-07
splice O 0 0.0006657917401753366
- O 0 0.030910708010196686
site O 0 0.0002551226643845439
mutations O 0 4.566045754472725e-05
had O 0 4.473763056012103e-06
no O 0 2.3985137431736803e-07
reflection O 0 6.177731961543032e-07
on O 0 6.988158929743804e-06
the O 0 5.146444436832098e-06
phenotype O 0 0.0004003079666290432
. O 0 8.771245120442472e-06

All O 0 6.8149229264236055e-06
patients O 0 4.645401349989697e-05
manifested O 0 6.486978236353025e-06
classical O 0 1.910459832288325e-05
A B-Disease 1 0.9998577833175659
- I-Disease 1 0.9999042749404907
T I-Disease 1 0.9999994039535522
and O 0 5.196308393351501e-06
increased O 0 9.817547379498137e-07
cellular O 0 1.0307939191989135e-05
radioresistant O 0 3.391257268958725e-05
DNA O 0 3.980692781624384e-05
synthesis O 0 4.9361318815499544e-05
. O 0 7.245027063618181e-06

Determination O 0 8.189627988031134e-05
of O 0 7.591132771267439e-07
the O 0 5.472070370160509e-07
genomic O 0 2.371226628383738e-06
structure O 0 8.800695923127932e-07
of O 0 8.722039979147667e-08
the O 0 6.088895929678984e-07
COL4A4 O 0 0.00026396766770631075
gene O 0 3.884184934577206e-06
and O 0 2.1408659733879176e-07
of O 0 2.5094198008446256e-07
novel O 0 0.0004161965916864574
mutations O 0 0.08579555153846741
causing O 0 0.24793007969856262
autosomal B-Disease 1 0.9999910593032837
recessive I-Disease 1 0.9999990463256836
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 0.0005724543589167297

Autosomal B-Disease 1 0.9999959468841553
recessive I-Disease 1 0.9999992847442627
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00012251103180460632
a O 0 5.492702257470228e-05
progressive O 0 0.38904231786727905
hematuric B-Disease 1 0.9962406158447266
glomerulonephritis I-Disease 1 0.9999997615814209
characterized O 0 0.009265394881367683
by O 0 1.4784029190195724e-05
glomerular B-Disease 0 0.018829142674803734
basement I-Disease 0 0.47213056683540344
membrane I-Disease 0 0.03347017616033554
abnormalities I-Disease 1 0.9890368580818176
and O 0 1.0102514352183789e-05
associated O 0 2.8782487788703293e-06
with O 0 1.4561857142325607e-06
mutations O 0 2.002688961511012e-05
in O 0 5.172810801923333e-07
either O 0 3.2164726349037664e-07
the O 0 5.544297891901806e-07
COL4A3 O 0 0.0007047060644254088
or O 0 5.074317073194834e-07
the O 0 3.0822911867289804e-07
COL4A4 O 0 9.954113920684904e-05
gene O 0 1.5581121033392265e-06
, O 0 4.689562516091428e-08
which O 0 2.730388182214938e-08
encode O 0 2.2289503931460786e-07
the O 0 1.899390298376602e-07
alpha3 O 0 5.942926509305835e-05
and O 0 2.8109604954806855e-06
alpha4 O 0 0.0001744870824040845
type O 0 3.258823198848404e-05
IV O 0 0.1798841655254364
collagen O 0 0.00029194593662396073
chains O 0 7.30047031538561e-05
, O 0 2.1246787582640536e-06
respectively O 0 8.964727385318838e-06
. O 0 3.3735143460944528e-06

To O 0 7.3767491812759545e-06
date O 0 8.844398507790174e-06
, O 0 3.6656558677350404e-07
mutation O 0 4.431038007624011e-07
screening O 0 2.4294681111314276e-07
in O 0 5.5343782889849535e-08
the O 0 6.079414305304454e-08
two O 0 3.3598834647818876e-07
genes O 0 1.338865786237875e-06
has O 0 5.629972747556167e-06
been O 0 3.469942157607875e-06
hampered O 0 1.8289932995685376e-05
by O 0 1.6158196558535565e-07
the O 0 2.135382857204604e-07
lack O 0 2.9568727200057765e-07
of O 0 8.069753221207066e-08
genomic O 0 5.986514679534594e-06
structure O 0 1.0253133041260298e-05
information O 0 4.726036877400475e-06
. O 0 4.011802957393229e-06

We O 0 5.070531551609747e-05
report O 0 8.241398063546512e-06
here O 0 2.263189884388339e-07
the O 0 7.270585200558344e-08
complete O 0 6.06108642386971e-07
characterization O 0 4.500431259657489e-06
of O 0 6.646840944313226e-08
the O 0 2.037849355929211e-07
48 O 0 7.261022005877749e-07
exons O 0 1.077481670108682e-06
of O 0 2.764629059015533e-08
the O 0 3.114204787380004e-07
COL4A4 O 0 0.00011444975825725123
gene O 0 1.657311372582626e-06
, O 0 8.409578100554427e-08
a O 0 2.1795355564790952e-07
comprehensive O 0 2.0454206151043763e-06
gene O 0 2.6550746952125337e-06
screen O 0 5.78203480472439e-06
, O 0 5.410031462815823e-07
and O 0 2.3454829545244138e-07
the O 0 9.920703547550147e-08
subsequent O 0 2.5071042841773306e-07
detection O 0 7.869880960242881e-07
of O 0 5.536236002967598e-08
10 O 0 1.4630719533670344e-06
novel O 0 5.527580469788518e-06
mutations O 0 1.3496533938450739e-05
in O 0 5.959145141787303e-07
eight O 0 6.869196658954024e-05
patients O 0 0.010051660239696503
diagnosed O 1 0.6552603840827942
with O 0 0.00022291421191766858
autosomal B-Disease 1 0.9999972581863403
recessive I-Disease 1 0.9999991655349731
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 0.00031353719532489777

Furthermore O 0 0.00018366998119745404
, O 0 3.662165227069636e-06
we O 0 3.9101166748878313e-07
identified O 0 4.15084173255309e-07
a O 0 1.3121005792982032e-07
glycine O 0 6.807998488511657e-06
to O 0 2.6840339728551044e-07
alanine O 0 1.0451739171912777e-06
substitution O 0 1.6534704627702013e-07
in O 0 1.2404737503857177e-07
the O 0 2.4121257524711837e-07
collagenous O 0 7.057671609800309e-05
domain O 0 9.76738874669536e-07
that O 0 1.9386708061119862e-07
is O 0 2.115780972644643e-07
apparently O 0 1.604661633791693e-06
silent O 0 4.566164761854452e-07
in O 0 5.175499850906817e-08
the O 0 1.023817901568691e-07
heterozygous O 0 6.684830395897734e-07
carriers O 0 3.102533980836597e-07
, O 0 2.1967157692870387e-07
in O 0 3.2209663913818076e-07
11 O 0 5.623222023132257e-06
. O 0 7.718003871559631e-06

5 O 0 7.153175101848319e-05
% O 0 2.482105855960981e-06
of O 0 1.4140333348677814e-07
all O 0 7.919106081999416e-08
control O 0 3.1081895031093154e-06
individuals O 0 7.134257629104468e-08
, O 0 3.2252606274596474e-07
and O 0 4.2155079427175224e-07
in O 0 2.328993247147082e-07
one O 0 3.1105895459404564e-07
control O 0 9.664150866228738e-07
individual O 0 1.6941656610924838e-07
homozygous O 0 1.3503024547389941e-06
for O 0 1.4301613759926113e-07
this O 0 2.8587419365067035e-07
glycine O 0 3.425620889174752e-05
substitution O 0 7.844817446311936e-06
. O 0 7.071113031997811e-06

There O 0 2.6646515834727325e-05
has O 0 1.8549445712778834e-06
been O 0 3.7926784557384963e-07
no O 0 8.155305408763525e-08
previous O 0 3.2947025374596706e-07
finding O 0 1.0411493889250778e-07
of O 0 1.587544495862403e-08
a O 0 3.1451409654437157e-07
glycine O 0 7.541009381384356e-06
substitution O 0 3.2861800036698696e-07
that O 0 2.8325888479230343e-07
is O 0 1.9771678694269212e-07
not O 0 7.495371789900673e-08
associated O 0 1.4231571299205825e-07
with O 0 7.310104166435849e-08
any O 0 3.2249252512883686e-07
obvious O 0 4.417992840899387e-06
phenotype O 0 0.00012331598554737866
in O 0 4.845406692766119e-06
homozygous O 0 5.756287646363489e-05
individuals O 0 8.987428827822441e-07
. O 0 7.0085484367155004e-06

Founder O 0 0.005366545170545578
BRCA1 O 0 0.054424215108156204
and O 0 0.0002443583507556468
BRCA2 O 0 0.030727984383702278
mutations O 0 0.00023903071996755898
in O 0 4.998872555006528e-06
French O 0 0.00039429659955203533
Canadian O 0 0.04287358745932579
breast B-Disease 1 0.9999550580978394
and I-Disease 1 0.9995446801185608
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.7762708012014627e-05
. O 0 1.3948571904620621e-05

We O 0 2.0692805264843628e-05
have O 0 5.162712568562711e-07
identified O 0 7.326336231017194e-07
four O 0 3.5018788935303746e-07
mutations O 0 1.535546743980376e-06
in O 0 6.594134305260013e-08
each O 0 3.5357583527684255e-08
of O 0 1.3678969423835952e-07
the O 0 8.886778960004449e-05
breast B-Disease 1 0.9993833303451538
cancer I-Disease 1 0.5630354881286621
- O 0 0.028452914208173752
susceptibility O 0 0.00034727976890280843
genes O 0 3.137213298032293e-06
, O 0 1.4700398196509923e-06
BRCA1 O 0 0.00010004893556470051
and O 0 1.0782520803331863e-05
BRCA2 O 0 0.0003842153528239578
, O 0 5.380394441090175e-07
in O 0 2.112180084168358e-07
French O 0 3.858195123029873e-05
Canadian O 0 0.006886238697916269
breast B-Disease 1 0.9987189769744873
cancer I-Disease 1 0.832448422908783
and O 0 0.03985624387860298
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 3.184854676874238e-06
from O 0 1.829336383707414e-06
Quebec O 0 0.00014027357974555343
. O 0 1.2895067811768968e-05

To O 0 2.388550819887314e-05
identify O 0 2.9096479920553975e-05
founder O 0 0.00015403285215143114
effects O 0 4.1133909689961e-05
, O 0 2.041511379502481e-06
we O 0 4.0913943166742683e-07
examined O 0 3.173527375111007e-06
independently O 0 2.827411890393705e-06
ascertained O 0 2.793870044115465e-05
French O 0 4.373286719783209e-05
Canadian O 0 0.00032367956009693444
cancer B-Disease 0 0.0006956910947337747
families O 0 1.1337009198086889e-07
for O 0 5.992678353550218e-08
the O 0 7.884261776780477e-08
distribution O 0 3.1948647460922075e-07
of O 0 8.630065906345408e-08
these O 0 8.966593156856106e-08
eight O 0 5.3716667025582865e-06
mutations O 0 0.00012882407463621348
. O 0 8.663230801175814e-06

Mutations O 0 0.0034129295963793993
were O 0 2.1672045477316715e-05
found O 0 2.887726168410154e-06
in O 0 7.874850780353881e-07
41 O 0 4.219902621116489e-06
of O 0 3.544280104961217e-07
97 O 0 1.705048453004565e-05
families O 0 5.128096745465882e-06
. O 0 1.1548579095688183e-05

Six O 0 1.0375802958151326e-05
of O 0 6.067969025025377e-07
eight O 0 3.43022907145496e-06
mutations O 0 2.0731837139464915e-05
were O 0 7.367858643192449e-07
observed O 0 8.395712711717351e-07
at O 0 8.456850082438905e-07
least O 0 8.109777240861149e-07
twice O 0 9.527511792839505e-06
. O 0 8.430827620031778e-06

The O 0 3.978287350037135e-05
BRCA1 O 0 0.0011857450008392334
C4446T O 0 0.00013761893205810338
mutation O 0 6.384630250977352e-05
was O 0 1.4248481420509052e-05
the O 0 1.2426487216998794e-07
most O 0 1.0451505971786901e-07
common O 0 1.2996857776670367e-06
mutation O 0 6.670198217761936e-06
found O 0 2.4800685878290096e-06
, O 0 3.1756601970300835e-07
followed O 0 3.2545611361456395e-07
by O 0 1.9245619853336393e-07
the O 0 2.657993263710523e-06
BRCA2 O 0 0.005636443383991718
8765delAG O 0 0.0004497008631005883
mutation O 0 0.0001466850662836805
. O 0 8.192305358534213e-06

Together O 0 2.7774392947321758e-05
, O 0 3.702486765178037e-06
these O 0 2.9208220553300634e-07
mutations O 0 5.336511094355956e-06
were O 0 8.567951681470731e-07
found O 0 6.859979748696787e-07
in O 0 3.0665901817883423e-07
28 O 0 2.180750925617758e-06
of O 0 1.4286182192790875e-07
41 O 0 8.408168469031807e-06
families O 0 2.2074196692756232e-07
identified O 0 2.830973471645848e-06
to O 0 2.5302713879682415e-07
have O 0 3.609038401464204e-07
a O 0 7.091007319104392e-06
mutation O 0 6.827107426943257e-05
. O 0 5.94685343457968e-06

The O 0 1.2796051123586949e-05
odds O 0 6.228181882761419e-05
of O 0 6.260270311031491e-07
detection O 0 3.2893417483137455e-06
of O 0 4.537371367518972e-08
any O 0 2.432602030921771e-08
of O 0 4.181729096330855e-08
the O 0 4.6001525788597064e-07
four O 0 8.270814760180656e-06
BRCA1 O 0 0.025978196412324905
mutations O 0 8.647984213894233e-05
was O 0 1.4354168342833873e-05
18 O 0 3.5681391636899207e-06
. O 0 4.165842256043106e-06

7x O 0 0.010311589576303959
greater O 0 2.6216604965156876e-05
if O 0 8.45138401928125e-07
one O 0 1.006744199116838e-07
or O 0 6.814259734255756e-08
more O 0 5.600545094353038e-08
cases O 0 1.0112704558196128e-06
of O 0 0.001664491486735642
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 5.251036782283336e-06
also O 0 1.7088898403017083e-06
present O 0 1.4954510163533996e-07
in O 0 1.401075735429913e-07
the O 0 9.587691920387442e-07
family O 0 2.782919727906119e-05
. O 0 1.5748071746202186e-05

The O 0 9.566534572513774e-06
odds O 0 6.248015415621921e-05
of O 0 4.1793771288212156e-07
detection O 0 3.256121317463112e-06
of O 0 1.0761922908386623e-07
any O 0 6.893584725276014e-08
of O 0 7.342887187178349e-08
the O 0 5.955157007520029e-07
four O 0 1.9694945876835845e-05
BRCA2 O 0 0.32537251710891724
mutations O 0 0.00010024652146967128
was O 0 1.4806238141318318e-05
5 O 0 1.2027918273815885e-05
. O 0 8.416094715357758e-06

3x O 0 0.02514178864657879
greater O 0 2.4553639377700165e-05
if O 0 1.1179893135704333e-06
there O 0 7.824562686664649e-08
were O 0 2.1378484404976916e-07
at O 0 3.1220343998938915e-07
least O 0 5.045388462576739e-08
five O 0 1.8455348538282124e-07
cases O 0 3.235084307107172e-07
of O 0 2.1670680325769354e-06
breast B-Disease 1 0.9990237951278687
cancer I-Disease 0 0.161587655544281
in O 0 8.105694746518566e-07
the O 0 2.0215252334310208e-06
family O 0 2.9853690648451447e-05
. O 0 1.6968666386674158e-05

Interestingly O 0 0.00043702221591956913
, O 0 2.5807746624195715e-06
the O 0 1.2985604769255588e-07
presence O 0 1.1345715478228158e-07
of O 0 1.0711831777143743e-07
a O 0 0.0003735079662874341
breast B-Disease 1 0.9998108744621277
cancer I-Disease 0 0.12318089604377747
case O 0 2.9600853395095328e-06
< O 0 2.060832230199594e-06
36 O 0 1.190797320305137e-06
years O 0 2.200668376417525e-07
of O 0 8.507863213935707e-08
age O 0 1.3346996183827287e-06
was O 0 6.397927791113034e-06
strongly O 0 5.009229084862454e-07
predictive O 0 8.682483780830808e-07
of O 0 3.6424051330641305e-08
the O 0 1.533559412791874e-07
presence O 0 6.149774378627626e-08
of O 0 1.039922370438262e-08
any O 0 1.4828845706915672e-08
of O 0 2.7216429998588865e-08
the O 0 3.2894845958253427e-07
eight O 0 5.216586941969581e-06
mutations O 0 3.2180058042285964e-05
screened O 0 2.5619572625146247e-05
. O 0 4.922349489788758e-06

Carriers O 0 3.5045071854256094e-05
of O 0 7.81347978318081e-07
the O 0 4.190480069610203e-07
same O 0 4.952258336743398e-07
mutation O 0 8.907247206479951e-07
, O 0 9.292853775377807e-08
from O 0 1.9215958602103456e-08
different O 0 2.7205945940522724e-08
families O 0 1.0900335212227219e-07
, O 0 1.1109580810853004e-07
shared O 0 1.303373124983409e-07
similar O 0 4.290893684810726e-07
haplotypes O 0 1.9772405721596442e-05
, O 0 5.505351055035135e-07
indicating O 0 7.913955073490797e-07
that O 0 8.926118510999004e-08
the O 0 6.007234532035e-08
mutant O 0 1.3190705203669495e-06
alleles O 0 3.6304896866568015e-07
were O 0 3.98062212525474e-07
likely O 0 3.704616347022238e-07
to O 0 2.0061541761151602e-07
be O 0 1.1293597168560154e-07
identical O 0 1.7335111124339164e-06
by O 0 3.245287700792687e-07
descent O 0 1.772963696566876e-05
for O 0 2.7303656224830775e-07
a O 0 1.993548494283459e-06
mutation O 0 4.435791652213084e-06
in O 0 3.8144062841638515e-07
the O 0 1.0281784170729225e-06
founder O 0 0.00029545981669798493
population O 0 2.048884198302403e-06
. O 0 2.9592499686259544e-06

The O 0 2.8176111754874e-06
identification O 0 2.3168786356109194e-06
of O 0 2.1461337951222959e-07
common O 0 8.20153763925191e-06
BRCA1 O 0 0.0073003098368644714
and O 0 9.526336361886933e-05
BRCA2 O 0 0.01770344004034996
mutations O 0 3.512878538458608e-05
will O 0 3.184017884905188e-07
facilitate O 0 5.331442594069813e-07
carrier O 0 6.507238140329719e-06
detection O 0 3.9403662412951235e-06
in O 0 8.256158707808936e-07
French O 0 7.868466491345316e-05
Canadian O 0 0.006010161247104406
breast B-Disease 1 0.9969197511672974
cancer I-Disease 1 0.8112210631370544
and O 0 0.03357575461268425
breast B-Disease 1 0.9999988079071045
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 2.054329524980858e-05
. O 0 1.2623308066395111e-05

Are O 0 1.0725753782026004e-05
Dp71 O 0 0.00032789859687909484
and O 0 2.1841851776116528e-05
Dp140 O 0 0.0003331005573272705
brain O 0 0.0006711347959935665
dystrophin O 0 8.363444794667885e-05
isoforms O 0 1.1381166586943436e-05
related O 0 5.698590484826127e-06
to O 0 6.464103989856085e-06
cognitive B-Disease 0 0.0007053444278426468
impairment I-Disease 0 0.4049775004386902
in O 0 0.005583072081208229
Duchenne B-Disease 1 0.9999991655349731
muscular I-Disease 1 0.9999908208847046
dystrophy I-Disease 1 0.999991774559021
? O 0 0.0005705287912860513

Molecular O 0 0.001263821730390191
study O 0 2.7954472898272797e-05
and O 0 7.472983270417899e-06
neuropsychological O 0 7.769493822706863e-05
analysis O 0 1.9530614281393355e-06
were O 0 4.471207546430378e-07
performed O 0 1.169648840004811e-06
concurrently O 0 3.2818704198689375e-07
on O 0 7.873418326198589e-06
49 O 0 7.290659414138645e-05
patients O 0 9.488584510108922e-06
with O 0 4.4337437429931015e-05
Duchenne B-Disease 1 0.9999994039535522
muscular I-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999997615814209
( O 0 0.012469383887946606
DMD B-Disease 1 0.9999998807907104
) O 0 9.723635230329819e-06
in O 0 5.487403313964023e-07
order O 0 1.136622742592408e-07
to O 0 1.5807316344762512e-07
find O 0 1.5061310421060625e-07
a O 0 3.6527791280605015e-07
molecular O 0 3.647533276307513e-06
explanation O 0 5.292365017339762e-07
for O 0 1.913444123147201e-07
the O 0 1.9937101569666993e-06
cognitive B-Disease 0 7.185834692791104e-05
impairment I-Disease 0 0.00014889228623360395
observed O 0 8.397919373237528e-06
in O 0 4.598639407049632e-06
most O 0 7.670056220376864e-05
DMD B-Disease 1 1.0
patients O 0 0.017736930400133133
. O 0 1.2615509149327409e-05

Complete O 0 4.083717067260295e-05
analysis O 0 3.8402372410928365e-06
of O 0 3.254728824231279e-07
the O 0 6.566565389221068e-07
dystrophin O 0 7.037423347355798e-05
gene O 0 1.086585416487651e-05
was O 0 1.243893893843051e-05
performed O 0 3.3558210361661622e-06
to O 0 9.417112067922062e-08
define O 0 6.288963732004049e-07
the O 0 2.0869157424385776e-07
localization O 0 1.6205061683649546e-06
of O 0 1.7589087519809254e-07
deletions O 0 1.143253393820487e-05
and O 0 2.1563025711657247e-06
duplications O 0 8.697436896909494e-06
in O 0 7.574630558337958e-07
relation O 0 6.992719363552169e-07
to O 0 5.400092959462199e-07
the O 0 1.3340010127649293e-06
different O 0 5.263305411062902e-06
DMD B-Disease 1 0.9999990463256836
promoters O 0 0.0025124335661530495
. O 0 1.7774484149413183e-05

Qualitative O 0 0.0003649030113592744
analysis O 0 1.730294206936378e-05
of O 0 1.372820292999677e-06
the O 0 1.5788649534442811e-06
Dp71 O 0 0.00014855916379019618
transcript O 0 0.0001467197434976697
and O 0 1.59494913987146e-06
testing O 0 2.6835144240067166e-07
for O 0 3.042716656409539e-08
the O 0 4.1958944763109685e-08
specific O 0 3.7215418302594117e-08
first O 0 3.971460955654038e-07
exon O 0 3.203864025635994e-06
of O 0 7.198006102271393e-08
Dp140 O 0 3.5274031233711867e-06
were O 0 7.160103336900647e-07
also O 0 5.352391099222586e-07
carried O 0 1.1217185829082155e-06
out O 0 1.092005732061807e-06
. O 0 3.567016392480582e-06

Neuropsychological O 0 0.00770418718457222
analysis O 0 7.787839422235265e-05
assessed O 0 5.992316800984554e-05
verbal O 0 2.8576687327586114e-05
and O 0 1.055051961884601e-05
visuospatial O 0 0.00032922421814873815
intelligence O 0 2.355715332669206e-05
, O 0 1.2998642660022597e-06
verbal O 0 2.9184991490183165e-06
memory O 0 4.751918822876178e-05
, O 0 1.916535666168784e-06
and O 0 1.421032152393309e-06
reading O 0 5.834590410813689e-06
skills O 0 6.239383765205275e-06
. O 0 6.647552254435141e-06

Comparison O 0 3.178326733177528e-05
of O 0 1.5433175803991617e-06
molecular O 0 3.7435205740621313e-05
and O 0 1.3105830475979019e-05
psychometric O 0 0.00031384825706481934
findings O 0 7.556207856396213e-05
demonstrated O 0 3.8397242860810366e-06
that O 0 1.8115139255314716e-07
deletions O 0 3.07285699818749e-06
and O 0 1.014200506688212e-06
duplications O 0 1.1949599866056815e-05
that O 0 9.715076885186136e-07
were O 0 5.801011866424233e-07
localized O 0 2.2000483568263007e-06
in O 0 5.744286681874655e-07
the O 0 6.717640985698381e-07
distal O 0 4.3652868043864146e-05
part O 0 2.484014657966327e-06
of O 0 1.163558138728149e-07
the O 0 3.352873534367973e-07
gene O 0 1.6479212945341715e-06
seemed O 0 4.15584850088635e-07
to O 0 6.619261228024698e-08
be O 0 7.611156149778253e-08
preferentially O 0 1.2634089898710954e-06
associated O 0 1.3953541611044784e-06
with O 0 4.258112767274724e-06
cognitive B-Disease 0 0.0011695169378072023
impairment I-Disease 0 0.002708110027015209
. O 0 2.8551110517582856e-05

Two O 0 2.9549595637945458e-05
altered O 0 7.953956082928926e-05
Dp71 O 0 0.0001756137644406408
transcripts O 0 1.490421527705621e-05
and O 0 3.965137125305773e-07
two O 0 1.2887709033293504e-07
deleted O 0 1.7647873846726725e-06
Dp140 O 0 1.720460659271339e-06
DNA O 0 2.212980916738161e-06
sequences O 0 1.6303340544254752e-07
were O 0 1.6385531864671066e-07
found O 0 4.2300939639972057e-07
in O 0 2.6442469902576704e-07
four O 0 8.24552625999786e-06
patients O 0 2.7146103093400598e-05
with O 0 3.759964238270186e-05
severe O 1 0.915752112865448
cerebral B-Disease 1 0.9863895773887634
dysfunction I-Disease 0 0.41812950372695923
. O 0 4.715996692539193e-05

These O 0 1.5176749002421275e-05
findings O 0 1.4826556252955925e-05
suggest O 0 1.6674132439220557e-06
that O 0 7.93809959986902e-08
some O 0 1.2084452549743219e-08
sequences O 0 3.277666138501445e-08
located O 0 2.7100298893856234e-07
in O 0 2.5518025381643383e-07
the O 0 2.4966035994111735e-07
distal O 0 1.5374445865745656e-05
part O 0 6.04559261319082e-07
of O 0 7.423719949883889e-08
the O 0 3.711438125719724e-07
gene O 0 2.7321289053361397e-06
and O 0 1.2379568943288177e-06
, O 0 3.130346328816813e-07
in O 0 8.650039262647624e-08
particular O 0 1.1758914553183786e-07
, O 0 2.968131695979537e-07
some O 0 1.4312364271518163e-07
DMD B-Disease 1 0.999565064907074
isoforms O 0 2.157470817110152e-06
expressed O 0 4.0002973378250317e-07
in O 0 3.1462056426789786e-07
the O 0 2.497316017979756e-06
brain O 0 0.032812848687171936
may O 0 3.302569894003682e-05
be O 0 2.8942832841494237e-07
related O 0 3.6073316778129083e-07
to O 0 6.256945539462322e-07
the O 0 3.590545702536474e-06
cognitive B-Disease 0 0.00035868550185114145
impairment I-Disease 0 0.0003472790995147079
associated O 0 5.373951807996491e-06
with O 0 4.017517494503409e-05
DMD B-Disease 1 1.0
. O 0 6.91338354954496e-05
. O 0 1.5549650925095193e-05

I1307K O 0 0.0009011702495627105
APC O 0 0.0008132689399644732
and O 0 1.4148877198749688e-05
hMLH1 O 0 8.299545879708603e-05
mutations O 0 1.9743840312003158e-05
in O 0 1.9821804642106144e-07
a O 0 9.851161166807287e-07
non O 0 6.994573141128058e-06
- O 0 0.00025149688008241355
Jewish O 0 1.656854510656558e-05
family O 0 4.712400823336793e-06
with O 0 4.907893071504077e-06
hereditary B-Disease 1 0.9861407279968262
non I-Disease 1 0.7158693075180054
- I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00010985455446643755

We O 0 2.0594747184077278e-05
describe O 0 1.0372103133704513e-05
a O 0 1.5622633782186313e-06
French O 0 5.1144375902367756e-05
Canadian O 0 0.00011648622603388503
hereditary B-Disease 1 0.9278376698493958
non I-Disease 0 0.4077240824699402
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.006032649893313646
HNPCC B-Disease 1 0.9734500050544739
) O 0 1.8769531379803084e-05
kindred O 0 0.00014283906784839928
which O 0 1.6375719269490219e-06
carries O 0 2.522145678085508e-06
a O 0 1.911716253744089e-06
novel O 0 1.0433183888380881e-05
truncating O 0 0.00018321818788535893
mutation O 0 6.613256846321747e-05
in O 0 2.1367570752772735e-06
hMLH1 O 0 0.0002817570057231933
. O 0 2.392099668213632e-05

Interestingly O 0 0.00023755191068630666
, O 0 5.756517111876747e-06
the O 0 5.926093535890686e-07
I1307K O 0 1.4579779417545069e-05
APC O 0 3.6146586353424937e-05
polymorphism O 0 1.8551463654148392e-05
, O 0 6.709208832944569e-07
associated O 0 2.3069229371230904e-07
with O 0 7.654568889847724e-08
an O 0 1.3817308399666217e-06
increased O 0 2.559417589509394e-05
risk O 0 0.00012595886073540896
of O 0 0.09881104528903961
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.8528622604208067e-05
is O 0 4.832052695746825e-07
also O 0 1.1309305136819603e-06
present O 0 1.5128870245462167e-07
in O 0 2.2344116246131307e-07
this O 0 3.7011204767622985e-07
family O 0 1.5723820979474112e-05
. O 0 1.2519938536570407e-05

The O 0 9.976023648050614e-06
I1307K O 0 5.824881009175442e-05
polymorphism O 0 6.281715468503535e-05
has O 0 3.063400072278455e-06
previously O 0 2.5489719064353267e-06
only O 0 1.0239408965162511e-07
been O 0 5.16742147738114e-07
identified O 0 2.7672094802255742e-06
in O 0 1.6343972220056457e-07
individuals O 0 1.2337237009774071e-08
of O 0 8.920484617647162e-08
self O 0 5.90436247875914e-05
- O 0 0.3292514979839325
reported O 0 0.02058519423007965
Ashkenazi O 0 0.00021238575573079288
Jewish O 0 5.518341822607908e-06
origins O 0 1.8910246581071988e-05
. O 0 8.714540854271036e-06

In O 0 7.450702014466515e-06
addition O 0 9.570873089614906e-07
, O 0 6.78666992826038e-07
in O 0 1.553069637338922e-07
this O 0 1.31311466589068e-07
family O 0 3.144503807561705e-06
, O 0 1.0223694744126988e-06
there O 0 5.2771845560073416e-08
appears O 0 1.1141299864902976e-06
to O 0 1.5820241117125988e-07
be O 0 1.313133424218904e-07
no O 0 6.60655956608025e-08
relationship O 0 1.5476109638257185e-07
between O 0 1.1351820461413809e-07
the O 0 4.937592166243121e-07
I1307K O 0 5.716198756999802e-06
polymorphism O 0 3.1830450097913854e-06
and O 0 4.6972522227406444e-07
the O 0 2.522111799407867e-07
presence O 0 1.9284054530999128e-07
or O 0 4.901480679109227e-07
absence O 0 7.349913175858092e-07
of O 0 1.6421870441263309e-06
cancer B-Disease 0 0.0011154541280120611
. O 0 1.1452549415480462e-06
. O 0 2.8247056889085798e-06

Identification O 0 2.657642289705109e-05
of O 0 1.2139813634348684e-06
a O 0 2.7220535230298992e-06
novel O 0 6.7238979681860656e-06
mutation O 0 3.6658134376921225e-06
of O 0 1.7432729748634301e-07
the O 0 2.5599001673981547e-06
CPO O 0 0.0018112004036083817
gene O 0 1.1964683608312043e-06
in O 0 8.800597584013303e-08
a O 0 1.1306760825391393e-06
Japanese O 0 3.1414281693287194e-05
hereditary B-Disease 0 0.038088008761405945
coproporphyria I-Disease 0 0.0035267784260213375
family O 0 5.479800529428758e-05
. O 0 1.6171443348866887e-05

Hereditary B-Disease 1 0.9996809959411621
coproporphyria I-Disease 1 0.9935894012451172
( O 0 0.0022293950896710157
HCP B-Disease 1 0.8651424646377563
) O 0 1.4798728443565778e-05
is O 0 9.986370059777983e-07
an O 0 6.44217652734369e-06
autosomal B-Disease 1 0.9948593378067017
dominant I-Disease 1 0.9979178309440613
disease I-Disease 1 0.983207106590271
characterized O 0 7.42839984013699e-05
by O 0 5.550029072765028e-06
a O 0 0.003212760901078582
deficiency B-Disease 0 0.07003367692232132
of I-Disease 0 8.381888960684591e-07
coproporphyrinogen I-Disease 0 0.010986512526869774
oxidase I-Disease 0 4.018314939457923e-05
( O 0 2.3912380129331723e-06
CPO O 0 0.0021639345213770866
) O 0 5.476215960698028e-07
caused O 0 6.728258199473203e-07
by O 0 7.340366181551872e-08
a O 0 1.9236881598772015e-06
mutation O 0 6.8885169639543165e-06
in O 0 7.49339847061492e-07
the O 0 4.165699010627577e-06
CPO O 0 0.01743875816464424
gene O 0 2.0857505660387687e-05
. O 0 4.937733137921896e-06

Only O 0 8.653223630972207e-06
11 O 0 6.269289315241622e-06
mutations O 0 3.192250005668029e-06
of O 0 5.6058350850207717e-08
the O 0 2.8250892114556336e-07
gene O 0 5.530364433070645e-06
have O 0 7.171160518737452e-07
been O 0 2.8963011118321447e-06
reported O 0 7.405138603644446e-05
in O 0 1.234159844898386e-05
HCP B-Disease 1 0.9821495413780212
patients O 0 0.00021096630371175706
. O 0 6.914186087669805e-06

We O 0 3.227594424970448e-05
report O 0 8.979231097328011e-06
another O 0 5.750211471422517e-07
mutation O 0 2.881451337088947e-06
in O 0 1.5473437997570727e-07
a O 0 1.4782640391786117e-06
Japanese O 0 2.239373316115234e-05
family O 0 2.3500881070503965e-05
. O 0 1.0362938155594748e-05

Polymerase O 0 0.0007164440467022359
chain O 0 0.00045006300206296146
reaction O 0 1.1361496035533492e-05
- O 0 2.678610871953424e-05
single O 0 4.184544195595663e-06
strand O 0 0.00011851971066789702
conformational O 0 3.7982269986969186e-06
polymorphism O 0 5.7991483117803e-06
and O 0 3.2137711514224065e-07
direct O 0 3.606210441375879e-07
sequence O 0 7.331040592362115e-07
analyses O 0 3.1918330023472663e-06
demonstrated O 0 1.0007821629187674e-06
a O 0 1.2316755828578607e-06
C O 0 2.952880458906293e-05
to O 0 7.533158168371301e-07
T O 0 2.1155654394533485e-05
substitution O 0 8.056297673419976e-08
in O 0 5.5662745523932244e-08
exon O 0 1.0592403896225733e-06
1 O 0 2.7575964622883475e-07
of O 0 2.767857942842511e-08
the O 0 2.902952189742791e-07
CPO O 0 6.269274308579043e-05
gene O 0 3.2699796292945393e-07
at O 0 1.6306729833104328e-07
nucleotide O 0 7.874836001064978e-07
position O 0 2.8420154194463976e-06
85 O 0 1.0497091125216684e-06
, O 0 3.186356707374216e-07
which O 0 3.9285137631850375e-07
lies O 0 1.237895503436448e-06
in O 0 2.8420893727343355e-07
the O 0 3.6263165270611353e-07
putative O 0 1.2188072105345782e-05
presequence O 0 2.6241919840686023e-05
for O 0 1.717790212296677e-07
targeting O 0 2.5383201318618376e-06
to O 0 1.3682457620234345e-06
mitochondria O 0 3.530160756781697e-05
. O 0 2.0396242689457722e-05

This O 0 9.47722583077848e-06
mutation O 0 1.3389434570854064e-05
changes O 0 8.315423087879026e-07
the O 0 1.6589054041560303e-07
codon O 0 7.509781312364794e-07
for O 0 7.393931866772618e-08
glutamine O 0 6.933128702257818e-07
to O 0 5.010242176695101e-08
a O 0 1.727217693314742e-07
termination O 0 8.202524668377009e-07
codon O 0 6.285077915890724e-07
at O 0 2.656369133546832e-07
amino O 0 6.838992021585e-07
acid O 0 1.0279059097229037e-05
position O 0 7.901958269940224e-06
29 O 0 3.097717490163632e-05
. O 0 5.324529411154799e-06

MaeI O 0 0.0014079376123845577
restriction O 0 2.4759428924880922e-05
analysis O 0 6.8356866904650815e-06
showed O 0 3.3560131669219118e-06
two O 0 1.1310442715739555e-07
other O 0 6.247334027875695e-08
carriers O 0 3.260469725319126e-07
in O 0 1.4760732369722973e-07
the O 0 8.231158403759764e-07
family O 0 2.7804684577859007e-05
. O 0 1.3282046893436927e-05

The O 0 2.9391982025117613e-05
C O 0 0.001501245889812708
- O 0 0.2750051021575928
T O 0 0.07510621100664139
mutation O 0 3.696383373608114e-06
is O 0 6.52340403917151e-08
located O 0 1.377038216787696e-07
within O 0 3.3916712993686815e-08
a O 0 4.739930261621339e-07
recently O 0 5.1172605708416086e-06
proposed O 0 6.479617695731577e-07
putative O 0 2.4540449885535054e-06
alternative O 0 8.147513881340274e-07
translation O 0 8.351631777259172e-07
initiation O 0 3.991528387814469e-07
codon O 0 5.014581802242901e-06
( O 0 6.144410917841014e-07
TIC O 0 1.6797997886897065e-05
- O 0 1.262159912585048e-05
1 O 0 2.825465571731911e-06
) O 0 1.169330445804917e-07
, O 0 6.411558928220984e-08
supporting O 0 1.5990399049314874e-07
that O 0 3.5167113310308196e-07
TIC O 0 1.6446916561108083e-05
- O 0 2.1600631953333504e-05
1 O 0 2.8365402613417245e-06
is O 0 9.649355092733458e-08
the O 0 1.5003307396455057e-07
real O 0 2.926732349806116e-06
TIC O 0 1.5864654415054247e-05
rather O 0 1.6932578716932767e-07
than O 0 2.04246447310652e-07
TIC O 0 1.815540781535674e-05
- O 0 1.4137734979158267e-05
2 O 0 4.290241577109555e-06
. O 0 8.743541002331767e-07
. O 0 3.161408358209883e-06

Human B-Disease 0 5.318426337908022e-05
complement I-Disease 0 4.8025092837633565e-05
factor I-Disease 0 0.0006250609294511378
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9992855191230774
associated O 0 0.00030037027318030596
with O 0 0.016412628814578056
hemolytic B-Disease 1 0.9999997615814209
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.001020269119180739

This O 0 7.047939561743988e-06
study O 0 2.769052116491366e-06
reports O 0 1.4795447214055457e-06
on O 0 2.249078534077853e-06
six O 0 3.379058853170136e-06
cases O 0 6.663673275397741e-07
of O 0 2.800426500471076e-06
deficiency B-Disease 0 0.002653813920915127
in I-Disease 0 2.727133505686652e-07
the I-Disease 0 2.7975440275440633e-07
human I-Disease 0 1.4325789265967614e-07
complement I-Disease 0 5.036144443693047e-07
regulatory I-Disease 0 1.1532624739629682e-06
protein I-Disease 0 8.557249202567618e-06
Factor I-Disease 0 4.575106231641257e-06
H I-Disease 1 0.9999995231628418
( O 0 7.33672322894563e-06
FH O 0 0.0022068554535508156
) O 0 1.293829683390868e-07
in O 0 2.8631093940134633e-08
the O 0 3.108617008251713e-08
context O 0 1.3604748971829395e-07
of O 0 6.680955948468181e-07
an O 0 0.03885079175233841
acute B-Disease 1 0.999984860420227
renal I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
. O 0 0.00013136633788235486

Five O 0 4.832365902984748e-06
of O 0 3.0055852562327345e-07
the O 0 3.6372128420225636e-07
cases O 0 2.5669427827779145e-07
were O 0 4.496286294397578e-07
observed O 0 9.550421964377165e-07
in O 0 4.790007324118051e-07
children O 0 1.7399009948348976e-06
presenting O 0 4.244156662025489e-05
with O 0 0.030257316306233406
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.09420477598905563
HUS B-Disease 1 0.999998927116394
) O 0 0.00016208674060180783
. O 0 3.318975359434262e-05

Two O 0 5.439579126687022e-06
of O 0 3.890588402555295e-07
the O 0 7.944141202642641e-07
children O 0 3.973809270974016e-06
exhibited O 0 3.120566179859452e-05
a O 0 0.0001506716653238982
homozygous O 1 0.6259123682975769
deficiency O 1 0.5692317485809326
characterized O 0 2.4819146346999332e-05
by O 0 6.008747845953621e-07
the O 0 4.997210112378525e-07
absence O 0 2.429134724479809e-07
of O 0 3.358396583053036e-08
the O 0 1.5991649604529812e-07
150 O 0 2.381864732114991e-07
- O 0 1.1203651411051396e-05
kD O 0 3.6654846553574316e-06
form O 0 9.68161657510791e-08
of O 0 6.182363421203263e-08
Factor O 0 9.195805432682391e-07
H O 1 0.9999878406524658
and O 0 1.6425364037786494e-06
the O 0 2.494540183306526e-07
presence O 0 1.2550613348594197e-07
, O 0 1.1546298850362291e-07
upon O 0 4.599261771431884e-08
immunoblotting O 0 2.9907193948019994e-06
, O 0 3.613714838479609e-08
of O 0 5.238951494845878e-09
the O 0 6.06602483799179e-08
42 O 0 1.3046582125753048e-06
- O 0 1.1565155546122696e-05
kD O 0 2.6119627364096232e-05
Factor O 0 8.46399871079484e-07
H O 1 0.9964547157287598
- O 0 2.0578372641466558e-05
like O 0 1.7818058495322475e-07
protein O 0 9.047376465787238e-07
1 O 0 2.9779573651467217e-06
( O 0 1.986353055372092e-07
FHL O 0 9.947941180143971e-06
- O 0 1.5430792700499296e-05
1 O 0 1.353567085971008e-06
) O 0 5.439790484729201e-08
and O 0 1.5153460708461353e-07
other O 0 3.400753598725714e-07
FH O 0 0.026405641809105873
- O 0 0.00017631138325668871
related O 0 2.8061901957698865e-06
protein O 0 4.61207901025773e-06
( O 0 6.654997832811205e-07
FHR O 0 0.00015485548647120595
) O 0 7.662543453079707e-07
bands O 0 5.389769739849726e-06
. O 0 4.770486157212872e-06

Southern O 0 0.00032365298829972744
blot O 0 0.010516450740396976
and O 0 1.1752801583497785e-05
PCR O 0 1.774521660991013e-05
analysis O 0 3.906706069756183e-07
of O 0 4.9855334083304115e-08
DNA O 0 2.116524456141633e-06
of O 0 7.726163886445647e-08
one O 0 1.9843662357743597e-06
patient O 0 9.010135727294255e-06
with O 0 1.0520087926124688e-05
homozygous O 0 0.39208880066871643
deficiency O 0 0.34127601981163025
ruled O 0 6.956269771762891e-06
out O 0 3.314200114346022e-07
the O 0 1.4606389697746636e-07
presence O 0 5.912815836950358e-08
of O 0 1.7605426450018058e-08
a O 0 3.6768034306078334e-07
large O 0 6.076655836295686e-07
deletion O 0 4.8203664846369065e-06
of O 0 8.992849132027914e-08
the O 0 1.6501323898410192e-06
FH O 0 0.0024618988391011953
gene O 0 1.7627218085181084e-06
as O 0 1.6757347509610554e-07
the O 0 4.899578698314144e-07
underlying O 0 0.00010260113776894286
defect O 0 7.770012598484755e-05
for O 0 3.3942712889256654e-06
the O 0 0.00010794203990371898
deficiency O 0 0.1496291607618332
. O 0 1.8998765881406143e-05

The O 0 2.9110603918525157e-06
other O 0 3.938251893487177e-07
four O 0 9.626869541534688e-07
children O 0 1.1179124612681335e-06
presented O 0 1.5528371477557812e-06
with O 0 6.95595144861727e-06
heterozygous O 0 0.005982612259685993
deficiency O 0 0.11870314180850983
and O 0 3.7425879781949334e-06
exhibited O 0 1.4618704881286249e-05
a O 0 1.7058025605365401e-06
normal O 0 2.3866223273216747e-06
immunoblotting O 0 5.5647207773290575e-05
pattern O 0 3.4319698443141533e-06
of O 0 4.4095134654753565e-08
proteins O 0 1.074039204240762e-07
of O 0 1.0805776184952265e-07
the O 0 7.6197634371055756e-06
FH O 1 0.7274320125579834
family O 0 6.058671715436503e-05
. O 0 1.3825314454152249e-05

Factor B-Disease 0 0.06909008324146271
H I-Disease 1 1.0
deficiency I-Disease 1 0.9980862140655518
is O 0 1.986895995287341e-06
the O 0 5.847486477250641e-07
only O 0 4.63216247226228e-06
complement B-Disease 1 0.9997240900993347
deficiency I-Disease 1 0.9999995231628418
associated O 0 4.437554889591411e-05
with O 0 2.211999162682332e-05
HUS B-Disease 1 0.9999922513961792
. O 0 0.00012361786502879113

These O 0 5.3426883823703974e-06
observations O 0 1.2632652214961126e-05
suggest O 0 1.7510938050691038e-06
a O 0 6.484563073172467e-07
role O 0 1.8958409100378049e-06
for O 0 4.7242792788892984e-06
FH O 0 0.34071725606918335
and O 0 2.6454061298863962e-05
/ O 0 0.00016522323130629957
or O 0 1.4287655858424841e-06
FH O 0 0.0006033360841684043
receptors O 0 1.0245206567560672e-06
in O 0 2.0109638398935203e-07
the O 0 1.2202667676319834e-06
pathogenesis O 0 0.001618209877051413
of O 0 1.6939142369665205e-05
idiopathic O 1 0.999419093132019
HUS B-Disease 1 0.9999984502792358
. O 0 3.553679562173784e-05
. O 0 2.41355701291468e-05

Further O 0 2.5317989639006555e-05
evidence O 0 4.326348062022589e-06
for O 0 2.1760256174729875e-07
a O 0 8.95286802915507e-07
major O 0 1.3189586525186314e-06
ancient O 0 1.8721013475442305e-05
mutation O 0 0.21812251210212708
underlying O 1 0.9748918414115906
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 6.198129995027557e-05
linkage O 0 0.001512947608716786
disequilibrium O 0 0.030050065368413925
studies O 0 5.406006494013127e-06
in O 0 3.046863525923982e-07
the O 0 3.909863153239712e-07
Japanese O 0 1.1430789527366869e-05
population O 0 2.910732746386202e-06
. O 0 6.018318799760891e-06

The O 0 0.0898640900850296
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9731214046478271
DM B-Disease 1 1.0
) O 0 0.00030796846840530634
mutation O 0 4.824146526516415e-05
is O 0 1.2764804750986514e-06
an O 0 4.164205620327266e-06
unstable O 0 0.15852762758731842
( O 0 9.75815510173561e-06
CTG O 0 0.00016464543296024203
) O 0 5.161890044291795e-07
n O 0 1.4384972928382922e-05
repeat O 0 6.408309218386421e-06
, O 0 2.455001890666608e-07
present O 0 6.706183341975702e-08
at O 0 2.4989930125229876e-07
a O 0 2.447560802920634e-07
copy O 0 1.80896222445881e-06
number O 0 3.883937083060118e-08
of O 0 2.002088272945457e-08
5 O 0 3.058078846152057e-06
- O 0 4.338410872151144e-05
37 O 0 3.5261891753179953e-06
repeats O 0 2.950665930256946e-06
on O 0 1.1599566960285301e-06
normal O 0 7.517003837165248e-07
chromosomes O 0 1.2239801208124845e-06
but O 0 1.8068554652472812e-07
amplified O 0 8.096917554212268e-07
to O 0 9.431726510911176e-08
50 O 0 1.0279054407646981e-07
- O 0 7.436030500684865e-06
3000 O 0 2.314959374416503e-06
copies O 0 7.609974090883043e-06
on O 0 0.00014448976435232908
DM B-Disease 1 0.9999994039535522
chromosomes O 0 0.0003206682449672371
. O 0 8.23593836685177e-06

Previous O 0 0.0003798551915679127
findings O 0 9.329152817372233e-05
in O 0 3.112140348093817e-06
Caucasian O 0 0.00024318878422491252
populations O 0 3.6173883017909247e-06
of O 0 3.6108355061514885e-07
a O 0 0.00020810062414966524
DM B-Disease 1 1.0
founder O 0 0.08797475695610046
chromosome O 0 0.00012339999375399202
raise O 0 1.0424106449136161e-06
a O 0 4.623899201305903e-07
question O 0 1.7971646570913435e-07
about O 0 3.541853388355776e-08
the O 0 1.2070381671946961e-07
molecular O 0 5.882342520635575e-06
events O 0 2.349118517486204e-07
involved O 0 2.1858009802144807e-07
in O 0 1.0989410981210312e-07
the O 0 3.9979209986995556e-07
expansion O 0 1.6451356714242138e-05
mutation O 0 3.919118535122834e-05
. O 0 5.726155904994812e-06

To O 0 2.0800202037207782e-05
investigate O 0 9.14425982045941e-06
whether O 0 7.783551723150595e-07
a O 0 1.5810044260433642e-06
founder O 0 0.0001633014326216653
chromosome O 0 0.0001241515710717067
for O 0 1.9141025404678658e-06
the O 0 1.993177465919871e-05
DM B-Disease 1 1.0
mutation O 0 4.171094042249024e-05
exists O 0 1.1955827972087718e-07
in O 0 4.138026810096562e-08
the O 0 6.29166265753156e-08
Japanese O 0 1.2163187648184248e-06
population O 0 1.1143770706212308e-07
, O 0 5.969371841274551e-08
we O 0 4.090332339501401e-08
genotyped O 0 1.9645051452243933e-06
families O 0 3.6866904196131145e-08
using O 0 2.0957170931978908e-07
polymorphic O 0 8.809783139440697e-06
markers O 0 3.906800702679902e-05
near O 0 3.8564590795431286e-05
the O 0 4.854814960708609e-06
( O 0 2.4361786472582025e-06
CTG O 0 0.00012969723320566118
) O 0 5.172026362743054e-07
n O 0 1.5060209989314899e-05
repeat O 0 1.7736165318638086e-05
region O 0 4.831619207834592e-06
and O 0 1.8186108263762435e-06
constructed O 0 5.562158185057342e-05
haplotypes O 0 0.0005797816556878388
. O 0 2.2247750166570768e-05

Six O 0 1.830176006478723e-05
different O 0 1.3454794043354923e-06
haplotypes O 0 6.951097020646557e-05
were O 0 7.182007266237633e-06
found O 0 7.10789890945307e-06
and O 0 3.37898381985724e-05
DM B-Disease 1 0.9999998807907104
alleles O 0 3.756602018256672e-05
were O 0 2.9252562399051385e-06
always O 0 1.512067683506757e-06
haplotype O 0 0.00014550320338457823
A O 0 4.985045234207064e-05
. O 0 1.61794014275074e-05

To O 0 1.923406307469122e-05
find O 0 3.564068265404785e-06
an O 0 2.641774301537225e-07
origin O 0 3.0607844792029937e-07
of O 0 1.2348141353868414e-07
the O 0 2.9542022730311146e-06
( O 0 2.55979762187053e-06
CTG O 0 5.2606603276217356e-05
) O 0 3.310501028863655e-07
n O 0 7.627659215359017e-06
repeat O 0 5.076256911706878e-06
mutation O 0 8.846370747050969e-07
and O 0 4.096845032108831e-07
to O 0 2.8028472343066824e-07
investigate O 0 4.4187666503603396e-07
the O 0 3.804241188731794e-08
mechanism O 0 4.974733158746858e-08
of O 0 2.144087751787538e-08
the O 0 1.3863727588159236e-07
expansion O 0 1.6478835505040479e-06
mutation O 0 8.956181432040466e-07
in O 0 5.98378093741303e-08
the O 0 5.317265916460201e-08
Japanese O 0 9.717838338474394e-07
population O 0 5.592816165744807e-08
we O 0 1.8720228922575188e-08
have O 0 2.3555923434059878e-08
studied O 0 1.498298871638326e-07
90 O 0 2.279816158079484e-07
Japanese O 0 6.167951141833328e-06
DM B-Disease 1 0.9999971389770508
families O 0 3.019372343260329e-07
comprising O 0 5.8913709466423825e-08
190 O 0 3.00844163803049e-07
affected O 0 2.0928608535086823e-07
and O 0 2.5978229700740485e-07
130 O 0 1.3735391348745907e-06
unaffected O 0 1.3952469089417718e-05
members O 0 1.2646144114114577e-06
. O 0 4.490322226047283e-06

The O 0 4.7447778342757374e-05
results O 0 7.88872130215168e-05
suggest O 0 1.8997085362570942e-06
that O 0 6.61393499967744e-08
a O 0 1.7472109448135598e-07
few O 0 9.943607892637374e-08
common O 0 2.3582362018714775e-07
ancestral O 0 7.768233444949146e-06
mutations O 0 2.808808676491026e-05
in O 0 4.1478818957330077e-07
both O 0 4.942519922224164e-07
Caucasian O 0 6.153536378405988e-05
and O 0 2.4332484827027656e-06
Japanese O 0 3.452460987318773e-06
populations O 0 1.8705242155192536e-07
have O 0 5.548393033905086e-08
originated O 0 8.524562389311541e-08
by O 0 2.968062595698484e-08
expansion O 0 2.430205086056958e-07
of O 0 6.02481406986044e-08
an O 0 5.896642960578902e-07
ancestral O 0 6.760869837307837e-06
n O 0 0.0001377693988615647
= O 0 1.0254051630909089e-05
5 O 0 2.0573640995280584e-06
repeat O 0 4.952314156980719e-06
to O 0 3.079993291521532e-07
n O 0 8.355268619197886e-06
= O 0 6.593167654500576e-06
19 O 0 2.841002014974947e-06
- O 0 1.5093106412678026e-05
37 O 0 3.6854855807177955e-06
copies O 0 9.900390978145879e-06
. O 0 6.043019766366342e-06

These O 0 5.610301741398871e-06
data O 0 4.082366103830282e-06
support O 0 5.282743700263381e-07
multistep O 0 4.171391992713325e-06
models O 0 2.4087701149255736e-06
of O 0 1.3637314566494751e-07
triplet O 0 0.00032134278444573283
repeat O 0 3.9492799260187894e-05
expansion O 0 1.4875000715619535e-06
that O 0 1.8283459723988926e-07
have O 0 8.567889153709984e-08
been O 0 1.1160936708165536e-07
proposed O 0 2.8574743282661075e-07
for O 0 6.818341375947057e-07
both O 0 1.4135713172436226e-05
DM B-Disease 1 1.0
and O 0 0.0004413397400639951
Friedreichs B-Disease 0 0.10893750935792923
ataxia I-Disease 1 0.8692229986190796
. O 0 3.6056781027582474e-06
. O 0 6.768947059754282e-06

The O 0 7.406757958960952e-06
molecular O 0 2.5073723008972593e-05
basis O 0 9.585730367689393e-06
of O 0 8.030617755139247e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.6918037292489316e-06
the O 0 3.041002685222338e-07
western O 0 3.222599389118841e-06
Cape O 0 1.0748403838078957e-05
, O 0 2.5264424152737774e-07
South O 0 3.931377250410151e-07
Africa O 0 1.0141657185158692e-06
. O 0 2.4948476493591443e-06

Deficiency B-Disease 1 0.9927805066108704
of I-Disease 0 1.9289934698463185e-06
the I-Disease 0 4.3333949406587635e-07
sixth I-Disease 0 9.338157724414486e-06
component I-Disease 0 1.2611578767973697e-06
of I-Disease 0 1.101364759392709e-07
human I-Disease 0 3.848765572911361e-07
complement I-Disease 0 1.4487651469607954e-06
( O 0 1.24995176520315e-06
C6 O 0 0.01637549139559269
) O 0 1.4221695892047137e-06
has O 0 1.0202830935668317e-06
been O 0 1.2050109035044443e-06
reported O 0 4.996670668333536e-06
in O 0 5.331289898435898e-08
a O 0 1.9970372022726224e-07
number O 0 1.356353891424078e-07
of O 0 2.6929223295724114e-08
families O 0 4.012573029399391e-08
from O 0 3.7427195564987414e-08
the O 0 1.7128107288044703e-07
western O 0 2.0407755982887466e-06
Cape O 0 9.652513654145878e-06
, O 0 3.823868723884516e-07
South O 0 8.020020914045745e-07
Africa O 0 2.2994338451098884e-06
. O 0 2.995109298353782e-06

Meningococcal B-Disease 1 0.9996337890625
disease I-Disease 1 0.9967928528785706
is O 0 2.6447074560564943e-05
endemic O 0 2.703532481973525e-05
in O 0 2.5883859962050337e-06
the O 0 1.7004880419335677e-06
Cape O 0 3.0274793971329927e-05
and O 0 7.60481327688467e-07
almost O 0 5.431082428231093e-08
all O 0 2.0202783446165995e-08
pedigrees O 0 1.0326979236197076e-06
of O 0 1.1606406360442634e-06
total O 0 0.06780664622783661
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.38467531139031e-06
C6Q0 O 0 0.0018747993744909763
) O 0 5.255056976238848e-07
have O 0 1.9834983788769023e-07
been O 0 9.931634394888533e-07
ascertained O 0 1.4105348782322835e-05
because O 0 3.3111734865087783e-07
of O 0 1.7205131825903663e-06
recurrent O 1 0.9322901368141174
disease O 0 0.12397442758083344
. O 0 1.406584033247782e-05

We O 0 2.0314151697675698e-05
have O 0 1.0023007916970528e-06
sequenced O 0 2.3006357423582813e-06
the O 0 1.3856602265605034e-07
expressed O 0 1.466350028067609e-07
exons O 0 1.3575383945862995e-06
of O 0 7.674509561184095e-08
the O 0 4.633902221939934e-07
C6 O 0 0.0018561047036200762
gene O 0 2.046357167273527e-06
from O 0 4.446743062658243e-08
selected O 0 8.504019177735245e-08
cases O 0 4.360884986454039e-08
and O 0 2.355844372914362e-07
have O 0 1.5754326909700467e-07
found O 0 5.889213525733794e-07
three O 0 1.3080567669021548e-06
molecular O 0 0.005995173007249832
defects O 1 0.9085920453071594
leading O 0 3.014762478414923e-05
to O 0 4.274248567526229e-06
total O 0 0.0002478035166859627
deficiency O 0 0.0021493909880518913
879delG O 0 1.6582012904109433e-05
, O 0 1.1189813449163921e-06
which O 0 3.7816266740264837e-07
is O 0 8.871584356029416e-08
the O 0 1.13479238450509e-07
common O 0 3.1938518532115268e-06
defect O 0 2.302196116943378e-05
in O 0 1.590668432527309e-07
the O 0 3.6247053003535257e-07
Cape O 0 8.076487574726343e-06
and O 0 1.1005569149347139e-06
hitherto O 0 2.762652911769692e-06
unreported O 0 1.2033389111820725e-06
, O 0 2.2993278037120035e-07
and O 0 3.5306203471918707e-07
1195delC O 0 3.924599695892539e-06
and O 0 6.903162557136966e-07
1936delG O 0 5.892331500945147e-06
, O 0 1.8143667546155484e-07
which O 0 1.4979316631524853e-07
have O 0 9.808453427240238e-08
been O 0 8.084356295512407e-07
previously O 0 7.087883204803802e-06
reported O 0 8.546874596504495e-06
in O 0 1.5355351479229284e-07
African O 0 3.64546366427021e-07
- O 0 5.370630242396146e-05
Americans O 0 4.527474629867356e-06
. O 0 4.77986759506166e-06

We O 0 2.2378426365321502e-05
also O 0 1.1257718597335042e-06
show O 0 6.110570893724798e-07
that O 0 3.3549266476029516e-08
the O 0 4.5436937767817653e-08
879delG O 0 9.068134204426315e-06
and O 0 3.7333768432290526e-06
1195delC O 0 0.0003757998638320714
defects O 0 0.23279286921024323
are O 0 1.9798717687535827e-07
associated O 0 1.025308506541478e-06
with O 0 1.3500783779818448e-06
characteristic O 0 0.002999912714585662
C6 O 1 0.9997060894966125
/ O 0 0.07678257673978806
C7 O 0 0.011399160139262676
region O 0 1.9328022972331382e-05
DNA O 0 4.389146852190606e-05
marker O 0 1.7425945770810358e-05
haplotypes O 0 4.674174851970747e-05
, O 0 5.630856207972101e-07
although O 0 1.4575039131159429e-07
small O 0 2.8994330136811186e-07
variations O 0 1.2629425327759236e-05
were O 0 2.8227022994542494e-06
observed O 0 9.446627700526733e-06
. O 0 6.420684258046094e-06

The O 0 4.132912727072835e-05
1936delG O 0 0.0008183857426047325
defect O 0 0.002101578051224351
was O 0 6.316182407317683e-05
observed O 0 2.675378482308588e-06
only O 0 1.490558645400597e-07
once O 0 7.251105671457481e-07
in O 0 2.9667955914192135e-07
the O 0 1.8574198179521773e-07
Cape O 0 1.0311193364032079e-05
, O 0 3.6410858683666447e-07
but O 0 1.1191441018354453e-07
its O 0 9.462734738008294e-07
associated O 0 4.980694939149544e-06
haplotype O 0 0.0001679034176049754
could O 0 5.097223038319498e-06
be O 0 1.25598842259933e-06
deduced O 0 3.0348159270943142e-05
. O 0 7.840658327040728e-06

The O 0 7.180705779319396e-06
data O 0 3.9570600165461656e-06
from O 0 2.165909762652518e-07
the O 0 2.2943773103634157e-07
haplotypes O 0 1.2013679224764928e-05
indicate O 0 1.9059239093621727e-06
that O 0 8.530124517847071e-08
these O 0 1.744843913797922e-08
three O 0 5.301473038343829e-07
molecular O 0 0.0012833933578804135
defects O 1 0.5451501607894897
account O 0 3.914686658390565e-06
for O 0 1.0477828027433134e-06
the O 0 9.77066156337969e-06
defects O 0 0.2168441116809845
in O 0 5.748808007410844e-07
all O 0 2.3301387486185376e-08
the O 0 1.6546155734431522e-07
38 O 0 2.1378616565925768e-06
unrelated O 0 9.089380910154432e-07
C6Q0 O 0 0.00014190126967150718
individuals O 0 5.844777106744914e-08
we O 0 6.77918023939128e-08
have O 0 8.333127965443055e-08
studied O 0 6.964274916754221e-07
from O 0 1.6749886810885073e-07
the O 0 8.303322260871937e-07
Cape O 0 0.00011161689326399937
. O 0 8.902125955501106e-06

We O 0 1.7105372535297647e-05
have O 0 7.03166620041884e-07
also O 0 6.280907882683096e-07
observed O 0 4.40478970631375e-07
the O 0 1.5770635286571633e-07
879delG O 0 2.5610876036807895e-05
defect O 0 2.465812758600805e-05
in O 0 2.709944624257332e-07
two O 0 2.580718046374386e-06
Dutch O 1 0.6795564293861389
C6 B-Disease 1 1.0
- I-Disease 1 0.999996542930603
deficient I-Disease 1 0.9999974966049194
kindreds O 0 0.00014289790124166757
, O 0 7.046031669233344e-07
but O 0 5.988930240619084e-08
the O 0 1.344918558743302e-07
879delG O 0 2.217708606622182e-05
defect O 0 1.3007549569010735e-05
in O 0 4.937959374728962e-07
the O 0 5.140113330526219e-07
Cape O 0 2.488759309926536e-05
probably O 0 2.518953351682285e-06
did O 0 3.1046263870848634e-07
not O 0 1.8694645831374146e-08
come O 0 1.6887657494635278e-08
from O 0 2.1164664687489676e-08
The O 0 1.764868642339934e-07
Netherlands O 0 1.11113149614539e-05
. O 0 7.159052302085911e-07
. O 0 3.546535253917682e-06

Complement B-Disease 1 0.5491401553153992
C7 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999998807907104
: O 0 1.9057539248024113e-05
seven O 0 2.7508697257871972e-06
further O 0 1.8211064798379084e-06
molecular O 0 0.0008262458140961826
defects O 1 0.9142810106277466
and O 0 3.69255690202408e-06
their O 0 4.873779289482627e-06
associated O 0 2.829639743140433e-05
marker O 0 0.0003147930547129363
haplotypes O 0 0.0020020771771669388
. O 0 2.766070610960014e-05

Seven O 0 3.127925447188318e-05
further O 0 5.031990895076888e-06
molecular O 0 2.0060148017364554e-05
bases O 0 9.628131010686047e-06
of O 0 0.0001665949384914711
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 7.550825557700591e-06
described O 0 0.0001227978355018422
. O 0 1.7162594303954393e-05

All O 0 1.6883266198419733e-06
these O 0 2.799996536850813e-07
new O 0 2.349293708903133e-06
molecular O 0 0.0001860711636254564
defects O 0 0.046145305037498474
involve O 0 4.694252027093171e-07
single O 0 9.661187505116686e-06
- O 0 9.628843690734357e-05
nucleotide O 0 6.288870736170793e-06
events O 0 2.034014698892861e-07
, O 0 3.727232638084388e-07
deletions O 0 1.3769229099125369e-06
and O 0 3.4712752494669985e-07
substitutions O 0 4.791327796738187e-07
, O 0 1.0533297256642982e-07
some O 0 1.076610711692183e-08
of O 0 2.3736598464552117e-08
which O 0 1.1885167623404413e-06
alter O 0 1.6833020708872937e-05
splice O 0 6.0497226513689384e-05
sites O 0 9.454219025428756e-07
, O 0 2.401986307631887e-07
and O 0 3.969276178850123e-07
others O 0 1.9299577616038732e-06
codons O 0 1.2940464330313262e-05
. O 0 3.7471095311047975e-06

They O 0 7.205380825325847e-06
are O 0 9.820752921996245e-08
distributed O 0 7.574573857027644e-08
along O 0 9.414149104713943e-08
the O 0 3.0149584517857875e-07
C7 O 0 0.0004115972842555493
gene O 0 4.431301476870431e-06
, O 0 8.694965458744264e-08
but O 0 1.6450080408958456e-08
predominantly O 0 4.242156848022205e-08
towards O 0 7.595131279458656e-08
the O 0 1.9089239344793896e-07
3 O 0 5.852864433109062e-06
end O 0 1.1983893273281865e-05
. O 0 5.810779384773923e-06

All O 0 5.697824690287234e-06
were O 0 2.8437996206776006e-06
found O 0 1.246443730451574e-06
in O 0 3.960341530273581e-07
compound O 0 2.4721681256778538e-05
heterozygous O 0 5.141416113474406e-05
individuals O 0 1.2682377246164833e-06
. O 0 4.92778826810536e-06

The O 0 8.90517039806582e-05
C6 O 1 0.9051122069358826
/ O 0 0.06599307060241699
C7 O 0 0.01948089711368084
marker O 0 0.00027789900195784867
haplotypes O 0 0.0004214025684632361
associated O 0 8.131097274599597e-06
with O 0 1.4844489442111808e-06
most O 0 2.681757541722618e-05
C7 B-Disease 1 0.9999698400497437
defects I-Disease 1 0.9992851614952087
are O 0 1.2813005696443724e-06
tabulated O 0 2.1125473722349852e-05
. O 0 1.0731233714977861e-06
. O 0 2.6201887521892786e-06

A O 0 0.00010745126928668469
genome O 0 3.7198482459643856e-05
- O 0 5.352322114049457e-05
wide O 0 1.5131437294257921e-06
search O 0 1.535211481495935e-06
for O 0 1.437854166397301e-06
chromosomal O 0 0.000697970564942807
loci O 0 1.893630724225659e-05
linked O 0 0.0008975317468866706
to O 0 5.304886872181669e-05
mental O 0 0.006670072209089994
health O 0 3.0293798772618175e-05
wellness O 0 7.194960926426575e-05
in O 0 3.509063844830962e-06
relatives O 0 4.262020866008243e-06
at O 0 7.968156751303468e-06
high O 0 0.0002358808706048876
risk O 0 5.912142660235986e-05
for O 0 8.320742927026004e-05
bipolar B-Disease 1 0.9999983310699463
affective I-Disease 1 0.9998941421508789
disorder I-Disease 0 0.4986419677734375
among O 0 3.9318985045611043e-07
the O 0 4.819704599867691e-07
Old O 0 1.168858761957381e-05
Order O 0 1.2315605317780864e-06
Amish O 0 0.00012926288763992488
. O 0 1.0199114512943197e-05

Bipolar B-Disease 1 0.9999983310699463
affective I-Disease 1 0.9999949932098389
disorder I-Disease 1 0.9999933242797852
( O 0 0.004284427035599947
BPAD B-Disease 1 0.9999998807907104
; O 1 0.5099906325340271
manic B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999997615814209
depressive I-Disease 1 0.9999998807907104
illness I-Disease 1 0.9862728714942932
) O 0 6.188408406160306e-06
is O 0 1.0752480648079654e-06
characterized O 0 7.276110409293324e-06
by O 0 6.966347427805886e-07
episodes O 0 5.204050467000343e-06
of O 0 3.2318709486389707e-07
mania B-Disease 0 0.009478521533310413
and O 0 1.980099295906257e-05
/ O 0 0.0006856843829154968
or O 0 3.6990140870329924e-06
hypomania B-Disease 0 0.000932056806050241
interspersed O 0 6.847379154351074e-06
with O 0 6.742543519067112e-07
periods O 0 4.3559657569858246e-06
of O 0 4.291550339985406e-06
depression B-Disease 0 0.000247966090682894
. O 0 1.2622453141375445e-05

Compelling O 0 6.536719592986628e-05
evidence O 0 7.441110028594267e-06
supports O 0 2.776006112981122e-06
a O 0 8.180791724043956e-07
significant O 0 1.1719399708454148e-06
genetic O 0 3.7889583381911507e-06
component O 0 2.2565852759726113e-06
in O 0 5.893415959690174e-07
the O 0 1.7685007378531736e-06
susceptibility O 0 0.00015038202400319278
to O 0 9.333279194834176e-06
develop O 0 0.00015350016474258155
BPAD B-Disease 1 0.9999916553497314
. O 0 9.747799776960164e-05

To O 0 1.682714901107829e-05
date O 0 1.8104179616784677e-05
, O 0 1.0526322284931666e-06
however O 0 2.780844567951135e-07
, O 0 2.1135100780611538e-07
linkage O 0 9.692121238913387e-06
studies O 0 1.0498753226784174e-06
have O 0 2.37365156863234e-07
attempted O 0 8.329445336130448e-06
only O 0 6.834317645143528e-08
to O 0 3.7991586054886284e-07
identify O 0 6.245712029340211e-06
chromosomal O 0 0.00032571147312410176
loci O 0 1.1209166586922947e-05
that O 0 3.1641773148294305e-06
cause O 0 3.50428172168904e-06
or O 0 3.6140531278761046e-07
increase O 0 9.488144883107452e-07
the O 0 6.57500606848771e-07
risk O 0 3.6590060972230276e-06
of O 0 7.333844678214518e-07
developing O 0 5.7143708545481786e-05
BPAD B-Disease 1 0.999992847442627
. O 0 6.887351628392935e-05

To O 0 3.605508027249016e-05
determine O 0 5.103750481794123e-06
whether O 0 4.584110797622998e-07
there O 0 1.5042103029827558e-07
could O 0 4.03124516878961e-07
be O 0 1.0301213393404396e-07
protective O 0 1.4075485523790121e-06
alleles O 0 4.164417930496711e-07
that O 0 1.9433855413808487e-07
prevent O 0 4.858001716456783e-07
or O 0 3.2273621286549314e-07
reduce O 0 3.8255939216469415e-06
the O 0 1.0940239008050412e-06
risk O 0 1.4966281014494598e-06
of O 0 1.3505867002550076e-07
developing O 0 9.559986210661009e-06
BPAD B-Disease 1 0.9999902248382568
, O 0 1.4205213574314257e-06
similar O 0 1.2228106527345517e-07
to O 0 2.3392661319121544e-07
what O 0 1.3461863090924453e-07
is O 0 2.455840331094805e-07
observed O 0 9.438841175324342e-07
in O 0 8.330925425070745e-07
other O 0 1.859439908002969e-05
genetic B-Disease 1 0.9999995231628418
disorders I-Disease 1 0.9999995231628418
, O 0 6.106054115662118e-06
we O 0 7.906592713879945e-07
used O 0 5.5751846957718953e-05
mental O 0 0.0013417942682281137
health O 0 1.0791870408866089e-05
wellness O 0 5.708395838155411e-05
( O 0 7.613659249727789e-07
absence O 0 4.0001177126214316e-07
of O 0 6.433953103623935e-07
any O 0 6.47157576167956e-05
psychiatric B-Disease 1 0.986060380935669
disorder I-Disease 0 0.020075736567378044
) O 0 3.7154714505049924e-07
as O 0 2.7664498247759184e-07
the O 0 5.0460914735595e-07
phenotype O 0 2.6551746486802585e-05
in O 0 6.779986847504915e-07
our O 0 1.003622628559242e-06
genome O 0 3.13705777443829e-06
- O 0 3.549976827343926e-05
wide O 0 1.8485642385712708e-06
linkage O 0 2.881608816096559e-05
scan O 0 4.2563282477203757e-05
of O 0 5.5077986615970076e-08
several O 0 7.233791166072479e-08
large O 0 3.557724426173081e-07
multigeneration O 0 6.779048271710053e-05
Old O 0 5.383687494031619e-06
Order O 0 2.9127053835509287e-07
Amish O 0 1.5095208254933823e-05
pedigrees O 0 2.224528907390777e-05
exhibiting O 0 6.197497896209825e-06
an O 0 1.213550717693579e-06
extremely O 0 4.996398729417706e-06
high O 0 4.713335874839686e-05
incidence O 0 0.0074340179562568665
of O 0 1.0896342246269342e-05
BPAD B-Disease 1 0.9999992847442627
. O 0 0.00011158933921251446

We O 0 4.4181437260704115e-05
have O 0 9.439714290238044e-07
found O 0 7.230465257634933e-07
strong O 0 3.4186217590104206e-07
evidence O 0 2.9747201324425987e-07
for O 0 1.2982533803551632e-07
a O 0 1.939103185577551e-06
locus O 0 3.2537151128053665e-05
on O 0 0.0003504933847580105
chromosome O 0 0.001540081575512886
4p O 0 0.07089441269636154
at O 0 1.455510482628597e-05
D4S2949 O 0 1.244598752236925e-05
( O 0 2.2723533277257957e-07
maximum O 0 6.753187449248799e-07
GENEHUNTER O 0 0.00016526102263014764
- O 0 5.8451190852792934e-05
PLUS O 0 8.633664037915878e-06
nonparametric O 0 9.826663699641358e-06
linkage O 0 8.1940943346126e-06
score O 0 1.9603783130150987e-06
= O 0 1.0839100468729157e-05
4 O 0 4.810498012375319e-06
. O 0 2.9398782430689607e-07
05 O 0 7.652372914890293e-06
, O 0 3.1935363153934304e-07
P O 0 0.00012104144116165116
= O 0 4.420310688146856e-06
5 O 0 1.4006270703248447e-06
. O 0 1.0652379245357224e-07
22 O 0 4.939306563755963e-07
x O 0 1.3351565030461643e-05
10 O 0 2.7502926513989223e-06
( O 0 1.7550600261984073e-07
- O 0 1.1876707503688522e-05
4 O 0 2.3139498807722703e-05
) O 0 3.771779688577226e-07
; O 0 1.1597327898016374e-07
SIBPAL O 0 9.64892387855798e-06
Pempirical O 0 3.234027872167644e-06
value O 0 2.477569580605632e-07
< O 0 2.2388995546407386e-07
3 O 0 6.417988629436877e-07
x O 0 1.9751334548345767e-05
10 O 0 1.7905250615513069e-06
( O 0 1.8568707105259818e-07
- O 0 2.682979902601801e-05
5 O 0 1.0749879947979935e-05
) O 0 2.634061218032002e-07
) O 0 9.98475400137977e-08
and O 0 6.933552185728331e-07
suggestive O 0 5.08881066707545e-06
evidence O 0 4.315010642130801e-07
for O 0 8.899191783484639e-08
a O 0 2.422181523797917e-06
locus O 0 3.784371801884845e-05
on O 0 0.013003716245293617
chromosome O 1 0.5433135032653809
4q O 1 0.9985178112983704
at O 0 1.0844384632946458e-05
D4S397 O 0 1.970885023183655e-05
( O 0 2.2117227160833863e-07
maximum O 0 7.467971840924292e-07
GENEHUNTER O 0 0.00020973743812646717
- O 0 5.731736746383831e-05
PLUS O 0 9.959786439139862e-06
nonparametric O 0 6.504967132059392e-06
linkage O 0 4.677307515521534e-06
score O 0 1.8713501503953012e-06
= O 0 6.839469278929755e-06
3 O 0 4.489971161092399e-06
. O 0 6.320343004517781e-07
29 O 0 4.640465704142116e-06
, O 0 4.314924524351227e-07
P O 0 0.0003830070490948856
= O 0 4.585117494571023e-06
2 O 0 2.019950898102252e-06
. O 0 2.0632734276659903e-07
57 O 0 1.3154877933629905e-06
x O 0 1.6471263734274544e-05
10 O 0 1.1143052915940643e-06
( O 0 1.1576101144328277e-07
- O 0 1.2438749763532542e-05
3 O 0 7.224734872579575e-06
) O 0 2.1596228805265127e-07
; O 0 1.3709203017242544e-07
SIBPAL O 0 1.3267969734442886e-05
Pempirical O 0 5.244551175564993e-06
value O 0 2.1874902245144767e-07
< O 0 3.969435340422933e-07
1 O 0 5.716617579309968e-07
x O 0 2.23842725972645e-05
10 O 0 1.8430441741656978e-06
( O 0 3.571056197415601e-07
- O 0 5.771468931925483e-05
3 O 0 3.815161107922904e-05
) O 0 5.315501425684488e-07
) O 0 3.846112051064665e-08
that O 0 4.214301441152202e-08
are O 0 5.148522319586846e-08
linked O 0 3.9833856135373935e-05
to O 0 3.2726038625696674e-05
mental O 0 0.0011180737055838108
health O 0 2.8156153348390944e-05
wellness O 0 0.00013772383681498468
. O 0 1.2226395483594388e-05

These O 0 1.1742830793082248e-05
findings O 0 1.455148321838351e-05
are O 0 1.6739697628054273e-07
consistent O 0 8.412632155341271e-07
with O 0 2.449214093758201e-07
the O 0 4.4233621565581416e-07
hypothesis O 0 2.3702702947048238e-06
that O 0 9.583507676325098e-08
certain O 0 3.047090046948142e-08
alleles O 0 4.141517990774446e-07
could O 0 5.56843986032618e-07
prevent O 0 4.5926174152555177e-07
or O 0 2.640590537339449e-07
modify O 0 3.226683247703477e-06
the O 0 1.0228023938907427e-06
clinical O 0 5.614337624137988e-06
manifestations O 0 2.3419386252498953e-06
of O 0 9.80280333351402e-07
BPAD B-Disease 1 0.9999996423721313
and O 0 1.5113919289433397e-05
perhaps O 0 1.1788112033173093e-06
other O 0 1.0241943755318061e-06
related O 0 0.00011748584802262485
affective B-Disease 1 0.993719220161438
disorders I-Disease 1 0.965339720249176
. O 0 3.935714630642906e-05

Segregation O 0 0.008171569555997849
distortion O 1 0.8175551295280457
in O 0 0.012718893587589264
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.004356833174824715

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997356534004211
DM B-Disease 1 1.0
) O 0 0.00024450261844322085
is O 0 1.8115932789442013e-06
an O 0 6.402554845408304e-06
autosomal B-Disease 1 0.8402555584907532
dominant I-Disease 1 0.8862193822860718
disease I-Disease 1 0.7246538996696472
which O 0 3.671922286230256e-06
, O 0 8.572660021854972e-07
in O 0 1.939177423082583e-07
the O 0 4.0753346297606186e-07
typical O 0 6.229543032532092e-06
pedigree O 0 7.537137571489438e-05
, O 0 5.331646093509335e-07
shows O 0 1.3434238610443572e-07
a O 0 1.1046720516105779e-07
three O 0 3.378306985268864e-07
generation O 0 4.163713128946256e-06
anticipation O 0 2.921314262493979e-06
cascade O 0 7.821426697773859e-05
. O 0 8.49203388497699e-06

This O 0 1.6640880858176388e-05
results O 0 0.0001376774744130671
in O 0 0.00016617799701634794
infertility B-Disease 1 0.9999790191650391
and O 1 0.9997851252555847
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0012316995998844504
CDM B-Disease 0 0.0036792480386793613
) O 0 1.8188969761467888e-06
with O 0 2.2666070265131566e-07
the O 0 1.5267082744685467e-06
disappearance O 0 8.230214734794572e-05
of O 0 6.9799862103536725e-06
DM B-Disease 1 1.0
in O 0 4.5593365939566866e-05
that O 0 5.696498647012049e-06
pedigree O 0 0.00019549697753973305
. O 0 1.7517637388664298e-05

The O 0 7.820361133781262e-06
concept O 0 3.1212948670145124e-06
of O 0 9.356076589028817e-07
segregation O 0 1.1197028470633086e-05
distortion O 0 0.0003332403430249542
, O 0 1.8161322259402368e-06
where O 0 2.388834730027156e-07
there O 0 1.9413899821074665e-08
is O 0 5.170823058620044e-08
preferential O 0 3.937395547382039e-07
transmission O 0 1.2764000985043822e-06
of O 0 1.9709883503082892e-08
the O 0 7.684528924301048e-08
larger O 0 2.3275011074019858e-07
allele O 0 2.464665158186108e-06
at O 0 2.6450793484400492e-06
the O 0 6.010862307448406e-06
DM B-Disease 1 0.9999998807907104
locus O 0 0.00019193082698620856
, O 0 2.007678631343879e-06
has O 0 5.952368837824906e-07
been O 0 2.4725818548176903e-07
put O 0 3.254536409258435e-07
forward O 0 2.0934638200742484e-07
to O 0 3.0204552103896276e-07
explain O 0 7.377898896265833e-07
partially O 0 5.012095243728254e-06
the O 0 2.6401144737064897e-07
maintenance O 0 1.2999464161111973e-05
of O 0 2.4945359200501116e-06
DM B-Disease 1 0.9999998807907104
in O 0 6.660091457888484e-06
the O 0 1.35411187329737e-06
population O 0 2.025890807999531e-06
. O 0 3.370491413079435e-06

In O 0 1.79130001924932e-05
a O 0 1.1779990927607287e-05
survey O 0 9.244069224223495e-05
of O 0 3.0888227229297627e-06
DM B-Disease 1 1.0
in O 0 3.404620656510815e-05
Northern O 0 2.036469777522143e-05
Ireland O 0 3.7007172068115324e-05
, O 0 1.1936272130697034e-06
59 O 0 3.1239214877132326e-06
pedigrees O 0 8.842618626658805e-06
were O 0 3.869452484650537e-06
ascertained O 0 6.780256808269769e-05
. O 0 9.243686690751929e-06

Sibships O 0 0.0013110059080645442
where O 0 5.868878361070529e-06
the O 0 2.3835372076064232e-07
status O 0 1.4468112397025834e-07
of O 0 1.7875681379564412e-08
all O 0 1.3320258673843455e-08
the O 0 5.895619992202228e-08
members O 0 1.1650915610061929e-07
had O 0 2.0706766008515842e-06
been O 0 4.893984169029864e-07
identified O 0 2.4072546693787444e-06
were O 0 4.716279988770111e-07
examined O 0 1.0084813766297884e-06
to O 0 2.379317436407291e-07
determine O 0 3.040944420718006e-07
the O 0 1.1277237632612014e-07
transmission O 0 2.9091872875142144e-06
of O 0 9.634348430154205e-08
the O 0 3.870910404657479e-06
DM B-Disease 1 0.9999996423721313
expansion O 0 1.662630347709637e-05
from O 0 1.0545895747782197e-06
affected O 0 2.775715017833136e-07
parents O 0 8.96761989110928e-08
to O 0 9.821352620065227e-08
their O 0 1.032491127261892e-06
offspring O 0 2.2486672605737112e-05
. O 0 4.071165221830597e-06

Where O 0 2.0907673388137482e-05
the O 0 3.843486865662271e-06
transmitting O 0 0.00026913179317489266
parent O 0 5.842828250024468e-05
was O 0 2.1010831915191375e-05
male O 0 2.439391664665891e-06
, O 0 7.74333614117495e-07
58 O 0 9.706088349048514e-06
. O 0 4.491200343181845e-06

3 O 0 5.340513962437399e-05
% O 0 1.645526367610728e-06
of O 0 1.4630396094617026e-07
the O 0 7.163129112086608e-07
offspring O 0 1.4072147678234614e-05
were O 0 4.39695122622652e-06
affected O 0 3.2982424613692274e-07
, O 0 2.0376181453229947e-07
and O 0 3.023683348146733e-07
in O 0 1.6626432852717699e-07
the O 0 1.7982208078137774e-07
case O 0 4.852296910939913e-07
of O 0 3.0277686136059856e-08
a O 0 1.9216124655940803e-06
female O 0 1.0993118849000894e-05
transmitting O 0 0.00012183209764771163
parent O 0 1.240773326571798e-05
, O 0 7.265774115694512e-07
68 O 0 1.1705678844009526e-05
. O 0 9.113684427575208e-06

7 O 0 0.00034820270957425237
% O 0 1.97716144612059e-05
were O 0 7.68612062529428e-06
affected O 0 1.1327977517794352e-05
. O 0 1.035582408803748e-05

Studies O 0 6.849265628261492e-05
on O 0 8.107093890430406e-06
meiotic O 0 0.00012683519162237644
drive O 0 8.997923578135669e-05
in O 0 8.533152140444145e-05
DM B-Disease 1 1.0
have O 0 1.5453999367309734e-05
shown O 0 9.64190121521824e-07
increased O 0 3.3031372481673316e-07
transmission O 0 1.2369160913294763e-06
of O 0 1.7897582083037378e-08
the O 0 1.0916917858594388e-07
larger O 0 2.658490245721623e-07
allele O 0 2.8656938866333803e-06
at O 0 1.342943846793787e-06
the O 0 3.488776201265864e-06
DM B-Disease 1 0.9999998807907104
locus O 0 6.319103704299778e-05
in O 0 3.430091737754992e-06
non O 0 4.744085526908748e-05
- O 1 0.7276453375816345
DM O 1 0.9999995231628418
heterozygotes O 0 0.00015747291035950184
for O 0 2.4049738840403734e-06
CTGn O 0 0.0005331914871931076
. O 0 1.7857257262221538e-05

This O 0 9.002337719721254e-06
study O 0 2.84772113445797e-06
provides O 0 6.392149884959508e-07
further O 0 3.6280462722970697e-07
evidence O 0 4.903332637695712e-07
that O 0 3.124932845821604e-07
the O 0 2.0871873402938945e-06
DM B-Disease 1 0.9999996423721313
expansion O 0 1.927022822201252e-05
tends O 0 2.4779196792223956e-06
to O 0 2.651739805514808e-07
be O 0 3.2074575528895366e-07
transmitted O 0 6.452635261666728e-06
preferentially O 0 1.3784107068204321e-05
. O 0 4.993021775590023e-06

Diagnosis O 1 0.9989610910415649
of O 0 0.00045729256817139685
hemochromatosis B-Disease 1 0.9999994039535522
. O 0 0.001319650444202125

If O 0 0.0002763817901723087
untreated O 1 0.6437041759490967
, O 0 0.0002885808644350618
hemochromatosis B-Disease 1 0.9999998807907104
can O 0 0.0008560865535400808
cause O 0 0.0008169813663698733
serious O 0 0.002550026634708047
illness O 0 0.024123607203364372
and O 0 2.0228317225701176e-05
early B-Disease 0 0.00019705291197169572
death I-Disease 0 0.0001526659616502002
, O 0 7.141336482163751e-07
but O 0 2.022681258040393e-07
the O 0 2.033090822806116e-06
disease O 0 3.631034633144736e-05
is O 0 2.46655019964237e-07
still O 0 7.031371183074953e-07
substantially O 0 9.79933793132659e-06
under O 0 2.6383002023067093e-06
- O 1 0.9605032801628113
diagnosed O 1 0.8273407220840454
. O 0 8.933942808653228e-06

The O 0 6.686145297862822e-06
cornerstone O 0 3.49134425050579e-05
of O 0 4.2059505744873604e-07
screening O 0 2.573870460764738e-06
and O 0 1.263204126189521e-06
case O 0 6.622379942200496e-07
detection O 0 1.505993054706778e-06
is O 0 1.4489390309790906e-07
the O 0 1.267566460683156e-07
measurement O 0 8.229955710703507e-06
of O 0 5.624555683425569e-07
serum O 0 1.3750944162893575e-05
transferrin O 0 1.5728890502941795e-05
saturation O 0 2.4665462206030497e-06
and O 0 1.8331594731080258e-07
the O 0 3.59023005103154e-07
serum O 0 1.1830349649244454e-05
ferritin O 0 3.8306770875351503e-05
level O 0 5.18585329700727e-06
. O 0 6.07168976785033e-06

Once O 0 9.576850425219163e-05
the O 0 5.3830817705602385e-06
diagnosis O 0 0.00701010599732399
is O 0 2.0958718778274488e-06
suspected O 0 0.0001527786662336439
, O 0 6.433801445382414e-06
physicians O 0 1.4841120901110116e-06
must O 0 1.4887686461406702e-07
use O 0 3.033891289305757e-07
serum O 0 5.893781235499773e-06
ferritin O 0 2.5074559744098224e-05
levels O 0 9.492434855928877e-07
and O 0 1.6462090570712462e-06
hepatic O 0 0.0006198427290655673
iron O 0 0.03269505500793457
stores O 0 0.00013074323942419142
on O 0 0.0008822964155115187
liver O 0 0.06330391019582748
biopsy O 0 0.30648186802864075
specimens O 0 7.637281669303775e-06
to O 0 3.1473332455789205e-06
assess O 0 5.162552042747848e-05
patients O 0 3.1537779250356834e-06
for O 0 4.286975041623009e-08
the O 0 1.2378797009660047e-07
presence O 0 4.191639106920775e-07
of O 0 6.450368914556748e-07
iron B-Disease 1 0.7984306812286377
overload I-Disease 0 0.0030043257866054773
. O 0 1.553669608256314e-05

Liver O 1 0.9999067783355713
biopsy O 1 0.9992761015892029
is O 0 2.497185232641641e-05
also O 0 2.045594328592415e-06
used O 0 5.991215630274382e-07
to O 0 1.3655377983923245e-07
establish O 0 2.4383862751165e-07
the O 0 1.600776329269138e-07
presence O 0 1.614439497643616e-07
or O 0 2.849916995728563e-07
absence O 0 4.196991199023614e-07
of O 0 6.023986998116015e-07
cirrhosis B-Disease 0 0.14434930682182312
, O 0 4.739586529467488e-06
which O 0 2.811654894685489e-06
can O 0 1.7594064729564707e-06
affect O 0 1.376314594381256e-05
prognosis O 0 0.09499701857566833
and O 0 2.0524495994322933e-05
management O 0 5.3432500862982124e-05
. O 0 7.175551218097098e-06

A O 0 0.0001264572056243196
DNA O 0 0.00022308599727693945
- O 0 0.0002739349438343197
based O 0 7.651687155885156e-06
test O 0 5.565615879277175e-07
for O 0 7.43827612836867e-08
the O 0 1.7799919760363991e-07
HFE O 0 5.9366448112996295e-05
gene O 0 1.8742273368843598e-06
is O 0 6.54004850275669e-08
commercially O 0 1.0658196742951986e-06
available O 0 8.917746185943543e-08
, O 0 4.36259917080406e-08
but O 0 1.7013876529858862e-08
its O 0 1.296492797564497e-07
place O 0 7.885823265496583e-07
in O 0 3.277300777426717e-07
the O 0 1.6173920585060841e-06
diagnosis O 0 0.014979569241404533
of O 0 1.217259978147922e-05
hemochromatosis B-Disease 1 1.0
is O 0 6.076991121517494e-05
still O 0 1.0447620297782123e-05
being O 0 3.3872993299155496e-06
evaluated O 0 8.016892934392672e-06
. O 0 2.7853295705426717e-06

Currently O 0 3.787292371271178e-05
, O 0 9.20866170872614e-07
the O 0 7.242543631491571e-08
most O 0 5.4414925898527144e-08
useful O 0 1.1771761165846328e-07
role O 0 2.2565025403764594e-07
for O 0 2.701241328395554e-07
this O 0 1.2289893902561744e-07
test O 0 4.984231054550037e-07
is O 0 1.1644761599427511e-07
in O 0 5.026207361424895e-08
the O 0 7.663699364002241e-08
detection O 0 3.7707543469878146e-06
of O 0 2.3835991669329815e-06
hemochromatosis B-Disease 1 0.9999997615814209
in O 0 1.0680128980311565e-05
the O 0 8.427962256973842e-07
family O 0 1.583018615747278e-06
members O 0 1.1147001544031809e-07
of O 0 9.872268691424324e-08
patients O 0 7.244228186209511e-07
with O 0 3.5458345593042395e-08
a O 0 7.464023383363383e-06
proven O 0 0.00014128560724202543
case O 0 1.329233668911911e-06
of O 0 2.421208478153858e-07
the O 0 2.3981208869372495e-05
disease O 0 0.0014233133988454938
. O 0 7.801725587341934e-06

It O 0 1.3491797290043905e-05
is O 0 1.1999010212093708e-06
crucial O 0 4.373331648821477e-06
to O 0 5.356601104722358e-05
diagnose O 1 0.9996881484985352
hemochromatosis B-Disease 1 1.0
before O 1 0.6104170083999634
hepatic B-Disease 1 0.9999690055847168
cirrhosis I-Disease 1 0.9999270439147949
develops O 0 0.005642459262162447
because O 0 1.3178132576285861e-05
phlebotomy O 0 0.009188882075250149
therapy O 0 0.0003605113015510142
can O 0 7.293443559319712e-06
avert O 0 0.11342624574899673
serious O 1 0.897311270236969
chronic O 1 0.9999972581863403
disease O 1 0.7028519511222839
and O 0 1.0111284609592985e-05
can O 0 8.261743005277822e-07
even O 0 2.9081977004352666e-07
lead O 0 6.717988526361296e-06
to O 0 1.2982512771486654e-06
normal O 0 1.940869879035745e-06
life O 0 2.8540912353491876e-06
expectancy O 0 1.712456469249446e-05
. O 0 6.7233833078717e-07
. O 0 3.4102149584214203e-06

Prevalence O 0 0.0017286513466387987
of O 0 2.5243257368856575e-06
the O 0 1.1735751286323648e-06
I1307K O 0 2.3726046492811292e-05
APC B-Disease 0 1.6777119526523165e-05
gene O 0 1.7601751096663065e-06
variant O 0 3.865741746267304e-06
in O 0 2.645238339482603e-07
Israeli O 0 5.795073775516357e-06
Jews O 0 8.955976795732568e-07
of O 0 4.408033404956768e-08
differing O 0 3.833698372091021e-07
ethnic O 0 9.429079455003375e-07
origin O 0 3.0533492463291623e-06
and O 0 2.40465669776313e-05
risk O 0 0.0002707118692342192
for O 0 0.36758309602737427
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 8.482672274112701e-05

BACKGROUND O 0 0.0005965741584077477
& O 0 0.00410874467343092
AIMS O 0 3.059487062273547e-05
Israeli O 0 6.57746704746387e-06
Jews O 0 6.556022640324954e-07
of O 0 1.0056675847636143e-07
European O 0 5.0880580602097325e-06
birth O 0 2.0180648789391853e-05
, O 0 1.182179630632163e-06
i O 0 6.422084197765798e-07
. O 0 5.0816147734167316e-08
e O 0 1.552894843825925e-07
. O 0 3.4247786828700555e-08
, O 0 7.35722878175693e-08
Ashkenazim O 0 1.7299570345130633e-06
, O 0 1.6849185158207547e-07
have O 0 1.31012129145347e-07
the O 0 2.5158803964586696e-06
highest O 1 0.9996558427810669
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.013940631411969662
of O 0 2.0932701261244802e-07
any O 0 2.713081528327166e-07
Israeli O 0 3.1380153814097866e-05
ethnic O 0 9.814499208005145e-06
group O 0 7.885126251494512e-05
. O 0 8.021451321837958e-06

The O 0 1.623507523618173e-05
I1307K O 0 8.745260129217058e-05
APC B-Disease 0 0.0001101703237509355
gene O 0 1.750496267050039e-05
variant O 0 4.81964998471085e-05
was O 0 2.5431627364014275e-05
found O 0 2.789492555166362e-06
in O 0 1.064474759004952e-06
6 O 0 5.5652250011917204e-05
. O 0 1.6045656593632884e-05

1 O 0 3.279161683167331e-05
% O 0 2.3771949599904474e-06
of O 0 2.330179569298707e-07
American O 0 1.7869837165562785e-06
Jews O 0 1.759581095939211e-06
, O 0 5.735697641284787e-07
28 O 0 5.257332986730034e-07
% O 0 4.980220680295133e-08
of O 0 6.261888785275005e-08
their O 0 0.0009900559671223164
familial O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.281911267549731e-05
, O 0 6.241497771952709e-07
but O 0 2.1119586790518952e-07
not O 0 5.707597239279494e-08
in O 0 1.099500863688263e-07
non O 0 2.3262391550815664e-06
- O 0 8.3784521848429e-05
Jews O 0 2.9374499717960134e-05
. O 0 5.276145657262532e-06

We O 0 2.055954246316105e-05
assessed O 0 2.3434387912857346e-05
the O 0 1.1426758419474936e-06
I1307K O 0 3.5589662729762495e-05
prevalence O 0 8.527279715053737e-05
in O 0 4.824785833079659e-07
Israeli O 0 6.1037949308229145e-06
Jews O 0 7.110171509339125e-07
of O 0 3.124780079133416e-08
differing O 0 3.2186264320444025e-07
ethnic O 0 1.001752252705046e-06
origin O 0 3.5670095712703187e-06
and O 0 4.277805419405922e-05
risk O 0 0.00016674751532264054
for O 0 0.3016548454761505
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 8.059164974838495e-05

METHODS O 0 9.605870582163334e-05
DNA O 0 6.695240153931081e-05
samples O 0 2.7907219646294834e-06
from O 0 2.0901862285427342e-07
500 O 0 3.227903846436675e-07
unrelated O 0 3.5057348668487975e-07
Jews O 0 2.5352761667818413e-07
of O 0 4.603500869393429e-08
European O 0 1.2613492117452552e-06
or O 0 5.80313667342125e-07
non O 0 5.449821856018389e-07
- O 0 8.485775651934091e-06
European O 0 1.660502448430634e-06
origin O 0 5.952635433459363e-07
, O 0 1.2061762788562191e-07
with O 0 9.384191912431561e-08
or O 0 2.4252182129202993e-07
without O 0 7.468015184031174e-08
a O 0 1.0274089845552226e-06
personal O 0 7.77551940700505e-06
and O 0 1.0906614079431165e-05
/ O 0 0.0007154225604608655
or O 0 1.7694151210889686e-06
family O 0 1.4920591411282658e-06
history O 0 2.84736586309009e-07
of O 0 4.406049924909894e-07
neoplasia B-Disease 0 0.0015072711976245046
, O 0 2.2289300432021264e-06
were O 0 4.762458729601349e-07
examined O 0 1.0959473684124532e-06
for O 0 8.36756228750346e-08
the O 0 1.1437526126201192e-07
I1307K O 0 2.983415242852061e-06
variant O 0 4.378765424917219e-06
by O 0 1.3140667931565986e-07
the O 0 2.5577790552233637e-07
allele O 0 5.220827461016597e-06
- O 0 4.189040191704407e-05
specific O 0 6.364248292811681e-07
oligonucleotide O 0 0.0002685596700757742
( O 0 1.6196423757719458e-06
ASO O 0 0.0006463954341597855
) O 0 6.203294447004737e-07
method O 0 4.738375537272077e-06
. O 0 4.578702373692067e-06

RESULTS O 0 0.0010511340806260705
In O 0 1.6597014109720476e-06
persons O 0 5.370249596126087e-07
at O 0 2.013294533753651e-06
average O 0 5.245616921456531e-05
risk O 0 0.00015295010234694928
for O 1 0.7998823523521423
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.1711774277500808e-05
I1307K O 0 1.862893986981362e-05
was O 0 2.3880473236204125e-05
found O 0 1.6587977142989985e-06
in O 0 5.752811489401211e-07
5 O 0 1.648771831241902e-05
. O 0 9.058263458427973e-06

0 O 0 0.00010003099305322394
% O 0 1.968110836969572e-06
of O 0 1.0943477946057101e-07
120 O 0 2.802382255140401e-07
European O 0 1.1942136097786715e-06
and O 0 1.66597646966693e-06
1 O 0 1.0226201084151398e-05
. O 0 6.392756404238753e-06

6 O 0 0.0001063504460034892
% O 0 1.9244441773480503e-06
of O 0 1.5562766009225015e-07
188 O 0 1.2169662113592494e-06
non O 0 3.0697112833877327e-06
- O 0 5.0151422328781337e-05
European O 0 9.192698598781135e-06
Jews O 0 8.337868166563567e-06
( O 0 7.21679782600404e-07
P O 0 0.0003507465880829841
= O 0 6.855571882624645e-06
0 O 0 1.3722208223043708e-06
. O 0 4.3361936263863754e-07
08 O 0 4.569315024127718e-06
) O 0 5.462674721457006e-07
. O 0 2.3496768335462548e-06

It O 0 1.9228487872169353e-05
occurred O 0 2.1816078515257686e-05
in O 0 2.4751516320975497e-06
15 O 0 7.222235126391752e-06
. O 0 6.832388862676453e-06

4 O 0 9.718729415908456e-05
% O 0 2.5302163066953653e-06
of O 0 2.6291471044714854e-07
52 O 0 1.1777182407968212e-05
Ashkenazi O 0 0.00018440597341395915
Israelis O 0 0.00015676007024012506
with O 0 4.382245970191434e-05
familial O 1 0.994576096534729
cancer B-Disease 1 0.9960605502128601
( O 0 8.445352250419091e-06
P O 0 0.38465452194213867
= O 0 7.961726078065112e-05
0 O 0 7.907868166512344e-06
. O 0 1.2621084124475601e-06
02 O 0 5.431078989204252e-06
) O 0 1.3558366163124447e-07
and O 0 4.604985122114158e-07
was O 0 1.3308419511304237e-05
not O 0 2.046131584165778e-07
detected O 0 8.875609864844591e-07
in O 0 8.383761240793319e-08
51 O 0 1.2392550843287609e-06
non O 0 5.781179766017885e-07
- O 0 6.134333034424344e-06
European O 0 1.2437744771887083e-06
Jews O 0 2.395654746578657e-06
at O 0 5.848094133398263e-06
increased O 0 7.202986307675019e-05
cancer B-Disease 0 0.04016340896487236
risk O 0 1.7774704247131012e-05
. O 0 7.314647518796846e-06

Colorectal B-Disease 1 0.9999126195907593
neoplasia I-Disease 1 0.7874259948730469
occurred O 0 0.000847638410050422
personally O 0 9.608554682927206e-05
or O 0 1.4063328990232549e-06
in O 0 4.0055843442132755e-07
the O 0 1.43488279036319e-07
families O 0 7.549174796395164e-08
of O 0 4.807727549405172e-08
13 O 0 1.0597616437735269e-06
of O 0 7.462961093551712e-08
20 O 0 8.628886121186952e-07
Ashkenazi O 0 2.6007282940554433e-05
I1307K O 0 1.470592110308644e-06
carriers O 0 1.9425442587817088e-07
, O 0 7.800942825042512e-08
8 O 0 3.092183646913327e-07
of O 0 6.807660213326017e-08
whom O 0 6.814156222390011e-06
also O 0 7.750325494271237e-06
had O 0 8.43497855385067e-06
a O 0 3.0516550850734347e-06
personal O 0 6.204103101481451e-06
or O 0 2.1108644432388246e-06
family O 0 3.2766713502496714e-06
history O 0 4.2759876350828563e-07
of O 0 1.5904166730251745e-06
noncolonic O 0 0.11326389759778976
neoplasia B-Disease 0 0.015752071514725685
. O 0 2.510705053282436e-05

CONCLUSIONS O 0 0.0005821016384288669
The O 0 4.66916935693007e-06
I1307K O 0 3.835395909845829e-05
APC O 0 7.466317038051784e-05
variant O 0 9.566572407493368e-05
may O 0 5.135584615345579e-06
represent O 0 9.425360047998765e-08
a O 0 1.3375985190577921e-06
susceptibility O 0 0.00010490347631275654
gene O 0 4.096365955774672e-05
for O 0 0.0012233619345352054
colorectal B-Disease 1 1.0
, I-Disease 0 1.1523122338985559e-05
or I-Disease 0 4.87689476358355e-07
other I-Disease 0 4.0097123132909473e-07
, I-Disease 0 5.681947186531033e-06
cancers I-Disease 0 0.001689417753368616
in O 0 1.7595139070181176e-06
Ashkenazi O 0 0.0008751124260015786
Jews O 0 5.954843345534755e-06
, O 0 7.93681920185918e-07
and O 0 1.006079855869757e-06
partially O 0 2.358529673074372e-05
explains O 0 2.6960087780025788e-06
the O 0 2.608328770747903e-07
higher O 0 7.682867362746038e-06
incidence O 0 0.02638288401067257
of O 0 0.3311486840248108
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.934896530059632e-06
European O 0 3.6287365219322965e-05
Israelis O 0 0.0007786393398419023
. O 0 2.4728236894588917e-05

Systematic O 0 0.00014551512140315026
analysis O 0 1.2599854017025791e-05
of O 0 1.2901718946523033e-06
coproporphyrinogen O 0 0.001080106827430427
oxidase O 0 0.00033082696609199047
gene O 0 0.004009066615253687
defects O 1 0.9895976185798645
in O 0 2.383396895311307e-05
hereditary B-Disease 1 0.9226214289665222
coproporphyria I-Disease 1 0.5523720383644104
and O 0 4.201667252345942e-05
mutation O 0 5.5507181969005615e-05
update O 0 8.18375701783225e-05
. O 0 9.309543202107307e-06

Hereditary B-Disease 1 0.9998145699501038
coproporphyria I-Disease 1 0.9914142489433289
( O 0 0.0008069728501141071
HC B-Disease 1 0.9906588792800903
) O 0 5.542710277950391e-05
is O 0 3.1011102237243904e-06
an O 0 4.699521014117636e-05
acute O 1 0.9619332551956177
hepatic B-Disease 1 0.9999922513961792
porphyria I-Disease 1 0.9999992847442627
with O 0 0.003972996026277542
autosomal O 1 0.997811496257782
dominant O 0 0.4894215166568756
inheritance O 1 0.6419496536254883
caused O 0 0.019883358851075172
by O 0 1.0118249520019162e-05
deficient B-Disease 0 0.0007295547984540462
activity I-Disease 0 6.583577487617731e-07
of I-Disease 0 4.883848419012793e-07
coproporphyrinogen I-Disease 0 0.007455792743712664
III I-Disease 0 0.09637445956468582
oxidase I-Disease 0 8.109452028293163e-05
( O 0 4.89872763864696e-06
CPO O 0 0.0005096386885270476
) O 0 1.094977960747201e-06
. O 0 3.0232731660362333e-06

Clinical O 0 0.0033830914180725813
manifestations O 0 0.00010450848640175536
of O 0 3.468777322268579e-06
the O 0 4.862611967837438e-05
disease O 0 0.012627272866666317
are O 0 3.0231583991735533e-07
characterized O 0 1.7746197045198642e-05
by O 0 6.892729743412929e-06
acute O 0 0.002318968763574958
attacks O 0 0.0012534561101347208
of O 0 0.00011477172665763646
neurological B-Disease 1 0.9999613761901855
dysfunction I-Disease 0 0.48966673016548157
often O 0 1.3342832971829921e-05
precipitated O 0 6.63244427414611e-05
by O 0 9.555596989230253e-07
drugs O 0 1.5168136542342836e-06
, O 0 2.71122161166204e-07
fasting O 0 2.1239250145299593e-06
, O 0 1.5174878171819728e-06
cyclical O 0 0.0001428935502190143
hormonal O 0 6.357218808261678e-05
changes O 0 1.0615966630211915e-06
, O 0 1.3569998600360123e-06
or O 0 2.4157399820978753e-05
infectious B-Disease 0 0.0025019999593496323
diseases I-Disease 0 0.0037287308368831873
. O 0 1.8608874597703107e-05

Skin O 1 0.9999821186065674
photosensitivity O 1 0.999790608882904
may O 0 0.017150478437542915
also O 0 6.73610429657856e-06
be O 0 5.5846606983323e-07
present O 0 1.632762746339722e-06
. O 0 5.244075964583317e-06

The O 0 8.724386134417728e-06
seven O 0 4.056322268297663e-06
exons O 0 4.21088479924947e-05
, O 0 1.3620044683193555e-06
the O 0 3.2983558639898547e-07
exon O 0 2.8821199521189556e-05
/ O 0 5.7353016018169e-05
intron O 0 3.803644722211175e-05
boundaries O 0 4.894091034657322e-07
and O 0 6.746068379470671e-07
part O 0 2.3086573719410808e-07
of O 0 6.416917130991351e-08
3 O 0 1.9639767288026633e-06
noncoding O 0 1.3836454400006915e-06
sequence O 0 9.721715343857795e-08
of O 0 3.582448115935222e-08
the O 0 3.450146266459342e-07
CPO O 0 0.00014723438653163612
gene O 0 8.943139278017043e-07
were O 0 2.397841569745651e-07
systematically O 0 4.6305103751365095e-06
analyzed O 0 9.81009748102224e-07
by O 0 4.346751225625667e-08
an O 0 1.5397554875562491e-07
exon O 0 1.4965345144446474e-05
- O 0 1.5505225746892393e-05
by O 0 8.671610771671112e-07
- O 0 0.00022788810019847006
exon O 0 0.00020380729984026402
denaturing O 0 0.00019286622409708798
gradient O 0 0.00023376644821837544
gel O 0 0.004364936612546444
electrophoresis O 0 8.183257887139916e-05
( O 0 3.632387688412564e-07
DGGE O 0 2.4107184799504466e-05
) O 0 1.6522930934570468e-07
strategy O 0 2.756316348495602e-07
followed O 0 1.0364654201566736e-07
by O 0 2.1315043952085944e-08
direct O 0 1.1767518515171105e-07
sequencing O 0 1.7661277524894103e-06
in O 0 4.229392231991369e-07
seven O 0 1.400733935952303e-06
unrelated O 0 5.195491212361958e-06
heterozygous O 0 6.703025974275079e-06
HC B-Disease 1 0.7249409556388855
patients O 0 3.8897895137779415e-05
from O 0 4.143113869758963e-07
France O 0 2.3387527107843198e-05
, O 0 2.7519611194293248e-06
Holland O 0 3.457221100688912e-05
, O 0 5.114242753734288e-07
and O 0 8.556340844734223e-07
Czech O 0 8.82779058883898e-05
Republic O 0 8.145189895003568e-06
. O 0 8.679655365995131e-06

Seven O 0 7.654770161025226e-05
novel O 0 6.598301843041554e-05
mutations O 0 7.641102274646983e-05
and O 0 1.4291634897745098e-06
two O 0 7.648395126125251e-07
new O 0 1.4810545508225914e-05
polymorphisms O 0 0.000823227281216532
were O 0 1.7290436517214403e-05
detected O 0 8.976772369351238e-05
. O 0 8.165411600202788e-06

Among O 0 1.3630461580760311e-05
these O 0 1.219947989739012e-06
mutations O 0 6.113209110480966e-06
two O 0 5.670243012900755e-07
are O 0 4.680590848238353e-07
missense O 0 5.855401104781777e-05
( O 0 6.538264756272838e-07
G197W O 0 4.732856723421719e-06
, O 0 1.0603430382616352e-06
W427R O 0 2.443587391098845e-06
) O 0 1.967497951227415e-07
, O 0 8.244028038006945e-08
two O 0 1.7909914618030598e-07
are O 0 1.0337330280663082e-07
nonsense O 0 4.602158242050791e-06
( O 0 2.1360469304454455e-07
Q306X O 0 1.5047440911075682e-06
, O 0 3.515125399644603e-07
Q385X O 0 1.0416275699753896e-06
) O 0 1.1202675409549556e-07
, O 0 3.727737052372504e-08
two O 0 5.1713552551291286e-08
are O 0 4.2117545007158697e-08
small O 0 2.875177074201929e-07
deletions O 0 1.641617200220935e-05
( O 0 4.987264787814638e-07
662de14bp O 0 2.7127603061671834e-06
; O 0 3.2312792086486297e-07
1168del3bp O 0 6.6691295614873525e-06
removing O 0 4.2968068214577215e-07
a O 0 7.262240728778124e-07
glycine O 0 2.2120138964965008e-05
at O 0 2.4976400254672626e-06
position O 0 1.7640403484620037e-06
390 O 0 1.663382363403798e-06
) O 0 2.7703518412636186e-07
, O 0 1.8832507464594528e-07
and O 0 1.2623694090052595e-07
one O 0 1.2043200570133195e-07
is O 0 6.896201654171819e-08
a O 0 3.8284957781797857e-07
splicing O 0 7.823634950909764e-05
mutation O 0 2.0037126887473278e-05
( O 0 2.722853196246433e-07
IVS1 O 0 7.231320341816172e-05
- O 0 5.811919618281536e-05
15c O 0 9.535065146337729e-06
- O 0 5.894360219826922e-05
- O 0 0.0002244570350740105
> O 0 5.6116505220416e-06
g O 0 5.863357728230767e-05
) O 0 1.6731286223148345e-07
which O 0 9.498596398316295e-08
creates O 0 8.889487901342363e-08
a O 0 1.5519680118813994e-07
new O 0 4.6640062123515236e-07
acceptor O 0 3.871652552334126e-06
splice O 0 0.00016600902017671615
site O 0 3.888165520038456e-05
. O 0 5.043983037467115e-06

The O 0 1.4375797945831437e-05
pathological O 0 0.00011933587666135281
significance O 0 1.4007459867571015e-06
of O 0 2.0387824406498112e-07
the O 0 5.533876219487865e-07
point O 0 9.061219316208735e-06
mutations O 0 4.801432169188047e-06
G197W O 0 1.8988844203704502e-06
, O 0 2.9758379582744965e-07
W427R O 0 1.2648653182623093e-06
, O 0 2.3479402955217665e-07
and O 0 1.2738097154851857e-07
the O 0 8.456238731469057e-08
in O 0 4.976773766429687e-07
- O 0 0.00015195476589724422
frame O 0 0.0006182226934470236
deletion O 0 4.789894228451885e-05
390delGly O 0 2.1828316675964743e-05
were O 0 9.972817451853189e-07
assessed O 0 3.8879178987372143e-07
by O 0 3.086543998165325e-08
their O 0 7.113169431249844e-08
respective O 0 1.5298228106530587e-07
expression O 0 1.642849838390248e-07
in O 0 4.688480359504865e-08
a O 0 1.9370997961232206e-07
prokaryotic O 0 2.291108529561825e-07
system O 0 1.931477413563698e-07
using O 0 3.913895909590792e-07
site O 0 1.6548332496313378e-05
- O 0 0.00021401053527370095
directed O 0 7.1122858571470715e-06
mutagenesis O 0 8.398866339121014e-05
. O 0 6.827021934441291e-06

These O 0 1.157845417765202e-05
mutations O 0 6.628978735534474e-05
resulted O 0 7.801457286404911e-06
in O 0 1.208474941449822e-06
the O 0 6.471743745350977e-07
absence O 0 2.337184014322702e-06
or O 0 5.940487994848809e-07
a O 0 1.6936290876401472e-06
dramatic O 0 4.007194365840405e-05
decrease O 0 4.243294461048208e-05
of O 0 8.734023708711902e-07
CPO O 0 0.0017876437632367015
activity O 0 4.774072749569314e-06
. O 0 4.457453087525209e-06

The O 0 6.482314802269684e-06
two O 0 2.035376155617996e-06
polymorphisms O 0 7.543666288256645e-05
were O 0 2.099064431604347e-06
localized O 0 6.382473657140508e-06
in O 0 9.018019113682385e-07
noncoding O 0 1.0718330486270133e-05
part O 0 5.012679480387305e-07
of O 0 5.530156954591803e-08
the O 0 2.5714365392559557e-07
gene O 0 1.4421236755879363e-06
1 O 0 2.263620217490825e-06
) O 0 8.325200440140179e-08
a O 0 8.307623602377134e-07
C O 0 0.000211708465940319
/ O 0 5.791708827018738e-05
G O 0 0.00023385247914120555
polymorphism O 0 3.162023404001957e-06
in O 0 3.4856691399909323e-07
the O 0 8.194424481189344e-07
promotor O 0 0.00010184569691773504
region O 0 7.678809197386727e-06
, O 0 4.242124873599096e-07
142 O 0 7.514946105402487e-07
bp O 0 6.197160837473348e-05
upstream O 0 9.784272378965397e-07
from O 0 2.6851777690239942e-08
the O 0 3.3381390096565156e-08
transcriptional O 0 3.2690226703380176e-07
initiation O 0 2.4845164148246113e-07
site O 0 4.661525508709019e-06
( O 0 1.9964259934113215e-07
- O 0 8.616653758508619e-06
142C O 0 9.970459359465167e-06
/ O 0 2.1589612515526824e-05
G O 0 0.00012297135253902525
) O 0 2.2655437703633652e-07
, O 0 1.56460416178561e-07
and O 0 3.038703653146513e-07
2 O 0 2.185872972404468e-06
) O 0 1.0990564192070451e-07
a O 0 7.859253514652664e-07
6 O 0 2.6927818908006884e-05
bp O 0 0.0010182366240769625
deletion O 0 7.3910719038394745e-06
polymorphism O 0 1.8498691360946395e-06
in O 0 3.0461023925454356e-07
the O 0 1.6709424244254478e-07
3 O 0 5.1616079872474074e-06
noncoding O 0 2.6469795102457283e-06
part O 0 1.6379313194647693e-07
of O 0 6.351055503728276e-08
the O 0 1.231628516507044e-06
CPO O 0 0.0005076595116406679
gene O 0 9.286737281399837e-07
, O 0 1.538182203830729e-07
574 O 0 6.294351351243677e-07
bp O 0 3.6905559682054445e-05
downstream O 0 9.91900833469117e-07
of O 0 3.154681138539672e-08
the O 0 2.441674382680503e-07
last O 0 2.427875642752042e-06
base O 0 4.003728122370376e-07
of O 0 1.949772965303964e-08
the O 0 1.3327684200703516e-07
normal O 0 9.193454957312497e-07
termination O 0 2.6546138087724103e-06
codon O 0 2.302422444699914e-06
( O 0 2.870119715225883e-07
+ O 0 7.91918773757061e-06
574 O 0 4.849928245675983e-06
delATTCTT O 0 2.2559230274055153e-05
) O 0 1.0492926776350942e-06
. O 0 2.1138134798093233e-06

Five O 0 3.4633823815966025e-05
intragenic O 0 0.0006077968864701688
dimorphisms O 0 0.0004261093563400209
are O 0 1.024553853312682e-06
now O 0 3.923886140455579e-07
well O 0 2.4799192033242434e-07
characterized O 0 3.212620640624664e-06
and O 0 8.325595786118356e-07
the O 0 4.264954895916162e-07
high O 0 4.199848262942396e-06
degree O 0 2.0144718746450962e-06
of O 0 2.283336613118081e-07
allelic O 0 1.6089759810711257e-05
heterogeneity O 0 5.69245166843757e-05
in O 0 7.690077836741693e-06
HC B-Disease 1 0.820932149887085
is O 0 1.007772698358167e-05
demonstrated O 0 1.51654887758923e-06
with O 0 5.8122488155731844e-08
seven O 0 2.600009167963435e-07
new O 0 2.999265689140884e-07
different O 0 3.7057322543887494e-08
mutations O 0 1.0093954188050702e-06
making O 0 9.150125634960204e-08
a O 0 2.2535861887718056e-07
total O 0 2.863268662167684e-07
of O 0 2.1807457528666419e-07
nineteen O 0 5.0240840209880844e-05
CPO O 0 0.19716043770313263
gene B-Disease 0 0.0011095961090177298
defects I-Disease 1 0.9006080031394958
reported O 0 7.488863047910854e-05
so O 0 4.2311313563914155e-07
far O 0 7.931083132461936e-07
. O 0 8.332586389769858e-07
. O 0 3.934643245884217e-06

Coincidence O 0 0.0001146572976722382
of O 0 1.3027459999648272e-06
two O 0 1.6695294107194059e-06
novel O 0 7.494707915611798e-06
arylsulfatase O 0 0.00012209343549329787
A O 0 1.0734257557487581e-05
alleles O 0 5.583602614933625e-06
and O 0 3.0837220492685447e-06
mutation O 0 9.676255103840958e-06
459 O 0 8.946689376898576e-06
+ O 0 4.7390796680701897e-05
1G O 0 0.00011135633394587785
> O 0 1.7583062117410009e-06
A O 0 7.600311278110894e-07
within O 0 4.35162910150666e-08
a O 0 2.46133436121454e-06
family O 0 2.219333327957429e-05
with O 0 0.0003450554213486612
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999995231628418
: O 0 2.2785234250477515e-06
molecular O 0 2.419623569949181e-06
basis O 0 3.368212162513373e-07
of O 0 4.3626823753584176e-07
phenotypic O 0 6.131197005743161e-05
heterogeneity O 0 0.0006147941458038986
. O 0 3.9088881749194115e-05

In O 0 2.9737531804130413e-05
a O 0 7.540232672909042e-06
family O 0 9.834126103669405e-06
with O 0 9.198138286592439e-07
three O 0 5.133626018505311e-06
siblings O 0 1.6529325876035728e-05
, O 0 2.5670334480309975e-07
one O 0 1.568071326119025e-07
developed O 0 1.3672022305399878e-06
classical O 0 1.9805545889539644e-05
late O 0 0.02682570181787014
infantile O 1 0.9990893602371216
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 0.00046774247311986983
MLD B-Disease 1 0.9999943971633911
) O 0 9.36953892960446e-06
, O 0 2.7758790110965492e-06
fatal O 0 0.0004726865445263684
at O 0 1.4129540431895293e-05
age O 0 1.5697816024839994e-06
5 O 0 4.268350494385231e-06
years O 0 1.0934501233350602e-06
, O 0 1.987398974279131e-07
with O 0 9.847610726865241e-07
deficient O 0 0.0019799654837697744
arylsulfatase O 0 0.00026967807207256556
A O 0 0.0001337787543889135
( O 0 2.7286475869914284e-06
ARSA O 0 0.001036707777529955
) O 0 3.1844857062424126e-07
activity O 0 2.0298580238886643e-07
and O 0 4.2103087594114186e-07
increased O 0 2.9266823275975185e-06
galactosylsulfatide O 0 0.0008352799923159182
( O 0 5.44478007213911e-06
GS O 1 0.9999700784683228
) O 0 4.484810233407188e-06
excretion O 0 1.2921596862724982e-05
. O 0 5.172803867026232e-06

The O 0 7.02354282111628e-06
two O 0 1.1155131005580188e-06
other O 0 2.762424173852196e-07
siblings O 0 1.5444244127138518e-05
, O 0 1.9332846932229586e-06
apparently O 0 9.409152880834881e-06
healthy O 0 1.3035114534432068e-06
at O 0 1.995053025893867e-06
12 O 0 2.561939481893205e-06
( O 0 2.4549245836169575e-07
1 O 0 2.0213710740790702e-06
/ O 0 8.334275662491564e-06
2 O 0 1.7500755120636313e-06
) O 0 1.2143722472046647e-07
and O 0 4.853556561101868e-07
15 O 0 9.087214607461647e-07
years O 0 7.803068911016453e-07
, O 0 2.0833483915794204e-07
respectively O 0 9.001874445857538e-07
, O 0 1.3279523614073696e-07
and O 0 2.5357840627293626e-07
their O 0 5.756395466960385e-07
father O 0 1.069331574399257e-05
, O 0 1.5561579402856296e-06
apparently O 0 4.791021638084203e-06
healthy O 0 3.982824523518502e-07
as O 0 2.1325725185761257e-07
well O 0 2.5136665726677165e-07
, O 0 1.0254825610900298e-06
presented O 0 4.820996309717884e-06
ARSA O 0 0.0016973803285509348
and O 0 1.8989019736181945e-05
GS O 1 0.9997029900550842
values O 0 8.01193266397604e-07
within O 0 5.685475557015707e-08
the O 0 1.2086830736279808e-07
range O 0 1.930325879584416e-06
of O 0 3.1376916922454257e-06
MLD B-Disease 1 0.9999949932098389
patients O 0 0.00029021204682067037
. O 0 7.317451945709763e-06

Mutation O 0 0.0002819012734107673
screening O 0 2.4501310690538958e-05
and O 0 1.4103568446444115e-06
sequence O 0 1.3044181059740367e-06
analysis O 0 2.203178837589803e-06
disclosed O 0 3.32942399836611e-05
the O 0 3.689617358304531e-07
involvement O 0 1.1256880725341034e-06
of O 0 6.473651126270852e-08
three O 0 2.8697968446067534e-07
different O 0 2.0023293245685636e-07
ARSA O 0 0.009977766312658787
mutations O 0 1.3714064152736682e-05
being O 0 1.4519572744120524e-07
the O 0 6.46121662839505e-08
molecular O 0 1.6394408248743275e-06
basis O 0 4.4410728605726035e-07
of O 0 6.355793402690324e-07
intrafamilial O 0 0.0018221272621303797
phenotypic O 0 0.00018322815594729036
heterogeneity O 0 0.0006881658337078989
. O 0 5.146433613845147e-05

The O 0 4.211832856526598e-05
late O 0 0.0004328340000938624
infantile O 1 0.9456080198287964
patient O 0 0.1998487412929535
inherited O 0 0.03688868135213852
from O 0 1.1921247278223746e-05
his O 0 0.0001366756478091702
mother O 0 9.696383494883776e-05
the O 0 5.004387730878079e-07
frequent O 0 4.628624992619734e-06
0 O 0 1.1257008736720309e-05
- O 0 0.00038335483986884356
type O 0 2.0833531380048953e-05
mutation O 0 9.654906534706242e-06
459 O 0 2.126971594407223e-06
+ O 0 1.0154054507438559e-05
1G O 0 3.8625799788860604e-05
> O 0 8.066435839282349e-07
A O 0 2.3853388029237976e-06
, O 0 5.955594701845257e-07
and O 0 5.959281565992569e-07
from O 0 2.2027722934581107e-07
his O 0 2.0753557691932656e-05
father O 0 4.6592260332545266e-05
a O 0 3.7473525935638463e-06
novel O 0 6.8420913521549664e-06
, O 0 3.32794911628298e-07
single O 0 1.150375737779541e-06
basepair O 0 1.619565773580689e-05
microdeletion O 0 6.346311693050666e-06
of O 0 3.456640129684274e-08
guanine O 0 3.7294122989806056e-07
at O 0 2.5670064474070386e-07
nucleotide O 0 1.0919870874204207e-06
7 O 0 2.9870766411477234e-06
in O 0 2.4430602252323297e-07
exon O 0 1.4635515071859118e-05
1 O 0 6.367603418766521e-06
( O 0 3.997074600192718e-07
7delG O 0 1.2902042726636864e-05
) O 0 9.379098173667444e-07
. O 0 3.3822570912889205e-06

The O 0 1.516744578111684e-05
two O 0 7.840149919502437e-06
clinically O 0 0.002598571591079235
unaffected O 0 0.00012088641233276576
siblings O 0 3.899884904967621e-05
carried O 0 4.328163868194679e-06
the O 0 6.606924785046431e-07
maternal O 0 3.719344749697484e-05
mutation O 0 1.1044417988159694e-05
459 O 0 4.752866971102776e-06
+ O 0 2.8129878046456724e-05
1G O 0 7.876889867475256e-05
> O 0 1.7757053001332679e-06
A O 0 1.819762701416039e-06
and O 0 1.1126678600703599e-06
, O 0 2.769041600458877e-07
on O 0 9.242058354175242e-07
their O 0 4.059500611219846e-07
paternal O 0 4.394234565552324e-06
allele O 0 2.430873564662761e-06
, O 0 2.1230513880254875e-07
a O 0 1.8638272081261675e-07
novel O 0 1.0920089152932633e-06
cytosine O 0 1.268542519028415e-06
to O 0 8.39313756273441e-08
thymidine O 0 8.67313428898342e-06
transition O 0 1.2893785878986819e-06
at O 0 5.480071081365168e-07
nucleotide O 0 1.9767578578466782e-06
2435 O 0 1.4547431419487111e-05
in O 0 7.839034878998064e-07
exon O 0 1.4415693840419408e-05
8 O 0 5.411489382822765e-06
, O 0 3.4406633631078876e-07
resulting O 0 2.3597998222157912e-07
in O 0 1.0376027859138048e-07
substitution O 0 1.144417112186602e-07
of O 0 1.376736236124998e-07
alanine O 0 3.597992326831445e-05
464 O 0 1.4749723959539551e-05
by O 0 3.368499392308877e-06
valine O 0 0.019699303433299065
( O 0 2.121524175890954e-06
A464V O 0 3.8086647691670805e-05
) O 0 2.7784317353507504e-06
. O 0 4.860782155446941e-06

The O 0 3.27248199027963e-05
fathers O 0 7.768411887809634e-05
genotype O 0 0.00046487286454066634
thus O 0 1.1427367098804098e-05
was O 0 2.3986971427802928e-05
7delG O 0 0.0003380435227882117
/ O 0 0.0002653972478583455
A464V O 0 5.096641325508244e-05
. O 0 1.0270258826494683e-05

Mutation O 0 0.0006055067642591894
A464V O 0 0.00023322545166593045
was O 0 4.546510899672285e-05
not O 0 2.3045767250096105e-07
found O 0 2.3471029919619468e-07
in O 0 5.437539130070945e-07
18 O 0 1.780305137799587e-05
unrelated O 0 0.0001834923168644309
MLD B-Disease 1 0.9999996423721313
patients O 0 0.00022418881417252123
and O 0 1.0020064564741915e-06
50 O 0 1.8328707938053412e-06
controls O 0 7.83900250098668e-05
. O 0 1.5138110939005855e-05

A464V O 0 0.0006642800872214139
, O 0 7.067445494612912e-06
although O 0 1.3379647043620935e-06
clearly O 0 1.7994935888054897e-06
modifying O 0 4.420816821948392e-06
ARSA O 0 0.008367501199245453
and O 0 5.3748066420666873e-05
GS O 1 0.9999971389770508
levels O 0 1.930291546159424e-05
, O 0 5.663930551236263e-07
apparently O 0 2.0879936073470162e-06
bears O 0 2.2953806819714373e-06
little O 0 1.332904275841429e-07
significance O 0 2.626483421863668e-07
for O 0 1.056899236573372e-06
clinical O 0 4.2404767555126455e-06
manifestation O 0 5.969764515612042e-06
of O 0 4.443150373845128e-06
MLD B-Disease 1 0.9999958276748657
, O 0 6.6935722315975e-06
mimicking O 0 2.1642466890625656e-05
the O 0 8.920346772356424e-07
frequent O 0 6.340157415252179e-05
ARSA O 0 0.1323912888765335
pseudodeficiency O 0 0.0016886460362002254
allele O 0 0.00019406194041948766
. O 0 1.9709659682121128e-05

Our O 0 7.58721143938601e-05
results O 0 3.673515675473027e-05
demonstrate O 0 3.2739351354393875e-06
that O 0 1.4833959482984937e-07
in O 0 1.8675868318496214e-07
certain O 0 6.055008725525113e-07
genetic O 0 0.0002618036523927003
conditions O 0 0.00421709381043911
MLD B-Disease 1 0.9999982118606567
- O 0 0.20973823964595795
like O 0 1.0295795618731063e-05
ARSA O 0 0.003903141710907221
and O 0 2.1983763872412965e-05
GS O 1 0.9999488592147827
values O 0 2.3150189463194693e-06
need O 0 9.035333903284481e-08
not O 0 2.6405595932033066e-08
be O 0 3.4692359207610934e-08
paralleled O 0 2.853797468560515e-06
by O 0 5.790234808955574e-06
clinical O 0 0.006313921883702278
disease O 0 0.00035039649810642004
, O 0 2.10419031532183e-07
a O 0 6.73620661473251e-07
finding O 0 1.2346273479124648e-06
with O 0 1.9703511497937143e-06
serious O 0 2.573632991698105e-05
diagnostic O 0 0.00018585856014396995
and O 0 3.409026248846203e-05
prognostic O 0 0.012423451989889145
implications O 0 5.7561886933399364e-05
. O 0 1.097001677408116e-05

Moreover O 0 0.00021368349553085864
, O 0 7.553951490990585e-06
further O 0 1.946406655406463e-06
ARSA O 0 0.0011690016835927963
alleles O 0 1.760400118655525e-05
functionally O 0 1.733359385980293e-05
similar O 0 5.839116283823387e-07
to O 0 6.593215289285581e-07
A464V O 0 1.3901494639867451e-05
might O 0 1.287922259507468e-06
exist O 0 1.607855608654063e-07
which O 0 2.0354059415694792e-07
, O 0 1.4307234152965975e-07
together O 0 8.839811727057167e-08
with O 0 3.029389290531981e-07
0 O 0 3.690344965434633e-05
- O 0 0.01767970621585846
type O 0 8.653313852846622e-05
mutations O 0 8.447897562291473e-05
, O 0 5.437214440462412e-06
may O 0 8.425281703239307e-05
cause O 0 1.0881388334382791e-05
pathological O 0 0.00011346113024046645
ARSA O 1 0.5873134732246399
and O 0 0.0002192634274251759
GS O 1 0.9999995231628418
levels O 0 1.6510093701072037e-05
, O 0 3.873270202348067e-07
but O 0 9.581442839134979e-08
not O 0 2.8876499413854617e-07
clinical O 0 3.0892467748344643e-06
outbreak O 0 4.791853029928461e-07
of O 0 1.1577967029552383e-07
the O 0 2.0491717805271037e-05
disease O 0 0.0023149698972702026
. O 0 2.8422539344319375e-06
. O 0 5.65820937481476e-06

Human O 0 0.00997946597635746
MLH1 O 1 0.999482274055481
deficiency O 1 0.9997727274894714
predisposes O 0 0.0057274214923381805
to O 0 0.00012620097550097853
hematological B-Disease 1 0.9887102246284485
malignancy I-Disease 1 0.9996084570884705
and O 0 0.001942513627000153
neurofibromatosis B-Disease 1 0.9993889331817627
type I-Disease 0 0.0002891451877076179
1 I-Disease 0 0.00010258978727506474
. O 0 1.9702498320839368e-05

Heterozygous O 0 0.0008625033660791814
germ O 0 0.014414443634450436
- O 0 0.0028035587165504694
line O 0 0.00023257882276084274
mutations O 0 2.9778591851936653e-05
in O 0 2.6185924184574105e-07
the O 0 3.90364846225566e-07
DNA O 0 8.366396650671959e-05
mismatch O 0 0.0003723127883858979
repair O 0 0.014011252671480179
genes O 0 1.1311461094010156e-05
lead O 0 7.404093048535287e-05
to O 0 6.405096064554527e-05
hereditary B-Disease 1 0.9999712705612183
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00011350897693773732

The O 0 0.0002864432753995061
disease O 0 0.11007469892501831
susceptibility O 0 0.0006108650704845786
of O 0 1.7879194729175651e-06
individuals O 0 1.1882968919962877e-06
who O 0 3.1240142561728135e-05
constitutionally O 0 2.1396412194008008e-05
lack O 0 7.243751838359458e-07
both O 0 3.3605564908611996e-07
wild O 0 9.927091014105827e-06
- O 0 0.0019026814261451364
type O 0 8.96103483682964e-06
alleles O 0 2.3295981463888893e-06
is O 0 1.1557727930266992e-06
unknown O 0 7.998503861017525e-06
. O 0 5.960371709079482e-06

We O 0 1.705428985587787e-05
have O 0 8.443810770586424e-07
identified O 0 1.3555072655435652e-06
three O 0 2.996498267293646e-07
offspring O 0 4.450766937225126e-06
in O 0 1.248666194442194e-06
a O 0 0.00023614437668584287
hereditary B-Disease 1 0.9999978542327881
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0008793695014901459
who O 0 8.351108408533037e-05
developed O 0 5.9891412092838436e-05
hematological B-Disease 0 0.27756014466285706
malignancy I-Disease 0 0.36120355129241943
at O 0 1.4887836186971981e-05
a O 0 2.296068032592302e-06
very O 0 8.441701311312499e-07
early O 0 1.4816097973380238e-05
age O 0 1.3111941825627582e-06
, O 0 2.631106212902523e-07
and O 0 2.3387286773868254e-07
at O 0 4.059477305418113e-07
least O 0 3.75390101226003e-08
two O 0 3.88500431824923e-08
of O 0 2.2423948919936265e-08
them O 0 6.469478819326469e-08
displayed O 0 1.0944851283056778e-06
signs O 0 2.418673147985828e-06
of O 0 7.850840120227076e-07
neurofibromatosis B-Disease 1 0.8144751787185669
type I-Disease 0 3.168430703226477e-05
1 I-Disease 0 7.471330172847956e-05
( O 0 2.6535585675446782e-06
NF1 B-Disease 0 0.00020739903266075999
) O 0 1.424098286406661e-06
. O 0 3.089712436121772e-06

DNA O 0 0.00017495172505732626
sequence O 0 1.0061919965664856e-05
analysis O 0 3.208903535778518e-06
and O 0 1.013908558888943e-06
allele O 0 4.227160843583988e-06
- O 0 1.9724495359696448e-05
specific O 0 2.696749845654267e-07
amplification O 0 4.3597351577773225e-06
in O 0 3.10280029225396e-07
two O 0 1.1572706171136815e-06
siblings O 0 3.4943022910738364e-05
revealed O 0 3.571168417693116e-05
a O 0 7.946483492560219e-06
homozygous O 0 5.67872375540901e-05
MLH1 O 0 0.0013069049455225468
mutation O 0 4.052653457620181e-05
( O 0 7.054617867652269e-07
C676T O 0 1.2813073226425331e-05
- O 0 0.00016651061014272273
- O 0 0.003285581711679697
> O 0 2.1436197130242363e-05
Arg226Stop O 0 0.00013433891581371427
) O 0 2.365503178225481e-06
. O 0 4.171542968833819e-06

Thus O 0 4.326792623032816e-05
, O 0 2.6294783310731873e-06
a O 0 4.299095962778665e-06
homozygous O 0 6.110125104896724e-05
germ O 0 0.0020589600317180157
- O 0 0.002012296812608838
line O 0 0.00032750939135439694
MLH1 O 0 0.002216937253251672
mutation O 0 5.563786908169277e-05
and O 0 7.862838174332865e-06
consequent O 0 0.0036049471236765385
mismatch O 1 0.9894593954086304
repair O 1 0.9999972581863403
deficiency O 1 0.9992018342018127
results O 0 5.027362203691155e-05
in O 0 1.6172408550119144e-06
a O 0 5.417295324150473e-05
mutator O 1 0.5929006934165955
phenotype O 0 0.10137119889259338
characterized O 0 0.00013901990314479917
by O 0 3.523709165165201e-05
leukemia B-Disease 1 0.9984092116355896
and O 0 0.002320319414138794
/ O 1 0.9911854863166809
or O 0 0.4347017705440521
lymphoma B-Disease 1 1.0
associated O 0 0.003519257064908743
with O 0 2.4097163986880332e-05
neurofibromatosis B-Disease 1 0.9969449639320374
type I-Disease 0 4.7792949771974236e-05
1 I-Disease 0 3.5663939343066886e-05
. O 0 2.6225161491311155e-06
. O 0 3.5763735013460973e-06

Missense O 0 0.01220832671970129
mutations O 0 0.0022304155863821507
in O 0 2.8662732347584097e-06
the O 0 1.4184513474901905e-07
most O 0 5.7386973395523455e-08
ancient O 0 1.8830047565643326e-07
residues O 0 3.0064650218264433e-06
of O 0 9.248012844409459e-08
the O 0 5.454694473883137e-07
PAX6 O 0 0.0001328753278357908
paired O 0 1.0520579053263646e-05
domain O 0 1.4167223980621202e-06
underlie O 0 6.950142960704397e-06
a O 0 1.761142357281642e-06
spectrum O 0 1.7846125047071837e-05
of O 0 1.8971624740515836e-05
human O 0 0.2969795763492584
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999986886978149
malformations I-Disease 1 0.999993085861206
. O 0 0.0002990814973600209

Mutations O 0 0.0012315226485952735
of O 0 2.5548322355462005e-06
the O 0 2.9672758046217496e-06
human O 0 1.0463214493938722e-05
PAX6 O 0 0.008770439773797989
gene O 0 0.002557898173108697
underlie O 1 0.7898960709571838
aniridia B-Disease 1 1.0
( O 0 0.3779785931110382
congenital B-Disease 1 0.9999996423721313
absence I-Disease 0 4.990810339222662e-05
of I-Disease 0 2.3056657028064365e-06
the I-Disease 0 2.4517627025488764e-05
iris I-Disease 1 0.9914650321006775
) O 0 3.0601356684201164e-06
, O 0 2.807778116675763e-07
a O 0 1.5837509863558807e-06
rare O 0 1.4396569895325229e-05
dominant O 0 0.025901595130562782
malformation B-Disease 1 0.9756091833114624
of I-Disease 0 2.74215790341259e-06
the I-Disease 0 1.71226365637267e-05
eye I-Disease 0 0.32729488611221313
. O 0 2.19644425669685e-05

The O 0 1.1268586604273878e-05
spectrum O 0 1.1733395695046056e-05
of O 0 7.983254590726574e-07
PAX6 O 0 0.0021200792398303747
mutations O 0 0.000631278904620558
in O 0 3.3254382287850603e-05
aniridia B-Disease 1 0.9999998807907104
patients O 0 0.0029177661053836346
is O 0 1.094629169529071e-06
highly O 0 1.172832185147854e-06
biased O 0 1.7114507500082254e-05
, O 0 3.638454870724672e-07
with O 0 1.0917646164898542e-07
92 O 0 1.4777932619836065e-06
% O 0 7.150196523753038e-08
of O 0 2.2748809058725783e-08
all O 0 1.497121928650813e-07
reported O 0 0.0002403273683739826
mutations O 0 7.49016408008174e-06
leading O 0 5.085026714368723e-06
to O 0 2.7205535388930002e-06
premature O 0 2.808155295497272e-05
truncation O 0 8.124298801703844e-06
of O 0 1.5122392937882978e-07
the O 0 6.938288379387814e-07
protein O 0 1.0950324394798372e-05
( O 0 2.4439714252366684e-07
nonsense O 0 2.046652070930577e-06
, O 0 8.94353462399522e-08
splicing O 0 1.6675404594934662e-06
, O 0 1.398017843712296e-07
insertions O 0 1.0449327874084702e-06
and O 0 1.0518685940041905e-06
deletions O 0 5.02259399581817e-06
) O 0 3.8027033610887884e-07
and O 0 3.5697928524314193e-07
just O 0 2.042232551957568e-07
2 O 0 1.9702008557942463e-06
% O 0 1.21126433327845e-07
leading O 0 1.3437980328490085e-07
to O 0 2.1561692875593508e-08
substitution O 0 1.9948153351379005e-08
of O 0 1.1274221556334396e-08
one O 0 1.9540978257737152e-07
amino O 0 8.866135203788872e-07
acid O 0 8.879217602952849e-06
by O 0 2.0850160353802494e-07
another O 0 3.0380683710973244e-06
( O 0 1.6831788798299385e-06
missense O 0 5.00071000715252e-05
) O 0 2.7634698653855594e-06
. O 0 6.018536623741966e-06

The O 0 9.094626875594258e-06
extraordinary O 0 4.085532509634504e-06
conservation O 0 9.911472034218605e-07
of O 0 1.347161031617361e-07
the O 0 2.1666926386387786e-07
PAX6 O 0 2.1533849576371722e-05
protein O 0 1.694734237389639e-06
at O 0 2.806661996146431e-07
the O 0 3.590752939430786e-08
amino O 0 3.6611211839954194e-07
acid O 0 1.927077619257034e-06
level O 0 1.300460326092434e-07
amongst O 0 1.614644276060062e-07
vertebrates O 0 8.098400030576158e-07
predicts O 0 5.409438017522916e-05
that O 0 4.6963296540525334e-07
pathological O 0 2.6990759579348378e-05
missense O 0 9.27631845115684e-05
mutations O 0 4.345723209553398e-05
should O 0 6.541320658470795e-07
in O 0 2.7749473474614206e-07
fact O 0 2.3271503835076146e-07
be O 0 1.6707926420167496e-07
common O 0 2.7029935267819383e-07
even O 0 3.792772815813805e-07
though O 0 1.6599499019775976e-07
they O 0 7.158083548119976e-08
are O 0 2.3258850845309098e-08
hardly O 0 1.6820094117520057e-07
ever O 0 4.0325292616216757e-07
seen O 0 3.696390422192053e-06
in O 0 4.800278475158848e-06
aniridia B-Disease 1 0.9999990463256836
patients O 0 0.00017369777197018266
. O 0 4.70998293167213e-06

This O 0 4.1428711483604275e-06
indicates O 0 4.798278041562298e-06
that O 0 2.143896011830293e-07
there O 0 4.660751429241827e-08
is O 0 7.712353777833414e-08
a O 0 1.4666482002212433e-06
heavy O 0 0.0016197746153920889
ascertainment O 0 0.0006833876832388341
bias O 0 3.504005871945992e-05
in O 0 2.724193564063171e-07
the O 0 5.322339191593528e-08
selection O 0 1.1562982393797938e-07
of O 0 2.737540967245877e-07
patients O 0 3.2152931908058235e-06
for O 0 3.4469758247723803e-07
PAX6 O 0 0.00010777173156384379
mutation O 0 1.0319071407138836e-05
analysis O 0 1.0844526059372583e-06
and O 0 8.656457453071198e-07
that O 0 2.0701777714293712e-07
the O 0 3.889178685767547e-07
missing O 0 2.1147363440832123e-05
PAX6 O 0 0.0010585630079731345
missense O 0 0.000535817292984575
mutations O 0 0.0001697640836937353
frequently O 0 1.2201586287119426e-05
may O 0 5.361440344131552e-05
underlie O 0 0.00015935649571474642
phenotypes O 0 0.00010984104301314801
distinct O 0 9.6279018180212e-06
from O 0 8.033631274884101e-06
textbook O 0 0.0005019528325647116
aniridia B-Disease 1 0.9999916553497314
. O 0 9.2978028988e-05

Here O 0 2.4970993763417937e-05
we O 0 1.4550015521308524e-06
present O 0 3.2155892881746695e-07
four O 0 4.952891003995319e-07
novel O 0 8.196720045816619e-06
PAX6 O 0 0.00030118352151475847
missense O 0 0.00032825456582941115
mutations O 0 5.963665898889303e-05
, O 0 6.391254032678262e-07
two O 0 6.231256861610746e-07
in O 0 2.473532731528394e-06
association O 0 1.0182515097767464e-06
with O 0 9.658907629273017e-07
atypical O 0 0.00010138097422895953
phenotypes O 0 0.0001495617616456002
ectopia B-Disease 0 0.011602315120398998
pupillae I-Disease 0 0.020514972507953644
( O 0 1.182860842163791e-06
displaced B-Disease 0 1.7285914282183512e-06
pupils I-Disease 0 7.377403107966529e-06
) O 0 8.20998138806317e-06
and O 0 0.006246993318200111
congenital B-Disease 1 0.9999995231628418
nystagmus I-Disease 1 0.8355401754379272
( O 0 3.132011443085503e-06
searching B-Disease 0 7.337394890782889e-06
gaze I-Disease 0 7.221838313853368e-05
) O 0 7.756165700811835e-07
, O 0 1.3571742840667866e-07
and O 0 1.4583521590338933e-07
two O 0 2.1268388650241832e-07
in O 0 1.293578293370956e-06
association O 0 1.3572338275480433e-07
with O 0 5.887866194598246e-08
more O 0 4.2143378209402726e-07
recognizable O 0 0.00036154731060378253
aniridia B-Disease 1 0.9999568462371826
phenotypes O 0 0.0007093610474839807
. O 0 1.4045815078134183e-05

Strikingly O 0 0.0010372368851676583
, O 0 5.097179837321164e-06
all O 0 1.1708726077586107e-07
four O 0 3.79703237740614e-07
mutations O 0 2.9424099921016023e-06
are O 0 2.352736494515284e-08
located O 0 1.747960993725428e-07
within O 0 4.579662515880045e-08
the O 0 2.521096860164107e-07
PAX6 O 0 2.015353129536379e-05
paired O 0 1.95057828022982e-06
domain O 0 3.3094499940489186e-07
and O 0 3.1782718679096433e-07
affect O 0 1.3671757415067987e-07
amino O 0 2.8398000040397164e-07
acids O 0 4.073694697126484e-07
which O 0 1.8210667462881247e-07
are O 0 1.4061753539351685e-08
highly O 0 4.8084242365575847e-08
conserved O 0 1.0052207244370948e-07
in O 0 9.607354911622679e-08
all O 0 1.7534748764092e-08
known O 0 4.1840146991489746e-07
paired O 0 1.485108782617317e-06
domain O 0 1.0710948572523193e-06
proteins O 0 1.178482989416807e-06
. O 0 2.977804115289473e-06

Our O 0 2.0228220819262788e-05
results O 0 6.971152743062703e-06
support O 0 3.4149039151998295e-07
the O 0 1.493109635930523e-07
hypothesis O 0 9.150838309324172e-07
that O 0 4.685637478019089e-08
the O 0 4.818670618078613e-08
under O 0 8.094186654261648e-08
- O 0 3.106998065049993e-06
representation O 0 2.2123724363609654e-07
of O 0 2.420211160369945e-07
missense O 0 0.00014356058090925217
mutations O 0 8.274186257040128e-05
is O 0 1.6683214880686137e-06
caused O 0 5.515121756616281e-06
by O 0 1.0563833257037913e-06
ascertainment O 0 0.0003424850292503834
bias O 0 6.655968900304288e-05
and O 0 4.557538886729162e-06
suggest O 0 8.477780966131832e-07
that O 0 4.733352909624955e-08
a O 0 4.984621000403422e-07
substantial O 0 2.3434176910086535e-06
burden O 0 5.216855697653955e-06
of O 0 8.511798341714893e-07
PAX6 B-Disease 0 0.06922022998332977
- I-Disease 1 0.962113082408905
related I-Disease 0 0.001852535642683506
disease I-Disease 0 0.0013152268948033452
remains O 0 5.557211352424929e-06
to O 0 1.047058503900189e-06
be O 0 9.59193585003959e-07
uncovered O 0 4.576848368742503e-05
. O 0 2.0521106307569426e-06
. O 0 4.298997737350874e-06

The O 0 2.152506021957379e-05
chromosomal O 0 0.0007758599822409451
order O 0 1.8685788063521613e-06
of O 0 4.926421297568595e-07
genes O 0 2.9370387437666068e-06
controlling O 0 1.4178295714373235e-05
the O 0 1.707456135591201e-06
major O 0 2.2359386093739886e-06
histocompatibility O 0 2.0098597815376706e-05
complex O 0 4.255303792888299e-06
, O 0 1.303014414588688e-06
properdin O 0 2.6400080969324335e-05
factor O 0 8.58140424497833e-07
B O 0 1.73573807842331e-05
, O 0 1.7968784504773794e-06
and O 0 5.712986967409961e-05
deficiency B-Disease 0 5.2528546802932397e-05
of I-Disease 0 2.424949308021951e-08
the I-Disease 0 2.328455792621753e-07
second I-Disease 0 4.483039901970187e-06
component I-Disease 0 6.904347742420214e-07
of I-Disease 0 1.0026013086417151e-07
complement I-Disease 0 3.5082407521258574e-06
. O 0 6.720308192598168e-06

The O 0 1.150539901573211e-05
relationship O 0 6.234541615413036e-06
of O 0 1.6417425285908394e-07
the O 0 1.576489268018122e-07
genes O 0 3.316144443488156e-07
coding O 0 5.311272161634406e-06
for O 0 1.0385348332420108e-06
HLA O 0 5.591120134340599e-05
to O 0 2.480960006323585e-07
those O 0 4.4260964671138936e-08
coding O 0 1.8785918882713304e-06
for O 0 3.4216063227177074e-07
properdin O 0 1.8173685020883568e-05
Factor O 0 4.6037908418838924e-07
B O 0 6.662791292910697e-06
allotypes O 0 1.2598123248608317e-05
and O 0 3.6827307212661253e-06
for O 0 1.4177943739923649e-05
deficiency B-Disease 0 6.940267485333607e-05
of I-Disease 0 3.312755580964222e-08
the I-Disease 0 4.606179686561518e-07
second I-Disease 0 4.312301825848408e-06
component I-Disease 0 5.277059358377301e-07
of I-Disease 0 4.139763731814128e-08
complement I-Disease 0 1.4206581226972048e-06
( O 0 7.884740398367285e-07
C2 O 0 5.3874504374107346e-05
) O 0 9.372097338200547e-07
was O 0 4.336683559813537e-06
studied O 0 4.3869223986803263e-07
in O 0 1.4887318400269578e-07
families O 0 1.6377751421714493e-07
of O 0 1.063394165612408e-06
patients O 0 4.185661964584142e-05
with O 0 3.261282108724117e-05
connective O 1 0.9977333545684814
tissue O 1 0.9999815225601196
disorders O 1 0.9941768646240234
. O 0 4.766018537338823e-05

Patients O 0 0.010152885690331459
were O 0 5.080160008219536e-06
selected O 0 3.6649987578130094e-07
because O 0 1.3531703757507785e-07
they O 0 8.617449509529251e-08
were O 0 2.100154716799807e-07
heterozygous O 0 1.102013584386441e-06
or O 0 1.4493498383671977e-06
homozygous O 0 7.962963718455285e-05
for O 0 0.00041793484706431627
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999994039535522
. O 0 0.00013645192666444927

12 O 0 0.00010901399946305901
families O 0 3.6907472349412274e-06
with O 0 8.482245448249159e-07
15 O 0 1.828558424676885e-06
matings O 0 4.46858030045405e-05
informative O 0 3.878322240780108e-05
for O 0 0.0011117750545963645
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
were O 0 2.8347849365673028e-05
found O 0 1.1516904123709537e-05
. O 0 3.5937966913479613e-06

Of O 0 1.2460380276024807e-05
57 O 0 3.843894592137076e-05
informative O 0 8.013637852855027e-06
meioses O 0 0.00018677256593946368
, O 0 1.0376141972301411e-06
two O 0 1.1919796349957323e-07
crossovers O 0 4.267186341166962e-06
were O 0 3.59758502099794e-07
noted O 0 3.69396900623542e-07
between O 0 3.731230151515774e-07
the O 0 0.0007658828399144113
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999998927116394
gene O 0 4.892732704320224e-06
and O 0 2.889961194796342e-07
the O 0 2.4346775262529263e-07
HLA O 0 0.0002146037295460701
- O 0 6.110590766184032e-05
B O 0 7.223956345114857e-06
gene O 0 5.015663759877498e-07
, O 0 3.9883467195522826e-08
with O 0 2.3865345255558168e-08
a O 0 5.177869866201945e-07
recombinant O 0 9.432118872609863e-07
fraction O 0 5.882500317966333e-07
of O 0 1.8684561098325503e-07
0 O 0 2.5790333893382922e-05
. O 0 1.3159271475160494e-05

035 O 0 0.10247636586427689
. O 0 0.0011096579255536199

A O 0 0.0003287252620793879
lod O 0 0.07005365192890167
score O 0 1.4822287084825803e-05
of O 0 4.069066505962837e-07
13 O 0 8.810102372081019e-06
was O 0 6.54995028526173e-06
calculated O 0 1.4038940889804508e-06
for O 0 4.114990304060484e-07
linkage O 0 0.00012294546468183398
between O 0 0.0066516525112092495
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.2522706785821356e-05
HLA O 0 0.00038770813262090087
- O 0 0.0001142347464337945
B O 0 1.2738531950162724e-05
at O 0 1.3572778811976605e-07
a O 0 8.62623110720051e-08
maximum O 0 1.743716921964733e-07
likelihood O 0 1.8201343721102603e-07
value O 0 2.952050870419498e-08
of O 0 1.5850785572979476e-08
the O 0 6.248299655453593e-08
recombinant O 0 3.951577411953622e-07
fraction O 0 2.677027168829227e-07
of O 0 1.4709833351389534e-07
0 O 0 1.2353314559732098e-05
. O 0 9.507723916613031e-06

04 O 0 0.02555447816848755
. O 0 0.0002918084501288831

18 O 0 8.350169082405046e-05
families O 0 1.8220897572973627e-06
with O 0 7.881403121245967e-07
21 O 0 6.496326022897847e-06
informative O 0 1.5128941868169932e-06
matings O 0 2.054090509773232e-05
for O 0 8.286938850687875e-07
both O 0 4.26332434244614e-07
properdin O 0 7.34019631636329e-05
Factor O 0 9.297363021687488e-07
B O 0 6.960663085919805e-06
allotype O 0 2.095066156471148e-05
and O 0 2.5197800823661964e-06
HLA O 0 0.0001949060388142243
- O 0 0.00013836314610671252
B O 0 2.4243901862064376e-05
were O 0 1.2399017350617214e-06
found O 0 2.714797119551804e-06
. O 0 7.0105870690895244e-06

Of O 0 5.941173185419757e-06
72 O 0 2.4694629246369004e-05
informative O 0 8.07431570137851e-06
meioses O 0 0.00011119280679849908
, O 0 8.158850164363685e-07
three O 0 2.252247810474728e-07
recombinants O 0 3.7458670703927055e-05
were O 0 1.6131741631397745e-06
found O 0 5.522346100406139e-07
, O 0 5.31142738680046e-08
giving O 0 2.6208303083308238e-08
a O 0 1.978112749156935e-07
recombinant O 0 5.759821988249314e-07
fraction O 0 3.992621202542068e-07
of O 0 1.0687301710277097e-07
0 O 0 1.5887364497757517e-05
. O 0 1.668317781877704e-05

042 O 0 0.012398899532854557
. O 0 0.0004725642502307892

A O 0 0.00026307927328161895
lod O 0 0.039784494787454605
score O 0 7.407563316519372e-06
of O 0 3.1052985605128924e-07
16 O 0 2.9078669285809156e-06
between O 0 7.121558951439511e-07
HLA O 0 0.0018433077493682504
- O 0 0.0004007380921393633
B O 0 1.8117443687515333e-05
and O 0 3.920026188097836e-07
Factor O 0 1.1137246502812559e-07
B O 0 2.5122217266471125e-06
allotypes O 0 8.830323167785536e-06
was O 0 4.528687895799521e-06
calculated O 0 9.913494523061672e-07
at O 0 1.8866842310671927e-07
a O 0 1.5472714665065723e-07
maximum O 0 4.1948143802983395e-07
likelihood O 0 4.5157869976719667e-07
value O 0 3.608659326914676e-08
of O 0 1.6704987615412392e-08
the O 0 1.0890568091781461e-07
recombinant O 0 5.748627245338866e-07
fraction O 0 4.687264549829706e-07
of O 0 1.6830266247325198e-07
0 O 0 1.354101095785154e-05
. O 0 1.3453868632495869e-05

04 O 0 0.012186645530164242
. O 0 0.00019873106793966144

A O 0 3.221847509848885e-05
crossover O 0 4.583243207889609e-05
was O 0 6.517877773148939e-05
shown O 0 7.026055754977278e-07
to O 0 7.507089350156093e-08
have O 0 5.778236911169188e-08
occurred O 0 2.3747156774334144e-07
between O 0 4.855611734910781e-08
genes O 0 1.7457702483625326e-07
for O 0 8.468005319173244e-08
Factor O 0 2.2783946462823224e-07
B O 0 5.656142548104981e-06
and O 0 1.5528460153291235e-06
HLA O 0 0.00015025187167339027
- O 0 0.00015452744264621288
D O 0 0.0030274391174316406
, O 0 2.3102694512999733e-07
in O 0 1.1606168470734701e-07
which O 0 8.894811003301584e-07
HLA O 0 0.00014638995344284922
- O 0 0.0002845247508957982
D O 0 0.00147369469050318
segregared O 0 2.0492028852459043e-05
with O 0 2.5618928134463204e-07
HLA O 0 0.00011941931734327227
- O 0 1.8218817785964347e-05
A O 0 1.0972150448651519e-05
and O 0 4.432201876625186e-06
B O 0 2.9078171792207286e-05
. O 0 5.069599865237251e-06

These O 0 8.630247975816019e-06
studies O 0 2.839658463926753e-06
suggest O 0 9.573201396051445e-07
that O 0 8.564507680830502e-08
the O 0 5.2298489094937395e-08
genes O 0 1.3847594004801067e-07
for O 0 1.8849057425995852e-07
Factor O 0 1.3461429944072734e-06
B O 0 0.0014234748668968678
and O 0 0.027348684147000313
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999988079071045
are O 0 1.4501625855700695e-07
located O 0 1.9053881317177002e-07
outside O 0 1.017161110894449e-07
those O 0 3.867599929208154e-08
for O 0 2.522482134281745e-07
HLA O 0 0.0001346330827800557
, O 0 4.5010227722741547e-07
that O 0 3.239436807689344e-08
the O 0 3.2977133912481804e-08
order O 0 4.714944168426882e-08
of O 0 7.056617334910698e-08
genese O 0 3.5131532058585435e-05
is O 0 1.057996541931061e-06
HLA O 0 1.7442540411138907e-05
- O 0 7.231772997329244e-06
A O 0 5.490049261425156e-06
, O 0 1.2423696489349823e-06
- O 0 2.047562156803906e-05
B O 0 1.2051524208800402e-05
, O 0 5.056670602243685e-07
- O 0 4.615498619386926e-05
D O 0 0.000930255395360291
, O 0 1.9363352521395427e-07
Factor O 0 1.1305999692012847e-07
B O 0 5.562523710977985e-06
allotype O 0 0.0002133392554242164
, O 0 0.0010103360982611775
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999983310699463
, O 0 4.193962297449616e-07
that O 0 3.3360002760218777e-08
the O 0 7.670543311633082e-08
genes O 0 9.333645039077965e-07
coding O 0 9.352293272968382e-05
for O 0 0.0011184127070009708
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 5.620691354124574e-06
Factor O 0 4.3387913706283143e-07
B O 0 5.77811078983359e-06
allotypes O 0 7.67204437579494e-06
are O 0 1.985466013820769e-08
approximately O 0 4.0346520790990326e-08
3 O 0 8.498568604409229e-07
- O 0 9.797936399991158e-06
- O 0 4.2391446186229587e-05
5 O 0 1.5654520666430471e-06
centimorgans O 0 1.960959707503207e-06
from O 0 2.718955371960874e-08
the O 0 8.402523121731065e-08
HLA O 0 2.3789596525602974e-05
- O 0 8.454700036963914e-06
A O 0 1.0800004019984044e-05
and O 0 6.939082595636137e-06
HLA O 0 0.00016998824139591306
- O 0 0.0003116736770607531
B O 0 1.2192280337330885e-05
loci O 0 4.167731617599202e-07
, O 0 1.0054316135210684e-07
and O 0 1.6591253881870216e-07
that O 0 1.1951121337006043e-07
the O 0 2.644516712280165e-07
apparent O 0 5.582383437285898e-06
lack O 0 2.395350122696982e-07
of O 0 5.169195915755154e-08
recombinants O 0 1.6150421288330108e-05
between O 0 1.7119909045959503e-07
the O 0 1.809590486345769e-07
Factor O 0 3.9148329733507126e-07
B O 0 1.2570701983349863e-05
gene O 0 8.326665010827128e-06
and O 0 0.0021055229008197784
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 1.1027243999706116e-05
suggests O 0 5.545525141315011e-07
that O 0 5.085609799948543e-08
these O 0 5.871199082463363e-09
two O 0 2.17504648958311e-07
genes O 0 1.2920557992401882e-06
lie O 0 9.141583177552093e-06
in O 0 3.5365141570764536e-07
close O 0 9.166193422061042e-07
proximity O 0 1.4203967566572828e-06
to O 0 1.0406287174191675e-06
one O 0 9.432605452275311e-07
another O 0 5.306188995746197e-06
. O 0 7.556602668046253e-06

Distribution O 0 3.438673593336716e-05
of O 0 2.466169917170191e-06
emerin O 0 0.00035416969330981374
and O 0 1.1634494512691163e-05
lamins O 0 0.00014795735478401184
in O 0 1.3771684734820155e-06
the O 0 1.2067520174241508e-06
heart O 0 8.59943320392631e-05
and O 0 1.7573740933585213e-06
implications O 0 1.6102414974739077e-06
for O 0 2.2194781195139512e-06
Emery B-Disease 1 0.9457874894142151
- I-Disease 1 0.9995854496955872
Dreifuss I-Disease 1 0.9999651908874512
muscular I-Disease 1 0.9994596838951111
dystrophy I-Disease 1 0.99967360496521
. O 0 5.99977356614545e-05

Emerin O 0 0.0017208770150318742
is O 0 5.387704277381999e-06
a O 0 1.400739279233676e-06
nuclear O 0 1.2811141459678765e-05
membrane O 0 1.8993335970662883e-06
protein O 0 3.521252438076772e-06
which O 0 5.014506427869492e-07
is O 0 1.5850730505917454e-07
missing O 0 9.880045581667218e-07
or O 0 8.234973734033701e-07
defective O 0 3.374739389983006e-05
in O 0 7.562485734524671e-06
Emery B-Disease 1 0.9883785843849182
- I-Disease 1 0.9999727010726929
Dreifuss I-Disease 1 0.9999961853027344
muscular I-Disease 1 0.9999892711639404
dystrophy I-Disease 1 0.9999970197677612
( O 0 8.796103793429211e-05
EDMD B-Disease 1 0.9999974966049194
) O 0 1.6967404008028097e-05
. O 0 7.638475835847203e-06

It O 0 2.414722075627651e-05
is O 0 5.293152867125173e-07
one O 0 1.2884967759418942e-07
member O 0 2.02649061975535e-07
of O 0 1.6124216628554677e-08
a O 0 1.580470780027099e-06
family O 0 5.1762631301244255e-06
of O 0 8.714471846360539e-07
lamina O 0 0.003347027348354459
- O 0 0.0012468589702621102
associated O 0 2.6476104721950833e-06
proteins O 0 1.0012176687723695e-07
which O 0 1.8318156946861563e-07
includes O 0 1.7109724126385117e-07
LAP1 O 0 7.592437759740278e-05
, O 0 6.687304789920745e-07
LAP2 O 0 5.193720426177606e-05
and O 0 4.8915248953562696e-06
lamin O 0 0.0004446307721082121
B O 0 0.00015826619346626103
receptor O 0 1.3848619346390478e-05
( O 0 4.549414370558225e-06
LBR O 0 0.0002606581838335842
) O 0 3.1707170364825288e-06
. O 0 6.447025498346193e-06

A O 0 0.00011269234528299421
panel O 0 3.0236707971198484e-05
of O 0 7.483242825401248e-07
16 O 0 3.7615989185724175e-06
monoclonal O 0 7.5433904385135975e-06
antibodies O 0 3.7079637422721134e-06
( O 0 1.014855570247164e-06
mAbs O 0 6.374833901645616e-06
) O 0 4.1936542061193904e-07
has O 0 5.29776855273667e-07
been O 0 4.515847251695959e-07
mapped O 0 2.081990942315315e-06
to O 0 1.3418322453162546e-07
six O 0 1.0567566732788691e-07
specific O 0 2.092060213954028e-08
sites O 0 7.895758358245075e-08
throughout O 0 4.747874271515684e-08
the O 0 5.2066486233570686e-08
emerin O 0 3.815330273937434e-06
molecule O 0 2.464025499193667e-07
using O 0 1.8345551211496058e-07
phage O 0 5.124783228893648e-07
- O 0 1.5656670484531787e-06
displayed O 0 1.430953915360078e-07
peptide O 0 7.378617539188781e-08
libraries O 0 3.076270616020338e-08
and O 0 9.33874986230876e-08
has O 0 1.685357204905813e-07
been O 0 7.699448900666539e-08
used O 0 1.038361077121408e-07
to O 0 3.0675991524731216e-07
localize O 0 2.5678180463728495e-05
emerin O 0 9.790689364308491e-05
in O 0 2.36622076954518e-06
human O 0 1.2520705467977677e-06
and O 0 1.977078318304848e-05
rabbit O 0 0.20848610997200012
heart O 0 0.016032669693231583
. O 0 2.3120483092498034e-05

Several O 0 3.1560786737827584e-05
mAbs O 0 0.00011845428525703028
against O 0 2.7393086838856107e-06
different O 0 6.298855055320018e-07
emerin O 0 8.160674042301252e-05
epitopes O 0 5.920317562413402e-05
did O 0 4.079957307112636e-06
not O 0 1.3276216748181469e-07
recognize O 0 3.382201327895018e-07
intercalated O 0 1.1819248584288289e-06
discs O 0 3.1118590413825586e-05
in O 0 1.7737741018208908e-06
the O 0 2.357930952712195e-06
heart O 0 0.00035982290864922106
, O 0 1.1512471473906771e-06
though O 0 1.699368112895172e-07
they O 0 4.450918211773569e-08
recognized O 0 1.0914190795574541e-07
cardiomyocyte O 0 9.027045052789617e-06
nuclei O 0 3.3812507354014087e-06
strongly O 0 1.4988163457019255e-06
, O 0 9.299644432303467e-08
both O 0 5.125271940187304e-08
at O 0 3.998039233010786e-07
the O 0 2.717758320613939e-07
rim O 0 1.695177888905164e-05
and O 0 1.5392988643725403e-06
in O 0 3.159902632887679e-07
intranuclear O 0 1.62291617016308e-05
spots O 0 1.3741222346652648e-06
or O 0 1.0841796438398887e-06
channels O 0 8.668627742736135e-06
. O 0 4.9999694056168664e-06

A O 0 0.0001350625534541905
polyclonal O 0 0.0012012101942673326
rabbit O 0 0.0007445650990121067
antiserum O 0 0.00035408325493335724
against O 0 1.4545225894835312e-05
emerin O 0 0.0002818260109052062
did O 0 1.2049570614180993e-05
recognize O 0 5.062890409135434e-07
both O 0 1.6282767489883554e-07
nuclear O 0 1.008161052595824e-05
membrane O 0 1.9308267837914173e-06
and O 0 1.313482016485068e-06
intercalated O 0 2.9336067655094666e-06
discs O 0 4.008517134934664e-05
but O 0 4.646948355002678e-07
, O 0 9.41704030310575e-08
after O 0 1.711080130917253e-07
affinity O 0 8.214707492015805e-08
purification O 0 6.18739477431518e-07
against O 0 1.0571477560006315e-07
a O 0 2.376990551056224e-07
pure O 0 1.7228283013537293e-06
- O 0 0.00033030667691491544
emerin O 0 5.181659071240574e-05
band O 0 5.608815172308823e-06
on O 0 3.866796589591104e-07
a O 0 4.174278274149401e-07
western O 0 6.476710495917359e-06
blot O 0 0.0015403639990836382
, O 0 9.550057029628078e-07
it O 0 2.581892317721213e-07
stained O 0 3.403633672860451e-05
only O 0 8.303300802481317e-08
the O 0 1.6850921724653745e-07
nuclear O 0 2.5330717107863165e-05
membrane O 0 1.4204334547684994e-05
. O 0 7.378268946922617e-06

These O 0 1.0257768735755235e-05
results O 0 8.984036867332179e-06
would O 0 4.915622753287607e-07
not O 0 8.356015257504623e-08
be O 0 5.184223539345112e-08
expected O 0 4.921288905279653e-07
if O 0 1.0962300223127386e-07
immunostaining O 0 1.2471865375118796e-05
at O 0 1.0266273875458864e-06
intercalated O 0 6.865614636808459e-07
discs O 0 1.702984627627302e-05
were O 0 6.986759899518802e-07
due O 0 1.722210782872935e-07
to O 0 5.320796603314193e-08
a O 0 2.7997884899377823e-07
product O 0 8.336083396898175e-07
of O 0 2.7735019614283374e-08
the O 0 2.592447572169476e-07
emerin O 0 4.884618101641536e-05
gene O 0 1.6364963357773377e-06
and O 0 9.334054311693762e-07
, O 0 3.6907928802065726e-07
therefore O 0 1.0018423779456498e-07
, O 0 5.8356651067015264e-08
cast O 0 2.8911495064676274e-07
some O 0 2.781183283673272e-08
doubt O 0 1.908496187752462e-07
upon O 0 6.56176410984699e-08
the O 0 2.666180876076396e-07
hypothesis O 0 3.011302942468319e-05
that O 0 1.9819412045762874e-05
cardiac B-Disease 1 0.9801183938980103
defects I-Disease 1 0.94782555103302
in O 0 2.751107058429625e-05
EDMD B-Disease 1 1.0
are O 0 1.0445230145705864e-05
caused O 0 5.886220151296584e-06
by O 0 2.9330706752261904e-07
absence O 0 4.327551152982778e-07
of O 0 1.4964139438689017e-07
emerin O 0 0.00016609419253654778
from O 0 9.408671530763968e-07
intercalated O 0 1.2049927136104088e-05
discs O 0 0.0002837537322193384
. O 0 1.0503516023163684e-05

Although O 0 3.4083241189364344e-05
emerin O 0 0.0002574316749814898
was O 0 1.4596140317735262e-05
abundant O 0 8.238469604293641e-07
in O 0 1.8560049852567317e-07
the O 0 1.4565605965799477e-07
membranes O 0 1.143046461038466e-06
of O 0 1.465551804358256e-07
cardiomyocyte O 0 9.920919546857476e-05
nuclei O 0 1.3659817341249436e-05
, O 0 9.094150072996854e-07
it O 0 4.121077665786288e-07
was O 0 4.598863142746268e-06
absent O 0 3.278732663147821e-07
from O 0 3.52591875696362e-08
many O 0 3.5068509873781295e-08
non O 0 1.5236915942296037e-06
- O 0 0.00024756474886089563
myocyte O 0 0.0003439073043409735
cells O 0 6.074122211430222e-06
in O 0 2.396897116341279e-07
the O 0 3.515904154482996e-06
heart O 0 0.0004265457973815501
. O 0 2.5590758014004678e-05

This O 0 4.138345502724405e-06
distribution O 0 1.929882273543626e-06
of O 0 3.8562126292163157e-07
emerin O 0 0.0003078404988627881
was O 0 3.472960815997794e-05
similar O 0 1.538056011440858e-07
to O 0 1.2384488456973486e-07
that O 0 5.1674906131893295e-08
of O 0 7.043989569410769e-08
lamin O 0 4.200208786642179e-05
A O 0 1.4063480193726718e-05
, O 0 5.322618221725861e-07
a O 0 6.667766569989908e-07
candidate O 0 2.569272055552574e-06
gene O 0 9.307982509199064e-07
for O 0 2.4930326958383375e-07
an O 0 3.198655576852616e-06
autosomal O 0 0.002272368408739567
form O 0 9.768918971531093e-06
of O 0 2.0181474610581063e-05
EDMD B-Disease 1 0.9999992847442627
. O 0 0.00013526050315704197

In O 0 4.050250572618097e-05
contrast O 0 4.178251765551977e-05
, O 0 1.0190899956796784e-05
lamin O 0 0.002608486684039235
B1 O 0 0.03599213436245918
was O 0 5.641384268528782e-05
absent O 0 1.4262566310208058e-06
from O 0 2.0052530658176693e-07
cardiomyocyte O 0 1.9337463527335785e-05
nuclei O 0 1.547181273053866e-05
, O 0 1.3505277820513584e-06
showing O 0 7.4922786552633625e-06
that O 0 1.224297648150241e-06
lamin O 0 0.0005319169140420854
B1 O 0 0.005126702133566141
is O 0 6.55744145205972e-07
not O 0 5.017031767806657e-08
essential O 0 3.4870545562171174e-08
for O 0 6.244582095860096e-08
localization O 0 9.225090025211102e-07
of O 0 1.0366117209059666e-07
emerin O 0 4.1258994315285236e-05
to O 0 5.613538291981968e-07
the O 0 1.1820827694464242e-06
nuclear O 0 0.0002383082319283858
lamina O 0 0.0013626373838633299
. O 0 1.551336026750505e-05

Lamin O 1 0.9487000703811646
B1 O 1 0.8862173557281494
is O 0 1.7515316358185373e-05
also O 0 1.8546156752563547e-06
almost O 0 7.295755608538457e-07
completely O 0 5.162838988326257e-06
absent O 0 5.536459411814576e-06
from O 0 9.178360755868198e-07
skeletal O 0 0.002603683155030012
muscle O 0 0.0006098655285313725
nuclei O 0 0.0005982319125905633
. O 0 2.9343618734856136e-05

In O 0 0.00028578401543200016
EDMD B-Disease 1 0.9999829530715942
, O 0 5.454051461128984e-06
the O 0 1.4195028086305683e-07
additional O 0 8.224961334235559e-08
absence O 0 2.1124803595284902e-07
of O 0 1.7240874683466245e-07
lamin O 0 0.0025082926731556654
B1 O 0 0.03631111606955528
from O 0 5.995781521050958e-06
heart O 0 0.00017483500414527953
and O 0 1.9556859115255065e-05
skeletal O 0 0.01306708250194788
muscle O 0 0.00011771741264965385
nuclei O 0 4.8716716264607385e-05
which O 0 4.648783942684531e-06
already O 0 2.2888227704243036e-06
lack O 0 4.826553094972041e-07
emerin O 0 9.17875295272097e-05
may O 0 5.362770480132895e-06
offer O 0 9.201983175444184e-08
an O 0 6.558736487249917e-08
alternative O 0 5.06849914927443e-07
explanation O 0 2.725251135871076e-07
of O 0 5.5183665637059676e-08
why O 0 3.50949505900644e-07
these O 0 5.7357972593763407e-08
tissues O 0 3.571931756596314e-06
are O 0 1.4052307051315438e-07
particularly O 0 1.132762236011331e-06
affected O 0 1.6282469914585818e-06
. O 0 1.2902062280772952e-06
. O 0 4.5976225919730496e-06

Genetic O 0 0.000350340356817469
mapping O 0 7.222513522719964e-05
of O 0 1.9667245396703947e-06
the O 0 6.480522642959841e-06
copper B-Disease 0 0.10259246826171875
toxicosis I-Disease 0 0.009510242380201817
locus O 0 2.5507795726298355e-05
in O 0 1.9713490928552346e-06
Bedlington O 0 0.00043704223935492337
terriers O 0 0.013383433222770691
to O 0 1.580732350703329e-05
dog O 0 0.0004255219828337431
chromosome O 0 0.0001747419883031398
10 O 0 2.57934766523249e-06
, O 0 2.2993803838744498e-07
in O 0 7.735615525916728e-08
a O 0 1.493269110142137e-06
region O 0 2.345753091503866e-05
syntenic O 0 0.00013577430217992514
to O 0 1.9573126337490976e-06
human O 0 1.3043720628047595e-06
chromosome O 0 0.00011007329885615036
region O 0 1.8674207240110263e-05
2p13 O 0 6.450479850172997e-05
- O 0 0.00021494161046575755
p16 O 0 7.45929210097529e-05
. O 0 9.104423952521756e-06

Abnormal O 1 0.9863601922988892
hepatic B-Disease 1 0.9998043179512024
copper I-Disease 1 0.9307793378829956
accumulation I-Disease 0 0.0005879499949514866
is O 0 2.0407951524248347e-06
recognized O 0 5.894900141356629e-07
as O 0 3.1629763270757394e-06
an O 0 0.0015562449116259813
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
in O 0 9.433012019144371e-05
man O 0 0.005921094212681055
, O 0 5.010948370909318e-06
mouse O 0 2.4311970264534466e-05
, O 0 4.539978817774681e-06
rat O 0 0.002862287685275078
and O 0 8.549019185011275e-06
dog O 0 0.0005727190291509032
. O 0 1.9365235857549123e-05

The O 0 2.2356944100465626e-05
major O 0 1.1187892596353777e-05
cause O 0 1.1112078027508687e-05
of O 0 2.3332313503487967e-06
hepatic B-Disease 1 0.9693964123725891
copper I-Disease 1 0.9675624966621399
accumulation I-Disease 0 0.0001983324036700651
in O 0 6.63002811052138e-06
man O 0 3.4617911296663806e-05
is O 0 4.454944075860112e-07
a O 0 1.6327237517543836e-06
dysfunctional O 0 4.075158358318731e-05
ATP7B O 0 0.003384190145879984
gene O 0 4.940045619150624e-05
, O 0 1.3910141205997206e-05
causing O 0 0.0007418037857860327
Wilson B-Disease 0 0.26455777883529663
disease I-Disease 0 0.17637115716934204
( O 0 1.4437830941460561e-05
WD B-Disease 1 0.971875786781311
) O 0 1.0949801435344853e-05
. O 0 9.965790923160966e-06

Mutations O 0 0.0011862138053402305
in O 0 2.823117029038258e-06
the O 0 5.968347522866679e-07
ATP7B O 0 0.00041965508717112243
genes O 0 5.537267497857101e-06
have O 0 3.9037900023686234e-07
also O 0 6.511073138426582e-07
been O 0 4.904337629341171e-07
demonstrated O 0 8.736473091630614e-07
in O 0 5.937803848610201e-07
mouse O 0 4.436700328369625e-05
and O 0 3.508707231958397e-05
rat O 0 0.051777567714452744
. O 0 2.1359592210501432e-05

The O 0 1.878365765151102e-05
ATP7B O 0 0.0010580401867628098
gene O 0 3.5510805901139975e-05
has O 0 2.103260612784652e-06
been O 0 5.11914663547941e-07
excluded O 0 4.974647822564293e-07
in O 0 6.432259169741883e-08
the O 0 1.2904077095754474e-07
much O 0 3.7554053733401815e-07
rarer O 0 2.309721094206907e-05
human O 0 5.130576482770266e-06
copper B-Disease 1 0.7348384261131287
overload I-Disease 0 0.03330949321389198
disease O 0 0.00011354988237144426
non B-Disease 0 1.813916696846718e-06
- I-Disease 0 0.00010778345313156024
Indian I-Disease 0 1.3036635209573433e-05
childhood I-Disease 0 0.0004599107487592846
cirrhosis I-Disease 0 0.4689919352531433
, O 0 8.677601726958528e-06
indicating O 0 6.603098881896585e-05
genetic O 0 0.0002889318857342005
heterogeneity O 0 0.0015325380954891443
. O 0 5.228526424616575e-05

By O 0 1.6742789739510044e-05
investigating O 0 1.718357452773489e-05
the O 0 2.186677875215537e-06
common O 0 0.00020801951177418232
autosomal O 1 0.9990233182907104
recessive O 1 0.9998334646224976
copper B-Disease 1 0.9999711513519287
toxicosis I-Disease 1 0.999950647354126
( O 0 7.735649705864489e-05
CT B-Disease 1 0.9994953870773315
) O 0 2.8756094252457842e-06
in O 0 8.924516237129865e-07
Bedlington O 0 0.0011480816174298525
terriers O 0 0.14015576243400574
, O 0 3.485553634163807e-06
we O 0 7.973258675519901e-08
have O 0 3.6451712759344446e-08
identified O 0 3.20130595810042e-07
a O 0 2.0059148653217562e-07
new O 0 2.080978447338566e-06
locus O 0 9.386218152940273e-06
involved O 0 2.7312978545523947e-06
in O 0 4.007332245237194e-05
progressive O 1 0.9999243021011353
liver B-Disease 1 1.0
disease I-Disease 1 0.9999986886978149
. O 0 7.702525908825919e-05

We O 0 2.393106115050614e-05
examined O 0 1.8037264453596435e-05
whether O 0 1.9574881662265398e-06
the O 0 1.5592195268254727e-06
WD B-Disease 0 0.17281192541122437
gene O 0 3.489240407361649e-05
ATP7B O 0 0.0004436326853465289
was O 0 3.3048130717361346e-05
also O 0 1.149292302216054e-06
causative O 0 2.9677512429771014e-06
for O 0 2.0103245788050117e-06
CT B-Disease 1 0.98062664270401
by O 0 1.1896190699189901e-06
investigating O 0 1.6438401644336409e-06
the O 0 1.130022837969591e-06
chromosomal O 0 0.0028834997210651636
co O 0 0.001902684336528182
- O 0 0.00010262540308758616
localization O 0 1.0929561540251598e-05
of O 0 2.3377609181807202e-07
ATP7B O 0 0.0002759297494776547
and O 0 1.606636942597106e-06
C04107 O 0 1.2749633242492564e-06
, O 0 3.736221998451583e-08
using O 0 7.949858371603113e-08
fluorescence O 0 1.1804446558016934e-06
in O 0 7.158123480621725e-07
situ O 0 3.113040293101221e-05
hybridization O 0 8.275414074887522e-06
( O 0 4.288193906631932e-07
FISH O 0 7.634295798197854e-06
) O 0 1.1477062571429997e-06
. O 0 3.3443070606153924e-06

C04107 O 0 0.0009090728126466274
is O 0 8.055318176047876e-06
an O 0 1.4037160553925787e-06
anonymous O 0 7.508974249503808e-06
microsatellite O 0 0.0001566140999784693
marker O 0 0.00018150891992263496
closely O 0 3.967859811382368e-05
linked O 0 0.00034570967545732856
to O 0 2.7289277568343095e-05
CT B-Disease 1 0.9982786178588867
. O 0 5.238688027020544e-05

However O 0 5.928238533670083e-05
, O 0 8.027283001865726e-06
BAC O 0 7.70968254073523e-05
clones O 0 2.2474645447800867e-05
containing O 0 6.053449510545761e-07
ATP7B O 0 9.705282718641683e-05
and O 0 9.414254122930288e-07
C04107 O 0 2.6899865588347893e-06
mapped O 0 6.461860721174162e-06
to O 0 2.9851634053557063e-07
the O 0 2.1980170572533098e-07
canine O 0 3.2056741474661976e-05
chromosome O 0 0.00012036052066832781
regions O 0 3.7092652291903505e-06
CFA22q11 O 0 8.741376223042607e-05
and O 0 3.3387905205017887e-06
CFA10q26 O 0 5.217324724071659e-05
, O 0 1.1641702712950064e-06
respectively O 0 1.206475872095325e-06
, O 0 2.369971241478197e-07
demonstrating O 0 5.263734692562139e-07
that O 0 4.11841000413915e-07
WD B-Disease 0 0.3160896599292755
cannot O 0 1.7860022580862278e-06
be O 0 1.5079362469805346e-07
homologous O 0 2.1492996893357486e-06
to O 0 1.2865723874710966e-05
CT B-Disease 1 0.9918631315231323
. O 0 2.0312098058639094e-05

The O 0 2.071798371616751e-05
copper O 0 0.00021022155124228448
transport O 0 4.628815077012405e-06
genes O 0 1.9245064777351217e-06
CTR1 O 0 9.896890696836635e-05
and O 0 5.518078978639096e-06
CTR2 O 0 0.0003405650204513222
were O 0 2.4287601263495162e-06
also O 0 5.252231858321466e-07
excluded O 0 3.740286445008678e-07
as O 0 1.2986905062462029e-07
candidate O 0 4.797230417352694e-07
genes O 0 2.447252995807503e-07
for O 0 6.299858341662912e-07
CT B-Disease 1 0.9927797913551331
since O 0 4.492961124924477e-06
they O 0 1.377647720346431e-07
both O 0 1.3932051956544456e-07
mapped O 0 2.1250993086141534e-05
to O 0 3.6067922337679192e-06
canine O 0 0.0003821875434368849
chromosome O 0 0.002188843907788396
region O 0 0.00021313778415787965
CFA11q22 O 0 0.001958075212314725
. O 0 1.9627970686997287e-05

2 O 0 0.0004059869097545743
- O 0 0.0011305754305794835
22 O 0 3.627535988925956e-05
. O 0 1.4378705600393005e-05

5 O 0 0.000880058913026005
. O 0 0.00018930109217762947

A O 0 3.890397783834487e-05
transcribed O 0 4.4655254896497354e-05
sequence O 0 3.199045977453352e-06
identified O 0 3.9423130147042684e-06
from O 0 1.1465353111361765e-07
the O 0 1.1466063654097525e-07
C04107 O 0 7.199103038146859e-06
- O 0 1.997182516788598e-05
containing O 0 1.5014171594884829e-06
BAC O 0 4.36450463894289e-05
was O 0 8.088188224064652e-06
found O 0 2.562063627919997e-07
to O 0 5.2725766863659373e-08
be O 0 1.8977022619992567e-08
homologous O 0 7.428535298004135e-08
to O 0 9.879765627829329e-08
a O 0 5.751708727075311e-07
gene O 0 1.6105947224787087e-06
expressed O 0 1.5726796220860706e-07
from O 0 9.193755090564082e-08
human O 0 3.1688682611275e-07
chromosome O 0 5.165442780707963e-05
2p13 O 0 1.488245470682159e-05
- O 0 8.99931401363574e-05
p16 O 0 3.0240662454161793e-06
, O 0 2.458052108522679e-07
a O 0 5.321831508808827e-07
region O 0 3.222885197828873e-06
devoid O 0 1.683991399659135e-06
of O 0 9.534699785263001e-08
any O 0 2.1106720282659808e-07
positional O 0 2.658587800397072e-05
candidate O 0 3.79900484404061e-05
genes O 0 1.32369923449005e-05
. O 0 6.802702500863234e-06

Molecular O 0 0.0002541026333346963
analysis O 0 6.266300715651596e-06
of O 0 3.5621172855826444e-07
the O 0 6.309364266599005e-07
APC B-Disease 0 1.2376509403111413e-05
gene O 0 8.17916088635684e-07
in O 0 1.2736383325773204e-07
205 O 0 3.1649148013457307e-07
families O 0 2.091651793989513e-07
: O 0 1.4906994749708247e-07
extended O 0 1.5210302990453783e-06
genotype O 0 0.00024579119053669274
- O 0 0.014615360647439957
phenotype O 0 0.0005382394883781672
correlations O 0 2.06791974051157e-05
in O 0 2.789960944937775e-06
FAP B-Disease 0 1.0746302905317862e-05
and O 0 1.439760126231704e-06
evidence O 0 4.1455288624092645e-07
for O 0 4.855824542460141e-08
the O 0 8.083001290515313e-08
role O 0 3.3154867651319364e-07
of O 0 1.0092763602642663e-07
APC B-Disease 0 5.573393536906224e-06
amino O 0 7.891548534644244e-07
acid O 0 1.0022922651842237e-05
changes O 0 2.8170065888843965e-06
in O 0 0.0093225734308362
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.11376483738422394
. O 0 5.838366996613331e-05

BACKGROUND O 0 0.0004029885749332607
/ O 0 0.0005651771207340062
AIMS O 0 1.6689798940205947e-05
The O 0 3.547986295870942e-07
development O 0 3.0317212349473266e-06
of O 0 0.0029474738985300064
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1160504072904587e-05
a O 0 2.254126911793719e-06
variable O 0 1.0854141692107078e-05
range O 0 1.858799805631861e-06
of O 0 6.719755560880003e-07
extracolonic O 0 0.003977013286203146
manifestations O 0 0.0003200458304490894
in O 0 0.00040417889249511063
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 0.0017007759306579828
FAP B-Disease 0 0.000346736196661368
) O 0 2.7583091650740243e-06
is O 0 1.4304504247775185e-07
the O 0 6.830473608943066e-08
result O 0 3.6870918052045454e-07
of O 0 9.93386350955916e-08
the O 0 1.8486840644982294e-06
dominant O 0 0.00028497810126282275
inheritance O 0 0.004338396247476339
of O 0 0.008742003701627254
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9999998807907104
( O 0 3.823574661510065e-05
APC B-Disease 0 0.00020259966549929231
) O 0 3.4480056001484627e-06
gene O 0 4.379530582809821e-05
mutations O 0 0.00024649922852404416
. O 0 1.498105120845139e-05

In O 0 1.412626625096891e-05
this O 0 6.586202516700723e-07
study O 0 5.052688720752485e-07
, O 0 1.473049877631638e-07
direct O 0 1.8655325106919918e-07
mutation O 0 1.2946755987286451e-06
analysis O 0 2.1817504602950066e-07
of O 0 5.175845174676397e-08
the O 0 5.592447109847853e-07
APC B-Disease 0 1.1149143574584741e-05
gene O 0 1.4972076769481646e-06
was O 0 3.0885928481438896e-06
performed O 0 1.195558184008405e-06
to O 0 2.328282704411322e-07
determine O 0 3.0202472771634348e-06
genotype O 0 0.000157522750669159
- O 0 0.004535825923085213
phenotype O 0 0.00012201251956867054
correlations O 0 5.295897153700935e-06
for O 0 3.8111119238237734e-07
nine O 0 5.12395581608871e-06
extracolonic O 0 0.00011425228149164468
manifestations O 0 4.25299094786169e-06
and O 0 5.55039321170625e-07
to O 0 1.9615588087162905e-07
investigate O 0 7.307203304662835e-07
the O 0 3.4292764894416905e-07
incidence O 0 2.912104537244886e-05
of O 0 2.648166059771029e-07
APC B-Disease 0 6.442575249820948e-05
mutations O 0 4.883764177066041e-06
in O 0 3.2844002362253377e-07
non O 0 0.00014911292237229645
- O 1 0.9998369216918945
FAP O 1 0.9999610185623169
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 5.0795239076251164e-05

METHODS O 0 0.00011733818973880261
The O 0 4.68575444756425e-06
APC B-Disease 0 5.2663272072095424e-05
gene O 0 1.1668428669509012e-05
was O 0 5.3194130487099756e-06
analysed O 0 1.3770082887276658e-06
in O 0 2.487119559191342e-07
190 O 0 1.0011104905061075e-06
unrelated O 0 2.9360417101997882e-06
FAP B-Disease 0 1.0010331607190892e-05
and O 0 1.3917153864895226e-06
15 O 0 2.860582299035741e-06
non O 0 8.329817501362413e-05
- O 1 0.999900221824646
FAP O 1 0.9999843835830688
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00013474535080604255
using O 0 1.9520596197253326e-06
denaturing O 0 0.00024344514531549066
gradient O 0 0.0008418429060839117
gel O 0 0.018871769309043884
electrophoresis O 0 4.9422738811699674e-05
, O 0 1.4980160756294936e-07
the O 0 4.126283670302655e-08
protein O 0 4.842362386625609e-07
truncation O 0 4.809167421626626e-06
test O 0 1.1804829682660056e-06
, O 0 1.335497472609859e-07
and O 0 1.9291834973955702e-07
direct O 0 1.5084784763530479e-06
sequencing O 0 3.5806417145067826e-05
. O 0 1.5127979168028105e-05

RESULTS O 0 0.0016198293305933475
Chain O 0 0.00010670048504834995
terminating O 0 2.0795700038434006e-05
signals O 0 9.020539437187836e-06
were O 0 7.714780281276035e-07
only O 0 1.0719680432202949e-07
identified O 0 2.3296336166822584e-06
in O 0 1.5831017208256526e-06
patients O 0 1.6989304185699439e-06
belonging O 0 8.499297905473213e-07
to O 0 4.5443178464665834e-07
the O 0 9.78220100478211e-07
FAP B-Disease 0 2.386667620157823e-05
group O 0 2.8214049962116405e-05
( O 0 3.143833282592823e-07
105 O 0 5.3713902161689475e-06
patients O 0 1.0748383829195518e-05
) O 0 8.290970754387672e-07
. O 0 5.269809662422631e-06

Amino O 0 8.737792813917622e-05
acid O 0 8.979314588941634e-05
changes O 0 1.7620629932935117e-06
were O 0 7.764675729049486e-07
identified O 0 9.075029083760455e-07
in O 0 1.9546662599623232e-07
four O 0 4.874495061812922e-06
patients O 0 3.648375013654004e-06
, O 0 1.1237772667982426e-07
three O 0 8.501310588826527e-08
of O 0 5.7187232727073933e-08
whom O 0 2.167626007576473e-06
belonged O 0 1.942995822901139e-06
to O 0 7.563126303011813e-08
the O 0 1.1706034541703048e-07
non O 0 2.3947479803609895e-06
- O 0 0.00014740209735464305
FAP O 0 3.08779017359484e-05
group O 0 0.00015394855290651321
of O 0 0.0014556518290191889
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0010435644071549177
. O 0 1.0353908692195546e-05

Genotype O 1 0.5580095052719116
- O 0 0.43718284368515015
phenotype O 0 0.014866861514747143
correlations O 0 0.00032500611268915236
identified O 0 0.00011937230738112703
significant O 0 2.5195445232384373e-06
differences O 0 5.753487585025141e-06
in O 0 1.834180579862732e-06
the O 0 5.334219963515352e-07
nature O 0 8.648518701193098e-07
of O 0 1.1814228884077238e-07
certain O 0 1.9737730383440066e-07
extracolonic O 0 0.00015797431115061045
manifestations O 0 2.0506926375674084e-05
in O 0 2.9168852506700205e-06
FAP B-Disease 0 0.00011078154784627259
patients O 0 1.2744898413075134e-05
belonging O 0 1.2083769433957059e-06
to O 0 3.39273270810736e-07
three O 0 2.880050260500866e-06
mutation O 0 7.78225512476638e-05
subgroups O 0 5.3171384934103116e-05
. O 0 1.2057525964337401e-05

CONCLUSIONS O 0 0.0003206835244782269
Extended O 0 4.150461245444603e-05
genotype O 0 0.002825259231030941
- O 0 0.07974599301815033
phenotype O 0 0.001050502760335803
correlations O 0 4.524987161858007e-05
made O 0 6.173112069518538e-06
in O 0 1.8185899079981027e-06
this O 0 3.7080519632581854e-07
study O 0 1.295438892157108e-06
may O 0 4.342734428064432e-06
have O 0 4.427861455269522e-08
the O 0 5.7740173531328765e-08
potential O 0 2.1650176051934977e-07
to O 0 2.3922180503177515e-07
determine O 0 2.621720796014415e-07
the O 0 6.67097239670511e-08
most O 0 5.19092218098649e-08
appropriate O 0 4.1504133463377e-08
surveillance O 0 6.314372171800642e-07
and O 0 1.2005511962343007e-06
prophylactic O 0 1.7468040823587216e-05
treatment O 0 6.043837856850587e-06
regimens O 0 1.499117956882401e-06
for O 0 4.1535420791660727e-07
those O 0 3.773808998630557e-07
patients O 0 9.603523949408554e-07
with O 0 5.8721082041302e-07
mutations O 0 3.9988306525629014e-05
associated O 0 1.7998145267483778e-06
with O 0 2.1325124635040993e-06
life O 0 0.00019560735381674021
threatening O 0 0.0070920418947935104
conditions O 0 0.00023091961338650435
. O 0 1.7903965272125788e-05

This O 0 6.7889563979406375e-06
study O 0 3.3011358482326614e-06
also O 0 2.0037937247252557e-06
provided O 0 4.935393462801585e-07
evidence O 0 3.1019453672342934e-07
for O 0 2.1702744845697453e-07
the O 0 8.10622793778748e-07
pathological O 0 2.3959628379088826e-05
nature O 0 3.430091055633966e-07
of O 0 6.42992858956859e-08
amino O 0 8.022192901080416e-07
acid O 0 8.780887583270669e-06
changes O 0 1.8622654351929668e-07
in O 0 2.202016275987262e-07
APC O 0 6.253275387280155e-06
associated O 0 3.0947560958338727e-07
with O 0 6.931661999942662e-08
both O 0 3.6512255974230357e-07
FAP B-Disease 0 8.195344889827538e-06
and O 0 2.083401113850414e-06
non O 0 9.823120490182191e-05
- O 1 0.9998214840888977
FAP O 1 0.9999805688858032
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.000405793049139902
. O 0 1.915274879138451e-06
. O 0 5.333870376489358e-06

Inherited B-Disease 1 0.9999924898147583
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999973773956299
and O 1 0.9749398827552795
cancer B-Disease 1 0.9985048770904541
risk O 0 3.3837688533822075e-05
of O 0 3.8609817920587375e-07
the O 0 4.179666575510055e-06
APC O 0 0.00026417235494591296
I1307K O 0 7.593877671752125e-05
polymorphism O 0 8.105400047497824e-05
. O 0 1.2422283361956943e-05

Germ O 0 0.018801577389240265
- O 0 0.0004914557212032378
line O 0 1.4452723007707391e-05
and O 0 6.851532248219883e-07
somatic O 0 4.679270659835311e-06
truncating O 0 1.3663035133504309e-05
mutations O 0 1.3314703210198786e-05
of O 0 1.321425884270866e-07
the O 0 5.943253995610576e-07
APC B-Disease 0 2.0174760720692575e-05
gene O 0 1.6475504480695236e-06
are O 0 4.748707382873363e-08
thought O 0 3.2211045208896394e-07
to O 0 5.818537260893208e-07
initiate O 0 0.000304090091958642
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.8377733826637268
formation O 0 0.0013217434752732515
in O 0 0.025265060365200043
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.021877471357584
sporadic O 1 0.9694953560829163
colorectal O 1 1.0
carcinogenesis O 1 0.9981191754341125
, O 0 5.997656990075484e-05
respectively O 0 8.307582174893469e-05
. O 0 1.1588705092435703e-05

Recently O 0 0.0004018177860416472
, O 0 2.62754315372149e-06
an O 0 1.2551754480227828e-06
isoleucine O 0 0.02055981568992138
- O 0 0.01826917752623558
- O 0 0.00297748576849699
> O 0 6.508634669444291e-06
lysine O 0 3.517095683491789e-05
polymorphism O 0 5.527495886781253e-06
at O 0 1.9286699171061628e-06
codon O 0 5.313379460858414e-06
1307 O 0 2.524539377191104e-05
( O 0 3.5805496167995443e-07
I1307K O 0 1.1773776122936397e-06
) O 0 7.142767088907931e-08
of O 0 1.7182546940830434e-08
the O 0 3.362284530794568e-07
APC B-Disease 0 2.3025781047181226e-05
gene O 0 1.4059334034755011e-06
has O 0 5.83480243676604e-07
been O 0 4.9814036628959e-07
identified O 0 1.3300299315233133e-06
in O 0 1.4983545781888097e-07
6 O 0 3.943990122934338e-06
% O 0 2.894909982842364e-07
- O 0 5.6996341299964115e-06
7 O 0 4.269193141226424e-06
% O 0 5.687926574182711e-08
of O 0 1.7955914088929603e-08
the O 0 5.243132932264416e-07
Ashkenazi O 0 0.00034447922371327877
Jewish O 0 2.3338508981396444e-05
population O 0 3.971665137214586e-06
. O 0 4.320105745136971e-06

To O 0 3.07442678604275e-05
assess O 0 5.20491084898822e-05
the O 0 1.7143580635092803e-06
risk O 0 1.9646643067972036e-06
of O 0 8.191597800077943e-08
this O 0 1.3173617219308653e-07
common O 0 2.0826780655625043e-06
APC B-Disease 0 3.104919596808031e-05
allelic O 0 8.966728273662739e-06
variant O 0 0.00013582661631517112
in O 0 0.00016519581549800932
colorectal O 1 1.0
carcinogenesis O 1 0.8649370074272156
, O 0 1.393803995597409e-05
we O 0 3.2733433386056277e-07
have O 0 8.799439399354014e-08
analyzed O 0 5.449676336866105e-07
a O 0 1.7929944817751675e-07
large O 0 3.320245696158963e-07
cohort O 0 4.231706498103449e-06
of O 0 2.698862147099135e-07
unselected O 0 5.7183937315130606e-05
Ashkenazi O 0 0.00035275943810120225
Jewish O 0 7.1995218604570255e-06
subjects O 0 2.1316036509233527e-06
with O 0 4.0616873775434215e-06
adenomatous B-Disease 0 0.13301190733909607
polyps I-Disease 0 0.4736848771572113
and O 0 3.0357421564985998e-05
. O 0 3.225932960049249e-05
or O 1 0.9864704012870789
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.3623903214465827e-06
for O 0 1.8559343573087972e-07
the O 0 1.337425032943429e-06
APC O 0 0.0001238723925780505
I1307K O 0 4.723230085801333e-05
polymorphism O 0 6.250577280297875e-05
. O 0 1.1424903277656995e-05

The O 0 1.6551930457353592e-05
APC O 0 7.345918129431084e-05
I1307K O 0 3.3786101994337514e-05
allele O 0 3.4145246900152415e-05
was O 0 1.6552530723856762e-05
identified O 0 4.433393769431859e-06
in O 0 7.498630907321058e-07
48 O 0 3.979851044277893e-06
( O 0 1.253123684819002e-07
10 O 0 1.6786026435511303e-07
. O 0 7.509323296517323e-08
1 O 0 1.0781744776977575e-06
% O 0 2.016090832057671e-07
) O 0 6.707565347596756e-08
of O 0 1.132304916495741e-07
476 O 0 4.069419082952663e-05
patients O 0 3.070283855777234e-05
. O 0 6.803869837312959e-06

Compared O 0 0.00011731043923646212
with O 0 7.359627716141404e-07
the O 0 2.620778616346797e-07
frequency O 0 1.8884354631154565e-06
in O 0 1.8166157644827763e-07
two O 0 1.043350081886274e-07
separate O 0 6.12097551311308e-07
population O 0 2.398742537934595e-07
control O 0 4.596591622885171e-07
groups O 0 5.0774392690300374e-08
, O 0 9.907090259275719e-08
the O 0 1.0918688531091902e-07
APC O 0 5.0653279686230235e-06
I1307K O 0 1.9488861653371714e-06
allele O 0 1.9059020814893302e-06
is O 0 1.8018154435139877e-07
associated O 0 2.0947439338669938e-07
with O 0 1.5078211390573415e-07
an O 0 2.2402716695069103e-06
estimated O 0 7.188557901827153e-06
relative O 0 4.882032044406515e-06
risk O 0 1.6944175058597466e-06
of O 0 2.2471736826901179e-07
1 O 0 4.414156137499958e-05
. O 0 1.649446494411677e-05

5 O 0 0.00018254455062560737
- O 0 0.0005370894214138389
1 O 0 4.605737194651738e-05
. O 0 1.5347313819802366e-05

7 O 0 0.00416141003370285
for O 0 0.0034393209498375654
colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9730114340782166
( O 0 3.6858924431726336e-05
both O 0 5.3241838031681255e-06
P O 1 0.693061351776123
= O 0 0.000373451184714213
. O 0 4.455956968740793e-06
01 O 0 5.2829265769105405e-05
) O 0 1.3600341617348022e-06
. O 0 4.0889394767873455e-06

Furthermore O 0 0.00015485001495108008
, O 0 5.5702903409837745e-06
compared O 0 4.798182089871261e-06
with O 0 5.209490154811647e-07
noncarriers O 0 0.00045985638280399144
, O 0 3.613071612562635e-06
APC O 0 1.0470961569808424e-05
I1307K O 0 4.998996246285969e-06
carriers O 0 5.424755613603338e-07
had O 0 4.3142904360138346e-07
increased O 0 1.4883697474488145e-07
numbers O 0 1.2684951400387945e-07
of O 0 2.1975642994220834e-07
adenomas B-Disease 0 0.07686357200145721
and O 0 0.36566296219825745
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9998370409011841
per O 0 0.0006322293193079531
patient O 0 0.0004282729350961745
( O 0 1.9087760847469326e-06
P O 0 0.08834727853536606
= O 0 0.00016975015751086175
. O 0 2.2001322577125393e-06
03 O 0 7.561562142655021e-06
) O 0 1.3445824720292876e-07
, O 0 5.562517912949261e-08
as O 0 8.000710494115992e-08
well O 0 6.331811874815685e-08
as O 0 1.8374301191670384e-07
a O 0 1.1070444543292979e-06
younger O 0 3.6930782698618714e-06
age O 0 1.1797604884122848e-06
at O 0 5.8024065765494015e-06
diagnosis O 0 0.0006162366480566561
. O 0 1.3322984159458429e-05

We O 0 2.9211052606115118e-05
conclude O 0 2.1396330339484848e-05
that O 0 2.758909261046938e-07
the O 0 1.7971031240904267e-07
APC O 0 1.593674096511677e-05
I1307K O 0 4.2614683479769155e-06
variant O 0 6.503943950519897e-06
leads O 0 2.9021459795330884e-06
to O 0 1.2810207863367395e-06
increased O 0 1.431224518455565e-05
adenoma B-Disease 1 0.9999971389770508
formation O 0 2.6885430997936055e-05
and O 0 2.5095112050621537e-06
directly O 0 2.1334329858291312e-07
contributes O 0 3.0516503102262504e-07
to O 0 9.425917824046337e-08
3 O 0 6.997642572059704e-07
% O 0 1.3723199288051546e-07
- O 0 2.298898607477895e-06
4 O 0 1.8981565972353565e-06
% O 0 5.429300742321175e-08
of O 0 1.5561379740347547e-08
all O 0 2.3663260151352006e-07
Ashkenazi O 1 0.5241835713386536
Jewish O 1 0.9961649179458618
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 7.434713916154578e-05

The O 0 8.791176696831826e-06
estimated O 0 7.963712960190605e-06
relative O 0 7.078764156176476e-06
risk O 0 5.3283692977856845e-06
for O 0 6.196010531311913e-07
carriers O 0 1.6295348359562922e-06
may O 0 1.947821601788746e-06
justify O 0 4.312579449106124e-07
specific O 0 8.92358187343234e-08
clinical O 0 8.897186489775777e-07
screening O 0 3.0489741220662836e-07
for O 0 1.0446004949926646e-07
the O 0 9.97778570877017e-08
360 O 0 3.3128490031231195e-06
, O 0 2.9980591875755636e-07
000 O 0 1.2302204766001523e-07
Americans O 0 8.101476822730547e-08
expected O 0 1.7335726454348332e-07
to O 0 1.2358484013930138e-07
harbor O 0 5.788302132714307e-06
this O 0 8.250540872722922e-08
allele O 0 1.120435626944527e-06
, O 0 3.0310857823678816e-07
and O 0 4.314476029776415e-07
genetic O 0 2.3412999325955752e-06
testing O 0 4.5082140331942355e-07
in O 0 8.912270743621775e-08
the O 0 6.804778251989774e-08
setting O 0 6.247858550523233e-07
of O 0 2.171756960933635e-07
long O 0 5.246241471468238e-06
- O 0 0.0008046745206229389
term O 0 3.574081347323954e-05
- O 0 0.00010614688653731719
outcome O 0 1.1419740985729732e-05
studies O 0 9.27171186049236e-07
may O 0 3.6295243717177073e-06
impact O 0 2.2685130716126878e-06
significantly O 0 0.00023446825798600912
on O 1 0.9999414682388306
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.00018516815907787532
in O 0 6.498529501186567e-07
this O 0 2.98898640949119e-07
population O 0 2.146288579751854e-06
. O 0 2.7958180908171926e-06

Localization O 0 0.0003300935495644808
of O 0 8.175696166290436e-06
human O 0 9.53737435338553e-06
BRCA1 O 0 0.0005377748166210949
and O 0 5.016384875489166e-06
its O 0 8.79968956724042e-06
loss O 0 3.568455213098787e-05
in O 0 9.363761819258798e-07
high O 0 8.675765457155649e-06
- O 0 0.00010017208114732057
grade O 0 2.081964885292109e-05
, O 0 8.795611279310833e-07
non B-Disease 0 1.7101099729188718e-05
- I-Disease 1 0.562597930431366
inherited I-Disease 1 0.9894728064537048
breast I-Disease 1 0.9998965263366699
carcinomas I-Disease 1 0.9999996423721313
. O 0 0.00014574427041225135

Although O 0 1.0337530511606019e-05
the O 0 3.8588541428907774e-07
link O 0 4.264151357347146e-06
between O 0 9.68124481914856e-07
the O 0 2.0237001081113704e-05
BRCA1 O 1 0.9833590388298035
tumour B-Disease 1 1.0
- O 0 0.08441033214330673
suppressor O 0 0.0005331975989975035
gene O 0 3.343729258631356e-05
and O 0 2.0227951608831063e-05
hereditary B-Disease 1 0.9996119141578674
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9999948740005493
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.4270977974083507e-06
established O 0 5.462466106109787e-07
, O 0 2.4707244961064134e-07
the O 0 8.43270768768889e-08
role O 0 5.273758461044054e-07
, O 0 2.778145926640718e-07
if O 0 3.113257207587594e-08
any O 0 1.2055077824868476e-08
, O 0 6.408612307495787e-08
of O 0 7.247352584727196e-08
BRCA1 O 0 0.00011558952246559784
in O 0 1.5921042404443142e-06
non B-Disease 0 2.6188467018073425e-05
- I-Disease 0 0.4438936710357666
familial I-Disease 1 0.8574269413948059
cancers I-Disease 1 0.9977905750274658
is O 0 7.399641162919579e-06
unclear O 0 3.261630263295956e-05
. O 0 7.763988833175972e-06

BRCA1 O 1 0.826143205165863
mutations O 0 0.0030568819493055344
are O 0 1.8624497215569136e-06
rare O 0 5.069415692560142e-06
in O 0 4.431242359714815e-06
sporadic B-Disease 0 0.0017341898055747151
cancers I-Disease 1 0.9831207990646362
, O 0 9.957259862858336e-06
but O 0 2.1454188754432835e-06
loss O 0 1.4755295524082612e-05
of O 0 6.602124926757824e-07
BRCA1 O 0 0.016838204115629196
resulting O 0 7.3922496994782705e-06
from O 0 3.7262196883602883e-07
reduced O 0 4.4772632463718764e-06
expression O 0 5.989833198327688e-07
or O 0 2.4878951876416977e-07
incorrect O 0 2.1153259694983717e-06
subcellular O 0 4.053387328895042e-06
localization O 0 8.818575224722736e-06
is O 0 6.720537157889339e-07
postulated O 0 1.2352445537544554e-06
to O 0 1.7220908432591386e-07
be O 0 4.745176340748003e-08
important O 0 2.0969460834407982e-08
in O 0 2.112528676434522e-07
non B-Disease 0 1.3484362170856912e-05
- I-Disease 0 0.3257322609424591
familial I-Disease 1 0.9047964811325073
breast I-Disease 1 0.9999867677688599
and I-Disease 1 0.9976651668548584
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
. O 0 6.921014573890716e-05

Epigenetic O 0 0.011193636804819107
loss O 0 0.47760528326034546
, O 0 2.677070915524382e-05
however O 0 1.9917792997148354e-06
, O 0 4.848707817473041e-07
has O 0 6.425245828722836e-07
not O 0 1.445350790163502e-07
received O 0 1.9148954777392646e-07
general O 0 1.3719784419663483e-07
acceptance O 0 8.319864832628809e-07
due O 0 8.627314969089639e-07
to O 0 2.907975726884615e-07
controversy O 0 1.770754209928782e-07
regarding O 0 1.0049581078419578e-07
the O 0 1.0523496740688643e-07
subcellular O 0 4.027631348435534e-06
localization O 0 3.962826667702757e-06
of O 0 3.4189935149697703e-07
BRCA1 O 0 7.803300832165405e-05
proteins O 0 9.066075676855689e-07
, O 0 5.889196472708136e-07
reports O 0 4.5377305468718987e-07
of O 0 4.6089301264373717e-08
which O 0 1.1610225101321703e-06
have O 0 2.7844802730214724e-07
ranged O 0 5.662234912051645e-07
from O 0 3.4948051563787885e-08
exclusively O 0 2.8677447971858783e-07
nuclear O 0 1.580227581143845e-05
, O 0 2.2743608951714123e-07
to O 0 9.596219996410582e-08
conditionally O 0 1.4533106877934188e-05
nuclear O 0 1.1001634447893593e-05
, O 0 1.4403104842131143e-07
to O 0 7.594146467226892e-08
the O 0 4.786947442880773e-07
ER O 0 0.0032368614338338375
/ O 0 3.6731933505507186e-05
golgi O 0 1.3171499631425831e-05
, O 0 1.6742474429065624e-07
to O 0 6.567348265207329e-08
cytoplasmic O 0 1.7189452137245098e-06
invaginations O 0 1.3059305274509825e-05
into O 0 3.21232192845855e-07
the O 0 6.042445193088497e-07
nucleus O 0 1.7363969163852744e-05
. O 0 8.652827091282234e-06

In O 0 1.4626347365265246e-05
an O 0 1.6537275087102898e-06
attempt O 0 8.224557859648485e-06
to O 0 1.5452056914000423e-06
resolve O 0 4.735267339128768e-06
this O 0 2.8468934942793567e-07
issue O 0 5.568068672801019e-07
, O 0 3.0754614499528543e-07
we O 0 8.503970150286477e-08
have O 0 1.46676413237401e-07
comprehensively O 0 3.677347194752656e-05
characterized O 0 8.430763955402654e-06
19 O 0 9.993867934099399e-06
anti O 0 1.5916055417619646e-05
- O 0 0.01710190251469612
BRCA1 O 0 0.005525392945855856
antibodies O 0 1.9605746274464764e-05
. O 0 7.76117667555809e-06

These O 0 1.1847770110762212e-05
reagents O 0 2.2782065570936538e-05
detect O 0 3.0256120226113126e-05
a O 0 9.218775289809855e-07
220 O 0 1.6461117411381565e-06
- O 0 3.7831414374522865e-05
kD O 0 2.0369845515233465e-05
protein O 0 9.897917152557056e-07
localized O 0 4.1099781356024323e-07
in O 0 5.187388651961555e-08
discrete O 0 7.202984306786675e-07
nuclear O 0 2.4574814233346842e-05
foci O 0 2.8709881007671356e-05
in O 0 6.453266792050272e-07
all O 0 9.413250978695942e-08
epithelial O 0 1.307079401158262e-05
cell O 0 0.0001812666014302522
lines O 0 2.0219771613483317e-05
, O 0 2.850006524113269e-07
including O 0 4.90868927727206e-08
those O 0 5.502380773236837e-08
derived O 0 1.847956127676298e-06
from O 0 9.977907211577985e-06
breast B-Disease 0 0.23449616134166718
malignancies I-Disease 0 0.008391909301280975
. O 0 4.6906563511583954e-05

Immunohistochemical O 0 0.002215317450463772
staining O 0 0.0009620695491321385
of O 0 2.123436024703551e-05
human O 0 6.041305823600851e-05
breast O 0 0.21967782080173492
specimens O 0 4.6742417907807976e-05
also O 0 1.6936653992161155e-05
revealed O 0 6.611087883356959e-05
BRCA1 O 0 0.00031851930543780327
nuclear O 0 0.00012677389895543456
foci O 0 0.0004947600536979735
in O 0 2.8181593734188937e-05
benign O 1 0.5676715970039368
breast O 1 0.9774027466773987
, O 0 5.082217830931768e-05
invasive B-Disease 0 0.20064695179462433
lobular I-Disease 1 0.9999377727508545
cancers I-Disease 1 0.9996428489685059
and O 0 1.2765407518600114e-05
low B-Disease 0 7.643550634384155e-05
- I-Disease 0 0.4913651943206787
grade I-Disease 0 0.20034724473953247
ductal I-Disease 1 0.9997355341911316
carcinomas I-Disease 1 0.9999995231628418
. O 0 0.0001192152121802792

Conversely O 0 0.0010984480613842607
, O 0 2.3928436348796822e-05
BRCA1 O 0 0.0005420074448920786
expression O 0 7.007866770436522e-06
was O 0 1.886805875983555e-05
reduced O 0 3.4679439977480797e-06
or O 0 5.136232630320592e-07
undetectable O 0 3.4582867556309793e-06
in O 0 8.73287717695348e-08
the O 0 4.735692016311077e-08
majority O 0 1.4516859891955392e-07
of O 0 3.7001811392656236e-08
high O 0 4.8404049266537186e-06
- O 0 0.002610595664009452
grade O 0 0.00012973422417417169
, O 0 1.11795943666948e-05
ductal B-Disease 1 0.6914306879043579
carcinomas I-Disease 1 0.9999998807907104
, O 0 8.074732249951921e-06
suggesting O 0 2.4257833501906134e-06
that O 0 1.473401169960198e-07
absence O 0 2.712287141548586e-07
of O 0 3.6855169582850067e-07
BRCA1 O 0 0.007224229630082846
may O 0 1.6544796380912885e-05
contribute O 0 1.858851703673281e-07
to O 0 1.3176658342217706e-07
the O 0 2.090766457740756e-07
pathogenesis O 0 1.6078653061413206e-05
of O 0 5.713925688155541e-08
a O 0 1.1268674597886275e-06
significant O 0 8.880791710907943e-07
percentage O 0 1.6980387954390608e-05
of O 0 1.9997578419861384e-06
sporadic B-Disease 0 0.17534612119197845
breast I-Disease 1 0.9999464750289917
cancers I-Disease 1 0.9949268102645874
. O 0 1.022292417474091e-05
. O 0 6.739793207088951e-06

